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A dramatic increase in knowledge regarding the molecular biology of brain tumors 
has been established over the past few years, and this has lead to the development of 
novel therapeutic strategies for these patients.  In this book a review of the options 
available for the clinical management of patients with these tumors are outlined.   In 
addition advances in radiology both for pre-operative diagnostic purposes along with 
surgical planning are described.  Furthermore a review of newer developments in 
chemotherapy along with the evolving field of photodynamic therapy both for intra-
operative management and subsequent therapy is provided.  A discussion of certain 
surgical management issues along with tumor induced epilepsy is included.  Finally a 
discussion of the management of certain unique problems including brain metastases, 
brainstem glioma, central nervous system lymphoma along with issues involving 
patients with a brain tumor and pregnancy is provided.
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Dr. Lichtor is a practicing neurosurgeon. He has a 
number of research interests, and his brain tumor work 
is largely focused on the development of a DNA vaccine 
for treatment of primary and metastatic intracerebral 
tumors. In particular Dr. Lichtor has shown that vac-
cines prepared by transfer of DNA from the tumor into 
a highly immunogenic cell line can encompass the array 
of tumor antigens that characterize the patient’s neoplasm. Poorly im-
munogenic tumor antigens, characteristic of malignant cells, can become 
strongly antigenic if they are expressed by highly immunogenic cells. The 
introduction of the vaccine directly into the tumor bed of animals with 
an intracerebral tumor stimulates a systemic cellular anti-tumor immune 
response associated with a prolongation of survival. It is hopeful that this 
vaccine strategy will be efficacious in the treatments of patients with brain 
tumors. Dr. Lichtor is a member of the neurosurgery faculty at Rush Uni-
versity Medical Center in Chicago, Illinois.
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Although technical advances have resulted in marked improvements in the ability to diagnose
and surgically treat primary and metastatic brain tumors, the incidence and mortality rates of
these tumors is increasing. Particularly affected are young adults and the elderly. The present
standard treatment modalities following surgical resection including cranial irradiation and
systemic or local chemotherapy each have limited efficacy and serious adverse side effects.
Furthermore the relatively few long-term survivors are inevitably left with cognitive deficits
and other disabilities. The difficulties in treating malignant gliomas can be attributed to sever‐
al factors. Glial tumors are inherently resistant to radiation and standard cytotoxic chemo‐
therapies. The existence of blood-brain and blood-tumor barriers impede drug delivery to the
tumor and adjacent brain infiltrated with tumor. In addition the low therapeutic index be‐
tween tumor sensitivity and toxicity to normal brain severely limits the ability to systemically
deliver therapeutic doses of drugs or radiation therapy to the tumor. New treatment strategies
for the management of patients with these tumors are urgently needed.
In this book a review of the important features involving the clinical management of patients
with these tumors are outlined. In addition advances in radiology both for pre-operative diag‐
nostic purposes along with surgical planning are described. Furthermore a review of newer
developments in chemotherapy along with the evolving field of photodynamic therapy both
for intra-operative management and subsequent therapy is provided. Hopefully this informa‐
tion coupled with advances in the understanding of the pathology and molecular biology of
brain tumors which are also outlined in this book will translate into additional novel therapeu‐
tic treatment strategies that should lead to the prolongation of survival without a decline in
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Navigated Brain Stimulation (NBS) for Pre-Surgical
Planning of Brain Lesion in Critical Areas: Basic
Principles and Early Experience
Concetta Alafaci, Alfredo Conti and
Francesco Tomasello
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53216
1. Introduction
Modern neurosurgery attempts to get the difficult goal of combining an "aggressive" resec‐
tion of brain tumors with the fundamental purpose of preserving brain functions and best
possible quality of life.
One of the most important evolutions of neurosurgical therapies is the opportunity to pro‐
vide a customized surgical intervention by using modern methods to "map" the eloquent
areas of the brain. This allows the identification of brain functional areas to be preserved
from possible inadvertent intraoperative damage.
Direct cortical stimulation (DCS) is an intraoperative technique that uses electrodes placed
directly on the exposed cortical surface of the brain to stimulate activity of functional areas
by simultaneously recording the evoked responses peripherally. DCS is very precise and re‐
liable and can be considered the gold standard in brain mapping and intraoperative func‐
tional monitoring. Nevertheless, the neurosurgeon discovers the spatial relationship
between the disease and eloquent cortical surfaces only after having completed a cranioto‐
my and dural opening.
A pre-surgical mapping method would give the opportunity to plan the treatment of brain
diseases optimizing many aspects of the surgical treatment, including patient positioning,
type of anesthesia, size of craniotomy, and extent of resection. Moreover, pre-surgical map‐
ping would allow more precise prediction of the efficacy and risks of treatments that can be
discussed with the patient and influence the therapeutic strategy.
© 2013 Alafaci et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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New techniques have been proposed in an attempt to provide a reliable method for the
functional study that can be, however, exploited pre-operatively. The most recent of these
methods of mapping cortical activities is navigated brain stimulation (NBS), which is based
on the neurophysiological technique of transcranial magnetic stimulation (TMS) of the cere‐
bral cortex combined with the conventional neuronavigation. Basic principles of NBS will be
here discussed together with our preliminary experience using this technique in different
neurosurgical diseases.
2. Navigated Brain Stimulation for mapping the motor system
Navigated brain stimulation is a technique for mapping the motor cortex using a transcrani‐
al magnetic stimulation (TMS) of brain areas. In NBS, conventional TMS is combined with a
sophisticated neuronavigation software that allows the navigation of each single “stimulat‐
ed” point in the cortex. The electromagnetic stimulus delivered by the TMS coil overcomes
the activation threshold of the underlying motor neurons, so that the impulse may propa‐
gate to the corticospinal tract determining a muscle contraction. Muscles responses to elec‐
tric field (motor evoked potential, MEP) are recorded using EMG channels (Figure 1).
Figure 1. The navigated brain stimulation system Nexstim (Nexstim Ltd., Helsinki, Finland). With NBS, conventional
transcranial magnetic stimulation is combined with a neuronavigation system that allows precise identification of
each single “stimulated” point in the cortex on three-dimensional imaging study of the patient brain. Muscles re‐
sponses to electric field (motor evoked potential, MEP) are recorded using EMG channels. The motor map obtained
can be used for pre-surgical planning and integrated in the neuronavigation during surgical procedures.
This technique, that has been very recently developed [14], has several exciting clinical and
research applications including:
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Mapping motor areas for surgical oncology and epilepsy
Checking the integrity of post-stroke motor system
Mapping the motor response in post-traumatic spinal cord injury
Mapping of the areas that control language
Guiding the implantation of stimulating electrodes in the motor cortex
Stimulating the brain plasticity
Treating pain, tinnitus, depression
The first studies on NBS confirmed the safety and tolerability of this technique with no ad‐
verse events including pain and seizures, despite the majority of patients in the series had a
history of epilepsy. Few patients may have a slight discomfort, and even fewer, a transient
headache [14-16].
2.1. Transcranial Magnetic Stimulation
Transcranial magnetic stimulation is a noninvasive technique that allows a focal cortical
stimulation. TMS uses electromagnetic induction to produce weak electric currents using a
rapidly changing magnetic field. A plastic-enclosed coil of wire is held next to the skull and
when activated, it produces a magnetic field oriented orthogonally to the plane of the coil.
The magnetic field passes unimpeded through the skin and skull, inducing an oppositely di‐
rected current in the brain that activates nearby nerve cells in much the same way as cur‐
rents applied directly to the cortical surface. The magnetic cortical stimulation is, therefore, a
tool to drive in the brain an electrical stimulus generated outside of the head.
The method has, however, an inherent limitation: using a single coil the stimulus that results
is not particularly focal and the magnetic field does not penetrate very deeply into the brain.
This limitation has been solved through the use of "figure eight " or "butterfly" coils that
make the area of overlap of the stimulus significantly more focal and increase the depth of
the effect. A single stimulus generated by means of TMS lasts less than 1 ms; despite its
brevity it has sufficient power to trigger the activation of many neurons below the coil and a
consequent physiological complex chain reaction in the brain tissue that lasts for 50 - 100 ms.
In fact, if initially only the neurons immediately below the coil reach the action potential,
then it propagates through the synapses also to the adjacent neurons so that the neural re‐
sponse results amplified. This activation of neurons can then be followed by an inhibitory
postsynaptic potential and by a period of electrical silence [17].
2.2. Electromyography
The NBS system records motor evoked potentials (MEP) produced by TMS through an elec‐
tromyography system. Cortical representation of each muscle is a function of its level of in‐
nervation, being this latter an index of the degree of fineness of the movements that each
muscle can accomplish. The muscles of the face, hand and leg have an extensive somatotop‐
ic cortical representation, and recording EMG activity of these muscles allow an almost com‐
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plete map of the primary motor cortex. It is possible to simultaneously map up to 6 muscles
using the 6 EMG channels available in the NBS system.
Muscles of the thenar eminence are usually chosen in the group of muscles of the hand for
their wide cortical representation (Figure 1). The mental muscle, being simple to relax for
the patient, is frequently used for the group of facial muscles. The tibialis muscle is com‐
monly used for leg function mapping [6].
It is possible to characterize the motor cortex on the basis of the amplitude of the MEP of
each stimulated point. A map of colored dots, built on the basis of EMG recordings, pro‐
vides the accurate localization of the motor cortex at end of the procedure (Figure 2).
Figure 2. The NBS System uniquely determines the actual location of the stimulating electric field (E-field) in the cor‐
tex. Moving the transcranial magnetic stimulation coil over the patient’s head, it is always possible to see, in real-time,
the stimulation location, strength and direction in the 3-D intracranial rendering. During the mapping, the areas in the
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2.3. Neuronavigation
The NBS can accurately display, in a 3D rendering of the individual patient’s magnetic reso‐
nance image (MRI), the induced electric field generated by TMS (Figure 3). A standard volu‐
metric MRI is uploaded in the NBS System to obtain a detailed 3D rendering of the head and
intracranial structures. Visualization of the brain cortex can be obtained by a tool that allow
a layer-by-layer peeling of the skin, bone and dura mater to view the 3D rendering of the
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors6
brain at any desired intracranial depth. Overlay fMRI, DTI or PET data on the 3D rendering
is needed can be registered as well.
With  the  patent  wearing  a  head tracker  (eye-frame),  a  pointer  registers  12  scalp  points
and computer-aided landmark identification ensures accurate alignment to the MRI data
(Figure 3).
Figure 3. With the patent wearing a head tracker (eyeframe), computer-aided landmark identification ensures accu‐
rate alignment of the patient to the MRI data.
Therefore, the NBS system determines the actual location of the stimulating electric field in
the cortex, taking into account the size and shape of the individual patient’s head, as well as
the TMS coil and stimulator parameters. Moving the TMS coil over the patient’s head, it is
possible to always see, in real-time, the electric field location, strength and direction in the 3-
D intracranial rendering. As the session proceeds, a map of the cortical somatotopy, can be
created and a post-hoc analysis can be performed offline.
3. Other potential clinical applications of NBS
3.1. Mapping the language
The identification of cortical areas controlling the language can be performed by direct corti‐
cal stimulation. The cortical area responsible for the motor function of language can local‐
ized by the so-called "speech arrest" caused by its electrical stimulation. Prerequisite of this
type of mapping is that the patient must be awake and cooperative. Nevertheless, these con‐
ditions cannot be always achieved, especially when patients are children or poorly coopera‐
tive adults. In these patients, therefore, it is imperative to find a method of tracking and
monitoring the language during a surgery performed under general anesthesia.
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In a recent study, navigated TMS was used in combination with video recording of the pa‐
tient involved in an objects naming task [10]. A repetitive TMS (rTMS) must be used to this
purpose. A train of five consecutive TMS pulses was delivered at repetition rate of 5 Hz [4]
and with intensity range 80–110% of the motor threshold (MT). The induced electric field
ranged between 45 and 80 V/m. To cover speech-related activity and make the possible
speech arrest more clear, the train started 300 ms after the presentation of the picture.
Video recording was used for post-hoc review of "errors" caused by repetitive navigated
TMS. During stimulation of cortical areas in proximity of the Broadman 44 area, complete
anomia and semantic errors have been recorded. In some patients, the stimulation of the
right cortex produced similar errors.
Three different cortical areas in the frontal cortex have been identified as responsible for the
arrest of speech: primary motor areas negative (NMA), opercular portion of Broca's area
(Brodmann area 44) and area of primary motor cortex (M1). M1 cortex is responsible for con‐
trolling muscle movements necessary for vocalization, whereas the pars opercularis of Bro‐
ca's area is responsible for phonological tasks. The responses of the laryngeal muscles can be
clearly distinguished by their different latencies to stimulation: stimulation of the M1 produ‐
ces a short latency response (SLR), whereas stimulation of the part opercularis of the Broca's
area produces a long latency response (LLR) [3].
3.2. Therapeutic use of navigated TMS
Repetitive TMS (rTMS) has a potential therapeutic effect in several psychiatric and neuro‐
logical diseases as well as in stroke and pain. In October 2008, the FDA approved rTMS in
the USA for the treatment of major depressive disorders in adults who have failed at least
one antidepressant medication.
With rTMS, one challenge is finding the optimal location and dose. In fact, despite multiple
successful investigations showing positive effects of rTMS in depression, recent reports have
indicated that non-responders may have received rTMS to suboptimal locations [6]. Naviga‐
tion can help the identification of the optimal brain structure for targeting rTMS, but solving
this problem still leaves the question of dose optimization. While specific pulse train param‐
eters have been extensively reviewed in the literature, there is little knowledge of the intra‐
cranial strength of applied stimulation and dose-response behavior.
With regard to stroke, MEPs s may have an important role in quantifying the remaining ca‐
pacity of the motor cortex and the corticospinal tract to generate muscular activity [13]. Na‐
vigated TMS may show the development of post-stroke neuronal plasticity with shifting of
the primary representation areas. This advances our prognostic evaluation and offers in‐
sights for innovative therapeutic strategies [11].
The stimulation of the motor cortex through surgically implanted epidural electrodes is a
safe and effective technique to treat chronic neuropathic pain. About ten years ago, it was
demonstrated that repetitive TMS of the motor cortex could also produce analgesic effects in
patients with neuropathic pain resistant to drugs. Since rTMS is not invasive, the technique
is particularly suited to the study of the mechanisms involved in the modulation induced by
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cortical stimulation. Furthermore, the use of a navigated repetitive TMS may increase accu‐
racy and reliability of the procedure. It exploits the ability to view "hot spots" of cortical
stimulation, provided by the maximum amplitude of motor evoked potentials in the mus‐
cles of the painful body area, directly on the three-dimensional reconstruction of magnetic
resonance imaging of the brain of each individual patient.
There is a critical frequency of stimulation to achieve the analgesic effect of rTMS. Repet‐
itive TMS of the motor cortex has been proven of relieving pain when applied high frequen‐
cy (> 5Hz), but not at low frequency (<1 Hz). The high frequencies are used to enhance
synaptic transmission, without regard to time of stimulation, while the low frequency would
be inhibitory. Unlike the frequency, increasing the intensity does not potentiate the analge‐
sic effect of the stimulation. This is because the increased intensity only leads to recruit‐
ment of fibers placed in the deepest portion of the cortex, while the pain relief is achieved
by activating neural circuitry in the upper layers of the cortex. The peak of analgesic ef‐
fect of repetitive TMS due to synaptic plasticity, is reported from about 2-3 days after a
single  session of  rTMS and can last  for  a  week.  The  use  in  daily  sessions  of  rTMS for
several weeks may increase the degree and duration of pain reduction, beyond the time
of stimulation. To date,  however,  the long-term relief,  can only be achieved by implant‐
ing epidural motor cortex stimulation.
It has also been shown that the analgesic effect of rTMS depends on the precise location of
the site of stimulation on the precentral gyrus contralateral to the site of pain. Conventional‐
ly, TMS relies solely on the skull anatomy. Using navigated TMS, it is possible to directly
visualize the target area. For the hand, the target is located at the knee of the median motor
gyrus, which is easily identifiable in 90% of cases, in the front portion of the central sulcus. If
the hand knob cannot be accurately identified, the target can be set at the level of the appa‐
rent interruption of the central sulcus corresponding to the motor representation of the mus‐
cles of the hand. In rare cases where neither the joint nor the apparent interruption of the
motor central sulcus can be identified (3% of cases), the target can be identified on the front
arm of the central sulcus at the level of the superior frontal sulcus. The effectiveness of re‐
petitive TMS depends also on the orientation of the coil. Analgesia is usually obtained when
the coil has an antero-posterior orientation in the precentral gyrus. Repetitive TMS may
modulate affective and emotional components of pain, perhaps connected with the effects of
stimulation on limbic structures. A positive response to rTMS could be used to identify pa‐
tients responding to epidural stimulation surgery, even though a negative response is not an
exclusion criterion for the implant [1].
4. Materials and methods
All patients admitted to our clinic from November 2011 to May 2012 with lesions (primary
brain tumors, brain metastases, vascular malformations) in the motor area underwent pre‐
operative mapping by NBS (Nexstim system 4, Nexstim Ltd., Helsinki, Finland).
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Ten patients (5 women and 5 men), aged between 27 and 82 years (mean age = 54 years) un‐
derwent NBS. Four patients underwent also preoperative DTI tractography. Seven patients
had a lesion of the left cerebral hemisphere.
Neuroimaging was performed using a 1.5-T MRI unit acquiring high-resolution T1 weight‐
ed (T1-w) isotropic volumetric data set with a 3D-magnetization prepared rapid gradient
echo (3D-MPRAGE) sequence with 1 x 1 x 1 mm voxel size. During the same session DTI
was performed. Patients were imaged with parallel imaging technique (IPAT GRAPPA im‐
plementation with acceleration factor of 2) and a 4-channel coil with different parameters of
the same diffusion-weighted echo-planar sequence with a diffusion-weighted single-shot
spin echo, echoplanar sequence with isotropic voxel of 2.3 x 2.3 x 2.3 mm.
Diffusion tensor images were transferred to a personal computer, converted in analyze for‐
mat and then initially corrected for the effects of eddy-current-induced distortion using FSL
modules. After returning them to the DICOM format the images were then processed with
the Diffusion Toolkit software (Martinos Center for Biomedical Imaging, Massachusetts
General Hospital, Boston, MA, USA) to calculate voxel-based fractional anisotropy maps. Fi‐
ber tracking was then performed with the same software using the interpolated streamline
propagation algorithm.
The NBS study was performed using a "figure-eight" coil applied perpendicular to the sagit‐
tal line of the patient head, with an inclination of 45° and with a posterior-to-anterior flow of
direct current.
The procedure was performed according to the following steps:
1. the patient's brain MRI was uploaded in the NBS system so that it can to elaborate a
three-dimensional reconstruction; layer–by-layer peeling of superficial cortical struc‐
tures was performed.
2. the electrodes for recording of electromyographic activity were placed on the surface of
the muscles to be activated. Amplitude and latency of evoked potentials engines from 6
EMG channels will be automatically calculated and recorded.
3. The patient wore a special eye-frame for the "head tracking". The operator then tracked
the head of the patient with a pointer.  The NBS system aligned the points virtually
drawn on the patient's head with their corresponding coordinates on the 3D magnet‐
ic resonance.
4. The TMS was then performed. Once the brain area for the target muscle was found,
the NBS System found the patient’s individual motor threshold (MT). With the stim‐
ulator output now set to the optimal mapping intensity, the NBS System automatical‐
ly  and  reliably  measured  MEPs  –  enabling  the  high  spatial  resolution  needed  for
accurate mapping.
5. Before NBS mapping, the resting motor threshold of each individual patient (resting
motor threshold = minimal intensity of stimulation that can elicit at least 5 of 10 PEM,
with an amplitude of 50 mV ) was determined. The cortex of patients was thus activated
with a stimulation intensity of 20-30% higher than the resting motor threshold.
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6. A cortical somatotopic map was generated by stimulating different parts of the cortex,
and identifying those in which the motor response was more intense.
7. The whole data set including the volumetric MRI and a co-registered functional map
were exported and uploaded into the operative neuronavigation system.
The motor area has been mapped, on average, twice for each patient: the first mapping was
usually carried out one week before surgery. The second determination was obtained the
day before surgery.
In one patient, rTMS was performed in order to map language areas. This was done at a fre‐
quency of 5 Hz with trains of 7 stimuli (because the area of language is placed in a deepest
portion of the cortex than the area motor) and a very low intensity (close to the motor
threshold) to minimize the risk of seizures.
Motor evoked potentials of the following muscles were recorded: first interosseous, for the
group of muscles of the hand; the tibialis anterior, for the group of muscles of the leg; men‐
tal muscle, for the group of muscles of the face.
The software classified the recorded MEP intensities using a chromatic scale of four colors:
white, yellow, red, gray. Adjoining white spots (maximum cortical representation of the
muscle activated by TMS) with yellow and red spots (MEPs of intermediate intensity, and
excluding the grey points (no muscle activation following stimulation of that point = no cort‐
ical representation of the muscle at that point), the profile of the motor cortex was so elabo‐
rated offline (Figure 4).
Figure 4. Once the representation area for the target muscle has been found, the NBS System finds thepatient’s indi‐
vidual motor threshold (MT). With the stimulator output now set to the optimal mapping intensity, the NBS System
automatically and reliably measures MEPs enabling the high spatial resolution needed for accurate mapping.
The data obtained were exported and uploaded on a neuronavigation system Stealthstation
7 (Medtronic, Louisville, CO) and used in the operating room during surgery (Figure 5).
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Figure 5. Once the mapping has been completed it is possible exporting images in DICOM format to the neuronaviga‐
tor. In the operating room, NBS cortical maps may facilitate the optimal placement of direct cortical stimulation elec‐
trodes and facilitate surgical guidance.
5. Results and Discussion
All patients underwent gross total resection of tumors or vascular malformations. Post-oper‐
atively, only 1 out of 10 patients presented a right facial paresis of the central type associated
to motor aphasia; both recovered within 48 hours. In 5 of the patients neurological examina‐
tion showed no changes as compared to the pre-operative status. Finally, 4 patients had an
improvement of neurologic status (Figure 6).
With regard to the tolerability of NBS, we did not record any discomfort for the patients, nor
side effects or seizures due to the cortical stimulation, despite the majority of patients had a
history of epilepsy (9 of 10 patients).
In this our preliminary experience, albeit the limitation of a small number of cases, NBS met
the expectations with successful clinical results. Up to now, functional magnetic resonance
imaging (fMRI) was the only non-invasive and readily available method to study brain func‐
tions, cognitive activities and potential functional circuitry. fMRI technique uses BOLD
(blood oxygenation level dependent) sequences, namely a sequence able to detect increased
level of cerebral blood flow and oxygen consumption of brain areas that are activated by ap‐
propriate stimulation tests. Although it is less available, positron emission tomography
(PET) is the alternative technique that measures the oxygen or glucose consumption of acti‐
vated brain areas. Both fMRI and PET have a sufficient spatial resolution, but a low tempo‐
ral resolution. Moreover, the growth of brain tumors may transform local vascularization
and cell metabolism, for which a method sensitive to hemodynamic or metabolic changes,
may be less accurate.
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Figure 6. Preoperative MRI (upper left) and post-operative CT (upper right) imaging of a patient with a low grade
gliomas of the right pre-rolandic area. The day after surgery the patient present no motor deficits.
Finally, these examinations could be cumbersome, or even not feasible in children and in pa‐
tients with severe neurological impairments.
Navigated brain stimulation, among the methods of pre-operative brain mapping, has a
number of potential advantages. Actually, NBS possesses a very high temporal resolution,
since the muscle response to the stimulus electromagnetic is immediate, just as for the DCS.
The spatial resolution is extremely high since we can record difference of cortical response
within few millimeters. Furthermore, it does not passively record brain activity during vol‐
untary patient movements, but detect an electromyographic response evoked by the TMS.
The identification of the relationships between the lesion and the motor area was possible in
all our patients, whereas conventional MRI studies had only provided information on the
location of the lesion and its possible relationship with the anatomical structures (e.g. precen‐
tral gyrus), but no information on their functional relevance. The peculiarity of the NBS, with
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tions, cognitive activities and potential functional circuitry. fMRI technique uses BOLD
(blood oxygenation level dependent) sequences, namely a sequence able to detect increased
level of cerebral blood flow and oxygen consumption of brain areas that are activated by ap‐
propriate stimulation tests. Although it is less available, positron emission tomography
(PET) is the alternative technique that measures the oxygen or glucose consumption of acti‐
vated brain areas. Both fMRI and PET have a sufficient spatial resolution, but a low tempo‐
ral resolution. Moreover, the growth of brain tumors may transform local vascularization
and cell metabolism, for which a method sensitive to hemodynamic or metabolic changes,
may be less accurate.
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Figure 6. Preoperative MRI (upper left) and post-operative CT (upper right) imaging of a patient with a low grade
gliomas of the right pre-rolandic area. The day after surgery the patient present no motor deficits.
Finally, these examinations could be cumbersome, or even not feasible in children and in pa‐
tients with severe neurological impairments.
Navigated brain stimulation, among the methods of pre-operative brain mapping, has a
number of potential advantages. Actually, NBS possesses a very high temporal resolution,
since the muscle response to the stimulus electromagnetic is immediate, just as for the DCS.
The spatial resolution is extremely high since we can record difference of cortical response
within few millimeters. Furthermore, it does not passively record brain activity during vol‐
untary patient movements, but detect an electromyographic response evoked by the TMS.
The identification of the relationships between the lesion and the motor area was possible in
all our patients, whereas conventional MRI studies had only provided information on the
location of the lesion and its possible relationship with the anatomical structures (e.g. precen‐
tral gyrus), but no information on their functional relevance. The peculiarity of the NBS, with
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respect to the DCS, resides in the possibility of obtaining the cortical mapping preoperative‐
ly. Therefore, the surgeon gains the ability to make an accurate surgical plan before the patient
arrives in the operating room. This allows a more accurate definition of the craniotomy site
and its size, selection of extent of surgical resection prior to surgery, and last but not least, the
possibility to predict neurological  outcome of treatment and to provide a more accurate
information to the patient. In our series, for instance, the indication for surgery was primari‐
ly determined on the basis of histology presumed by imaging studies and/or medical histo‐
ry, the location and the size of the lesion, its relation with the cerebral vessels, taking also into
account patient age and the risks of comorbidity. Nevertheless, the information obtained with
NBS influenced the overall surgical strategy with a planned treatment of extensive resection
of noneloquent areas with maximal preservation of the motor area.
NBS functional maps were than “navigated” during surgical resection of the lesion and
combined with DCS. The NBS and DCS share similarities, so that the combined use is relia‐
ble and can be of great utility. The pre-operative plan, obtained on the basis of NBS, can be
applied intraoperatively with the support of DCS. The spatial deviation between DCS and
NBS data ranges within the calculated accuracy of the nTMS system, which is 5.73 mm [18].
Such precision has been documented in previous reports on nTMS accuracy, indicating that
a spatial resolution of 5 mm is obtainable [2,7,8].
Furthermore, it should be noticed that for lower extremity mapping, nTMS was possible
more frequently than DCS, most likely because of the comparatively large stimulated corti‐
cal volume, which was calculated to be 1–2 cm3 for the figure-8 coil used [9].
NBS can also map the cortical areas involved in the control of language. We attempted the
use of repetitive transcranial magnetic stimulation (rTMS), with trains of stimuli (between 5
and 10), in that the areas to be mapped are positioned deeper than the area motor of the
hand or leg, and the stimulation is made almost at "threshold" level. The use of the repetitive
stimulation increases the depth of the stimulus but the low intensity prevents the onset of
epileptic seizures. The localization is done by displaying, on the 3D reconstruction of the im‐
age of magnetic resonance imaging of the patient, the "hot spot" corresponding to the
"speech arrest", i.e. from the errors generated in the naming of objects that are shown, on a
screen, to the patient in the course of stimulation. The moments of speech arrest are filmed
by a video camera and subsequently analyzed. The method is very promising for the presur‐
gical planning, but also in the neurophysiological study of neuronal networks underlying
the function of language. In fact, previous studies have suggesteda revision of the current
view, perhaps too simplistic, that Broca's and Wernicke's areas were the only ones involved
in the control of language. Already fMRI showed that cortico-cortical connections are much
more complex [12]. However, studies in patients with intracranial lesions were found to be
more reliable when performed by nTMS; this method, in fact, does not possess the "limit" of
relying on cerebral blood flow or metabolism, which could be altered in the presence of
brain pathologies. Moreover, fMRI shows the entire cortical network underlying a specific
activity, such as aspects of language. The combination with NBS may identify the hierarchy
that exists between the different functional areas.
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A further opportunity of NBS is the possibility to be integrated in the treatment planning of
stereotactic radiosurgery. Radiosurgery is an ablative procedure, but it lacks the possibility
of intraoperative brain function mapping and monitoring. NBS is a very good candidate.
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1. Introduction
Neuroimaging has evolved from Computed Tomography (CT), CT-Positron Emission
Tomography (CT-PET) and Magnetic Resonance Imaging (MRI) scanner in 1970s and 1980s to
functional MRI (fMRI), Diffusion Tensor Imaging (DTI) and Magnetic Source Imaging (MSI)
or Magnetoencephalography-MRI (MEG-MRI) fusion in 1990s and 2000s. Anatomical and
functional neuroimages are currently regarded by most as vital in planning for brain tumors
surgery. These anatomical and functional neuroimages can be fused and exported to the
neuronavigation system in the operating theatre (Figure 1). Collectively, these images are
known as extraoperative neuroimages. On the contrary, intraoperative neuroimages are
images that obtained intraoperatively and can be exported regularly to the navigation system.
The intraoperative images can be obtained by using either intraoperative CT (iCT), MRI (iMRI)
or ultrasound [3D-iUS) [1-3]. Safer and successful brain tumors surgery requires not only
neuroimages-guided surgery but also properly defined the eloquent (important and function‐
al) cortices and monitoring of the vital areas of the brain and other organs. Awake surgery
with intraoperative brain mapping, and surgery under general anaesthesia with intraoperative
monitoring (IOM) which are guided by neuroimages are two operative techniques for brain
tumors that are currently regarded by most as gold standard [4-8]. This chapter describes the
current functional neuroimaging modalities (fMRI, DTI and MSI), brain mapping, surgery
© 2013 Idris et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
[8] Krings, T., Buchbinder, B. R., Butler, W. E., Chiappa, K. H., Jiang, H. J., Rosen, B. R.,
et al. (1997). Stereotactic transcranial magnetic stimulation: correlation with direct
electrical cortical stimulation. Neurosurgery, 41, 1319-1326.
[9] Levy, W. J., Amassian, V. E., Schmid, U. D., & Jungreis, C. (1991). Mapping of motor
cortex gyral sites non-invasively by transcranial magnetic stimulation in normal sub‐
jects and patients. Electroencephalogr Clin Neurophysiol, 43, 51-75.
[10] Lioumis, P., Zhdanov, A., Mäkelä, N., Lehtinen, H., Wilenius, J., Neuvonen, T., Han‐
nula, H., Deletis, V., Picht, T., & Mäkelä, J. P. (2012). A novel approach for document‐
ing naming errors induced by navigated transcranial magnetic stimulation. J Neurosci
Methods, 204, 349-54.
[11] Mäkelä, J. P., Vitikainen, A. M., Lioumis, P., Paetau, R., Ahtola, E., Kuusela, L., Val‐
anne, L., Blomstedt, G., & Gaily, E. (2012). Functional plasticity of the motor cortical
structures demonstrated by navigated TMS in two patients with epilepsy. Brain Stim‐
ul. May 23. [Epub ahead of print].
[12] Ojemann, G., & Mateer, C. (1979). Human language cortex: localization of memory,
syntax, and sequential motor-phoneme identification systems. Science, 205(4413),
1401-1403.
[13] Peurala, S. H., Tarkka, I. M., Juhakoski, M., Könönen, M., Karhu, J., Jäkälä, P., et al.
(2008). Restoration of normal cortical excitability and gait ability in acute stroke after
intensive rehabilitation. Cerebrovasc Dis, 26, 208-209.
[14] Picht, T., Mularski, S., Kuehn, B., Vajkoczy, P., Kombos, T., & Suess, O. (2009). Navi‐
gated transcranial magnetic stimulation for preoperative functional diagnostics in
brain tumor surgery. Neurosurgery, 93-98.
[15] Picht, T., Mularski, S., Kuehn, B., Vajkoczy, P., Kombos, T., & Suess, O. (2009). Navi‐
gated transcranial magnetic stimulation for preoperative functional diagnostics in
brain tumor surgery. Neurosurgery, 65, 93-98.
[16] Picht, T., Schulz, J., Hanna, M., Schmidt, S., Suess, O., & Vajkoczy, P. (2012). Assess‐
ment of the influence of navigated transcranial magnetic stimulation on surgical
planning for tumors in or near the motor cortex. Neurosurgery, 70(5), 1248-1256.
[17] Rothwell, J. (2010). TMS principles. Proceedings 2nd International Workshop on Navigat‐
ed Brain Stimulation in Neurosurgery, Berlin, Germany, October 08-09.
[18] Ruohonen, J., & Karhu, J. (2010). Navigated transcranial magnetic stimulation. Neuro‐
physiol Clin, 40, 7-17.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors16
Chapter 2
Functional MRI, Diffusion Tensor Imaging, Magnetic
Source Imaging and Intraoperative Neuromonitoring
Guided Brain Tumor Resection in Awake and Under
General Anaesthesia
Zamzuri Idris, W M Nazaruddin W Hassan,
Muzaimi Mustapha, Badrisyah Idris,
Rahman Izaini Ghani and Jafri Malin Abdullah
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52032
1. Introduction
Neuroimaging has evolved from Computed Tomography (CT), CT-Positron Emission
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under awake and unconscious states with intraoperative neuromonitorings as adjuncts and
techniques to plan and guide the surgeon to resect the brain tumors successfully. We also
describe briefly the current treatment modalities for residual brain tumors after the surgery
and new concept of brain oscillations and networks as derived from the functional neuroi‐
magings and awake surgery.
Figure 1. Neuronavigation system in the operating theatre (Medtronic StealthStation TREONTM cranial software; Med‐
tronic Inc., Minneapolis, USA)
2. Neuroimaging
Functional  MRI,  MSI (MEG-MRI) and transcranial  magnetic  stimulation (TMS) are three
current  extraoperative methods that  are widely used to locate the eloquent areas of  the
brain.  Functional  MRI is  based on the increase in cerebral  blood flow that  accompanies
neural  activities.  The  primary  form  of  fMRI  uses  the  blood-oxygen-level-dependent
(BOLD) contrast (Figure 2A). In contrast, functional mapping of the brain by using MSI is
based on measuring the magnetic fields generated by brain activity (Figure 2B).  A basic
neural generator of MEG is a magnetometer which consists of a pickup coil paired with a
superconducting current detector or better known as superconducting quantum interfer‐
ence  device  (SQUID).  MEG consists  of  a  rigid whole-head helmet  containing up to  306
sensors. The sampling rate can reach up to 5 kHz on all  channels.  The superconducting
sensing technology necessary to keep instrumental noise levels at less than a few femtote‐
sla per square root hertz requires cooling at -269°C with liquid helium [9]. A magnetical‐
ly  shielded  room  made  of  layers  of  metal  alloys  attenuates  external  perturbations  and
makes MEG recordings possible (Figure 2C). The equivalent current dipole (ECD) meth‐
od has been the primary means of analyzing clinical MEG data to identify the location of
source  activity.  Beamforming  is  a  relatively  new  technique  introduced  to  analyse  the
brain signals. It is useful to analyse brain activity that may involve multiple active brain
regions or networks [10].  Transcranial magnetic stimulation brain mapping is performed
by stimulating the cortex with the external figure-of-eight coil (is preferred than circular
coil) and single pulse technique, and recording the resulting motor or language responses
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(note:  repetitive  pulses  or  rTMS  is  preferred  than  single  pulse  technique  for  language
mapping) on the navigated anatomical MRI, MSI or fMRI images (see subheading 4.4).
Figure 2. A: Functional MRI depicts the motor hand area lies anterior to the tumor. B: Magnetoencephalography lo‐
calizes the area for visual evoked magnetic field. C: MEG recording.
Diffusion Tensor Imaging is an anatomical white matter imaging that is useful to elucidate
details of the white matter fibres and tracts (Figure 3A). It is an MRI-based technique that can
demonstrate white matter anatomy by measuring the directional anisotropy of water (~ non-
uniform water flow) [11]. Essentially, in the analysis of the DTI data, a tensor model is used to
represent the orientation of the fibers. If there are areas where single fiber population is
predominant, the principal diffusion direction is aligned with the white matter fiber tract
direction. By following the principal diffusion directions, we can estimate the main directions
and reconstruct the fiber tracks, process known as tractography. These reconstructions may
then be displayed in 3D, providing a detailed map of the configuration of the tracts and their
relationship to other structures [12, 13]. A variety of summary statistics have been proposed
to describe the degree to which anisotropy is evident, one of the most common being fractional
anisotropy (FA). FA tells the integrity of the fibres and ranged from 0 to 1 (Figure 3B).
Nonetheless, one should aware of possible erroneous tractography or erroneous FA values for
crossing, kissing, merging or diverging fibres which commonly occurs at subcortical short U
fibres and callosal-corona radiata-junctional areas.
Figure 3. A: Tractography shows various tracts inside the white matter. Blue signifies up-down or down-up fibres, red
signifies right-left or left-right fibres and green signifies anterior-posterior or posterior-anterior orientated fibres. B:
DTI with FA values.
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under awake and unconscious states with intraoperative neuromonitorings as adjuncts and
techniques to plan and guide the surgeon to resect the brain tumors successfully. We also
describe briefly the current treatment modalities for residual brain tumors after the surgery
and new concept of brain oscillations and networks as derived from the functional neuroi‐
magings and awake surgery.
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neural  activities.  The  primary  form  of  fMRI  uses  the  blood-oxygen-level-dependent
(BOLD) contrast (Figure 2A). In contrast, functional mapping of the brain by using MSI is
based on measuring the magnetic fields generated by brain activity (Figure 2B).  A basic
neural generator of MEG is a magnetometer which consists of a pickup coil paired with a
superconducting current detector or better known as superconducting quantum interfer‐
ence  device  (SQUID).  MEG consists  of  a  rigid whole-head helmet  containing up to  306
sensors. The sampling rate can reach up to 5 kHz on all  channels.  The superconducting
sensing technology necessary to keep instrumental noise levels at less than a few femtote‐
sla per square root hertz requires cooling at -269°C with liquid helium [9]. A magnetical‐
ly  shielded  room  made  of  layers  of  metal  alloys  attenuates  external  perturbations  and
makes MEG recordings possible (Figure 2C). The equivalent current dipole (ECD) meth‐
od has been the primary means of analyzing clinical MEG data to identify the location of
source  activity.  Beamforming  is  a  relatively  new  technique  introduced  to  analyse  the
brain signals. It is useful to analyse brain activity that may involve multiple active brain
regions or networks [10].  Transcranial magnetic stimulation brain mapping is performed
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coil) and single pulse technique, and recording the resulting motor or language responses
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(note:  repetitive  pulses  or  rTMS  is  preferred  than  single  pulse  technique  for  language
mapping) on the navigated anatomical MRI, MSI or fMRI images (see subheading 4.4).
Figure 2. A: Functional MRI depicts the motor hand area lies anterior to the tumor. B: Magnetoencephalography lo‐
calizes the area for visual evoked magnetic field. C: MEG recording.
Diffusion Tensor Imaging is an anatomical white matter imaging that is useful to elucidate
details of the white matter fibres and tracts (Figure 3A). It is an MRI-based technique that can
demonstrate white matter anatomy by measuring the directional anisotropy of water (~ non-
uniform water flow) [11]. Essentially, in the analysis of the DTI data, a tensor model is used to
represent the orientation of the fibers. If there are areas where single fiber population is
predominant, the principal diffusion direction is aligned with the white matter fiber tract
direction. By following the principal diffusion directions, we can estimate the main directions
and reconstruct the fiber tracks, process known as tractography. These reconstructions may
then be displayed in 3D, providing a detailed map of the configuration of the tracts and their
relationship to other structures [12, 13]. A variety of summary statistics have been proposed
to describe the degree to which anisotropy is evident, one of the most common being fractional
anisotropy (FA). FA tells the integrity of the fibres and ranged from 0 to 1 (Figure 3B).
Nonetheless, one should aware of possible erroneous tractography or erroneous FA values for
crossing, kissing, merging or diverging fibres which commonly occurs at subcortical short U
fibres and callosal-corona radiata-junctional areas.
Figure 3. A: Tractography shows various tracts inside the white matter. Blue signifies up-down or down-up fibres, red
signifies right-left or left-right fibres and green signifies anterior-posterior or posterior-anterior orientated fibres. B:
DTI with FA values.
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2.1. Intra- and extraoperative neuroimages and neuronavigation
fMRI, MSI and DTI images are regarded as extraoperative images. They can be fused with
anatomical images such as MRI or CT and exported to the neuronavigation. Neuronavigation
is a large computer commonly located inside the operating theatre. It helps the surgeon to
correlate and localize the eloquent areas of the brain and quickly identify the area of the lesion
[14, 15]. Nonetheless, extraoperative images are limited in several ways. They could not give
an imaging-update to the operating surgeon with the new images and they may become
invalid due to brain shift whenever there is cerebrospinal fluid leak [16]. To solve these
problems, an intraoperative imaging modality such as 3D-iUS, iCT (Figure 4) and iMRI can
update the operating surgeon with the new and current images. The ultrasound based
neuronavigation is interesting and cost a lot less than iCT or iMRI. Combination of these
neuroimages with awake brain mapping surgery is regarded by most as a gold standard for
brain tumor surgery which lies near the eloquent area of the cortex [17-23].
Figure 4. Intraoperative CT with endoscopic and neuronavigational systems.
2.2. Archimedes principle, brain shift and validness of extraoperative neuroimages
The CSF baths the brain and spinal cord, and occupies the ventricular system as well as the
subarachnoid spaces or cisterns. The average brain weights 50 g in CSF and 1400 g without
CSF [24]. The reduction in brain weight is believed to have resulted from the antigravity effect
of CSF buoyancy. In this respect, we motion that there are three ways to overcome gravity: a)
acceleration or aerodynamic force b) buoyant force and c) object with no (or negative) mass or
time. Speeding rocket or aeroplanes, with their force of accelerations, is the obvious examples
of resisting the earth gravity, whilst buoyant force achieves the same effect by reducing the
weight of an object within a buoyant setting, say in a fluid or water environment. Archimedes
in 212 BC had first coined the buoyant force as “any submerged object is subject to a greater
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pressure force on its lower surface than on its upper surface, creating a tendency for the object
to rise. This tendency is counteracted by the weight of the object, which will sink if it is heavier
than the surrounding fluid and will rise if it is lighter. If the object weights the same as an
equivalent volume of the fluid, it will be in equilibrium and remains motionless” (Figure 5).
Since we know that the average brain’s weight is only 50 g in CSF (and the actual weight is
1400 g), buoyant force created by CSF has succeeded to overcome the gravity force. In this
context, buoyant force exerts a lifting effect against gravity and creates a “floating brain”. The
buoyant environment is disturbed once either there is communication between our normal
atmosphere with intracranial compartment (gradual obliteration of buoyant environment) or
in presence of CSF leak (fast obliteration of buoyant environment)[25, 26]. During craniotomy
for brain tumor surgery, brain shift normally happens when there is removal of CSF. Shift in
the brain makes the extraoperative images used in neuronavigation fast to be invalid. In
conclusion, despite different patient’s positioning adopted during imaging and surgery, the
extraoperative images incorporated to the neuronavigation system would remain reliable as
long as no CSF leak or removal occurs at the actual surgery.
Figure 5. The Archimedes principle: any submerged object is in equilibrium and remains motionless whenever weight
of the object (F1) equals to object lower surface fluid pressure (F2).
2.3. Intraoperative neuroimages
The microgravity or buoyant environment created by CSF vanishes once the brain becomes a
non-floating organ. At time of actual surgery, opening in CSF cisterns would irrevocably lead
to leakage of CSF and hence conversion of buoyant to non-buoyant environment of the brain.
Consequently, the localisation onto or into the brain as guided by the extraoperative neuroi‐
mages would become imprecise. Thus, surgery that requires precise brain localisation should
pay meticulous attention to avoid CSF leak by appropriate positioning of the patient or by
using intraoperative neuroimages [27, 28]. Intraoperative neuroimages give updated images
to the operating neurosurgeon which can be done on a regular basis. However, note that any
extraoperative functional images that are fused with intraoperative images remain inaccurate
because of distortion of the brain in the non-buoyant environment and the brain contour itself
tends to be different in shape due to the surgery. Therefore, iCT, iMRI or 3D-iUS such as
SonoWand system (SonoWand InviteTM Elekta) appears crucially useful to guide the surgeon
on the amount and site of the residual (Figure 6), but for a precise functional brain mapping,
it is best done under awake state [15, 16, 21].
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Figure 6. Intraoperative ultrasound using SonoWand system (Elekta) by which the neurosurgeon was informed with
the new updated-brain-tumor images.
3. Brain mapping
Mapping the eloquent areas of the brain is vital prior to the definitive tumoral resection. This is
especially true for tumors located close to or within the eloquent areas of the brain. Lately, as a
result from knowledge gained from intraoperative brain mapping, the previously labeled non-
eloquent areas of the brain are no longer considered silent brain areas. These areas appeared to
be active and and involved in various loops for many brain functions including language,
movements and neurocognition. De Benedictis and Duffau in 2011 highlighted the relatively
new concept whereby the entire cerebral cortex is involved in execution of functions. The one-
to-one correspondence between cortical location and function seems inappropriate to explain
the complexity of brain processing, especially for higher functions. The brain processing is cur‐
rently viewed as many-to-one or one-to-many correlations. Many-to-one concept means multiple
brain areas are able to process a single function whilst one-to-many refers to the concept of one
region of the brain is capable in eliciting more than one brain functions [30, 31]. Intraoperative
brain mapping can be done by using either intraoperative cortical stimulating electrodes such
as Ojemann bipolar neurostimulator (Radionics, Inc., Burlington, MA) or grid/strip electrodes,
and either done under general anaesthesia or awake state. As a common practice, brain map‐
ping is done under fully awake state using bipolar neurostimulator.
3.1. Technical aspects of brain stimulation
Brain stimulation is currently regarded as important. Brain stimulation is commonly divided
into extracranial (or transcranial) and intracranial stimulations. Intracranial stimulation can be
further divided into superficial brain stimulation such as cortical-subcortical stimulation and
deep brain stimulation. The cortical-subcortical stimulation is commonly used to detect the
functional areas of the cortex and subcortical pathways (white matter tracts) prior to and after
removal of brain lesions. In contrast to superficial brain stimulation, deep brain stimulation is
currently used to treat some neurological or psychiatric diseases. Treating those diseases by
giving electrical stimulation works by altering the oscillation rates and amplitudes of the in‐
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volved networks [32-35]. Transcranial or extracranial stimulation can either be transcranial
electrical-digitimer (transcranial electrical stimulation) or magnetic stimulation coil, better
known as transcranial magnetic stimulation (TMS) which uses to map the brain motor and lan‐
guage cortices and to treat some neurological or psychiatric diseases [36-38] (see subheading
4.40). Table 1 and figure 7 depict those three common methods of brain stimulation.
Parameters commonly used in electrical brain stimulation (Type of macrostimulation)
[note: microstimulation uses glass pipette to penetrate single cell]
Direct cortical electrical stimulation
(source: neurostimulator such as
Ojemann neurostimulator)
Deep brain stimulation (DBS) (source: Internal






a) Pulse type can either be
monophasic or biphasic pulses.
a) Continuous or reverse pulse type [this
differs from mode of stimulation commonly
called: unipolar (the case or IPG is positive
and a single contact on the lead as cathode.
Commonly use because greater current
spread typically allows lower stimulation
settings) or bipolar mode [2 contacts on the
leads as anode and another as cathode –
produces narrower field of current spread or
more focus effect).
a) Bidirectional square waves (with
each cycle, one negative and one
positive pulse) or some other pulse
type such as brief pulses etc.
b) Frequency: 25 – 60 Hz (low
frequency < 30 Hz; intermediately
high frequency 30 – 100 Hz: Both
normally cause stimulatory effects).
b) Frequency range of 2 - 185 Hz (high
frequency > 100 Hz). In DBS, high frequency
stimulation or ‘hyperstimulation‘ is used
(inhibitory effect on neuronal firing) and
mostly at 130 - 185 Hz.
b) Commonly, the frequency ranges
from 50 – 130 Hz.
c) Pulse width 0.5 – 1 msec and
pulse intervals (length of time
between individual impulses; but
sometimes it can also mean pulse
width) of 1 - 4 msec.
c) Pulse width of 60 – 450 µsec. c) Single pulse or 2 - 5 train of
pulses [0.2 – 0.5 msec pulse width)
with 2 - 4 msec interstimulus
interval (pulse interval)
d) Intensity of stimulation:
microscale [0 – 0.9 mA) to
macroscale stimulation [1 – 20 mA).
d) Intensity of stimulation: 0 - 10.5 V (voltage
is mostly used) or 0.5 – 2.5 mA (current).
d) Intensity of maximum
stimulation is 200 mA
[100 to 750 V)
(note: for TMS, the stimulus
intensity is in the percentage
[0-100%], normally at 70 – 90% of
magnetic tesla)
Table 1. Comparison among three brain stimulation methods.
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Figure 7. Three methods of brain stimulation. A: Direct cortical stimulation. B: Deep brain area stimulation (in this
case, bilateral subthalamic nucleus stimulation or STN-DBS). C: Transcranial Magnetic Stimulation (TMS) using magnet‐
ic coils. Note, the induced current in the neural tissues flows in opposite direction to the current generated in the coils
and electric energy always coexist with magnetic force (electro-magnetic force).
The most crucial part of brain stimulation is the technical aspects. The elements to this include
the stimulator device, the stimulation parameters consisting of pulse type, pulse width (pulse
interval), frequency of stimulation, intensity of the stimulation and the stimulation probe. The
followings are key points mentioned by Szelenyi et al. that any neurosurgeon who practices
direct cortical electrical stimulation need to be familiar with [4]:
i. Stimulator device - Constant-current stimulators are considered safer and more
reliable than the constant-voltage stimulators. Unlike the constant-voltage stimula‐
tors, constant current stimulators deliver the current independently from the
impedance or resistance of the cortical-subcortical surface. Therefore, it is safer and
more reliable because constant current is delivered irrespective of possible changes
in resistance of brain tissues.
ii. Pulse type – It can be monophasic or biphasic pulse (Figure 8). The first phase of the
pulse should be anodal because a lower stimulation intensity is needed to see a
stimulation effect. If a monophasic pulse is used, it should be anodal or positive and
if biphasic pulse is used, it should be in an anodal/cathodal mode.
iii. Pulse width – The monophasic anodal pulse duration can vary between 0.1 – 2 msec.
For biphasic current, the duration of the pulse includes both, the positive and negative
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phases. Therefore, only half of the pulse duration is anodal and effective for stimu‐
lation.
iv. Frequency of stimulation – Transcortical stimulation requires only a low frequency
stimulation ranges from 25 – 60 Hz. The most commonly applied frequency is 50-60
Hz.
v. Intensity of the stimulation – For safety reason, the maximum transcortical stimula‐
tion intensity should not exceed 40 µC/cm2/phase and is commonly limited to 16 - 20
mA.
vi. Stimulation probe – Bipolar probe with two ball tips separated by 6 – 10 mm is our
probe of choice (Ojemann neurostimulator), the current density appears homogenous
and well concentrated at the stimulation site. In contrast, monopolar electrode (single
tip) with a frontal reference electrode would cause wider or spacious stimulation
effects that leads to the probability of stimulating brain tissues at a more distant site.
Figure 8. Monophasic and biphasic pulse type.
3.2. Intraoperative brain mapping and awake tumoral surgery
Prior to proper positioning, scalp block is performed at six sites of scalp nerve innervations
using mixture of 25 mls ropivacaine 0.75% and adrenaline 5 ug/ml. Additional 20 mls of the
same local anaesthetic is infiltrated at the pinning and incision site. Then, the patient is
positioned supine with in-situ bladder catheterisation, head fixation in flexed position with
the pins and Mayfield head clamp and the thorax is elevated to 40 degrees to ensure comfort
to the patient (Figure 9A). Neuronavigation system is arranged such that the monitor is
situated at the feet end. Prior to craniotomy, conscious sedation is achieved with dexmedeto‐
midine infusion between 0.2 – 0.5 ug/kg/hr and remifentanil target controlled infusion between
0.25 – 1 ng/ml. Oxygen is only supplied via nasal prong throughout the surgery and the patient
is not intubated at all. Needles electromyography (EMG) (or surface EMG electrodes) are
inserted into muscles thought to be related to brain mapping (Figure 9B). For the upper limbs,
dorsal interrosseus, thenar or hypothenar muscles, brachioradialis, biceps, deltoid and
pectoralis major are commonly selected. For the lower limbs, common ones include first dorsal
interrosseus, anterior tibialis, gastrocnemius, soleus and anterolateral thigh muscles. For facial
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muscles, frontalis and orbicularis oris are preferred. In addition to the above mentioned sites
for either surface or needle EMG, surface EMG electrode is commonly used for mapping of
pharngeal region (anterior neck). Needles EMG are considered important because of their
ability to detect muscular response with low amplitudes of stimulation parameters. With that
low stimulation parameters, afterdischarges will unlikely occur, intraoperative seizures are
prevented and true effect of stimulation is identified. This principle is thought as important
for cases with history of focal seizures and tumor is located near the cortical areas which elicit
spikes, polyspikes or spike- or sharpwaves on MEG [39, 40]. Registration of neuronavigation
system is made after the head is fixed to the Mayfield head clamp. Extraoperative neuroimages
are then used to localise the tumor and functional cortical areas. The planned skin incision is
marked to cover the tumor and the identified eloquent areas noted on fMRI, DTI and/or MEG.
The craniotomy is made large enough to expose brain cortex for mapping purposes. Surgical
patties that are soaked with lignocaine are placed onto the dura for few minutes and all sedative
medications are stopped. Patient is started to be fully alert on opening the dura layer. Neuro‐
navigation probe is then used to confirm the tumor, eloquent cortex and areas identified on
extraoperative neuroimages. CSF leak is kept minimal by proper positioning of the patient’s
head and no arachnoid opening is made until tumoral resection begun.
Figure 9. A: Awake craniotomy procedure and B: Intraoperative neuromonitoring with EMGs or motor evoked poten‐
tials (MEPs).
Brain mapping is acquired using Ojemann cortical neurostimulator. Stimulating parameters
are set normally at anodal biphasic pulse polarity, 50-60 Hz pulse frequency, 0.5-1 milliseconds
pulse width/duration (ranges from 0.1 to 2 ms) or pulse intervals and current starting at 1 mA,
then increasing gradually until the response is obtained. The sensory response in forms of
abnormal sensations is normally noted at 3 – 4 mA stimulus intensity, the motor response is
higher at around 3 – 5 mA, manifested as movements or contractions (important to ask the
feeling of pharyngeal muscles contraction inside the throat) and EMG responses. If negative
motor phenomenon is suspected, especially mapping at the region of association motor cortex,
the stimulation induced muscle inhibition can be done by asking the patient to continuously
extend and flex the wrist while doing the stimulation (the movement is inhibited by the
stimulation). For the language assessment, the longer duration of stimulation is oftenly needed
[2 msec pulse width) and every stimulation should start after the patient has said an intro‐
ductory sentence. The speech or counting arrest is normally noted at 4 – 6 mA. Although no
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convincing data to support the association between preoperative epilepsy and intraoperative
seizures, in the case of a patient known to have seizures or epilepsy, the following precautions
are undertaken for cortical stimulation [39, 41]:
i. The antiepileptic drugs must be served prior and on day of surgery (Consider to load
the antiepileptic prior to craniotomy in operating theatre if anti-epileptics were
missed).
ii. Get the anaesthetist prepared for intravenous diazepam or lorazepam throughout
the procedure.
iii. The operating neurosurgeon must ensure the cold isotonic saline or Hartmann’s/
Ringer solution is available when needed.
iv. The bipolar stimulating parameters should be started at low values. For patient with
history of focal seizure, stimulation is started at low values, example: 20 - 50 Hz pulse
frequency, highest micro or lowest macroscale stimulation intensity which subse‐
quently increase to higher values. Needle EMG to detect the responses and nearby
grid or strip electrodes to detect afterdischarges are preferred.
v. Short train or train-of-two to five stimulation technique by using monopolar probe
or strip electrodes [which commonly used for continuous motor evoked potential
(MEP) monitoring] thought to reduce the risk (anodal constant current, or 2-5 pulses,
individual pulse width of 0.3 – 0.5 msec and stimulus interval 3 - 4 msec).
vi. Given enough resting time prior to restimulation (or bath the cortex with cold saline
prior to restimulation). Never stimulate same cortical area twice successively
[stimulate the cortex which is located closed to and far from the lesion alternately].
Cold irrigation of brain surface is made possible by preparing cold isotonic saline or cold
Hartmann’s/Ringer solution. This is important to treat episode of seizures or afterdischarges
during cortical stimulation. Afterdischarges are type of clinical or subclinical seizure record‐
ings which persist despite stopping the stimulation. These can be in the form of polyspike
bursts, spike-waves, sequential spikes, rhythmic waves or mixed, usually with more than 10
seconds duration or with clinical seizures. Figure 10 and 11 show the intraoperative brain
mapping procedures in our centre and table 2 shows the summary of stimulation effects of
various common brain areas as reported by Duffau [42].
The removal of the tumor is made after confirming the functions of identified cortex. Addi‐
tional knowledge to the operating surgeon regarding the functions of the adjacent cortices
would remind him not to injure them during tumoral resection. In addition, knowledge gained
from brain mapping can be used to supplement knowledge in neurosciences [43, 44]. For tumor
that involves eloquent cortices such as motor cortex, maximal tumoral resection is the aim
since most patients already presented with gross neurological deficits secondary to the tumor.
If no or minimal deficit is noted prior to definitive surgery, tumoral resection should be made
less aggressive by sparing those in the eloquent cortices. Depending upon the intraoperative
fresh frozen biopsy results (if no biopsy done prior to excision), this tumoral residual volume
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muscles, frontalis and orbicularis oris are preferred. In addition to the above mentioned sites
for either surface or needle EMG, surface EMG electrode is commonly used for mapping of
pharngeal region (anterior neck). Needles EMG are considered important because of their
ability to detect muscular response with low amplitudes of stimulation parameters. With that
low stimulation parameters, afterdischarges will unlikely occur, intraoperative seizures are
prevented and true effect of stimulation is identified. This principle is thought as important
for cases with history of focal seizures and tumor is located near the cortical areas which elicit
spikes, polyspikes or spike- or sharpwaves on MEG [39, 40]. Registration of neuronavigation
system is made after the head is fixed to the Mayfield head clamp. Extraoperative neuroimages
are then used to localise the tumor and functional cortical areas. The planned skin incision is
marked to cover the tumor and the identified eloquent areas noted on fMRI, DTI and/or MEG.
The craniotomy is made large enough to expose brain cortex for mapping purposes. Surgical
patties that are soaked with lignocaine are placed onto the dura for few minutes and all sedative
medications are stopped. Patient is started to be fully alert on opening the dura layer. Neuro‐
navigation probe is then used to confirm the tumor, eloquent cortex and areas identified on
extraoperative neuroimages. CSF leak is kept minimal by proper positioning of the patient’s
head and no arachnoid opening is made until tumoral resection begun.
Figure 9. A: Awake craniotomy procedure and B: Intraoperative neuromonitoring with EMGs or motor evoked poten‐
tials (MEPs).
Brain mapping is acquired using Ojemann cortical neurostimulator. Stimulating parameters
are set normally at anodal biphasic pulse polarity, 50-60 Hz pulse frequency, 0.5-1 milliseconds
pulse width/duration (ranges from 0.1 to 2 ms) or pulse intervals and current starting at 1 mA,
then increasing gradually until the response is obtained. The sensory response in forms of
abnormal sensations is normally noted at 3 – 4 mA stimulus intensity, the motor response is
higher at around 3 – 5 mA, manifested as movements or contractions (important to ask the
feeling of pharyngeal muscles contraction inside the throat) and EMG responses. If negative
motor phenomenon is suspected, especially mapping at the region of association motor cortex,
the stimulation induced muscle inhibition can be done by asking the patient to continuously
extend and flex the wrist while doing the stimulation (the movement is inhibited by the
stimulation). For the language assessment, the longer duration of stimulation is oftenly needed
[2 msec pulse width) and every stimulation should start after the patient has said an intro‐
ductory sentence. The speech or counting arrest is normally noted at 4 – 6 mA. Although no
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convincing data to support the association between preoperative epilepsy and intraoperative
seizures, in the case of a patient known to have seizures or epilepsy, the following precautions
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i. The antiepileptic drugs must be served prior and on day of surgery (Consider to load
the antiepileptic prior to craniotomy in operating theatre if anti-epileptics were
missed).
ii. Get the anaesthetist prepared for intravenous diazepam or lorazepam throughout
the procedure.
iii. The operating neurosurgeon must ensure the cold isotonic saline or Hartmann’s/
Ringer solution is available when needed.
iv. The bipolar stimulating parameters should be started at low values. For patient with
history of focal seizure, stimulation is started at low values, example: 20 - 50 Hz pulse
frequency, highest micro or lowest macroscale stimulation intensity which subse‐
quently increase to higher values. Needle EMG to detect the responses and nearby
grid or strip electrodes to detect afterdischarges are preferred.
v. Short train or train-of-two to five stimulation technique by using monopolar probe
or strip electrodes [which commonly used for continuous motor evoked potential
(MEP) monitoring] thought to reduce the risk (anodal constant current, or 2-5 pulses,
individual pulse width of 0.3 – 0.5 msec and stimulus interval 3 - 4 msec).
vi. Given enough resting time prior to restimulation (or bath the cortex with cold saline
prior to restimulation). Never stimulate same cortical area twice successively
[stimulate the cortex which is located closed to and far from the lesion alternately].
Cold irrigation of brain surface is made possible by preparing cold isotonic saline or cold
Hartmann’s/Ringer solution. This is important to treat episode of seizures or afterdischarges
during cortical stimulation. Afterdischarges are type of clinical or subclinical seizure record‐
ings which persist despite stopping the stimulation. These can be in the form of polyspike
bursts, spike-waves, sequential spikes, rhythmic waves or mixed, usually with more than 10
seconds duration or with clinical seizures. Figure 10 and 11 show the intraoperative brain
mapping procedures in our centre and table 2 shows the summary of stimulation effects of
various common brain areas as reported by Duffau [42].
The removal of the tumor is made after confirming the functions of identified cortex. Addi‐
tional knowledge to the operating surgeon regarding the functions of the adjacent cortices
would remind him not to injure them during tumoral resection. In addition, knowledge gained
from brain mapping can be used to supplement knowledge in neurosciences [43, 44]. For tumor
that involves eloquent cortices such as motor cortex, maximal tumoral resection is the aim
since most patients already presented with gross neurological deficits secondary to the tumor.
If no or minimal deficit is noted prior to definitive surgery, tumoral resection should be made
less aggressive by sparing those in the eloquent cortices. Depending upon the intraoperative
fresh frozen biopsy results (if no biopsy done prior to excision), this tumoral residual volume
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can mostly be treated conservatively with regular clinical assessment and imaging (mostly for
low grade tumors) or by precision radiation therapy (for high grade tumors) either using
stereotactic radiotherapy (SRT), radiosurgery (SRS) or intraoperative radiotherapy (IORT) and
chemotherapy. Sometimes, patient presents with focal seizures and radiologically as well as
histologically confirmed benign looking tumor is found at the eloquent area of the cortex,
resection of this tumor should be done after thorough investigation to determine if the epileptic
focus arises outside the tumoral and eloquent areas. If so, resection of the tumor (simple
surgery) is made together with resection of normal looking and non eloquent cortical epileptic
Site of electrical stimulation Effects
Left Insula Articulatory disturbances or autonomic disturbances
Left dominant supplementary motor area Transient speech disorders or mild objective language deficits.
Later mild word finding difficulty. Other possibility: agraphia
Left superior longitudinal fascicle (subcoritcal and
lateral to the ventricle)
Conduction aphasia (poor repetition), disconnection syndrome
Left inferior frontal gyrus Reduce capacity for articulate speech/Broca or motor aphasia
Left superior posterior temporal gyrus Wernicke aphasia/Disturbance in speech comprehension
Left angular gyrus Alexia with agraphia
Right hemispheric language cortex (language
disturbances noted during patient having seizures
or on presurgical neuropshychological assessments
or language activation in the right hemisphere
noted on fMRI)
Crossed aphasia
Temporo-parietal-occipital or optic radiation areas Transient visual disturbance such as perception of shadow or
illusion at certain visual field quadrant
Right angular or temporal gyrus Complex vestibulo-somatosensory sensations such as out-of-body
sensory illusion
Right superior temporal gyrus or supramarginal
gyrus or superior longitudinal fascicle
Deficit in visual search (transient spatial neglect)
Left parietal lobe (near left angular gyrus) Impaired calculation (multiplication and substraction)
Temporo-parietal or frontal areas Recent memory can be affected (especially, left temporal cortex)
Anterior temporal lobe or dominant frontal
premotor area
Famous face recognition affected
Frontal eye field Ocular deviation or saccade suppression (inattention)
Right posterior perisylvian cortex Facial emotion recognition
Primary motor cortex Movements or motor evoked response
Primary sensory cortex Abnormal sensations
Table 2. The stimulation effects of various common brain areas.
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focus (epilepsy surgery). However, if the adjacent normal looking cortical epileptic focus is an
eloquent area, multiple subpial transections by using epilepsy knife is a more appropriate
choice [45]. The tumoral edge, margin between abnormal and normal looking cortices are
stimulated to identify eloquent cortices and important white matter fibres. Information gained
from DTI can be used to identify white matter fibres which normally located at the base of the
tumor. Therefore, neurostimulation should also be made at the base to identify and confirm
those tracts which normally feasible at the end of the surgery. Hemostasis was properly
secured prior to closure of the dura. Closure is made in layers after resedation. The patient is
normally observed for 24 hours in neurointensive care prior to discharge to a normal ward.
Figure 10. A: Intraoperative brain mapping prior to tumor resection. When areas labeled as A, C, 4 and 5 are stimulat‐
ed, one would note facial twitching and EMG responses. B: After tumor resection, subcortical stimulation should be
done to assess the white matter tracts. C: DTI shows splaying of white matter fibres around the tumor. D: DTI taken
months after the surgery revealed more white matter fibres at previous tumor site.
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can mostly be treated conservatively with regular clinical assessment and imaging (mostly for
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stereotactic radiotherapy (SRT), radiosurgery (SRS) or intraoperative radiotherapy (IORT) and
chemotherapy. Sometimes, patient presents with focal seizures and radiologically as well as
histologically confirmed benign looking tumor is found at the eloquent area of the cortex,
resection of this tumor should be done after thorough investigation to determine if the epileptic
focus arises outside the tumoral and eloquent areas. If so, resection of the tumor (simple
surgery) is made together with resection of normal looking and non eloquent cortical epileptic
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Later mild word finding difficulty. Other possibility: agraphia
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Conduction aphasia (poor repetition), disconnection syndrome
Left inferior frontal gyrus Reduce capacity for articulate speech/Broca or motor aphasia
Left superior posterior temporal gyrus Wernicke aphasia/Disturbance in speech comprehension
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disturbances noted during patient having seizures
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or language activation in the right hemisphere
noted on fMRI)
Crossed aphasia
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illusion at certain visual field quadrant
Right angular or temporal gyrus Complex vestibulo-somatosensory sensations such as out-of-body
sensory illusion
Right superior temporal gyrus or supramarginal
gyrus or superior longitudinal fascicle
Deficit in visual search (transient spatial neglect)
Left parietal lobe (near left angular gyrus) Impaired calculation (multiplication and substraction)
Temporo-parietal or frontal areas Recent memory can be affected (especially, left temporal cortex)
Anterior temporal lobe or dominant frontal
premotor area
Famous face recognition affected
Frontal eye field Ocular deviation or saccade suppression (inattention)
Right posterior perisylvian cortex Facial emotion recognition
Primary motor cortex Movements or motor evoked response
Primary sensory cortex Abnormal sensations
Table 2. The stimulation effects of various common brain areas.
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focus (epilepsy surgery). However, if the adjacent normal looking cortical epileptic focus is an
eloquent area, multiple subpial transections by using epilepsy knife is a more appropriate
choice [45]. The tumoral edge, margin between abnormal and normal looking cortices are
stimulated to identify eloquent cortices and important white matter fibres. Information gained
from DTI can be used to identify white matter fibres which normally located at the base of the
tumor. Therefore, neurostimulation should also be made at the base to identify and confirm
those tracts which normally feasible at the end of the surgery. Hemostasis was properly
secured prior to closure of the dura. Closure is made in layers after resedation. The patient is
normally observed for 24 hours in neurointensive care prior to discharge to a normal ward.
Figure 10. A: Intraoperative brain mapping prior to tumor resection. When areas labeled as A, C, 4 and 5 are stimulat‐
ed, one would note facial twitching and EMG responses. B: After tumor resection, subcortical stimulation should be
done to assess the white matter tracts. C: DTI shows splaying of white matter fibres around the tumor. D: DTI taken
months after the surgery revealed more white matter fibres at previous tumor site.
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Figure 11. Intraoperative brain mapping under awake state. Cavernoma is identified on image guided system (IGS) or
neuronavigation which then resected after complete mapping of adjacent cortical areas.
3.3. Extraoperative brain mapping
Other method of brain mapping is known as extraoperative brain mapping which can be done
by using extraoperative neuroimages such as fMRI, MSI, transmagnetic stimulation (TMS) and
subdural electrodes (Figure 12A). Subdural grid or strip electrodes (electrocorticography [EcoG]
or intracranial EEG [iEEG]) are commonly used to record the epileptic discharges and hence
identify the epileptic focus prior to resection (mapping the epileptogenic zones) [46]. They can
also be used to stimulate the cortex to identify the functional areas of the cortex and to detect
afterdischarges during cortical stimulation (functional brain mapping). Brain mapping using
grid or strip electrodes are commonly used to identify the language functional areas in cases
where the tumor lies closed to language cortices [47]. The electrodes are implanted and secured
adequately, clear intraoperative surgical images captured and a thorough language assess‐
ment is completed outside the operating theatre. This method is preferred because: a) calmer
and appropriate environment outside the operating theatre, b) absence of any residual sedative
effects from the drugs used during craniotomy and c) ample time to assess various language
functions optimally.
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Combined extra- and intraoperative brain mapping is used in our institution. Our findings in
comparing extra- with intraoperative brain mapping are in agreement with others, yielding
MSI or MEG-MRI signals correlated better with intraoperative cortical stimulation for motor
cortices (Figure 12B)[48]. The maximum intraoperative motor response is noted at area which
corresponds with area of maximum magnetic signal or vector for motor evoked task. None‐
theless, the information obtained from fMRI should not be regarded as totally unreliable, this
is because multiple areas or networks have been shown to be involved in cognitive or motor
tasks at different scales [31, 49]. Our experience in awake surgery did show similar findings
whereby multiple areas at opposite hemisphere recorded using scalp EEG had shown multiple
evoked responses to the electrical stimulation. This finding is further elaborated under the
heading of brain waves, oscillations and networks.
Figure 12. A: Grid electrodes are commonly used to map, stimulate the cortex and to detect afterdischarges. B: Com‐
bined extra- and intraoperative information gained from various modalities.
The drawback of brain mapping using fMRI, MSI, TMS is anatomical inaccuracy due to brain
shift during surgery and technologically speaking, they lack reliability at an individual scale
[42]. Likewise, extraoperative brain mapping with subdural electrodes is limited in terms of
inability to stimulate or map the subcortical areas (Figure 12A). Therefore, intraoperative brain
mapping of cortical-subcortical brain areas using bipolar probe neurostimulation is regarded
as more valid and adaptable than extraoperative brain mapping methods [50]. Nonetheless,
not all patients with brain tumors can be operated in awake state. The exclusion criteria include:
a) deep seated tumor, b) very young (< 14 years old) or elderly patient (> 65 years old), c) non-
educated or non-motivated patients, d) agitative or fretful patients, e) demented patients, and
f) presence of other co-morbidity. In such cases, surgery under general anaesthesia is fre‐
quently undertaken and therefore new methods in ensuring safety to the patients are required.
In that respect, intraoperative monitoring (IOM) seems as an ideal option where it can monitor
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inability to stimulate or map the subcortical areas (Figure 12A). Therefore, intraoperative brain
mapping of cortical-subcortical brain areas using bipolar probe neurostimulation is regarded
as more valid and adaptable than extraoperative brain mapping methods [50]. Nonetheless,
not all patients with brain tumors can be operated in awake state. The exclusion criteria include:
a) deep seated tumor, b) very young (< 14 years old) or elderly patient (> 65 years old), c) non-
educated or non-motivated patients, d) agitative or fretful patients, e) demented patients, and
f) presence of other co-morbidity. In such cases, surgery under general anaesthesia is fre‐
quently undertaken and therefore new methods in ensuring safety to the patients are required.
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the functions of the neurons and nerve tracts of the nervous system during state of uncon‐
sciousness [6, 7, 51].
4. Intraoperative neuromonitoring for brain tumor surgery
Intraoperative monitoring or neuromonitoring (IOM) is an electrophysiological technique to
monitor the functions of neurons and/or nerve tracts during surgery which provides infor‐
mation regarding functional integrity of nervous system in a patient who is anaesthetized and
otherwise could not be examined neurologically. IOM consists of somatosensory evoked
potential (SSEP), motor evoked potential (MEP), brainstem auditory evoked potential (BAEP),
visual evoked potential (VEP), electromyography (EMG) and electroencephalography (EEG).
IOM records spontaneous activity for averaged EEG and non averaged EMG, and evoked
response resulted from external stimulation for averaged values of VEP, BAEP, SSEP and MEP.
The recorded spontaneous activities are affected by factors such as ischaemia, mechanical
injury, blood pressure, body temperature, anaesthetic regime, electrocardiography, electrical
interference and muscle activity. During monitoring, ones should be watchful of: a) drop in
the amplitude of the response, b) increase in the latency of the response and c) change in the
waveform. The goals of IOM are therefore to identify impaired function along the monitored
pathways, to alert the surgeon to any impending complications and to reduce risk of postop‐
erative neurological sequelae.
Figure 13. A: Intraoperative neuromonitoring set-up in our operating theatre B: Patient was operated under general
anaesthesia with various neuromonitorings.
In general, alarms in neuromonitoring include evoked potentials of ≥ 50% reduction in am‐
plitude and/or increment in latency of ≥ 10%; for EMGs, a change in morphology; and for
EEGs monitoring as hints for impending ischaemia or mechanical compression, a decrease
or loss in high frequency component, an increase in high amplitude of slower component,
burst suppression (periods of silence alteration with periods of activity) which occurs typi‐
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cally in more severe ischaemia and finally flat EEG which is the severest form of an insult.
Figure 13A and B show typical IOM set-up in our operating theatre.
4.1. Upper and lower limbs SSEP
Somatosensory evoked potentials monitor the status of ascending white matter fibres from
upper or lower limbs. The recording electrodes are situated strategically at certain points along
the monitored pathways, for instance, the Erb point for upper limb SSEP commonly records
the N9 waveform generated at the brachial plexus (N for negativity - the wave is deflected
upwards and P for positivity - the wave is deflected downwards, its amplitude or shape is
important; values 9 signifies the expected time for electrical wave to reach the recorded point
from the stimulation site in ‘milliseconds‘ or better known as latency. Velocity is therefore value
of measured distance with a tape from the stimulus site to the recorded site and divided with
its latency). Table 3 summarises the stimulation parameters, stimulation and recording sites
and examples of surgeries that require these types of monitoring.
Upper limb SSEP (ULSSEP)
Stimulation parameters Stimulation and Recording Sites Surgeries requiring ULSSEP and
tips
Stimulus duration: 250 usec.
Stimulus intensity: 20 - 30 mA
Stimulus rate: 4 - 5 Hz.
(note: distal stimulation and
recording proximally in the direction
in which physiological sensory
conduction occurs is known as
orthodromic. Antidromic study or
method is the reverse)
Stimulation site:
Median nerve has the most sensory
connections within the palm of the hand
therefore optimal choice for obtaining
ULSSEP. Stimulate the ulnar nerve for cases
where T1 nerve root is at risk since median
nerve is only innervated by C6 - 7 nerve
roots.
Recording site:
a) Erbs - Generator site is Brachial plexus:
waveform N9
b) C2 (cervical level 2) Cervical/medullary:
wavefrom N13
c) CP3 - Left somatosensory cortex:
wavefrom N20 - P25








syringomyelia, intra and extra dural
spinal tumors.
Damage to the spinal cord or cortex
should never result in a loss of the
Erbs point. Loss of the Erbs point (N9)
indicates a peripheral injury or
decrease temperature of the arm.
Always be sure of exactly where the
lesion is located on the patient you
are about to monitor. It helps
predicting when and where a
change may occur during surgery
(peak monitoring hours)
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the functions of the neurons and nerve tracts of the nervous system during state of uncon‐
sciousness [6, 7, 51].
4. Intraoperative neuromonitoring for brain tumor surgery
Intraoperative monitoring or neuromonitoring (IOM) is an electrophysiological technique to
monitor the functions of neurons and/or nerve tracts during surgery which provides infor‐
mation regarding functional integrity of nervous system in a patient who is anaesthetized and
otherwise could not be examined neurologically. IOM consists of somatosensory evoked
potential (SSEP), motor evoked potential (MEP), brainstem auditory evoked potential (BAEP),
visual evoked potential (VEP), electromyography (EMG) and electroencephalography (EEG).
IOM records spontaneous activity for averaged EEG and non averaged EMG, and evoked
response resulted from external stimulation for averaged values of VEP, BAEP, SSEP and MEP.
The recorded spontaneous activities are affected by factors such as ischaemia, mechanical
injury, blood pressure, body temperature, anaesthetic regime, electrocardiography, electrical
interference and muscle activity. During monitoring, ones should be watchful of: a) drop in
the amplitude of the response, b) increase in the latency of the response and c) change in the
waveform. The goals of IOM are therefore to identify impaired function along the monitored
pathways, to alert the surgeon to any impending complications and to reduce risk of postop‐
erative neurological sequelae.
Figure 13. A: Intraoperative neuromonitoring set-up in our operating theatre B: Patient was operated under general
anaesthesia with various neuromonitorings.
In general, alarms in neuromonitoring include evoked potentials of ≥ 50% reduction in am‐
plitude and/or increment in latency of ≥ 10%; for EMGs, a change in morphology; and for
EEGs monitoring as hints for impending ischaemia or mechanical compression, a decrease
or loss in high frequency component, an increase in high amplitude of slower component,
burst suppression (periods of silence alteration with periods of activity) which occurs typi‐
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cally in more severe ischaemia and finally flat EEG which is the severest form of an insult.
Figure 13A and B show typical IOM set-up in our operating theatre.
4.1. Upper and lower limbs SSEP
Somatosensory evoked potentials monitor the status of ascending white matter fibres from
upper or lower limbs. The recording electrodes are situated strategically at certain points along
the monitored pathways, for instance, the Erb point for upper limb SSEP commonly records
the N9 waveform generated at the brachial plexus (N for negativity - the wave is deflected
upwards and P for positivity - the wave is deflected downwards, its amplitude or shape is
important; values 9 signifies the expected time for electrical wave to reach the recorded point
from the stimulation site in ‘milliseconds‘ or better known as latency. Velocity is therefore value
of measured distance with a tape from the stimulus site to the recorded site and divided with
its latency). Table 3 summarises the stimulation parameters, stimulation and recording sites
and examples of surgeries that require these types of monitoring.
Upper limb SSEP (ULSSEP)
Stimulation parameters Stimulation and Recording Sites Surgeries requiring ULSSEP and
tips
Stimulus duration: 250 usec.
Stimulus intensity: 20 - 30 mA
Stimulus rate: 4 - 5 Hz.
(note: distal stimulation and
recording proximally in the direction
in which physiological sensory
conduction occurs is known as
orthodromic. Antidromic study or
method is the reverse)
Stimulation site:
Median nerve has the most sensory
connections within the palm of the hand
therefore optimal choice for obtaining
ULSSEP. Stimulate the ulnar nerve for cases
where T1 nerve root is at risk since median
nerve is only innervated by C6 - 7 nerve
roots.
Recording site:
a) Erbs - Generator site is Brachial plexus:
waveform N9
b) C2 (cervical level 2) Cervical/medullary:
wavefrom N13
c) CP3 - Left somatosensory cortex:
wavefrom N20 - P25








syringomyelia, intra and extra dural
spinal tumors.
Damage to the spinal cord or cortex
should never result in a loss of the
Erbs point. Loss of the Erbs point (N9)
indicates a peripheral injury or
decrease temperature of the arm.
Always be sure of exactly where the
lesion is located on the patient you
are about to monitor. It helps
predicting when and where a
change may occur during surgery
(peak monitoring hours)
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Lower limb SSEP (LLSSEP)
Stimulation parameters Stimulation and Recording Sites Surgeries requiring LLSSEP and
tips
Stimulus duration: 250 usec.
Stimulus intensity: 20 - 30 mA




a) C2 (cervical level 2) - Generator site is
cervical/medullary: waveform N31
b) CPz - Midline somatosensory cortex:
waveform N37-P45
c) CP3 - Left somatosensory cortex:
waveform N37-P45







cord, syringomyelia, spinal tumor.
LLSSEP can be difficult to obtain
especially in older patients or those
with oedema surrounding the
ankles. In this context, do increase
the stimulus intensity to 40 - 50 mA
[2X)
Loss of LLSSEP is not always an
indicator of spinal cord or brain
injury, decrease in response can be
due to peripheral injury.
If U/LLSSEP showed partial or total
recovery of the responses by the end,
often indicates a positive outcome.
Table 3. Summary of stimulation parameters, stimulation and recording sites and examples of surgeries that require
SSEP monitorings.
4.2. Brainstem auditory evoked potentials (BAEP)
BAEP monitors the auditory pathways from peripheral to central components. Auditory clicks
are delivered directly to the external auditory canal via the foams that are firmly secured and
the responses were recorded at A1 and A2 sites (superior to the ears). In BAEP, there are 7
waves generated, each wave or peak has a specific generator site, loss of a particular peak can
help you locate where the intraoperative injury has occurred. Figure 14 shows the pattern of
BAEP waveforms. The putative generator sites of the major components of the BAEPs are as
follows: Peak I - post-synaptic distal cochlear nerve; Peak II - ipsilateral cochlear nucleus in
the upper medulla; Peak III - superior olivary complex in the pons (ipsi and contralateral);
Peak IV - ascending lateral lemniscus in the pons (ipsi and contralateral); Peak V - inferior
colliculus in the midbrain (ipsi and contralateral); Peak VI - medial geniculate in the thalamus
and Peak VII - thalamo-cortical auditory radiations or auditory cortex. BAEPs are primarily
analyzed for the presence of waves I, III, and V; waves II and IV have been found to be
inconsistent even in normal adults, therefore not considered significant for clinical interpre‐
tation [52]. Wave V is the most clearly defined because it has the largest amplitude and a
characteristic sharp drop immediately after it and the wave that most likely to be present
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despite hearing deficits and manipulation of stimulation and recording parameters. Wave V
of the BAEP is therefore considered as the most important component of BAEP [52, 53].
Figure 14. Brainstem auditory evoked potential (BAEP) waveforms.
Interpreting BAEP (also SSEP/MEP) requires baselines waveforms. Baselines are ideally
obtained just prior to surgical manipulation and after positioning in the operating theatre as a
mean of comparison to subsequent averages throughout the case in order to detect any
changes. BAEPs that are reliably recorded intraoperatively provide good indication of good
neurological outcome. Transient changes are often associated with good prognosis, examples:
retraction, manipulation, or compression of the auditory nerve, cerebellum, or brainstem tend
to produce transient and reversible changes. Note that these changes usually manifest as
increases in latency but with persistence of the insult, loss of BAEP components may occur
that could lead to signficant neurological deficits. Specifically, criteria for evaluation of BAEP
changes are based on two variables:
i. Latency (timing) - Absolute latency for waves I, III, and V and interpeak latency for
waves I-III, III-V, and I-V
ii. Amplitude - Amplitude of waves I and V and amplitude ratio of wave V/I
Generally accepted standard of significant change is a latency increase of peak V exceeding
1.5 ms and a decrease of 50% or more in amplitude [52, 53]. Good communication between the
surgeon and neurophysiologist is vital to detect early any significant changes which can urge
fast intervention by the surgeon and a subsequent change in the surgical procedure and
outcomes. Table 4 summarises the stimulation parameters, stimulation and recording sites and
recommended types of surgery for BAEP.
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Lower limb SSEP (LLSSEP)
Stimulation parameters Stimulation and Recording Sites Surgeries requiring LLSSEP and
tips
Stimulus duration: 250 usec.
Stimulus intensity: 20 - 30 mA
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mean of comparison to subsequent averages throughout the case in order to detect any
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neurological outcome. Transient changes are often associated with good prognosis, examples:
retraction, manipulation, or compression of the auditory nerve, cerebellum, or brainstem tend
to produce transient and reversible changes. Note that these changes usually manifest as
increases in latency but with persistence of the insult, loss of BAEP components may occur
that could lead to signficant neurological deficits. Specifically, criteria for evaluation of BAEP
changes are based on two variables:
i. Latency (timing) - Absolute latency for waves I, III, and V and interpeak latency for
waves I-III, III-V, and I-V
ii. Amplitude - Amplitude of waves I and V and amplitude ratio of wave V/I
Generally accepted standard of significant change is a latency increase of peak V exceeding
1.5 ms and a decrease of 50% or more in amplitude [52, 53]. Good communication between the
surgeon and neurophysiologist is vital to detect early any significant changes which can urge
fast intervention by the surgeon and a subsequent change in the surgical procedure and
outcomes. Table 4 summarises the stimulation parameters, stimulation and recording sites and
recommended types of surgery for BAEP.
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Brainstem auditory evoked potentials (BAEP)
Stimulation parameters Stimulation and Recording Sites Surgeries requiring BAEP
Stimulus duration: 100 usec.
Stimulus intensity: 100 – 120 peSPL.
Stimulus rate: 11 to 30 Hz.
Stimulation site
Auditory clicks delivered directly to the
external auditory canal.
Recording site
a) A1 - Left auditory pathway and
brainstem
b) A2 - Right auditory pathway and
brainstem
Skullbase tumor, posterior fossa tumor,
acoustic neuroma, CPA tumor,
microvascular decompression, basilar
aneurysm, post fossa AVM and EC-IC
bypass.
Table 4. Summary of stimulation parameters, stimulation and recording sites and recommended types of surgery for
BAEP.
4.3. Electromyography (EMG) and F-wave
Any electrical or magnetic stimulation along the motor pathways will  generate involved
muscles compound evoked or action potentials, better known as CMAP [compound mus‐
cles evoked/action potential – a type of motor evoked potential (MEP) and/or EMG (mus‐
cle  activity).  IOM  that  uses  EMG  does  monitor  wave  as  well  as  its  sound.  On  some
occasions, muscles twitching, contraction or movement can be noted during the monitor‐
ing. It is used during resection of tumor that is located close to motor nerves, for instan‐
ces,  cerebellopontine  angle  (CPA)  tumoral  surgery  whereby  muscles  innervated  by  the
facial nerve (orbicularis oris, oculi and nasalis) are monitored using EMGs. The most im‐
portant factor affecting EMG monitoring is the depth of muscle paralysis. This can be de‐
termined by delivering a train of four electrical pulses at approximately 25 mA to usually
median or  facial  nerve,  and observing resulting number  of  twitches:  four  twitches  sug‐
gesting no paralysis whereas zero twitches suggesting complete paralysis. For monitoring
purposes, ones should have at least 3 twitches in order to detect EMG activity. Interpreta‐
tion criteria for significant EMG activity are:
i. Sustained firing of a high frequency train lasting for tens of seconds
ii. Large bursts of EMG activity of complex morphology
iii. Sudden bursts of high amplitude spikes
These patterns of activity are usually indicative of nerve irritation but also confirm that the
pathway to the specific muscles are intact. Other tips during monitoring are always helpful to
turn the volume up high on EMG monitoring machine so that one can hear the EMG activity.
If a nerve root can not be electrically stimulated after repeated trials, it may be safe to conclude
that the nerve is no longer functionally intact. Figure 15 illustrates the muscle responses that
you might get from stimulating the motor cortex, motor pathway, root or nerve.
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Figure 15. Muscle recording from motor cortical stimulation produces CMAP (which is a type of MEP) or 3 subtypes
EMG responses (note: the MEP and EMG monitorings normally display on two different monitors).
F waves (F for foot where they were first described) are a type of late motor response. When
a motor nerve axon is electrically stimulated at any point, an action potential is propagated in
both directions away from the initial stimulation site. The distally propagated impulse gives
rise to the CMAP or M response. However, an impulse also conducts proximally to the anterior
horn cell, depolarising the axon hillock and causing the axon to backfire which leads to a small
additional muscle depolarisation (F wave) at a longer latency (Figure 16). Because of the long
pathway, normal values have to be related to limb length or body height. F waves allow testing
of proximal segments of the nerves or roots that would otherwise be inaccessible to routine
studies.
Figure 16. Schematic representation of M and F waves.
4.4. Transcranial electrical and magnetic stimulation and transcortical stimulation
Transcranial electrical stimulation (TES) can be done by using electrical-digitimer stimulation
which normally sets at stimulus intensity of 100 to 750 V (max 200 mA), stimulus duration of
0.3-0.5 msec and train of 2 - 5 pulses with 2-4 msec interstimulus interval. On the contrary, the
transcranial magnetic stimulation (TMS) uses magnetic stimulation coil to generate electrical
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Brainstem auditory evoked potentials (BAEP)
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These patterns of activity are usually indicative of nerve irritation but also confirm that the
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additional muscle depolarisation (F wave) at a longer latency (Figure 16). Because of the long
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4.4. Transcranial electrical and magnetic stimulation and transcortical stimulation
Transcranial electrical stimulation (TES) can be done by using electrical-digitimer stimulation
which normally sets at stimulus intensity of 100 to 750 V (max 200 mA), stimulus duration of
0.3-0.5 msec and train of 2 - 5 pulses with 2-4 msec interstimulus interval. On the contrary, the
transcranial magnetic stimulation (TMS) uses magnetic stimulation coil to generate electrical
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current in the brain tissue [54, 55]. The stimulus intensity can be adjusted from 0 to 100% of
the magnetic tesla (normally for single pulse motor mapping, 80-90 % stimulus intensity is
needed). The stimulation sites can be determined by image guided system (preferred) or based
on the scalp EEG 10-20 system electrodes: the left and right motor cortex correspond to C3 and
C4 electrode regions (sometimes use C1 and C2 electrode areas). Recordings are made at the
spinal cord or nerve level in forms of motor evoked potentials (MEP:wave forms/neurogenic
potentials – repetitive or train of pulses are needed to produce MEPs for continuous monitoring of the
waveforms/pathway, therefore transcortical method, strip or grid electrodes are preferred to create
persistent stimulation), or on the surface (surface electrode) or inside (needle – well tolerated)
the muscles in forms of either MEP [note: when MEP is recorded in or on the surface of the muscle,
it is commonly called as CMAP. This can be either at rest - resting MEP or with grip – facilitated
MEP] or EMG responses (EMG:muscle activity/myogenic potentials) [56, 57]. Examples of
recorded muscles are dorsal interrosseus, abductor pollicis brevis, brachioradialis, biceps,
deltoid, thenar or hypothenar muscles or extensor digitorum longus for upper limb and first
dorsal interrosseous, extensor hallucis longus, tibialis anterior, gastrocnemius, soleus,
anterolateral thigh groups of muscles for the lower limb and for the face; frontalis and
orbicularis oris in awake state and orbicularis oculi, oris or nasalis in unconscious state.
Examples of Surgeries requiring MEP are for tumors located along the pyramidal-descending
pathways (transcranial stimulation is better since craniotomy is not desired just for the purpose to
only stimulate the motor cortex) or those near or embedded within the motor strip and cortex
(transcortical stimulation is better because craniotomy for tumor resection can also incorporate the motor
strips). Eventhough transcranial magnetic stimulation is less painful, transcranial electrical
stimulation is the optimal choice for obtaining MEPs because it is capable of delivering a more
stable stimulus. Total intravenous anaesthesia (TIVA) should be requested before the case
begins, since inhalational anaesthetics will reduce the MEPs amplitude. It is helpful to be in
constant communication with anaesthesiologist in order to know level of paralysis as an aid
in interpretation.
Transcranial Magnetic Stimulation (TMS) is a method to non-invasively probe and reversibly
alter neural processing in the human brain. TMS relies on the Faraday principles of electro‐
magnetic induction to generate electrical currents in neural tissue [58]. The direct impact of a
TMS is limited to a patch of cortex of a few square centimetres and the induced field falls off
exponentially with distance. The effective penetration depth of TMS is estimated to be ~ 2 cm
[59]. The intensity of the stimuli can be controlled by changing the current intensity flowing
in the coil, thus changing the magnitude of the induced magnetic field and of the secondarily
induced electrical field. The focus of the magnetic field depends on the shape of the stimulation
coil: figure-of-eight shaped coil (preferred for mapping) or circular coil. The former provides
a more focal stimulation, allowing proper mapping of the cortex and the latter induces a more
widely distributed electric field allowing for bihemispheric stimulation [60]. The operator can
also control the frequency of the delivered stimuli which will determine the effects of TMS on
the targetted region of the brain. Frameless stereotactic system helps to precisely localise the
brain region during the procedure (Figure 17). Technique for TMS can be either single pulse
TMS (spTMS) which can be used to study motor evoked potentials and map the brain cortex,
paired-pulse TMS (ppTMS) to study the inhibitory and facilitatory interactions in the cortex
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and repetitive TMS (rTMS) whereby a train of TMS pulses of the same intensity applied to a
single brain area at a given frequency that can range from 1 – 20 Hz. Lower frequencies of
rTMS in the 1 Hz range, can suppress excitability of motor cortex, while 20 Hz stimulation can
cause temporary increase in cortical excitability [61, 62]. rTMS is mainly used to study the
brain-behaviour relationship and mapping the language cortex. Important to note that in a
child of less than 10 years old, it may not yield localising response due to relative inexcitibility
of child cortex [63]. The contraindication to brain stimulation is presence of pacemaker; and
relative contraindication for transcranial stimulation is presence of holes or fracture of skull.
Figure 17. A: The navigated transcranial magnetic stimulation. B: The site of the stimulation is identified on the navi‐
gation image.
Transcortical stimulation has been discussed in details at earlier headings and commonly
applied in awake surgery. It is a direct method for cortical stimulation which commonly uses
neurostimulator (more precised to elicit EMGs: for brain mapping – tumor within or closed to eloquent
cortices) or strip/grid electrodes for repetitive firing of stimuli to elicit MEP-waves for contin‐
uous motor tract monitoring (example: use for insular region tumor where the surgical approach is
at the inferior part relative to the strip/grid electrodes-continuous-stimulation site) rather than coils
(non-focal and need larger craniotomy than usual). In general, it requires craniotomy and com‐
monly applies for tumour at region of motor cortex, subcortical motor areas or adjacent to the
descending motor pathways. The Penfield technique using neurostimulator is used for
transcortical brain mapping: 50-60 pulses per second (frequency 50 – 60 Hz) on motor cortex
or subcortically via continuous cortical stimulation over few seconds, with initial current of 1
mA, if no movement or contraction elicited, increase by 1 mA till 16 mA [64]. If no response,
then consider non-functional (Rules of maximum stimulation: < 20 mA for direct (transcortical) and
< 200 mA for transcranial/indirect stimulation).
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current in the brain tissue [54, 55]. The stimulus intensity can be adjusted from 0 to 100% of
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it is commonly called as CMAP. This can be either at rest - resting MEP or with grip – facilitated
MEP] or EMG responses (EMG:muscle activity/myogenic potentials) [56, 57]. Examples of
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deltoid, thenar or hypothenar muscles or extensor digitorum longus for upper limb and first
dorsal interrosseous, extensor hallucis longus, tibialis anterior, gastrocnemius, soleus,
anterolateral thigh groups of muscles for the lower limb and for the face; frontalis and
orbicularis oris in awake state and orbicularis oculi, oris or nasalis in unconscious state.
Examples of Surgeries requiring MEP are for tumors located along the pyramidal-descending
pathways (transcranial stimulation is better since craniotomy is not desired just for the purpose to
only stimulate the motor cortex) or those near or embedded within the motor strip and cortex
(transcortical stimulation is better because craniotomy for tumor resection can also incorporate the motor
strips). Eventhough transcranial magnetic stimulation is less painful, transcranial electrical
stimulation is the optimal choice for obtaining MEPs because it is capable of delivering a more
stable stimulus. Total intravenous anaesthesia (TIVA) should be requested before the case
begins, since inhalational anaesthetics will reduce the MEPs amplitude. It is helpful to be in
constant communication with anaesthesiologist in order to know level of paralysis as an aid
in interpretation.
Transcranial Magnetic Stimulation (TMS) is a method to non-invasively probe and reversibly
alter neural processing in the human brain. TMS relies on the Faraday principles of electro‐
magnetic induction to generate electrical currents in neural tissue [58]. The direct impact of a
TMS is limited to a patch of cortex of a few square centimetres and the induced field falls off
exponentially with distance. The effective penetration depth of TMS is estimated to be ~ 2 cm
[59]. The intensity of the stimuli can be controlled by changing the current intensity flowing
in the coil, thus changing the magnitude of the induced magnetic field and of the secondarily
induced electrical field. The focus of the magnetic field depends on the shape of the stimulation
coil: figure-of-eight shaped coil (preferred for mapping) or circular coil. The former provides
a more focal stimulation, allowing proper mapping of the cortex and the latter induces a more
widely distributed electric field allowing for bihemispheric stimulation [60]. The operator can
also control the frequency of the delivered stimuli which will determine the effects of TMS on
the targetted region of the brain. Frameless stereotactic system helps to precisely localise the
brain region during the procedure (Figure 17). Technique for TMS can be either single pulse
TMS (spTMS) which can be used to study motor evoked potentials and map the brain cortex,
paired-pulse TMS (ppTMS) to study the inhibitory and facilitatory interactions in the cortex
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and repetitive TMS (rTMS) whereby a train of TMS pulses of the same intensity applied to a
single brain area at a given frequency that can range from 1 – 20 Hz. Lower frequencies of
rTMS in the 1 Hz range, can suppress excitability of motor cortex, while 20 Hz stimulation can
cause temporary increase in cortical excitability [61, 62]. rTMS is mainly used to study the
brain-behaviour relationship and mapping the language cortex. Important to note that in a
child of less than 10 years old, it may not yield localising response due to relative inexcitibility
of child cortex [63]. The contraindication to brain stimulation is presence of pacemaker; and
relative contraindication for transcranial stimulation is presence of holes or fracture of skull.
Figure 17. A: The navigated transcranial magnetic stimulation. B: The site of the stimulation is identified on the navi‐
gation image.
Transcortical stimulation has been discussed in details at earlier headings and commonly
applied in awake surgery. It is a direct method for cortical stimulation which commonly uses
neurostimulator (more precised to elicit EMGs: for brain mapping – tumor within or closed to eloquent
cortices) or strip/grid electrodes for repetitive firing of stimuli to elicit MEP-waves for contin‐
uous motor tract monitoring (example: use for insular region tumor where the surgical approach is
at the inferior part relative to the strip/grid electrodes-continuous-stimulation site) rather than coils
(non-focal and need larger craniotomy than usual). In general, it requires craniotomy and com‐
monly applies for tumour at region of motor cortex, subcortical motor areas or adjacent to the
descending motor pathways. The Penfield technique using neurostimulator is used for
transcortical brain mapping: 50-60 pulses per second (frequency 50 – 60 Hz) on motor cortex
or subcortically via continuous cortical stimulation over few seconds, with initial current of 1
mA, if no movement or contraction elicited, increase by 1 mA till 16 mA [64]. If no response,
then consider non-functional (Rules of maximum stimulation: < 20 mA for direct (transcortical) and
< 200 mA for transcranial/indirect stimulation).
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4.5. Visual evoked potential (VEP)
Goggles containing light emiting diode stimulates retina by light produces evoked responses
of occipital cortex at O1 and O2 electrodes or better known as visual evoked potentials (VEPs).
P100 of positive polarity and has 100 msec latency is usually used for IOM. Because of high
percentage of false positivity associated with VEP, It is mainly used in chiasmatic, optic nerve
or sellar region tumour surgery and requires very conservative interpretation (note: patient
can close the eyelids during VEP monitoring).
4.6. Tips on anaesthesia
Our IOM anaesthetic protocol encourages use of propofol infusion, opiod infusion (alfentanil
etc), with or without inhalational N2O of less than 50% and intravenous infusion of muscle
relaxant with limited dosage, during EMG and/or MEP procedures. Bispectral EEGs (BIS) is





SSEP Both techniques of anaesthesia, either inhalational anaesthesia or total intravenous
anaesthesia (TIVA) can be used. TIVA can be done with combination of propofol infusion and
opioid infusion (remifentanil, sufentanil, alfentanil or fentanyl). Propofol and remifentanil
combination is preferable TIVA technique because it can be delivered using target-controlled
infusion (TCI) technique. TCI is a technique to deliver certain drugs using special infusion pump
incorporated with a software that contains a pharmacokinetic profile of the drugs. If only SSEP
is monitored, muscle relaxant can be used if necessary.
EMG Both techniques of anaesthesia, either inhalational anaesthesia or TIVA can be used. The only
important thing is to avoid muscle relaxant during the testing. If muscle relaxant is initially
used, it needs to be stopped earlier or reversed when necessary during EMG monitoring
MEP TIVA is the main anaesthesia technique. Inhalational agents are better totally avoided except
desflurane supplement just limited between 0.2- 0.3 minimum alveolar concentration (MAC) is
reported to be acceptable in combination with TIVA. Muscle relaxant is better avoided. If
indicated to be used, paralysis should be minimal or limited: 1 - 2 twitches per 4 train. Bite block
may be used to avoid tongue injury.
Table 5. The anaesthetic tips during IOM procedures.
4.7. Brain tumor surgery under general anaesthesia and neuromonitoring
Intraoperative neuromonitoring is  commonly utilised to monitor the status of  important
neurostructures or tracts whenever surgical removal is planned for tumor that lies close
to  them.  This  seems  important  whenever  surgery  is  planned  under  general  anaethesia
(GA). Under non-awake state, monitoring neurological status of the patient is impossible,
therefore many surgeons rely on alternative techniques of IOM to safeguard those neural
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structures. The first example is an elderly lady with right frontal high grade tumor pre‐
sented with left upper limb weakness. The surgery was done under GA with neuronavi‐
gation  guided  surgery  and  motor  cortex  stimulation  with  EMG monitoring.  The  MEG-
MRI  (MSI)  extraoperative  images  were  uploaded  to  the  neuronavigation  system
(Medtronic StealthStation TREONTM, Minneapolis, USA) and were used to localise the tu‐
mor and left leg motor area (Figure 18A). Prior to removal of the tumor, the transcortical
motor stimulation was made to localise the hand and facial areas (Figure 18B). Tumor re‐
moval was uneventful and immediately after, she received adjuvant intraoperative radia‐
tion therapy (IORT) to the periphery and chemotherapy (Figure 18C).
Figure 18. A: MSI was used to localize the eloquent cortices. B: Limited motor cortex stimulation can still be done un‐
der general anesthesia as long as no muscle relaxant was given and EMG recordings were made at specific muscles. C:
Adjuvant intraoperative radiation therapy (IORT) for residual tumor.
The second case illustration was the ventral brainstem tumor arisen years after radiation
therapy to the neck and parotid region for extracranial meningiomas (Figure 19A). The surgery
was done under GA and endoscopic true endonasal transphenoidal transclival approach was
used to debulk the tumor (Figure 19B). SSEP, BAEP and multiple lower cranial nerve EMGs
(V – Masseter, VI – lateral rectus, VII – nasalis, orbicularis oris and oculi, IX and X – endotracheal tube
with adhesive EMG sensors [note: surface EMG electrode at anterior neck is valid for purpose of cortical
brain mapping], XI - upper sternomastoid and XII – tongue muscles) were used to safeguard the
important neural structures (Figure 19C). Extraoperative neuroimages were used to localise
the tumor and important white matter tracts in the brainstem (Figure 19D). Tumor debulking
was completed without causing new neurological deficits (Figure 19E).
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4.5. Visual evoked potential (VEP)
Goggles containing light emiting diode stimulates retina by light produces evoked responses
of occipital cortex at O1 and O2 electrodes or better known as visual evoked potentials (VEPs).
P100 of positive polarity and has 100 msec latency is usually used for IOM. Because of high
percentage of false positivity associated with VEP, It is mainly used in chiasmatic, optic nerve
or sellar region tumour surgery and requires very conservative interpretation (note: patient
can close the eyelids during VEP monitoring).
4.6. Tips on anaesthesia
Our IOM anaesthetic protocol encourages use of propofol infusion, opiod infusion (alfentanil
etc), with or without inhalational N2O of less than 50% and intravenous infusion of muscle
relaxant with limited dosage, during EMG and/or MEP procedures. Bispectral EEGs (BIS) is





SSEP Both techniques of anaesthesia, either inhalational anaesthesia or total intravenous
anaesthesia (TIVA) can be used. TIVA can be done with combination of propofol infusion and
opioid infusion (remifentanil, sufentanil, alfentanil or fentanyl). Propofol and remifentanil
combination is preferable TIVA technique because it can be delivered using target-controlled
infusion (TCI) technique. TCI is a technique to deliver certain drugs using special infusion pump
incorporated with a software that contains a pharmacokinetic profile of the drugs. If only SSEP
is monitored, muscle relaxant can be used if necessary.
EMG Both techniques of anaesthesia, either inhalational anaesthesia or TIVA can be used. The only
important thing is to avoid muscle relaxant during the testing. If muscle relaxant is initially
used, it needs to be stopped earlier or reversed when necessary during EMG monitoring
MEP TIVA is the main anaesthesia technique. Inhalational agents are better totally avoided except
desflurane supplement just limited between 0.2- 0.3 minimum alveolar concentration (MAC) is
reported to be acceptable in combination with TIVA. Muscle relaxant is better avoided. If
indicated to be used, paralysis should be minimal or limited: 1 - 2 twitches per 4 train. Bite block
may be used to avoid tongue injury.
Table 5. The anaesthetic tips during IOM procedures.
4.7. Brain tumor surgery under general anaesthesia and neuromonitoring
Intraoperative neuromonitoring is  commonly utilised to monitor the status of  important
neurostructures or tracts whenever surgical removal is planned for tumor that lies close
to  them.  This  seems  important  whenever  surgery  is  planned  under  general  anaethesia
(GA). Under non-awake state, monitoring neurological status of the patient is impossible,
therefore many surgeons rely on alternative techniques of IOM to safeguard those neural
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structures. The first example is an elderly lady with right frontal high grade tumor pre‐
sented with left upper limb weakness. The surgery was done under GA with neuronavi‐
gation  guided  surgery  and  motor  cortex  stimulation  with  EMG monitoring.  The  MEG-
MRI  (MSI)  extraoperative  images  were  uploaded  to  the  neuronavigation  system
(Medtronic StealthStation TREONTM, Minneapolis, USA) and were used to localise the tu‐
mor and left leg motor area (Figure 18A). Prior to removal of the tumor, the transcortical
motor stimulation was made to localise the hand and facial areas (Figure 18B). Tumor re‐
moval was uneventful and immediately after, she received adjuvant intraoperative radia‐
tion therapy (IORT) to the periphery and chemotherapy (Figure 18C).
Figure 18. A: MSI was used to localize the eloquent cortices. B: Limited motor cortex stimulation can still be done un‐
der general anesthesia as long as no muscle relaxant was given and EMG recordings were made at specific muscles. C:
Adjuvant intraoperative radiation therapy (IORT) for residual tumor.
The second case illustration was the ventral brainstem tumor arisen years after radiation
therapy to the neck and parotid region for extracranial meningiomas (Figure 19A). The surgery
was done under GA and endoscopic true endonasal transphenoidal transclival approach was
used to debulk the tumor (Figure 19B). SSEP, BAEP and multiple lower cranial nerve EMGs
(V – Masseter, VI – lateral rectus, VII – nasalis, orbicularis oris and oculi, IX and X – endotracheal tube
with adhesive EMG sensors [note: surface EMG electrode at anterior neck is valid for purpose of cortical
brain mapping], XI - upper sternomastoid and XII – tongue muscles) were used to safeguard the
important neural structures (Figure 19C). Extraoperative neuroimages were used to localise
the tumor and important white matter tracts in the brainstem (Figure 19D). Tumor debulking
was completed without causing new neurological deficits (Figure 19E).
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Figure 19. A: Ventral brainstem tumor. B: Endoscopic view during resection. C: Intraoperative neuromonitoring re‐
cordings during surgery. D: Neuronavigational images during resection. E: Postoperative image.
5. Brain tumor and adjuvant precision radiation therapy
Several factors known to influence the prognosis of high grade tumors include tumor resection
without causing deterioration in patient’s neurological functions, adjuvant radiotherapy and
chemotherapy [65, 66]. Since high grade tumors tend to be infiltrative in nature, precision
radiation therapy should target both the tumor and its infiltrative margin. Hochberg and Pruitt
performed series of autopsy studies in patients with high grade brain tumors, where the
microscopic margin of tumour was within 2 cm of the enhanced region [67]. This rule of 2 - 3
cm margin from the tumour in radiation therapy seems practical with precision radiation
therapy.
Stereotactic radiosurgery (SRS) is an external irradiation technique in which multiple colli‐
mated beams of radiation are stereotactically aimed at a radiographically discrete target
volume to deliver a single, high dose of radiation to a small volume of tissue (commonly ≤ 3
cm in diameter) (Figure 20A). Stereotactic radiotherapy (SRT) is a technique whereby high
precision techniques of SRS with potential radiobiological benefits of fractionation are
combined. Therefore SRT involves multiple irradiation sessions and generally used for brain
tumors that are irregular in shape and larger than 3 cm in diameter (Figure 20B). Intraoperative
or intrabeam radiation therapy (IORT) is a type of intraoperative brachytherapy in which the
therapeutic irradiation is administered immeditaley after surgical debulking of brain tumors
(Figure 21B). These three techniques of precision radiation therapy are commonly used in our
centre to treat high grade tumors after surgical debulking.
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Figure 20. A: Stereotactic radiosurgery (SRS) planning for brain tumor. B: Brain tumor planning for stereotactic radio‐
therapy (SRT).
In many instances, surgical resection of the tumour is required to reduce the tumor bulk to
suit adjuvant therapy, but radiating the empty tumoral bed with SRS seems inappropriate.
Besides, size of the tumor is also a limiting factor for SRS. As for the time-consuming SRT
technique, it is potentially inaccurate because of the different timing of radiation with non-
fixed referral points. Thus, such limitations of the two techniques made IORT our most
favourable option [66]. The key advantages of IORT are: a) radiation to the tumoral bed can
be administered directly after surgical resection; b) radiation can be given circumferentially
from the centre of the empty tumoral bed whereby the plan tumour volume is better defined
and irradiated; and c) size of the tumor is not a hindrance for high dose irradiation therapy.
At our centre, the IORT procedure had been performed under general anaesthesia immediately
after completing the tumoral resection or few days after the surgery. Patient’s head was fixed
with Mayfield head clamped and rotated adequately so that the tumoral bed localises at the
uppermost part. The tumoural bed was measured in all three dimensions and filled up with
wet tissue-equivalent cotton strips. Beam directions measured by means of a specially
constructed device called the BDI (beam direction indicator). The beam direction was selected
according to the shape and depth of the resection cavity and the region presumed at risk of
recurrence. The intended beam direction was maintained by using BDI. The BDI consists of a
mobile arm with several joints which can be mounted at the edge of the operating table and
prepared for the placement of radiation source or better known as Intrabeam Miniature X-ray
Source (xRS). The applicator or probe was then fixed to the radiation source. A complete set
of spherical applicators or probes from 1.5 to 5.0 cm in diameter are available to enable accurate
placement into the tumoral bed, ensuring contact with all surfaces of the treatment area, and
uniform dose delivery. The spherical applicator or probe was selected according to the
diameter of the resection cavity including a safety margin of at least 1-2 cm. The electron energy
was chosen according to the depth of the resection cavity including a margin of at least 1 cm.
Dosage of focal irradiation therapy was calculated in Gy and administered intraoperatively
(Figure 21A and B).
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Figure 19. A: Ventral brainstem tumor. B: Endoscopic view during resection. C: Intraoperative neuromonitoring re‐
cordings during surgery. D: Neuronavigational images during resection. E: Postoperative image.
5. Brain tumor and adjuvant precision radiation therapy
Several factors known to influence the prognosis of high grade tumors include tumor resection
without causing deterioration in patient’s neurological functions, adjuvant radiotherapy and
chemotherapy [65, 66]. Since high grade tumors tend to be infiltrative in nature, precision
radiation therapy should target both the tumor and its infiltrative margin. Hochberg and Pruitt
performed series of autopsy studies in patients with high grade brain tumors, where the
microscopic margin of tumour was within 2 cm of the enhanced region [67]. This rule of 2 - 3
cm margin from the tumour in radiation therapy seems practical with precision radiation
therapy.
Stereotactic radiosurgery (SRS) is an external irradiation technique in which multiple colli‐
mated beams of radiation are stereotactically aimed at a radiographically discrete target
volume to deliver a single, high dose of radiation to a small volume of tissue (commonly ≤ 3
cm in diameter) (Figure 20A). Stereotactic radiotherapy (SRT) is a technique whereby high
precision techniques of SRS with potential radiobiological benefits of fractionation are
combined. Therefore SRT involves multiple irradiation sessions and generally used for brain
tumors that are irregular in shape and larger than 3 cm in diameter (Figure 20B). Intraoperative
or intrabeam radiation therapy (IORT) is a type of intraoperative brachytherapy in which the
therapeutic irradiation is administered immeditaley after surgical debulking of brain tumors
(Figure 21B). These three techniques of precision radiation therapy are commonly used in our
centre to treat high grade tumors after surgical debulking.
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Figure 20. A: Stereotactic radiosurgery (SRS) planning for brain tumor. B: Brain tumor planning for stereotactic radio‐
therapy (SRT).
In many instances, surgical resection of the tumour is required to reduce the tumor bulk to
suit adjuvant therapy, but radiating the empty tumoral bed with SRS seems inappropriate.
Besides, size of the tumor is also a limiting factor for SRS. As for the time-consuming SRT
technique, it is potentially inaccurate because of the different timing of radiation with non-
fixed referral points. Thus, such limitations of the two techniques made IORT our most
favourable option [66]. The key advantages of IORT are: a) radiation to the tumoral bed can
be administered directly after surgical resection; b) radiation can be given circumferentially
from the centre of the empty tumoral bed whereby the plan tumour volume is better defined
and irradiated; and c) size of the tumor is not a hindrance for high dose irradiation therapy.
At our centre, the IORT procedure had been performed under general anaesthesia immediately
after completing the tumoral resection or few days after the surgery. Patient’s head was fixed
with Mayfield head clamped and rotated adequately so that the tumoral bed localises at the
uppermost part. The tumoural bed was measured in all three dimensions and filled up with
wet tissue-equivalent cotton strips. Beam directions measured by means of a specially
constructed device called the BDI (beam direction indicator). The beam direction was selected
according to the shape and depth of the resection cavity and the region presumed at risk of
recurrence. The intended beam direction was maintained by using BDI. The BDI consists of a
mobile arm with several joints which can be mounted at the edge of the operating table and
prepared for the placement of radiation source or better known as Intrabeam Miniature X-ray
Source (xRS). The applicator or probe was then fixed to the radiation source. A complete set
of spherical applicators or probes from 1.5 to 5.0 cm in diameter are available to enable accurate
placement into the tumoral bed, ensuring contact with all surfaces of the treatment area, and
uniform dose delivery. The spherical applicator or probe was selected according to the
diameter of the resection cavity including a safety margin of at least 1-2 cm. The electron energy
was chosen according to the depth of the resection cavity including a margin of at least 1 cm.
Dosage of focal irradiation therapy was calculated in Gy and administered intraoperatively
(Figure 21A and B).
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Figure 21. A: Dosage processing prior to irradiation for intrabeam Miniature X-ray Source (xRS). B: Intraoperative radi‐
ation therapy procedure, the histologically confirmed tumor bed was irradiated immediately after the surgery.
After completion of the procedure, absolute hemostasis was achieved, dura was closed
primarily and the wound was closed in layers. After an interval of 3 – 4 weeks, standard
external beam irradiation was started in patients receiving IORT. Besides intracavitary
technique of IORT (using spherical applicator as explained above), interstitial IORT is an
alternative and commonly used for deep seated high grade brain tumor, such as thalamic
gliomas. Initially, tumoral biopsy was made using stereotactic frame (CRW) and once the
intraoperative fresh frozen biopsy results confirmed a high grade tumor, the irradiation source
was mounted onto the stereotactic frame and the radiation tip was localized into the central
part of the tumor for proper irradiation (Figure 22A and B).
Figure 22. A: Tumoral biopsy procedure completed prior to interstitial IORT. B: An accurate irradiation was adminis‐
tered by using CRW stereotactic frame after knowing the fresh frozen biopsy results.
6. New concept – Brain waves, oscillations and networks
Oscillation with synchronisation does exist inside (~ small universe) and outside (large
universe) our brain. Neural oscillation can be stratified into microscale-oscillation (activity of
a single neuron), mesoscale-oscillation (activity of local group of neurons or vertices) and
macroscale-oscillation (neural activity of different brain regions/networks). Neurons can
generate action potentials or spike trains (multiple action potentials in sequence) at microscale
oscillation and can be studied using intracellular single-unit recordings. When a group of
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neurons firing action potentials, synaptic interactions play major role to synchronise the input
to other brain regions. Synchronised firing patterns give rise to large-amplitude mesoscale
oscillations of local field potentials which can be detected by using EEG or MEG. Neural
oscillations which arise from interactions between or among brain regions are known as
macroscale-oscillation. It forms various network loops with edges and vertices inside our brain
and it is also best detected by using EEG or MEG [31, 68-72]. Neuronal property of creating
oscillation inside our brain is important for normal brain functioning. Neural oscillation
contributes to neural coding, brain rhythms with different types or frequency of oscillatory
activity [5 type of brain waves: gamma (above 30 Hz), beta [13 – 30 Hz), alpha ( 8 – 13 Hz), theta [4
– 8 Hz) and delta [0.5 – 4 Hz); sleep spindles; Mu waves; thalamocortical oscillations; epileptic seizures
and bursting] and fast information processing and transfer. Interestingly, neural oscillations
also play an important role in many neurological disorders such as excessive synchronisation
during seizure in epilepsy or tremors in movement disorders [69]. Lately, it is also being used
in controlling the external devices in brain-computer interface [73-74]. Its principle has a
potential basis to invent new devise which can restore the functions of the paretic limbs by
implanting the devices and get connected to the residual survived-brain networks (an example:
a case with middle-cerebral-artery infarct with hemiparesis, infarctectomy is performed prior to rewiring
using advanced DTI and the procedure is completed with implantation of cortical-subcortical stimula‐
tory device) and subsequently programming the oscillatory outputs (rhythms and amplitudes)
via wireless external computers.
Apart from intrinsic properties of neurons, network properties are also an important source
of oscillatory activity. The introduction of modern network theory of small-world or scale-free
networks appears plausible to describe the real complex brain networks [49, 69]. Small-world
network has high clustering coefficient (many vertices/brain areas/rhythms-generating-brain
areas) and short path length (connections or edges between vertices/white matter tracts on
DTI), and is therefore regarded as the best and economical network model to explain our
extremely efficient brain networks or loops. Oscillations produced by the networks are
synchronised-large-scale oscillations which can be recorded by using EEG or MEG and studied
for:
i. Evoked and event related potentials (ERPs). Evoked or event activity is the brain
responses that are directly related to stimulus-related activity. Evoked potentials are
commonly used for sensory or motor stimulus, and ERPs are mainly for cognitive
tasks. They are obtained by stimulus-locked averaging (averaging different trials at
fixed latencies around the presentation of a stimulus). In this analysis, the spontane‐
ous brain activity is regarded as noise and one only focuses on evoked or event related
responses
ii. Resting-state activity or spontaneous activity. Oscillatory activities do exist when
subjects do not engage in any activity. It is used to study brain maturiy in different
ages or pathology, seizure focus, level of consciousness and many else
iii. Complex analysis for brain networks, using neurodynamics-mathematical models or
formula of statistical-physics such as spectral analysis (for large-scale data)
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Figure 21. A: Dosage processing prior to irradiation for intrabeam Miniature X-ray Source (xRS). B: Intraoperative radi‐
ation therapy procedure, the histologically confirmed tumor bed was irradiated immediately after the surgery.
After completion of the procedure, absolute hemostasis was achieved, dura was closed
primarily and the wound was closed in layers. After an interval of 3 – 4 weeks, standard
external beam irradiation was started in patients receiving IORT. Besides intracavitary
technique of IORT (using spherical applicator as explained above), interstitial IORT is an
alternative and commonly used for deep seated high grade brain tumor, such as thalamic
gliomas. Initially, tumoral biopsy was made using stereotactic frame (CRW) and once the
intraoperative fresh frozen biopsy results confirmed a high grade tumor, the irradiation source
was mounted onto the stereotactic frame and the radiation tip was localized into the central
part of the tumor for proper irradiation (Figure 22A and B).
Figure 22. A: Tumoral biopsy procedure completed prior to interstitial IORT. B: An accurate irradiation was adminis‐
tered by using CRW stereotactic frame after knowing the fresh frozen biopsy results.
6. New concept – Brain waves, oscillations and networks
Oscillation with synchronisation does exist inside (~ small universe) and outside (large
universe) our brain. Neural oscillation can be stratified into microscale-oscillation (activity of
a single neuron), mesoscale-oscillation (activity of local group of neurons or vertices) and
macroscale-oscillation (neural activity of different brain regions/networks). Neurons can
generate action potentials or spike trains (multiple action potentials in sequence) at microscale
oscillation and can be studied using intracellular single-unit recordings. When a group of
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neurons firing action potentials, synaptic interactions play major role to synchronise the input
to other brain regions. Synchronised firing patterns give rise to large-amplitude mesoscale
oscillations of local field potentials which can be detected by using EEG or MEG. Neural
oscillations which arise from interactions between or among brain regions are known as
macroscale-oscillation. It forms various network loops with edges and vertices inside our brain
and it is also best detected by using EEG or MEG [31, 68-72]. Neuronal property of creating
oscillation inside our brain is important for normal brain functioning. Neural oscillation
contributes to neural coding, brain rhythms with different types or frequency of oscillatory
activity [5 type of brain waves: gamma (above 30 Hz), beta [13 – 30 Hz), alpha ( 8 – 13 Hz), theta [4
– 8 Hz) and delta [0.5 – 4 Hz); sleep spindles; Mu waves; thalamocortical oscillations; epileptic seizures
and bursting] and fast information processing and transfer. Interestingly, neural oscillations
also play an important role in many neurological disorders such as excessive synchronisation
during seizure in epilepsy or tremors in movement disorders [69]. Lately, it is also being used
in controlling the external devices in brain-computer interface [73-74]. Its principle has a
potential basis to invent new devise which can restore the functions of the paretic limbs by
implanting the devices and get connected to the residual survived-brain networks (an example:
a case with middle-cerebral-artery infarct with hemiparesis, infarctectomy is performed prior to rewiring
using advanced DTI and the procedure is completed with implantation of cortical-subcortical stimula‐
tory device) and subsequently programming the oscillatory outputs (rhythms and amplitudes)
via wireless external computers.
Apart from intrinsic properties of neurons, network properties are also an important source
of oscillatory activity. The introduction of modern network theory of small-world or scale-free
networks appears plausible to describe the real complex brain networks [49, 69]. Small-world
network has high clustering coefficient (many vertices/brain areas/rhythms-generating-brain
areas) and short path length (connections or edges between vertices/white matter tracts on
DTI), and is therefore regarded as the best and economical network model to explain our
extremely efficient brain networks or loops. Oscillations produced by the networks are
synchronised-large-scale oscillations which can be recorded by using EEG or MEG and studied
for:
i. Evoked and event related potentials (ERPs). Evoked or event activity is the brain
responses that are directly related to stimulus-related activity. Evoked potentials are
commonly used for sensory or motor stimulus, and ERPs are mainly for cognitive
tasks. They are obtained by stimulus-locked averaging (averaging different trials at
fixed latencies around the presentation of a stimulus). In this analysis, the spontane‐
ous brain activity is regarded as noise and one only focuses on evoked or event related
responses
ii. Resting-state activity or spontaneous activity. Oscillatory activities do exist when
subjects do not engage in any activity. It is used to study brain maturiy in different
ages or pathology, seizure focus, level of consciousness and many else
iii. Complex analysis for brain networks, using neurodynamics-mathematical models or
formula of statistical-physics such as spectral analysis (for large-scale data)
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From the experiences at our centre, we presented three clinical examples that display features
of brain oscillation which were detected by the aforementioned three main studied methods.
Case 1: This is an example of an evoked response to display brain oscillation (Figure 23). A 51-
year-old man presented with mild left upper limb and facial weakness without history of focal
seizures. The brain MRI disclosed a tumoral lesion at right motor cortex. DTI revealed the
lesion was surrounded by important pyramidal tracts. He underwent awake tumoral surgery
and the tumor was successfully removed. Prior to tumor removal, cortical stimulation was
made at right hand motor cortex [60 Hz, 2 ms pulse interval, at 3 – 4 mA) which was confirmed
by EMGs responses in the left hand’s muscles. Interestingly, there were also obvious evoked
potentials responses detected by the opposite side scalp EEGs. Since there is falx structure at
the midline, the transfer of the electrical waves from right to left cerebral hemisphere must
have gone through appropriate anatomical pathways or loops (corpus callosum or thalamo‐
cortical loops). This case example proves that inside our brain, there are networks or loops that
play significant role in exhibiting their functions.
Figure 23. A: Craniotomy for tumor resection was on the right and scalp electrodes were inserted on the left. B: Intra‐
operative image shows functional brain areas labeled A-C and 1. When area labeled B was stimulated, evoked re‐
sponses were noted mainly at F3-C3 and C3-P3 at opposite hemisphere (C). D: The stimulated and responded areas
seen on DTI.
Case 2: This is an example of resting state or spontaneous activity to display brain oscillation
(Figure 24). A 41-year-old man who had posterior limb of right internal capsule haemorrhage
secondary to cerebral arteriovenous malformation (AVM). He has weakness and dystonia of
his left hand. The spontaneous MEG recordings before radiosurgical treatment revealed
marked slowings of brain waves at both, right and left motor cortices. This case illustrates
lesioning at one point in the network or loop would cause bilateral spontaneous brain waves
abnormality. Comparatively similar to above conclusion, it suggests that brain networks or
loops do exist in our brain, and they contribute significantly to brain functions.
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Figure 24. A: The AVM anatomical area was fused with Schaltenbrand-Wahren atlas. B: Spontaneous MEG recordings
prior to SRS, shows slowing at bilateral motor cortices. C: Radiosurgical planning for that AVM.
Case 3: This is our third example to display brain oscillation through complex mathematical model
analysis. Figure 25 disclosed MEG fast-fourier-transformation (fft) analysis for spontaneous
brain waves, recorded before and after brain tumor removal in both hemisphere. The tumor
was located at frontotemporoparietal brain region. The detail analysis revealed marked
changes in brain waves patterns after tumor removal not only in the hemisphere which harbors
the tumor, but also in the opposite hemisphere. More activities or less slowing waves patterns
were recorded in both hemispheres after tumor resection. This corresponds to marked
improvement in patient clinical status. This proves that brain networks or loops do exist in our
brain and work via brain waves oscillation.
Figure 25. MEG fast-fourier-transformation analysis for brain tumor patient, before and after the surgery for both
hemispheres. Analysis revealed enhanced activities in both hemispheres after the surgery.
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From the experiences at our centre, we presented three clinical examples that display features
of brain oscillation which were detected by the aforementioned three main studied methods.
Case 1: This is an example of an evoked response to display brain oscillation (Figure 23). A 51-
year-old man presented with mild left upper limb and facial weakness without history of focal
seizures. The brain MRI disclosed a tumoral lesion at right motor cortex. DTI revealed the
lesion was surrounded by important pyramidal tracts. He underwent awake tumoral surgery
and the tumor was successfully removed. Prior to tumor removal, cortical stimulation was
made at right hand motor cortex [60 Hz, 2 ms pulse interval, at 3 – 4 mA) which was confirmed
by EMGs responses in the left hand’s muscles. Interestingly, there were also obvious evoked
potentials responses detected by the opposite side scalp EEGs. Since there is falx structure at
the midline, the transfer of the electrical waves from right to left cerebral hemisphere must
have gone through appropriate anatomical pathways or loops (corpus callosum or thalamo‐
cortical loops). This case example proves that inside our brain, there are networks or loops that
play significant role in exhibiting their functions.
Figure 23. A: Craniotomy for tumor resection was on the right and scalp electrodes were inserted on the left. B: Intra‐
operative image shows functional brain areas labeled A-C and 1. When area labeled B was stimulated, evoked re‐
sponses were noted mainly at F3-C3 and C3-P3 at opposite hemisphere (C). D: The stimulated and responded areas
seen on DTI.
Case 2: This is an example of resting state or spontaneous activity to display brain oscillation
(Figure 24). A 41-year-old man who had posterior limb of right internal capsule haemorrhage
secondary to cerebral arteriovenous malformation (AVM). He has weakness and dystonia of
his left hand. The spontaneous MEG recordings before radiosurgical treatment revealed
marked slowings of brain waves at both, right and left motor cortices. This case illustrates
lesioning at one point in the network or loop would cause bilateral spontaneous brain waves
abnormality. Comparatively similar to above conclusion, it suggests that brain networks or
loops do exist in our brain, and they contribute significantly to brain functions.
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Figure 24. A: The AVM anatomical area was fused with Schaltenbrand-Wahren atlas. B: Spontaneous MEG recordings
prior to SRS, shows slowing at bilateral motor cortices. C: Radiosurgical planning for that AVM.
Case 3: This is our third example to display brain oscillation through complex mathematical model
analysis. Figure 25 disclosed MEG fast-fourier-transformation (fft) analysis for spontaneous
brain waves, recorded before and after brain tumor removal in both hemisphere. The tumor
was located at frontotemporoparietal brain region. The detail analysis revealed marked
changes in brain waves patterns after tumor removal not only in the hemisphere which harbors
the tumor, but also in the opposite hemisphere. More activities or less slowing waves patterns
were recorded in both hemispheres after tumor resection. This corresponds to marked
improvement in patient clinical status. This proves that brain networks or loops do exist in our
brain and work via brain waves oscillation.
Figure 25. MEG fast-fourier-transformation analysis for brain tumor patient, before and after the surgery for both
hemispheres. Analysis revealed enhanced activities in both hemispheres after the surgery.




Intraoperative use of anatomical and functional neuroimages plays crucial roles to quickly
identify the tumor and to better define the eloquent areas of the brain. This extraoperative-
neuroimages guided brain mapping approach commonly combines either with intraoperative
brain mapping technique when patients with brain tumors undergo awake craniotomy
surgery or with intraoperative neuromonitoring technique when surgery was done under
general anaethesia. Both techniques appear to be useful to the neurosurgeons and acceptable
to the patients whilst ensuring a safer removal of brain tumors. Besides, information gained
from awake surgery, neuromonitoring and functional neuroimagings expands further insights
and potential novel understanding in the field of fundamental and cognitive neurosciences.
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Intraoperative use of anatomical and functional neuroimages plays crucial roles to quickly
identify the tumor and to better define the eloquent areas of the brain. This extraoperative-
neuroimages guided brain mapping approach commonly combines either with intraoperative
brain mapping technique when patients with brain tumors undergo awake craniotomy
surgery or with intraoperative neuromonitoring technique when surgery was done under
general anaethesia. Both techniques appear to be useful to the neurosurgeons and acceptable
to the patients whilst ensuring a safer removal of brain tumors. Besides, information gained
from awake surgery, neuromonitoring and functional neuroimagings expands further insights
and potential novel understanding in the field of fundamental and cognitive neurosciences.
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1. Introduction
Intracranial tumors represent a significant health problem. The annual incidence of primary
and secondary central Nervous system neoplasms ranges from 10 to 17 per 100.000 persons.
The main histological types of brain tumors in adults include: high-grade (gliomas, primary
cerebral lymphomas, medulloblastomas), low-grade (meningiomas, acoustic neuromas, neu‐
rofibromas) and Secondaries (common malignancies spreading to the brain include lung
cancer, breast cancer, stomach cancer, prostate cancer, thyroid cancer, colorectal cancer, mel‐
anoma and kidney cancer). In recent years, the diagnosis of brain tumors has considerable
progressed due to continuous advances in neuroradiology.
Neuroradiology is a part of general radiology dedicated to the diagnostic examination of the
brain and spinal cord. The history of neuroradiology, as a whole, reflects the history of radi‐
ological development. It is, on one hand, the history of collaboration of radiologists, neurol‐
ogists and neurosurgeons in the development of clinical methods of Central Nervous
System (CNS) radiological examination. On the other hand, it is the history of collaboration
of physicists, mathematicians, engineers and radiologists in the design and creation of new
devices for brain and diagnostics of spinal cord diseases.
Neuroradiology began in the early 1900s as soon after Roentgen discovered X-rays. He
made the first X-ray image - a skull - in December 1895. X-rays promptly became the new
tool in physics research and in medicine, providing many opportunities to visualize the in‐
ternal structures of the human body. This was followed by the development of ventriculog‐
raphy in 1918 while the 1920s was the era of pneumoencephalography development thanks
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1. Introduction
Intracranial tumors represent a significant health problem. The annual incidence of primary
and secondary central Nervous system neoplasms ranges from 10 to 17 per 100.000 persons.
The main histological types of brain tumors in adults include: high-grade (gliomas, primary
cerebral lymphomas, medulloblastomas), low-grade (meningiomas, acoustic neuromas, neu‐
rofibromas) and Secondaries (common malignancies spreading to the brain include lung
cancer, breast cancer, stomach cancer, prostate cancer, thyroid cancer, colorectal cancer, mel‐
anoma and kidney cancer). In recent years, the diagnosis of brain tumors has considerable
progressed due to continuous advances in neuroradiology.
Neuroradiology is a part of general radiology dedicated to the diagnostic examination of the
brain and spinal cord. The history of neuroradiology, as a whole, reflects the history of radi‐
ological development. It is, on one hand, the history of collaboration of radiologists, neurol‐
ogists and neurosurgeons in the development of clinical methods of Central Nervous
System (CNS) radiological examination. On the other hand, it is the history of collaboration
of physicists, mathematicians, engineers and radiologists in the design and creation of new
devices for brain and diagnostics of spinal cord diseases.
Neuroradiology began in the early 1900s as soon after Roentgen discovered X-rays. He
made the first X-ray image - a skull - in December 1895. X-rays promptly became the new
tool in physics research and in medicine, providing many opportunities to visualize the in‐
ternal structures of the human body. This was followed by the development of ventriculog‐
raphy in 1918 while the 1920s was the era of pneumoencephalography development thanks
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to the work of Walter Dandy, a prominent neurosurgeon at Johns Hopkins Hospital [1]. The
1930s were marked by the introduction of cerebral angiography. From 1935 to 1946, the phe‐
nomenon of nuclear magnetic resonance was discovered [2]. The 1950s and 1960s witnessed
questions for practical solutions of tomography problems in neuroradiology and subsequent
development of electronics and computer techniques. The 1970s and 1980s were the years of
wide introduction of Computed Tomography (CT) in the clinical setting. When CT became
available, the use of uncomfortable procedures was abruptly stopped because CT could de‐
pict the ventricular system and the intracranial suarachnoid spaces directly, without intro‐
ducing air into the subarachnoid space itself [3]. As regard to the development of cerebral
angiography, in the early 1960s, it was performed by means of direct puncture of the com‐
mon carotid artery and the vertebral artery. In the late 1960s and early 1970s cerebral an‐
giography was predominantly performed by means of selective catheter angiography
following puncture of the femoral artery [3]. Progress in neuroradiology continued rapidly
with the development of MR imaging in the late 1970s and early 1980s. The advantages of
MRI imaging were that it could be performed in any plane and with various pulse sequen‐
ces, obtaining more details of the cerebral anatomy [4]. By the end of 20th century, Magnetic
Resonance Imaging (MRI) had been strongly incorporated into the clinical practice, and in
some cases (spinal cord examination) became a method of choice compared to the CT. The
high tissue resolution and the wide variety of types of contrast for MR images are typical for
MRI. Currently, MRI employs several physical factors defining the brightness of tissue on
the image such as: proton density; Т1 and Т2 relaxation time of protons in tissue; movement
of protons in the large vessels with a blood–cerebrospinal fluid (CSF) flow and passage of
protons through a capillary net; random thermal water molecule motion; anisotropy of the
diffusion proton motion and magnetic susceptibility of tissues; chemical shift of proton’s
resonance frequency in molecular complexes. In addition, volumetric CT and super-fast
MRI have opened wide diagnostic opportunities of CNS examination not only on a level of
anatomic structures (simulation and support of surgery, endoscopy), but also on a level of
molecular and gene biology. Neuroradiology has become the quantitative method of brain
function examination, able to monitor and predict the results of therapeutic treatment and
surgical intervention of many diseases [5].
Further development of neuroradiology is closely linked with the increase of processing
speed and improvements in computer technologies, increase of (MRI) magnetic field induc‐
tion, development of “open” magnets for biopsy, intra-operative control, examination of
critical patients.
This chapter focuses on the role of the most commonly used advanced MR imaging techni‐
ques – perfusion imaging, diffusion-weighted imaging, and MRI spectroscopy- for the diag‐
nosis of the most common brain tumors in adults.
1.2. Conventional MRI imaging
When dealing with a patient with a brain tumor, standard X-rays and CT scan is initially
used in the diagnostic process. However, MRI is generally more useful because it provides
detailed informations about tumor type, position and size, tumor anatomy, cellular struc‐
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ture and vascular supply, making it an important tool for the diagnosis, treatment and mon‐
itoring of the disease. For this reason, MRI is the study of choice of brain tumors.
Discussion of MRI physic details is beyond the scope of this chapter. The concept that is im‐
portant to remind is that conventional MRI exploits three physical properties of tissue pro‐
tons to generate signal imaged as areas of different contrast, which reflect the anatomy and
physiology of the organ under investigation. Those protons properties which contribute to
MRI signal generation are Proton Density (defined as the number of hydrogen protons per
unit of volume of tissue), T1 relaxation time (which is the time requested to recover 63% of
the longitudinal magnetization) and T2 relaxation time (which is defined as the time re‐
quested to recover 63% of the transverse magnetization to be lost). T1 and T2 relaxation time
and proton density are all specific for different type of tissues and increase as the magnet`s
field strength increases [6]. In all three types of images, bright areas correspond to tissue
with high signal intensity (i.e. areas with large transverse magnetization) and are referred to
as hyperintense, whereas dark areas correspond to low signal intensity (i.e. small transverse
magnetization) and are referred to as hypointense.
Different types of acquisition of MR imaging give different informations (table 1):
• T1-weighted images give a lot of anatomical informations as well as informations about
venous sinus permeability or pathologic blush. CSF is dark and fat is white in T1-weight‐
ed sequences. Lesions bright in T1- weighted sequences are: fat (lipoma, dermoid), suba‐
cute haemorrhage (metHb), metastatic melanoma (melanotic), protein-containing fluid
(colloid cyst) and paramagnetic agents (gadolinium).
• T2-weighted images give informations about oedema, arteries and sinus permeability.
Water is white in T2- weighted sequences, fat appears intermediate to dark, and haemato‐
mas have a variable signal intensity. Some dark lesions on T2-weighted images are acute
haemorrhage (deoxyHb), haemosiderin, iron and mucinous lesions.
• A proton density-weighted image is an image primarily dependent on the density of pro‐
tons in the imaging volume. The higher the number of protons in a given unit of tissue,
the brighter the signal is. Proton density-weighted images have excellent grey matter–
white matter contrast, as their brain CSF contrast is much lower. It is useful to study basal
nuclei anatomy and differentiate lacunar infarctions from Virchow-Robin spaces, and to
evaluate also cerebral gliosis.
Conventional MRI gives morphological informations about brain tumors. Some authors
name Conventional MRI as Morphological MRI, to differentiate it from Functional MRI that
will be discussed later. Those morphological informations are both macroscopic and micro‐
scopic (T2 sequences give useful information in this sense, with a low signal intensity in the
presence of calcification, melanin, lipids and haemosiderin). The vascularization of the neo‐
plasm can be seen with the typical vessel aspect characterized by absence of signal in all se‐
quences (the so called “Signal Void”).
Most of the tumors are iso-hypointense in T1 and hyperintense in DP and T2. A hyperinten‐
sity in T1, however, can only be caused by fat (lipomas) and paramagnetic substances, such
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to the work of Walter Dandy, a prominent neurosurgeon at Johns Hopkins Hospital [1]. The
1930s were marked by the introduction of cerebral angiography. From 1935 to 1946, the phe‐
nomenon of nuclear magnetic resonance was discovered [2]. The 1950s and 1960s witnessed
questions for practical solutions of tomography problems in neuroradiology and subsequent
development of electronics and computer techniques. The 1970s and 1980s were the years of
wide introduction of Computed Tomography (CT) in the clinical setting. When CT became
available, the use of uncomfortable procedures was abruptly stopped because CT could de‐
pict the ventricular system and the intracranial suarachnoid spaces directly, without intro‐
ducing air into the subarachnoid space itself [3]. As regard to the development of cerebral
angiography, in the early 1960s, it was performed by means of direct puncture of the com‐
mon carotid artery and the vertebral artery. In the late 1960s and early 1970s cerebral an‐
giography was predominantly performed by means of selective catheter angiography
following puncture of the femoral artery [3]. Progress in neuroradiology continued rapidly
with the development of MR imaging in the late 1970s and early 1980s. The advantages of
MRI imaging were that it could be performed in any plane and with various pulse sequen‐
ces, obtaining more details of the cerebral anatomy [4]. By the end of 20th century, Magnetic
Resonance Imaging (MRI) had been strongly incorporated into the clinical practice, and in
some cases (spinal cord examination) became a method of choice compared to the CT. The
high tissue resolution and the wide variety of types of contrast for MR images are typical for
MRI. Currently, MRI employs several physical factors defining the brightness of tissue on
the image such as: proton density; Т1 and Т2 relaxation time of protons in tissue; movement
of protons in the large vessels with a blood–cerebrospinal fluid (CSF) flow and passage of
protons through a capillary net; random thermal water molecule motion; anisotropy of the
diffusion proton motion and magnetic susceptibility of tissues; chemical shift of proton’s
resonance frequency in molecular complexes. In addition, volumetric CT and super-fast
MRI have opened wide diagnostic opportunities of CNS examination not only on a level of
anatomic structures (simulation and support of surgery, endoscopy), but also on a level of
molecular and gene biology. Neuroradiology has become the quantitative method of brain
function examination, able to monitor and predict the results of therapeutic treatment and
surgical intervention of many diseases [5].
Further development of neuroradiology is closely linked with the increase of processing
speed and improvements in computer technologies, increase of (MRI) magnetic field induc‐
tion, development of “open” magnets for biopsy, intra-operative control, examination of
critical patients.
This chapter focuses on the role of the most commonly used advanced MR imaging techni‐
ques – perfusion imaging, diffusion-weighted imaging, and MRI spectroscopy- for the diag‐
nosis of the most common brain tumors in adults.
1.2. Conventional MRI imaging
When dealing with a patient with a brain tumor, standard X-rays and CT scan is initially
used in the diagnostic process. However, MRI is generally more useful because it provides
detailed informations about tumor type, position and size, tumor anatomy, cellular struc‐
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ture and vascular supply, making it an important tool for the diagnosis, treatment and mon‐
itoring of the disease. For this reason, MRI is the study of choice of brain tumors.
Discussion of MRI physic details is beyond the scope of this chapter. The concept that is im‐
portant to remind is that conventional MRI exploits three physical properties of tissue pro‐
tons to generate signal imaged as areas of different contrast, which reflect the anatomy and
physiology of the organ under investigation. Those protons properties which contribute to
MRI signal generation are Proton Density (defined as the number of hydrogen protons per
unit of volume of tissue), T1 relaxation time (which is the time requested to recover 63% of
the longitudinal magnetization) and T2 relaxation time (which is defined as the time re‐
quested to recover 63% of the transverse magnetization to be lost). T1 and T2 relaxation time
and proton density are all specific for different type of tissues and increase as the magnet`s
field strength increases [6]. In all three types of images, bright areas correspond to tissue
with high signal intensity (i.e. areas with large transverse magnetization) and are referred to
as hyperintense, whereas dark areas correspond to low signal intensity (i.e. small transverse
magnetization) and are referred to as hypointense.
Different types of acquisition of MR imaging give different informations (table 1):
• T1-weighted images give a lot of anatomical informations as well as informations about
venous sinus permeability or pathologic blush. CSF is dark and fat is white in T1-weight‐
ed sequences. Lesions bright in T1- weighted sequences are: fat (lipoma, dermoid), suba‐
cute haemorrhage (metHb), metastatic melanoma (melanotic), protein-containing fluid
(colloid cyst) and paramagnetic agents (gadolinium).
• T2-weighted images give informations about oedema, arteries and sinus permeability.
Water is white in T2- weighted sequences, fat appears intermediate to dark, and haemato‐
mas have a variable signal intensity. Some dark lesions on T2-weighted images are acute
haemorrhage (deoxyHb), haemosiderin, iron and mucinous lesions.
• A proton density-weighted image is an image primarily dependent on the density of pro‐
tons in the imaging volume. The higher the number of protons in a given unit of tissue,
the brighter the signal is. Proton density-weighted images have excellent grey matter–
white matter contrast, as their brain CSF contrast is much lower. It is useful to study basal
nuclei anatomy and differentiate lacunar infarctions from Virchow-Robin spaces, and to
evaluate also cerebral gliosis.
Conventional MRI gives morphological informations about brain tumors. Some authors
name Conventional MRI as Morphological MRI, to differentiate it from Functional MRI that
will be discussed later. Those morphological informations are both macroscopic and micro‐
scopic (T2 sequences give useful information in this sense, with a low signal intensity in the
presence of calcification, melanin, lipids and haemosiderin). The vascularization of the neo‐
plasm can be seen with the typical vessel aspect characterized by absence of signal in all se‐
quences (the so called “Signal Void”).
Most of the tumors are iso-hypointense in T1 and hyperintense in DP and T2. A hyperinten‐
sity in T1, however, can only be caused by fat (lipomas) and paramagnetic substances, such
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as melanin (melanoma metastases) and different degradation products of hemoglobin. Tu‐
mors with high cellularity (medulloblastomas, lymphomas) are characterized by a hyperin‐
tensity in DP and relatively low signal on T2-weighted images. Meningiomas are usually
isointense in all sequences, and- if small - may be disregarded on the basic examination.
The cystic-necrotic areas usually associated with malignant tumor such as glioblastoma mul‐
tiforme (GBM) are markedly hypointense on T1 and hyperintense on T2. Signal can be differ‐
entiated, in most cases, from that of CSF in the proton density, as necrotic areas are slightly
hyperintense, while CSF is slightly hypointense. It is important the concentration of proteins
within cystic tumors, being the hyperintensity in the T2 sequences directly proportional to the
protein concentration. It must be noted, on the other hand, that when the protein concentra‐
tion in the cystic lesion is too high there can be a paradoxal hyperintensity in T1 and hypoin‐
tensity in T2 sequences. The hemorrhagic areas cause the typical alterations of signal that
follow the steps of degradation of haemoglobin. Calcifications are highlighted as areas of signal
void, hypointense in T2 and DP. Perilesional edema is characterized as an area slightly hypo‐
intense on T1 and hyperintense in DP and T2. The mass effect can be evaluated in a much
more accurate way than CT in studying the behavior of convolutions of the brain. A lesion
may be considered intra-axial if it expands the adjacent cerebral convolutions. Anyway an
intra-axial lesion may invade the meninges (eg, metastasis, glioblastoma multiforme) and an
extra-axial lesions can invade the brain tissue (eg, dural metastases).
Another important sequences in MRI is “Fluid Attenuated Inversion Recovery” (FLAIR) also
called the “dark fluid technique”. It is used to remove the effects of fluid from the result‐
ing images. Lesions that are normally covered by bright fluid signals on T2-weighted im‐
ages are visible by FLAIR. Its use is very common in many specific diseases, such as multiple
sclerosis. Particularly, the correct evaluation of site and extension of the tumour is an impor‐
tant step to define the possibility of surgical resection. FLAIR sequences, available in 3D
form on modern MRI equipment, seem to be mandatory to assess the extension of a glio‐
ma, usually with a hyperintense signal. 3D T1 weighted GRE sequences can provide im‐
ages with high inplane spatial  resolution without interslice gaps.  This technique can be,
therefore, very useful, after gadolinium injection, to obtain volumetric MRI data that can be
reconstructed in any desired plane,  suitable for presurgical  planning or surgical  naviga‐
tion system.
Another important tool in MRI imaging is the use of contrast medium. Gadolinium, a rare
earth metal, is frequently used in MRI. The paramagnetic properties of gadolinium affect
free protons and hence shorten Tl-weighted signal. Gadolinium is not visualized but its ef‐
fect on free protons. Increased concentrations of gadolinium will result in high signal, i.e.
enhancement, on Tl weighting. It highlights areas of blood-brain barrier breakdown, areas
of inflammation and increased vascularity. Marked enhancement is normally visible in the
pituitary gland, choroid plexus, nasal mucosa and turbinates, and in slowflowing blood in
vessels. Contrast enhancement is frequently used to improve detection and definition of tu‐
mors, infections, meningeal diseases, vascular diseases and "post-operative spine". Gadolini‐
um is an extremely safe substance and has been used worldwide with less side-effects
compared to iodinated contrast media. Gadolinium is a substance that allows the study of
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the blood-brain barrier permeability in brain tumors: low-grade tumors, which contain ca‐
pillaries with a structure similar to the normal nervous tissue with tight junction, are charac‐
terized by no enhancement, while high-grade tumors have pathological capillaries with a
high enhancement after gadolinium administration, expression of the blood-brain barrier
disruption. As regard to extra-axial tumors, they usually have high enhancement because,
being extra-axial lesions, they have no blood-brain barrier.
Basically the most important goals of conventional MRI in the diagnosis of brain tumors are:
- discover the lesion and define its nature (blood, ischaemia, tumor).
- localize the lesion (intra- or extra-axial, above or under the tentorium) and define its limits
and relations with the surrounding structures, with the use of gadolinium.
- evaluate mass effect (compression, dislocations, cerebral erniation).
- evaluate the characteristics (necrosis, calcifications, surrounding oedema, haemorrhage,
rupture of blood-brain barrier).
- give indications about the most probable histological nature and grade of malignancy of
the tumor.
- define the vascularization and the relations with the closest cerebral vessels (very impor‐
tant in meningiomas, where it is necessary to evaluate the feeding arteries, in order to con‐
sider the possibility of a preoperative endovascular embolization, and the possible
infiltration of dural sinus or cerebral vessels).
Substance On T1 weighting On T2 weighting
Water Black White
Fat White Gray/white
White matter Gray Gray/black





Intervertebral disk Gray White
Air Black Black
Hematoma Depends on the phase Depend on the phase
Most pathology Gray/black White
Table 1. Signal intensity on MRI
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as melanin (melanoma metastases) and different degradation products of hemoglobin. Tu‐
mors with high cellularity (medulloblastomas, lymphomas) are characterized by a hyperin‐
tensity in DP and relatively low signal on T2-weighted images. Meningiomas are usually
isointense in all sequences, and- if small - may be disregarded on the basic examination.
The cystic-necrotic areas usually associated with malignant tumor such as glioblastoma mul‐
tiforme (GBM) are markedly hypointense on T1 and hyperintense on T2. Signal can be differ‐
entiated, in most cases, from that of CSF in the proton density, as necrotic areas are slightly
hyperintense, while CSF is slightly hypointense. It is important the concentration of proteins
within cystic tumors, being the hyperintensity in the T2 sequences directly proportional to the
protein concentration. It must be noted, on the other hand, that when the protein concentra‐
tion in the cystic lesion is too high there can be a paradoxal hyperintensity in T1 and hypoin‐
tensity in T2 sequences. The hemorrhagic areas cause the typical alterations of signal that
follow the steps of degradation of haemoglobin. Calcifications are highlighted as areas of signal
void, hypointense in T2 and DP. Perilesional edema is characterized as an area slightly hypo‐
intense on T1 and hyperintense in DP and T2. The mass effect can be evaluated in a much
more accurate way than CT in studying the behavior of convolutions of the brain. A lesion
may be considered intra-axial if it expands the adjacent cerebral convolutions. Anyway an
intra-axial lesion may invade the meninges (eg, metastasis, glioblastoma multiforme) and an
extra-axial lesions can invade the brain tissue (eg, dural metastases).
Another important sequences in MRI is “Fluid Attenuated Inversion Recovery” (FLAIR) also
called the “dark fluid technique”. It is used to remove the effects of fluid from the result‐
ing images. Lesions that are normally covered by bright fluid signals on T2-weighted im‐
ages are visible by FLAIR. Its use is very common in many specific diseases, such as multiple
sclerosis. Particularly, the correct evaluation of site and extension of the tumour is an impor‐
tant step to define the possibility of surgical resection. FLAIR sequences, available in 3D
form on modern MRI equipment, seem to be mandatory to assess the extension of a glio‐
ma, usually with a hyperintense signal. 3D T1 weighted GRE sequences can provide im‐
ages with high inplane spatial  resolution without interslice gaps.  This technique can be,
therefore, very useful, after gadolinium injection, to obtain volumetric MRI data that can be
reconstructed in any desired plane,  suitable for presurgical  planning or surgical  naviga‐
tion system.
Another important tool in MRI imaging is the use of contrast medium. Gadolinium, a rare
earth metal, is frequently used in MRI. The paramagnetic properties of gadolinium affect
free protons and hence shorten Tl-weighted signal. Gadolinium is not visualized but its ef‐
fect on free protons. Increased concentrations of gadolinium will result in high signal, i.e.
enhancement, on Tl weighting. It highlights areas of blood-brain barrier breakdown, areas
of inflammation and increased vascularity. Marked enhancement is normally visible in the
pituitary gland, choroid plexus, nasal mucosa and turbinates, and in slowflowing blood in
vessels. Contrast enhancement is frequently used to improve detection and definition of tu‐
mors, infections, meningeal diseases, vascular diseases and "post-operative spine". Gadolini‐
um is an extremely safe substance and has been used worldwide with less side-effects
compared to iodinated contrast media. Gadolinium is a substance that allows the study of
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the blood-brain barrier permeability in brain tumors: low-grade tumors, which contain ca‐
pillaries with a structure similar to the normal nervous tissue with tight junction, are charac‐
terized by no enhancement, while high-grade tumors have pathological capillaries with a
high enhancement after gadolinium administration, expression of the blood-brain barrier
disruption. As regard to extra-axial tumors, they usually have high enhancement because,
being extra-axial lesions, they have no blood-brain barrier.
Basically the most important goals of conventional MRI in the diagnosis of brain tumors are:
- discover the lesion and define its nature (blood, ischaemia, tumor).
- localize the lesion (intra- or extra-axial, above or under the tentorium) and define its limits
and relations with the surrounding structures, with the use of gadolinium.
- evaluate mass effect (compression, dislocations, cerebral erniation).
- evaluate the characteristics (necrosis, calcifications, surrounding oedema, haemorrhage,
rupture of blood-brain barrier).
- give indications about the most probable histological nature and grade of malignancy of
the tumor.
- define the vascularization and the relations with the closest cerebral vessels (very impor‐
tant in meningiomas, where it is necessary to evaluate the feeding arteries, in order to con‐
sider the possibility of a preoperative endovascular embolization, and the possible
infiltration of dural sinus or cerebral vessels).
Substance On T1 weighting On T2 weighting
Water Black White
Fat White Gray/white
White matter Gray Gray/black





Intervertebral disk Gray White
Air Black Black
Hematoma Depends on the phase Depend on the phase
Most pathology Gray/black White
Table 1. Signal intensity on MRI
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1.3. Digital Subtraction Angiography (DSA)
Catheter angiography is an invasive technique which has progressively become safer with the
introduction of DSA, non-iodate contrast media and improved catheters and guide wires.
The right femoral artery is punctured using the Seldinger technique. The catheter is then ad‐
vanced up to the aortic arch and then, selectively, into the required artery. The catheters are
usually 4F or 5F in size and pre-shaped to facilitate selective catheterization. Once in posi‐
tion in the desired artery, the formal DSA is undertaken with the contrast injection by hand
or mechanical pump. Multiple projections are used to demonstrate the vasculature and im‐
ages are obtained as far as the venous phase in several planes. Commonly, the internal caro‐
tid circulation is studied in lateral, posteroanterior 20° and oblique projection, e.g. 30°
cranio-caudal, 30° lateral.
The posterior circulation is studied in lateral and Townes' projection (30° fronto-occipital).
Numerous supplementary projections can be performed according to which vessel has to be
demonstrated. This is particularly Important in the diagnosis of aneurysms where a clear
demonstration of the neck of the aneurysm is required, especially if endovascular treatment
has to be considered.
Local complications occur in about 5% of cases and range from self-limiting hematoma to
fatal retroperitoneal hematoma. Vessel injury can result in pseudo-aneurysm, arteriovenous
fistula and distal emboli.
Systemic complications are related to the contrast media or, very occasionally, to local anes‐
thetics and sedation. Contrast media reactions are common to all radiological procedures us‐
ing iodinated contrast. The risk is increased by history of previous reaction and in asthma
sufferers, where the risk of severe reaction is about 0.2%. Neurological complications range
from headache to disabling stroke or death. The risks are increased in the older population
(over 50 years), particularly if there is atherosclerosis, vasculitis or sickle cell disease.
Cerebral DSA remains the investigation of choice in a number of conditions despite improve‐
ments in Doppler ultrasound, MRAand CTA. The most common reason for its use is in
the investigation of Subarachnoid hemorrhage (SAH), where DSA remains the gold stand‐
ard.  Other  indications  for  angiography  include:  assessment  of  aneurysms  (e.g.fusiform,
dissecting,  mycotic,  giant)  that  have not  presented with SAH; assessment of  AVMs and
other vascular lesions, such as carotido-cavernous fistula or dural fistula; investigation of
various cerebrovascular disorders, such as vasculitis and demonstration of tumor vascular‐
ity, particularly if pre-operative embolization has been considered. This is particularly true
for intracranial meningiomas. Meningiomas are commonly supplied by dural arteries such
as middle meningeal artery, accessory meningeal arery, ascending pharyngeal,  or occipi‐
tal  transmastoid  perforating  branches  of  the  external  carotid  artery.  Dural  arteries  also
include the tentorial and infratentorial trunk branches of the internal carotid artery, as well
as the posterior meningeal branch of the vertebral artery. Secondary supply to meningio‐
mas may be  derived from pial  branches  (of  the  anterior,  middle  and posterior  cerebral
arteries).  Embolization involves the devascularization of the tumor’s supply through the
placement of an embolic agent via a microcatheter into the feeding arteries. Because men‐
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ingiomas are usually vascularized,  preoperative tumor embolization can easily complete
tumor resection by diminishing operative time and intraoperative blood loss [7]. Diagnos‐
tic angiography can also identify important informations for the surgeon such as a poten‐
tial occlusion of a dural sinus adjacent to the tumor and the pattern of collateral venous
drainage around such an occlusion.
Angiography in gliomas is not specific. Many gliomas, especially low-grade, are seen as
avascular or hypovascular areas surrounded by displaced normal vessels. High-grade glio‐
mas may show intense tumor neovascularization in a disorganized pattern, a prominent tu‐
mor blush in the mid-arterial phase, hypovascular areas representing necrosis or cysts and
arteriovenous shunting with early draining veins which represent the most angiographically
common finding in glioblastoma multiforme. These characteristics do not allow the differen‐
tiation of a primary glioblastoma from a secondary lesion. Some authors propose the possi‐
bility to use DSA in patients with brain metastases, in order to get a regional chemoinfusion
to the arteries feeding the metastatic foci [8].
1.4 . New Functional Methods in Neuroradiology
The increase of the processing speed of CT and MRI scanners, the invention of new data-
registration technologies and the algorithms of data-processing transfer neuroradiology al‐
lowed great development in neuroradiology. Functional MRI can detect areas of the brain
having increased neuronal and metabolic activity, and areas of damage in the brain–blood
barrier. It makes a quantitative assessment of microvascular permeability of brain tissue,
evaluates the state of receptors on the cell surface as well as hormonal activity, and reveals
the presence of certain antigen and protein structures [5]. Thus, CT and MRI perform diag‐
nostics not only on a cellular, but also on a molecular level. Diffusion, perfusion, MR spec‐
troscopy and functional MRI belong to the so-called methods of molecular visualization.
1.4.1. Diffusion Weighted Imaging
Diffusion is the basic physical process occurring during the cell’s metabolic reactions. Kinet‐
ic energy leads to Brownian motion (random walk) of molecules (thermal motion; the speed
is about 10–3 mm2/s). As a whole, the molecular motion of protons in physiological systems
is divided into three types:
1. movements with moderate speed in macroscopic vessels (about 10–100 mm/s);
2. slow flow in a capillary net, or perfusion (the speed is about 0.1–10 mm/s); and
3. diffusion motion of molecules (the speed is about 10–3 mm2/s).
Blood flow in large vessels is measured as a volume-in-time unit, perfusion flow (a local
blood flow) is measured as the volume of blood passing in and out of a given tissue weight
(volume) per unit of time and the diffusion factor is estimated by the average square of the
distance made by molecules for a time unit.
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1.3. Digital Subtraction Angiography (DSA)
Catheter angiography is an invasive technique which has progressively become safer with the
introduction of DSA, non-iodate contrast media and improved catheters and guide wires.
The right femoral artery is punctured using the Seldinger technique. The catheter is then ad‐
vanced up to the aortic arch and then, selectively, into the required artery. The catheters are
usually 4F or 5F in size and pre-shaped to facilitate selective catheterization. Once in posi‐
tion in the desired artery, the formal DSA is undertaken with the contrast injection by hand
or mechanical pump. Multiple projections are used to demonstrate the vasculature and im‐
ages are obtained as far as the venous phase in several planes. Commonly, the internal caro‐
tid circulation is studied in lateral, posteroanterior 20° and oblique projection, e.g. 30°
cranio-caudal, 30° lateral.
The posterior circulation is studied in lateral and Townes' projection (30° fronto-occipital).
Numerous supplementary projections can be performed according to which vessel has to be
demonstrated. This is particularly Important in the diagnosis of aneurysms where a clear
demonstration of the neck of the aneurysm is required, especially if endovascular treatment
has to be considered.
Local complications occur in about 5% of cases and range from self-limiting hematoma to
fatal retroperitoneal hematoma. Vessel injury can result in pseudo-aneurysm, arteriovenous
fistula and distal emboli.
Systemic complications are related to the contrast media or, very occasionally, to local anes‐
thetics and sedation. Contrast media reactions are common to all radiological procedures us‐
ing iodinated contrast. The risk is increased by history of previous reaction and in asthma
sufferers, where the risk of severe reaction is about 0.2%. Neurological complications range
from headache to disabling stroke or death. The risks are increased in the older population
(over 50 years), particularly if there is atherosclerosis, vasculitis or sickle cell disease.
Cerebral DSA remains the investigation of choice in a number of conditions despite improve‐
ments in Doppler ultrasound, MRAand CTA. The most common reason for its use is in
the investigation of Subarachnoid hemorrhage (SAH), where DSA remains the gold stand‐
ard.  Other  indications  for  angiography  include:  assessment  of  aneurysms  (e.g.fusiform,
dissecting,  mycotic,  giant)  that  have not  presented with SAH; assessment of  AVMs and
other vascular lesions, such as carotido-cavernous fistula or dural fistula; investigation of
various cerebrovascular disorders, such as vasculitis and demonstration of tumor vascular‐
ity, particularly if pre-operative embolization has been considered. This is particularly true
for intracranial meningiomas. Meningiomas are commonly supplied by dural arteries such
as middle meningeal artery, accessory meningeal arery, ascending pharyngeal,  or occipi‐
tal  transmastoid  perforating  branches  of  the  external  carotid  artery.  Dural  arteries  also
include the tentorial and infratentorial trunk branches of the internal carotid artery, as well
as the posterior meningeal branch of the vertebral artery. Secondary supply to meningio‐
mas may be  derived from pial  branches  (of  the  anterior,  middle  and posterior  cerebral
arteries).  Embolization involves the devascularization of the tumor’s supply through the
placement of an embolic agent via a microcatheter into the feeding arteries. Because men‐
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ingiomas are usually vascularized,  preoperative tumor embolization can easily complete
tumor resection by diminishing operative time and intraoperative blood loss [7]. Diagnos‐
tic angiography can also identify important informations for the surgeon such as a poten‐
tial occlusion of a dural sinus adjacent to the tumor and the pattern of collateral venous
drainage around such an occlusion.
Angiography in gliomas is not specific. Many gliomas, especially low-grade, are seen as
avascular or hypovascular areas surrounded by displaced normal vessels. High-grade glio‐
mas may show intense tumor neovascularization in a disorganized pattern, a prominent tu‐
mor blush in the mid-arterial phase, hypovascular areas representing necrosis or cysts and
arteriovenous shunting with early draining veins which represent the most angiographically
common finding in glioblastoma multiforme. These characteristics do not allow the differen‐
tiation of a primary glioblastoma from a secondary lesion. Some authors propose the possi‐
bility to use DSA in patients with brain metastases, in order to get a regional chemoinfusion
to the arteries feeding the metastatic foci [8].
1.4 . New Functional Methods in Neuroradiology
The increase of the processing speed of CT and MRI scanners, the invention of new data-
registration technologies and the algorithms of data-processing transfer neuroradiology al‐
lowed great development in neuroradiology. Functional MRI can detect areas of the brain
having increased neuronal and metabolic activity, and areas of damage in the brain–blood
barrier. It makes a quantitative assessment of microvascular permeability of brain tissue,
evaluates the state of receptors on the cell surface as well as hormonal activity, and reveals
the presence of certain antigen and protein structures [5]. Thus, CT and MRI perform diag‐
nostics not only on a cellular, but also on a molecular level. Diffusion, perfusion, MR spec‐
troscopy and functional MRI belong to the so-called methods of molecular visualization.
1.4.1. Diffusion Weighted Imaging
Diffusion is the basic physical process occurring during the cell’s metabolic reactions. Kinet‐
ic energy leads to Brownian motion (random walk) of molecules (thermal motion; the speed
is about 10–3 mm2/s). As a whole, the molecular motion of protons in physiological systems
is divided into three types:
1. movements with moderate speed in macroscopic vessels (about 10–100 mm/s);
2. slow flow in a capillary net, or perfusion (the speed is about 0.1–10 mm/s); and
3. diffusion motion of molecules (the speed is about 10–3 mm2/s).
Blood flow in large vessels is measured as a volume-in-time unit, perfusion flow (a local
blood flow) is measured as the volume of blood passing in and out of a given tissue weight
(volume) per unit of time and the diffusion factor is estimated by the average square of the
distance made by molecules for a time unit.
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The image appearance in “isotropic” Diffusion Weighted Imaging (DWI) is based on the
principle that molecules in any living tissue routinely undergo random (brownian) motion.
Isotropic DW images are typically obtained by measuring loss of signal after a pulse se‐
quence that consists of a series of two sequential gradient pulses added to a 90°–180° spin-
echo sequence on either side of the 180° pulse [9]. The degree of MR signal loss after
application of the second gradient pulse is related to two factors:
a. the duration and strength of the magnetic field gradients and
b. the diffusion coefficient of the substance.
The apparent diffusion coefficient (ADC) is a value that describes microscopic water diffusi‐
bility in the presence of factors that restrict diffusion within tissues (eg, cell membranes, vis‐
cosity). The ADC can be derived on a voxel-by-voxel basis and depicted on an ADC map,
which allows ADCs in specific regions to be measured by using regions of interest. Meas‐
urement of the ADC would be expected to be useful in tumor assessment because variations
in water content (and diffusivity), which can be found within tumors for various reasons
(eg, necrosis, variations in cellularity) and adjacent to tumors (eg, vasogenic edema), pro‐
vide information that is not readily available from conventional MR imaging.
The motion of the water molecules in live tissues occurs within the cell limits (the limited
diffusion), as well as in intercellular spaces among structures, which restrict the molecules
motion but still leaves them some freedom for manoeuvring between obstacles (the compli‐
cated diffusion). Water diffusion inside extracellular space is inversely proportional to the
density of the intracellular space constituents.
The tendency for water molecules to diffuse in some directions rather than equally in all di‐
rections is termed “anisotropy.” Highly compact white matter fiber tracts exhibit a high de‐
gree of anisotropy, and less compact white matter pathways exhibit lesser degrees of
anisotropy. All types of white matter typically show greater degrees of anisotropy than are
seen in gray matter structures, which have a low degree of anisotropy.
Diffusion Tensor Imaging (DTI) represents a magnetic resonance imaging method that is
expression of fractional water anisotrophy (FA) and is available in many modern clinical
scanners. DTI is similar to DWI but involves the collection of additional data necessary to
define the tensor (vector) which describes the preferential direction and magnitude of wa‐
ter diffusion. FA maps has been used to investigate the microstructure of white matter that
can be altereted in many pathologic conditions such as brain tumors. DTI provides a sensi‐
tive means to detect alterations in the integrity of white matter structures. In fact, in many
settings, white matter abnormalities can be seen on diffusion-tensor images being not evi‐
dent on routine MR images [2,3]. Diffusion-tensor imaging also provides a means of depict‐
ing white matter pathways (tractography). This may be useful in neurosurgical procedures
by preoperatively depicting important white matter tracts, helping determine infiltration of
white matter tracts by tumor, and providing evidence of degeneration of white matter tracts
distal to tumor sites (ie, wallerian degeneration). In the real biological environment, water
molecules can encounter natural barriers, such as cellular membranes and large albumin
molecules, which can interfere with free motion of protons. Therefore, in practice, the appa‐
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors62
rent diffusion coefficient is calculated, and its value is lower than diffusion coefficient for
pure water at temperature.
All diffusion-weighted examinations are performed without contrast injection. This is impor‐
tant for critically ill and restless patients, and especially for special examinations of brain
development in children, beginning with the prenatal period. In the last case, DWI enables to
obtain both the additional qualitative (visualization) and quantitative tissue characteristics.
1.4.1.2. Clinical Application of DWI and DTI
Today, DWI is one of the fastest and highly specific methods of early-phase ischaemic stroke
diagnostics (within 6 h of onset), during which there is a therapeutic window for restoration
of the affected brain tissue. In acute phase of stroke, the affected area on DWI typically has a
high MR signal, whereas the surrounding tissues look dark. The ADC maps provide a re‐
verse-in-brightness picture. Diffusion ADC maps are a tool in the diagnosis and monitoring
of cerebral ischaemia.
DWI provides invaluable informations for inflammatory lesions of brain and spinal cord
(abscesses, empyema). Purulent abscess content has a typical hyperintense MR signal on
DWI and can be easily visualised on pretreatment (before draining) and as well on postoper‐
ative images. In addition, DWI can be used in the assessment of drainage intervention effec‐
tiveness or in the case of verification of the purulent complication in incision wound.
DWI and ADC maps provide great help in the diagnosis of brain tumors, providing addi‐
tional diagnostic informations for differentiation of neoplasms with similar signs on T1 and
T2 MRI (glioma, tumours with ring-shaped contrast accumulation), peritumoral oedema
(vasogenic or cytotoxic) or the presence or absence of intratumoral cysts, only to name a few
[10]. At the same time, as some authors demonstrate, DWI data alone do not allow differen‐
tiation between benign astrocytoma and anaplastic tumours, or between anaplastic astrocy‐
toma and glioblastoma [5].
In many observations, the peripheral part of a tumor (as a rule in the case of malignant glio‐
mas) is hyperintense on DWI; presumably it is linked to more dense cellular arrangement in
the most actively growing tumor area (accordingly, there is a limitation on diffusive proton
motion in this area). In fact, it has been demonstrated that the higher the tumor cellularity is
the greater is the ADC value . It is demonstrated that value of ADC higher than 100 x 10–3
mm2/s is typical of high grade tumors while ADC values lower than 100 x 10–3 mm2/s are
related to low grade lesion [11].
A low ADC in an intra-axial neoplasm should raise suspicion for lymphoma or metastatis,
depending on the conventional MRI appearance, because the higher cellularity of these tu‐
mors generally produces an ADC which is significantly lower than in glioma. However, al‐
though most gliomas have a higher ADC (related to their lower cellularity), a number of
case reports have demonstrated a low ADC in a small number of glioblastoma. Thus it is
important to integrate DWI with other advanced and conventional neuroimaging data for
accurate clinical interpretation [12].
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The image appearance in “isotropic” Diffusion Weighted Imaging (DWI) is based on the
principle that molecules in any living tissue routinely undergo random (brownian) motion.
Isotropic DW images are typically obtained by measuring loss of signal after a pulse se‐
quence that consists of a series of two sequential gradient pulses added to a 90°–180° spin-
echo sequence on either side of the 180° pulse [9]. The degree of MR signal loss after
application of the second gradient pulse is related to two factors:
a. the duration and strength of the magnetic field gradients and
b. the diffusion coefficient of the substance.
The apparent diffusion coefficient (ADC) is a value that describes microscopic water diffusi‐
bility in the presence of factors that restrict diffusion within tissues (eg, cell membranes, vis‐
cosity). The ADC can be derived on a voxel-by-voxel basis and depicted on an ADC map,
which allows ADCs in specific regions to be measured by using regions of interest. Meas‐
urement of the ADC would be expected to be useful in tumor assessment because variations
in water content (and diffusivity), which can be found within tumors for various reasons
(eg, necrosis, variations in cellularity) and adjacent to tumors (eg, vasogenic edema), pro‐
vide information that is not readily available from conventional MR imaging.
The motion of the water molecules in live tissues occurs within the cell limits (the limited
diffusion), as well as in intercellular spaces among structures, which restrict the molecules
motion but still leaves them some freedom for manoeuvring between obstacles (the compli‐
cated diffusion). Water diffusion inside extracellular space is inversely proportional to the
density of the intracellular space constituents.
The tendency for water molecules to diffuse in some directions rather than equally in all di‐
rections is termed “anisotropy.” Highly compact white matter fiber tracts exhibit a high de‐
gree of anisotropy, and less compact white matter pathways exhibit lesser degrees of
anisotropy. All types of white matter typically show greater degrees of anisotropy than are
seen in gray matter structures, which have a low degree of anisotropy.
Diffusion Tensor Imaging (DTI) represents a magnetic resonance imaging method that is
expression of fractional water anisotrophy (FA) and is available in many modern clinical
scanners. DTI is similar to DWI but involves the collection of additional data necessary to
define the tensor (vector) which describes the preferential direction and magnitude of wa‐
ter diffusion. FA maps has been used to investigate the microstructure of white matter that
can be altereted in many pathologic conditions such as brain tumors. DTI provides a sensi‐
tive means to detect alterations in the integrity of white matter structures. In fact, in many
settings, white matter abnormalities can be seen on diffusion-tensor images being not evi‐
dent on routine MR images [2,3]. Diffusion-tensor imaging also provides a means of depict‐
ing white matter pathways (tractography). This may be useful in neurosurgical procedures
by preoperatively depicting important white matter tracts, helping determine infiltration of
white matter tracts by tumor, and providing evidence of degeneration of white matter tracts
distal to tumor sites (ie, wallerian degeneration). In the real biological environment, water
molecules can encounter natural barriers, such as cellular membranes and large albumin
molecules, which can interfere with free motion of protons. Therefore, in practice, the appa‐
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rent diffusion coefficient is calculated, and its value is lower than diffusion coefficient for
pure water at temperature.
All diffusion-weighted examinations are performed without contrast injection. This is impor‐
tant for critically ill and restless patients, and especially for special examinations of brain
development in children, beginning with the prenatal period. In the last case, DWI enables to
obtain both the additional qualitative (visualization) and quantitative tissue characteristics.
1.4.1.2. Clinical Application of DWI and DTI
Today, DWI is one of the fastest and highly specific methods of early-phase ischaemic stroke
diagnostics (within 6 h of onset), during which there is a therapeutic window for restoration
of the affected brain tissue. In acute phase of stroke, the affected area on DWI typically has a
high MR signal, whereas the surrounding tissues look dark. The ADC maps provide a re‐
verse-in-brightness picture. Diffusion ADC maps are a tool in the diagnosis and monitoring
of cerebral ischaemia.
DWI provides invaluable informations for inflammatory lesions of brain and spinal cord
(abscesses, empyema). Purulent abscess content has a typical hyperintense MR signal on
DWI and can be easily visualised on pretreatment (before draining) and as well on postoper‐
ative images. In addition, DWI can be used in the assessment of drainage intervention effec‐
tiveness or in the case of verification of the purulent complication in incision wound.
DWI and ADC maps provide great help in the diagnosis of brain tumors, providing addi‐
tional diagnostic informations for differentiation of neoplasms with similar signs on T1 and
T2 MRI (glioma, tumours with ring-shaped contrast accumulation), peritumoral oedema
(vasogenic or cytotoxic) or the presence or absence of intratumoral cysts, only to name a few
[10]. At the same time, as some authors demonstrate, DWI data alone do not allow differen‐
tiation between benign astrocytoma and anaplastic tumours, or between anaplastic astrocy‐
toma and glioblastoma [5].
In many observations, the peripheral part of a tumor (as a rule in the case of malignant glio‐
mas) is hyperintense on DWI; presumably it is linked to more dense cellular arrangement in
the most actively growing tumor area (accordingly, there is a limitation on diffusive proton
motion in this area). In fact, it has been demonstrated that the higher the tumor cellularity is
the greater is the ADC value . It is demonstrated that value of ADC higher than 100 x 10–3
mm2/s is typical of high grade tumors while ADC values lower than 100 x 10–3 mm2/s are
related to low grade lesion [11].
A low ADC in an intra-axial neoplasm should raise suspicion for lymphoma or metastatis,
depending on the conventional MRI appearance, because the higher cellularity of these tu‐
mors generally produces an ADC which is significantly lower than in glioma. However, al‐
though most gliomas have a higher ADC (related to their lower cellularity), a number of
case reports have demonstrated a low ADC in a small number of glioblastoma. Thus it is
important to integrate DWI with other advanced and conventional neuroimaging data for
accurate clinical interpretation [12].
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In other brain neoplasms—in particular meningiomas and neurinomas— DWI may predict
tumour histological type, with high reliability even before surgery. Based on this method
data, the epidermoid and arachnoid cysts can be precisely differentiated. In fact DWI has a
sensivity and specificy of over 90% for distinguishing epidermoid (low ADC) from aracnoid
cyst (high ADC) and distinguishing abscess (low ADC) from necrotic tumor (high ADC).
The viscous keratin and cholesterol in epidermoid and the viscous and cellular pus in ab‐
scess produce a very low ADC that distinguishes these lesions from increased diffusivity in
necrotic tumor and from normal or slightly low diffusivity in demyelinating plaque. Menin‐
giomas, a lower ADC has been demonstrated in atypical and malignant subtypes. It is also
demonstrated that the eterogeneity of ADC within tumor reflects heterogeneity of cellularity
within it [12].
Recently, DWI and DTI methods have begun to be applied to visualisation of a neural tract
lines—tractography. This is a new and promising technique that enables non-invasive view‐
ing of the brain neural tracts [13]. Despite some technical problems, the first results in trac‐
tography application to neurosurgery seem promising [5]. It is possible to plan operational
access and to estimate the scope of brain hematoma to be removed, taking into account neu‐
ral tracts and their involvement in the pathological process (dislocation–deformation, inva‐
sion, damage), with an aim to maximise the radical tumour resection and to minimise the
subsequent complications [14].
In gliomas, the infiltration of the tumor disrupts the organization of the white matter tracts:
FA derived from DTI defines of the degree of tumor infiltration. [12]. Some studies also sug‐
gest that DTI may distinguish vasogenic edema in brain metastases and meningiomas from
non-enhancing tumor infiltration in gliomas. It has to be considered that white matter adja‐
cent to glioma generally contains different proportions of vasogenic edema and tumor infil‐
tration at different distances from the center of the tumor, making more difficult to define an
unbiased region of interest for valid data analysis.
1.4.2. Perfusion Weighted Imaging
Perfusion studies are useful to quantify blood movement supplying each element of organ
or tissue volume. It is widely known that, unlike the majority of parenchymatous tissue,
brain tissue does not accumulate glucose, and brain cells can produce energy via anaerobic
glycolysis only for several minutes.
Meanwhile, the brain consumes about 25% of all glucose consumed in the entire body, and
for neurons, the uninterrupted and sufficient supply of oxygen and glucose is necessary.
There are complex mechanisms of autoregulation that manage brain perfusion to satisfy the
demands of the nervous system for energy (released in a course of metabolic processes).
There are several modern quantitative methods of brain haemodynamic examination: MRI,
CT with contrast enhancement, CT with Xe, single-photon emission computed tomography
(SPECT) imaging and positron emission tomography (PET). The obvious advantages of CT
and MRI are minimally invasive, high sensitivity in tissue microcirculation assessment, high
resolution, the short examination time (within the framework of standard protocols), and
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last, but not least, the reproducibility of results. The most widespread perfusion examina‐
tion in neuroradiology is based on intravenous bolus administration (CT and MRI). The dy‐
namic studies of bolus passage demonstrate its distribution in tissue in each given image
pixel, depending on time. The following main haemodynamic characteristics are used for
quantitative assessment: cerebral blood flow (CBF), cerebral blood volume (CBV) and mean
transit time (MTT).
The blood flow characteristics are measured in the ratio to 100 g of brain tissue. According‐
ly, the value of CBV is measured in millilitres per 100 g of brain tissue, and CBF is measured
in millilitres per 100 g per minute. The local (regional) CBV is defined as percentage of blood
volume in a single element of brain tissue volume. MTT is measured in seconds.
Perfusion CT
CT approaches to perfusion imaging were first proposed in the early 1980s. However, clini‐
cal uses of perfusion CT were slow to progress because the technique suffered initially from
relatively limited imaging volumes and poor temporal resolution. With the advent of multi‐
detector CT, rapid scanning of larger volumes at faster speeds has been possible. Also, be‐
cause CT uses ionizing radiation while MR imaging does not, MR imaging would seem to
offer an advantage. However, CT techniques requiring lower milliampere-second values
have been developed, associated to lower radiation dose. The use of iodinated contrast
agents, with the associated risks of allergic reaction and nephrotoxicity, remains a drawback
in some patients. However, perfusion CT has some clear advantages compared to perfusion
MR imaging. CT scanners are generally more widely available, and CT does not suffer from
magnetic susceptibility artefacts, which can compromise perfusion MR images when hemor‐
rhage or other causes of magnetic susceptibility effect are present in the area of interest.
Initial analyses of CT data with deconvolution methods used indicator-dilution methods
that suffered from the same problems as dynamic susceptibility contrast (DSC) MR ap‐
proaches. The modern spiral CT scanners present new opportunities in tissue perfusion ex‐
amination during the first passage of the iodide contrast bolus. This method has high
resolution and provides quantitative assessments of tissue perfusion, and currently, it is one
of the most perspective methods. Perfusion CT is based on analysis of CT density increase
during contrast media passage through brain vascular structures. Contrast bolus (iodine
agent with concentration 350–370 mg/ml, speed of administration is 4 ml/s) is administered
intravenously. Spiral CT obtains a series of scans with 1-s intervals, within 50–60 s after con‐
trast administration
Perfusion MRI (PWI)
There are MRI methods of haemodynamic perfusion examination, aided by exogenous and
endogenous markers. The methods of perfusion assessment during contrast bolus passage
are called perfusion-weighted MRI, or PWI. Perfusion-Weighted MRI can be performed by
using either a gradient-echo or a spin-echo pulse sequence. Gradient-echo DSC sequences
tend to be more sensitive to larger vessels, such as veins, in the imaged region. Spin-echo
DSC techniques tend to show greater sensitivity to smaller vessels (and therefore are more
representative of capillary density) or tumor-specific vessels.
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In other brain neoplasms—in particular meningiomas and neurinomas— DWI may predict
tumour histological type, with high reliability even before surgery. Based on this method
data, the epidermoid and arachnoid cysts can be precisely differentiated. In fact DWI has a
sensivity and specificy of over 90% for distinguishing epidermoid (low ADC) from aracnoid
cyst (high ADC) and distinguishing abscess (low ADC) from necrotic tumor (high ADC).
The viscous keratin and cholesterol in epidermoid and the viscous and cellular pus in ab‐
scess produce a very low ADC that distinguishes these lesions from increased diffusivity in
necrotic tumor and from normal or slightly low diffusivity in demyelinating plaque. Menin‐
giomas, a lower ADC has been demonstrated in atypical and malignant subtypes. It is also
demonstrated that the eterogeneity of ADC within tumor reflects heterogeneity of cellularity
within it [12].
Recently, DWI and DTI methods have begun to be applied to visualisation of a neural tract
lines—tractography. This is a new and promising technique that enables non-invasive view‐
ing of the brain neural tracts [13]. Despite some technical problems, the first results in trac‐
tography application to neurosurgery seem promising [5]. It is possible to plan operational
access and to estimate the scope of brain hematoma to be removed, taking into account neu‐
ral tracts and their involvement in the pathological process (dislocation–deformation, inva‐
sion, damage), with an aim to maximise the radical tumour resection and to minimise the
subsequent complications [14].
In gliomas, the infiltration of the tumor disrupts the organization of the white matter tracts:
FA derived from DTI defines of the degree of tumor infiltration. [12]. Some studies also sug‐
gest that DTI may distinguish vasogenic edema in brain metastases and meningiomas from
non-enhancing tumor infiltration in gliomas. It has to be considered that white matter adja‐
cent to glioma generally contains different proportions of vasogenic edema and tumor infil‐
tration at different distances from the center of the tumor, making more difficult to define an
unbiased region of interest for valid data analysis.
1.4.2. Perfusion Weighted Imaging
Perfusion studies are useful to quantify blood movement supplying each element of organ
or tissue volume. It is widely known that, unlike the majority of parenchymatous tissue,
brain tissue does not accumulate glucose, and brain cells can produce energy via anaerobic
glycolysis only for several minutes.
Meanwhile, the brain consumes about 25% of all glucose consumed in the entire body, and
for neurons, the uninterrupted and sufficient supply of oxygen and glucose is necessary.
There are complex mechanisms of autoregulation that manage brain perfusion to satisfy the
demands of the nervous system for energy (released in a course of metabolic processes).
There are several modern quantitative methods of brain haemodynamic examination: MRI,
CT with contrast enhancement, CT with Xe, single-photon emission computed tomography
(SPECT) imaging and positron emission tomography (PET). The obvious advantages of CT
and MRI are minimally invasive, high sensitivity in tissue microcirculation assessment, high
resolution, the short examination time (within the framework of standard protocols), and
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last, but not least, the reproducibility of results. The most widespread perfusion examina‐
tion in neuroradiology is based on intravenous bolus administration (CT and MRI). The dy‐
namic studies of bolus passage demonstrate its distribution in tissue in each given image
pixel, depending on time. The following main haemodynamic characteristics are used for
quantitative assessment: cerebral blood flow (CBF), cerebral blood volume (CBV) and mean
transit time (MTT).
The blood flow characteristics are measured in the ratio to 100 g of brain tissue. According‐
ly, the value of CBV is measured in millilitres per 100 g of brain tissue, and CBF is measured
in millilitres per 100 g per minute. The local (regional) CBV is defined as percentage of blood
volume in a single element of brain tissue volume. MTT is measured in seconds.
Perfusion CT
CT approaches to perfusion imaging were first proposed in the early 1980s. However, clini‐
cal uses of perfusion CT were slow to progress because the technique suffered initially from
relatively limited imaging volumes and poor temporal resolution. With the advent of multi‐
detector CT, rapid scanning of larger volumes at faster speeds has been possible. Also, be‐
cause CT uses ionizing radiation while MR imaging does not, MR imaging would seem to
offer an advantage. However, CT techniques requiring lower milliampere-second values
have been developed, associated to lower radiation dose. The use of iodinated contrast
agents, with the associated risks of allergic reaction and nephrotoxicity, remains a drawback
in some patients. However, perfusion CT has some clear advantages compared to perfusion
MR imaging. CT scanners are generally more widely available, and CT does not suffer from
magnetic susceptibility artefacts, which can compromise perfusion MR images when hemor‐
rhage or other causes of magnetic susceptibility effect are present in the area of interest.
Initial analyses of CT data with deconvolution methods used indicator-dilution methods
that suffered from the same problems as dynamic susceptibility contrast (DSC) MR ap‐
proaches. The modern spiral CT scanners present new opportunities in tissue perfusion ex‐
amination during the first passage of the iodide contrast bolus. This method has high
resolution and provides quantitative assessments of tissue perfusion, and currently, it is one
of the most perspective methods. Perfusion CT is based on analysis of CT density increase
during contrast media passage through brain vascular structures. Contrast bolus (iodine
agent with concentration 350–370 mg/ml, speed of administration is 4 ml/s) is administered
intravenously. Spiral CT obtains a series of scans with 1-s intervals, within 50–60 s after con‐
trast administration
Perfusion MRI (PWI)
There are MRI methods of haemodynamic perfusion examination, aided by exogenous and
endogenous markers. The methods of perfusion assessment during contrast bolus passage
are called perfusion-weighted MRI, or PWI. Perfusion-Weighted MRI can be performed by
using either a gradient-echo or a spin-echo pulse sequence. Gradient-echo DSC sequences
tend to be more sensitive to larger vessels, such as veins, in the imaged region. Spin-echo
DSC techniques tend to show greater sensitivity to smaller vessels (and therefore are more
representative of capillary density) or tumor-specific vessels.
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These examination methods are currently widely used in MR diagnostics, especially in com‐
bination with MR angiography and MR spectroscopy. PWI uses changes of T1 or T2 tissues
contrast due to infusion of gadolinium into blood as a contrast agent. Normally, gadolinium
does not pass through blood–brain barrier. It can pass into intracellular spaces only in cases
of blood–brain barrier disruptions. The CM bolus is administrated quickly (about 2–3 s); the
speed of administration is 4–5 ml/s and is higher than in the standard infusion. The bolus
passage on consecutive (in time) scans corresponds to the sharp decrease of MR signal inten‐
sity. In the process of CM bolus passage through the vascular system, multiple registration
of the image from the same location occurs (usually it is 10 different levels).
The scanning takes place for 1–2 min. The graph of intensity decrease during CM bolus pas‐
sage provides the curve “signal intensity–time” in each pixel of the scan. The form of this
curve for arteries and veins provides arterial and venous function data. With these data, the
haemodynamic tissue parameters are calculated. The regional CBV (rCBV) is estimated on
the basis of area under curve “concentration–time”; the MTT calculation is performed on the
basis of centre of gravity in CM distribution position, regional CBF (rCBF) = rCBV/MTT. The
perfusion maps are built in “off-line” mode in the specialised workstations. The method of
dynamic T1 MRI is used in cases of examination of CM distribution in extracellular spaces.
1.4.2.3. Clinical Applications of CT and MRI Perfusion
Currently, perfusion examinations are performed to estimate the haemodynamic of brain tu‐
mours, monitor tumour-state after chemo- and radiotherapy, detect the tumour recurrence
and radiation necrosis. This procedure gives informations in cases of brain injury and CNS
damage like ischaemia, hypoxia, large-arteries stenosis, blood diseases, vasculitis and moya‐
moya disease. Epilepsy, migraine, vasospasm, various mental diseases (including demen‐
tia), autism, and so forth are prospective in terms of perfusion methods application.
CT and MRI perfusion allow building of parametric maps and quantitative characterization
of areas of hyper- and hypo-perfusion, which is very important in diagnosis of tumours and
cerebrovascular diseases. Perfusion maps provide important additional information about
characteristics of normal and pathological tissues (in areas of tumour, oedema, necrosis). In
neurosurgery, Perfusion Weighted Imaging (PWI) is used in primary differential diagnosis
of tumor grading, in particular gliomas. However, perfusion CT and MRI do not specifically
allow differentiating tumours according their histology, nor does it enable estimation of the
tumour spreading into brain tissue [5].
The hyperperfusion in the structure of astrocytoma can indicate increase of tumour malig‐
nancy because the degree of perfusion is related to the development of abnormal vascular
net (angiogenesis). In other words, the tumor perfusion is related to the grade of the tumor
itself and the most important value to evaluate it is rCBV (higher rCBV values indicates high
grade tumors while rCBV values < 1,5 are usually related to tumor with low grade of malig‐
nancy) [15]. Maia et al demonstrated that rCBV correlates with the vascular endothelial
growth factors (VEGF) which is expression of the angiogenesis in gliomas [16].
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If the abnormal vascular net in a tumour can be the evidence of its aggressiveness, on the
other hand the decrease of perfusion in a tumour tissue under the influence of chemo- or
radiotherapy can be a sign of response to treatment. The use of PWI in target selection for
stereotactic intervention is helpful, especially in cases of gliomas characterized by full ab‐
sence of contrast accumulation with the use of standard CT and MRI. (Fig 1 c)
PWI potential is higher in assessment of histological type and spreading of extra-axial neo‐
plasms than of intra-axial ones. PWI successfully visualizes meningiomas and neurinomas
of cerebellopontine angle, according to the high haemodynamic parameters of these tumors.
In addition, it has been demonstrated that there is a clear correlation between local blood
flow (CBF, CBV) and direct angiography data in patients with meningiomas. The tumours
with radiopaque shadows in the early capillary phase of angiography have high perfusion,
and such tumours are characterised by high risk of a intraoperational bleeding. CT PWI data
are highly specific in demonstrating the blood supply of haemangiomas located in posterior
cranial fossa; in this case, early and marked contrasting is combined with high perfusion.
PWI is also successfully used in differential diagnosis of postoperative residual tumour
growth and radionecrosis. In both cases, standard CT and MR examinations can show the
accumulation of contrast in the lesion and blood–brain barrier disruption. Blood–brain barri‐
er disruptions cause CM extravasation in pathological tissues, with subsequent contrast ac‐
cumulation. However, the pathophysiological reasons in both cases are different. For
tumoral tissues, the perfusion increase or the reaching of normal perfusion level are typical,
while in necrotic tissues the blood supply is absent. Blood–brain barrier disruption in tu‐
mours is related to the invasive growth of tumour cells and vascular wall damage. In case of
radionecrosis, the disruption of blood– brain barrier is an initial step, but the radionecrosis
is characterized by a decrease perfusion level (iso- or hypoperfusion). The areas of radionec‐
rosis appear as areas of weak blood filling on CBV maps.
Undoubtedly, ischaemic brain damage takes the first place in the frequency of PWI methods
used. Currently, PWI is an integral part of diagnostics in patients in whom cerebral ischae‐
mia is suspected. The first clinical PWI application in brain lesion diagnostic in humans was
performed for stroke diagnosis. At present, perfusion MRI is the only method to verify early
ischaemia, is capable to show the haemodynamic decrease in certain brain areas (as the
main mechanism of ischaemic damage), even in the first minutes after appearance of focal
neurogical deficit.
1.4.3. Proton MR Spectroscopy
MR spectroscopy (MRS) is a non-invasive method of brain metabolism assessment. Proton
(1Н) МRS is based on a “chemical shift” which is the change of proton resonant frequency.
This term was developed by N. Ramsey in 1951, for defining a distinction between frequen‐
cies of separate spectral peaks. The chemical shift measured unit is in parts per million
(ppm). The main metabolites and corresponding values of the chemical shift are: N-acetylas‐
partate (NAA), 2 ppm; choline (Cho), 3.2 ppm; creatine (Cr), 3.03 and 3.94 ppm; myo-inositol
(mI), 3.56 ppm; glutamate and glutamine (Glx), 2.1–2.5 ppm; lactate (Lac), 1.32 ppm; and a
complex of lipids (Lip), 0.8–1.2 ppm.
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These examination methods are currently widely used in MR diagnostics, especially in com‐
bination with MR angiography and MR spectroscopy. PWI uses changes of T1 or T2 tissues
contrast due to infusion of gadolinium into blood as a contrast agent. Normally, gadolinium
does not pass through blood–brain barrier. It can pass into intracellular spaces only in cases
of blood–brain barrier disruptions. The CM bolus is administrated quickly (about 2–3 s); the
speed of administration is 4–5 ml/s and is higher than in the standard infusion. The bolus
passage on consecutive (in time) scans corresponds to the sharp decrease of MR signal inten‐
sity. In the process of CM bolus passage through the vascular system, multiple registration
of the image from the same location occurs (usually it is 10 different levels).
The scanning takes place for 1–2 min. The graph of intensity decrease during CM bolus pas‐
sage provides the curve “signal intensity–time” in each pixel of the scan. The form of this
curve for arteries and veins provides arterial and venous function data. With these data, the
haemodynamic tissue parameters are calculated. The regional CBV (rCBV) is estimated on
the basis of area under curve “concentration–time”; the MTT calculation is performed on the
basis of centre of gravity in CM distribution position, regional CBF (rCBF) = rCBV/MTT. The
perfusion maps are built in “off-line” mode in the specialised workstations. The method of
dynamic T1 MRI is used in cases of examination of CM distribution in extracellular spaces.
1.4.2.3. Clinical Applications of CT and MRI Perfusion
Currently, perfusion examinations are performed to estimate the haemodynamic of brain tu‐
mours, monitor tumour-state after chemo- and radiotherapy, detect the tumour recurrence
and radiation necrosis. This procedure gives informations in cases of brain injury and CNS
damage like ischaemia, hypoxia, large-arteries stenosis, blood diseases, vasculitis and moya‐
moya disease. Epilepsy, migraine, vasospasm, various mental diseases (including demen‐
tia), autism, and so forth are prospective in terms of perfusion methods application.
CT and MRI perfusion allow building of parametric maps and quantitative characterization
of areas of hyper- and hypo-perfusion, which is very important in diagnosis of tumours and
cerebrovascular diseases. Perfusion maps provide important additional information about
characteristics of normal and pathological tissues (in areas of tumour, oedema, necrosis). In
neurosurgery, Perfusion Weighted Imaging (PWI) is used in primary differential diagnosis
of tumor grading, in particular gliomas. However, perfusion CT and MRI do not specifically
allow differentiating tumours according their histology, nor does it enable estimation of the
tumour spreading into brain tissue [5].
The hyperperfusion in the structure of astrocytoma can indicate increase of tumour malig‐
nancy because the degree of perfusion is related to the development of abnormal vascular
net (angiogenesis). In other words, the tumor perfusion is related to the grade of the tumor
itself and the most important value to evaluate it is rCBV (higher rCBV values indicates high
grade tumors while rCBV values < 1,5 are usually related to tumor with low grade of malig‐
nancy) [15]. Maia et al demonstrated that rCBV correlates with the vascular endothelial
growth factors (VEGF) which is expression of the angiogenesis in gliomas [16].
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If the abnormal vascular net in a tumour can be the evidence of its aggressiveness, on the
other hand the decrease of perfusion in a tumour tissue under the influence of chemo- or
radiotherapy can be a sign of response to treatment. The use of PWI in target selection for
stereotactic intervention is helpful, especially in cases of gliomas characterized by full ab‐
sence of contrast accumulation with the use of standard CT and MRI. (Fig 1 c)
PWI potential is higher in assessment of histological type and spreading of extra-axial neo‐
plasms than of intra-axial ones. PWI successfully visualizes meningiomas and neurinomas
of cerebellopontine angle, according to the high haemodynamic parameters of these tumors.
In addition, it has been demonstrated that there is a clear correlation between local blood
flow (CBF, CBV) and direct angiography data in patients with meningiomas. The tumours
with radiopaque shadows in the early capillary phase of angiography have high perfusion,
and such tumours are characterised by high risk of a intraoperational bleeding. CT PWI data
are highly specific in demonstrating the blood supply of haemangiomas located in posterior
cranial fossa; in this case, early and marked contrasting is combined with high perfusion.
PWI is also successfully used in differential diagnosis of postoperative residual tumour
growth and radionecrosis. In both cases, standard CT and MR examinations can show the
accumulation of contrast in the lesion and blood–brain barrier disruption. Blood–brain barri‐
er disruptions cause CM extravasation in pathological tissues, with subsequent contrast ac‐
cumulation. However, the pathophysiological reasons in both cases are different. For
tumoral tissues, the perfusion increase or the reaching of normal perfusion level are typical,
while in necrotic tissues the blood supply is absent. Blood–brain barrier disruption in tu‐
mours is related to the invasive growth of tumour cells and vascular wall damage. In case of
radionecrosis, the disruption of blood– brain barrier is an initial step, but the radionecrosis
is characterized by a decrease perfusion level (iso- or hypoperfusion). The areas of radionec‐
rosis appear as areas of weak blood filling on CBV maps.
Undoubtedly, ischaemic brain damage takes the first place in the frequency of PWI methods
used. Currently, PWI is an integral part of diagnostics in patients in whom cerebral ischae‐
mia is suspected. The first clinical PWI application in brain lesion diagnostic in humans was
performed for stroke diagnosis. At present, perfusion MRI is the only method to verify early
ischaemia, is capable to show the haemodynamic decrease in certain brain areas (as the
main mechanism of ischaemic damage), even in the first minutes after appearance of focal
neurogical deficit.
1.4.3. Proton MR Spectroscopy
MR spectroscopy (MRS) is a non-invasive method of brain metabolism assessment. Proton
(1Н) МRS is based on a “chemical shift” which is the change of proton resonant frequency.
This term was developed by N. Ramsey in 1951, for defining a distinction between frequen‐
cies of separate spectral peaks. The chemical shift measured unit is in parts per million
(ppm). The main metabolites and corresponding values of the chemical shift are: N-acetylas‐
partate (NAA), 2 ppm; choline (Cho), 3.2 ppm; creatine (Cr), 3.03 and 3.94 ppm; myo-inositol
(mI), 3.56 ppm; glutamate and glutamine (Glx), 2.1–2.5 ppm; lactate (Lac), 1.32 ppm; and a
complex of lipids (Lip), 0.8–1.2 ppm.
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Multinuclear MRS, based on phosphorus, carbon and other element nuclei, are entering the
clinical practice.
Currently in proton MRS, two basic methods are used, single voxel (SV) and multivoxel
(MV, or chemical shift imaging). MRS is a single-stage detection of spectra from several
brain areas.
MV-MRS simultaneously obtains MR spectra for several voxels, and thus it is possible to
compare spectra from different  elements in an examination area.  Processing of  the MV-
MRS data enables construction of a parametrical map of brain. The concentration of partic‐
ular metabolites on this map is marked by colour, and thus it is possible to visualize the
metabolite distribution in brain, i.e. to obtain an image weighed on the chemical shift. NAA
is the most visible peak in the 1Н spectrum (at 2 ppm). In the adult brain, NAA plays at
least two roles:
1. as a predecessor of brain lipids, and
2. as a participant in coenzyme A interactions.
Some researchers believe that NAA is metabolically inert, and it participates only in mainte‐
nance of “deficiency anion” balance in neutral tissues, so it is the indicator of processes with
neurotransmitter–neuromodulator participation, and its basic function is to be the form of
free storage of aspartate. In an adult brain, the concentration of NAA in the cortex is higher
than in the white matter, as the majority of NAA is located in neurons and their branches.
Due to the mainly neuronal and axonal NAA location, the NAA peak decreases in cases of
neurodegenerative diseases.
The choline contribution is a sum of signals from several choline-containing chemical com‐
pounds (phosphoryl choline, glycerophosphoryl choline and free choline), and probably to‐
gether with choline, which is present in a form of a polar head group in lipid membranes.
MRS might not detect the compounds of choline embedded in a membrane; however, in the
case of cell membrane destruction caused by the disease, choline is released, accumulated
and may be them detected. Choline is a structural component of cellular membranes, espe‐
cially myelin membranes. The choline peak tends to increase in highly malignant tumours
and neurodegenerative diseases. Focal inflammation, which leads to considerable local cel‐
lularity and often to significant cellular membranes damages, could also result in increasing
of choline peak.
The creatine peak at 3.03 ppm is caused by protons of methyl (CH3) group of creatine, phos‐
phocreatine, lysine and glutathione. It appears that phosphocreatine is the basic molecule
for maintenance of energy-dependent systems in all brain cells. Its concentration is maximal
in cerebellum, followed by grey, and then by white, matter. Usually, it is assumed that the
general creatine level is stable in different situations; therefore, the height of creatine peak is
often used as reference in comparison with the height of other metabolites peaks.
MI  has  two  peaks  at  3.56  and  4.06  ppm,  and  it  is  supposed  to  function  as  storage  of
membranous phosphoinositides,  which are  the  second messengers  of  the  hormonal  sys‐
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tems and participate in CNS enzyme regulation. It is one of the major growth factors, and
it  is  a predecessor of  phosphatidylinositol,  which in turn is  a part  of  the lipid layers of
cellular membranes.  It  is  primarily located in glial  cells  and,  therefore,  could serve as a
specific glial marker.
The low combined peak at 3.56 ppm is from glycine and inositol-1-phosphate.
Another important metabolite that can be detected is lactate, which is a marker of anaerobic
glycolisis. Lactate is detected by its typical doublet located in 1Н MRS spectra around 1.32
ppm. It is believed that lactate, if found in greater quantities, especially in the first hours of
life, is an indicator of brain damage. Lactate concentration varies as the brain matures: it is
higher in newborns and in less-matured areas of the brain, such as parietal, anterior frontal
and temporal. In more mature brains, lactate concentration is higher, for example in the bas‐
al ganglia and central gyri. Lactate is also a pathological metabolite in cases of high grade
tumours, together with lipids (frequency range 0,8-1,3 ppm) that represent a marker of mye‐
lin disruption and necrosis.
Currently, the following areas of proton MRS clinical application are: injury, metabolic and
mitochondrial damages, as well as inflammatory and volumetric disorders.
1.4.3.1. Proton MR Spectroscopy and Brain Tumours
MRS is now widely used to estimate various volumetric brain formations [17]. The most im‐
portant goals of H-MRS are:
- differentiate neoplastic from non-neoplastic lesion. MRS accuracy is 95% to 100% in distinguish‐
ing neoplastic from non-neoplastic lesions. Cho is considered the most specific marker of in‐
tracranial neoplasm and increase in Cho levels and Cho/Cr and Cho/NAA ratio is very
suggestive of neoplasm.
- differentiate primary neoplasm versus metastases. Absent or practically absent NAA and Cr
levels are suggestive of a metastatic lesion. If the spectral analysis of the peritumoral region
shows an increase in Cho level, it is probably an infiltration related to primary neoplasm. If
there’s no increase in Cho level it is probably vasogenic edema associated with metastasis.
- indicate tumor grade and extension. Sensitivity, specificity and accuracy of proton MRS are
100%, 86% and 96% respectively, in discriminating between high and low grade neoplasm.
The most important metabolites to estimate tumour grade are Cho (higher Cho levels are re‐
lated to cell density and correlate with the grade of the tumors), Lactate (there’s a correct
correlation between lactate levels and tumor grade), lipids (they are tipically found in high
grade tumors), NAA and Cr (they usually decrease in high grade tumors), Mi (In low grade
tumors Mi/Cr ratio is typically greater than in high grade tumors).
- assess the ideal site for biopsy: if performed in the site where the Cho/NAA ratio is maximum
the biopsy will show high tumor infiltration.
- demonstrate tumour extension: intracranial neoplasm often extend beyond enhancement
demonstrated in gadolinium-enhanced MRI. The high signal area on T2 surrounding the ne‐
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Multinuclear MRS, based on phosphorus, carbon and other element nuclei, are entering the
clinical practice.
Currently in proton MRS, two basic methods are used, single voxel (SV) and multivoxel
(MV, or chemical shift imaging). MRS is a single-stage detection of spectra from several
brain areas.
MV-MRS simultaneously obtains MR spectra for several voxels, and thus it is possible to
compare spectra from different  elements in an examination area.  Processing of  the MV-
MRS data enables construction of a parametrical map of brain. The concentration of partic‐
ular metabolites on this map is marked by colour, and thus it is possible to visualize the
metabolite distribution in brain, i.e. to obtain an image weighed on the chemical shift. NAA
is the most visible peak in the 1Н spectrum (at 2 ppm). In the adult brain, NAA plays at
least two roles:
1. as a predecessor of brain lipids, and
2. as a participant in coenzyme A interactions.
Some researchers believe that NAA is metabolically inert, and it participates only in mainte‐
nance of “deficiency anion” balance in neutral tissues, so it is the indicator of processes with
neurotransmitter–neuromodulator participation, and its basic function is to be the form of
free storage of aspartate. In an adult brain, the concentration of NAA in the cortex is higher
than in the white matter, as the majority of NAA is located in neurons and their branches.
Due to the mainly neuronal and axonal NAA location, the NAA peak decreases in cases of
neurodegenerative diseases.
The choline contribution is a sum of signals from several choline-containing chemical com‐
pounds (phosphoryl choline, glycerophosphoryl choline and free choline), and probably to‐
gether with choline, which is present in a form of a polar head group in lipid membranes.
MRS might not detect the compounds of choline embedded in a membrane; however, in the
case of cell membrane destruction caused by the disease, choline is released, accumulated
and may be them detected. Choline is a structural component of cellular membranes, espe‐
cially myelin membranes. The choline peak tends to increase in highly malignant tumours
and neurodegenerative diseases. Focal inflammation, which leads to considerable local cel‐
lularity and often to significant cellular membranes damages, could also result in increasing
of choline peak.
The creatine peak at 3.03 ppm is caused by protons of methyl (CH3) group of creatine, phos‐
phocreatine, lysine and glutathione. It appears that phosphocreatine is the basic molecule
for maintenance of energy-dependent systems in all brain cells. Its concentration is maximal
in cerebellum, followed by grey, and then by white, matter. Usually, it is assumed that the
general creatine level is stable in different situations; therefore, the height of creatine peak is
often used as reference in comparison with the height of other metabolites peaks.
MI  has  two  peaks  at  3.56  and  4.06  ppm,  and  it  is  supposed  to  function  as  storage  of
membranous phosphoinositides,  which are  the  second messengers  of  the  hormonal  sys‐
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tems and participate in CNS enzyme regulation. It is one of the major growth factors, and
it  is  a predecessor of  phosphatidylinositol,  which in turn is  a part  of  the lipid layers of
cellular membranes.  It  is  primarily located in glial  cells  and,  therefore,  could serve as a
specific glial marker.
The low combined peak at 3.56 ppm is from glycine and inositol-1-phosphate.
Another important metabolite that can be detected is lactate, which is a marker of anaerobic
glycolisis. Lactate is detected by its typical doublet located in 1Н MRS spectra around 1.32
ppm. It is believed that lactate, if found in greater quantities, especially in the first hours of
life, is an indicator of brain damage. Lactate concentration varies as the brain matures: it is
higher in newborns and in less-matured areas of the brain, such as parietal, anterior frontal
and temporal. In more mature brains, lactate concentration is higher, for example in the bas‐
al ganglia and central gyri. Lactate is also a pathological metabolite in cases of high grade
tumours, together with lipids (frequency range 0,8-1,3 ppm) that represent a marker of mye‐
lin disruption and necrosis.
Currently, the following areas of proton MRS clinical application are: injury, metabolic and
mitochondrial damages, as well as inflammatory and volumetric disorders.
1.4.3.1. Proton MR Spectroscopy and Brain Tumours
MRS is now widely used to estimate various volumetric brain formations [17]. The most im‐
portant goals of H-MRS are:
- differentiate neoplastic from non-neoplastic lesion. MRS accuracy is 95% to 100% in distinguish‐
ing neoplastic from non-neoplastic lesions. Cho is considered the most specific marker of in‐
tracranial neoplasm and increase in Cho levels and Cho/Cr and Cho/NAA ratio is very
suggestive of neoplasm.
- differentiate primary neoplasm versus metastases. Absent or practically absent NAA and Cr
levels are suggestive of a metastatic lesion. If the spectral analysis of the peritumoral region
shows an increase in Cho level, it is probably an infiltration related to primary neoplasm. If
there’s no increase in Cho level it is probably vasogenic edema associated with metastasis.
- indicate tumor grade and extension. Sensitivity, specificity and accuracy of proton MRS are
100%, 86% and 96% respectively, in discriminating between high and low grade neoplasm.
The most important metabolites to estimate tumour grade are Cho (higher Cho levels are re‐
lated to cell density and correlate with the grade of the tumors), Lactate (there’s a correct
correlation between lactate levels and tumor grade), lipids (they are tipically found in high
grade tumors), NAA and Cr (they usually decrease in high grade tumors), Mi (In low grade
tumors Mi/Cr ratio is typically greater than in high grade tumors).
- assess the ideal site for biopsy: if performed in the site where the Cho/NAA ratio is maximum
the biopsy will show high tumor infiltration.
- demonstrate tumour extension: intracranial neoplasm often extend beyond enhancement
demonstrated in gadolinium-enhanced MRI. The high signal area on T2 surrounding the ne‐
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oplasm may represent vasogenic edema, tumor infiltration, and or abnormalities induced by
radiotherapy and chemiotherapy.
- demonstrate tumour progression: Cho and lactate levels are considered prognostic factors in
patients with intracranial neuroepithelial tumors. An increase in Cho levels > 140% in the
lesion is related to high risk of tumor progression.Tumor progression is characterized by an
increase in Cho levels greater than 45%, while in tumors that do not progress Cho levels de‐
crease, maintain or rise less than 35%.
- demonstrate therapeutic response: Proton MRS is very useful in follow therapeutic response,
identify residual or recurrent tumor earlier than conventional MRI and, above all, differenti‐
ate residual or recurrent tumor from post-treatment abnormalities. Evidence of radiation ne‐
crosis is typically observed within 6 months and is characterized by reduced Cho and
increased lipid and lactate levels or by a normal spectral pattern. Postradiation and postche‐
motherapy necrotic areas are usually characterized by absent or decreased brain metabolites
(NAA, Cr, Cho, Mi), elevated lipid and lactate levels, large peak between 0 and 2 ppm indi‐
cating cell necrosis products.
Definitively, even if it is impossible to predict with sufficient confidence the neoplasm histo‐
logical type, nevertheless, the majority of researchers agree that tumoural processes as a
whole are characterised by a low NAA–Cr ratio, increase in Cho–Cr ration, and in some cas‐
es, by the lactate peak.
In the majority of performed MRS examinations, proton spectroscopy is used in differential
diagnostics of astrocytoma, ependymoma and primitive neuroepithelial tumors (PNET).
Typical signs of astrocytoma and ependymoma are the decrease in the NAA–Cho ratio and
increase in the ratio of Lac–Cho peaks in relation to those in a healthy hemisphere. Although
the typical pattern of glioma spectra is well defined with high choline and low or absent
NAA peaks, with lipid and lactate peaks often seen in GBM, studies of MRS for prediction
of tumor histology have not shown sufficient specificity to make MRS a clinically useful ad‐
junct in most cases.
MRS of extra-axial tumors that do not arise from glial precursors, such as meningiomas,
generally reveals very high choline and no NAA, because the tumors contain no neurons.
Although the presence of a very high alanine peak in rare meningioma’s subtype can be use‐
ful to suggest the diagnosis, a recent well-controlled study suggests that the presence of low
levels of alanine detected in up to 80% of meningioma is not useful because it is detected in
similar frequency in metastases and schwannoma [12].
In comparison to these tumours, PNET are characterized by an increase in the NAA–Cho ra‐
tio and a lower Lac– Cho ratio, which is related to a higher level of Cho in patients with
PNET, as with malignant neoplasm. For astrocytoma, in general, the increase of the Cho
peak, the change of mI peak (depends on the malignancy level), the significant reduction of
the NAA peak and the appearance of a Lac peak are typical.
For low grade astrocytoma, the reduction of NAA peak is typical, and the increase of Cho
peak is observed. The height of the mI peak can remain unchanged, or it can not rise signifi‐
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cantly in comparison with contralateral tissues not affected by tumours. The Lac peak is
characterised by small elevation, and in rare cases, it cannot be detected at all. The Cho and
Lak peak rises, while the mI peak falls with the increase of malignancy level—in particular,
in cases of anaplastic astrocytoma. The NAA peak is reduced in comparison with its height
in the spectrum of benign astrocytoma.
The marked or full reduction of NAA and mI peaks, and the sharp increase of the Lac peak,
are observed in spectrum of glioblastoma, which is characterised by the presence of necrotic
areas. At the same time, the Lip peak appears and overlaps the Lac peak and these peaks
look like single complex. Generally, the height of Cho peak is sharply increased.
It is important to use MRS during postoperatory period for diagnostics of the continued ne‐
oplasm growth, tumour relapse or radiation necrosis. As a rule, treatment of brain tumours
is a combination of surgery with chemo- and radiotherapy. However, current methods and
doses of radiotherapy could cause death of tumour cells and also of normal cells, especially
in cases of lowered sensitivity threshold for radiotherapy. First, vassels endothelium cells
suffer, then brain oedema appears, and as a result, a zone of radiation necrosis could appear.
According to statistics, in more than 5% of all patients who undergo radiotherapy because of
a tumor, brain damage is diagnosed by the end of the first year near the tumour as well as in
other areas.
The diagnosis of lymphomas is an important neuroradiology problem. Differential diagno‐
sis of these tumours based on only routine CT and MRI is complicated, and combined che‐
mo- and radiotherapy treatment is more preferable than surgical removal [5]. Therefore, the
correct diagnosis influences the tactic choice in the treatment and prognosis of the disease.
In the majority of cases, it is necessary to differentiate lymphomas with glial tumours and
metastases. The common trend of changes in peaks of Cho, Lac and NAA is observed in
lymphoma spectrum as well as in that of astrocytoma. However, these changes are different.
With the lymphoma spectrum, the changes of peak heights are not so expressed. The Cho
peak moderately increases, and the increased of peak of the Lac–Lip complex is substantial,
whereas the decrease in the NAA peak is not significant.
1.4.4. Functional MRI
Brain activity mapping enables to reveal the areas of neuronal activation in response to tests,
motor, sensor, and other stimuli. Until recently, similar mapping was performed with the
help of radionuclide methods: PET and SPECT imaging. Functional MRI (fMRI) is based on
increase of brain haemodynamics in response to cortical neuronal activity due to a certain
stimulus [18; 19]. BOLD (Blood Oxygenation Level Dependent contrast) EPI-GRE registers hy‐
perintense MR signal from active areas of the brain cortex. The registration time of one MR
image is about 100 ms. fMRI signal intensity, registered by physiological load, is compared
with the intensity, registered in the event of its lack. During MRI examination, the stimula‐
tion periods (duration of 30 s) alternate with control periods (without stimulation) of the
same duration. The areas of statistically significant MR signal increasing during activation,
revealed in the course of subsequent mathematical processing of images, correspond to
areas of neuronal activity. They are marked with colour— in this way the neuronal activity
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oplasm may represent vasogenic edema, tumor infiltration, and or abnormalities induced by
radiotherapy and chemiotherapy.
- demonstrate tumour progression: Cho and lactate levels are considered prognostic factors in
patients with intracranial neuroepithelial tumors. An increase in Cho levels > 140% in the
lesion is related to high risk of tumor progression.Tumor progression is characterized by an
increase in Cho levels greater than 45%, while in tumors that do not progress Cho levels de‐
crease, maintain or rise less than 35%.
- demonstrate therapeutic response: Proton MRS is very useful in follow therapeutic response,
identify residual or recurrent tumor earlier than conventional MRI and, above all, differenti‐
ate residual or recurrent tumor from post-treatment abnormalities. Evidence of radiation ne‐
crosis is typically observed within 6 months and is characterized by reduced Cho and
increased lipid and lactate levels or by a normal spectral pattern. Postradiation and postche‐
motherapy necrotic areas are usually characterized by absent or decreased brain metabolites
(NAA, Cr, Cho, Mi), elevated lipid and lactate levels, large peak between 0 and 2 ppm indi‐
cating cell necrosis products.
Definitively, even if it is impossible to predict with sufficient confidence the neoplasm histo‐
logical type, nevertheless, the majority of researchers agree that tumoural processes as a
whole are characterised by a low NAA–Cr ratio, increase in Cho–Cr ration, and in some cas‐
es, by the lactate peak.
In the majority of performed MRS examinations, proton spectroscopy is used in differential
diagnostics of astrocytoma, ependymoma and primitive neuroepithelial tumors (PNET).
Typical signs of astrocytoma and ependymoma are the decrease in the NAA–Cho ratio and
increase in the ratio of Lac–Cho peaks in relation to those in a healthy hemisphere. Although
the typical pattern of glioma spectra is well defined with high choline and low or absent
NAA peaks, with lipid and lactate peaks often seen in GBM, studies of MRS for prediction
of tumor histology have not shown sufficient specificity to make MRS a clinically useful ad‐
junct in most cases.
MRS of extra-axial tumors that do not arise from glial precursors, such as meningiomas,
generally reveals very high choline and no NAA, because the tumors contain no neurons.
Although the presence of a very high alanine peak in rare meningioma’s subtype can be use‐
ful to suggest the diagnosis, a recent well-controlled study suggests that the presence of low
levels of alanine detected in up to 80% of meningioma is not useful because it is detected in
similar frequency in metastases and schwannoma [12].
In comparison to these tumours, PNET are characterized by an increase in the NAA–Cho ra‐
tio and a lower Lac– Cho ratio, which is related to a higher level of Cho in patients with
PNET, as with malignant neoplasm. For astrocytoma, in general, the increase of the Cho
peak, the change of mI peak (depends on the malignancy level), the significant reduction of
the NAA peak and the appearance of a Lac peak are typical.
For low grade astrocytoma, the reduction of NAA peak is typical, and the increase of Cho
peak is observed. The height of the mI peak can remain unchanged, or it can not rise signifi‐
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cantly in comparison with contralateral tissues not affected by tumours. The Lac peak is
characterised by small elevation, and in rare cases, it cannot be detected at all. The Cho and
Lak peak rises, while the mI peak falls with the increase of malignancy level—in particular,
in cases of anaplastic astrocytoma. The NAA peak is reduced in comparison with its height
in the spectrum of benign astrocytoma.
The marked or full reduction of NAA and mI peaks, and the sharp increase of the Lac peak,
are observed in spectrum of glioblastoma, which is characterised by the presence of necrotic
areas. At the same time, the Lip peak appears and overlaps the Lac peak and these peaks
look like single complex. Generally, the height of Cho peak is sharply increased.
It is important to use MRS during postoperatory period for diagnostics of the continued ne‐
oplasm growth, tumour relapse or radiation necrosis. As a rule, treatment of brain tumours
is a combination of surgery with chemo- and radiotherapy. However, current methods and
doses of radiotherapy could cause death of tumour cells and also of normal cells, especially
in cases of lowered sensitivity threshold for radiotherapy. First, vassels endothelium cells
suffer, then brain oedema appears, and as a result, a zone of radiation necrosis could appear.
According to statistics, in more than 5% of all patients who undergo radiotherapy because of
a tumor, brain damage is diagnosed by the end of the first year near the tumour as well as in
other areas.
The diagnosis of lymphomas is an important neuroradiology problem. Differential diagno‐
sis of these tumours based on only routine CT and MRI is complicated, and combined che‐
mo- and radiotherapy treatment is more preferable than surgical removal [5]. Therefore, the
correct diagnosis influences the tactic choice in the treatment and prognosis of the disease.
In the majority of cases, it is necessary to differentiate lymphomas with glial tumours and
metastases. The common trend of changes in peaks of Cho, Lac and NAA is observed in
lymphoma spectrum as well as in that of astrocytoma. However, these changes are different.
With the lymphoma spectrum, the changes of peak heights are not so expressed. The Cho
peak moderately increases, and the increased of peak of the Lac–Lip complex is substantial,
whereas the decrease in the NAA peak is not significant.
1.4.4. Functional MRI
Brain activity mapping enables to reveal the areas of neuronal activation in response to tests,
motor, sensor, and other stimuli. Until recently, similar mapping was performed with the
help of radionuclide methods: PET and SPECT imaging. Functional MRI (fMRI) is based on
increase of brain haemodynamics in response to cortical neuronal activity due to a certain
stimulus [18; 19]. BOLD (Blood Oxygenation Level Dependent contrast) EPI-GRE registers hy‐
perintense MR signal from active areas of the brain cortex. The registration time of one MR
image is about 100 ms. fMRI signal intensity, registered by physiological load, is compared
with the intensity, registered in the event of its lack. During MRI examination, the stimula‐
tion periods (duration of 30 s) alternate with control periods (without stimulation) of the
same duration. The areas of statistically significant MR signal increasing during activation,
revealed in the course of subsequent mathematical processing of images, correspond to
areas of neuronal activity. They are marked with colour— in this way the neuronal activity
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maps are built and these maps are imposed on T1 MRI sequences. Map construction meth‐
ods (for instance, brain wave algorithms) subtract images obtained during neuron stimula‐
tion from control images obtained in the absence of stimulation. The subtracted image is
imposed on a control scan according to its location, and areas of increased neuronal activity
are marked with colour. The revealed functionally significant areas could be “imposed” on a
T1 MRI sequence of the same section or on a three-dimensional (3D) brain model, and thus
it is possible to estimate the ratio between the affected area (tumour) and functionally active
brain areas, for example, motor, sensory or visual cortex.
1.4.4.1. Clinical Application of fMRI
Neuronal activity mapping enables planning the surgical approach and studying the patho‐
physiological processes in brain. This method is used in neurosurgery to study cognitive
functions. Its perspective is in revealing the epileptic foci. Currently, fMRI is an integral part
of MRI protocol in patients with brain tumours located close to functional critical brain
areas. In the majority of cases, the examination results adequately reflect the location of sen‐
somotor, speech and acoustical areas of brain cortex. However, according to the literature,
8–30% of all observation are not informative due to motion artefacts, lack of precise tests ex‐
ecution by the patients and damage to the above-mentioned cortical centres by tumours. In
cases in which fMRI can localize active cortical areas, in 87% of cases there is a correspond‐
ence with the results of intraoperational electrophysiological methods, within 1-cm limits,
and in 13% of cases, within 2 cm. This is evidence of the high accuracy of the fMRI technique
[20]. Performing fMRI (currently it is conducted for somatosensory and visual cortices) and
tractography with mapping of the functionally active cortical areas, pyramidal or optic
tracts is becoming a standard in patient suffering from lesions located in eloquent areas. Im‐
position of these maps over 3D brain images is promising within the framework of one MRI
examination for patients with brain tumours who are going to be operated. Based on these
data, neurosurgeons plan the interventional approach and estimate the volume of neoplasm
resection, and radiologists assess the areas of radiation and its distribution in tumour.
Conclusions
Advances in imaging technology have led to a better understanding of brain tumors and
have advanced neuro-imaging from a purely anatomical to functional assessment of the
nervous system.
MRI is the preferred imaging study for brain tumors diagnosis, providing detailed informa‐
tions on lesion type, size and location. Although gadolinium-enhanced T1-weighted images
and T2-weighted images are the MRI modalities of choice for the initial assessment, their
usefulness in identifying tumor types, distinguishing tumors from nontumoral lesions, and
assessing treatment effects is limited. For this reason, these sequences are used in combina‐
tion with other MRI technicques, including Diffusion Weighted Imagin (DWI), Diffusion-
Tensor-Imaging (DTI), Perfusion MRI, and Magnetic Resonance Spectroscopy (MRS). The
most important application of MRI is intraoperative MRI (iMRI). Used with or without corti‐
cal stimulation, iMRI can maximize tumor resection while minimizing damage to healthy
tissue, reducing the risk of neurological deficits and improving patient survival [21].
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Advanced brain tumor MRI evaluation can now routinely produce an impressive array of in
vivo data reflecting tumor cellularity, metabolism, invasiveness, neocapillary density and
permeability. Ongoing technical improvements and additional metrics, currently reported
in the literature in a preliminary way, promise to bring to the clinic further dramatic increas‐
es in the quantity and quality of imaging data over the next years [12]. The greatest current
challenge in advanced tumor imaging is the need for a new tumor classification method that
can allow better integration of advanced imaging data into brain tumors research and clini‐
cal decision making. In essence, what is needed is a significant revision of brain tumor no‐
sology. It is conceivable that a new tumor classification, advanced-MRI metrics in addition
to nucleoside positrone emission tomography data and cellular and molecular microarray
data could define novel pathophysiologically relevant subtypes that would better predict
brain tumor patient prognoses and responses to targeted chemotherapeutic agents, than our
current histopathologic grading system. A number of recent reports have been published
evaluating imaging markers by direct comparison with molecular genotype [16] and pheno‐
type and patient outcomes [22]. This approach seems likely to become the dominant para‐
digm in the future [12].
Figure 1. a) MRI Flair sequences demonstrate a frontal lesion with homogenous hyperintensity. b) T1 weighted MRI
with gadolinium administration demonstrating no enhancement of the lesion. c) Perfusion CT scan showing a circular
area of the tumor with higher r-CBV, expression of hypervascularization of that part of the tumor. d) MRI Spectroscopy
showing an increased choline/NAA ratio. The neuroradiological findings suggested the diagnosis of low grade glioma
with an area within it of higher grade (the area with hypervascularization). Definitive histological results was positive
for anaplastic oligodendroglioma.
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maps are built and these maps are imposed on T1 MRI sequences. Map construction meth‐
ods (for instance, brain wave algorithms) subtract images obtained during neuron stimula‐
tion from control images obtained in the absence of stimulation. The subtracted image is
imposed on a control scan according to its location, and areas of increased neuronal activity
are marked with colour. The revealed functionally significant areas could be “imposed” on a
T1 MRI sequence of the same section or on a three-dimensional (3D) brain model, and thus
it is possible to estimate the ratio between the affected area (tumour) and functionally active
brain areas, for example, motor, sensory or visual cortex.
1.4.4.1. Clinical Application of fMRI
Neuronal activity mapping enables planning the surgical approach and studying the patho‐
physiological processes in brain. This method is used in neurosurgery to study cognitive
functions. Its perspective is in revealing the epileptic foci. Currently, fMRI is an integral part
of MRI protocol in patients with brain tumours located close to functional critical brain
areas. In the majority of cases, the examination results adequately reflect the location of sen‐
somotor, speech and acoustical areas of brain cortex. However, according to the literature,
8–30% of all observation are not informative due to motion artefacts, lack of precise tests ex‐
ecution by the patients and damage to the above-mentioned cortical centres by tumours. In
cases in which fMRI can localize active cortical areas, in 87% of cases there is a correspond‐
ence with the results of intraoperational electrophysiological methods, within 1-cm limits,
and in 13% of cases, within 2 cm. This is evidence of the high accuracy of the fMRI technique
[20]. Performing fMRI (currently it is conducted for somatosensory and visual cortices) and
tractography with mapping of the functionally active cortical areas, pyramidal or optic
tracts is becoming a standard in patient suffering from lesions located in eloquent areas. Im‐
position of these maps over 3D brain images is promising within the framework of one MRI
examination for patients with brain tumours who are going to be operated. Based on these
data, neurosurgeons plan the interventional approach and estimate the volume of neoplasm
resection, and radiologists assess the areas of radiation and its distribution in tumour.
Conclusions
Advances in imaging technology have led to a better understanding of brain tumors and
have advanced neuro-imaging from a purely anatomical to functional assessment of the
nervous system.
MRI is the preferred imaging study for brain tumors diagnosis, providing detailed informa‐
tions on lesion type, size and location. Although gadolinium-enhanced T1-weighted images
and T2-weighted images are the MRI modalities of choice for the initial assessment, their
usefulness in identifying tumor types, distinguishing tumors from nontumoral lesions, and
assessing treatment effects is limited. For this reason, these sequences are used in combina‐
tion with other MRI technicques, including Diffusion Weighted Imagin (DWI), Diffusion-
Tensor-Imaging (DTI), Perfusion MRI, and Magnetic Resonance Spectroscopy (MRS). The
most important application of MRI is intraoperative MRI (iMRI). Used with or without corti‐
cal stimulation, iMRI can maximize tumor resection while minimizing damage to healthy
tissue, reducing the risk of neurological deficits and improving patient survival [21].
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permeability. Ongoing technical improvements and additional metrics, currently reported
in the literature in a preliminary way, promise to bring to the clinic further dramatic increas‐
es in the quantity and quality of imaging data over the next years [12]. The greatest current
challenge in advanced tumor imaging is the need for a new tumor classification method that
can allow better integration of advanced imaging data into brain tumors research and clini‐
cal decision making. In essence, what is needed is a significant revision of brain tumor no‐
sology. It is conceivable that a new tumor classification, advanced-MRI metrics in addition
to nucleoside positrone emission tomography data and cellular and molecular microarray
data could define novel pathophysiologically relevant subtypes that would better predict
brain tumor patient prognoses and responses to targeted chemotherapeutic agents, than our
current histopathologic grading system. A number of recent reports have been published
evaluating imaging markers by direct comparison with molecular genotype [16] and pheno‐
type and patient outcomes [22]. This approach seems likely to become the dominant para‐
digm in the future [12].
Figure 1. a) MRI Flair sequences demonstrate a frontal lesion with homogenous hyperintensity. b) T1 weighted MRI
with gadolinium administration demonstrating no enhancement of the lesion. c) Perfusion CT scan showing a circular
area of the tumor with higher r-CBV, expression of hypervascularization of that part of the tumor. d) MRI Spectroscopy
showing an increased choline/NAA ratio. The neuroradiological findings suggested the diagnosis of low grade glioma
with an area within it of higher grade (the area with hypervascularization). Definitive histological results was positive
for anaplastic oligodendroglioma.
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Figure 2. a) MRI Flair sequences demonstrate a frontal lesion with involvement of corpus callosum and bilateral ex‐
trinsecation (butterfly glioma). b) T1 weighted MRI with gadolinium administration demonstrating disomogenous en‐
hancement of the lesion.. c): Perfusion CT scan showing a high vascularization of the tumor with high r-CBV. d) MRI
Spectroscopy showing an increased choline/NAA ratio (higher than in case 1). The neuroradiological findings suggest‐
ed the diagnosis of high grade glioma. Definitive histological results were positive for glioblastoma multiformis.
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brain tumours. An x-ray of the skull may detect changes that can lead to suspicion of a tu‐
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It is important to distinguish tumoural from non-tumoural lesions, and to determine their
spatial location. New, advanced imaging CT and MRI techniques provide more detailed
characteristics of brain tumours, and thus, more choices of appropriate therapeutic manage‐
ment of the patient. These techniques also play a significant role in monitoring the effect of
the therapy.
Diagnosis of tumours has improved considerably due to the introduction of new imaging
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Radiology Imaging Techniques of Brain Tumours
MODALITY IMPORTANCE
CT screening method
MRI method of choice
DSA
mostly used for determination of blood supply and
embolization of hypervascular tumours
US intraoperative navigation
X – ray limited
Conventional invasive X – ray methods obsolete
Table 1. Importance of radiology imaging techniques in the diagnosis of brain tumours.




















monitoring the effect of treatment
exclude recurrence
distinguishing recurrent tumour from radiation necrosis
Table 2. Role of radiology imaging techniques in brain tumours
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2. Conventional imaging methods
For decades, diagnostic imaging dominated conventional non-invasive and invasive meth‐
ods, and later invasive contrast x-ray techniques. During the second half of the twentieth cen‐
tury, a number of different projection x-ray radiographs of the head and their modifications, as
well as complex invasive contrast imaging techniques, such as pneumoencephalography, ven‐
triculography, and myelography, were improved [1]. Another imaging method is ultrasonog‐
raphy, which can be used for neuronavigation during operation of brain tumours.
2.1. Conventional non-invasive X-ray methods
In the past, conventional non-invasive x-ray examination (radiography of the head) was the
basic diagnostic method in neuroradiology. The baseline projections are posteroanterior
(PA) and lateral x-ray projections of the skull. A PA projection is centred by orbitomeatal
lines and provides anatomical information about the skull and frontal structures. A lateral
projection shows the configuration of the skull and the skull base.
Modification of a PA projection by Caldwell with an x-ray beam inclination of 15°–23°, cau‐
dal to the orbitomeatal line, provides a clearer view of the os petrosum. With an x-ray beam
inclination of 37°, caudal to the orbitomeatal line, we obtain a semiaxial Waters projection,
which shows paranasal cavities and structures of the zygomaticomaxillar complex. An x-ray
beam inclination of 30°, caudal to the orbitomeatal line, in the anteroposterior (AP) direction
provides the Towne's projection, which is appropriate for imaging the os spheoidale, foramen
magnum, and pyramids, and their dorsal edges in particular.
Figure 1. Sella turcica (lateral projection): destruction by tumour
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A submentovertical projection is an axial projection of the skull with the x-ray beam passing
approximately perpendicular to the orbitomeatal line, and is suitable for imaging the os sphe‐
noidale and the base middle fossa foramina. The Stenvers projection with a 45° rotation of the
head from the PA line, and with a caudal x-ray beam inclination of 10°–15°, is the most com‐
mon projection for imaging the os petrosum, providing a good display of the tip of the pyra‐
mid, the structures of the inner ear, and the meatus acusticus internus. The Schüller projection
is a lateral projection with a caudal x-ray beam inclination of 30° and is employed for en‐
hanced imaging and evaluation of the processus mastoideus pneumatization. A modification
of these projections is a lateral projection by Runström I, with an x-ray beam inclination of
15° and a projection by Runström II with a caudal x-ray beam inclination of 45° [1]. Other
special projections focus on the sella turcica (Figure 1.), canalis opticus.
2.2. Conventional invasive X-ray methods
Pneumoencephalography is an imaging method in which the lumbar or suboccipital ap‐
proach is used to instill air into the cerebral ventricles and the subarachnoid spaces after re‐
moving approximately 10–30 mL of cerebrospinal fluid [2].
Ventriculography is an imaging method in which, through a trepanation hole, air is intro‐
duced into each lateral brain ventricle after the collection of cerebrospinal fluid [3].
These imaging x-ray methods are currently not used in clinical practice.
Before the era of CT and MRI, panangiography was the essential imaging technique of neu‐
roradiology in the diagnosis of brain tumours. A brain tumour manifests itself in angio‐
graphic images by indirect signs, such as dislocation of intracranial arteries, depending on
tumour size and location; tumoural vessels filling with the contrast medium, tumour vascu‐
larization; or vascular occlusion and stenosis [2].
With the onset of CT and MRI, the position of angiography has gradually changed. Current‐
ly, due to a new generation of digital radiological technology and rapid development of in‐
tracranial catheterization techniques and instrumentation, digital subtraction angiography is
a highly specialized imaging method in interventional radiology, with many therapeutic im‐
plications.
2.3. Ultrasound
Ultrasound is a widely available, non-invasive diagnostic method without negative biologi‐
cal effects. Principally, it is applied, in the primary examination of the brain in prenatal and
postnatal diagnoses, and in the examination of cerebral arteries. Currently, ultrasonography,
used in planning operational strategy and choice of neurosurgery access, has been replaced
by new, and more accurate, neuronavigation systems using MRI data. Ultrasound with a
high-frequency transducer can be used to monitor changes during brain tumour operations
in real time [1] (Figure 2.).
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Figure 2. Intraoperative ultrasound navigation with colour flow mapping, showing peripheral vascularization of a
brain tumour with solid and cystic parts
3. Computed Tomography – CT
From its first test scan on a mouse, in 1967, to current medical practice, the CT scanner has
become a core imaging tool. Initially financed by money from Beatles' record sales, the first
patient scan was performed in 1971. Only 8 years later, a Nobel Prize in Physics and Medi‐
cine was awarded to Gofrey Newbold Hounsfield and Allan McLeod Cormack for their dis‐
covery [4]. The prototype (EMI Ltd.) was installed at Atkinson Morley’s Hospital in South
London where the first patient, a middle aged lady with a suspected frontal lobe tumour,
was scanned on 1st October 1971 [5].
The rapid development of CT scanners, a new generation of CT devices, and advanced post‐
processing technologies in recent years has enabled the creation of progressive, advanced
CT protocols for the diagnosis of individual anatomical regions with respect to the patholog‐
ical processes that can be diagnosed. Technological improvements and new CT applications
in neuroradiology are mainly related to CT angiography and CT perfusion with a dynamic
contrast agent bolus [1].
The basic CT examination of brain tumours involves standard non-contrast enhanced and
contrast enhanced imaging (Figure 3.). Compared to MR, CT is superior in the detection of
calcification and bone abnormalities, and it is also less time consuming.
In CT diagnosis, depending on the type of examination, iodinated contrast agents are ad‐
ministered, in different quantities and by different modes. Iodinated contrast agents are div‐
ided into ionic, high-osmolar contrast agents and non-ionic, low-osmolar or iso-osmolar
contrast agents. Intravenous administration of contrast agents may cause various negative
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allergic reactions, which are divided into early (within 20 min) and late effects. In practice,
non-ionic contrast media are generally preferred as, due to their low osmolarity, they result
in significantly fewer negative effects [6].
Figure 3. Contrast enhanced CT of brain tumour: irregular peripheral enhancement of glioblastoma (the image dis‐
played is of the same patient as displayed in Figure 2)
Examination of blood vessels using CT angiography is a non-invasive imaging method
which is conducted in various ways: imaging individual sections, maximum-intensity pro‐
jection (MIP), shaded surface display (SSD), the volume-rendering technique (VRT), multi-
planar reconstruction (MPR), and virtual angiography. Improvement in the quality of CT
angiography, and the new generation of CT equipment gives rise to the possibility of longer
scans, faster scan times with display of the arterial phase of contrast filling with the lowest
venous infiltration, and better resolution with improved vascular details.
CT perfusion (Figure 4.) in the diagnosis of brain tumours allows assessment of tumours on
the microvascular level through a dynamic scanning sequence during an intravenous bolus
injection of a contrast agent. This is a relatively new technique that is used in neuroimaging
for quantitative and qualitative assessment of cerebral perfusion by the parameters of cere‐
bral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and time to
peak (TTP). Maps with colour-coded flow rates can be obtained by using postprocessing
software. Due to this technique, it is possible to assess the state of vascularization and hae‐
modynamics of brain tumours and their differentiation [7 - 9].
4. Magnetic resonance imaging – MRI
Historically, many scientists have contributed to the study of NMR (MRI), which led to con‐
struction of reliable MR scanners for clinical practice. Isidor Isaac Rabi in 1930 began by
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studying the magnetic properties of atomic nuclei (Nobel Prize in Physics in 1944) [10]. The
first successful nuclear magnetic resonance experiment with NMR precision measurements
was made independently in 1946 by Felix Bloch and Edward Mills Purcell (they jointly re‐
ceived the Nobel Prize in Physics in 1952). In 1971, Raymond Vahan Damadian, measured
T1 and T2 relaxation times of excised normal and cancerous rat tissue and stated that tu‐
mour tissue had longer relaxation times than normal tissue. He is the inventor of the first
MR Scanning Machine (1977) [11]. In March 1973 Paul C. Lauterbur published the first 2D
NMR images of two 1 mm capillaries filled with water [10] and in 1974 the image of thoracic
cavity of mouse. He called his imaging method zeugmatography. This term was later re‐
placed by NMR imaging [12]. Peter Mansfield with Grannel described the use of magnetic
field gradients to acquire spatial information in NMR. P.C. Lauterbur and Sir Peter Mans‐
field received the Nobel Prize in 1952. The first commercial MR scanner (Picker Ltd.) in Eu‐
rope was installed in 1983 in Manchester Medical School.
Figure 4. CT perfusion of a brain tumour across the solid part of the tumour (the image displayed is of the same pa‐
tient as displayed in Figure 2).
The main advantages of MRI are the possibilities of imaging individual anatomical regions
in vivo with high tissue contrast, imaging in arbitrary planes, non-invasivity, and the ab‐
sence of demonstrable detrimental effects on human health. Qualitative evaluation of tissues
allows for four basic physical attributes: T1 and T2 relaxation, proton density, motion, and
flow.
4.1. Conventional MRI techniques
Conventional MRI techniques provide information about the anatomical conditions of brain
tissue, the tumour itself, and its relationship with its surroundings. In contrast to CT, con‐
ventional MRI techniques are significantly more sensitive, but as they are nonspecific, they
often provide limited information about tumour physiology.
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The conventional MRI protocol in the diagnosis of brain tumours includes standard T1-
weighted imaging (spin echo [SE], turbo spin echo [TSE], gradient echo, three-dimensional
[3D] sequences, and dynamic studies), T2-weighted imaging (SE, fast spin echo [FSE] or
TSE, and 3D sequences), “dark fluid” T2-weighted imaging (proton density [PD] and fluid-
attenuated inversion recovery [FLAIR]), gradient echo (GRE T2, T2 * GRE, and GRE 3D T1),
inversion recovery (IR) (FLAIR, T1 IR, and short-time inversion recovery [STIR]), and fat
suppression (FS) (STIR and T1 FS) [13] (Figure 5.).
Figure 5. Sagittal non-contrast enhanced T1W image: hyperintense signal of pericallosal lipoma.
Brain tumours show variable pathomorphological manifestations in MRI, which depend on
the structure of different types of tumours. They may have a homogeneous or an inhomoge‐
neous structure, and depending on whether they are focal lesions or infiltrative and grow‐
ing, they are sharply contoured or diffuse [14].
In general, brain tumours in T1-weighted imaging are hypo- or isointense and in T2-weighted
imaging are hyper- or isointense. The tumour’s signal is modified by the intralesional propor‐
tion of individual components. Tumours may contain solid, cystic, necrotic, or haemorrhagic
components, fatty tissue, or an increased proportion of protein in intracystic components. Not
all tumours cause oedema of the brain tissue, which may have a different range [13, 15].
In some cases, visualization of brain tumours in non-contrast imaging can be difficult; there‐
fore administration of a paramagnetic contrast agent is necessary. Contrast enhancement of
brain tumours is variable and dependent on tumour neovascularization.
MRI shows intracranial arteries, veins, and venous sinuses at high-quality. Magnetic reso‐
nance angiography (MRA) can be implemented using several techniques: phase-contrast MRA
(PC MRA), time-of-flight MRA (TOF MRA), and contrast-enhanced MRA (CE MRA) [16].
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Tumour angiogenesis can be dynamically monitored in vivo by 3D-CTA and 4D-CE-MRA.
Of the two methods, 3D-CTA has better spatial resolution, but 4D-CE-MRA allows temporal
resolution of tumour angiogenesis [17].
MRA allows detailed evaluation of intracranial vascular structures, not only because of
purely pathological changes of vascular origin, but also in relation to brain tumours.
4.1.1. Contrast agents
In addition to non-contrast enhanced imaging, magnetic resonance examination is realized
with contrast agents, which improves visualization and demarcation of the tumour. Con‐
trast agents used in MRI are paramagnetic substances containing gadolinium chelates; they
cause shortening of the T1 and T2 relaxation times, resulting in a stronger T1 and a lower T2
signal, and they also increase the contrast between two tissues with different quantities of
the contrast agent. Increase of T1 signal is more significant, compared with the degree of
weakness of the T2 signal; therefore T1-weighted sequences are used after contrast adminis‐
tration (Figures 6-8.).
Figure 6. Axial contrast enhanced T1W image: homogeneous enhancement of multiple meningiomas right supraten‐
torial in patient with neurofibromatosis type 2.
Contrast agents for MRI can be divided into several categories: intravenous contrast agents,
which include the majority of non-specific and specific contrast agents; oral contrast agents
for display purposes of the gastrointestinal tract; and interstitial contrast agents. According
to the space distribution of contrast agents, they are classified into extracellular organ-non‐
specific and intracellular organ-specific contrast agents. In the diagnosis of brain tumours
intravenous extracellular organ-non-specific contrast agents are used, which have the ability
to pass through the blood–brain barrier [18].
Different types of contrast enhancement and common types of brain tumour are listed in
Table 3.
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Tumour angiogenesis can be dynamically monitored in vivo by 3D-CTA and 4D-CE-MRA.
Of the two methods, 3D-CTA has better spatial resolution, but 4D-CE-MRA allows temporal
resolution of tumour angiogenesis [17].
MRA allows detailed evaluation of intracranial vascular structures, not only because of
purely pathological changes of vascular origin, but also in relation to brain tumours.
4.1.1. Contrast agents
In addition to non-contrast enhanced imaging, magnetic resonance examination is realized
with contrast agents, which improves visualization and demarcation of the tumour. Con‐
trast agents used in MRI are paramagnetic substances containing gadolinium chelates; they
cause shortening of the T1 and T2 relaxation times, resulting in a stronger T1 and a lower T2
signal, and they also increase the contrast between two tissues with different quantities of
the contrast agent. Increase of T1 signal is more significant, compared with the degree of
weakness of the T2 signal; therefore T1-weighted sequences are used after contrast adminis‐
tration (Figures 6-8.).
Figure 6. Axial contrast enhanced T1W image: homogeneous enhancement of multiple meningiomas right supraten‐
torial in patient with neurofibromatosis type 2.
Contrast agents for MRI can be divided into several categories: intravenous contrast agents,
which include the majority of non-specific and specific contrast agents; oral contrast agents
for display purposes of the gastrointestinal tract; and interstitial contrast agents. According
to the space distribution of contrast agents, they are classified into extracellular organ-non‐
specific and intracellular organ-specific contrast agents. In the diagnosis of brain tumours
intravenous extracellular organ-non-specific contrast agents are used, which have the ability
to pass through the blood–brain barrier [18].
Different types of contrast enhancement and common types of brain tumour are listed in
Table 3.
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Figure 7. First patient examination. Axial contrast enhanced T1W image displays almost no contrast enhancement in
the right frontal
Figure 8. Second patient examination. Axial contrast enhanced T1W image displays irregular peripheral enhancement
of right frontal tumour (the image displayed is of the same patient as displayed in Figure 7, 3 months later; glioblasto‐
ma was confirmed by histology).
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Different types of contrast enhancement
no enhancement Low grade astrocytoma
diffuse homogeneous Meningioma
diffuse inhomogeneous Pleomorphic xanthoastrocytoma
ring enhancement Metastasis
irregular peripheral enhancement Glioblastoma
mural nodule enhancement Haemangioblastoma
Table 3. Different types of contrast enhancement of brain tumours and common types of brain tumour.
4.2. Advanced MRI techniques
Early and accurate diagnosis is the first precondition of the successful treatment of brain tu‐
mours. The basic method of determining species diagnosis and grading is the histopatholog‐
ical examination. Biopsy is an invasive method with the risk of possible complications. At
the time of the development and practical use of modern, advanced diagnostic techniques,
the role of radiodiagnostic imaging modalities was not limited to the assessment of patho‐
logical-anatomical conditions [9].
Advanced magnetic resonance techniques in neuroradiology evaluate changes at the micro‐
vascular, haemodynamic, and cellular levels of brain tumours, and in addition to structural
changes, evaluate changes at the metabolic and biochemical levels [19].
Incorporation of new diagnostic techniques, such as diffusion-weighted imaging (DWI), dif‐
fusion tensor imaging (DTI), tractography, perfusion-weighted imaging (PWI), magnetic
resonance spectroscopy (MRS), and functional MRI (fMRI), into the diagnostic protocol al‐
lows us to obtain detailed information about tumour lesions. This presents the best possibili‐
ty of accurate grading of brain tumours in the preoperative time, allowing us to select the
most appropriate therapeutic management for the patients [20].
New techniques lead to better quality monitoring of the effects of therapy.
4.2.1. Diffusion-weighted imaging (DWI)
The theory of diffusion is based on constant, disordered, random motion of water molecules
in all directions (Brownian motion). Biological tissues in which diffusion is the same in all
directions is isotropic; if diffusion is restricted in one direction, tissues are anisotropic. The
most common barrier to diffusion is the cell wall. Cerebrospinal fluid is the isotropic field;
diffusion in gray matter in all directions compared to the liquor is limited but also isotropic.
White matter is the anisotropic region because here diffusion progresses with greater inten‐
sity in the direction within axons [21].
DWI is echo-planar imaging that measures the random motion of water molecules (i.e. diffu‐
sion in biological tissue). The diffusion capacity of water protons is tissue-specific and cre‐
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ates a specific contrast on DWI. On diffusion sequences, the motion of water protons in
biological tissue causes changes in the signal. These signal changes are quantified by calcu‐
lating the apparent diffusion coefficient map (ADC) [22] (Figure 9.).
DWI, which is currently a routine part of imaging protocols, plays an important role in the
assessment of the cellularity of biological tissue. In the diagnosis of brain tumours, DWI is
applicable in differential diagnosis of cystic lesions, abscesses, necrosis, and metastases. In
addition, DWI has a fundamental role in the evaluation of the age of brain ischemia, in
imaging of traumatic changes, and in evaluation activities of demyelinating lesions [23].
Possibilities of using the ADC in differential diagnosis of intracranial tumours, and differen‐
tiating peritumoural oedema and infiltration, have been studied since the beginning of the
21st century. Most studies have concluded that the ADC is useful for distinguishing peritu‐
moural infiltration only and cannot provide information on the degree of differentiation of
glial tumours. However, they found that in tumour tissue with high cellularity, ADC values
were reduced compared to tumours with low cellularity; thus the probability of higher
grading is reduced for solid tumours with high values of the ADC. For tumours with a cyst‐
ic component, such as glioblastoma multiforme, the relationship between the ADC and the
grading is below the level of statistical significance [24].
Figure 9. Axial ADC map showing the right frontal hyperintensity of a tumour (the image displayed is of the same
patient as displayed in Figure 7).
4.2.2. Diffusion tensor imaging (DTI)
DTI is an advanced magnetic resonance technique that allows visualization of white matter
tracts, and describes the movement of water molecules by using two parameters, mean dif‐
fusivity (MD) and fractional anisotropy (FA), which represent the directionality of water dif‐
fusion [25].
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The postprocessing of DTI data using software generates maps of FA and ADC using DWI
images. Reduction of FA surrounding white matter of the tumour indicates the suspicion of
peritumoural white matter infiltration by tumoural elements [26]. Using 3D software appli‐
cations, 3D image tracts are created, allowing imaging of the spatial configuration of white
matter structures, such as the corticospinal tract, and configuration of the corpus callosum
[27]. DTI is able to demonstrate structural changes of white matter tracts related to brain tu‐
mours, such as the detection of alterations, integrity, or dislocation of individual tracts (Fig‐
ure 10.).
Thus, DTI provides other important information that can help distinguish infiltrative grow‐
ing tumours from bounded tumours and, together with assessment of the ADC and conven‐
tional MRI with a contrast agent, the grading of tumours can be better specified [28 - 30].
Figure 10. DTI: destruction and deviation of white matter tracts by anaplastic astrocytoma.
4.2.3. Perfusion-weighted imaging (PWI)
The rapid growth of cells is a result of the increased metabolic demands of a tumour. Cellu‐
lar hypoglycaemia and hypoxia result in the production of cytokines of angiogenesis (vaso‐
active endothelial growth factor) followed by tumour neovascularization, which leads to a
higher volume of blood flow through tumour tissue. Tumour neovascularization and hae‐
modynamic changes are the basic principles of perfusion MRI, which evaluate the blood
supply to brain tissue by four parameters: CBV (the quantity of blood in a given volume in
mL/100mg), CBF (the blood flow in brain tissue in mL/100g/min), MTT (the average time for
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arteriovenous passage of blood in a given volume in seconds), and TTP (the average time to
maximum density in the scanning area in seconds) [31, 32].
PWI uses fast, dynamic, epiplanar imaging sequences with a bolus of a paramagnetic con‐
trast agent, 0.2 mmol/kg body weight, at an injection rate of 5 mL/s, approximately 5-10 sec‐
onds after the start of imaging sequences, followed by an injection of 20-30 mL of saline. The
passage of the contrast agent through vascularized parts of the tumour leads to a reduction
in signal intensity. Converting the values of individual parameters by postprocessing to the
colour range creates maps with different blood flows. Regional cerebral, and tumour, vascu‐
larity is correlated with the CBV.
With PWI it is possible to determine tumour grading non-invasively. In general, high-grade
tumours have higher CBV values than low-grade tumours. PWI is also used for localization
of the parts of a tumour with a high degree of vascularity for the purpose of stereotactic bi‐
opsy. PWI helps to define the edge of a tumour, which is important in planning surgical
treatment radiotherapy. PWI is also used to monitor the effect of treatment on patients. In
the field of radiation changes, using conventional magnetic resonance techniques, it is diffi‐
cult to differentiate the eventual recurrence of a tumour. Postirradiation changes have lower
CBV values, and through PWI, it is possible to detect areas with increased perfusion, which
correspond to tumour recurrence. Increasing specificity in these cases allows the combina‐
tion of PWI with MRS [33].
4.2.4. Magnetic resonance spectroscopy (MRS)
Based on recent achievements in the field of MRS, the diagnostic proportion of proton MRS
has significantly increased, in the past decade progressing from basic and clinical research to
routine clinical practice. MRS is a non-invasive method and currently is part of the ad‐
vanced diagnostic protocol in neuroradiology. MRS can determine pathological changes in
brain tissue long before conventional techniques [34].
MRS provides biochemical and metabolic information about brain tumours and their sur‐
rounding tissues. Thus MRS, contributes significantly to the distinguishing of tumour from
non-tumour lesions, the type of diagnosis and tumour grading in preoperative time, oedema
from infiltrative growing tumours, the monitoring of tumour response to treatment and dis‐
tinguishing postirradiation necrosis from tumour recurrence [35].
MRS by non-invasive and non-destructive methods detects, in vivo in brain tissue, diagnos‐
tically important compounds such as those containing choline (Cho – a key marker of cell
membrane stability), creatine (Cr – an indicator of the energy status, often used as a refer‐
ence value), N-acetylaspartate (NAA – the main indicator of the structure and function of
neurons), lactate (Lac – in normal tissue its concentration is on the edge of detectability and
is increased in anaerobic metabolism), and lipids. The magnetic resonance spectrum of hu‐
man brain metabolites is relatively constant [36].
Changes in biochemical processes at the cellular level precede macroscopic changes; there‐
fore, MRS is able to detect the development of pathological processes in brain tissue before
conventional MRI techniques. MRS and MRI use magnetic characteristics of the atomic nu‐
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cleus; in obtaining the signal, they work on the same physical principle, but the data proc‐
essing and interpretation for each are different. MRI provides detailed information about the
pathological-anatomical state of brain tissue [37].
Whereas, MRS detects metabolic signals and results in a spectrum in which the position of
the signal of a specific metabolite is expressed on the horizontal axis in chemical shifts speci‐
fied in parts per million (ppm), and the vertical axis reflects the intensity of the signal. The
chemical shift and shape of the signal is characteristic for each metabolite [38] (Figure 11.).
Figure 11. MRS: a typical sample 1H MR spectrum in the lesion. Cre2, Cho, Cre, NAA, lac (the image displayed is of the
same patient as displayed in Figure 10).
In practice, there are two basic techniques of MRS, single voxel spectroscopy (SVS) and
chemical shift imaging (CSI). The result of SVS is one spectrum, which shows the overall
distribution of individual metabolites in a limited volume of tissue (voxel) in a volume of
2-8 mL. CSI measures the concentration of metabolites in a selected volume of brain tissue
divided into many small voxels. The result is an individual spectrum for each voxel, and the
imaging of the distribution of the concentration of individual metabolites in the examined
area is produced as a spectroscopic map (Figure 12.).
In clinical practice, MRS is realized through the anatomical imaging of brain tissue using
conventional MRI. The spectra are displayed together with conventional MRI images, which
characterize the anatomical location of the measured area selected for spectroscopy [38].
The results of the spectra are evaluated by the relative intensity of the signals and the ratios
of observed metabolites are typically set to creatine or choline (for example, NAA/Cr, NAA/
Cho, or NAA/Cr + Cho). Different types of tumours are manifested by a characteristic spec‐
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troscopic profile. Primary tumours are characterized by reducing the concentrations of NAA
and N-acetylaspartylglutamate, Cr, and creatinephosphate, and increasing the concentra‐
tions of Cho and (in astrocytoma) inositol (Ins). Increased concentrations of Lac and lipids
(Lip) are characteristic of necrosis. Peritumoural oedema is characterized by low concentra‐
tions of all metabolites. The interpretation of results may not be accurate using ratios in the
evaluation of the spectra; therefore, different quantification programs using standard refer‐
ence values are currently being tested and used [35 - 36].
Figure 12. MRS: Coloured metabolic map of the metabolic ratio of total cholines to the signal of the total NAA signal
(not resolved to its components), tCho:tNAA (the imaged displayed is of the same patient as displayed in Figure 10).
4.2.5. Functional magnetic resonance imaging (fMRI)
Functional magnetic resonance imaging (fMRI) is an MRI procedure that indirectly meas‐
ures the brain activity by means of deoxyhaemoglobin concentration or blood perfusion
changes.
The 1st technique, known as BOLD (blood oxygenation level dependent), is the most popu‐
lar and frequently used [39]; a relative decrease in deoxyhaemoglobin concentration in the
active brain tissue, due to an excessive increase of regional blood flow, and corresponding
increase of oxyhaemoglobin. Oxyhaemoglobin is, however, less effectively deoxygenated by
active brain tissue compared to inactive brain tissue in physiological conditions. Relative
changes of diamagnetic oxyhaemoglobin and paramagnetic deoxyhaemoglobin can be easi‐
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ly measured by fast T2-weighted echo-planar (EPI) acquisitions. Their temporal resolution,
approximately 100 ms per image slice, is good enough to compare several brain images in
rest and active (performing sensory, motor or cognitive task) conditions. The statistical maps
that result from this, coregistered with structural MRI (Figure 13.), can provide precise infor‐
mation (in the order of millimetres) about the position and the size of brain regions involved
in the processing of each respective task, and, sometimes the dynamics of such processing.
The 2nd group of techniques can evaluate the changes of blood flow in brain tissue using
special exogenous diffusible tracers like fluorinated halocarbons, deuterated water, 17O -wa‐
ter and 13C-hydrocarbons, or magnetically labelled endogenous blood water (arterial spin la‐
belled perfusion, ASL). The latter technique is non-invasive and very promising for future
clinical applications. It can substitute some nuclear medicine diagnostic methods while pro‐
viding images with better spatial and temporal resolution. Compared to BOLD techniques,
ASL can provide not only relative differential maps, but it also provides quantifiable infor‐
mation about absolute blood flow values (in ml/g/min) in selected brain regions [40]. Thus,
it can show the regions activated by some tasks, and also pathological tissue with increased
or decreased perfusion compared to normal brain tissue [41]. However, the intrinsic signal-
to-noise ratio of ASL is lower compared to BOLD measurements, and currently the majority
of scanners are not equipped with the respective product sequences to perform routine clini‐
cal ASL procedures.
Figure 13. fMRI: activation of motor cortex during physical stimulation.
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Presently, in tumour imaging, fMRI is used predominantly for the preoperative localization
of eloquent cortical regions that may have been displaced, distorted or compressed by the
tumour [42]. FMRI can provide an alternative to invasive mapping techniques (IMTs), with
many benefits, particularly in those patients that are unable to undergo awake craniotomy
or other stereotactic diagnostic procedures. FMRI data can be very helpful in neuronaviga‐
tion, especially if the eloquent region is hidden in the depth of sulci and/or cannot be stimu‐
lated during the surgery [43].
The sensitivity of fMRI recordings can be increased by the use of stronger magnetic fields. A
shorter scanning procedure, higher signal-to-noise-ratio, and increased spatial resolution of
the resultant images favour the usage of 3T and are stronger compared to conventional 1,5T
scanners [44].
However, the limitations of fMRI are not a result of poor engineering or the low power of
the scanners; the main pitfalls are due to complicated functional brain organization and in‐
appropriate diagnostic protocols that ignore this organization [45]. There are always several
brain regions involved in the processing of every sensory/motor/cognitive task. It is upon
the examiner to choose the best one, to adjust the statistical thresholds of the fMRI map
(which determines the number and the size of activated brain regions), and to recognize
which regions are eloquent.
A coregistration of the data provided by several different functional and/or structural MRI
techniques (e.g. BOLD, ASL, diffusion tensor imaging, MR spectroscopy, 23Na-MRI) is suita‐
ble for future improvements of functional MRI diagnostics.
4.2.6. Neuronavigation and intraoperative imaging modalities
Introduction of CT, MRI, and microsurgical operating techniques into clinical practice have
resulted in progress in the neurosurgical therapy of brain tumours. The application of new
MRI techniques and microsurgery allows for the resection of tumours in functionally impor‐
tant brain regions.
Neuronavigation is a common method of preoperative localization of brain tumours. It uses
imaging materials of preoperative MRI examinations, 3D sequences and DTI and fMRI data,
that are transferred to a computer database of a neuronavigation device; which, after data
processing and registering of the patient's head position, allows for planning of an optimal
trajectory for operating on the brain tumour [46].
According to the virtual reality planning, neurosurgeons could obtain more anatomic infor‐
mation and choose the best approach for tumour resection, which would result in a better
prognosis for patients [47].
The disadvantage of current navigation systems is that it is impossible to update data dur‐
ing the neurosurgical procedure. A shift in brain structures and tracts of white matter as a
result of the evacuation of cerebrospinal fluid, tumour resection, or gravity makes naviga‐
tion inaccurate. These disadvantages deal intraoperative using of imaging methods – intrao‐
perative ultrasonography and MRI [48].
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Intraoperative  MRI  displays  actual  dynamic  changes  in  deformable  brain  tissue  during
surgery, and helps in early detection of potential tumour residue. Data transfer from in‐
traoperative  MRI  to  the  neuronavigation  system is  possible,  and  data  for  neuronaviga‐
tion can be updated repeatedly.  For this purpose,  different types of  magnetic  resonance
devices are used. The presence of a magnetic field requires the use of compatible surgi‐
cal instruments.
Intraoperative ultrasonography with new devices and high resolution is a cheaper alterna‐
tive to MRI, with the advantage of imaging in real time; it provides actual images of the tu‐
mour, surrounding structures, and major blood vessels during surgery [1].
5. Digital subtraction angiography - DSA
Digital subtraction angiography (DSA) is a computer-assisted x-ray technique that subtracts
images of bone and soft tissue to permit viewing of the cardiovascular system [49].
At the beginning of the process of subtraction, an image (the mask) is obtained before arrival
of contrast material at the area of interest, and the mask image is placed into one of two digi‐
tal memories. Then, one or more subsequent images are obtained after the arrival of a con‐
trast bolus and placed into a second digital memory. The mask image is digitally subtracted
from the succeeding contrast image, resulting in contrast-filled structures that are rendered
visible free of background detail. Subtraction is performed in real time [50].
Iodine contrast media are used for the visualization of vessels, however cerebral angiogra‐
phy using gadolinium as an alternative contrast medium in a patient with severe allergy to
iodinated contrast medium may be performed [51].
Radiation, today known as X-rays, was discovered by the German physicist Wilhelm Rönt‐
gen (March 27, 1845–February 10, 1923) on November 8, 1895 [52]. Discovery of X-rays is
ranked as one of the best discoveries in medicine. X-rays are electromagnetic waves. The
range of wavelengths corresponding to diagnostic imaging span from about 0.1 nm (at 12.4
keV) to 0.01 nm (at 124 keV) [53]. This type of radiation is ionizing.
In a  vacuum X-ray tube,  the electrons that  make up the beam are emitted by a  heated
cathode filament.  The electrons are then focused and accelerated towards the focal  spot
by a high voltage that is applied between the cathode filament and the anode. A genera‐
tor is used to supply the X-ray tube with a controlled high voltage between the cathode
and anode, and a controlled current to the cathode. The electron beam strikes the rotat‐
ing anode “target” and part  of  its  kinetic  energy (less  than 1%) is  converted into X-ray
photons, while the rest is converted into heat, which heats up the anode. The X-ray beam
leaves  the  tube  through the  tube  window and passes  onto  the  patient.  Some of  the  X-
rays pass through the patient,  while  some are absorbed.  The resulting radiation pattern
is detected by a flat panel digital X-ray detector (FPD).
FPD system is superior to the image intensifier as it  visualizes small intracranial vessels
combined with a significant reduction of radiation dose, and is able to create high-quali‐
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ty 3D DSA images on which high spatial resolution allows precise visualization of small
vessels,  such  as  perforating  vessels  [54].  DSA  images  are  then  displayed  on  the  LCD
monitor  with  high  resolution  and  different  screen  layouts,  which  can  be  connected  to
several image sources.
The first carotid angiography was performed by Portuguese Egas Moniz (1874-1955) in 1927;
he is considered as a pioneer of cerebral angiography. He reported the first case of cerebral
angiography at the Societe de Neurologie in Paris on July 7, 1927 [55]. Surprisingly, most an‐
giograms were performed to visualize the intracranial portion of the carotids in cases of tu‐
mours, to look for abnormal displacement of arterial branches, with little interest in the
vascular disease itself [56].
The technique, how to obtain safe access to blood vessels was published by Sven-Ivar Sel‐
dinger (1921-1998) in 1953 [57]. DSA is an invasive technique, performed using a catheter;
the most commonly used approach is the transfemoral approach. At the end of angiogra‐
phy, the puncture site can be safely closed by a closure device [58].
DSA is used to detect the blood vessels supplying the brain tumours, and also to control the
hypervascular tumour embolization (meningiomas, paragangliomas, haemangiopericyto‐
mas, juvenile nasopharyngeal angiofibromas and intraaxially located tumours: haemangio‐
blastomas (Figure 14.), hypervascularized metastases and ependymomas). Presurgical or
palliative embolization of a tumour can be performed by either an intraarterial catheteriza‐
tion approach or direct puncture of the tumour artery [59].
DSA may also be used for a balloon occlusion test [60]. Although 4D-CE-MRA may be use‐
ful for evaluating tumour stain in hypervascular brain, head and neck tumours, it is not able
to replace DSA in planning interventional procedures [61].
Modern biplane DSA devices are very useful for neurovascular interventions, which also al‐
lows: 2D and 3D navigation for advanced embolization guidance; overlay of a DSA refer‐
ence image over the matching live fluoro for guidance with less contrast media and less
dose; cross-sectional imaging to view anatomical structures of tumours in combination with
the feeding vessels of the tumour; single-colour vascular flow visualization from a 2D DSA
image series to visualize tumour perfusion tumour vascularization, tumour blush and dem‐
onstrate postembolization result; to fuse the dataset with a preprocedural CT, MR or PET
image to show tumour activity; synchronize the 3D image to the gantry position; PACS con‐
nectivity; the reporting of patient exposure following an intervention.
Modern systems update dynamically to movements of the C-arm, table, zoom and source-
to-image distance to facilitate efficient workflow during interventional procedures. By pro‐
viding more effective and faster guidance, this potentially reduces the use of contrast agents
and radiation dose. Pulse frequencies can be adapted to clinical needs according to the
ALARA principle (As Low as Reasonably Achievable).
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Figure 14. DSA (right vertebral angiogram): intra-axial hypervascularized haemangioblastoma supplied mainly by
right anterior inferior cerebellar artery.
6. Conclusion
Radiology has an important role in the diagnosis of brain tumours. A significant factor for
success in the treatment of brain tumours is the determination of the extent of the tumour
and infiltration of important structures using the CT and MRI imaging methods. Currently,
conventional CT protocols, and particularly MRI protocols, have been expanded by sophisti‐
cated new techniques that are used in practice. They have significantly contributed to the
more detailed species diagnosis of tumours, and to a more accurate estimate of their malig‐
nant potential and relationship to the surrounding tissue. With the new techniques, we can
evaluate not only detailed tumour morphology, but also the character of the tumour at the
microvascular, haemodynamic and cellular level, and the metabolic and biochemical level.
With new methods of imaging, exact operational planning approaches on brain tissue can be
achieved. Postoperative monitoring of the effect of therapy is highly refined, with more ac‐
curate detection of tumour recurrence, and differentiation from postoperative and postra‐
diation changes. Some characteristics of selected brain tumours are presented in Tables 4
and 5.
Hybrid systems have presented new possibilities in brain tumour imaging. The hybrid brain
PET/MR allows for molecular, anatomical and functional imaging with uncompromised MR
image quality and a high accordance of PET results between PET/MR and PET/CT [62].
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Table 5. Characteristics of selected intracranial tumours in adults
Tables 4 and 5 are modified according to [13 – 14, 63 - 64].
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1. Introduction
1.1. Diagnostic ability of 201thallium SPECT and 99mtechnetium methoxyisobutylisonitrile
SPECT for patients with initial glioma
Single photon emission computed tomography (SPECT) is a valuable diagnostic modality
for the evaluation of brain tumor malignancy and activity. Thallium-201 (Tl) SPECT and
Technetium-99m methoxyisobutylisonitrile (Tc-MIBI) SPECT were clinically used to evalu‐
ate brain tumor malignancy and activity. In addition, both early and delayed images were
taken depending on the preference of each institute. The results of SPECT examinations al‐
ways include some false positive or false negative findings. The diagnostic value of brain tu‐
mor SPECT has been evaluated using sensitivities and specificities with arbitrary cut off
values [1-8]. These arbitrary cut off values depend on the measurement methods used by
each institute, as a result, studies using these arbitrary cut off values are not useful for eval‐
uating tumor malignancy at other institutes.
A receiver operating characteristic (ROC) analysis is useful for evaluating the diagnostic
ability of different examinations that include some errors [9, 10]. In order to investigate the
ability of each SPECT modality to evaluate tumor malignancy, each SPECT modality was di‐
rectly compared for the patients with an initial glioma using an ROC analysis. The hypothe‐
sis is that the one SPECT modality is superior to any other modalities for grading glioma.
1.2. Methods
The study population included 59 patients  with glioma who were admitted to Tsukuba
University  hospital  between 1999  and 2005  and who underwent  SPECT imaging.  None
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1.1. Diagnostic ability of 201thallium SPECT and 99mtechnetium methoxyisobutylisonitrile
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of  the  patients  had received any  previous  radiation  therapy to  the  brain  and recurrent
cases  were  excluded.  Tl  and  Tc-MIBI  SPECT  images  were  taken  before  surgery,  radia‐
tion or chemotherapy in most patients.  The SPECT images were taken after surgery but
before  radiation  or  chemotherapy  in  one  patient.  All  pathological  diagnoses  were  con‐
firmed  after  the  surgical  removal  of  the  tumor.  The  benign  group  included  low  grade
astrocytomas (n=23) and a central neurocytoma (n=1) while the malignant group includ‐
ed anaplastic  astrocytomas (n=10)  and glioblastomas (n=25).  The benign group included
13 men and 11 women,  ranging from 3 to 59 years  of  age and the median age was 32
years  old.  The malignant  group included 17 men and 18 women,  ranging from 7 to  79
years of age and the median age was 55 years old.
Tl SPECT and Tc-MIBI SPECT images were obtained 15 min (early) and 3 hr (delayed) after
the intravenous injection of 74 MBq of Tl chloride or 740 MBq of Tc-MIBI using a multi-detector
SPECT machine (E.CAM, Siemens Medical, Malvern, PA) and a high resolution collimator
(LEHR, Siemens Medical, Malvern, PA). The Butterworth pre-correction filter and the Chang
method were used for pre and post attenuation corrections. The Ramp filter was used for
reconstruction. The image matrixes for Tl and MIBI SPECT were 64x64 and 128x128. The pixel
sizes for Tl and MIBI SPECT were 6.61mm and 3.31mm. The slice thickness both of Tl and MIBI
SPECT was 6.61mm.
The Regions of Interest (ROI) were set on tumor and contra-lateral normal white matter
in reconstructed SPECT images.  The ROIs were customized for each patient.  In the cas‐
es  with  a  hot  tracer  uptake  into  the  tumor,  the  ROIs  were  placed  at  homogeneously
high  uptake  areas.  In  cases  with  no  tracer  uptake,  the  ROIs  were  placed  at  suspected
tumor areas using the MRI findings as references.  All  ROIs were selected by independ‐
ent  radiology technologists.  Tumor/Normal  (T/N)  ratios  were calculated as  the  ratios  of
radioactivity in the ROIs.  The diagnostic abilities of the T/N ratios for malignancy were
analyzed  by  an  ROC  analysis  using  the  ROCKIT1.1B2  Beta  and  PlotROC.xls  software
programs  (University  of  Chicago).  The  area  z-score  (Az)  values  were  calculated  from
the  areas  under  the  ROC  curves  and  the  diagnostic  accuracy  was  compared  between
each  imaging  modality.  Any  differences  in  the  Az  values  were  analyzed  using  the  bi‐
variate x2 test.
1.3. Results
Figure 1 shows the ROC curves. The vertical axis is the true positive fraction (TPF) that
means sensitivity and the horizontal axis is the false positive fraction (FPF) that is same
value  of  1-specificity.  The  ROC curve  of  the  early  MIBI  shifted  to  upper  right  and the
sensitivity  was  better  than the  other  in  the  high FPF area,  however  the  sensitivity  was
low in the low FPF area.  The ROC curve of  the delayed MIBI shifted to the upper left
and showed well  balanced high sensitivity and specificity.  The ROC curves of the early
and  delayed  Tl  were  almost  same  and  showed  lower  sensitivity  and  specificity  than
that of the delayed MIBI in most areas.
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of  the  patients  had received any  previous  radiation  therapy to  the  brain  and recurrent
cases  were  excluded.  Tl  and  Tc-MIBI  SPECT  images  were  taken  before  surgery,  radia‐
tion or chemotherapy in most patients.  The SPECT images were taken after surgery but
before  radiation  or  chemotherapy  in  one  patient.  All  pathological  diagnoses  were  con‐
firmed  after  the  surgical  removal  of  the  tumor.  The  benign  group  included  low  grade
astrocytomas (n=23) and a central neurocytoma (n=1) while the malignant group includ‐
ed anaplastic  astrocytomas (n=10)  and glioblastomas (n=25).  The benign group included
13 men and 11 women,  ranging from 3 to 59 years  of  age and the median age was 32
years  old.  The malignant  group included 17 men and 18 women,  ranging from 7 to  79
years of age and the median age was 55 years old.
Tl SPECT and Tc-MIBI SPECT images were obtained 15 min (early) and 3 hr (delayed) after
the intravenous injection of 74 MBq of Tl chloride or 740 MBq of Tc-MIBI using a multi-detector
SPECT machine (E.CAM, Siemens Medical, Malvern, PA) and a high resolution collimator
(LEHR, Siemens Medical, Malvern, PA). The Butterworth pre-correction filter and the Chang
method were used for pre and post attenuation corrections. The Ramp filter was used for
reconstruction. The image matrixes for Tl and MIBI SPECT were 64x64 and 128x128. The pixel
sizes for Tl and MIBI SPECT were 6.61mm and 3.31mm. The slice thickness both of Tl and MIBI
SPECT was 6.61mm.
The Regions of Interest (ROI) were set on tumor and contra-lateral normal white matter
in reconstructed SPECT images.  The ROIs were customized for each patient.  In the cas‐
es  with  a  hot  tracer  uptake  into  the  tumor,  the  ROIs  were  placed  at  homogeneously
high  uptake  areas.  In  cases  with  no  tracer  uptake,  the  ROIs  were  placed  at  suspected
tumor areas using the MRI findings as references.  All  ROIs were selected by independ‐
ent  radiology technologists.  Tumor/Normal  (T/N)  ratios  were calculated as  the  ratios  of
radioactivity in the ROIs.  The diagnostic abilities of the T/N ratios for malignancy were
analyzed  by  an  ROC  analysis  using  the  ROCKIT1.1B2  Beta  and  PlotROC.xls  software
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the most benign gliomas and the Tl SPECT findings of a pilocytic astrocytoma are reported to
show a variable uptake [8].
1.4.2. Tc-MIBI SPECT
Tc-MIBI SPECT is reported to be useful to diagnose brain tumor recurrence [22, 23], high S-
phase fraction and aneuploidy [24], tumor volume and survival [25, 26], and, differential
diagnosis of radiation necrosis [27]. The Tc-MIBI index, the ratio of radioactivity of the ROI at
the lesion and normal brain, was used to differentiate low and high grade gliomas [28],
recurrence and radiation necrosis [22] and the estimation of the prognosis [25, 26]. However
there are some false positive and false negative cases reported [23]. Tc-MIBI is concentrated in
the mitochondria as the result of active diffusion due to increased metabolic needs [22]. Tc-
MIBI uptake is determined by tumor malignancy, viability, density, oxygenation, vascular
supply, and blood brain barrier (BBB) disruption [29]. These factors are not linearly correlated,
because glioblastoma, the most malignant form of glioma, is pathologically heterogeneous
including internal necrosis. False negative MIBI SPECT may occur due to the lack of contrast
uptake on MRI and masked by other normal tissue uptake. This was seen in temporal and
periventricular tumors [23], because Tc-MIBI is physiologically taken into the orbita, naso‐
pharyngeal tissues, pituitary, scalp and choroid plexus [30]. Some of the false positive results
were due to recent radiation induced local disruption of the BBB [23].
The pixel  size  of  MIBI  SPECT was smaller  than that  of  Tl  SPECT in  this  study.  There‐
fore,  MIBI  SPECT has a  higher  spatial  resolution than Tl  SPECT.  This  study investigat‐
ed  the  diagnostic  ability  of  SPECT  for  glioma  malignancy.  Higher  spatial  resolution
might influence the diagnostic ability with small or heterogeneous tumors. However, all
of  the  gliomas  in  this  study  were  larger  than  the  pixel  size.  In  addition,  most  of  the
malignant  tumors in  this  study were highly heterogeneous in both of  MRI and SPECT.
Only the  higher  spatial  resolution of  MIBI  SPECT could not  explain the  slightly  higher
diagnostic  ability  of  MIBI  SPECT  than  that  of  Tl  SPECT.  Some  authors  have  reported
that  Tc-MIBI  SPECT  has  higher  sensitivity  and  specificity  than  that  of  Tl  SPECT  for
adult and childhood brain tumors and differential  diagnosis of recurrence and radiation
necrosis  [26,  27,  31].  However,  other  authors  did  not  [32].  This  discrepancy  may  be
caused  by  small  and  heterogeneous  patient  populations  and  arbitrary  selected  cut  off
values.  In  Tl  SPECT there  is  some normal  brain  uptake,  this  makes  T/N ratio  low.  Tc-
MIBI  has  high  photon  energy  level  and  higher  tumor/background  ratio  in  comparison
with Tl  SPECT and yields clear  SPECT images and high sensitivity for  malignant  brain
tumor [22, 27, 31].
P-glycoprotein is one of the drug efflux pumps in the cell membrane and it acts to remove Tc-
MIBI from tumor cells [33, 34]. Other studies have suggested that p-glycoprotein expression
in malignant glioma is the cause of false negative with Tc-MIBI SPECT [35-37]. The effect of p-
glycoprotein expression on clinical Tc-MIBI SPECT images has been investigated, and this
effect was negligible in the diagnosis of brain tumor malignancy [38]. Henze also reported that
p-glycoprotein efflux does not contribute to false negative MIBI SPECT, since MIBI washout
did not occur between the early and late SPECT scans [39].
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1.4.3. ROC analysis
Many facilities use a cut off value to evaluate tumor malignancy in Tl or Tc-MIBI SPECT [1,
4-8]. Serizawa reported that simple inter-institutional comparisons of Tl indices are not
possible because measurement methods are different in each institute [7].
Most diagnostic tests have some errors and the results are influenced by arbitrary selected cut
off values. ROC analysis is useful to evaluate the diagnostic values of each examination that
yield some false positive or false negative results [9, 10]. Henze reported that ROC analysis
comparing I-123-iodo-α-methyl-L-tyrosine (IMT), Tc-MIBI SPECT and F-18-fluorodeoxyglu‐
cose positron emission computed tomography (FDG PET) for detection of tumor progression
in irradiated low-grade astrocytoma demonstrated that IMT yielded best diagnostic accuracy
[29]. ROC analysis has better diagnostic power than the arbitrary cut off method and inde‐
pendent disease prevalence and decision-making threshold [29]. ROC analysis also provides
adequate cut off value with appropriate sensitivity and specificity. Because SPECT image
accuracy is dependent on SPECT machine quality, acquisition algorithm, and injected isotope
dose, each facility should determine its own cut off value to provide an adequate diagnosis
from an ROC analysis of own data.
Some facilities omitted the acquisition of delayed images due to their limited examination time.
However, the current results demonstrated the superior diagnostic value of delayed images
in both of Tl and Tc-MIBI SPECT. These results revealed both Tl and Tc-MIBI SPECT are useful
for the diagnosis of gliomas. However, the SPECT study is not perfect, there are still some false
positive and false negative findings. Multi-modality imaging studies may therefore help to
diagnose brain tumors more correctly. If it is necessary to limit SPECT examinations due to
medical economical issues related to the health insurance policy, then Tc-MIBI SPECT with a
delayed acquisition is therefore considered to be the most reasonable choice.
1.5. Conclusion
Both of Tl and Tc-MIBI SPECT are useful imaging modalities for the evaluation of glioma
malignancies. Although there was no statistically significant difference, delayed Tc-MIBI
SPECT demonstrated the best diagnostic value in our patients with glioma based on an ROC
analysis.
2. Coregistration of functional SPECT images and high resolution
anatomical MRI
2.1. Introduction
201Thallium Single Photon Emission Computed Tomography (Tl SPECT) is a useful functional
imaging modality for the diagnosis of malignancy and activity of brain tumors. One of the
drawbacks of Tl SPECT is its low spatial resolution. The coregistration of functional SPECT
images and high resolution anatomical magnetic resonance imaging (MRI) is considered to be
a reasonable method to improve the low spatial resolution of SPECT.
Recent Developments of Single Photon Emission Computed Tomography for the Diagnosis of Brain Tumors
http://dx.doi.org/10.5772/52352
111
the most benign gliomas and the Tl SPECT findings of a pilocytic astrocytoma are reported to
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2.1. Introduction
201Thallium Single Photon Emission Computed Tomography (Tl SPECT) is a useful functional
imaging modality for the diagnosis of malignancy and activity of brain tumors. One of the
drawbacks of Tl SPECT is its low spatial resolution. The coregistration of functional SPECT
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a reasonable method to improve the low spatial resolution of SPECT.
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Some methods developed for the coregistration of multiple images have been reported. One
is a prospective method using external markers[40-42]. Another is the retrospective methods
based on imaging data[43-46]. Prospective methods need prospective external fiducial marker
placement and only the image with the marker can be coregistered. Retrospective methods do
not need external markers, and therefore they are more flexible. Variable images can be
retrospectively coregistered using software programs.
A newly developed software Brain Easy Analysis Tool for 201Tl-SPECT (BEAT-Tl, Fuji Film
RI Pharma. Tokyo, Japan) was used for the coregistration of Tl SPECT and MRI in patients
with brain tumors. The feasibility and reliability of BEAT-Tl was evaluated for patients with
brain tumors.
2.2. Materials and methods
The patient population included 98 patients (47 men and 51 women). The age range was from
4 to 84 years of age and the median age was 54. All patients had been admitted to Tsukuba
University Hospital between 2004 and 2007. The brain MRI and Tl SPECT images were taken
within a 1 week interval. No anti-tumor therapy was administered between the examinations.
The sets of MRI and Tl SPECT examinations were taken for 120 times (59 times for men and
61 times for women). MRI showed mass lesions in all of the patients. The final diagnoses
included glioma, lymphoma, neurocytoma, metastasis, meningioma, radiation necrosis,
encephalitis and multiple sclerosis. Most patients underwent tumor removal surgery and the
pathological diagnoses were determined.
MRI was performed using the 1.5  Tesla  clinical  MRI scanner (Gyroscan NT Intera,  Phi‐
lips,  Netherlands).  T1  weighted  images  with  or  without  Gd-DTPA  enhancement,  T2
weighted images and Fluid attenuated inversion recovery images (FLAIR) were routine‐
ly acquired. Tl SPECT images were acquired 15 minutes (early image) and 3 hours (de‐
layed image)  after  the  intravenous injection of  74  MBq of  Thallium Chloride (Fuji  Film
RI  Pharma.  Tokyo,  Japan)  using  a  multi-detector  SPECT  machine  (E.CAM,  Siemens
Medical,  Erlangen, Germany) and a high resolution collimator (LEHR, Siemens Medical,
Erlangen,  Germany).  The  Butterworth  pre-correction  filter  and the  Chang method were
used for pre and post attenuation corrections.  The Ramp filter was used for reconstruc‐
tion.  The image matrixes  for  Tl  SPECT were 64 x  64.  Both the pixel  sizes  and the slice
thickness for Tl SPECT were 6.61mm.
The MRI and SPECT data were saved as Digital Imaging and Communications in Medi‐
cine  (DICOM)  formats.  The  DICOM  data  were  converted  to  the  analyze  format  using
File  Converter  Ver.  2.5  (Fuji  Film RI  Pharma.  Tokyo,  Japan).  Both  the  MRI  and SPECT
data  in  analyze  format  were  transferred to  the  co-registration  software  program BEAT-
Tl and then coregistered images were created. The BEAT-Tl program is based on Statis‐
tical  Parametric  Mapping  (SPM)  and  it  can  be  used  on  personal  computers  with  the
Windows operating system. The imaging quality,  clinical  usefulness  and the artifacts  of
the coregistered images were evaluated by visual inspection.
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2.3. Results
The coregistered images were easily and promptly created within one minute. The image
quality was sufficient. There were no large displacements of the MRI and SPECT images and
no major artifacts. The coregistration was fully automatic and no manual coregistration
procedure was required.
The small hot uptake in Tl SPECT always coincided with enhanced tumors in MRI. For large
tumors, Gd enhanced T1 weighted MRI showed relatively homogeneous enhancement.
However, Tl SPECT showed focal uptake of Tl in the homogeneously enhanced tumor.
Therefore, the coregistered images demonstrated metabolic heterogeneity on Tl SPECT. In
most patients, Tl hot uptake was in the Gd enhanced tumor. In some patients, Tl uptake was
observed outside of the Gd enhanced tumor.
2.4. Illustrative cases
Case 1:A 64-year-old female with an anaplastic oligodendroglioma
Tl uptakes were different between 2 fusion images of Gd enhanced T1 weighted MRI and early
Tl SPECT (Fig. 2, Lt) or delayed Tl SPECT (Fig.2,Rt). Tl uptakes were heterogeneous even
though the Gd enhanced tumor was homogenous. Most Tl uptakes were within the Gd
enhanced tumor. However the part of the delayed Tl uptake was out of the Gd enhanced area,
and therefore this region seemed to demonstrate tumor invasion into normal brain tissue.
Figure 2. Fusion images of Gd enhanced T1 weighted MRI and early Tl SPECT (Lt) or delayed Tl SPECT (Rt) of Case 1.
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Case 2: A 34-year-old male with a frontal glioblastoma.
A fusion image of the preoperative Gd enhanced MRI and delayed Tl SPECT (Fig 3, Lt) showed
Rt medial Tl uptake although the Gd enhanced tumor was located in the corpus callosum.
Because there was a tumor without Gd enhancement in the left frontal lobe, the left frontal
lobe and the tumor at the corpus callosum was removed. After radiation therapy of 60Gy, 2
months after the surgery, tumor recurrence was seen mainly in the Rt medial frontal lobe where
the hot Tl uptake was seen in Gd enhanced T1 weighted MRI (Fig 3, Rt).
Figure 3. Fusion image of preoperative Gd enhanced MRI and delayed Tl SPECT (Lt) and Gd enhanced T1 weighted
MRI (Rt) 2 months after the surgery.
2.5. Discussion
2.5.1. Usefulness of coregistration
The one of the major disadvantages of SPECT is the low spatial resolution caused by scattering
radiation. Because no anatomical landmarks are seen in Tl SPECT images, it is sometimes
difficult to precisely determine the locations of lesions and the relationships with normal
structures based on only Tl SPECT images. The coregistration of Tl SPECT and MRI has thus
completely solved these problems.
Even when tumors were found to be homogeneous in MRI, Tl SPECT showed metabolic
heterogeneity. These detailed analyses thus become possible by studying coregistration
images. Further pathological and clinical studies are expected to reveal the clinical significance
of these imaging modalities.
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2.5.2. Method of coregistration
Other methods for the coregistration of SPECT and MRI has been reported [45-47]. These
methods required meticulous and cumbersome procedures and long calculation time. In some
cases sufficient coregistration could not be achieved by automatic calculations and thus
required manual procedures.
The Brain easy analysis tool (BEAT, Fuji film RI Pharma, Tokyo, Japan) is the coregistration
program for cerebral blood flow (CBF) SPECT and MRI. BEAT uses automated image regis‐
tration (AIR http://bishopw.loni.ucla.edu/) as the coregistration algorithm and ratio image
uniformity (RIU) as the cost function. In CBF SPECT image, tracer uptake into normal brain
tissue is seen, so the contour of the brain tissue is clear. However, in the brain tumor SPECT
image, the tracer uptake into the normal brain tissue is negligible, so the contour of the normal
brain tissue is not seen. Because of these factors, the coregistration of brain tumor SPECT and
MRI has not been achieved using the same algorithm used for the coregistration of CBF SPECT
image and MRI.
BEAT-Tl uses statistical parametric mapping (SPM) 2 (http://www.fil.ion.ucl.ac.uk/spm/) as
the voxel based coregistration software and normalized mutual information (NMI) as the cost
function to evaluate coregistration accuracy. These algorithms allow automatic coregistration
of brain tumor SPECT and MRI with satisfactory accuracy.
The BEAT-Tl program runs on a normal personal computer without any problems. The usual
calculation time is within a minute, so it is simple for operators. The results could be fed back
to a busy daily clinical practice, so the clinical impact and efficacy are significant. In the current
study, the accuracy of the coregistration was satisfactory. There were no major errors or
artifacts.
SPECT/computed tomography (CT) or positron emission CT (PET)/CT are thus considered to
be alternative methods to create coregistration images. These hardware based coregistrations
must be more accurate than the software based coregistrations. Currently, however, these
machines are expensive and not available in most clinical settings. As the results, the coregis‐
tration software program is both a convenient and sufficiently accurate method to create
coregistration images in most clinical facilities.
2.5.3. Study limitation
The current study population was relatively small and this study did not evaluate every patient
admitted to this hospital. In the future, a prospective study will reveal the exact usefulness
and the limitations of the coregistration images of Tl SPECT and MRI.
The uptake of Tl into a lesion is affected by multiple factors, including tumor malignan‐
cy,  tumor  metabolism,  cell  density,  blood  brain  barrier  breakdown,  blood  flow,  blood
volume and capillary density [1,  5].  Therefore, the interpretation of Tl SPECT should be
done  cautiously.  The  fusion  of  Tl  SPECT  and  MRI  could  be  helpful  to  evaluate  the
mechanisms  of  Tl  uptake  into  lesions.  Although no  large  displacements  of  the  coregis‐
tration  were  seen  in  the  images  created  by  BEAT-Tl,  the  coregistration  error  was  not
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the hot Tl uptake was seen in Gd enhanced T1 weighted MRI (Fig 3, Rt).
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machines are expensive and not available in most clinical settings. As the results, the coregis‐
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coregistration images in most clinical facilities.
2.5.3. Study limitation
The current study population was relatively small and this study did not evaluate every patient
admitted to this hospital. In the future, a prospective study will reveal the exact usefulness
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measured  in  this  study.  In  order  to  investigate  the  coregistration  error,  stereotactic  or
image  guided  surgery  will  be  done  in  a  future  study.  One  of  the  problems  of  image
study  for  malignant  brain  tumors  is  the  heterogeneity.  Glioblastoma  multiforme  is
pathologically,  metabolically,  and radiologically  heterogeneous.  Pathological  radiological
correlations could reveal the meaning of each finding. Neurosurgeons could remove the
tumor; however,  the registration of the removed tissue at exact locations on each image
is  not  easy.  Image  guided  surgery  using  coregistration  image  should  facilitate  these
studies.  The  application  of  fusion  images  for  navigation  guided  neurosurgery  will  be
developed.
2.6. Conclusion
BEAT-Tl is a useful coregistration software program that is used to evaluate brain tumors. It
improves the spatial correlation of SPECT images and such coregistration images demonstrate
a metabolic heterogeneity in tumors that is not revealed in MRI.
3. Evaluation of glioma surgical extent using fusion image of Tl SPECT and
anatomical MRI
3.1. Introduction
In glioma surgery, removal extent has been evaluated using morphological image, such as MRI
or X-ray CT. These morphological images could not completely evaluated surgical removal
extent, because glioma is invasive tumor. The contribution of glioma surgery for the improve‐
ment of the prognosis is controversial [48, 49]. One of the causes of this discrepancy may be
the method of evaluation of glioma surgical extent. We evaluated the glioma surgical extent
using fusion image of metabolic Tl SPECT and anatomical MRI. Our hypothesis is these fusion
images could more precisely predict the prognosis of the patient received glioma removal
surgery.
3.2. Methods
From 2006 to 2008, 146 patients examined both of Tl SPECT and MRI at the same time under
the diagnosis of brain tumor. And 58 patients received tumor removal surgery after the
examinations. Only 36 patients who were examined MRI within 3 days after the surgery were
included because surgical modification of MRI increase after postoperative 4 days [50]. Finally
30 patients who have Gd-DTPA enhanced tumor in MRI and hot tumor uptake in Tl SPECT
were included in this study, in order to make image evaluation easy. Final patient population
included 17 male and 13 female, age range from 34 to 80 year-old. World Health Organization
(WHO) pathological grade are 10 grade 3 and 20 grade 4. Oligodendroglioma component was
recognized in 7 grade 3 tumors. All patients received adjuvant standard radiation and
chemotherapy.
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3.3. Results
Partial removal group were frequently seen in Grade 4. The removal rates with MRI and SPECT
were concordant for 24 cases. The removal rates with MRI were higher than those with SPECT
in 6 cases. So SPECT more efficiently revealed residual tumor than MRI did (Figure 4,5). The
time to progression was short in partial removal group with MRI and SPECT (Figure 6). The
removal rates, pathology and oligodendroglioma components were all related with the





(a): preoperative Gd-enhanced MRI showed left frontal non-enhanced low intensity tumor and Gd-enhanced tumor.
Enhanced tumor located at left medial frontal lobe and invaded into right medial frontal lobe.
(b): The fusion image of preoperative Tl-SPECT and MRI showed hot Tl uptake only at right medial frontal lobe.
(c): Postoperative Gd-enhanced MRI showed small residual enhanced tumor at right medial frontal lobe.
(d): The fusion image with Tl-SPECT demonstrated residual tumor at right medial frontal lobe. Surgical extents were
evaluated as subtotal removal by MRI, partial removal with Tl-SPECT.
(e): After radiation and chemotherapy, tumor recurrence occurred from right medial frontal residual tumor.
(Reproduced from Y Shibata, CI research 32:19-24, 2010 with permission.)
Figure 4. Case 1, 34 year-old man with glioblastoma. (same case as Fig 2-2)
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3.3. Results
Partial removal group were frequently seen in Grade 4. The removal rates with MRI and SPECT
were concordant for 24 cases. The removal rates with MRI were higher than those with SPECT
in 6 cases. So SPECT more efficiently revealed residual tumor than MRI did (Figure 4,5). The
time to progression was short in partial removal group with MRI and SPECT (Figure 6). The
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Figure 4. Case 1, 34 year-old man with glioblastoma. (same case as Fig 2-2)







(a): Preoperative Gd-enhanced MRI showed right parietal ring enhanced tumor and perifocal edema.
(b): The fusion image of preoperative Gd-enhanced MRI and Tl SPECT
(c): Postoperative Gd-enhanced MRI showed small residual enhanced tumor at right parietal lobe.
(d): The fusion image of preoperative Tl SPECT and MRI showed hot Tl uptake at right residual parietal lobe.
(e): After radiation and chemotherapy, tumor recurrence occurred from hot Tl uptake area.
(Reproduced from Y Shibata, CI research 32:19-24, 2010 with permission.)
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Figure 6. Kaplan-Meier curves of Time to Progression evaluated by rem val rate in MRI (Left) and SPECT (Right). Partial
removal groups (brown curves) showed significantly early recurrences than both of total (blue curves) and sub-total
removal groups (blue curves).
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3.4. Conclusion
The fusion image of preoperative Tl SPECT and postoperative MRI is more useful to evaluate
glioma removal extent than MRI only. Partial removal groups have poor prognosis, so
maximum surgical removal should be aimed using multimodal images including MRI and Tl
SPECT. The total removal of Tl SPECT positive lesion improves the prognosis and especially
prevents early recurrence.
Acknowledgements
I appreciate my mentors, collaborators and the patients.
Author details
Yasushi  Shibata
Department of Neurosurgery, Mito Medical Center, University of Tsukuba, Ibaraki, Japan
I declare that I have no conflict of interest.
References
[1] Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thalli‐
um-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg.
1989;71:342-6.
[2] Kosuda S, Shioyama Y, Kamata N, Suzuki K, Tanaka Y, Nakamura O, et al. [Differen‐
tial diagnosis between recurrence of brain tumor and radiation necrosis by 201Tl
SPECT]. Nippon Igaku Hoshasen Gakkai Zasshi. 1991;51:415-21. (In Japaese)
[3] Kosuda S, Fujii H, Aoki S, Suzuki K, Tanaka Y, Nakamura O, et al. Reassessment of
quantitative thallium-201 brain SPECT for miscellaneous brain tumors. Ann Nucl
Med. 1993;7:257-63.
[4] Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, et al. Diagnosis
of recurrent brain tumor: value of 201Tl SPECT vs 18F- fluorodeoxyglucose PET. Am
J Roentgenol. 1994;163:1459-65.
[5] Burkard R, Kaiser KP, Wieler H, Klawki P, Linkamp A, Mittelbach L, et al. Contribu‐
tion of thallium-201-SPECT to the grading of tumorous alterations of the brain. Neu‐
rosurg Rev. 1992;15:265-73.







(a): Preoperative Gd-enhanced MRI showed right parietal ring enhanced tumor and perifocal edema.
(b): The fusion image of preoperative Gd-enhanced MRI and Tl SPECT
(c): Postoperative Gd-enhanced MRI showed small residual enhanced tumor at right parietal lobe.
(d): The fusion image of preoperative Tl SPECT and MRI showed hot Tl uptake at right residual parietal lobe.
(e): After radiation and chemotherapy, tumor recurrence occurred from hot Tl uptake area.
(Reproduced from Y Shibata, CI research 32:19-24, 2010 with permission.)




MRI  (Left)  and  SPECT  (Right).  Partial  removal  groups  (brown  curves)  showed 3 
significantly  early  recurrences  than  both  of  total  (blue  curves)  and  sub‐total 4 
removal groups (blue curves). 5 
3.4.   Conclusion 6 
The  fusion  image of preoperative  Tl  SPECT  and postoperative MRI  is more 7 
useful to evaluate glioma removal extent than MRI only. Partial removal groups 8 
have  poor  prognosis,  so maximum  surgical  removal  should  be  aimed  using 9 
multimodal  images  including MRI and Tl SPECT. The total removal of Tl SPECT 10 
positive lesion improves the prognosis and especially prevents early recurrence. 11 
4. Conflict of interest 12 
 I declare that I have no conflict of interest. 13 
5. Acknowledgements 14 
 I appreciate my mentors, collaborators and the patients.  15 
16 
6. References 17 
[1] Black  KL,  Hawkins  RA,  Kim  KT,  Becker  DP,  Lerner  C,  Marciano  D.  Use  of 18 
thallium‐201 SPECT  to quantitate malignancy grade of gliomas.  J Neurosurg. 19 
1989;71:342‐6. 20 
[2] Kosuda  S,  Shioyama  Y,  Kamata  N,  Suzuki  K,  Tanaka  Y,  Nakamura  O,  et  al. 21 

















Figure 6. Kaplan-Meier curves of Time to Progression evaluated by rem val rate in MRI (Left) and SPECT (Right). Partial
removal groups (brown curves) showed significantly early recurrences than both of total (blue curves) and sub-total
removal groups (blue curves).
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors118
3.4. Conclusion
The fusion image of preoperative Tl SPECT and postoperative MRI is more useful to evaluate
glioma removal extent than MRI only. Partial removal groups have poor prognosis, so
maximum surgical removal should be aimed using multimodal images including MRI and Tl
SPECT. The total removal of Tl SPECT positive lesion improves the prognosis and especially
prevents early recurrence.
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Brain tumors are rare neoplasms, however, they represent the second commonest cancer in
childhood (the first being hemato-lymphoid neoplasms) and correspond to the main solid
tumor in the pediatric context (ages 0-19 years) [1]. In this setting, gliomas, and particularly
astrocytomas are the leading group. Pilocytic astrocytoma (PA) is the commonest brain tumor
in the ages 5-14 years and the second in the age ranges 0-4 years and 15-19 years, although it
represents about only 6% of all gliomas, according to the last Central Brain Tumors Registry
(CBTRUS) Report [1]. PA affects males and females equally, and the main affected ages are 6
to 13 years-old, with 75% of cases occurring at this ages [2; 3].
PAs present a good prognosis in general, with 10-year survival >90% [4]. However, about
10-20% of patients suffer with recurrence of completely excised lesions or growing of residual
lesions [4]. Besides, 2-3% of the cases may disseminate through the spinal cord [2; 4]. These
aggressive tumors are particularly more frequent in adults and older patients, which explains
the difference in the 10-year survival [5].Overall, the prognosis between children and adults
is significantly different [5]. While in children and young adults the 5-year survival is >90%,
in the group of 60+ years patients, this value is about 52% [5]. Likewise, the mortality rates
related to PAs are higher in adults than in children. Despite this could be explained by
differences in the location of these tumors in adults many evidences suggest that PA is in fact
a more aggressive neoplasm in older age groups [5].
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2. Anatomical location and neurorradiological features
The main location of PA is the cerebellum, with more than 60% of the cases occurring in
cerebellar hemispheres, however, it can arise all through the neuraxis, including hypothalamic
region, the optic-chiasmatic tract and spinal cord, with some cases involving the whole spinal
cord (“holocord pilocytic astrocytoma”) [2; 3; 6]- [9]. This wide distribution in the central
nervous system (CNS) may, in part, explain the differences in the prognosis of PA, since GTR
of a lesion located near or in eloquent areas of the CNS may be unachievable. In addition, some
locations present special features or are related to specific conditions. For example, multiple
tumors and tumors located in the optic-chiasmatic region are far more common in patients
with neurofibromatosis 1 (NF1), while supratentorial and spinal cord PAs are more frequent
in adults than in children [2; 5].
At neurorradiological exams, the typical finding is, generally, a non-infiltrative, well delimited
biphasic lesion, with a cystic, hipointense, area associated with a mural nodule, which can be
contrast-enhanced at magnetic resonance image (MRI) and computed tomography (CT),
however, diverse patterns as solid nodule or complete cystic lesions can be seen [2; 10] (Figure
1). In any case, perilesional edema is not commonly observed, as it is in high-grades primary
brain tumors [11]. Anecdotally, PA can be manifested as cerebral hemorrhage [12].
Figure 1. Neurorradiological features of Pilocytic Astrocytomas, after endovenous contrast injection. Note the absence
of perilesional edema, even in voluminous lesions. A- Cerebellar lesion – solid with cystic areas. This is the commonest
pattern of PA (MRI, coronal view). B- Cerebellar lesion, predominantly cystic with a mural nodule (CT, axial view). C-
solid, suprasselar lesion (MRI, coronal view).
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3. Clinical signs and symptoms
Due to its highly variable location in the neuraxis, the signs and symptoms of PA depend on
the affected area. As the most common location is the cerebellum, headache and neck pain,
vomiting, gait disturbance and visual abnormalities are usually referred [2; 3; 6; 13]. In
supratentorial tumors, the occurrence of seizures may be seen and is related to cortical
involvement [6]. In the hypothalamic area, PA may present with hormonal dysfunctions, for
example, diabetes insipidus, obesity [3; 11] and the diencephalic syndrome – emaciation,
hiperkinesis, irritability and accelerated growth [11]. The involvement of the optical pathway
is related to visual loss or visual-field deficits [6; 11]; proptosis presents only in large, intraor‐
bital tumors [6].
Clinical signs of intracranial hypertension, as hydrocephalus, papilledema, nistagmus, nausea
and vomiting are common in virtually all locations, because of the mass effect impinged by
the neoplasm [2; 3; 11]. On the other hand, smaller lesions may remain asymptomatic by some
variable time [11].
4. Histopathological aspects
Some histopathological features of PA are well-established, for instance, biphasic pattern, with
high- and low-cellularity areas; elongated (piloid) and rounded, oligodendroglial-like, cells
mixed in various proportions; microcystic areas; Rosenthal fibers, and eosinophilic granular
bodies are the commonest findings [2; 6] (Figure 2). In general, these findings support a
diagnosis of a low-grade astrocytoma (grade I), according to the World Health Organization
(WHO) criteria. However, features like microvascular proliferation, necrosis and degenerative
nuclear atypia, more commonly present in infiltrative, high-grade gliomas, may be seen
(Figure 3B, C). Diverse from infiltrative tumors, though, these features shall not be interpreted
as malignancy signs, unless they are associated to high mitotic activity [2; 3; 10]. Leptomenin‐
geal dissemination is quite common, and apparently is not related to aggressive behavior [14].
Calcification, hemorrhage and perivascular lymphocytic infiltration are less common (Figure
3A, D), but may be seen in some cases [10; 14]. Eventually, neuronal cells can be observed,
intermingled in the tumor, but they lack neoplastic features, and can be interpreted as
entrapped neurons [6; 10; 14].
Because of the great variation in histopathological appearance, the diagnosis of PA is usually
challenging, especially in minute biopsies, and greatly dependent upon correlation with
neurorradiological aspects [2; 3]. This can be such a dilemma, that some authors refer huge
discordance between pathologists, with half of PAs misdiagnosed as higher-grade tumors at
primary diagnosis [15].
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Figure 2. Histopathological aspects of Pilocytic Astrocytoma. All microphotographs represent H&E stain. A- Biphasic
pattern – high cellularity at left and lower cellularity at bottom right (100x). B- Round and piloid cells constitute this
tumor. Note the vasculature, with typical endothelia (200x). C- Rosenthal fibers (black arrow) and eosinophilic granu‐
lar body (white arrow) can be seen in higher cellular areas (200x). D- At bottom, a microcystic area is seen (40x).
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Figure 3. Some other histopathological aspects of Pilocytic Astrocytoma at the H&E stain. A- Microvascular prolifera‐
tion (200x) B- Areas of necrosis may be seen in some tumors – in this case, the necrosis is at right (40x). C- Calcification
foci near a microcystic area of tumor (40x). D- Lymphocytic cuffs may be present (200x).
4.1. Differential diagnosis
Differential diagnoses of PA include low- and high-grade gliomas and the identification of
different entities has great importance in the treatment choice and prognosis of patients.
Among low-grade tumors, the most important differential diagnoses include ganglioglioma;
pleomorphic xantoastrocytoma (PXA); grade II oligodendroglioma; and diffuse astrocitoma.
In these cases, tumor location, neurorradiological and immunohistochemical features can help
in the definition, and this will be better discussed later in next sections. Moreover, hypothala‐
mic lesions, especially in infants, must also be distinguished from pilomixoid astrocytoma, a
recently described tumor, stated as grade II variant of PA in the last WHO classification [2; 3].
On the other hand, anaplastic astrocytoma and anaplastic oligodendroglioma (WHO grade
III) are some of the high grade lesions that can be confounded with PA [2; 3] when there are
degenerative atypia and/or oligodendroglial-like areas in the tumor. Finally, glioblastoma
(GBM – WHO grade IV), the commonest and most aggressive astrocytoma, share various
histological and neurorradiological features with PA, which makes the diagnosis problematic
in some cases [16]- [18]. In these cases, clinical correlation and immunohistochemical markers
can be used for better defining the diagnosis.
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5. Immunohistochemistry in the diagnosis of pylocitic astrocytoma
In order to reduce misdiagnoses, some immunohistochemical markers can be used to elucidate
complicated cases. There are no specific markers for PA, but differences between expressions
of standard antibodies can help in the task. Some of the main immunohistochemical markers
are described herein:
5.1. Glial Fibrillary Acidic Protein (GFAP)
GFAP is a cytoplasmatic intermediate filament, component of the cytoskeleton of normal and
neoplastic astrocytes [3]. Like in all astrocytomas, GFAP is persistently, diffusely expressed in
PAs, which does not permit the delineation between PA and diffuse astrocytomas. However,
it may be a useful tool to differentiate PA from other gliomas, such as ependymomas and
oligodendrogliomas.
As described earlier, some PAs may present perivascular lymphocytic cuffs and neuronal cells
entrapped among the neoplastic astrocytes. These characteristics are also seen in ganglioglio‐
mas [6]. To rule out this possibility, GFAP may help, as stated since 1970s by Eng and Rubin‐
stein [19], since the neoplastic neuronal cells in this tumor are negative and may be highlighted
in contrast to the strongly positive neoplastic astrocytes with this marker – this pattern
corroborates the mixed nature of ganglioglioma. There are other immunohistochemical
markers that help in this differential diagnosis, in addition to GFAP, for example, CD34
(positive in gangliogliomas and negative in PAs) and Neu N (neuronal marker, useful in the
identification of neoplastic and entrapped neurons).
Secondly, since PAs may present oligodendroglial-like areas and calcifications, another utility
for the use of GFAP is to differentiate these areas (in a small sample, for example) from
oligodendrogliomas. Oligodendroglial tumors are mostly negative, however, a peculiar
pattern of perinuclear immunoreactivity was recognized after the description of the proto‐
plasmatic oligodendrocytes, present in almost 80% of oligodendrogliomas [17; 20]. Even in
those positive cases, the pattern contrasts to the cytoplasmatic, diffuse positivity seen in the
PAs. Other immunohistochemical markers can be used in a panel in order to refine this
diagnosis, for instance, OLIG-2, a transcription factor involved in oligodendroglial differen‐
tiation [21]. Although some weak immunnopositivity may be seen in astrocytomas (low and
high grades) and more than 70% of PAs may be immunoreactive for OLIG-2 [22], according
to some authors, OLIG-2 can significantly distinguish oligodendroglial and astrocytic tumors
[20; 21]. As these both markers (GFAP and OLIG-2) can be simultaneously expressed by PAs
and oligodendrogliomas, the interpretation of these immunohistochemical tests must take in
account other histopathological findings and even neurorradiological features.
Finally, although GBM is a also a tumor of astrocytic lineage, it may present a different pattern
of GFAP immunopositivity. Opposed to the diffuse positivity in PA, GBM is heterogeneously
immunoreactive, predominant at the periphery of the tumor or only focal. This happens
because the immunoexpression of GFAP tends to decrease with the malignant progression of
astrocytomas [16; 17; 23].
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In summary, GFAP is an important marker of astrocytic differentiation and can help to
distinguish PA from other low- and high grade gliomas, both through the presence or absence
of its immunoexpression and the different patterns (subcellular location and distribution over
the tumor areas) of immunopositivity.
5.2. Ki67
The non-histone nuclear protein ki67 is a protein codified by genes present in the chromo‐
some 10 [24; 25]. It is expressed in the nuclei of cells in all but G0 and early G1 phases of
the  cellular  cycle  [26],  which allows a  faithful  estimative  of  the  proliferative  index of  a
neoplasm.  As  PA is  a  grade  I  astrocytoma,  low proliferative  index  is  the  rule  in  these
tumors [2; 3] (Figure 4A) with medium values about 2% [14; 27], however medium values
as high as 4,4% have been related [10; 28].
Figure 4. Immunnohistochemical aspects, with avidin-biotin-peroxidade technique. A- Ki67 – nuclear positivity in
about 2% of neoplastic cells(100x). B- Galectin-3 – this case showed weak, diffuse immunopositivity and predominant
cytoplasmatic location (100x). C- Galectin-3 strong, diffuse positivity and the vascular endothelium showed no reac‐
tion (100x). D- CD31 reaction in the endothelia – delicate vessels in the tumor (200x).
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Proliferative index by ki67 expression is a well established prognostic factor in diffuse
astrocytomas [29], yet, its role in the prognosis of PA is controversial. In 2002, Roessler et al
did not show significant differences between cerebellar PA when comparing groups according
to the proliferative index with a cut-off value of 5% [28] and this result was further corroborated
by other study with even lower cut-off value of 3% [10]. Shortly after, Bowers et al (2003)
described a subset of PA with worse prognosis, when the proliferative index determined by
Ki67 was >2% [27]. More recently higher medium values (>10%) were described in recurrent
and more aggressive PAs [10], and this exceptionally high value is similar to the medium value
of proliferative index for GBM (12,28%) described earlier by the same group [29].
Although the proliferative index is  still  a  questionable  independent  prognostic  factor  of
PAs, it is well accepted that a strict follow up is needed in the cases with high prolifera‐
tive activity [10; 27].
5.3. Galectin-3
Galectin-3 (gal-3) is a carbohydrate-binding protein that binds specifically to β-galactosides
sugars. This protein is involved in various biological processes, such as cellular proliferation,
apoptosis, transcriptional regulation, intracellular signalization, adhesion and migration [30;
31]. The expression of gal-3 may be seen in both cytoplasm and nuclei of neoplastic cells
(particularly carcinomas) from various organs, such as thyroid, pancreas and prostate [32], but
the relation between hyper- or loss of expression and biologic behavior of the tumor varies
among the different organs [32].
In APs, gal-3 is expressed in the nuclei and cytoplasm of neoplastic cells in all cases of PA
described by various authors [2; 10; 32; 33], but lacks the expression in the vascular endothe‐
lia(Figure 4B, C), contrary to what it is seen in non-neoplastic brain parenchyma [10; 33] and
in astrocytomas grades II and III and oligodendroglial tumors, which permits a faithful
delineation from PA when facing tough cases [17; 31].
Gal-3 is not specific of PA, since other low-grade tumors, such as ependymomas and PXA also
present diffuse expression of gal-3 [10; 32; 33]. Interestingly, focal (heterogenous) expression
of gal-3 is also seen in GBM [2; 18; 32], and although the vast differences between the biological
behavior and molecular pathways of these tumors, this expression may be related to micro‐
vascular proliferation and breaking of hematological barrier (and contrast-enhancement at
neuroimage) seen in these both entities [10; 18].
Although various studies have tried to relate the intensity and extension of gal-3 expression
to the clinical behavior of PA, no prognostic significance was proved until now. Still, as gal-3
expression is a conspicuous finding in PAs, in a pattern that can be differentiated from other
grades of astrocytoma, this marker may be very useful in the tumor diagnosis [10; 18; 32; 33].
Besides, recently a group of authors described a close relationship between expression of gal-3
and activation of the RAF-MEK-ERK pathway in pancreatic cancer [34] and, as we shall see
later in this chapter, that is an important molecular pathway in the genesis of PA, so gal-3 may
be soon proved as a potential target for future treatments.
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6. Molecular biology of pilocytic astrocytomas
Since no prognostic factors have been identified to differentiate regular from the more
aggressive Pas [5; 10; 14], the genetic characteristics of the PAs have recently been investigated
to better understand and try to predict the behavior of this tumor. Among these alterations,
chromossomal abnormalities (structural or numerical, as the aneuploidies), single-gene
mutations and epigenetic damage are mechanisms that could launch the molecular pathway
of oncogenesis.
The molecular pathways of oncogenesis differ in PAs and diffuse astrocytomas. For example,
two growth factor receptors, EGFR and PDGFR, related to invasion and malignant progres‐
sion, which are frequently hyperexpressed in infiltrative diffuse astrocytomas had a lower
expression in PAs observed by different groups [35; 36]. Besides, other genes characteristically
altered in diffuse gliomas, as TP53 and PTEN are normally expressed in Pas [2; 35; 37].
No cytogenetic abnormalities were detected in PA at first, and the majority of PAs presented
normal karyotype, similar to fetal astrocytes [37], and the majority of the altered tumors were
from female and adult patients [2]. Since then, a lot of genes have been investigated. We shall
see the most studied genes in PAs in the subsequent sessions.
6.1. NF1 gene
The first genetic studies tried to establish some differences between sporadic PAs and NF1-
PA, which present a more aggressive behaviour. It was known that NF1-PAs present germline
mutations of NF1 (in contrast to somatic mutations in GBM of this gene) and this results in a
loss of expression of the gene and, at protein level, results in a defective protein, neurofibromin
[3], which lastly permits a constitutive activation of the RAS-RAF-MERK-ERK molecular
pathway [4], or the mTOR/AKT pathway, activated in more aggressive Pas [4].
The detection of NF1 mutations can be achieved by molecular methods, by verifying the
expression of the gene or even at IHC, through the expression (or loss of expression) of
neurofibromin. [2; 3]
6.2. The RAS-RAF-MEK-ERK signaling pathway
The studies of NF1 gene were “the initial indication that Mitogen-activated protein kinase
(MAPK) signaling might play a role in the development of PAs”, as stated by Jones et al (2011)
[4]. Since then, various groups have investigated the participant proteins of these pathways.
The MAPK pathways regulate fundamental biologic processes. In mammalian, there are 4
well-described MAPK pathways [38; 39] (Figure 5) and the most studied is the extracellular
signal-regulated kinase (ERK)1/2 [39]. Alterations of this pathway are described in both low and
high-grade astrocytomas [4], but molecular mechanisms differ between them.
In  summary,  the  ERK1/2  pathway is  triggered  by  the  binding  of  soluble  peptides  to  a
Tyrosin-kinase  receptor  (TKR)  at  the  cell  surface,  and initiates  a  cascade  of  events  that
terminates in the appropriated cellular response [40].  This pathway is related to various
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described by various authors [2; 10; 32; 33], but lacks the expression in the vascular endothe‐
lia(Figure 4B, C), contrary to what it is seen in non-neoplastic brain parenchyma [10; 33] and
in astrocytomas grades II and III and oligodendroglial tumors, which permits a faithful
delineation from PA when facing tough cases [17; 31].
Gal-3 is not specific of PA, since other low-grade tumors, such as ependymomas and PXA also
present diffuse expression of gal-3 [10; 32; 33]. Interestingly, focal (heterogenous) expression
of gal-3 is also seen in GBM [2; 18; 32], and although the vast differences between the biological
behavior and molecular pathways of these tumors, this expression may be related to micro‐
vascular proliferation and breaking of hematological barrier (and contrast-enhancement at
neuroimage) seen in these both entities [10; 18].
Although various studies have tried to relate the intensity and extension of gal-3 expression
to the clinical behavior of PA, no prognostic significance was proved until now. Still, as gal-3
expression is a conspicuous finding in PAs, in a pattern that can be differentiated from other
grades of astrocytoma, this marker may be very useful in the tumor diagnosis [10; 18; 32; 33].
Besides, recently a group of authors described a close relationship between expression of gal-3
and activation of the RAF-MEK-ERK pathway in pancreatic cancer [34] and, as we shall see
later in this chapter, that is an important molecular pathway in the genesis of PA, so gal-3 may
be soon proved as a potential target for future treatments.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors134
6. Molecular biology of pilocytic astrocytomas
Since no prognostic factors have been identified to differentiate regular from the more
aggressive Pas [5; 10; 14], the genetic characteristics of the PAs have recently been investigated
to better understand and try to predict the behavior of this tumor. Among these alterations,
chromossomal abnormalities (structural or numerical, as the aneuploidies), single-gene
mutations and epigenetic damage are mechanisms that could launch the molecular pathway
of oncogenesis.
The molecular pathways of oncogenesis differ in PAs and diffuse astrocytomas. For example,
two growth factor receptors, EGFR and PDGFR, related to invasion and malignant progres‐
sion, which are frequently hyperexpressed in infiltrative diffuse astrocytomas had a lower
expression in PAs observed by different groups [35; 36]. Besides, other genes characteristically
altered in diffuse gliomas, as TP53 and PTEN are normally expressed in Pas [2; 35; 37].
No cytogenetic abnormalities were detected in PA at first, and the majority of PAs presented
normal karyotype, similar to fetal astrocytes [37], and the majority of the altered tumors were
from female and adult patients [2]. Since then, a lot of genes have been investigated. We shall
see the most studied genes in PAs in the subsequent sessions.
6.1. NF1 gene
The first genetic studies tried to establish some differences between sporadic PAs and NF1-
PA, which present a more aggressive behaviour. It was known that NF1-PAs present germline
mutations of NF1 (in contrast to somatic mutations in GBM of this gene) and this results in a
loss of expression of the gene and, at protein level, results in a defective protein, neurofibromin
[3], which lastly permits a constitutive activation of the RAS-RAF-MERK-ERK molecular
pathway [4], or the mTOR/AKT pathway, activated in more aggressive Pas [4].
The detection of NF1 mutations can be achieved by molecular methods, by verifying the
expression of the gene or even at IHC, through the expression (or loss of expression) of
neurofibromin. [2; 3]
6.2. The RAS-RAF-MEK-ERK signaling pathway
The studies of NF1 gene were “the initial indication that Mitogen-activated protein kinase
(MAPK) signaling might play a role in the development of PAs”, as stated by Jones et al (2011)
[4]. Since then, various groups have investigated the participant proteins of these pathways.
The MAPK pathways regulate fundamental biologic processes. In mammalian, there are 4
well-described MAPK pathways [38; 39] (Figure 5) and the most studied is the extracellular
signal-regulated kinase (ERK)1/2 [39]. Alterations of this pathway are described in both low and
high-grade astrocytomas [4], but molecular mechanisms differ between them.
In  summary,  the  ERK1/2  pathway is  triggered  by  the  binding  of  soluble  peptides  to  a
Tyrosin-kinase  receptor  (TKR)  at  the  cell  surface,  and initiates  a  cascade  of  events  that
terminates in the appropriated cellular response [40].  This pathway is related to various
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fundamental  cellular  processes,  such  as  proliferation,  cellular  differentiation,  survival,
migration, and angiogenesis [41; 42].
The ERK cascade is constituted by RAS, Raf, MEK and ERK proteins [39], which are subse‐
quently activated during the process. After the binding of the extracellular peptide with the
TKR and its dimerization, it activates the RAS protein, which then activates the Raf family,
MEK and, finally, ERK protein [40; 43], that is present in the nuclei, to effectuate the response
to the.initiator sign [43]. The RAS-Raf league is considered the regulatory center of the ERK
cascade and mutations of any of this genes result in ERK pathway misregulation. It is important
to note that the mutations of these proteins are mutually exclusive [39].
The proteins of Raf family are the main effectors of RAS and their action is in phosphorylating
MEK 1 and MEK2 [44]. This family is a cytoplasmatic group of proteins, constituted by A-Raf,
B-Raf and C-Raf [43], proteins that present similar structure and biological features [44], although
they show different tissue distribution and capacity of activating the MEK proteins [45].
6.2.1. Oncogene BRAF
In humans, the most studied Raf protein is the B-Raf (BRAF), which is mutated in about 8% of
all human neoplasms [44], and in melanomas this rate can be as high as 60% of the cases, with
Figure 5. Integration of the MAPK pathways in the cellular response to various environmental stimuli. The sequential
phosphorilation of RAS-RAF-MEK ERK, after dimerization of TKR, and the role of negative regulation of NF1.
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the commonest mutation being point mutation V600E [46; 47].In the setting of PA, mutations
with constitutive activation of BRAF were demonstrated in up to 80% of cases, while they are
very rare in diffuse astrocytomas [48]. The mechanisms that explain a constitutive activation
of the BRAF are: i) point mutation V600E [44; 49; 50]; ii) duplication of a region in chromosome
7q [51; 52]; and iii) fusion between oncogenes BRAF and KIAA1549.
The point mutation V600E refers to a single glutamic acid for valin substitution at codon 600
of BRAF gene [44], which is the commonest BRAF missense mutation in human cancer [44;
46]. This mutation is not specific for PA and can be detected in various brain tumors, including
PXAs, gangliogliomas, and in up to 6% of GBMs [49; 50] and other tumors, such as thyroid
cancers and melanomas [44].
The BRAF duplications are due to a somatic rearrangement of the gene in sporadic PAs. It was
the first described genetic alteration of PAs [51; 52]. They are more frequent in gliomas in non-
cerebellar [52] location, including that of the optical pathways [53], both in NF1-related tumors
and in those sporadic ones. Nevertheless, other authors did not identify BRAF duplications in
NF1-related tumors, and suggested the activation of a different pathway (mTOR) in the genesis
of these frequently more aggressive tumors [54]
Finally, the fusion BRAF-KIAA1549 is present in 50-100% of the patients with PA [4; 55; 56].
This alteration is highly specific for PAs, and there is a growing tendency for using this marker
as a powerful tool of molecular diagnosis in surgical pathology routine [57]. Although this
fusion has recently been described in some other low-grade tumors, such as pilomixoid
astrocytoma, glioneuronal tumors and unclassifiable low grade gliomas [57; 58], clinical and
pathological correlation permit the diagnosis of PA in cases where diffuse component is
predominant at histology [57]. Also, this fusion is significantly more frequent in infratentorial
and optical pathways-located tumors [57].
The importance of studying the genetic mutations in PAs has grown, since many target
therapies  against  the  MAPKs  pathway  components  are  recently  being  developed.  For
example, concerning tumors with the V600E mutation, in 2012 two groups described the
use of Vemurafenib, a BRAF inhibitor, in melanoma [59] and in lung cancer [60], with good
results. In addition, other proteins of the ERK cascade can be targeted by novel drugs, as
Trametinib, a specific MEK inhibitor, that has also been used successfully in patients with
melanomas that present V600E mutation [61]. It is still unknown whether tumors harbor‐
ing the fusion BRAF-KIAA1549  are responsive to Vemurafenib and Trametinib. Concern‐
ing the former, the distinct studies showed the lack of patient’s response in the wildtype
BRAF [62]
At last, it is important to note that the resultant protein of the fusion BRAF-KIAA1549  is
cancer-specific  and it  is  potentially  a  target  for  future  treatments.  The  most  representa‐
tive  example  of  this  possibility  is  the  identification  of  the  fusion  BCR-ABL  in  chronic
myeloid leukemia (CML), in a similar molecular mechanism. The knowledge of this fusion
permitted the development of a target-drug, Imatinib, in the middle 2000´s [63].This drug
has changed the treatment and prognosis of the CML patients by controlling the disease,
with excellent tolerability.
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the commonest mutation being point mutation V600E [46; 47].In the setting of PA, mutations
with constitutive activation of BRAF were demonstrated in up to 80% of cases, while they are
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The BRAF duplications are due to a somatic rearrangement of the gene in sporadic PAs. It was
the first described genetic alteration of PAs [51; 52]. They are more frequent in gliomas in non-
cerebellar [52] location, including that of the optical pathways [53], both in NF1-related tumors
and in those sporadic ones. Nevertheless, other authors did not identify BRAF duplications in
NF1-related tumors, and suggested the activation of a different pathway (mTOR) in the genesis
of these frequently more aggressive tumors [54]
Finally, the fusion BRAF-KIAA1549 is present in 50-100% of the patients with PA [4; 55; 56].
This alteration is highly specific for PAs, and there is a growing tendency for using this marker
as a powerful tool of molecular diagnosis in surgical pathology routine [57]. Although this
fusion has recently been described in some other low-grade tumors, such as pilomixoid
astrocytoma, glioneuronal tumors and unclassifiable low grade gliomas [57; 58], clinical and
pathological correlation permit the diagnosis of PA in cases where diffuse component is
predominant at histology [57]. Also, this fusion is significantly more frequent in infratentorial
and optical pathways-located tumors [57].
The importance of studying the genetic mutations in PAs has grown, since many target
therapies  against  the  MAPKs  pathway  components  are  recently  being  developed.  For
example, concerning tumors with the V600E mutation, in 2012 two groups described the
use of Vemurafenib, a BRAF inhibitor, in melanoma [59] and in lung cancer [60], with good
results. In addition, other proteins of the ERK cascade can be targeted by novel drugs, as
Trametinib, a specific MEK inhibitor, that has also been used successfully in patients with
melanomas that present V600E mutation [61]. It is still unknown whether tumors harbor‐
ing the fusion BRAF-KIAA1549  are responsive to Vemurafenib and Trametinib. Concern‐
ing the former, the distinct studies showed the lack of patient’s response in the wildtype
BRAF [62]
At last, it is important to note that the resultant protein of the fusion BRAF-KIAA1549  is
cancer-specific  and it  is  potentially  a  target  for  future  treatments.  The  most  representa‐
tive  example  of  this  possibility  is  the  identification  of  the  fusion  BCR-ABL  in  chronic
myeloid leukemia (CML), in a similar molecular mechanism. The knowledge of this fusion
permitted the development of a target-drug, Imatinib, in the middle 2000´s [63].This drug
has changed the treatment and prognosis of the CML patients by controlling the disease,
with excellent tolerability.
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The molecular pathways of PAs are beginning to be faithfully recognized and some of the
molecules of these pathways have already some kind of target drug available for inhibition,
with efficacy proved in other kinds of tumors. As there are no studies with these novel drugs
in PAs, this can become a good direction for future clinical research.
7. Conclusion
Pilocytic astrocytoma is usually a tumor with good prognosis; however some eloquent
locations do not permit the total resection of lesions. In these cases and in the ones that can
recur even after gross total resection, the patients can suffer with physical limitations and even
death. The study of the molecular pathways of PA´s oncogenesis may represent a hope for
longer and better quality life for these patients. There is a wide field for research in order to
better understand this intriguing tumor, since the understanding of these mechanisms can turn
a potentially fatal in a controllable disease.
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1. Introduction
Pathological classification of brain tumors is the corner stone upon which the management
plan and treatment strategy depends. It is the pathologist who defines the “target” at which
the rest of the clinical team members aim their “weapons”. Despite of the great advancement
of the ancillary studies, the simple H&E stained slide remains an invaluable mean in the
diagnosis, classification and stratification of primary brain tumors. Slides should be interpret‐
ed in correlation with patient’s age and clinical presentation. Radiological findings substitute
the macroscopic/gross description in other organs and assessment of the location (supraten‐
torial, infratentorial, intra-ventricular), growth pattern (circumscribed versus infiltrative, solid
versus cystic), enhancement pattern (non-enhancing versus enhancing), and the presence or
absence of edema, necrosis, calcification should all be consolidated with the microscopic
findings in formulating the final diagnosis. The need for an expert neuropathologist is
becoming crucial in reviewing the cases before commencing on treatment [1-3]. The impor‐
tance of multidisciplinary clinics/teams cannot be overemphasized and neuropathologist plays
a central role in these clinics [4, 5]. In less developed countries, telemedicine and twinning
programs as well as affiliation with recognized international experts may offer an accessible
and relatively affordable tool which can help narrowing the knowledge and practice gaps, thus
providing patients in these countries with better standards of care [6, 7].
This chapter aims at providing a concise yet comprehensive description of the histology of the
most common neuroepithelial primary central nervous system tumors, based on the most
recent pathological classification of tumors of the CNS; 2007 WHO Classification of Tumours
of the CNS [8]. The morphological features as well as the most useful immunohistochemical
stains that can be used to support the diagnosis will be provided. In primary brain tumor there
is a considerable overlap in diagnostic features and morphological criteria that are used to
grade the tumor, which although is not the primary intention of this chapter, will be alluded
to briefly for sake of completeness.
© 2013 Al-Hussaini; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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Primary brain tumors are divided into 2 major groups, neuroepithelial and non-neuroepithe‐
lial tumors. Table-1.
I: Tumors of Neuroepithelial Tissue
II: Tumors of non-Neuroepithelial
Tissue
A: Glioma
C: Neuronal and mixed neuronal-
glial tumors
A: Tumors of the meninges









Pleomorphic astrocytoma Central neurocytoma Clear cell
Sub-ependymal giant cell astrocytoma Extra-ventricular neurocytoma Chordoid
Fibrillary astrocytoma Cerebellar liponeurocytoma Anaplastic
Anaplastic astrocytoma Papillary glio-neuronal tumor Papillary
Glioblastoma
Rosette forming tumor of the 4th
ventricle
Rhabdoid
Gliomatosis Cerebri D: Choroid plexus tumors 2. Primary Melanocytic lesions
2. Oligodendroglioma Choroid plexus papilloma
3. Other Neoplasms related to
meninges
3. Mixed oligo-astrocytoma Atypical choroid plexus papilloma Hemangioblastoma
4. Ependymoma Choroid plexus carcinoma
B: Cranial and paraspinal nerve
tumors
Myxo-papillary ependymoma E: Tumors of the pineal region C: Germ cell tumors
Sub-ependymoma Pineocytoma D: Tumors of the sellar region
Cellular ependymoma
Pineal parenchymal tumor of
intermediate differentiation
E: Hematopoietic cell tumors
Clear cell ependymoma Pineoblastoma
Tanycytic ependymoma Papillary tumor of the pineal region
B: Embryonal tumors F: Other neuroepithelial tumors
Medulloblastoma Angiocentric glioma
CNS- primitive neuroectodermal tumor Chordoid glioma of the 3rd ventricle
Atypical teratoid rhabdoid tumor Astroblastoma
Cribriform Neuroepithelial Tumor (CRINET); This tumor is a recently described neuroepithail tumor and is not part of the
WHO classification of primary brain tumors.
Table 1. WHO classification of tumors of the nervous system (2007) [8]
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2. Neuroepithelial group of tumors
2.1. Glial tumors
This is by far the most common group of central nervous system tumors, both in adults and
pediatrics. They are thought to originate from the brain framework cells; the glial cells. This
group is divided into several tumor families which are further divided into entities, patterns
and variants based on the presumed cell of origin and the growth pattern.
2.1.1. Astrocytic tumors
Circumscribed astrocytomas
a. Pilocytic astrocytoma (PA)/pilomyxoid astrocytoma(PMA)
Pilocytic astrocytoma (PA) is assumed to arise from reactive astrocytes [9], this tumor pre‐
dominates in children in the first decade of life and is the prototype of circumscribed tumors.
It typically involves midline structures most commonly the cerebellum followed by optic
pathway, hypothalamus, basal ganglion and thalamus but can occasionally arise elsewhere.
The morphological features are at large similar regardless of the site of origin with one
exception; the optic pathway glioma. Typically this is a biphasic tumor with compact and
microcystic areas, the proportion of which may vary from one tumor to the other. Proliferation
of bipolar spindle “piloid” cells with long fibrillary processes is seen mostly within the compact
areas “Figure 1”.
Figure 1. There is proliferation of piloid cells with elongated cytoplasmic processes. Rosenthal fibers are acidophilic
processes seen in these areas (arrow).
The microcystic areas, on the other hand show protoplasmic-like astrocytes with multi-polar
short cytoplasmic processes and small cell body with round to oval bland nuclei “Figure 2”.
Areas with oligodendroglial like proliferation can be encountered, especially in the posterior
fossa tumors. Various forms of vascular proliferation can be seen including reactive vascular
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Primary brain tumors are divided into 2 major groups, neuroepithelial and non-neuroepithe‐
lial tumors. Table-1.
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II: Tumors of non-Neuroepithelial
Tissue
A: Glioma
C: Neuronal and mixed neuronal-
glial tumors
A: Tumors of the meninges
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Sub-ependymal giant cell astrocytoma Extra-ventricular neurocytoma Chordoid
Fibrillary astrocytoma Cerebellar liponeurocytoma Anaplastic
Anaplastic astrocytoma Papillary glio-neuronal tumor Papillary
Glioblastoma
Rosette forming tumor of the 4th
ventricle
Rhabdoid
Gliomatosis Cerebri D: Choroid plexus tumors 2. Primary Melanocytic lesions
2. Oligodendroglioma Choroid plexus papilloma
3. Other Neoplasms related to
meninges
3. Mixed oligo-astrocytoma Atypical choroid plexus papilloma Hemangioblastoma
4. Ependymoma Choroid plexus carcinoma
B: Cranial and paraspinal nerve
tumors
Myxo-papillary ependymoma E: Tumors of the pineal region C: Germ cell tumors
Sub-ependymoma Pineocytoma D: Tumors of the sellar region
Cellular ependymoma
Pineal parenchymal tumor of
intermediate differentiation
E: Hematopoietic cell tumors
Clear cell ependymoma Pineoblastoma
Tanycytic ependymoma Papillary tumor of the pineal region
B: Embryonal tumors F: Other neuroepithelial tumors
Medulloblastoma Angiocentric glioma
CNS- primitive neuroectodermal tumor Chordoid glioma of the 3rd ventricle
Atypical teratoid rhabdoid tumor Astroblastoma
Cribriform Neuroepithelial Tumor (CRINET); This tumor is a recently described neuroepithail tumor and is not part of the
WHO classification of primary brain tumors.
Table 1. WHO classification of tumors of the nervous system (2007) [8]
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2. Neuroepithelial group of tumors
2.1. Glial tumors
This is by far the most common group of central nervous system tumors, both in adults and
pediatrics. They are thought to originate from the brain framework cells; the glial cells. This
group is divided into several tumor families which are further divided into entities, patterns
and variants based on the presumed cell of origin and the growth pattern.
2.1.1. Astrocytic tumors
Circumscribed astrocytomas
a. Pilocytic astrocytoma (PA)/pilomyxoid astrocytoma(PMA)
Pilocytic astrocytoma (PA) is assumed to arise from reactive astrocytes [9], this tumor pre‐
dominates in children in the first decade of life and is the prototype of circumscribed tumors.
It typically involves midline structures most commonly the cerebellum followed by optic
pathway, hypothalamus, basal ganglion and thalamus but can occasionally arise elsewhere.
The morphological features are at large similar regardless of the site of origin with one
exception; the optic pathway glioma. Typically this is a biphasic tumor with compact and
microcystic areas, the proportion of which may vary from one tumor to the other. Proliferation
of bipolar spindle “piloid” cells with long fibrillary processes is seen mostly within the compact
areas “Figure 1”.
Figure 1. There is proliferation of piloid cells with elongated cytoplasmic processes. Rosenthal fibers are acidophilic
processes seen in these areas (arrow).
The microcystic areas, on the other hand show protoplasmic-like astrocytes with multi-polar
short cytoplasmic processes and small cell body with round to oval bland nuclei “Figure 2”.
Areas with oligodendroglial like proliferation can be encountered, especially in the posterior
fossa tumors. Various forms of vascular proliferation can be seen including reactive vascular
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proliferation, vessels with hyalinized walls and granulation tissue like vessels, none of which
carries a prognostic significance. Conspicuous pleomorphic cells, some of which appear
multinucleated can be seen focally within tumor and are not associated with unfavorable
outcome. Rosenthal fibers which correspond to thick, tortuous bright acidophilic cytoplasmic
processes of variable length are seen mostly in the compact areas, while eosinophilic granular
bodies predominate in the microcystic foci, both of which representing products of degener‐
ation [9]. Calcifications with psammoma like spherules, perivascular inflammatory infiltrate
and hemosiderin-laden macrophages are detected in few tumors. Scattered mitotic figures and
foci of infarction-type necrosis can be identified in anotherwise typical pilocytic astrocytoma.
However; unlike fibrillary astrocytoma neither of these features warrant a higher grade
diagnosis [10]. Areas with diffusely infiltrative growth pattern with entrapment of normal
ganglion producing the “trapped neuron” appearance, can be seen in some tumors. In
addition; infiltration into the overlying leptomeninges can sometimes be encountered [9].
Cases that exhibited anaplastic features and persued a more malignant behavior are reported
in the literature, especially but not exclusively following radiotherapy [11]. The presence of
increased mitotic activity per high power field, hypercellularity, endothelial proliferation and/
or palisading necrosis should alert the pathologist to such a possibility. The diagnosis of
“anaplastic pilocytic astrocytoma” is the term proposed by the WHO book for such tumors [8,
9]. Atypical pilocytic astrocytoma is, on the other hand assigned to few tumors that display
few mitotic figures in conjunction with hypercellularity and marked nuclear atypia [8, 11].
Tumor cells are typically reactive with glial fibrillary acidic protein (GFAP) and vimentin.
Reactivity for synaptphysin but not other neuronal markers is seen in some cases [10].
Neurofilament protein (NFP) highlights occasional axons in the background or can be totally
negative thus is helpful in confirming the circumscribed nature of the tumor. Rosenthal fibers
are reactive for GFAP but not NFP in support of their origin from astrocytic processes. This
typically takes the form of positivity at the periphery of the fiber, with negative central core.
Figure  2.  The  microsystic  areas  are  composed  of  proliferation  of  protoplasmic  astrocytes.  Eosinophilic  granular
bodies are seen in these areas (red arrow).  Multinucleated giant cells  are somtimes seen in pilocytic astrocytoma
(black arrow).
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In Masson Trichrome special stain they appear bright red. Eosinophilic granular bodies (EGBs)
on the other hand are positive for PAS diastase, which highlights their variably-sized granular
appearance. Pilocytic astrocytomas are typically negative for P53 and EGFR, an important
differentiating point from low and high grade diffuse astrocytoma; respectively [10, 12]. MIB-1
labeling index is variable and can range from 1-8% [10, 13], and this does not seem to be
associated with prognosis [14]. BRAF immunostain has been recently described in some cases.
However; this is not helpful in determining BRAF duplication [10], the genetic signature of
pilocytic astrocytoma.
Pilomyxoid astrocytoma (PMA) is a distinctive tumor that occurs mostly in infants in the
hypothalamic/ supra-sellar region. As the name implies this tumor manifests prominent
myxoid stroma that can be highlighted with alcian blue stain and a monomorphic piloid
astrocytes that arrange themselves in a distinct perivascular growth pattern with sun-ray like
orientation “Figure 3”.
Figure 3. Distinct perivascular pseudorosette is seen in this case of pilomyxoid astrocytoma.
Few mitotic figures can be detected. Unlike pilocytic astrocytoma, there is no biphasic growth
pattern, Rosenthal fibers or eosinophilic granular bodies and infiltration into adjacent brain
parenchyma is more prominent [15]. Interestingly; some PMA cases have matured into
pilocytic astrocytoma following several recurrences [16], suggesting a close relation between
both tumors. The tumor cells demonstrate strong and diffuse positivity for GFAP and vimentin
and focal positivity for synaptophysin. Neurofilament protein highlights the limited infiltra‐
tion into adjacent parenchyma [17]. MIB-1 labeling index is around 5%, although higher figures
would still be compatible with the diagnosis.
b. Pleomorphic xantho-astrocytoma (PXA)
PXA is a superficially located tumor with close relation to the meninges that predominates in
the temporal lobe. It occurs in children and young adults with history of epilepsy [18].
Morphologically it is a composite tumor with a variegated appearance in which spindle cells
closely intermingle with small and large mononuclear and multinucleated bizarre tumor giant
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proliferation, vessels with hyalinized walls and granulation tissue like vessels, none of which
carries a prognostic significance. Conspicuous pleomorphic cells, some of which appear
multinucleated can be seen focally within tumor and are not associated with unfavorable
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processes of variable length are seen mostly in the compact areas, while eosinophilic granular
bodies predominate in the microcystic foci, both of which representing products of degener‐
ation [9]. Calcifications with psammoma like spherules, perivascular inflammatory infiltrate
and hemosiderin-laden macrophages are detected in few tumors. Scattered mitotic figures and
foci of infarction-type necrosis can be identified in anotherwise typical pilocytic astrocytoma.
However; unlike fibrillary astrocytoma neither of these features warrant a higher grade
diagnosis [10]. Areas with diffusely infiltrative growth pattern with entrapment of normal
ganglion producing the “trapped neuron” appearance, can be seen in some tumors. In
addition; infiltration into the overlying leptomeninges can sometimes be encountered [9].
Cases that exhibited anaplastic features and persued a more malignant behavior are reported
in the literature, especially but not exclusively following radiotherapy [11]. The presence of
increased mitotic activity per high power field, hypercellularity, endothelial proliferation and/
or palisading necrosis should alert the pathologist to such a possibility. The diagnosis of
“anaplastic pilocytic astrocytoma” is the term proposed by the WHO book for such tumors [8,
9]. Atypical pilocytic astrocytoma is, on the other hand assigned to few tumors that display
few mitotic figures in conjunction with hypercellularity and marked nuclear atypia [8, 11].
Tumor cells are typically reactive with glial fibrillary acidic protein (GFAP) and vimentin.
Reactivity for synaptphysin but not other neuronal markers is seen in some cases [10].
Neurofilament protein (NFP) highlights occasional axons in the background or can be totally
negative thus is helpful in confirming the circumscribed nature of the tumor. Rosenthal fibers
are reactive for GFAP but not NFP in support of their origin from astrocytic processes. This
typically takes the form of positivity at the periphery of the fiber, with negative central core.
Figure  2.  The  microsystic  areas  are  composed  of  proliferation  of  protoplasmic  astrocytes.  Eosinophilic  granular
bodies are seen in these areas (red arrow).  Multinucleated giant cells  are somtimes seen in pilocytic astrocytoma
(black arrow).
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In Masson Trichrome special stain they appear bright red. Eosinophilic granular bodies (EGBs)
on the other hand are positive for PAS diastase, which highlights their variably-sized granular
appearance. Pilocytic astrocytomas are typically negative for P53 and EGFR, an important
differentiating point from low and high grade diffuse astrocytoma; respectively [10, 12]. MIB-1
labeling index is variable and can range from 1-8% [10, 13], and this does not seem to be
associated with prognosis [14]. BRAF immunostain has been recently described in some cases.
However; this is not helpful in determining BRAF duplication [10], the genetic signature of
pilocytic astrocytoma.
Pilomyxoid astrocytoma (PMA) is a distinctive tumor that occurs mostly in infants in the
hypothalamic/ supra-sellar region. As the name implies this tumor manifests prominent
myxoid stroma that can be highlighted with alcian blue stain and a monomorphic piloid
astrocytes that arrange themselves in a distinct perivascular growth pattern with sun-ray like
orientation “Figure 3”.
Figure 3. Distinct perivascular pseudorosette is seen in this case of pilomyxoid astrocytoma.
Few mitotic figures can be detected. Unlike pilocytic astrocytoma, there is no biphasic growth
pattern, Rosenthal fibers or eosinophilic granular bodies and infiltration into adjacent brain
parenchyma is more prominent [15]. Interestingly; some PMA cases have matured into
pilocytic astrocytoma following several recurrences [16], suggesting a close relation between
both tumors. The tumor cells demonstrate strong and diffuse positivity for GFAP and vimentin
and focal positivity for synaptophysin. Neurofilament protein highlights the limited infiltra‐
tion into adjacent parenchyma [17]. MIB-1 labeling index is around 5%, although higher figures
would still be compatible with the diagnosis.
b. Pleomorphic xantho-astrocytoma (PXA)
PXA is a superficially located tumor with close relation to the meninges that predominates in
the temporal lobe. It occurs in children and young adults with history of epilepsy [18].
Morphologically it is a composite tumor with a variegated appearance in which spindle cells
closely intermingle with small and large mononuclear and multinucleated bizarre tumor giant
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cells with acidophilic cytoplasm “Figure 4”. Intra-nuclear cytoplasmic pseudo-inclusions are
frequently seen in the giant cells. Cytoplasmic lipidization in the form of intra-cytoplasmic
droplets that occupy much of the cytoplasm and displace the organelles and glial filaments to
the periphery is seen in tumor cells scattered through the tumor, hence the “xantho” prefix.
Figure 4. Multinucleated tumor giant cells are seen (right lower) admixed with cells with intracytplasmic fine lipid
droplets (arrow).
These lipidized cells can be prominent or alternatively can only be scattered through out the
tumor substance. Oil-red O confirms the intra-cytoplasmic lipid content on fresh material. An
infiltrating astrocytoma pattern is seen at the deeper aspect of the tumor and this does not
affect the outcome [19]. Invasion of the overlying meninges can be encountered in some
tumors, creating resemblance with meningioma. Striking positivity for reticulin stain with
fibers surrounding groups of cells or individual cells is seen in many tumors; probably
representing a reaction to infiltration of the meninges. The blood vessels show peri-vascular
lymphoplasmacytic infiltration. Eosinophilic granular bodies, but not Rosenthal fibers can be
seen scattered within the tumor substance. Despite of this alarming appearance mitotic figures
are not seen and necrosis is at best focal; important discriminating features from giant cell
glioblastoma [20]. GFAP labels the tumor cells including the giant cells, and is displaced to the
periphery in lipidized cells. Positivity for synaptophysin, NFP and CD34 in tumor cells has
been noted in some cases, rendering separation from ganglioglioma difficult [18, 20]. PXA with
anaplasia is reserved for tumors showing no or rare degeneration, increased mitoses ≥5 MF/
10HPFs and atypical mitoses [14]. MIB-1 and P53 are not helpful in predicting more aggressive
tumors, i.e. PXA with anaplasia [21].
c. Sub-ependymal giant cell astrocytoma (SEGA)
This intra-ventricular tumor is typically associated with tuberous sclerosis complex. It exhibits
proliferation of three cell types; large gemistocytes -like cells with perivascular pseudorosette
pattern, long spindle fibrillary astrocytes arranged in broad fascicles and giant cells, some with
ganglioid appearance “Figure 5”.
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Calcification is noted in some cases and can be prominent in long standing ones [22]. Various
combinations of glial and neuronal markers are reported in different cell population. Co-
expression of GFAP, neuron-specific enolase (NSE) and synaptophysin is noted in tumor cells,
including the spindle cells, while NFP is usually positive in ganglioid cells only. Mitosis,
vascular proliferation and necrosis do not seem to affect the prognosis [23, 24].
Figure 5. This intraventricular tumor shows admixture of large gemistocytic-like cells, ganglioid cells and spindle cells
in a fibrillary background.
Diffuse astrocytoma
This group of tumors is composed of proliferation of astrocytes that diffusely infiltrate pre-
existing brain parenchyma, thus precluding successful attempts at complete excision and cure.
In addition; there is a natural tendency for progression and transformation from lower into
high grades. On a rising scale of malignacy these tumors are divided into the following entities:
a. Fibrillary astrocytoma (FA,
FA is at the lower end of the malignancy scale, and can raise diagnostic difficulties with reactive
gliosis on one hand and circumscribed low grade astrocytoma on the other. Morphologically
there is proliferation of “well-differentiated“ fibrillary astrocytes with elongated, irregular and
hyperchromatic nuclei exhbiting angulated contours with many coma-shaped forms that lack
nucleoli “Figure 6”.
Thin cytoplasmic process originate from the cytoplasm and form the mesh-like fibrillary
background. Morphological variation include the proliferation of gemistocytic and protoplas‐
mic astrocytes. Gemistocytes contain a globular acidophilic cytoplasm with distinct membra‐
nous accentuation, eccentric irregular nuclei and thick cytoplasmic processes. Protoplasmic
astrocytes on the other hand show multi-polar cytoplasmic processes and grow in a myxoid
background, forming microcysts [25]. Features of anaplasia are lacking and mitoses are
generally not detected [25, 26]. GFAP positivity is seen both as haphazardly crossing processes
in which “naked” tumor nuclei are enmeshed, and as dense cytoplasmic rim positivity
surrouding the nuclei. Gemistocytes demonstrate diffuse cytoplasmic GFAP positivity with
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cells with acidophilic cytoplasm “Figure 4”. Intra-nuclear cytoplasmic pseudo-inclusions are
frequently seen in the giant cells. Cytoplasmic lipidization in the form of intra-cytoplasmic
droplets that occupy much of the cytoplasm and displace the organelles and glial filaments to
the periphery is seen in tumor cells scattered through the tumor, hence the “xantho” prefix.
Figure 4. Multinucleated tumor giant cells are seen (right lower) admixed with cells with intracytplasmic fine lipid
droplets (arrow).
These lipidized cells can be prominent or alternatively can only be scattered through out the
tumor substance. Oil-red O confirms the intra-cytoplasmic lipid content on fresh material. An
infiltrating astrocytoma pattern is seen at the deeper aspect of the tumor and this does not
affect the outcome [19]. Invasion of the overlying meninges can be encountered in some
tumors, creating resemblance with meningioma. Striking positivity for reticulin stain with
fibers surrounding groups of cells or individual cells is seen in many tumors; probably
representing a reaction to infiltration of the meninges. The blood vessels show peri-vascular
lymphoplasmacytic infiltration. Eosinophilic granular bodies, but not Rosenthal fibers can be
seen scattered within the tumor substance. Despite of this alarming appearance mitotic figures
are not seen and necrosis is at best focal; important discriminating features from giant cell
glioblastoma [20]. GFAP labels the tumor cells including the giant cells, and is displaced to the
periphery in lipidized cells. Positivity for synaptophysin, NFP and CD34 in tumor cells has
been noted in some cases, rendering separation from ganglioglioma difficult [18, 20]. PXA with
anaplasia is reserved for tumors showing no or rare degeneration, increased mitoses ≥5 MF/
10HPFs and atypical mitoses [14]. MIB-1 and P53 are not helpful in predicting more aggressive
tumors, i.e. PXA with anaplasia [21].
c. Sub-ependymal giant cell astrocytoma (SEGA)
This intra-ventricular tumor is typically associated with tuberous sclerosis complex. It exhibits
proliferation of three cell types; large gemistocytes -like cells with perivascular pseudorosette
pattern, long spindle fibrillary astrocytes arranged in broad fascicles and giant cells, some with
ganglioid appearance “Figure 5”.
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Calcification is noted in some cases and can be prominent in long standing ones [22]. Various
combinations of glial and neuronal markers are reported in different cell population. Co-
expression of GFAP, neuron-specific enolase (NSE) and synaptophysin is noted in tumor cells,
including the spindle cells, while NFP is usually positive in ganglioid cells only. Mitosis,
vascular proliferation and necrosis do not seem to affect the prognosis [23, 24].
Figure 5. This intraventricular tumor shows admixture of large gemistocytic-like cells, ganglioid cells and spindle cells
in a fibrillary background.
Diffuse astrocytoma
This group of tumors is composed of proliferation of astrocytes that diffusely infiltrate pre-
existing brain parenchyma, thus precluding successful attempts at complete excision and cure.
In addition; there is a natural tendency for progression and transformation from lower into
high grades. On a rising scale of malignacy these tumors are divided into the following entities:
a. Fibrillary astrocytoma (FA,
FA is at the lower end of the malignancy scale, and can raise diagnostic difficulties with reactive
gliosis on one hand and circumscribed low grade astrocytoma on the other. Morphologically
there is proliferation of “well-differentiated“ fibrillary astrocytes with elongated, irregular and
hyperchromatic nuclei exhbiting angulated contours with many coma-shaped forms that lack
nucleoli “Figure 6”.
Thin cytoplasmic process originate from the cytoplasm and form the mesh-like fibrillary
background. Morphological variation include the proliferation of gemistocytic and protoplas‐
mic astrocytes. Gemistocytes contain a globular acidophilic cytoplasm with distinct membra‐
nous accentuation, eccentric irregular nuclei and thick cytoplasmic processes. Protoplasmic
astrocytes on the other hand show multi-polar cytoplasmic processes and grow in a myxoid
background, forming microcysts [25]. Features of anaplasia are lacking and mitoses are
generally not detected [25, 26]. GFAP positivity is seen both as haphazardly crossing processes
in which “naked” tumor nuclei are enmeshed, and as dense cytoplasmic rim positivity
surrouding the nuclei. Gemistocytes demonstrate diffuse cytoplasmic GFAP positivity with
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membranous accentuation; an important discriminating point from mini-gemistocytes seen in
oligodendroglioma (see below). To support the infiltrating astrocytoma diagnosis NFP, P53
and IDH1 can be used. Neurofilament protein is useful to highlight the the infiltrative growth
pattern “Figure 7”.
Figure 7. Neurofilament protein immunostain highlights the neuronal processes, with negative tumor cells in be‐
tween confirming the infiltrative nature of the tumor.
P53 may be strongly positive in tumor cell nuclei versus the negative/ minimal staining in
gliosis. [27]. Recently; IDH1 antibody is reported to be positive in all infiltrating gliomas
(astrocytoma, oligodendroglioma and mixed oligo-astrocytoma) with granular cytoplasmic
reactivity pattern [20, 28].MIB-1 labeling index is low, although the cut-off value is not exactly
determined (see below) [29].
A recently described morphological pattern is the “glioneuronal tumor with neuropil-like
islands”, in which nodules of well differentiated neurocytic cells are embedded within and
Figure 6. Fibrillary astrocytoma with mild increase in cellularity with scattered dark, elongated and minimally irregular
nuclei (arrow).
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surround acellular synaptophysin-positive neuropil islands. These are seen focally in what is
an otherwise typical infiltrating astrocytoma of either fibrillary or anaplastic types [15]. There
is a relative abrupt transition between both components [30]. In these islands the cells are
positive for synaptophysin and NeuN, while the neuropil in the background displays granular
positivity for synaptophysin [17].
b. Anaplastic astrocytoma (AA)
AA occupies an intermediate position between fibrillary astrocytoma and glioblastoma.
Features of anaplasia include higher cellularity, greater degree of pleomorphism and increased
proliferation. The exact number of mitotic figures needed to separate this from FA is still
debatable and this feature should be evaluated in relation to the amount of tissue sample
examined. While the presence of a single mitotic figure in a small stereotactic biopsy justifies
assigning grade III to a tumor, the presence of a single mitotic figure in an ample biopsy after
careful searching and deeper sections might not be as relevant. In one study; >3MF/10HPFs
was the cut-off value proposed [27]. Ancillary studies might help in defining the proliferative
activity of a tumor and can be used to support the diagnosis of AA. Although cut-off values
are variable an elevated MIB-1 labeling index (>9%) and proliferative activity as measured by
PHH3 mitotic index (>4per 1000 cells) were found to be supportive of AA diagnosis over FA,
in which MIB-1 and PHH3 labeling indices were low (≤ 9% and ≤4 per 1000 cells) [27]. In
addition; MIB-1 labeling index prognostic value independent from histologic grade was
reported [14], which might be indicative of an early anaplastic transformation [31], even in the
absence of detectable mitoses.
c. Glioblastoma (GBM)
This is the most malignant and unfortunately the single most common primary brain tumor.
The essential features for the diagnosis of GBM are microvascular proliferation (MVP) and/or
necrosis whether palisading or not. Microvascular proliferation is loosely defined to include
endothelial hypertrophy, endothelial hyperplasia and glomeruloid vessels, in which multi‐
layered tufts of proliferating endothelium are accompanied by smooth muscles and peri‐
cytes“Figure 8” [32].
As the original name implies glioblastoma “multiforme” is characterized by heterogeneous
cell population with proliferation of fibrillary, gemistocytic and scattered tumor giant cells
“Figure 9”.
On the basis of their origin GBM is divided into primary (type II) and secondary (type I) types.
Primary GBM is a tumor of elderly patients, is characterized by short presenting history and
it arises de-novo with no detectable pre-existing lower grade tumor. Secondary GBM on the
other hand affects younger patients with prolonged history and is typically preceded by a
lower grade astrocytoma. Prognosis seems to be better for the secondary tumors. Whether a
tumor is primary or secondary GBM cannot be predicted on basis of morphologic features.
However; the presence of large vessel thrombosis with large areas of infarction-like necrosis
seems to be more prevalent in primary GBM. Immunohistochemically; reactivity for P53,
Histology of Primary Brain Tumors
http://dx.doi.org/10.5772/52356
153
membranous accentuation; an important discriminating point from mini-gemistocytes seen in
oligodendroglioma (see below). To support the infiltrating astrocytoma diagnosis NFP, P53
and IDH1 can be used. Neurofilament protein is useful to highlight the the infiltrative growth
pattern “Figure 7”.
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tween confirming the infiltrative nature of the tumor.
P53 may be strongly positive in tumor cell nuclei versus the negative/ minimal staining in
gliosis. [27]. Recently; IDH1 antibody is reported to be positive in all infiltrating gliomas
(astrocytoma, oligodendroglioma and mixed oligo-astrocytoma) with granular cytoplasmic
reactivity pattern [20, 28].MIB-1 labeling index is low, although the cut-off value is not exactly
determined (see below) [29].
A recently described morphological pattern is the “glioneuronal tumor with neuropil-like
islands”, in which nodules of well differentiated neurocytic cells are embedded within and
Figure 6. Fibrillary astrocytoma with mild increase in cellularity with scattered dark, elongated and minimally irregular
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is a relative abrupt transition between both components [30]. In these islands the cells are
positive for synaptophysin and NeuN, while the neuropil in the background displays granular
positivity for synaptophysin [17].
b. Anaplastic astrocytoma (AA)
AA occupies an intermediate position between fibrillary astrocytoma and glioblastoma.
Features of anaplasia include higher cellularity, greater degree of pleomorphism and increased
proliferation. The exact number of mitotic figures needed to separate this from FA is still
debatable and this feature should be evaluated in relation to the amount of tissue sample
examined. While the presence of a single mitotic figure in a small stereotactic biopsy justifies
assigning grade III to a tumor, the presence of a single mitotic figure in an ample biopsy after
careful searching and deeper sections might not be as relevant. In one study; >3MF/10HPFs
was the cut-off value proposed [27]. Ancillary studies might help in defining the proliferative
activity of a tumor and can be used to support the diagnosis of AA. Although cut-off values
are variable an elevated MIB-1 labeling index (>9%) and proliferative activity as measured by
PHH3 mitotic index (>4per 1000 cells) were found to be supportive of AA diagnosis over FA,
in which MIB-1 and PHH3 labeling indices were low (≤ 9% and ≤4 per 1000 cells) [27]. In
addition; MIB-1 labeling index prognostic value independent from histologic grade was
reported [14], which might be indicative of an early anaplastic transformation [31], even in the
absence of detectable mitoses.
c. Glioblastoma (GBM)
This is the most malignant and unfortunately the single most common primary brain tumor.
The essential features for the diagnosis of GBM are microvascular proliferation (MVP) and/or
necrosis whether palisading or not. Microvascular proliferation is loosely defined to include
endothelial hypertrophy, endothelial hyperplasia and glomeruloid vessels, in which multi‐
layered tufts of proliferating endothelium are accompanied by smooth muscles and peri‐
cytes“Figure 8” [32].
As the original name implies glioblastoma “multiforme” is characterized by heterogeneous
cell population with proliferation of fibrillary, gemistocytic and scattered tumor giant cells
“Figure 9”.
On the basis of their origin GBM is divided into primary (type II) and secondary (type I) types.
Primary GBM is a tumor of elderly patients, is characterized by short presenting history and
it arises de-novo with no detectable pre-existing lower grade tumor. Secondary GBM on the
other hand affects younger patients with prolonged history and is typically preceded by a
lower grade astrocytoma. Prognosis seems to be better for the secondary tumors. Whether a
tumor is primary or secondary GBM cannot be predicted on basis of morphologic features.
However; the presence of large vessel thrombosis with large areas of infarction-like necrosis
seems to be more prevalent in primary GBM. Immunohistochemically; reactivity for P53,
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MGMT and IDH1 is more frequent in secondary GBM, while positivity for EGFR is more
common in primary GBM [32].
Several GBM variants and patterns are described some of which might be prognostically
relevant, Table-2.
Giant cell glioblastoma (GCG)
GCG accounts approximately for 1.5- 5% of GMB cases [32]. This is characterized by the
predominance of bizarre markedly enlarged, often multinucleated tumor giant cells that tend
to grow in cohesive pattern with rich reticulin-positive stroma, accounting for the deceptively
circumscribed nature of the tumor seen radiologically. GFAP tends to be strongly positive in
many of the tumor cells. Up to 90% of these tumors are positive for P53 [20]. Recently; it was
shown that CD34 can be positive in giant cell glioblastoma, thus losing its discriminating power
Figure 8. Microvascular proliferation with glomeruloid growth pattern.
Figure 9. A case of GBM with large cells with abundant acidophilic cytoplasm at the upper left corner, and with intra-
nuclear inclusion seen in a single giant tumor cell. The lower right filed is composed of smaller cells. Note multiple
mitoses (arrows).
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from pleomorphic xanthoastrocytoma; its main differential diagnosis [33]. Giant cell glioblas‐
toma is claimed to carry a slightly better prognosis than classical GBM [20].
Gliosarcoma (GS)
This is a well-circumscribed, biphasic tumor that brings morphological remembrance to
“carcinosarcoma” in other sites. There is a near mutually exclusive staining for GFAP and
reticulin in the glial and mesenchymal components; respectively [34]. In the glial component
a clear GFAP-positive, reticulin-free usually fibrillary and sometimes gemistocytic astrocytes
proliferation is seen with necrosis and vascular proliferation. The sarcoma component, on the
other hand is typically GFAP-negative, and reticulin-rich. This component may be fibroblastic
with proliferation of long bundles of malignant spindle cells, or can show heterologous
component including smooth muscle, adipose tissue, cartilage and osteoid formation [32].
Glioblastoma with oligodendroglial component (GMB-O)
This is thought to represent a variant of glioblastoma with a probable better prognosis [35]. Its
relation to the mixed oligo-astrocytic tumors is discussed below. The essential component for
establishing this diagnosis is the presence of an oligodendroglial component in addition to the
astrocytic component in association with necrosis [15]. In 15-20% of tumors 1p/19q co-deletion
is detected.
Small cell glioblastoma (SCG)
This is characterized by proliferation of deceptively bland, uniform, small, round to slightly
elongated cells with minimal atypia, but with brisk mitoses. Of note is the rarity of micro-
vascular proliferation and necrosis in most cases [20]. GFAP is at best focally positive in thin
cytoplasmic processes. Resemblance to anaplastic oligodendroglioma is further accentuated
by the presence of tumor cell satellitosis, chicken-wire vascular proliferation and microcalci‐
fications [15, 20]. The disconnection between the bland cytology and the brisk mitosis should
act as a clue in this differential diagnosis. Furthermore; immunreactivity for EGFRvIII supports
the diagnosis of small cell GBM [20].
Glioblastoma with primitive neuroectodermal tumor (PNET)-like component
In this variant proliferation of a clone of primitive cells reminiscent of PNET/medulloblastoma
is seen, sometimes forming discrete nodule. The cells have high nuclear cytoplasmic ratio and
exhibit frequent neuroblastic and Homer-Wright rosettes. Features of anaplasia with cell-cell
wrapping, increased cell size with prominent nucleoli are seen in a subset of cases; thus
bringing resemblance to anaplastic/large cell medulloblastoma (see below). Mitotic activity is
brisk. Immunohistochemistry shows diffuse staining for neural markers including synapto‐
physin and NeuN and in many cases P53. GFAP is positive only in occasional cells. MIB-1
labeling index shows a nearly diffuse positivity (almost 100%) [31, 36].
Adenoid glioblastoma
This is an extremely rare variant that brings metastatic carcinoma into the differential diag‐
nosis. There is glandular-metaplastic component that intermingles with the better defined glial
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MGMT and IDH1 is more frequent in secondary GBM, while positivity for EGFR is more
common in primary GBM [32].
Several GBM variants and patterns are described some of which might be prognostically
relevant, Table-2.
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circumscribed nature of the tumor seen radiologically. GFAP tends to be strongly positive in
many of the tumor cells. Up to 90% of these tumors are positive for P53 [20]. Recently; it was
shown that CD34 can be positive in giant cell glioblastoma, thus losing its discriminating power
Figure 8. Microvascular proliferation with glomeruloid growth pattern.
Figure 9. A case of GBM with large cells with abundant acidophilic cytoplasm at the upper left corner, and with intra-
nuclear inclusion seen in a single giant tumor cell. The lower right filed is composed of smaller cells. Note multiple
mitoses (arrows).
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from pleomorphic xanthoastrocytoma; its main differential diagnosis [33]. Giant cell glioblas‐
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is seen, sometimes forming discrete nodule. The cells have high nuclear cytoplasmic ratio and
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wrapping, increased cell size with prominent nucleoli are seen in a subset of cases; thus
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physin and NeuN and in many cases P53. GFAP is positive only in occasional cells. MIB-1
labeling index shows a nearly diffuse positivity (almost 100%) [31, 36].
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This is an extremely rare variant that brings metastatic carcinoma into the differential diag‐
nosis. There is glandular-metaplastic component that intermingles with the better defined glial
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component. Reactivity for a variety of cytokeratins including CK7 can add further to the
confusion [32, 37].
Granular cell glioblastoma (GCA)
This is a deceptively bland tumor with proliferation of astrocytes showing abundant granular
PAS-positive cytoplasm and regular nuclei, so they can be confused with macrophages.
Reactivity with GFAP is the rule with few cases displaying EMA but not cytokeratin positivity.
P53 can be positive in few cases [32].
Table 2 summarizes the clinicopathological features of GBM variants ( From Miller et al with
modification) [32]
Tumor
Features 1ry 2ry Fib Gem GCA GC GS SCA GBM-O
Peak age (decade) 6-7 5-6 6-7 6-7 6-7 5-6 6-7 6-7 5-6
Circumscription … … - - +/- + + - -
Nuclear irregularity … … ++ + +/- +++ ++ +/- +
Perinuclear haloes … … - - - - - - ++
Cytoplasmic granules … … - - + - - - -
Multinucleated cells … … +/- +/- +/- +++ +/- +/- +/-
Reticulin meshwork … … - - +/- +/- +++ - -
PVI … … +/- ++ +/- + +/- +/- +/-
Mucin-filled
microcysts
… … +/- - - - - - +++
1ry, primary; 2ry, secondary; Fib, fibrillary; Gem, gemistocytic; GCA, granular cell astrocytoma; GC, giant cell; GS,
gliosarcoma; SCA, small cell astrocytoma; GBM-O, GBM with oligodendroglial features; …, no data available; -, absent;
+/-, infrequent; + to +++, increasing frequency; PVI, peri-vascular inflammation.
Table 2.
d. Gliomatosis cerebri
This entity has been shifted to join astrocytic tumors in 2007 classification. By definition; it is
an infiltrative tumor involving at least 2 lobes but lacking mass effect. When crossing from one
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side to the other it causes widening of the corpus callosum. Microscopically; there is an
infiltrative glioma, usually corresponding to grade III anaplastic astrocytoma and occasionally
to oligodendroglioma. Rarely grade II fibrillary astrocytoma or grade IV glioblastoma can be
encountered. Characteristically; the infiltrating malignant cells preserve the underlying
structures intact without destruction. P53 can highlight the tumor cells and MIB-1 labeling
index is variable reflecting the grade of the tumor [38, 39].
2.1.2. Oligodendroglioma
This  is  characterized  by  proliferation  of  monotonous  cells  with  regular  round,  uniform
nuclei  with  delicate  chromatin,  sharply  defined  nuclear  membrane  and  inconspicuous
nucleoli, brining a “highly-uniform” appearance on low power examination. In formalin-
fixed  tissue  there  is  clearing  artifact  creating  “haloes”  around tumor  cell  nuclei  due  to
shrinkage of the cytoplasm; a useful diagnostic clue, although not an absolute criteria for
diagnosis “Figure 10” [31].
Figure 10. A case of oligodendroglioma with monotonous fried-egg appearance, chicken-wire vascularity and scat‐
tered calcification (arrow).
However; a small eccentric acidophilic cytoplasm can sometimes be appreciated. Hypertrophy
of the cortical vessels leads to the development of the characteristic chicken-wire vascular
proliferation [35].Micro-calcification, extensive infiltration of the cortical structures with
perineural satellitosis and microcysts with basophilic mucinous contents are additional
diagnostic features [20]. In the anaplastic variant; the vascularity becomes more prominent
leading to the development of a nodular growth pattern at low power magnification. The cells
become larger and exhibit more abundant cytoplasm with vesicular nuclei and prominent
nucleoli; yet they retain their uniform appearance. There is increased cellularity with increased
mitosis (≥6 MF/10HPFs), microvascular proliferation and necrosis. Important companions are
the glio-fibrillary oligodendrocytes and the mini-gemistocytes “Figure 11”.
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Table 2.
d. Gliomatosis cerebri
This entity has been shifted to join astrocytic tumors in 2007 classification. By definition; it is
an infiltrative tumor involving at least 2 lobes but lacking mass effect. When crossing from one
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors156
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encountered. Characteristically; the infiltrating malignant cells preserve the underlying
structures intact without destruction. P53 can highlight the tumor cells and MIB-1 labeling
index is variable reflecting the grade of the tumor [38, 39].
2.1.2. Oligodendroglioma
This  is  characterized  by  proliferation  of  monotonous  cells  with  regular  round,  uniform
nuclei  with  delicate  chromatin,  sharply  defined  nuclear  membrane  and  inconspicuous
nucleoli, brining a “highly-uniform” appearance on low power examination. In formalin-
fixed  tissue  there  is  clearing  artifact  creating  “haloes”  around tumor  cell  nuclei  due  to
shrinkage of the cytoplasm; a useful diagnostic clue, although not an absolute criteria for
diagnosis “Figure 10” [31].
Figure 10. A case of oligodendroglioma with monotonous fried-egg appearance, chicken-wire vascularity and scat‐
tered calcification (arrow).
However; a small eccentric acidophilic cytoplasm can sometimes be appreciated. Hypertrophy
of the cortical vessels leads to the development of the characteristic chicken-wire vascular
proliferation [35].Micro-calcification, extensive infiltration of the cortical structures with
perineural satellitosis and microcysts with basophilic mucinous contents are additional
diagnostic features [20]. In the anaplastic variant; the vascularity becomes more prominent
leading to the development of a nodular growth pattern at low power magnification. The cells
become larger and exhibit more abundant cytoplasm with vesicular nuclei and prominent
nucleoli; yet they retain their uniform appearance. There is increased cellularity with increased
mitosis (≥6 MF/10HPFs), microvascular proliferation and necrosis. Important companions are
the glio-fibrillary oligodendrocytes and the mini-gemistocytes “Figure 11”.
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Figure 11. Minigemistocytes with whorling GFAP positive filaments. The tumor cells can be positive for GFAP. This is
especially seen in the perinuclear staining in glio-fibrillary oligodendrocytes and the diffuse cytoplasmic staining in the
mini-gemistocytes, thus potentiating confusion with infiltrating astrocytoma, or mixed oligo-astrocytoma [20]. In most
case; P53 [25]and vimentin [40]stains are negative thus helping in sorting out the differential diagnosis with astrocy‐
toma. A notable pitfall is the positivity of oligodendroglial tumors for neural markers including NeuN [41, 42], and
synaptophysin which reacts with a para-nuclear dot-like positivity [31].
2.1.3. Mixed oligo-astrocytoma
Mixed oligo-astrocytoma is one of the most common tumors associated with considerable
diagnostic difficulty and inter-observer variability [31]. A mixture of oligodendroglioma and
infiltrative diffuse astrocytoma is seen. Both components can be spatially separated (compact
variant) or they can be intermixed (diffuse variant). The minimum percentage of each com‐
ponent needed to establish the diagnosis is debatable, although a minimum of 10% astrocytic
component of either fibrillary or gemistocytic morphology was used in some studies [43]. In
the anaplastic variant; the tumors are highly cellular with pleomorphism and nuclear atypia,
mitosis (≥6 MF/10HPFs) and/or microvascular proliferation [31] which could be identified in
either or both components. Recent literature supports the up-grading into glioblastoma in the
presence of necrosis (see above) [17, 35].
2.1.4. Ependymoma
a. Myxo-papillary ependymoma
This is a slowly growing tumor that is almost exclusively seen in the cauda equina and filum
terminale of young adults. It is composed of hypo- and hypercellular areas. The hypocellular
areas show abundant mucicarmine-positive mucinous matrix with scattered epithelioid-
appearing cells. The hypercellular areas are formed of tumor cells arranged in papillary
structures. Cystic spaces filled with alcian-blue, PAS positive mucin separate the tumor cells
from the blood vessels “Figure 12”.
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Figure 12. In myxo-papillary ependymoma, alcian-blue positive cores surround vessels and cells grow in between
forming sheets and sometimes perivascular psuedorosettes.
The cells are bland with processes radiating to the walls of the vessels and are arranged in
single or multiple layers. Cribriform areas, sheets of cells and cells with clear cytoplasm can
occasionally be encountered, creating resemblance to metastatic carcinoma. Pleomorphic
cellular features, proliferation of vascular spaces, mitosis or necrosis are not seen, even in more
aggressive tumors [44].Tumor cells are reactive for GFAP and S-100 and MIB-1 labeling index
is low. A potential pitfall is positivity of the cells for pancytokeratin (AE1/AE3), cam 5.2 and
cytokeratin 7 [45]. EMA can show cytoplasmic positivity in few tumor cells, similar to the
pattern seen in other ependymoma (see below).
b. Sub-ependymoma
This mostly arises in the 4th followed by lateral ventricles [46]. Many cases are asymptomatic
and discovered incidentally, although symptoms of increased intra-cranial pressure are the
presenting features in others [47]. Morphologically; this is a well-delineated tumor that is
characterized by nodules of clustered isomorphic cells arranged against a fibrillary back‐
ground alternating with hypocellular fibrillary areas. Vague perivascular rosettes can be seen
“Figure 13”.
Focal cystic degeneration is noted [48], as well as vascular hyalinization, nuclear pleomor‐
phism and calcification [46]. This distinctive pattern may frequently be admixed with classical
ependymoma (See below). No mitotic figures, vascular proliferation or necrosis is detected in
most tumors. GFAP is diffusely positive in these cases. MIB-1 labeling index is extremely low
approaching zero [46].
c. Cellular ependymoma;
This is characterized by the presence uniform monomorphic cells extending their fine proc‐
esses radially to the walls of blood vessels creating a fibrillary cellular free zone around the
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phism and calcification [46]. This distinctive pattern may frequently be admixed with classical
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vessels and forming perivascular pseudorosettes. True rosettes and ependymal canals, where
clusters of ependymal cells are arranged around a lumen resembling spinal canal, are less
commonly encountered “Figure 14”.
Figure 14. Ependymal rosettes and canals can be seen in few cases. They are less common than perivascular pseu‐
dorosettes (arrow).
Feature of anaplasia include diffuse hypercellularity with diffuse nuclear pleomorphism,
vascular endothelial proliferation, palisading necrosis, increased mitosis (usually ≥5MF/
10HPFs) and elevated MIB-1 labeling index (≥20.5%) [27, 49]. Necrosis, in the absence of
palisading, is a common feature in posterior fossa tumors, and is not a poor prognostic feature
[31]. Interestingly; the identification of sub-ependymoma like areas in infratentorial ependy‐
moma seems to be associated with adverse outcome [14]. Another important microscopic
feature is the focal hypercellular nodules, in which focal increase in cellularity is associated
with nuclear pleomorphism and an increase in mitosis. In the absence of diffuse changes, these
Figure 13. Sub-ependymoma shows the typical microcysts formation, aggregated nuclei with nuclear-free zones
made up of fine fibrillary background.
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nodules are not associated with an adverse prognosis and as such may not warrant assigning
a higher grade to the tumor [49]. GFAP is variably positive in tumor cells, especially in
perivascular processes. EMA [50] and CD99 show charactersitic dot-like perinuclear cytoplas‐
mic positivity [51]. Other positive stains include other intermediate filaments like vimentin
and desmin [27].
d. Clear cell ependymoma
This is a tumor that predominates supratentorially and displays an enhancing cystic compo‐
nent in the majority of cases. It is characterized by proliferation of sheets of cells with round
nuclei and prominent, clear haloes. Focal ependymal perivascular pseudorosettes may be seen
but true rosettes and canals are not typical. Features of anaplasia including increased cellu‐
larity, mitosis and microvascular proliferation, and at least focal necrosis are frequent.
Reactivity for GFAP with perivascular accentuation, dot-like cytoplasmic EMA and CD99
staining should all help in reaching the appropriate diagnosis. MIB-1 labeling index is
increased especially in areas of increased mitosis. [52]. Clear cell ependymoma should be
differentiated from oligodendroglioma [20, 52].
e. Tanycytic ependymoma
This is primarily a tumor of the spinal cord, but occasional cases may arise from the third
ventricle or the hypothalamus. Tanycytic ependymoma posses an “astrocytoma-look”, with
solid proliferation of spindle cells with elongated processes and with at best focal ill-defined
ependymal psuedorosettes. The nuclei are uniform, round to oval with salt and pepper
chromatin, similar to other ependymoma “Figure 15“.
Figure 15. Tanycytic ependymoma is composed of “piloid” like tanycytes with only vague perivascular pseudorosettes
noted.
Strong GFAP positivity is seen in the elongated processes. Other positive markers include
S-100, vimentin and CD99 [20].
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They all share proliferation of small round blue cells with increased mitosis and apoptosis.
This group includes
a. Medulloblastoma
This is a primitive neuroectodermal tumor that arises from the cerebellum. It is the most
common malignant brain tumor in children and the most common embryonal tumor. Medul‐
loblastoma is thought to originate from a primitive cell type in the cerebellum. The multi-
potent progenitor cells of ventricular zone that forms the innermost boundary of the
cerebellum is the postulated origin of the classical medulloblastoma, while the external
germinal layer that lines the outside of the cerebellum; the external granular layer, is the
postulated origin of the desmoplastic medulloblastoma [53].
Several morphologic sub-types are recongized, some of which are prognostically relevant:
• Classic medulloblastoma; is the most common variant, and represents 66% of cases [54]. It
is composed of densely-packed cells with hyperchromatic, round, oval or carrot-shaped
nuclei with minimal cytoplasm “Figure 16”.
Figure 16. Sheets of tumor cells with Homer-Wright rosettes (right side) and neurocytic nodules (left) can be encoun‐
tered in typical medulloblastoma.
The cells are usually arranged in diffuse sheets, but trabeculae, spongioblastic pattern, Homer-
Wright rosettes and nodules can be identified. Necrosis, sometimes palisading, may be seen
in some tumors, and has been identified as an adverse prognostic feature [55].
• Desmoplastic/nodular medulloblastoma(DNM) and medulloblastoma with extensive
nodularity (MEN); both of these variants share the presence of reticulin-rich desmoplastic
component and a reticulin-free, nodular component showing comparatively extensive
neurocytic differentiation, fibrillary background, less mitoses and frequent apoptosis
“Figure 17”.
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Figure 17. Desmoplastic medulloblastoma with pale islands and internodular area giving a reactive lymph node like
appearance.
Both variants are claimed to be associated with better prognosis [54]. DNM can be seen in
children and adults and represents 25% of cases of medulloblastoma. MEN, on the other hand,
is characteristically seen in infants, where is accounts for 57% of medulloblastoma in this age
group and is associated with excellent outcome. Whereas the reticulin-rich component
predominates in DNM, and the presence of any percentage of nodularity and desmoplasia
qualifies the tumor for DNM subtype [56], the reticulin-free differentiating component
predominates in MEN, representing 96-100% of the tumor [57]. Thus MEN might be perceived
as an exaggerated form of DNM [15]. Importantly; the borders between the nodules and the
surrounding desmoplasia is usually sharp [54]. The presence of desmoplasia due to infiltration
of the meninges in the absence of nodules does not qualify the tumor as DNM [57] and vice
versa; the identification of less-delineated neurocytic nodules in the absence of desmoplasia
i.e.biphasic medulloblastoma is considered a variation of classical or sometimes anaplastic/
large cell medulloblastoma morphological patterns that is not assocaited with improved
outcome in some [54], but not all studies [55]. Immunohistochemistry helps further confirming
both growth patterns. The pale islands are synaptophysin positive with low MIB-1 labeling
index, while the inter-nodular areas are at best focally positive for synaptophysin with high
MIB-1 labeling index, in keeping with presence or absence of neuronal differentiation;
respectively.
• Anaplastic/large cell medulloblastoma; these are closely related variants that frequently co-
exist and account for17- 24 % of cases of medulloblastoma [54, 57]. In anaplastic medullo‐
blastoma there is marked nuclear pleomorphism with angular, crowded pleomorphic cells
with nuclear molding, cell-cell wrapping and numerous mitotic and apoptotic fig‐
ures“Figure 18”.
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This is a primitive neuroectodermal tumor that arises from the cerebellum. It is the most
common malignant brain tumor in children and the most common embryonal tumor. Medul‐
loblastoma is thought to originate from a primitive cell type in the cerebellum. The multi-
potent progenitor cells of ventricular zone that forms the innermost boundary of the
cerebellum is the postulated origin of the classical medulloblastoma, while the external
germinal layer that lines the outside of the cerebellum; the external granular layer, is the
postulated origin of the desmoplastic medulloblastoma [53].
Several morphologic sub-types are recongized, some of which are prognostically relevant:
• Classic medulloblastoma; is the most common variant, and represents 66% of cases [54]. It
is composed of densely-packed cells with hyperchromatic, round, oval or carrot-shaped
nuclei with minimal cytoplasm “Figure 16”.
Figure 16. Sheets of tumor cells with Homer-Wright rosettes (right side) and neurocytic nodules (left) can be encoun‐
tered in typical medulloblastoma.
The cells are usually arranged in diffuse sheets, but trabeculae, spongioblastic pattern, Homer-
Wright rosettes and nodules can be identified. Necrosis, sometimes palisading, may be seen
in some tumors, and has been identified as an adverse prognostic feature [55].
• Desmoplastic/nodular medulloblastoma(DNM) and medulloblastoma with extensive
nodularity (MEN); both of these variants share the presence of reticulin-rich desmoplastic
component and a reticulin-free, nodular component showing comparatively extensive
neurocytic differentiation, fibrillary background, less mitoses and frequent apoptosis
“Figure 17”.
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Figure 17. Desmoplastic medulloblastoma with pale islands and internodular area giving a reactive lymph node like
appearance.
Both variants are claimed to be associated with better prognosis [54]. DNM can be seen in
children and adults and represents 25% of cases of medulloblastoma. MEN, on the other hand,
is characteristically seen in infants, where is accounts for 57% of medulloblastoma in this age
group and is associated with excellent outcome. Whereas the reticulin-rich component
predominates in DNM, and the presence of any percentage of nodularity and desmoplasia
qualifies the tumor for DNM subtype [56], the reticulin-free differentiating component
predominates in MEN, representing 96-100% of the tumor [57]. Thus MEN might be perceived
as an exaggerated form of DNM [15]. Importantly; the borders between the nodules and the
surrounding desmoplasia is usually sharp [54]. The presence of desmoplasia due to infiltration
of the meninges in the absence of nodules does not qualify the tumor as DNM [57] and vice
versa; the identification of less-delineated neurocytic nodules in the absence of desmoplasia
i.e.biphasic medulloblastoma is considered a variation of classical or sometimes anaplastic/
large cell medulloblastoma morphological patterns that is not assocaited with improved
outcome in some [54], but not all studies [55]. Immunohistochemistry helps further confirming
both growth patterns. The pale islands are synaptophysin positive with low MIB-1 labeling
index, while the inter-nodular areas are at best focally positive for synaptophysin with high
MIB-1 labeling index, in keeping with presence or absence of neuronal differentiation;
respectively.
• Anaplastic/large cell medulloblastoma; these are closely related variants that frequently co-
exist and account for17- 24 % of cases of medulloblastoma [54, 57]. In anaplastic medullo‐
blastoma there is marked nuclear pleomorphism with angular, crowded pleomorphic cells
with nuclear molding, cell-cell wrapping and numerous mitotic and apoptotic fig‐
ures“Figure 18”.
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Figure 18. Anaplastic medulloblastoma with frequent cell wrapping (lower right), apoptosis and abnormal mitosis.
The nuclei are twice to three times the size of an RBC in moderate to severe anaplasia, thus
varying in size from 18-21 micrometers; respectively [57, 58]. Hyperchromasia per se is not
a defining feature of anaplasia. The large cell variant on the other hand is characterized by
large  spherical  cells  possessing  round  vesicular  nuclei  and  prominent  central  nucleo‐
li“Figure 19” [57, 58].
Figure 19. In large cell medulloblastoma; the cells have abudant cytoplasm, vesicular nuclei and prominent nucleoli.
Anaplasia is considered diffuse when seen involving every low power field, otherwise it
is considered focal. It is the diffuse, moderate to severe anaplasia that is associated with
poor prognosis. Anaplastic/large cell features can be detected in what appears to be DNM
or  in  recurrent  classical  medulloblastoma.  The  presence  of  features  of  DNM,  Homer-
Wright  rosettes  or  previously  classical  medulloblastoma  is  not  incompatible  with  the
diagnosis of anaplasia [31, 57, 58].
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• “Medulloblastoma with myogenic differentiation” and “medulloblastoma with melanotic
differentiation” are considered morphological patterns with divergent differentiation that
can be seen in any of the medulloblastoma variants, but with no effect on prognosis.
Respectively; desmin and myogenin positive rhabdomyoblasts and S-100 positive melanotic
tumor cells are seen in both patterns, hence the nomenclature [15].
In medulloblastoma, the tumor cells are positive for synaptophysin in up to 80% of cases, while
microtubule-associated protein 2 antibody (MAP2) is seen in cases with weak synaptophysin
reactivity [27]. CD99 is usually negative in contrast to peripheral PNET [59]. GFAP reactivity
can be seen in medulloblastoma cells in a perinuclear pattern and this might carry adverse
prognosis [27]. Diffuse positivity for P53 (strong nuclear stain in > 50%), ErbB2 (strong
membranous staining in ≥ 50% of tumor cells) and survivin (nuclear stain) is associated with
poor prognosis [56, 60-62]. TrK-C (strong cytoplasmic staining in >50% of tumor cells) and
beta-catenin (either diffuse, strong cytoplasmic and nuclear or nuclear staining in cell clusters
of at least 10% of nuclei among others with negligible or weak staining) are associated with
improved outcome [60, 63, 64]. MIB-1 labeling index is variable but with a mean that ranges
between 46.5-59.03%. The prognostic importance of elevated MIB-1 labeling index varies from
one study to another [56, 60], with higher figures reported among anaplastic/large cell variant,
and correlating with poor outcome [65].
b. CNS-primitive neuroectodermal tumor (CNS-PNET)
This is a heterogeneous group of poorly-differentiated primitive small round blue cells that
can be seen supratentorially, in the brainstem or in the spinal cord. Divergent differentiation
along neuronal/ ganglio-neuronal, epithelial or ependymal lines can be seen occasionally,
hence the neuroblastoma/ CNS ganglioneuroblastoma, medulloepithelioma and ependymo‐
blastoma variants; respectively [15]. The presence of necrosis adversely affects the outcome
[14]. Embryonal tumor with abundant neuropil and ependymoblastic rosettes (ETANTR) is a
newly described variant that is considered a hybrid tumor where both neuroblastic and
ependymoblastic differentiation co-exist. Characteristically; ETANTR has been reported to
have extra-copies of chromosome 2 [66] and 19q amplification [67].
CNS-PNET can show positivity for synaptophysin, GFAP and occasionally dot-like cytoplas‐
mic EMA, according to differentiation [68]. Of note is the total negativity for CD99 in contrast
to the peripheral type PNET tumors [69].
c. Atypical teratoid/rhabdoid tumor (AT/RT)
This tumor predominates in infants and can be seen in supratentorial and infratentorial
compartments. Growth pattern are predominantly diffuse in most cases with reticular and
papillary patterns noticed in few [70]. The typical cell, “rhabdoid cell” is seen in most but not
all tumors and is not an absolute prerequisite for establishing the diagnosis. It is a large cell
with eccentric acidophilic cytoplasm, vesicular nucleus with prominent nucleolus, reminiscent
of “rhabdomyoblasts” hence the name. Intra-cytoplasmic spherical filamentous inclusions are
identified in a proportion of rhabdoid cells“Figure 20”.
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Figure 18. Anaplastic medulloblastoma with frequent cell wrapping (lower right), apoptosis and abnormal mitosis.
The nuclei are twice to three times the size of an RBC in moderate to severe anaplasia, thus
varying in size from 18-21 micrometers; respectively [57, 58]. Hyperchromasia per se is not
a defining feature of anaplasia. The large cell variant on the other hand is characterized by
large  spherical  cells  possessing  round  vesicular  nuclei  and  prominent  central  nucleo‐
li“Figure 19” [57, 58].
Figure 19. In large cell medulloblastoma; the cells have abudant cytoplasm, vesicular nuclei and prominent nucleoli.
Anaplasia is considered diffuse when seen involving every low power field, otherwise it
is considered focal. It is the diffuse, moderate to severe anaplasia that is associated with
poor prognosis. Anaplastic/large cell features can be detected in what appears to be DNM
or  in  recurrent  classical  medulloblastoma.  The  presence  of  features  of  DNM,  Homer-
Wright  rosettes  or  previously  classical  medulloblastoma  is  not  incompatible  with  the
diagnosis of anaplasia [31, 57, 58].
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• “Medulloblastoma with myogenic differentiation” and “medulloblastoma with melanotic
differentiation” are considered morphological patterns with divergent differentiation that
can be seen in any of the medulloblastoma variants, but with no effect on prognosis.
Respectively; desmin and myogenin positive rhabdomyoblasts and S-100 positive melanotic
tumor cells are seen in both patterns, hence the nomenclature [15].
In medulloblastoma, the tumor cells are positive for synaptophysin in up to 80% of cases, while
microtubule-associated protein 2 antibody (MAP2) is seen in cases with weak synaptophysin
reactivity [27]. CD99 is usually negative in contrast to peripheral PNET [59]. GFAP reactivity
can be seen in medulloblastoma cells in a perinuclear pattern and this might carry adverse
prognosis [27]. Diffuse positivity for P53 (strong nuclear stain in > 50%), ErbB2 (strong
membranous staining in ≥ 50% of tumor cells) and survivin (nuclear stain) is associated with
poor prognosis [56, 60-62]. TrK-C (strong cytoplasmic staining in >50% of tumor cells) and
beta-catenin (either diffuse, strong cytoplasmic and nuclear or nuclear staining in cell clusters
of at least 10% of nuclei among others with negligible or weak staining) are associated with
improved outcome [60, 63, 64]. MIB-1 labeling index is variable but with a mean that ranges
between 46.5-59.03%. The prognostic importance of elevated MIB-1 labeling index varies from
one study to another [56, 60], with higher figures reported among anaplastic/large cell variant,
and correlating with poor outcome [65].
b. CNS-primitive neuroectodermal tumor (CNS-PNET)
This is a heterogeneous group of poorly-differentiated primitive small round blue cells that
can be seen supratentorially, in the brainstem or in the spinal cord. Divergent differentiation
along neuronal/ ganglio-neuronal, epithelial or ependymal lines can be seen occasionally,
hence the neuroblastoma/ CNS ganglioneuroblastoma, medulloepithelioma and ependymo‐
blastoma variants; respectively [15]. The presence of necrosis adversely affects the outcome
[14]. Embryonal tumor with abundant neuropil and ependymoblastic rosettes (ETANTR) is a
newly described variant that is considered a hybrid tumor where both neuroblastic and
ependymoblastic differentiation co-exist. Characteristically; ETANTR has been reported to
have extra-copies of chromosome 2 [66] and 19q amplification [67].
CNS-PNET can show positivity for synaptophysin, GFAP and occasionally dot-like cytoplas‐
mic EMA, according to differentiation [68]. Of note is the total negativity for CD99 in contrast
to the peripheral type PNET tumors [69].
c. Atypical teratoid/rhabdoid tumor (AT/RT)
This tumor predominates in infants and can be seen in supratentorial and infratentorial
compartments. Growth pattern are predominantly diffuse in most cases with reticular and
papillary patterns noticed in few [70]. The typical cell, “rhabdoid cell” is seen in most but not
all tumors and is not an absolute prerequisite for establishing the diagnosis. It is a large cell
with eccentric acidophilic cytoplasm, vesicular nucleus with prominent nucleolus, reminiscent
of “rhabdomyoblasts” hence the name. Intra-cytoplasmic spherical filamentous inclusions are
identified in a proportion of rhabdoid cells“Figure 20”.
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Figure 20. Typical case of AT/RT composed of cells with eccentric acidophilic cytoplasm and vesicular nuclei with
prominent nucleoli. Note the myxoid background in the lower left corner.
Other common cellular components included large pale cells and primitive small round blue
cells. Pale cells are characterized by vesicular nuclei, prominent nucleoli, and granular
vacuolated wispy or water clear cytoplasm lacking intra-cytoplasmic inclusions, while small
cells are cells with high nuclear: cytoplasmic ratio reminiscent of medulloblastoma/PNET [42,
71]. Admixture of all three cell components is noted in most cases. However; cases composed
entirely of one cell type are not uncommon. Variable mesenchymal structures including
myxoid changes, chondroid, lipoblastic and spindle cells elements can be seen. Occasional
cases may contain glandular or papillary structures as an evidence of epithelial differentiation.
Dystrophic calcifications and necrosis can be identified in some tumors.
Nowadays; the diagnosis of AT/RT can be confirmed by loss of INI1/BAF47 immunostain in
tumor cells nuclei with appropriate positive normal endothelial and mononuclear cell control
in the background [42]. In the rare instances of retained INI1/BAF47 nuclear stain, which is
seen in 2% of cases, positivity for a panel of other markers can help in suggesting the diagnosis.
A panel of EMA, synaptophysin, GFAP, vimentin, smooth muscle actin and pan-cytokeratin
can show various combination of positive staining and thus can be of help in suggesting the
diagnosis [27]. Confirmation by cytogenetics for monosomy 22 may be warranted in such cases.
Notably is the absence of desmin [72]. MIB-1 labeling index ranges between 30-50%.
2.3. Neuronal and mixed neuronal-glial tumors
This is the most heterogeneous and rapidly expanding group of tumors with many newly
recognized and added entities. As the name implies, many tumors are composed of a mixture
of glial and neuronal components.
a. Ganglioglioma (GG) and gangliocytoma
Frequently presenting as long standing chronic seizure, this biphasic tumor is most commonly
located in the temporal lobe and is seen mostly in children and young adults. This is a variably
circumscribed tumor with intimate mixture of disfigured and dysplastic neurons and neo‐
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plastic glial cells of varying proportions. The ganglion cells are characterized by cyto-archi‐
tectural disorientation with sub-cortical localization, abnormal aggregations and clustering.
Morphologically; the neurons show abnormal forms with frequent cytomegaly, bi- and
multinucleation, prominent nucleoli, and peri-membranous condensed Nissl substance [73].
The glial component can vary as well from pilocytic to diffuse astrocytoma to oligodendro‐
glioma like component ”Figure 21” [73, 74]. This is the proliferative component that ultimately
determines the biological behavioral of GG. Tumors composed predominantly of ganglion
cells, which are devoid of a glial component are termed gangliocytomas [73, 74]. Dysplastic
calcification (globules or incrustation), eosinophilic granular bodies and increased reticulin
meshwork can be seen in the background. Perivascular lymphocytes and scattered parenchy‐
mal plasma cells are common supportive features. An atypical or anaplastic ganglioglioma is
rarely encountered and can arise either de novo or at recurrences of a previously diagnosed
GG [74]. The presence of cellular atypia and pleomorphism, microvascular proliferation,
necrosis and elevated MIB-1 labeling index supports the diagnosis of anaplastic ganglioglioma
[17, 73]. It was suggested to lable tumors exhibiting features of anaplasia without necrosis as
atypical GG [74]. Gemistocytes identified in some tumors might represent an additional feature
of anaplasia [74].
Figure 21. Ganglioglioma with dysplastic ganglion cells that are haphazardely oriented with abnormal aggregation of
Nissl substance in the cytoplasm. Perivascular lymphocytic infiltrate is seen.
Immunohistochemically; the dysplastic ganglion cells are positive for synaptophysin, with
peri-somatic synaptophysin reactivity, chromogranin A, neurofilament protein and MAP2
[74-76], while the glial component is positive for GFAP. Dysplastic ganglions frequently fail
to  react  with NeuN, a  potentially  useful  marker  to  differentiate  dysplastic  from normal
neurons [42]. CD34 is reported to be positive in up to 80% of tumors; labeling the dysplas‐
tic  neurons,  being less  frequently positive in atypical  and anaplastic  tumors [74].  MIB-1
labeling index is seen in the glial component and is usually <1% [77] and labeling index
>5% is  associated with a  more aggressive behavior  (see  above).  P53 is  reported in  only
atypical/anaplastic tumors [74, 77].
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Figure 20. Typical case of AT/RT composed of cells with eccentric acidophilic cytoplasm and vesicular nuclei with
prominent nucleoli. Note the myxoid background in the lower left corner.
Other common cellular components included large pale cells and primitive small round blue
cells. Pale cells are characterized by vesicular nuclei, prominent nucleoli, and granular
vacuolated wispy or water clear cytoplasm lacking intra-cytoplasmic inclusions, while small
cells are cells with high nuclear: cytoplasmic ratio reminiscent of medulloblastoma/PNET [42,
71]. Admixture of all three cell components is noted in most cases. However; cases composed
entirely of one cell type are not uncommon. Variable mesenchymal structures including
myxoid changes, chondroid, lipoblastic and spindle cells elements can be seen. Occasional
cases may contain glandular or papillary structures as an evidence of epithelial differentiation.
Dystrophic calcifications and necrosis can be identified in some tumors.
Nowadays; the diagnosis of AT/RT can be confirmed by loss of INI1/BAF47 immunostain in
tumor cells nuclei with appropriate positive normal endothelial and mononuclear cell control
in the background [42]. In the rare instances of retained INI1/BAF47 nuclear stain, which is
seen in 2% of cases, positivity for a panel of other markers can help in suggesting the diagnosis.
A panel of EMA, synaptophysin, GFAP, vimentin, smooth muscle actin and pan-cytokeratin
can show various combination of positive staining and thus can be of help in suggesting the
diagnosis [27]. Confirmation by cytogenetics for monosomy 22 may be warranted in such cases.
Notably is the absence of desmin [72]. MIB-1 labeling index ranges between 30-50%.
2.3. Neuronal and mixed neuronal-glial tumors
This is the most heterogeneous and rapidly expanding group of tumors with many newly
recognized and added entities. As the name implies, many tumors are composed of a mixture
of glial and neuronal components.
a. Ganglioglioma (GG) and gangliocytoma
Frequently presenting as long standing chronic seizure, this biphasic tumor is most commonly
located in the temporal lobe and is seen mostly in children and young adults. This is a variably
circumscribed tumor with intimate mixture of disfigured and dysplastic neurons and neo‐
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plastic glial cells of varying proportions. The ganglion cells are characterized by cyto-archi‐
tectural disorientation with sub-cortical localization, abnormal aggregations and clustering.
Morphologically; the neurons show abnormal forms with frequent cytomegaly, bi- and
multinucleation, prominent nucleoli, and peri-membranous condensed Nissl substance [73].
The glial component can vary as well from pilocytic to diffuse astrocytoma to oligodendro‐
glioma like component ”Figure 21” [73, 74]. This is the proliferative component that ultimately
determines the biological behavioral of GG. Tumors composed predominantly of ganglion
cells, which are devoid of a glial component are termed gangliocytomas [73, 74]. Dysplastic
calcification (globules or incrustation), eosinophilic granular bodies and increased reticulin
meshwork can be seen in the background. Perivascular lymphocytes and scattered parenchy‐
mal plasma cells are common supportive features. An atypical or anaplastic ganglioglioma is
rarely encountered and can arise either de novo or at recurrences of a previously diagnosed
GG [74]. The presence of cellular atypia and pleomorphism, microvascular proliferation,
necrosis and elevated MIB-1 labeling index supports the diagnosis of anaplastic ganglioglioma
[17, 73]. It was suggested to lable tumors exhibiting features of anaplasia without necrosis as
atypical GG [74]. Gemistocytes identified in some tumors might represent an additional feature
of anaplasia [74].
Figure 21. Ganglioglioma with dysplastic ganglion cells that are haphazardely oriented with abnormal aggregation of
Nissl substance in the cytoplasm. Perivascular lymphocytic infiltrate is seen.
Immunohistochemically; the dysplastic ganglion cells are positive for synaptophysin, with
peri-somatic synaptophysin reactivity, chromogranin A, neurofilament protein and MAP2
[74-76], while the glial component is positive for GFAP. Dysplastic ganglions frequently fail
to  react  with NeuN, a  potentially  useful  marker  to  differentiate  dysplastic  from normal
neurons [42]. CD34 is reported to be positive in up to 80% of tumors; labeling the dysplas‐
tic  neurons,  being less  frequently positive in atypical  and anaplastic  tumors [74].  MIB-1
labeling index is seen in the glial component and is usually <1% [77] and labeling index
>5% is  associated with a  more aggressive behavior  (see  above).  P53 is  reported in  only
atypical/anaplastic tumors [74, 77].
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b. Desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA)
DIG is a massive, supratentorial tumor that primarily affects infants, usually younger than 6
months of age. It is characterized by superficial leptomeningeal attachment, multiple conspic‐
uous cysts, firm consistency and focal infiltration into adjacent brain parenchyma without clear
plane of resection [78].Microscopically; there is admixture of fibroblasts, neuroastroglial cells
and primitive cells, all enmeshed within a desmoplastic stoma, that can be highlighted by
reticulin and Massons's trichrome stains [79]. The proportion of the different cellular compo‐
nents varies from one tumor to the other. The astroglial cells are the most abundant cell
component, especially in regions of desmoplasia, are characterized by strap-like to polygonal,
GFAP positivity. The neuronal cells; on the other hand are more frequently seen in the less
desmoplastic areas, with proliferation of small abortive neurons to occasional polygonal
ganglioid cells with prominent nucleoli and Nissl substance that are reactive with synapto‐
physin and NFP. The proportion of the small primitive cells can vary from scattered to a
considerable amount in some tumors. It is within these areas that rare mitosis and foci of micro-
necrosis, but not endothelial proliferation can be detected [78, 79]. However; regardless of their
amount; this tumor continues to carry a favorable prognosis in most cases. MIB-proliferative
index is low with a mean of 6.5% [79]. There has been reported cases in the literature in which
the prognosis was not as favorable and resulted occasionally in patient’s death [80]. DIA shares
with DIG the desmoplasia and the astrocytic components, but not the neuronal or the primitive
cells [78].
c. Dys-embryoplastic neuroectodermal tumor (DNET)
The essential diagnostic features of this peculiar epilepsy-associated tumor are the combina‐
tion of cortical localization, multi-nodular architectures with nodules composed of glial cells
of either astrocytic or oligodendroglial or a mixture of both, foci of dysplasia in the adjacent
cortex and the “specific glioneuronal elements” [81]. These are composed of bundles of axons
lined by small S-100 positive, GFAP-negative oligodendrocytes with normal appearing
neurons floating within pale eosinophilic interstitial fluid i.e.“floating neurons”, all arranged
in columns perpendicular to the overlying cortex, and is strikingly similar from one case to
another. Thin capillaries run within the columns. When sectioned perpendicular to the
columns; the capillaries are seen to be rosetted by the oligodendroglial cells with the “floating
neurons” in between. Calcification can sometimes be seen. Two morphological forms exist; the
simple and complex forms [81]. In the simple form; only the “specific glioneuronal elements”
are seen within the cortex. The complex form, on the other hand; features the glial nodules
and/or cortical dysplasia in addition to the “specific glioneuronal elements”. The nuclei of the
oligodendrocytes within the nodules are frequently voluminous and multilobated “fleurettes-
like”, while the astrocytic component is usually in the form of pilocytic astrocytoma, sometimes
accompanied by the “vascular arcade” proliferation typically seen in cerebellar pilocytic
astrocytoma. Fibrillary astrocytoma, of both grades II and III like features can also be seen. The
presence of morphological features of anaplasia in the form of rare mitosis and necrosis can
occasionally be seen. MIB-1 labeling index is mostly negative in the simple form with rare
reactive cells in the complex form, although higher labeling index can be seen in some cases
according to the type and grade of the glioma seen within the nodules [81]. Cases can still be
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diagnosed as DNET even in the absence of histological appearances previously described, if
all of the following clinical and radiological features are fulfilled including 1)partial seizure
with or without secondary generalization beginning before the age of 20 years, 2)no neuro‐
logical deficit or stable congenital deficits, 3)cortical topography of the lesion as demonstrated
by MRI and 4) absence of mass effect on imaging. The underlying spectrum of histopathologic
entities that can be seen include mostly pilocytic and fibrillary astrocytoma [82].
d. Central neurocytoma
This tumor typically occupies the lateral ventricles or less commonly the third ventricle in
young adults without significant invasion into the adjacent brain tissue [83]. It is characterized
by proliferation of uniform round cells, embedded within and focally separated by a fibrillary
background, the “neuropil” giving an overall monotonous appearance ”Figure 22”.
Figure 22. Typical neurocytoma with monotonous tumor cells with vesicular chromatin and delicate capillary-sized
vessels. The background is fibrillary.
The tumor cells grow in sheets, clusters, “Indian filing” but rarely rosettes. The fibrillary areas
can be seen to form acellular aggregates, bringing resemblance to pineocytomatous rosettes
(see below). The nuclei are round to oval with finely speckled chromatin and occasional
prominent nucleoli. The cytoplasm is scanty and can be acidophilic or rarely clear. Calcifica‐
tion, which is seen throughout the tumor, and delicate-branching capillaries bring resemblance
to oligodendroglioma. Occasional cases show ganglion cells [17]. Mitosis is scarce and there is
usually no necrosis [15]. When present such features warrant the diagnosis of atypical
neurocytoma. Synaptophysin is strongly and diffusely positive in both the neurocytes and
neuropil. NeuN shows strong nuclear stain in tumor cells [42]. Other positive neural markers
include neurofilament protein and MAP2. Leu-7 can be positive but it is not specific as is
staining for neuron-specific enolase (NSE). Chromogranin is typically negative in both the
neurocytoma cells and neuropil [84]. Occasional positivity for GFAP can be seen in some
tumors [83]. MIB-1 labeling index is < 2% in typical cases [83]. An elevated MIB-1 labeling index
>3% correlates with poorer outcome [14].
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physin and NFP. The proportion of the small primitive cells can vary from scattered to a
considerable amount in some tumors. It is within these areas that rare mitosis and foci of micro-
necrosis, but not endothelial proliferation can be detected [78, 79]. However; regardless of their
amount; this tumor continues to carry a favorable prognosis in most cases. MIB-proliferative
index is low with a mean of 6.5% [79]. There has been reported cases in the literature in which
the prognosis was not as favorable and resulted occasionally in patient’s death [80]. DIA shares
with DIG the desmoplasia and the astrocytic components, but not the neuronal or the primitive
cells [78].
c. Dys-embryoplastic neuroectodermal tumor (DNET)
The essential diagnostic features of this peculiar epilepsy-associated tumor are the combina‐
tion of cortical localization, multi-nodular architectures with nodules composed of glial cells
of either astrocytic or oligodendroglial or a mixture of both, foci of dysplasia in the adjacent
cortex and the “specific glioneuronal elements” [81]. These are composed of bundles of axons
lined by small S-100 positive, GFAP-negative oligodendrocytes with normal appearing
neurons floating within pale eosinophilic interstitial fluid i.e.“floating neurons”, all arranged
in columns perpendicular to the overlying cortex, and is strikingly similar from one case to
another. Thin capillaries run within the columns. When sectioned perpendicular to the
columns; the capillaries are seen to be rosetted by the oligodendroglial cells with the “floating
neurons” in between. Calcification can sometimes be seen. Two morphological forms exist; the
simple and complex forms [81]. In the simple form; only the “specific glioneuronal elements”
are seen within the cortex. The complex form, on the other hand; features the glial nodules
and/or cortical dysplasia in addition to the “specific glioneuronal elements”. The nuclei of the
oligodendrocytes within the nodules are frequently voluminous and multilobated “fleurettes-
like”, while the astrocytic component is usually in the form of pilocytic astrocytoma, sometimes
accompanied by the “vascular arcade” proliferation typically seen in cerebellar pilocytic
astrocytoma. Fibrillary astrocytoma, of both grades II and III like features can also be seen. The
presence of morphological features of anaplasia in the form of rare mitosis and necrosis can
occasionally be seen. MIB-1 labeling index is mostly negative in the simple form with rare
reactive cells in the complex form, although higher labeling index can be seen in some cases
according to the type and grade of the glioma seen within the nodules [81]. Cases can still be
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diagnosed as DNET even in the absence of histological appearances previously described, if
all of the following clinical and radiological features are fulfilled including 1)partial seizure
with or without secondary generalization beginning before the age of 20 years, 2)no neuro‐
logical deficit or stable congenital deficits, 3)cortical topography of the lesion as demonstrated
by MRI and 4) absence of mass effect on imaging. The underlying spectrum of histopathologic
entities that can be seen include mostly pilocytic and fibrillary astrocytoma [82].
d. Central neurocytoma
This tumor typically occupies the lateral ventricles or less commonly the third ventricle in
young adults without significant invasion into the adjacent brain tissue [83]. It is characterized
by proliferation of uniform round cells, embedded within and focally separated by a fibrillary
background, the “neuropil” giving an overall monotonous appearance ”Figure 22”.
Figure 22. Typical neurocytoma with monotonous tumor cells with vesicular chromatin and delicate capillary-sized
vessels. The background is fibrillary.
The tumor cells grow in sheets, clusters, “Indian filing” but rarely rosettes. The fibrillary areas
can be seen to form acellular aggregates, bringing resemblance to pineocytomatous rosettes
(see below). The nuclei are round to oval with finely speckled chromatin and occasional
prominent nucleoli. The cytoplasm is scanty and can be acidophilic or rarely clear. Calcifica‐
tion, which is seen throughout the tumor, and delicate-branching capillaries bring resemblance
to oligodendroglioma. Occasional cases show ganglion cells [17]. Mitosis is scarce and there is
usually no necrosis [15]. When present such features warrant the diagnosis of atypical
neurocytoma. Synaptophysin is strongly and diffusely positive in both the neurocytes and
neuropil. NeuN shows strong nuclear stain in tumor cells [42]. Other positive neural markers
include neurofilament protein and MAP2. Leu-7 can be positive but it is not specific as is
staining for neuron-specific enolase (NSE). Chromogranin is typically negative in both the
neurocytoma cells and neuropil [84]. Occasional positivity for GFAP can be seen in some
tumors [83]. MIB-1 labeling index is < 2% in typical cases [83]. An elevated MIB-1 labeling index
>3% correlates with poorer outcome [14].
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e. Extra-ventricular neurocytoma (EVN)
EVN shares morphologic and immunophenotypic features with central neurocytoma. It arises,
however from the parenchyma, mostly in the cerebral hemispheres in adults [15, 84]. In
addition, Ganglion cell differentiation is a more frequent occurrence, being described in more
than half of the cases and can be either focal or diffuse [17, 84]. Frequent reactivity for GFAP
is seen in nearly half of cases [84].
f. Cerebellar liponeurocytoma
This is another biphasic tumor that occurs in adults. Originally described in the posterior fossa
mostly in the cerebellar hemispheres, cases with identical morphological features are also
being reported supratentorially, arising from the lateral ventricle [85]. Morphologically a well
differentiated neurocytic component composed of uniform round nuclei and minimal
cytoplasm is admixed with mature lipomatous component. Thin and occasionally hyalinized
vessels can be detected in the tumor as well as dispersed foci of neuropil. The tumor is diffusely
reactive for synaptophysin, NSE and NeuN. Other neuronal markers including chromogranin
and NFP can be focally positive. The lipomatous component shows cytoplasmic reactivity for
NFP, chromogranin, occasionally for GFAP and S-100 rimming the vacuoles. MIB-1 labeling
index is low (<1%) in the majority of cases [17].
g. Papillary glio-neuronal tumor (PGNT)
This tumor is characterized by pseudopapillae and less frequently by papillae, with hyalinized
cores lined by a single or multiple layers of hyperchromatic GFAP positive, S-100 positive
astrocytes that exhibit acidophilic cytoplasm. These are separated by sheets of synaptophysin
positive, Neu-N positive mature neuronal cells in the inter-papillary areas. The neurocytic
component includes neurocytes with vesicular nuclei and clear cytoplasm, ganglionoid cells
and ganglion cells [15]. A fibrillary or mucoid matrix is seen in the background and can form
nodules outside the papillary regions [30]. Sharp demarcation from the adjacent brain is seen.
Mitoses is rare or absent and microvascular proliferation and necrosis are not seen. MIB-1
labeling index is low usually in the range of 1-2%.
h. Rosette forming tumor of the 4th ventricle (RGNT)
This is another example of hybrid glial/neuronal tumor, that arises in midline structures,
mostly but not exclusively the 4th ventricle. It often shows involvement of the surrounding
periventricular tissue [30]. The neural component shows neuropil-rich rosettes and perivas‐
cular pseudorosettes that are lined by synaptophysin-positive neurocytes with clear cyto‐
plasm. A microcystic component with blue mucinous extracellular matrix is sometimes
described [17]. The glial component is in the form of pilocytic astrocytoma with Rosenthal
fibers and eosinophilic granular bodies [15]. No nuclear atypia or mitosis is seen. However;
vascular proliferation of the type seen in pilocytic astrocytoma can be encountered and should
not lead to the suggestion of anaplasia [30]. Reactivity for NSE and MAP2 can be seen in the
neural component, while GFAP and S-100 are positive in glial component. MIB-1 labeling
index is low.
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2.4. Choroid plexus tumors
These tumors originate within the ventricular system, and are composed of “epithelial-like”
cells reminiscent of choroid plexus [86].
a. Choroid plexus papilloma (CPP)
This is the most frequent entity in this group of tumors and is characterized by papillae lined
by a single layer of bland looking cuboidal to columnar epithelial-like cells with abundant
acidophilic cytoplasm, bland basal, round to oval nuclei [15]. Tubular or solid growths may
occasionally be encountered [86]. Rare mitotic figures, microscopic infiltration into adjacent
brain but not necrosis can be seen [14, 17]. Oncocytic changes, melanin deposition, calcification,
ossification, and xanthogranulomatous changes may occasionally be encountered [86].
b. Atypical choroid plexus papilloma (atypical CPP)
This recent addition is characterized by preservation of the papillary architecture similar to
papilloma, but with increased mitotic activity of ≥ 2 mitoses per 10 high power fields “Figure
23” [15, 87].
Figure 23. Atypical Choroid plexus tumor with typical papillary arrangement but several mitotic figures per high pow‐
er field (arrows).
The additional presence of at least 2 of the following features might warrant the diagnosis of
atypical CPP including increased cellularity, nuclear pleomorphism, solid growth and necrosis
[17]. However; these are not necessary for the diagnosis.
c. Choroid plexus carcinoma
This is the most aggressive entity in this group of tumors and is characterized microscopically
by blurring of the papillae with increased cellularity and pleomorphism in addition to features
of frank malignancy including brisk mitosis of >5 MF/10HPFs, and necrosis [15]. Diffuse
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invasion into brain parenchyma is often seen [17]. PAS positive, diastase resistant variably-
sized hyaline globules can be seen that are positive for alpha-1-antitrypsin [14].
The choroid plexus tumors are positive for cytokeratins, especially Cam 5.2, vimentin, S-100,
transthyretin, and GFAP, with stains being more positive in papilloma versus carcinoma. Two
recently described markers, stanniocalcin 1 and Kir 7.1 are claimed to be specific for choroid
plexus tumors. EMA is typically negative in choroid plexus tumors [17], while CK7/CK20 show
variable patterns and should be interpreted with caution [86]. MIB-1 proliferative index ranges
between 1.9% in CPP to 13.8% in CPC, with higher indices correlating with poor outcome [14].
2.5. Tumors of the pineal region
a. Pineocytoma
This is a histologically bland tumor composed of mature-looking pinealocytes [17]. The cells
are bland looking with amphophilic cytoplasm and round nuclei. Large fibrillary pineocy‐
tomatous rosettes and pseudorosettes can be seen. A pleomorphic variant is described with
giant cells and abnormally-shaped hyperchromatic nuclei and gangliocytic cells [88]. No
mitosis is seen in both variants. Immunostains are typically positive for NSE, synaptophysin,
chromogranin A and neurofilaments [89]. MIB labeling index is usually zero [90].
b. Pineal parenchymal tumor of intermediate differentiation (PPTID)
This group accounts for at least 20% of tumors of the pineal gland and shows intermediate
differentiation between pineocytoma and pineoblastoma [17]. They grow in sheets or lobules
and are composed of uniform cells with moderate nuclear atypia. Although occasional Homer
–Wright rosettes can be seen, pineocytoma-like rosettes are not reported. On the other hand;
this tumor lacks the primitive cell appearance and necrosis typically seen in pineoblastoma
[35]. According to the number of mitosis, proliferative index labeling and neurofilament
immunostains, these tumors are divided into two prognostically different groups [17, 89]. MIB
labeling index ranges between 5.2-11.2% [90].
c. Pineoblastoma
This is a small primitive tumor similar to CNS-PNET. It is hypercellular with proliferation of
primitive cells with scant cytoplasm, hyperchromatic nuclei, nuclear pleomorphism and
occasional prominent nucleoli. Frequent mitoses, necrosis and calcification can all be encoun‐
tered [91]. Immunostains for NSE, synaptophysin, chromogranin A and neurofilaments are
typically weak or negative [89]. MIB labeling index is around 36.4%-50% [90, 91].
d. Papillary tumor of the pineal region (PTPR)
This is the most recent addition to this group of tumors. It is seen both in children and adults. It
grows in papillae with hyalinized cores that are lined by epithelial-like cells. The cells are large
columnar to cuboidal, with pale to acidophilic cytoplasm and vesicular round nuclei, thus being
different from pineal parenchymal tumors. These tumors are positive for cytokeratin, S-100 and
vimentin with only focal positivity for GFAP [15]. EMA is usually negative or at best focally
positive; an important feature in the differential diagnosis with ependymoma [17].
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2.6. Other neuroepithelial tumors
a. Angiocentric glioma
This is probably a benign tumor that occurs in young adults with history of epilepsy. It is
cortically based and is characterized by monomorphous bipolar cells with an angiocentric
growth pattern, hence the name [15]. In most cases the cells tend to arrange themselves radially
around blood vessels. Additionally 2 important distinct growth patterns can be seen in a subset
of cases; the arrangement of the elongated tumor cells parallel to blood vessels causing
sometimes expansion of the perivascular spaces and the tendency of the tumor cells to
accumulate perpendicularly beneath the pia [17]. Immunostains are positive for EMA, GFAP,
S-100 and vimentin. Neuronal markers are negative.
b. Chordoid glioma of the third ventricle
This tumor usually arises from the anterior third ventricle and is characterized by cohe‐
sive clusters and cords of epithelial-like cells growing in a myxoid background [92], hence
the close resemblance to chordoma and chordoid meningioma [93], from which it should
be differentiated. The presence of lympho-plasmacytic infiltrate which can sometimes be
heavy with abundant Russell bodies is seen at the periphery and is helpful in supporting
the diagnosis.  Chondroid metaplasia can occasionally be encountered [94].  Reactivity for
GFAP and vimentin is the rule but with variable reactivity for S-100. EMA is positive in
the infiltrating plasma cells [20, 92].
c. Astroblastoma
A well circumscribed tumor that involves mostly the cerebral hemispheres, astroblastoma is
characterized by perivascular pseudorosettes with sclerosed fibrovascular cores, on which
broad cytoplasmic processes of astroblasts rest “Figure 24”.
Figure 24. In astroblastoma hyalinized blood vessels are surrounded by cells with broad-based cytoplasmic processes.
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This is in contrast to the fine tapering processes of classical ependymoma [20, 95]. A high grade
“malignant” variant is diagnosed when hypercellularity, increased mitoses, vascular prolif‐
eration and palisading necrosis are seen, otherwise the tumor is considered a low grade or
“benign” [14]. The tumor cell processes are strongly positive for vimentin and S-100, but focally
for GFAP with focal membranous EMA reactivity.
2.7. Recently described tumor entities that are not included in the most recent WHO
classification
a. Cribriform Neuroepithelial Tumor (CRINET)
This recently described tumor is composed of proliferation of a relatively small undifferenti‐
ated cells, arranged in cribriform, trabeculae, strands and focal compact areas exhibiting rosette
formation [96]. Well defined surfaces characterize the cellular strands, which exhibit elongated
nuclei but with no stratification. The cytoplasm is ill-defined and slightly acidophilic and the
nuclei posses dense chromatin and lack prominent nucleoli. Mitoses and necrosis are seen. The
tumor cells are immunoreactive for EMA highlights the surface as well as for vimentin, and
synaptophysin with focal expression of cytokeratin and S-100. Other markers including GFAP,
neurofilament, NeuN, chromogranin are negative. MIB-1 labeling index is elevated. Charac‐
teristically this tumor lack INI-1/Baf47 nuclear immunoreactivity, despite of lacking the typical
features of AT/RT including eccentric acidophilic cytoplasm, cytoplasmic inclusions and
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1. Introduction
Brain metastasis occurs with a fairly high frequency, in 25–35% of cancer patients [1]. Be‐
cause brain metastasis  directly affects  prognosis,  quality of  life  (QOL),  and performance
status  (PS),  treatment  is  crucial.  Survival  time is  reported to  be  1  month in  the  case  of
untreated brain metastasis [2], 2 months with steroid treatment alone [3], and 3-6 months
with whole-brain radiotherapy (WBRT) [4-7].  This  shows that  brain metastasis  is  a  seri‐
ously life-threatening condition.  Therapeutic  approaches have become more varied with
the  appearance  of  stereotactic  radiosurgery  (SRS),  and  establishment  of  multiple  treat‐
ment plans has become possible.  In addition to surgical resection (SR),  WBRT, and SRS,
systemic chemotherapy (SC) is also an option. The ideal treatment is to control the brain
metastasis  and prevent destruction of  the central  nervous system using combinations of
these therapeutic approaches. Among these multiple approaches, SR is effective in that it
enables  treatment  of  large  tumors  and early  improvement  of  symptoms,  which  are  not
possible with other approaches.  The indications for SR are expanded with the early im‐
provement of symptoms, leading particularly to improved QOL from the palliative view‐
point.  However,  SR  is  also  highly  invasive  compared  with  other  treatments,  and  the
indications are strict.  The standard surgical indication is single brain metastasis, and pa‐
tients with fairly good prognosis, such as those with good general condition, are selected
[8]. Recently, however, partly as a result of advances in imaging, the number of cases of
multiple brain metastases has been trending upward. This means that there are patients
in whom SR is excluded as an indication because of findings for multiple brain metasta‐
ses, and who cannot obtain the benefits of surgery. We provide aggressive treatment us‐
ing  the  same  surgical  indications  for  cases  of  multiple  brain  metastases  as  for  single
metastasis. The present study therefore investigated treatment outcomes and reported on
the effectiveness of SR for multiple brain metastases.
© 2013 Okuda and Kato; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
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2. Methods
Subjects were 100 patients with brain metastasis who underwent craniotomy and surgical
removal of tumors in the Department of Neurosurgery at Kinki University Hospital between
2004 and 2011. They included 54 patients with single brain metastasis and 46 with multiple
brain metastases. Details are shown in Table 1.
Characteristic Single Multiple
No. of cases 54 46
Age (mean) 63.3 61.3
Range 39-81 46-81












Size (mm, mean) 34.1 28.7
Table 1. Clinical characteristics of patients with single and multiple brain metastases
Surgical indications are shown in Figure 1, and treatments following surgery were done in
close conference with departments related to cancer, such as the Department of Radiation
Oncology and the Department of Medical Oncology. Each case was treated using a tailor-made
approach.
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Figure 1. Therapeutic strategies in brain metastases
The basic surgery was en bloc resection, with resection of a single site even in cases of multiple
metastases. During removal, we used fluorescence-guided surgery using fluorescein sodium
with transformation to a solid-type tumor by hydrofiber dressing for cystic lesions [9-11]. In
comparing survival time, duration of survival from the day of surgery until death was obtained
using the Kaplan-Meier method, and significant differences were determined with the log-
rank test. For all tests, a significance level of 5% was applied.




Subjects were 100 patients with brain metastasis who underwent craniotomy and surgical
removal of tumors in the Department of Neurosurgery at Kinki University Hospital between
2004 and 2011. They included 54 patients with single brain metastasis and 46 with multiple
brain metastases. Details are shown in Table 1.
Characteristic Single Multiple
No. of cases 54 46
Age (mean) 63.3 61.3
Range 39-81 46-81












Size (mm, mean) 34.1 28.7
Table 1. Clinical characteristics of patients with single and multiple brain metastases
Surgical indications are shown in Figure 1, and treatments following surgery were done in
close conference with departments related to cancer, such as the Department of Radiation
Oncology and the Department of Medical Oncology. Each case was treated using a tailor-made
approach.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors184
Figure 1. Therapeutic strategies in brain metastases
The basic surgery was en bloc resection, with resection of a single site even in cases of multiple
metastases. During removal, we used fluorescence-guided surgery using fluorescein sodium
with transformation to a solid-type tumor by hydrofiber dressing for cystic lesions [9-11]. In
comparing survival time, duration of survival from the day of surgery until death was obtained
using the Kaplan-Meier method, and significant differences were determined with the log-
rank test. For all tests, a significance level of 5% was applied.




Among the 100 patients, gross total resection was performed in 89%. Reasons for sub-total re‐
section were invasion into blood vessels or dura mater, huge tumor size, or tumor involving an
eloquent area. Follow-up treatments are shown in Figure 2. SC was also performed in 45 cases.
Figure 2. Postoperative treatments. Concurrent systematic chemotherapy was used in 45% of cases.
Central nervous system death occurred in 9% and 6 patients died within 3 months of surgery.
Three of these patients showed exacerbation of the primary cancer and three showed poor
control of brain metastases. For all 100 patients median survival time (MST) was 9.3 months,
the 1-year survival rate was 45%, the 2-year survival rate was 10%. A comparison of single and
multiple metastases is shown in Table 2.
Single Multiple
Median survival time (mo) 9.8 8.1
1- year survival rate (%) 44 46
2- year survival rate (%) 11 9
Table 2. Survival rate of single and multiple metastases
In this comparison by number of metastases, no significant differences were seen in survival
time, including 1-year survival rate, 2-year survival rate, or MST (Fig. 3).
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Figure 3. Comparison of survival times with single and multiple brain metastases. No statistically significant difference
was confirmed between the 2 groups (p=0.296).
In a comparison by number of metastases in patients with multiple metastases, no significant
difference in survival time was seen between patients with 2-3 metastases (MST, 8.8 months;
n=32) and those with ≥4 metastases (MST, 8.0 months; n=14) (Fig. 4).
Figure 4. Comparison of survival times according to number of metastases in cases of multiple brain metastases. No
statistically significant difference was confirmed between the 2 groups (p=0.149).
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In addition, new pathological findings were revealed through pathological diagnosis obtained
with SR, and the treatment strategy was changed in some cases. The case of a typical patient
is described below.
This patient was a 49-year-old woman who was undergoing chemotherapy for lung cancer
(adenocarcinoma). SC was continued for 4 courses, when she was switched to best supportive
care because of a lack of efficacy. In screening tests for headache and visual impairment, six
brain metastases were seen. At this point, multiple metastases to other organs were identified
and she was expected to live less than 3 months (Fig. 5A-C).
Figure 5. A) Contrast-enhanced MRI findings before treatment. A total of six metastases are seen, including a lesion
≥4 cm in diameter with ventricular invasion in the right occipital lobe. (B,C) Preoperative FDG-PET examination. Multi‐
ple metastases are seen in the lungs. (D) Contrast-enhanced MRI after treatment. All of the multiple lesions have dis‐
appeared. (E,F) FDG-PET examination following systemic chemotherapy. The lesions in the lungs are markedly reduced
in size.
Headache associated with increased intracranial pressure is difficult to treat, and SR was
performed for the right occipital lobe lesion with the aim of relieving symptoms. Symptoms
rapidly improved after surgery, and the pathological diagnosis was small cell cancer. Initially,
the diagnosis had been adenocarcinoma based on adenocarcinomatous tissue obtained from
bronchoscopic biopsy of the primary lung cancer. In fact, however, the tumor represented
mixed-type lung cancer with small cell cancer, and these brain metastases was thought to
represent a recurrence of the small cell cancer. WBRT was performed postoperatively and SC
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was applied using the approach used for small cell lung cancer. A marked decrease in systemic
lesions was seen (Fig. 5D-F). Ultimately, the patient survived 19 months after surgery. This
patient obtained a greater-than-expected benefit from surgery.
4. Discussion
Various biases are inherent in the treatment for brain metastasis, according to factors such as
the primary cancer or general condition. Moreover, because of the problem of brain function,
establishing a treatment plan can be difficult. In such circumstances, many reports with a fairly
high evidence level have described results for single brain metastasis. Reports on level I include
those of Patchell et al. [12] and Noordijk et al. [13] in the 1990s. SR + WBRT was established
for single brain metastasis based on these reports. In a report by Bindal et al. [14], SR for
multiple brain metastases was seen to be effective only in cases when all of the multiple brain
metastases could be removed. However, when all lesions could not be removed, no significant
difference was seen compared with WBRT alone, and SR was not considered effective. Based
on these findings, the priority came to be placed on WBRT monotherapy in cases of multiple
brain metastases, but treatment later diversified with active SRS intervention for brain
metastasis and in 1999 Kondziolka et al. [15] reported WBRT + SRS combination radiotherapy
for cases of multiple brain metastasis. With this approach, significantly longer survival times
were obtained compared with WBRT alone, and WBRT + SRS became the general therapy for
multiple brain metastases. In 2006, Aoyama et al. [16] also reported the efficacy of SRS
monotherapy for brain metastasis with ≤4 lesions. Various treatment strategies have thus been
reported, including not only conventional WBRT, but also combination with SRS and SRS
monotherapy. Recent reports have also suggested the efficacy of SC for multiple brain
metastases [17]. Up to this time, there has been little recognition of the efficacy of SC for brain
metastasis. A response rate of 60% has been reported, but the effect is temporary and MST is
less than 6 months in the majority of cases [18-20]. However, striking advances have recently
been made in SC, with the emergence of molecularly targeted drugs as a major breakthrough.
Drugs for lung cancer include gefitinib and erlotinib. The response rate to erlotinib is in cases
of brain metastasis with EGFR mutation, showing very high efficacy. In breast cancer, the
appearance of lapatinib is also reported to be effective against brain metastasis. SC will thus
likely become necessary as one therapeutic approach in brain metastasis, particularly for
patients with multiple brain metastases.
As mentioned above, various therapeutic approaches can be used for brain metastasis,
including SR, WBRT, SRS, and SC, and various combinations. In this situation, at our hospital,
we do not consider it necessary to select treatment based on the number of metastases, such
as single or multiple, and aggressively perform SR in cases of multiple metastases just as in
cases of single metastasis. Likewise in follow-up treatment, we implement tailor-made
treatment strategies matched to the individual patients. The results have shown no differences
in either MST or survival rate depending on the number of metastases, and good treatment
outcomes have been obtained in cases of multiple brain metastases. Today, when various
therapeutic approaches are available, performing SR to eliminate lesions at an early stage is
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highly effective. Early improvement of symptoms leads to improved PS and QOL, producing
new treatment opportunities. In addition, early elimination of brain metastatic lesions reduces
the steroid dosage as well as the possibility of radiation necrosis. The result is thought to lead
ultimately to longer survival times. In our investigation, prognosis tended to be better for the
group with fewer brain metastases (2-3 lesions), but the difference did not reach the level of
statistical significance. This suggests that there is no correlation between prognosis and the
number of metastases, including even single brain metastases. This is also supported by the
low probability of central nervous system death. The total number of patients in this study
was low (100 patients) and it was not a randomized controlled trial, so the results of evaluation
are not definitive. However, the advances in cancer treatment in recent years may necessitate
a rethink of the policy of determining treatment plans based on the number of metastases.
5. Conclusions
The efficacy of SR in multiple brain metastases was investigated. Survival time and sur‐
vival rate were not significantly different compared with single brain metastasis, and no
significant difference was seen in a comparison of survival time according to number of
metastases.  The  reasons  are  thought  to  be  that  tailor-made  therapeutic  strategies  using
the multimodalities advanced in recent years are effective. It may be time to rethink the
approach  of  determining  treatment  plans  based  on  the  number  of  metastases  in  thera‐
peutic strategies for brain metastases.
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1. Introduction
The 2008 American Cancer Society Registry data show that approximately 1.4 million Amer‐
icans are diagnosed with cancer every year of which 40% will go onto to develop brain
metastases. Consequently, the incidence of these secondary brain tumors is about four to
five times that of primary brain tumors [1, 2].
The past two decades have seen a large increase in treatment options, resulting in longer life
expectancy and better quality of life to a point where metastatic lesions are no longer the ma‐
jor cause of mortality in this patient group. This has made decision making on treatment mo‐
dality more complex. Evidence for local aggressive control through surgery and stereotactic
radiosurgery (SRS) [3–5] has resulted in a paradigm shift since the mid 1990’s when whole
brain radiation therapy (WBRT) was the mainstay of treatment. Now, treatment of metastat‐
ic tumors includes a full spectrum of medical providers including neurosurgeons, medical on‐
cologists, radiation oncologists, neurologists, and neuro-oncologists. This Chapter will focus
on the contemporary management of metastatic brain tumors using surgery, radiosurgery,
conventional radiation therapy, chemotherapy, steroids, anti-epileptics, and emerging modal‐
ities. Given the myriad of treatment options and the multiple providers utilizing them, the
substantiation for these treatments are vital for the clinician to make an evidence-based deci‐
sion. The information in this chapter will not only serve to guide the clinician in treatment
options, but also to focus the researcher on areas that need further investigation.
2. Radiation Therapy
Historically, whole brain radiation therapy (WBRT) was the mainstay for treatment of meta‐
static brain tumors. Today, it remains an important part of the treatment regime, although in
a more complimentary role.
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In the randomized control trial (RTC) of Patchell [6] a total of 48 patients were treated with
WBRT and either biopsy or complete surgical resection. The surgical group had a statistical‐
ly significant increase in survival (40 weeks) compared to the biopsy group (15 weeks)
(Ib/A). Freedom from death due to neurologic compromise, duration of functional inde‐
pendence and time to recurrence of a new brain lesion were all increased significantly as
well. All patients had a Karnofsky performance score (KPS) of at least 70 and patients with
acute neurological deterioration and radiosensitive tumors (SCLC, lymphoma, germ cell tu‐
mors, multiple myeloma or leukemia) were excluded from the study.
Another RCT done in Canada done by Mitz et al looked at 84 patients treated with WBRT
and surgery or WBRT alone [7]. This trial included patients who spent greater than 50% of
day in bed and MRI scans were not mandatory. They did not find any statistically signifi‐
cant difference in causes of death, quality of life, or overall survival. The lack of mandatory
MRI scans raised the possibility of patients with multiple lesions being included in the study
population.
Finally, a RTC done by Vecht et al [8] in the Netherlands looked at 63 patients and com‐
pared surgical resection plus WBRT to WBRT alone. Survival in the surgical group was sig‐
nificantly longer (10 months) compared with the non-surgical group (6 months). The
patients included in the trial were younger than 60 years, within 6 months of diagnosis, and
without progressive systemic disease.
In total, there are three randomized controlled trials (RCTs) [6-8] and three level II studies
[9-11] that show surgical resection plus WBRT is superior to WBRT alone for surgically ac‐
cessible single brain (verified by MRI) metastatic lesions in patients with limited extra crani‐
al disease who spend less than 50% of the day in bed. Taken together, there is level Ia/A
evidence supporting the use of surgical resection plus WBRT rather than WBRT alone.
3. WBRT dosing and fractionation schedule
There are 10 level I studies [12-20] including 9 RCT that have shown deviating from the
standard 30Gy in 10 fractions does not significantly change local control, neurocognitive
outcome or median survival in newly diagnosed adults with brain metastasis (Ia/A).
4. Surgical Resection
In the previous section we described the evidence for improved mortality outcomes in pa‐
tients with newly diagnosed single metastatic lesions undergoing surgical resection plus
WBRT compared to WBRT alone in terms of overall survival. Various groups have com‐
pared the effects of surgery alone to surgery plus WBRT given the known side effects of ra‐
dio therapy.
Patchel et al [3] studied 95 patients who underwent MRI verified complete surgical resection
and randomized them to receive WBRT or no further treatment. Tumor recurrence was 70%
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in the surgery alone group compared to 18% in the WBRT group (p<0.001). Recurrences
were lower for both the resection site and de novo lesions. There were fewer deaths from
neurologic causes in the WBRT (14% vs. 44%) but the study was not powered to analyze
overall survival. This RCT along with three retrospective cohort studies [21-23] provide lev‐
el Ib/A evidence for improved tumor control with surgical resection and WBRT compared to
surgical resection alone.
With the emergence of high dose single fraction radiotherapy groups have compared surgi‐
cal resection plus WBRT to stereotactic radiosurgery (SRS) alone. There has been one small
multicenter RCT in Germany by Muacevic et al [24] that enrolled a total of 64 patients with
KPS scores greater than 70 with single, small (<3cm) metastatic lesion into a surgical resec‐
tion plus WBRT group and a SRS group. Their primary outcome was overall survival but
they also looked at time of freedom from local recurrence. The only outcome that was statis‐
tically different between the groups was distant recurrence, which was higher in the SRS
alone group.
There have been four retrospective cohort studies [25-28] comparing surgical resection and
WBRT to SRS and WBRT. Taken together these studies provide level III/B evidence that sur‐
gical resection with WBRT is comparable to SRS with WBRT in terms of survival and local
recurrence. These studies also show that lesions larger than 3cm or those with significant
mass effect have better outcomes with surgical resection and WBRT.
5. Stereotactic radiosurgery
SRS has emerged as a less invasive focal treatment modality to treat metastatic lesion. There
have been two RCTs comparing single dose SRS and WBRT to WBRT alone.
Kondziolka et al [4] evaluated a total of 27 patients (KPS<70) with 2-4 solid metastatic le‐
sions less than 2.5cm in diameter and randomized them to receive SRS and WBRT or WBRT
alone. The primary outcome was image-defined local tumor control with median survival
being the secondary outcome. The study showed the local failure rate was 8% in the SRS
plus WBRT group compared to 100% in the WBRT group. The study was stopped prema‐
turely due to this significant benefit. This did not give the study enough power to look at
survival.
The other multicenter RCT [5] looked at a total of 272 patients with 1-3 solid metastatic le‐
sions (<4cm in diameter) and KPS of more than 70. They randomized patients into a group
undergoing WBRT plus SRS and WBRT alone. Their primary endpoint was median survival
which was statistically improved in the group receiving SRS (6.5 vs. 5.7 months). Superior
one year local control and improved KPS was also evident in the group receiving SRS.
There have also been three other retrospective series [29-31] looking at the above compari‐
sons which have supported the findings of the RCTs in regards to improved overall surviv‐
al, thus providing level Ia/A evidence for using single dose SRS with WBRT rather than
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el IIa/B evidence that SRS plus WBRT is superior in local tumor control and maintaining
functional status compared with WBRT alone in patients with less than 4 lesions.
There has been one RCT that compared SRS alone to WBRT plus SRS. This was a multi-insti‐
tutional study by Aoyama et al [32] that randomized patients with 1-4 solid brain metastatic
lesions (diameter <3cm) and KPS greater than 70 to received SRS alone or SRS with WBRT.
Median survival, which was the primary end point, was not statistically different between
the groups (8vs7.5 months). No difference was found in 1 year local control or neurologic
cause of death. Distant brain recurrence and the requirement for salvage therapy were sig‐
nificantly greater in the SRS alone group. There has also been a prospective cohort study
[30] along with 9 retrospective cohort studies [33-41] that have addressed this question. To‐
gether, there is level IIa/B evidence that SRS alone provides a similar survival advantage to
SRS and WBRT. There is also Ia/B evidence that WBRT provides improved distant site con‐
trol. For this reason patients only undergoing SRS require close monitoring so salvage thera‐
py can be delivered early to a de novo lesion.
A three arm prospective cohort study by Li et al [30] provides a comparison between SRS
alone and WBRT alone. The SRS alone group had improved neuroimaging response (87% vs.
38%), median time to progression (6.9 vs. 4 months) and longer median survival (9.3 vs. 5.7)
months. Although there have been no RCTs addressing this question data from the Li et al
trial and four other retrospective cohorts studies [42-45] provides level II/B evidence for SRS
alone being superior to WBRT alone in terms of survival for patients with up to 3 lesions.
6. Chemotherapy
Chemotherapy has remained the primary treatment modality for systemic metastases. How‐
ever, it is believed that brain metastases are selected to be chemoresistent because only re‐
sistant cells are able to survive systemic chemotherapy and make it to the brain.
Furthermore, the effectiveness of chemotherapy in the brain has remained a concern due to
the blood-brain barrier and active efflux pumps [46] limiting the effective dose in the central
nervous system. For this reason, chemotherapy has been less effective in treating CNS meta‐
stases. This is evident from a study [47] that involved treatment of metastatic SCLC which
showed decreased effectiveness from chemotherapy of CNS compared to system lesions.
There have been four RCTs [48-51] comparing WBRT plus chemotherapy to WBRT alone. A
multi-institutional RCT [48] studied patients who had histologically proven NSCLC and a
WHO performance status of 0, 1, or two and at least one brain metastasis on CT or MRI.
These patients either refused surgery or were deemed inoperable. The patients were
randomized to receive WBRT and Carboplatin or WBRT alone and the primary end point
was overall survival. The median survival was similar in both groups. The trial was halted
for poor accrual and did not show improved survival (Ib/A).
Another RCT was performed by Ushio et al [49] where patients with all lung cancer sub‐
types and projected survivals of greater than 4 months were randomized to WBRT, WBRT
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plus chloroethyl nitrosourea (CCNU), and WBRT plus CCNU plus tegafur. Patients were ex‐
cluded if they received any prior chemotherapy. The primary end point of tumor response
rates were 36%, 69%, and 74% respectively. The only statistically significant difference was
between WBRT and WBRT plus CCNU plus tegafur. The secondary end point of survival
showed no statistically significant difference (Ib/A).
The two other RCTs [50, 51] looked at temazolamide (TMZ) and radiotherapy and did not
show any statistically significant differences.
Taken together these studies provide level Ia/A evidence that adding chemotherapy to
WBRT does not improve survival. However, these trials did not take into account all histolo‐
gies, focusing on NSCLC and breast cancer and their results cannot be applied to chemo
sensitive tumors such as germinomas.
7. Re-treatment
There is very little data on managing recurrent metastasis. Detailed guidelines on this were
published by Ammirati et al in 2010 [52].
There have been three retrospective case series looking at the effects of repeating WBRT in
patients with brain recurrence following previous therapy. Post WBRT survival was 4-5
months in all series [53-55] (III/B).
Four case series [56-59] evaluated the effects of surgery on patients with recurrent or pro‐
gressive brain metastases. Median time to recurrence at local and distant sites was 5-8.4
months with survival ranging from 8.9-11.5 months (III/B).
There has been one prospective Phase/II study [59] that investigated the effects of SRS for
recurrent brain metastases. Twelve patients with progressive metastatic lesions, with at least
3 months of projected survival and who were previously treated with WBRT were given
SRS. The median survival was 6 months.
Currently, there is only enough evidence to give a level III/B recommendation for individu‐
alization of care based on functional status, extent of systemic and intracranial disease, pre‐
vious treatment type, primary cancer type, progression at original or distant site, and
enrollment in clinical trials. Taking this into consideration no further treatment of WBRT,
SRS or surgical excision can be recommended.
8. Prophylactic anticonvulsants
It is thought that brain metastases are unlikely to be as epileptogenic as primary gliomas
due to their less infiltrative nature. However, the role of prophylactic antiepileptic drugs
(AEDs) remains unclear. Mikklesen et al [60] has published evidence-based guidelines on




el IIa/B evidence that SRS plus WBRT is superior in local tumor control and maintaining
functional status compared with WBRT alone in patients with less than 4 lesions.
There has been one RCT that compared SRS alone to WBRT plus SRS. This was a multi-insti‐
tutional study by Aoyama et al [32] that randomized patients with 1-4 solid brain metastatic
lesions (diameter <3cm) and KPS greater than 70 to received SRS alone or SRS with WBRT.
Median survival, which was the primary end point, was not statistically different between
the groups (8vs7.5 months). No difference was found in 1 year local control or neurologic
cause of death. Distant brain recurrence and the requirement for salvage therapy were sig‐
nificantly greater in the SRS alone group. There has also been a prospective cohort study
[30] along with 9 retrospective cohort studies [33-41] that have addressed this question. To‐
gether, there is level IIa/B evidence that SRS alone provides a similar survival advantage to
SRS and WBRT. There is also Ia/B evidence that WBRT provides improved distant site con‐
trol. For this reason patients only undergoing SRS require close monitoring so salvage thera‐
py can be delivered early to a de novo lesion.
A three arm prospective cohort study by Li et al [30] provides a comparison between SRS
alone and WBRT alone. The SRS alone group had improved neuroimaging response (87% vs.
38%), median time to progression (6.9 vs. 4 months) and longer median survival (9.3 vs. 5.7)
months. Although there have been no RCTs addressing this question data from the Li et al
trial and four other retrospective cohorts studies [42-45] provides level II/B evidence for SRS
alone being superior to WBRT alone in terms of survival for patients with up to 3 lesions.
6. Chemotherapy
Chemotherapy has remained the primary treatment modality for systemic metastases. How‐
ever, it is believed that brain metastases are selected to be chemoresistent because only re‐
sistant cells are able to survive systemic chemotherapy and make it to the brain.
Furthermore, the effectiveness of chemotherapy in the brain has remained a concern due to
the blood-brain barrier and active efflux pumps [46] limiting the effective dose in the central
nervous system. For this reason, chemotherapy has been less effective in treating CNS meta‐
stases. This is evident from a study [47] that involved treatment of metastatic SCLC which
showed decreased effectiveness from chemotherapy of CNS compared to system lesions.
There have been four RCTs [48-51] comparing WBRT plus chemotherapy to WBRT alone. A
multi-institutional RCT [48] studied patients who had histologically proven NSCLC and a
WHO performance status of 0, 1, or two and at least one brain metastasis on CT or MRI.
These patients either refused surgery or were deemed inoperable. The patients were
randomized to receive WBRT and Carboplatin or WBRT alone and the primary end point
was overall survival. The median survival was similar in both groups. The trial was halted
for poor accrual and did not show improved survival (Ib/A).
Another RCT was performed by Ushio et al [49] where patients with all lung cancer sub‐
types and projected survivals of greater than 4 months were randomized to WBRT, WBRT
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors196
plus chloroethyl nitrosourea (CCNU), and WBRT plus CCNU plus tegafur. Patients were ex‐
cluded if they received any prior chemotherapy. The primary end point of tumor response
rates were 36%, 69%, and 74% respectively. The only statistically significant difference was
between WBRT and WBRT plus CCNU plus tegafur. The secondary end point of survival
showed no statistically significant difference (Ib/A).
The two other RCTs [50, 51] looked at temazolamide (TMZ) and radiotherapy and did not
show any statistically significant differences.
Taken together these studies provide level Ia/A evidence that adding chemotherapy to
WBRT does not improve survival. However, these trials did not take into account all histolo‐
gies, focusing on NSCLC and breast cancer and their results cannot be applied to chemo
sensitive tumors such as germinomas.
7. Re-treatment
There is very little data on managing recurrent metastasis. Detailed guidelines on this were
published by Ammirati et al in 2010 [52].
There have been three retrospective case series looking at the effects of repeating WBRT in
patients with brain recurrence following previous therapy. Post WBRT survival was 4-5
months in all series [53-55] (III/B).
Four case series [56-59] evaluated the effects of surgery on patients with recurrent or pro‐
gressive brain metastases. Median time to recurrence at local and distant sites was 5-8.4
months with survival ranging from 8.9-11.5 months (III/B).
There has been one prospective Phase/II study [59] that investigated the effects of SRS for
recurrent brain metastases. Twelve patients with progressive metastatic lesions, with at least
3 months of projected survival and who were previously treated with WBRT were given
SRS. The median survival was 6 months.
Currently, there is only enough evidence to give a level III/B recommendation for individu‐
alization of care based on functional status, extent of systemic and intracranial disease, pre‐
vious treatment type, primary cancer type, progression at original or distant site, and
enrollment in clinical trials. Taking this into consideration no further treatment of WBRT,
SRS or surgical excision can be recommended.
8. Prophylactic anticonvulsants
It is thought that brain metastases are unlikely to be as epileptogenic as primary gliomas
due to their less infiltrative nature. However, the role of prophylactic antiepileptic drugs
(AEDs) remains unclear. Mikklesen et al [60] has published evidence-based guidelines on




Forsyth et al [61] performed a RCT and studied anticonvulsant use in 100 patients with all
types of brain tumors and stratified them into primary and metastatic groups. Exclusion cri‐
terions were known seizures, life expectancy less than 4 weeks, allergies to AEDs, history of
substance abuse, and pregnancy. Most patients were treated with phenytoin. The primary
outcome was seizure occurrence at 3 months. The trial was halted early because the antici‐
pated seizure rate in the non AED arm was only 10% and the 3 month mortality was higher
than expected (30 vs. 15%). This lowered the power of the study and the authors reported no
difference between treatment groups.
Taking into account the known side effects of AEDs there is level III/B evidence for not us‐
ing them routinely for seizure prophylaxis in patients with newly diagnosed brain metasta‐
ses. Further studies are needed in this area and are currently underway.
9. Steroids
Steroids have an established role in controlling cerebral edema with dexamethasone typical‐
ly chosen due to its minimal mineralocorticoid activity. They are however not without side
effects including myelopathy, insulin resistance, and gastrointestinal bleeding. The role of
steroid use and timing are discussed in this section. Ryken et al [62] has published the evi‐
dence based guidelines on this topic in 2010.
Vechet et al [63] performed a RCT in patients with metastatic disease and a KPS of less than
80. This study evaluated the minimal effective dose of oral dexamethasone. The author
found no evidence for higher doses in patients who were not in immediate danger of hernia‐
tion. In moderately symptomatic patients doses of 4-8mg/day were equivalent to 16mg/day.
Given the minimal data, a level III/B recommendation can be made for the use of corticoste‐
roids with dexamethasone (4-8mg/day) as the glucocorticoid of choice, to provide tempora‐
ry symptomatic relief of elevated intracranial pressure. In patients experiencing severe
symptoms of elevated intracranial pressure a dose of 16mg/day can be recommended. Doses
should be tapered off over a 2 week period.
10. Emerging and investigational therapies
Plainly, successful control of brain tumors has not been uniformly achieved given the effica‐
cy and toxicity profile of the currently used modalities. Several new treatment modalities
are emerging including radiation sensitizers, local irradiation with balloon-based brachy‐
therapy, local chemotherapy with BCNU-impregnated polymers, and molecular targeting.
The evidence based guidelines for these modalities have been reviewed by Olson et al [64].
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11. Motexafin gadolinium
Motexafin gadolinium (MGd) is a metallotexaphrin that concentrates within tumors at high‐
er levels than within normal tissues. It is detectable on MRI scanners and although its exact
mechanism of action is unclear, it is thought to act as a radiation sensitizer. Two RCTs and
one prospective single arm study have studied this agent.
Carde et al studied the dosing of MGd and found 5mg/day with 30Gy of WBRT in 10 frac‐
tions to be best tolerated [65]. This led to a RCT of 410 patients that compared WBRT with
WBRT plus MGd in patients with brain metastasis [66]. Although the study showed no dif‐
ference in median survival or tumor response there was a 0.5 month delay in neurologic
progression in the MGd group. A Phase III RCT was then conducted that included 554 pa‐
tients with NSCLC. They were randomized to WBRT or WBRT plus MGd. No statistically
significant difference was found in neurologic progression between groups.
12. Efaproxiral
Efaproxiral is a radiation sensitizer that is thought to change the conformation of hemoglo‐
bin. This is thought to increased free radical formation by decreasing oxygen binding. The
two phase II studies done did not show any benefit in survival. There is level IIa/B evidence
that early use of efaproxiral with WBRT does not prolong survival.
13. Interstitial modalities
Interstitial modalities are defined as brachytherapy placed inside or next to the areas being
treated. There has been one retrospective cohort study by Ostertab and Kreth who implant‐
ed 125I seeds in spherical brain metastases with a diameter of 4cm or less, giving 60Gy to the
rim of the lesion [67]. No difference was found between WBRT and 125I to 125I alone. Two oth‐
er case [68, 69] series supported the feasibility of the modality but did not offer any evidence
for increased efficacy.
A phase II study by Rogers et al [70] evaluated the Glia Site Radiation Therapy System in
post resection surgical beds in patients with metastatic lesions. The system involved liquid
125I that could be injected via a balloon system from a subcutaneous reservoir. The median
survival was 40 weeks at 1 year of follow-up with tumor progression only being involved in
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Two single-arm studies evaluated surgery plus local chemotherapy with or without WBRT.
Nakagawa et al [71] used the DNA synthesis inhibitor 5-fluro-d-deoxyuridine (FdUrd) in
post resection tumor cavities via an Ommaya reservoir. This study only included 6 patients
and no comparative data were given. Ewend et al [72] prospectively studied 25 patients
with newly diagnosed solitary brain metastases treated with surgical resection. They used
the Gliadel Wafer and WBRT. Median survival was 33 weeks but again there was no compa‐
rative data (III/B).
Two case series [73, 74] investigated interstitial radiosurgery with the Photon Radiosurgery
System. Neither study had comparative data but showed a median survival of 8 months and
1-year survival of 53% (III/B).
Based on the current data there is no evidence to support the use of interstitial radiation,
chemotherapy or other modalities outside of clinical trials.
14. Molecularly targeted therapy
Currently there is no level 1 evidence for the use of molecularly targeted therapies in brain
metastasis. Given the promising theoretical advantage of these therapies prospective trials
focusing on survival, tumor control, and quality of life are warranted.
There have been a few case reports and single arm prospective studies [75-79] showing tu‐
mor response or stabilization in patients with metastatic NSCLC being treated with the re‐
ceptor tyrosine kinase inhibitor Gefitinib. Angiogenesis inhibitors such as bevacizumab, a
monoclonal antibody against vascular epidermal grown factor, is also being vigorously in‐
vestigated but no evidence based recommendation can yet be made.
15. Conclusion
Current treatment of brain metastasis is complex involving multiple specialists and modali‐
ties. Evidence based recommendations can be extremely helpful in making sense of the vast
array of treatment modalities when properly understood and utilized. They allow for con‐
temporary treatment regimens affording maximal patient survival and delayed neurologic
progression while pointing out gaps in current knowledge to direct future research. A key
knowledge gap is in quality of life outcomes. Also, little data exists for creative combination
treatments such as post-operative SRS to the operative bed without WBRT with frequent
surveillance imaging and for resection of 2+ metastatic lesions. The complete evidence based
guidelines [80] for metastatic brain tumors has recently been published and should be re‐
viewed by all clinicians who treat patients with brain metastasis.
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1. Introduction
Epilepsy in the general population occurs with an incidence of 44 per 100,000 person-years in
a population based study [1]. Symptomatic etiologies such as vascular injuries, infection, and
neoplasm are usually associated with a higher incidence of seizures and epilepsy. In the cancer
population, seizures arise mainly as a result of an infiltrative neoplastic process in the brain.
However, cancer treatment, metabolic causes, and paraneoplastic disease can also cause
seizures in this population despite the absence of a structural lesion. The etiology of epilepsy
in brain tumor patients includes primary malignancies and metastatic disease to the brain. A
multifaceted approach is required for treatment of seizures including surgery, radiation
treatment, chemotherapy, and antiepileptic drugs. A combination of treatments has the
potential of adverse effects and generally requires a multidisciplinary team.
This chapter will review the causes of epilepsy in cancer patients, incidence, treatment, the
role of electroencephalogram (EEG) and antiepileptic prophylaxis in this group of patients.
The factors which predispose seizures in these patients will also be reviewed, such as tumor
grade, histology and brain tumor morphology.
2. Incidence
The cumulative incidence of seizures in the general population is almost 10% by age 74. More
than 4% of the population has one unprovoked seizure by age 74 and 3% will develop epilepsy
[2]. Symptomatic etiologies such as brain tumors account for a higher percentage (30%-49%)
of all unprovoked seizures and epilepsy. Although brain tumors account for 4% of all epilep‐
sies, symptomatic seizures can occur in up to 85% of patients depending on tumor type and
location. In 30%-50% of patients with brain tumors a seizure is the presenting clinical sign.
© 2013 Avila; licensee InTech. This is an open access article distributed under the terms of the Creative
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However, up to 30% will develop seizures later in the course of their disease [2]. In the cancer
population seizures can occur for numerous reasons including primary brain tumors, brain
metastasis, paraneoplastic syndromes, and other etiologies such as toxic/metabolic, infection,
or from a reaction to cancer treatment [3]. Drug interactions and adverse drug effects are
important considerations in this population as many treatments may have neurologic adverse
effects and seizures are one such problem.
Incidence rates of epilepsy based on etiology including brain tumors, traumatic brain injuries,
central nervous system (CNS) infections, cerebrovascular disease, and other causes have been
determined [4]. Symptomatic etiologies such as brain injuries and brain tumors account for a
higher percentage (30%-50%) of all unprovoked seizures and epilepsy.
The incidence of seizures in patients with systemic cancer is estimated to be 5%, but for patients
with an intracranial neoplasm, seizure incidence may be as high as 30% [5,6]. There are several
factors which affect the incidence of seizures in brain tumor patients and these include age,
location of the lesion, histology, and the grade of the tumor. With regard to age, there is a
higher incidence in young patients and those over age 65 which mirrors the incidence of
epilepsy in the general population [7,8]. The reason for this finding is likely the higher
incidence of low grade brain tumors in children versus adults and the subsequent longer
survival rate [9].
3. Etiology
Location, grade, histology and tumor morphology are important contributors to seizure
incidence.
Cortical location is an important determinant for the development of seizures as neural
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Histology is an important contributor to the development of seizures and subsequent tumor
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has been shown to be directly correlated with the incidence of seizures [12]. There are several
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tissue and prevent normal regulation. Low-grade brain tumors such as gangliogliomas and
dysembryoplastic neuroepithelial tumors can have an almost 100% incidence of seizures
whereas the incidence rate is 60%-85% in low-grade astrocytomas and oligodendrogliomas
(Fig. 1) [13].
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Several other factors can affect epileptogenesis including imbalance between excitatory and
inhibitory pathways. Higher levels of excitatory neurotransmitters such as glutamate can
result in excitability of cortical neurons and therefore seizures [15]. Alkaline pH levels in
peritumoral brain tissue can also lead to epileptogenesis by disrupting levels of intracellular
and extracellular Na.
Morphologic changes in the peritumoral brain tissue such as aberrant neuronal migration,
persistent neurons and white matter, and changes in synaptic vesicles can result in seizures in
brain tumor patients. Changes in receptor binding sites for excitatory and inhibitory neuro‐
transmitters (GABA, NMDA) can affect epileptogenicity [16]. One example of this phenom‐
enon is seen in gliomas as they have been shown to have higher concentrations of inotropic
glutamate receptors which can lead to neuronal hyperexcitability with resultant seizures and
possible cell death [17].
Metastatic  lesions  account  for  a  smaller  percentage  of  patients  with  intracranial  neo‐
plasms who go on to develop seizures and epilepsy. Systemic cancers which occur more
commonly,  such  as  lung  and  breast  cancer,  tend  to  have  a  higher  incidence  of  brain
metastasis  and subsequent seizures.  Some cancers have a higher predilection for central
nervous  system metastasis  such  as  melanoma and,  depending  on  location,  may have  a
higher seizure frequency [18].
4.2. Treatment-related causes of seizures
Chemotherapy. Various chemotherapeutic agents can be toxic to the central nervous system
either directly or through other mechanisms which result in epileptogenesis or lower seizure
threshold.
Agents such as cytarabine, methotrexate, high-dose cisplatin, bevacizumab, ifosfamide,
vincristine, and nitrosoureas can cause seizures by direct central nervous system toxicity when
given systemically or in the case of methotrexate when given intrathecally [19].
Radiation therapy. For patients undergoing whole brain radiation for brain metastasis,
leptomeningeal disease, and for primary brain tumors, seizures can occur as a direct result of
radiation. Complications can occur acutely such as during radiation treatment. They can occur
early within weeks to months after radiation or they can occur late, 1-2 years after receiving
radiation treatment from radiation necrosis [19, 20].
4.3. Toxic/metabolic
Medication toxicity or withdrawal can result in symptomatic seizures. This can occur with
numerous different agents including antimicrobials, antipsychotic medication, antidepressant
medication, and, of course, antiepileptic drug medication.
Conditions which can cause seizures even in patients without cancer can also contribute to
seizures in those with a brain tumor such as renal or liver failure. Electrolyte disturbance
including disturbances of sodium, calcium, magnesium and glucose can precipitate seizures.
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Glucose disturbances in particular can also result in focal neurologic disturbances such as
seizures or stroke-like syndromes [21].
4.4. Paraneoplastic syndromes
There are several paraneoplastic syndromes which have been characterized and which
seizures are one symptom. Paraneoplastic limbic encephalitis has been associated with
numerous antibodies including anti-Hu, anti-Ma2, CRMP5, and amphiphysin. Recently,
antibodies have been associated with encephalitis and seizures in patients who may or may
not have a neoplasm. One such antibody has been the NMDA receptor antibody which was
initially described in women with ovarian teratoma but has also been found in children without
cancer [22].
5. Treatment
Treatment will be discussed for patients with brain tumor epilepsy. In general, treatment for
patients with systemic cancer without intracranial lesions will consist of antiepileptic drugs
only. In patients with intracranial lesions, there is a multifaceted approach which includes
antiepileptic drugs, surgery, chemotherapy, and radiation therapy.
5.1. Antiepileptic drugs
Antiepileptic drugs are a mainstay of treatment for seizures of any etiology. In patients with
cancer this is also true, but a consideration of drug interactions and drug metabolism is
important as patients receiving chemotherapy, with or without corticosteroids, can have
untoward drug interactions in combination with antiepileptic drugs [23]. This is usually the
case for some of the first generation antiepileptic drugs which can be hepatic enzyme inducers,
specifically of the cytochrome P-450 pathway. Drug interactions can also occur with antiepi‐
leptic drugs that are enzyme inhibitors. A benefit of the second and third generation antiepi‐
leptic drugs is that many are not metabolized through the same hepatic pathways as
chemotherapy agents or corticosteroids. In addition, there is less protein binding with these
agents which makes them more suitable for treatment in patients receiving concurrent
chemotherapy (Table 1).
Enzyme-inducing antiepileptic drugs can decrease the effects of corticosteroids and in turn
corticosteroids can also alter the metabolism of antiepileptic drugs resulting in decreased
serum levels [24]. Enzyme-inducing antiepileptic drugs can also have an effect on the serum
drug levels of chemotherapeutic agents such as nitrosureas, paclitaxel, cyclophosphamide,
etoposide, doxorubicin, and methotrexate. Temozolomide, an alkylating agent commonly
used for treating high-grade gliomas, has minimal CYP metabolism. One study documented
no effect of temozolomide on levels of topiramate or oxcarbazepine [25].
Treatment of seizures with antiepileptic drug therapy in brain tumor patients has been
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adjunctive treatment with agents such as levetiracetam, lamotrigine, or topiramate have been
reviewed and shown to be safe and efficacious in the brain tumor population. There are varying
degrees of success with reports of seizure reduction in many patients and a smaller percentage
achieving seizure freedom. Follow-up in these studies has been variable and difficult to
compare.
Side effects of antiepileptic drug treatment are an important consideration. In patients with
brain tumors who have undergone craniotomy, radiation treatment, and who may or may not
be receiving chemotherapy, additional toxicity from antiepileptic drugs can be additive.
Common side effects such as cognitive impairment, bone marrow suppression, liver dysfunc‐
tion, electrolyte abnormalities, and dermatologic reactions are important considerations in
patients receiving this antiepileptic drug therapy. Side effects are more frequent in patients
with brain tumors compared to the overall population with epilepsy as was noted in the 2000
AAN Practice Parameter [33].
A benefit to the newer antiepileptic drugs is that there are fewer interactions with chemo‐
therapy, they can be used in clinical trials aimed at treatment of brain tumors, and at times
there can be a better side effect profile. However, side effects from antiepileptic drugs can
be seen more often in patients with brain tumors. This is likely because patients with brain
tumors have fixed neurologic deficits which can be worsened in the setting of drug toxicity
of any kind.
Treatment with antiepileptic drugs in the cancer population should be similar to treatment for
anyone with localization related epilepsy. Monotherapy should be the goal with the lowest
possible dose to control seizures and to avoid adverse side effects. Drugs which control focal
seizures with secondary generalization are desired and agents such as lamotrigine, carbama‐
zepine, and oxcarbazepine are generally well-tolerated [34]. Other agents which can have an
Enzyme inducers (CYP 450) Non-enzyme inducers
Phenytoin Gabapentin
Carbamazepine Lamotrigine
Phenobarbital Valproic acid (enzyme inhibitor)







Table 1. List of antiepileptic drugs comparing those metabolized through the CYP 450 pathway and those that are
not
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effect on this population such as topiramate or valproic acid can be used. However, cognitive
side effects with topiramate may limit its dosing and therefore its efficacy. Valproic acid would
appear to be a good agent; however, it can cause drug interactions and liver toxicity. In patients
already receiving chemotherapy, the potential for liver toxicity and thrombocytopenia can be
a problem with valproic acid [35]. Valproic acid does have possible antitumor effects due to
inhibition of histone deacetylase (HDAC) [36]. There is recent evidence that in patients with
glioblastoma undergoing standard treatment, radiation treatment with concurrent temozolo‐
mide, receiving valproic acid for the treatment of seizures may be a survival benefit [35].
However, prospective studies examining this issue have yet to be performed. Whether this
survival benefit was seen due to HDAC effects or hepatic enzyme inhibitory properties was
unclear. In contrast, a study examining 620 patients with newly diagnosed glioblastoma found
an overall survival benefit and progression-free survival in patients who received an enzyme
inducing agent versus those who did not [37]. The role of enzyme inducing AEDs on survival
has not been established in the brain tumor population but is something that should be
prospectively analyzed in new clinical trials.
Levetiracetam and gabapentin have ideal properties in that neither is liver metabolized and
there are few if any drug interactions. In several retrospective studies, levetiracetam has been
well-tolerated in brain tumor patients but can be associated with mood disturbances [29, 30,
38]. Cognitive side effects and fatigue are also seen with use of this agent which can be
compounded in patients who have received brain radiation.
Author N Type Grade Primary AED Add-on
AED




234 R HGG VPA, CBZ, GBP,
LMT, others
13 NA
Maschio et al.27 14 P HGG, LGG LEV, VPA, LTG,
others
LCS 43 78
Wick et al.28 107 R HGG, LGG PHT, VPA, CBZ 30
Wagner et al.27 26 P HG VPA LEV 20 65
Mashio et al.30 19 P HG LTG, VPA, TPM,
OXC
LEV 47 72
Newton et al31 41 R HG PHT, CBZ LEV 59 90
Mashio et al.25 47 P HG, LG, BM PHT, CBZ, PB TPM 56 76
Perry et al.32 14 P HG PHT, CBZ,
Clobazam
GBP 57 100
N- number of patients; R- retrospective; P- prospective; HGG- high grade glioma; LGG-low grade glioma; HG- High grade;
LG- low grade; BM-brain metastases; LEV-levetiracetam; VPA-valproic acid; LTG- lamotrigine; GBP-gabapentin; CBZ-
carbamazepine; OXC-oxcarbazepine; LCS-lacosamide; TPM-topiramate; PB-phenobarbital
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There are generally two approaches to surgery for brain tumor patients. The first and most
important is gross total resection of either the primary brain tumor or a metastatic lesion. A
secondary consideration can be additional removal of a seizure focus (lesionectomy) for
patients who present with seizures as a symptom of their brain tumor. Circumstances which
can limit lesionectomy are the location of the seizure focus in an eloquent area of cortex. In the
brain tumor population, surgery is almost always geared towards gross total resection which
has shown on its own to improve outcomes from a seizure standpoint [39]. However, there
remains a significant population of patients who undergo brain tumor surgery and continue
to have seizures postoperatively. Patients with lesions near the motor cortex are more likely
not to be surgically "cured" as the lesion causing seizures is unlikely to be amenable to surgical
resection. Therefore, these patients remain with symptomatic partial epilepsy.
In tumor associated epilepsy, seizures generally arise from the peritumoral brain tissue and
not from the mass. Tumor tissue is generally electrically inert and does not give rise to seizures.
Electrocorticography (Ecog) performed intraoperatively may assist in identifying a seizure
focus and aid the neurosurgeon in removal of the lesion. A study reviewing 35 patients with
intractable temporal lobe epilepsy due to benign lesions (ganglioglioma, DNET, cavernoma)
found 3-year post-operative seizure rates to be improved in patients who underwent Ecog
with additional removal of spike-positive areas [40]. However, there is no universal standard
established.
For temporal lobe lesions, the additional resection of mesial structures may be beneficial in
some cases. A series with patients with low grade temporal lobe tumors (DNET, ganglioglio‐
ma) with associated hippocampal sclerosis suggest that lobectomy with hippocampectomy is
preferable to tumor resection alone [41]. Overall, prognostic factors which favor control of
epilepsy with surgery are a shorter duration of epilepsy prior to surgery, a single focus on
EEG, a single lesion on neuroimaging, and complete tumor resection [10,41,39].
5.3. Chemotherapy
Chemotherapy is one of the primary treatment modalities for all types of metastatic and
primary central nervous system tumors. The use of chemotherapy can result in seizure
reduction for patients with primary brain tumors. Recent studies retrospectively reviewing
the use of temozolomide or nitrosoureas in patients with low grade glioma have shown a
reduction in seizures with some patients achieving seizure freedom [42-44].
Additionally, in patients with subependymal giant cell astrocytomas with tuberous sclerosis
complex, the mTor inhibitor, everolimus, has been associated with reduction of subependymal
tumors and subsequent improvement in seizures. Whether this agent is antiepileptogenic in
itself or causes a reduction of tumor bulk which improves seizures remains to be seen [45].
5.4. Radiation therapy
Treatment for glioblastoma with surgery followed by radiation with concurrent temozolomide
has been established as a standard of care. There have been small studies which have shown
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that radiation treatment for malignant lesions has also resulted in improvement in seizures
independent of antiepileptic drug adjustment [46, 47]. The EORTC 22845 randomized trial of
long-term efficacy of early versus delayed radiation treatment for low grade brain tumors
revealed an improvement in seizure frequency at one year post treatment. Although later data
points were not collected, this study shows what has been evident in clinical practice which is
that radiation treatment for low-grade brain tumors can improve seizure frequency [48].
6. Antiepileptic drug prophylaxis
6.1. Postsurgical patients
The role of prophylactic anticonvulsant medications in the perioperative period has been
reviewed for numerous tumor types including primary brain tumors and brain metastasis.
Prophylaxis appears effective for preventing early postoperative seizures but does not appear
to affect the delayed development of epilepsy [49]. Current practice is to use prophylactic
anticonvulsants during the first week after surgery and then to discontinue after that time
period [50]. The data on these recommendations are derived from the older anticonvulsants,
phenytoin, phenobarbital, and valproic acid. The newer generation antiepileptic drugs have
not been studied as rigorously in this setting and therefore recommendations for their use is
limited. However, recent studies using levetiracetam in this setting have been promising in
that there are few if any drug interactions and minimal adverse effects related to the use of
this drug [51,52]. Certain tumor types may not benefit from the use of prophylactic anticon‐
vulsants in the perioperative period, such as meningioma, as seen in a recent meta analysis
[53]. Prospective studies are needed to determine the validity and efficacy of prophylactic
anticonvulsants in the perioperative period with newer generation antiepileptic drugs. In view
of the minimal drug interactions and favorable side effect profile of these drugs, they may have
a role in early seizure prophylaxis after craniotomy.
6.2. Brain tumor patients
Both the American Academy of Neurology and the Association for Neurologic Surgeons/
Congress of Neurologic Surgeons recommend against routine prophylaxis with antiepileptic
drugs for patients with primary brain tumors or brain metastasis without a history of seizures
[33,54]. Treatment is recommended only after patients with brain tumors experience a seizure.
7. Role of Electroencephalogram in brain tumor patients
Altered mental status is a common clinical manifestation in patients with brain tumors and
seizures are one cause of altered mental status. In patients with overt clinical seizures, the
diagnosis is usually not in question and therefore treatment can be started immediately for
this potentially life-threatening problem. However, in patients with subtle clinical signs of
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The workup in patients in whom seizures are suspected can be accomplished with routine
bedside EEG or long-term monitoring (LTM) with continuous video EEG recording. The use
of LTM has increased, especially in intensive care unit (ICU) settings. One study reported
seizures in 110 (19%) of 570 critically ill patients who had continuous video EEG, most of whom
were in an ICU setting. Of note, 101 of these patients had nonconvulsive seizures. Therefore,
in that setting, seizures would have been missed had EEG not been used [55]. Clinical suspicion
should be high in patients with structural brain lesions with altered mental status and an EEG
may be beneficial for evaluating these patients.
8. Conclusion
Epilepsy in cancer patients can be from numerous causes including the cancer itself, cancer
treatment, or toxic metabolic etiologies. Numerous factors contribute to the development of
epilepsy in these patients. Adverse effects due to cancer treatment and antiepileptic drugs
should be recognized early as patients with brain tumors and epilepsy are more likely to
experience adverse effects. Treatment will be multifaceted and include antiepileptic drugs,
surgery, chemotherapy, and radiation treatment. A multidisciplinary approach is usually
needed for treatment of these complicated patients.
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1. Introduction
Hughlings Jackson, in the nineteenth century, first noted that epilepsy could be the only clinical
manifestation of a primary brain tumour [1] (Figure 1). Among patients with epilepsy, the
incidence of brain tumours is about 4% [2] whereas the prevalence of epilepsy among patients
with brain tumours is over 30% [3] Seizures will herald the presence of a cerebral glioma in
20-45% of patients [4,5] and another 15-30% of patients will develop seizures during the course
of the condition [6]. In particular, epilepsy occurs in over 80% of patients with low-grade
gliomas [7] and 30-60% of those with high-grade gliomas [8]. Factors which favour epilepto‐
genesis in low-grade tumours appear related to slow growth kinetics coupled with cerebral
location [9,10]. The relative risk for a cerebral tumour following a diagnosis of epilepsy
approaches 20-fold overall compared with control and, when differentiated between malig‐
nant and benign tumours, it is about 26-fold and 10-fold, respectively [11]. It is highest for
those aged 15-44 years at the time of diagnosis of the epileptic condition and will persist for
several years afterward.
Apart from the adversity brought about by the growth of a cerebral tumour, a tumour-
associated epilepsy adds further disadvantage for the patient with its impact on the quality of
life and on the course of treatment. Epilepsy in brain tumour patients is often refractory to
pharmacological therapy. The unpredictability of seizure occurrence, particularly those
associated with a loss of consciousness, denies patients the ability to move freely in society,
promoting a sense of isolation. Adverse effects of antiepileptic medications, particularly when
taken in combination in those cases that are difficult to bring under control, may add to the
burden of those imposed by therapy dedicated to the tumour itself. Debate has also arisen over
the effect of some enzyme-inducing antiepileptic medications upon such therapy as certain of
these agents will induce hepatic P450 microsomal enzymes that could accelerate the metabo‐
lism of chemotherapeutic agents. Particular attention must be given to the view that, in
addition to the optimal removal of tumour, surgical intervention should be dedicated, as best
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as possible, to the elimination of the associated epilepsy with the ultimate aim of withdrawing
the antiepileptic medical regimen altogether. This requires a greater perspective upon the
neurobiology of this attendant condition in order to effect as best an outcome as possible for
the patient.
As more is becoming known of tumor biology and the putative factors underlying epilepto‐
genesis, a periodic review of the current status of glioma-associated epilepsy in this context is
mandatory. This chapter will review the principal clinical features of the epileptic condition,
its neurobiology as it pertains to etiological mechanisms, in particular, and the therapeutic
options, both medical and surgical, that seek to control it.
2. Neurobiology
The fundamental characteristic of epilepsy is the presence of recurrent, usually unprovoked
seizures that, when viewed electrographically, consist of paroxysmal, self-limiting, excessive
and synchronous discharge of a population of neuronoglial elements comprising a coherent
network, often limited in its topography. These elements are contained predominantly in the
cerebral cortex and, at the cellular level, manifest as unrestrained excitation attributable to
deregulatory mechanisms affecting membrane depolarization and repolarization. It is
important that we attempt to understand the phenomenon of epilepsy from a cellular and
molecular level by addressing the constituent elements that give rise to a region of excitability
Figure 1. Axial contrast-enhanced computed tomography (CT) images identify a large left temporo-occipital glioblas‐
toma. This 58 year old man acquired a medically intractable complex partial epilepsy 3 years previously and was inves‐
tigated then by noncontrast CT imaging which showed no abnormality. The presence of an implanted cardiac
defibrillator precluded magnetic resonance imaging.
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and from a network perspective to establish the relatedness of neuronoglial populations that
interact with one another to perpetuate the condition.
Previous literature regarding localization-related epileptogenicity referred to irritative and
ictal onset zones wherein the former designated the cerebrocortical area that generated
interictal spikes and the latter, that area responsible for initiating actual seizure activity. The
two zones, although related, were not necessarily congruent as in a perilesional environment.
This conceptualization is being supplanted by the realization of multiple limited functional
connectivities that exist in the brain which itself is seen as a complex integrated master network.
These connectivities are defined by statistical interdependencies or coherences as identified
by neurophysiological time series, particularly by electroencephalography (EEG) and magne‐
toencephalography (MEG) [12,13]. In essence, the strength of connections among network
nodes and their directionality may define for us the extent of epileptogenic territory. An altered
functional connectivity has been proposed in the case of both mesial temporal lobe epilepsy
[14] and tumour-associated epilepsy [15] patients. A pathologically increased theta or low
frequency band connectivity was found to be related to increased seizure activity in brain
tumour patients raising some consideration as to whether such findings may shed light on
peritumoural epileptogenesis. Greater appreciation of such local network behavior and the
integration of EEG, MEG and resting state functional MRI will allow a more definitive
interpretation of seizure vulnerability and a better disclosure of perilesional epileptogenicity
as it relates to network topology for use in the planning of surgical intervention.
At the cellular level, it is insufficient to describe epileptogenicity as a neuronal phenomenon
as the intimacy of neuronoglial interaction declares an inseparability of function of these two
essential cell types. The impact of astrocytes on neuronal function through influences upon
synaptic function and plasticity, provision of energy and regulation of local blood flow and
blood-brain integrity is profound [16]. Protoplasmic astrocytic processes surround neuronal
synapses and form gap junctions among one another [17] allowing electrotonic communication
through a local syncytium. Astrocytes bear sodium and potassium channels and demonstrate
excitability through regulated increases in intracellular calcium concentration [18,19]. These
elevations can be triggered by glutamate released during neuronal activity propagated to
neighbouring astrocytes via gap junctions and, in turn, cause the release of glutamate from
astrocytes into the extracellular space triggering receptor-mediated currents in neurons remote
from the original site of stimulation [20-24]. Higher concentrations of glutamine have been
found in gliomas [25] and glioma cells have been shown to take up and release glutamine [26,
27] providing a potential reservoir of precursor for glutamate production in the peritumoural
area. Otherwise, glutamate uptake has been demonstrated to be 100-fold lower in human
glioma cells compared to that in astrocytes and has been attributed to a reduction of sodium-
dependent glutamate transporters and an upregulation of cystine-glutamate exchange [28].
In fact, marked glutamate release in murine brain slices implanted with human-derived glioma
cells has been shown to induce epileptiform hyperexcitability in adjacent brain tissue [29].
Administration of sulfasalazine, an inhibitor of glutamate release, to tumour-bearing mice
reduced ictal behavior compared with untreated controls. Certain antiepileptic agents will also
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Synaptic interstitial homeostasis is provided by astrocytic processes through the maintenance
of fluid, pH and transmitter balance. The aquaporin 4 (AQP4) water channel and transporters
for potassium uptake [31, 32], proton shuttling mechanisms [33] and transporter-mediated
clearance of synaptic glutamate, glycine and gamma aminobutyric acid (GABA) [34] coupled
with the ability for an astrocytic gap junction-mediated syncytium to dissipate detrimental
accumulation of all such elements [35] argues for the essential nature of the neuonoglial
relationship. Glutamate also modulates astrocytic glycogen storage [36] and neuronal activity
may influence the passage of glucose metabolites through this same syncytium [37]. Reactive
astrocytosis in a peritumoural environment may contribute to epileptogenesis through the
release of glutamate [38, 30], compromise of blood-brain barrier integrity through production
of vascular endothelial growth factor [39], production of excess reactive oxygen species [40],
accentuation of inflammation through cytokine production [41, 139] and through AQP4
overactivity [32]. In the end, there are several putative epileptogenic mechanisms involving
the neuronoglial relationship which, individually or in concert, may promote and sustain ictal
behavior. Both the local infiltrative and structurally disruptive process of gliomatous invasion
and the altered neurochemistry of the peritumoral environment undoubtedly combine to bring
about the epileptogenicity.
Reduced numbers of both GABA- and somatostatin-containing interneurons in the area
adjacent to low-grade gliomas [42] suggests a change in peritumoural neuronal phenotype and
an alteration in the excitatory-inhibitory balance. A similar reduction in somatostatinergic
neurons has been demonstrated in the human hippocampus in mesial temporal epileptoge‐
nicity [43, 44] and in animal models of experimental epilepsy [45]. Other cellular alterations
demonstrated in animal models have raised suspicion regarding similar evolution in human
peritumoural epileptogenicity. Particular attention has been given to synaptic vesicle protein
2A, a membrane glycoprotein present in synaptic vesicles of neurons and a calcium regulator
in neurotransmitter release [46], as it is the binding site for the antiepileptic, levetiracetam [47].
It has been shown to have a low distribution in the cerebral cortex and hippocampus of
spontaneously epileptic rats [48] and its removal in knockout mice promotes severe seizure
development [49]. Expression of SV2A in human peritumoural cortex in both low- and high-
grade gliomas, however, was no different between those patients identified with epilepsy and
those without, suggesting different mechanisms of regulation of SV2A than in the models
examined (50).
Further attention has turned to signaling pathways that trigger epileptogenesis following a
cerebral insult. In particular, serine/threonine kinase (mTOR) activates several downstream
processes involved in protein synthesis, ribosomal biogenesis, cell growth and proliferation
[51]. As a consequence, it will respond to aberrant events in order to initiate a cellular reaction
and, indeed, has been found to be dysregulated in neurological disease including brain
tumours [52, 53]. Inhibition of mTOR by rapamycin attenuates the development of epilepsy
and interferes with epileptogenesis in the kainate model [54]. Its delivery even following an
induced status epilepticus succeeded in blocking the chronic phase of mTOR activation
demonstrating not only an antiepileptic but an antiepileptogenic effect.
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The influence of inflammatory factors in the mediation of epileptogenesis has also been
addressed in recent years. Seizures themselves are known to induce an upregulation of
cyclooxygenase-2 (COX-2) in neurons and, particularly, in non-neuronal cells [55]. This agent
is known to promote neurodegeneration of somatostatin-expressing GABAergic interneurons,
intensify cytokine reactivity and underlie the loss of integrity of the blood-brain barrier after
seizure activity [56]. Its involvement in the peritumoural region may explain the loss of
GABAergic neurons [42], in particular, and suggest a role in the mechanism for the epilepto‐
genic process here.
3. Clinical presentation
The standardized mortality ratio (SMR; ratio of observed and expected deaths) for patients
with recurrent seizures attributed to an acquired lesion such as a brain tumour during the first
two years is 4.3 [57]. The frequency of status epilepticus, with its attendant risk of morbidity
and mortality, increases from 3.8% in all patients with epilepsy to 9% in those with an
underlying lesion. Three primary factors influence the risk of acquiring epilepsy in the
presence of a cerebral glioma – glioma type, location and proximity to the cerebral mantle [10,
58]. As many as 80% of patients with oligodendrogliomas or gangliogliomas experience
seizures. Anaplastic astrocytomas carry a risk of 68% [59], similar to astrocytomas, and the risk
for glioblastomas is 29% to 37% [59, 10, 58]. The transitional histopathology of astrocytomas
and anaplastic astrocytomas, with the latter likely to retain regional features of the more
epileptogenic low-grade neoplasm, may explain the similarity in risk.
The propensity toward epileptogenicity by cerebral region varies considerably with the motor-
sensory region most susceptible and the occipital region less so [10, 60]. The motor-sensory
cortical region substantially raises the general risk of seizure occurrence for both the astrocy‐
toma (83%) and glioblastoma (53%) [59].
The semiology of partial epilepsy may, at times, provide useful lateralizing or localizing
information as to the whereabouts of a cerebral glioma. One of the more characteristic of such
occurrences is the classic uncinate fit or olfactory aura brought about by a lesion situated in
the uncus or lateral olfactory area in which the patient commonly experiences the recurrent
spontaneous sensation of a bad odour. Lateralized elementary visual hallucinations originate
typically in the vicinity of the calcarine cortex [61, 62] and gustatory hallucinations in the
parietal operculum and/or insula [3, 63]. Focal motor or sensory manifestations as simple
partial seizures, with or without a Jacksonian march, will also indicate the presence of a
centrally located tumour as will periods of speech arrest in cases of tumours in the dominant
hemisphere occupying the frontal opercular and inferior premotor or posterior temporal
convexity region. In these latter circumstances, certain subtle aspects of the clinical presenta‐
tion will shed further localizing information as in some loss of contralateral manual dexterity,
a widening of the contralateral palpebral fissure and lapses in the proficiency of speech.
Postictal manifestations may accentuate these features for variable periods of time. Although
versive head deviation at ictal onset has been shown to be unreliable as a lateralizing feature
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A detailed rendering of lobar-specific ictal manifestations may best be presented in a tabular
form for completeness (Table 1); however, as the majority of both low- and high-grade gliomas
appear in the fronto-temporal distribution, our particular attention may be drawn to the
anterior cerebral hemispheres to review some of the more common ictal features.
Frontal Orbitofrontal: olfactory hallucinations, experiential sensations, gestural automatisms, autonomic
features, speech arrest (likelihood of spread to mesial temporal area)
Dorsolateral: generalized event without warning, possible contraversive tonic head and eye motion
(likelihood of spread to rolandic area and transcallosally)
Cingulate: complex motor gestural and sexual automatisms, mood changes, urinary incontinence
(likelihood of spread transcallosally and to temporal lobe)
Supplementary: abduction and lateral rotation of upper arm with elbow flexion and tonic head
rotation to involved limb, vocalization, bicycling, scissoring of legs (likelihood of spread transcallosally)
Perirolandic: focal clonic motor activity, possible Jacksonian march
Temporal Mesiobasal: experiential sensations with epigastric features, déjà vu, memory flashes, behavioural
arrest, staring with oroalimentary automatisms (likelihood of spread to frontal and insular areas)
Opercular: auditory hallucinations, focal motor and sensory symptoms, vertigo (likelihood of spread
to insula and parietal area)
Convexity: complex visual hallucinations, vertigo, speech arrest (likelihood of spread to mesial
temporal and parietal areas)
Parietal Inferior: speech arrest/dysphasia, vertigo, arm/facial sensory and motor activity, tonic posturing, head
deviation
Superior: metamorphosia, asomatognosia, arm/leg sensory and motor activity, tonic posturing,
vertigo
Occipital Elementary contralateral visual phenomena – scotoma, hemianopia, phosphenes, object distortion
Table 1. Semiologies of Lobar Epilepsies
In the case of frontal lobe ictal origin, the tendency for rapid dissemination of discharge both
ipsi- and contralaterally and to generalize confounds our ability to localize or even lateralize
the condition. The seizure may manifest in a variety of forms – primary generalized, absence,
simple and complex partial [67-71]. Auras tend to be less frequent then in temporal lobe
epilepsy and, when present, rather nonspecific [72,70]. Prominent motor features with focal
tonic-clonic activity, adversive head and eye deviation and stereotypic motor automatisms
(i.e., fencing posture, scissoring) may develop [73, 74, 69, 63, 71, 70] and secondary generali‐
zation without evidence of focal onset occurs often, particularly in the case of seizures arising
in the dorsolateral frontal convexity [75, 63, 72]. There is also some vulnerability toward status
epilepticus of the convulsive [76] or of the complex partial [71] variety. By contrast, brief tonic
and absence-like seizures may occur [77]. Frontopolar seizures without spread are commonly
clinically silent whereas posterior spread may result in a loss of consciousness, focal tonic
motor activity and generalization [71]. Orbitofrontal seizures are typically complex partial in
nature and may be mixed with motor and gestural automatisms, olfactory hallucinations and
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autonomic signs, perhaps through connections with the mesial temporal structure via the
uncinate fasciculus. Seizures of cingulate origin may also be complex partial in nature with
similar motor and gestural automatisms in addition to sexual automatisms, mood changes and
urinary incontinence [78, 71]. Finally, supplementary motor seizures tend to be brief but
frequent and may manifest as an abduction and external rotation of the contralateral arm and
flexion of the elbow with the head directed toward the postured arm while the legs may be
flexed, extended or elevated [63]. Either vocalization or speech arrest may be apparent while
the patient remains conscious. Alternating locomotor activity, as in bicycling, may also be
witnessed. Many frontal lobe seizures, particularly of convexity origin and exclusive of
generalized events, are characterized by a rapid postictal recovery with little evidence of
fatigue.
Epilepsy of temporal lobe origin is commonly of a complex partial variety and, in the case of
a mesial origin, may be heralded by an aura of an experiential sort, followed or accompanied
by impaired consciousness, behavioural arrest, staring and subsequent automatic behaviour
as with oroalimentary automatisms (i.e., chewing, lip-smacking, swallowing) [79]. A postictal
fatigue of variable duration, sometimes profound, often follows. Those complex partial events
arising from an extratemporal source often begin with semipurposeful motor activity and
commonly do not manifest a behavioural arrest or stereotypical automatisms [80, 81]. Auras
appear in 80% of patients with a mesial temporal epileptogenicity and may be characterized
by epigastric sensations, déjà vu experiences and memory flashes [82]. Additional features to
those described above include uni- and bilateral tonic-clonic or dystonic posturing. Seizures
arising in the temporal opercular area may cause auditory hallucinations in addition to focal
motor or sensory experiences, depending upon subsequent spread of activity. Vestibular and
complex visual hallucinations may characterize the more posteriorly situated temporal
convexity ictal semiology. Language disturbance in the form of speech arrest, in particular, in
the ictal or postictal state, will often declare dominant hemispheric involvement.
4. Antiepileptic medical management
Apart from the issue of refractory seizures, patients with epilepsy attributable to a glioma are
threatened by potential interactions between antiepileptic and chemotherapeutic agents and
risks associated with toxicity of either.
All gliomas, whether low- or high grade, must be assessed for surgical resection in order to
optimize survival [83, 84, 85]. The literature has supported the notion of aggressive removal,
to the extent allowable, in any region of the brain and, to this end, the inclusion of the imme‐
diate peritumoural region in the resection volume affords the opportunity of removing
sufficient epileptogenic tissue to reduce or eliminate the presenting epilepsy or deny its further
evolution (Figure 2). Postoperative antiepileptic medical prophylaxis is advised for patients
with supratentorial gliomas. In a study of anaplastic gliomas, 36% of patients without
preoperative indication of epileptogenicity experienced a postoperative seizure [86]. In a
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preoperative indication of epileptogenicity experienced a postoperative seizure [86]. In a




stage (21% vs 39%) in patients receiving antiepileptic treatment compared with those left
untreated [87]. Moreover, no impairment of consciousness was witnessed in those treated
compared to 18% of those untreated, suggesting that a putative subclinical epileptogenicity
was averted. Postoperative complications (i.e., hemorrhage, worsening edema) raise the
likelihood of seizures during the initial 48 hour period by over two-fold, including status
epilepticus even in the presence of antiepileptic medical coverage [9]. Late postoperative
seizures were found to occur in 34% of those patients who had presented preoperatively with
seizure activity. Although a significant difference was not substantiated, the incidence of late-
onset epilepsy appeared lower in the treated patients (12% vs 21%) in the same study. The
interval between surgery and the first postoperative seizure was less than six months in 52%
of patients and the majority harboured a malignant glioma. Maintenance of therapeutic levels
is essential in judging the efficacy of treatment and maximizing serum levels to individual
tolerability is required before consideration is given to adding a second agent.
Figure 2. Axial magnetic resonance imaging identifies a predominant right insular tumour in a 62 year old man with a
3 year history of medically intractable complex partial epilepsy. Acute nausea followed by behavioural arrest, oroali‐
mentary automatisms and a postictal drowsiness began manifesting at an almost daily frequency with no distinct elec‐
troencephalographic features. Resection of this grade 2 oligoastrocytoma resulted in cessation of seizures
The risk of late postoperative seizure recurrence and a declared epileptogenicity may be judged
by a number of factors. These include, primarily, the extent of glioma removal with the
consequent reduction of tumour burden and elimination or reduction of vasogenic edema. The
proximity to cortical regions prone toward epileptogenicity where such regions have been left
intact (i.e., dominant mesial temporal region, motor-sensory region) must also be taken into
consideration. Exclusive of the inability to optimally remove the tumour and/or a sufficient
portion of the peritumoural region, the duration of preoperative epileptogenicity, postopera‐
tive complications (i.e., cerebrovascular compromise, intracerebral hemorrhage) and difficul‐
ties in maintaining adequate serum antiepileptic medication levels will also influence the
outcome.
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Several antiepileptic agents have appeared over the past two decades that have shown efficacy
and greater tolerability in patients with brain tumour-related epilepsy [88-92]. The side effect
profile of the traditional antiepileptic medications such as phenobarbital, phenytoin, carba‐
mazepine and valproic acid was such [93, 94, 5, 95] that it seemed often to take precedence
over the desire to reduce seizure activity [96]. The administration of phenobarbital, phenytoin
or primidone can markedly lower serum levels of carbamazepine and both valproic acid and
lamotrigine will increase the serum concentrations of an active metabolite, carbamaze‐
pine-10,11-epoxide. On the other hand, the half-life of phenytoin can be significantly shortened
and the serum level of valpoic acid may be reduced when delivered with carbamazapine.
Finally, agents such as calcium channel blockers, erythromycin and propoxyphene may elevate
plasma levels of carbamazepine when given concurrently. The incidence of severe rash (14%)
accompanying therapy with these agents is higher in patients undergoing radiation and
chemotherapy [93] and cognitive decline more pronounced [95]. Moreover, phenobarbital,
phenytoin and carbamazepine are potent inducers of P450 microsomal enzymes, particularly,
CYP 3A4 and CYP 2D6, and will putatively enhance metabolism of chemotherapeutic agents
degraded by these enzymes resulting in the reduction of plasma levels and reduced efficacy
[97, 98]. Some controversy regarding this effect has arisen, however, with some studies
declaring improved outcomes in the presence of enzyme-inducing antiepileptic medications
[99, 100]. Nevertheless, a decline in the use of the latter has occurred in recent years in favour
of the newer non-enzyme-inducing antiepileptics such as levetiracetam, lamotrigine and
vigabatrin which are relatively devoid of P450 microsomal enzyme induction or inhibition.
Oxcarbazepine and topiramate are weak inducers of CYP 3A4 and weak inhibitors of CYP
2C19 and zonisamide has shown variability but overall weak inducing and inhibiting effects
[101]. Valproic acid has been shown to be a potent inhibitor of microsomal enzymes and may
increase the toxicity of chemotherapy [101].
A total of 14 new antiepileptic medications have been approved by the Federal Drug Admin‐
istration (FDA) since 1992. These newer medications are safer, more tolerable, have, in general,
fewer interactions with one another and require less monitoring. Moreover, several medica‐
tions are under development which target other mechanisms underlying epileptogenicity
other than those which currently effect voltage-gated Na and Ca channels and GABA inhibi‐
tion. For instance, 2-deoxyglucose inhibits glycolysis and appears to have both antiepileptic
and antiepileptogenic effects. Both ezogabine and ICA-105665 affect voltage-activated
(KCNQ) potassium channels and are the first such agents dedicated to this ion channel.
Targetting receptors for the neuropeptide, galanin, also shows promise as an antiepileptic. An
AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropropionic acid) receptor antagonist,
perampanel, appears effective in patients with refractory partial epilepsy and is in the late
stages of clinical development. Because of the interest in neuroinflammation as a promoter of
epileptogenicity, an active inhibitor (VX-765) of caspase 1, the enzyme responsible for the
production of interleukin-1-beta, has been investigated and found to show longterm antiepi‐
leptic effects that may be relevant.
Of particular interest has been the discovery of an antiepileptic effect brought about by
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inhibition, such an agent would be particularly useful in patients with cerebral glioma-
associated epilepsy. Type 1 DNA topoisomerase (Top1) binds with DNA and relaxes the helix
at the time of torsional stresses associated with its replication and transcription [103]. In a
situation where transcription is generating supercoiled DNA to sustain high levels of RNA
synthesis, as in an area of excitability, such inhibition would be detrimental to the epileptic
process. Reduced Top1 activity could result in the inhibition of gene transcription critical for
efficient synaptic transmission or possibly result in an enhanced apoptosis of those cellular
elements involved in epileptogenic circuitry [104].
In the absence of postoperative seizure occurrence or recurrence for a period of 3 – 6 months
and in the absence of both imaging evidence of tumour recurrence and EEG evidence of
epileptiform features, a tapering regimen for the antiepileptic medication may be contemplat‐
ed. Where a patient has presented with a single ictal event preoperatively, the decision, as
dictated above, may be reached comfortably. In the case where there is uncertainty regarding
the veracity of a patient’s statement as to the absence of clinical seizure activity, the presence
of artefactual changes that may obscure tumour recurrence in potentially epileptogenic
territory on followup imaging and/or an inability by the electroencephalographer to ade‐
quately survey the cerebral cortex for hidden epileptogenicity, the decision to taper medication
must be tempered accordingly.
5. Surgery
Tumour resection alone results in good postoperative seizure control in those patients
presenting with a glioma-associated epilepsy [105, 9, 106]. As is often the case, a variable
amount of epileptogenic cortical tissue is removed in the process of optimizing the removal of
a glioma with its ill-defined border, affording the patient a good seizure outcome postopera‐
tively. When the peritumoural tissue removal is not satisfactory, postoperative seizure control
remains effectively unchanged [107, 108, 9, 106, 109, 58]. Image-guided stereotactic lesional
resection achieves a longterm seizure-free outcome in 57% of cases [108] whereas the inclusion
of peritumoural tissues in the resection volume raised this metric beyond 80% [110, 111]. The
realization that the peritumoural environment is critical in the promotion of most epileptic
manifestations has prompted the use of intraoperative electrocorticography in cases of low
grade gliomas, in particular, to increase the likelihood of capturing those responsible cortical
areas in the resection volume [112-116]. In a review of 45 patients with low grade gliomas and
intractable epilepsy, 53% were rendered seizure-free and no longer requiring antiepileptic
medical management after a mean followup of 54 months [112]. An additional 38% were
seizure-free but still required medical management, although reduced. A meta analysis of
studies addressing the benefit of resecting additional epileptogenic tissues showed that, in the
case of low grade gliomas, seizure-free outcome was 63%, in marked contrast to the 18%
seizure-free outcome achieved by lesionectomy alone [117]. Persistence of epileptiform activity
following resection of an epileptogenic area is associated with seizure recurrence [118] and,
hence, postresection electrocorticography has been promoted also [112]. When addressing
specifically complex partial epilepsy in the context of temporal lobe tumors, the use of
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electrocorticography clearly favoured outcome [119]. When a lesionectomy alone was per‐
formed, a seizure-free status of 18.8% was achieved compared with a 92.8% seizure-free
outcome when electrocorticography was used.
At times, in cases of low grade gliomas, the source of some of the epileptogenicity may be
remote from the tumor [106, 120]. Such occurrences may only be documented, in most cir‐
cumstances, with prolonged inpatient extraoperative electrocorticography and reflect the
engagement of an epileptogenic network type of activity in which remote nodes of epileptic
activity may attain sufficient independence to perpetuate clinical manifestations despite re‐
moval of the original offending lesion. Indeed, resection of a remote epileptogenic site in the
presence of an unresectable tumour has resulted in the relief of the epileptic condition [121].
Both the glioma type and its cerebral location typically determines its epileptogenic poten‐
tial. Although oligodendrogliomas are found more commonly in the frontal region (35%),
their epileptogenicity is better expressed in the temporal and temporoparietal regions where
about 80% will promote an epilepsy [122]. A distinct clinicopathological group of patients
with a protracted history of epilepsy attributable to the occurrence of a limbic or neocortical
glioma has been identified [123]. Most such gliomas were confined to the temporal (63%)
and occipital (18%) lobes and occupied limbic or perilimbic locations. The majority (61%)
were identified as low grade tumors although 17% were anaplastic despite a stable clinical
history of epilepsy with a mean of 15 years duration. Following resection of the tumour,
82% of the group of 60 patients studied were seizure-free after one year. A similar group,
consisting typically of low grade gliomas, has been studied more recently [124] and charac‐
terized by a low cellularity, lack of mitoses and the absence of certain protein expression,
such as the microtubule-associated protein (MAP2) which is critical in neurogenesis. The
protein stabilizes microtubules that are enriched in dendrites, implicating a role in stabiliz‐
ing dendritic shape during neuronal development. Microtubular assembly is therefore an es‐
sential step in neurogenesis. Patients are reported to have 50% fewer recurrences at 7.5 years
followup and an 80% ten year survival.
Complex partial epilepsy in the context of a temporal lobe tumour must always raise suspi‐
cion of a dual pathology with an associated atrophy of the ipsilateral hippocampus resulting
from cell loss, particularly in the CA4 region [125, 126]. In a series of 17 patients harbouring
temporal lobe tumours presenting with complex partial epilepsy, 12 were found to have
gliomas of which four were mixed gliomas (astrocytoma-oligodendroglioma), three were
low grade astrocytomas and two were classed as cellular astrocytomas [126]. Neuronal den‐
sities throughout all the hippocampal subfields including the granule cell layer were dimin‐
ished. Medially placed tumours were associated with the more dramatic changes than
laterally placed tumours. Where an atrophic hippocampus has been identified, resection of
both the lesion and the hippocampus is more likely to result in a seizure-free outcome [127].
6. Effect of ionizing radiation
Experience over the last several decades has indicated that ionizing radiation is capable of
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and occipital (18%) lobes and occupied limbic or perilimbic locations. The majority (61%)
were identified as low grade tumors although 17% were anaplastic despite a stable clinical
history of epilepsy with a mean of 15 years duration. Following resection of the tumour,
82% of the group of 60 patients studied were seizure-free after one year. A similar group,
consisting typically of low grade gliomas, has been studied more recently [124] and charac‐
terized by a low cellularity, lack of mitoses and the absence of certain protein expression,
such as the microtubule-associated protein (MAP2) which is critical in neurogenesis. The
protein stabilizes microtubules that are enriched in dendrites, implicating a role in stabiliz‐
ing dendritic shape during neuronal development. Microtubular assembly is therefore an es‐
sential step in neurogenesis. Patients are reported to have 50% fewer recurrences at 7.5 years
followup and an 80% ten year survival.
Complex partial epilepsy in the context of a temporal lobe tumour must always raise suspi‐
cion of a dual pathology with an associated atrophy of the ipsilateral hippocampus resulting
from cell loss, particularly in the CA4 region [125, 126]. In a series of 17 patients harbouring
temporal lobe tumours presenting with complex partial epilepsy, 12 were found to have
gliomas of which four were mixed gliomas (astrocytoma-oligodendroglioma), three were
low grade astrocytomas and two were classed as cellular astrocytomas [126]. Neuronal den‐
sities throughout all the hippocampal subfields including the granule cell layer were dimin‐
ished. Medially placed tumours were associated with the more dramatic changes than
laterally placed tumours. Where an atrophic hippocampus has been identified, resection of
both the lesion and the hippocampus is more likely to result in a seizure-free outcome [127].
6. Effect of ionizing radiation
Experience over the last several decades has indicated that ionizing radiation is capable of




radiosurgical treatment of cerebral arteriovenous malformations with an associated epilepsy
has been shown to have an antiepileptic effect even in the absence of angiographic evidence
of obliteration of the malformation [129]. In this latter series, seizures had ceased altogether in
55% of cases and a seizure-free interval had been maintained for a duration of followup of 2 –
8 years. In a review of patients presenting with glioma-associated epilepsy of long term, three
of four patients with frontal lobe tumours who had undergone biopsy and conventional
radiation therapy were found to be seizure-free during a followup of four years [106]. In the
same series, 83% of 23 patients who had undergone a resection followed by radiation therapy
also became seizure-free. In the shorter interval, recurrent seizures attributable to malignant
gliomas have been shown responsive to ionizing radiation [133]. Five of nine patients har‐
bouring a biopsy-proven malignant glioma and manifesting an intractable partial epilepsy
responded to treatment with a seizure-free outcome for the duration of their survival and the
remainder showed a reduction in frequency of greater than 75%.
Radiosurgical application in the case of nonlesional partial epilepsy has also been shown to be
beneficial in the longterm [134, 135], enough so that its use in the treatment of partial epilepsies
remains an option. Whether lesionally-associated or not, there is much yet to be understood
regarding the radiobiology of the effect upon the epileptic condition [136- 138].
7. Summary
Importantly, seizures will herald the presence of an underlying glioma, particularly in the
adult, and will result in intervention before any other clinical manifestation is realized. This
alone may afford the patient an opportunity to delay or avoid the inevitable loss of function
that occurs with the further growth of the tumour and its further malignant transformation.
Surgical intervention constitutes the most effective means by which an often intractable
glioma-associated epilepsy may be brought under control. The extent of peritumoural
resection is critical in this intervention and the use of intraoperative electrocorticography,
particularly in the case of a longstanding epilepsy, provides the necessary objective criteria by
which the surgeon will appreciate the location and extent of the epileptogenic surround.
Cerebrocortical mapping in the presence of electrographic monitoring allows the surgeon to
optimally perform such a resection by avoiding eloquent structure and concurrently reduce
the tumour burden further in the infiltrative zone.
There is great promise in future antiepileptic pharmaceutical applications as they apply
specifically to glioma therapy. Dual antiepileptic-antineoplastic effects may be realized. Better
understanding of the biology underlying the antiepileptic effect of ionizing radiation may
ultimately be used to guide therapy specifically to certain peritumoural areas where epilep‐
togenicity is expressed.
The presence of epilepsy diminishes the quality of life for the patient with a glioma and
dedicated effort is required to assure that the patient benefits maximally from intervention not
only to reduce tumour burden but to eliminate the epileptogenicity.
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1. Introduction
Gliomas, the most common primary brain tumors, are characterized by rapid proliferation,
marked infiltration, and poor prognosis and are known for their dismal outcomes (Iacob & Din‐
ca, 2009; Lefranc et al., 2006). The infiltrative nature of malignant glioma makes complete resec‐
tion  difficult,  as  tumor  margins  are  unclear.  Recurrence  of  glioma  takes  place  within
approximately 2 cm of the margins of the resected cavity owing to its invasive character (Aydin
et al., 2001; Wallner et al., 1989). The use of fluorescence to delineate tumor margins intraopera‐
tively has emerged as a safe and effective tool for increasing the extent of resection. Therefore,
methods that easily detect tumor margins during surgery would be extremely beneficial. 5-ami‐
nolevulinic acid (5-ALA) fluorescence-guided glioma resection is a rapidly growing, novel ap‐
proach to improve the extent of tumor resection with broad applications in both preclinical and
clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et al., 1998c). Intraopera‐
tive tumor fluorescence provided by the chemical compound 5-ALA assists surgeons in identi‐
fying the true tumor margin during resection of glial neoplasms, consequently increasing the
extent of the resection. 5-ALA is the most studied fluorescer and has been used in many clinical
trials, including a multicenter phase III randomized controlled trial. Recent controlled Phase III
clinical trials have demonstrated that this surgical method enables more complete resection of
contrast-enhancing lesions than conventional microsurgery and improves progression-free
survival in patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006).
Photodynamic therapy (PDT) is a treatment modality that takes advantage of the cytotoxic ef‐
fects induced by a photosensitizer and light in the presence of oxygen (Norum et al., 2009). This
© 2013 Teng et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 12
Current Applications of 5-ALA in
Glioma Diagnostics and Therapy
Lei Teng, Mitsutoshi Nakada, Yutaka Hayashi,
Takeshi Yoneyama, Shi-Guang Zhao and
Jun-Ichiro Hamada
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52428
1. Introduction
Gliomas, the most common primary brain tumors, are characterized by rapid proliferation,
marked infiltration, and poor prognosis and are known for their dismal outcomes (Iacob & Din‐
ca, 2009; Lefranc et al., 2006). The infiltrative nature of malignant glioma makes complete resec‐
tion  difficult,  as  tumor  margins  are  unclear.  Recurrence  of  glioma  takes  place  within
approximately 2 cm of the margins of the resected cavity owing to its invasive character (Aydin
et al., 2001; Wallner et al., 1989). The use of fluorescence to delineate tumor margins intraopera‐
tively has emerged as a safe and effective tool for increasing the extent of resection. Therefore,
methods that easily detect tumor margins during surgery would be extremely beneficial. 5-ami‐
nolevulinic acid (5-ALA) fluorescence-guided glioma resection is a rapidly growing, novel ap‐
proach to improve the extent of tumor resection with broad applications in both preclinical and
clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et al., 1998c). Intraopera‐
tive tumor fluorescence provided by the chemical compound 5-ALA assists surgeons in identi‐
fying the true tumor margin during resection of glial neoplasms, consequently increasing the
extent of the resection. 5-ALA is the most studied fluorescer and has been used in many clinical
trials, including a multicenter phase III randomized controlled trial. Recent controlled Phase III
clinical trials have demonstrated that this surgical method enables more complete resection of
contrast-enhancing lesions than conventional microsurgery and improves progression-free
survival in patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006).
Photodynamic therapy (PDT) is a treatment modality that takes advantage of the cytotoxic ef‐
fects induced by a photosensitizer and light in the presence of oxygen (Norum et al., 2009). This
© 2013 Teng et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
photodamage may be due to direct cytotoxicity, vascular damage, and inflammatory and im‐
munological responses (Castano et al., 2006). The relative importance of these pathways to the
therapeutic effects depends on the tissue oxygenation, photosensitizer formulation, distribu‐
tion, and light dosimeter (Norum et al., 2009). 5-ALA-induced protoporphyrin IX (PpIX) can al‐
so be used for 5-ALA-PDT rather than photodynamic diagnosis (PDD) by exposing the field to
either blue or red laser light; however, a red light at 632 nm would target a much larger tumor
volume owing to better light penetration (Eljamel et al., 2008). Activation of PpIX by red light in
combination with oxygen causes cell death by apoptosis and necrosis through the release of cy‐
totoxic singlet oxygen (Peng et al., 1997). This tool may aid in overcoming the hurdle of residual
tumor cells after traditional neurosurgery. Application of 5-ALA-PDT has been emerging as a
new field and is expected to create a major breakthrough in addressing several unsolved medi‐
cal issues, especially photokilling of residual neoplastic cells.
Developing technologies such as fluorescence operation-systems to enhance endogenous
fluorescence has fairly recently been shown to delineate brain tumor margins intraoperatively
(Babu & Adamson, 2012). 5-ALA fluorescence-guided resection shows great promise for
furthering our surgical abilities and will become the standard of care for patients diagnosed
with malignant glioma in the foreseeable future. The following review analyzes the recent
literature in an effort to describe how these modalities involving 5-ALA in glioma diagnostics
and therapy can and should be used in the treatment of patients with glioma. This article
reviews recent developments in the use of 5-ALA for simultaneous imaging and 5-ALA-
triggered photodamage in glioma patients (Figure 1).
2. General knowledge of 5–ALA
5-ALA (molecular weight, 167.6) is a natural biochemical precursor for heme synthesis in
living mammalian cells (Eljamel et al., 2008; Peng et al., 1997). Each cell metabolizes 5-ALA
along a set pathway toward heme production, inducing the synthesis of the endogenous flu‐
orescent molecule, PpIX, through metabolic conversion in the mitochondria (Bottomley &
Muller-Eberhard, 1988). When PpIX emits peak fluorescence at 635 nm with a peak excita‐
tion wavelength at 405 nm, it is observed as a red light through a filter that allows this
wavelength to pass. Clinical use of 5-ALA for PDT or PDD has also been reported in derma‐
tology, urology, neurosurgery, otorhinolaryngology, gynecology, and gastroenterology for
various epithelia and cancerous tissues (D'Hallewin et al., 1998; Guyon et al., 2012; Loning et
al., 2004; Piotrowski et al., 2004). In the USA, it has been used with the approval of the Food
and Drug Administration (FDA) as a therapeutic drug for solar keratosis. Its use has not yet
been approved by the pharmaceutical authority in Japan, and it is only used after obtaining
approval from the ethics committee of the respective institutes. The tumor tissue concentra‐
tion of the fluorescent dye peaks at 2–6 hours after oral administration and disappears by 12
hours. Administration of antacid should be avoided at the time of oral administration be‐
cause the dye is easily decomposed in the presence of alkali, and use of 5-ALA is contraindi‐
cated in cases of porphyria, a genetic disease. PpIX biosynthesized from 5-ALA is a
phototoxic substance, although the incidence of skin photosensitivity is lower than that re‐
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ported for conventional porphyrin derivatives (Stummer et al., 2006; Toda, 2008). When giv‐
en orally, 5-ALA has been shown to produce fluorescence in glial neoplasms both in vitro
and in vivo (Blake & Curnow, 2010). In addition, the fluorescence of PpIX is itself cytotoxic
and has the potential for use as an adjuvant photodynamic therapy for neoplastic tissue that
cannot be safely resected (Sherman et al., 2011). Since the administered 5-ALA is excreted
into the urine within 24 hours after oral administration and does not remain in the skin, the
occurrence of photosensitivity can be adequately prevented by avoiding sun exposure for
approximately 24 hours after administration.
Figure 1. Schematic representation of diagnostics and PDT of 5-ALA for glioma cells. The figure illustrates 5-ALA is
converted to PpIX in malignant gliomas via an oral-intake of exogenous 5-ALA. In the presence of an appropriate light
source with the specific wavelength, PpIX fluorescence acts bimodal function; fluorescence diagnostic marker and 5-
ALA-PDT. Red fluorescence acts as a discriminating marker to assist neurosurgeons to visualize the extent and margins
of tumors; 5-ALA-PDT results in a series of irreversible photochemical and photobiological events that cause directly
damage and killing glioma cells.
3. 5–ALA biology in glioma
5-ALA, the metabolic precursor of heme in the heme biosynthesis pathway, is not itself
fluorescent, but is metabolized into endogenous fluorescent PpIX (Gossner et al., 1998; Inoue
et al., 2007; Kennedy & Pottier, 1992; Loh et al., 1993; Peng et al., 1997). Heme biosynthesis
consists of a series of enzyme-catalyzed steps, involving 5-aminolevulinate synthases 1 and 2,
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5-aminolevulinate dehydratase, hydroxymethylbilane synthase, uroporphyrinogen III
synthase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase (CPOX), protopor‐
phyrinogen oxidase, and ferrochelatase (FECH). In addition to these enzymes, several
transporters are also involved in the biosynthesis and catabolism of heme and porphyrin,
including oligopeptide transporters 1 and 2 (PEPT1 and PEPT2) and the ABC transporters



































Figure 2. The porphyrin-heme biosynthetic pathway and putative mitochondrial transporters. The first step of heme
synthesis occurs in the mitochondrial matrix with the condensation of succinyl CoA and glycine by ALA synthase to
generate ALA. Oligopeptide transporters (PEPT1 or PEPT2) are responsible for the import of exogenous ALA from the
extracellular space into the cytoplasm of target cells. ALA is converted to coproporphyrinogen III by 4 enzymatic reac‐
tions. Then, coproporphyrinogen III is transported back into the mitochondrial intermembrane space (IMS), possibly
via ABCB6, where it is converted to protoporphyrinogen by protoporphyrinogen III oxidase. The conversion of proto‐
porphyrinogen to PpIX by protoporphyrinogen oxidase, its transport into the matrix and the addition of Fe2+ by ferro‐
chelatase (FECH) to generate heme are coupled processes. The transporter responsible for heme transfer across the
outer mitochondrial membrane remains unidentified. Heme formed from porphyrin is catabolized to biliverdin by the
microsomal enzyme heme oxygenase 1. Biliverdin is subsequently metabolized to bilirubin by biliverdin reductase.
ABCG2 transports porphyrins across the plasma membrane to maintain intracellular porphyrin homeostasis.
Porphyrins are synthesized from glycine and succinyl CoA via a series of enzymatic reactions.
The last enzymatic reaction is the conversion of PpIX to heme by FECH, which is located in
the inner mitochondrial membrane (Ferreira et al., 1995; Kemmner et al., 2008). Heme formed
from porphyrin is catabolized to biliverdin by the microsomal enzyme heme oxygenase 1.
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Subsequently, biliverdin is metabolized to bilirubin by biliverdin reductase. The PEPT1/PEPT2
(influx transporters) can transport exogenous ALA from the extracellular space into the
cytoplasm of target cells. ABCB6 is the ABC transporter responsible for the import of copro‐
porphyrinogen III into the mitochondria, whereas ABCG2 transports PpIX across the plasma
membrane to maintain intracellular PpIX homeostasis (Takahashi et al., 2011).
Oral-intake of 5-ALA results in the accumulation of PpIX in malignant gliomas. Because of the
presence of the blood-brain barrier (BBB), 5-ALA given via the oral route does not usually enter
the normal brain tissue. However, it can easily pass through the disrupted BBB found in the
glioma tissue (Stummer et al., 2003). PpIX that accumulates in the intracellular compartments
of tumor cells exhibits red fluorescence under excitation light of an appropriate wavelength
(Takahashi et al., 2011). PpIX-accumulating tumor cells can be visually discerned intraopera‐
tively from the surrounding normal cells that accumulate PpIX to a much lesser extent. To
date, little is known about the molecular mechanisms underlying PpIX accumulation in
malignant brain tumors after administration of 5-ALA; despite this, in the past decade, studies
on ALA focusing on the mechanism of 5-ALA uptake in glioma tissue have been conducted
by many research groups. Previously, our group revealed significantly greater down-regula‐
tion of FECH expression in glioblastomas than in normal brain tissues and that FECH plays a
role in the metabolism of 5-ALA in glioma (Teng et al., 2011). In addition, Takahashi et al.
demonstrated that the upregulated expression of the CPOX gene is correlated with the
intensity of tumor fluorescence induced by 5-ALA; they also found that the mRNA level of
ABCG2 was somewhat lower in the brain tumors with high ALA-induced fluorescence than
in those without ALA-induced fluorescence (Takahashi et al., 2011). Therefore, they assumed
that both the induction of the CPOX gene and the inhibition of ABCG2 would increase 5-ALA-
induced PpIX accumulation and thereby enhance the efficacy of 5-ALA-PDT in malignant
brain tumors. In agreement with this hypothesis, Zhao et al. demonstrated that ABCB6
expression levels were greatly elevated in human gliomas than in normal brain tissues and
correlated with glioma histologic grade, indicating a crucial role for ABCB6 in ALA metabo‐
lism and accumulation of PpIX in gliomas (Zhao et al., 2012).
Further studies are required to explore the detailed mechanism of 5-ALA uptake and improve
our knowledge concerning 5-ALA biology in gliomas.
4. 5–ALA guided neurosurgery
Many previous reports describing prognostic factors in patients with malignant gliomas
indicate that outcome is associated with the completeness of tumor removal (Stummer et al.,
1998a). Improving the prognosis of glioma patients cannot be achieved without considerable
effort to remove as much as of the lesion as possible. Since glioma tissue is not easily recognized
intraoperatively, methods that easily detect tumor margins during surgery would be extreme‐
ly beneficial. 5-ALA fluorescence-guided resection is a rapidly growing, novel approach in
treating glioma patients to improve the extent of tumor resection with broad applications in
both preclinical and clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et
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The last enzymatic reaction is the conversion of PpIX to heme by FECH, which is located in
the inner mitochondrial membrane (Ferreira et al., 1995; Kemmner et al., 2008). Heme formed
from porphyrin is catabolized to biliverdin by the microsomal enzyme heme oxygenase 1.
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Subsequently, biliverdin is metabolized to bilirubin by biliverdin reductase. The PEPT1/PEPT2
(influx transporters) can transport exogenous ALA from the extracellular space into the
cytoplasm of target cells. ABCB6 is the ABC transporter responsible for the import of copro‐
porphyrinogen III into the mitochondria, whereas ABCG2 transports PpIX across the plasma
membrane to maintain intracellular PpIX homeostasis (Takahashi et al., 2011).
Oral-intake of 5-ALA results in the accumulation of PpIX in malignant gliomas. Because of the
presence of the blood-brain barrier (BBB), 5-ALA given via the oral route does not usually enter
the normal brain tissue. However, it can easily pass through the disrupted BBB found in the
glioma tissue (Stummer et al., 2003). PpIX that accumulates in the intracellular compartments
of tumor cells exhibits red fluorescence under excitation light of an appropriate wavelength
(Takahashi et al., 2011). PpIX-accumulating tumor cells can be visually discerned intraopera‐
tively from the surrounding normal cells that accumulate PpIX to a much lesser extent. To
date, little is known about the molecular mechanisms underlying PpIX accumulation in
malignant brain tumors after administration of 5-ALA; despite this, in the past decade, studies
on ALA focusing on the mechanism of 5-ALA uptake in glioma tissue have been conducted
by many research groups. Previously, our group revealed significantly greater down-regula‐
tion of FECH expression in glioblastomas than in normal brain tissues and that FECH plays a
role in the metabolism of 5-ALA in glioma (Teng et al., 2011). In addition, Takahashi et al.
demonstrated that the upregulated expression of the CPOX gene is correlated with the
intensity of tumor fluorescence induced by 5-ALA; they also found that the mRNA level of
ABCG2 was somewhat lower in the brain tumors with high ALA-induced fluorescence than
in those without ALA-induced fluorescence (Takahashi et al., 2011). Therefore, they assumed
that both the induction of the CPOX gene and the inhibition of ABCG2 would increase 5-ALA-
induced PpIX accumulation and thereby enhance the efficacy of 5-ALA-PDT in malignant
brain tumors. In agreement with this hypothesis, Zhao et al. demonstrated that ABCB6
expression levels were greatly elevated in human gliomas than in normal brain tissues and
correlated with glioma histologic grade, indicating a crucial role for ABCB6 in ALA metabo‐
lism and accumulation of PpIX in gliomas (Zhao et al., 2012).
Further studies are required to explore the detailed mechanism of 5-ALA uptake and improve
our knowledge concerning 5-ALA biology in gliomas.
4. 5–ALA guided neurosurgery
Many previous reports describing prognostic factors in patients with malignant gliomas
indicate that outcome is associated with the completeness of tumor removal (Stummer et al.,
1998a). Improving the prognosis of glioma patients cannot be achieved without considerable
effort to remove as much as of the lesion as possible. Since glioma tissue is not easily recognized
intraoperatively, methods that easily detect tumor margins during surgery would be extreme‐
ly beneficial. 5-ALA fluorescence-guided resection is a rapidly growing, novel approach in
treating glioma patients to improve the extent of tumor resection with broad applications in
both preclinical and clinical settings (Stummer et al., 2000; Stummer et al., 1998b; Stummer et
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al., 1998c). In 1998, Stummer et al. first presented a detailed description of the technical
principles for 5-ALA fluorescence-guided microsurgical resection of malignant glioma tissue
(Stummer et al., 1998a). Subsequently, they performed a prospective study in 52 glioblastoma
patients and identified the usefulness of 5-ALA-induced tumor fluorescence for guiding tumor
resection. Recent controlled Phase III clinical trials have demonstrated that compared to
conventional microsurgery, 5-ALA fluorescence-guided microsurgical resection enables more
complete resection of contrast-enhancing lesions and improves progression-free survival in
patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006). After the rapid
development of the neurosurgical fluorescence operation microscope, several investigators
have recently demonstrated the feasibility of 5-ALA fluorescence-guided resection in patients
with glioma (Kuroiwa et al., 1998; Kuroiwa et al., 2001; Sherman et al., 2011). Widhalm et al.
also indicated that 5-ALA is a promising marker for intraoperative visualization of anaplastic
foci in diffusely infiltrating gliomas without contrast enhancement and showed that the
positive predictive value (PVV) of focal 5-ALA fluorescence for World Health Organization
(WHO) grade III glioma was 100% (sensitivity 89%) (Widhalm et al., 2010). In addition,
Nabavi’s group investigated the feasibility and selectivity of 5-ALA-induced fluorescence to
guide resection in recurrent gliomas (WHO grade III/IV) and found that 5-ALA fluorescence
(weak and strong) had a high PPV (97.2%) in all pathological-appearing tissues obtained from
354 biopsies performed in 36 patients (Nabavi et al., 2009). Based on these findings, they
suggested that 5-ALA fluorescence guidance is an effective surgical adjunct in the surgery of
recurrent malignant gliomas, and many other trials have displayed similar successful results
using 5-ALA fluorescence-guided resection in meningiomas to achieve optimal resection
(Coluccia et al., 2010; Kajimoto et al., 2007).
Despite the advantages of 5-ALA fluorescence, successful glioma resection often depends on
the neurosurgeon’s ability to distinguish residual tumor tissue from surrounding brain tissue
even with the assistance of PpIX fluorescence (Teng et al., 2011). The marginal area containing
infiltrating glioma cells shows vague fluorescence because the density of the glioma cells in
these areas is low and heterogeneous, resulting in insufficient 5-ALA uptake and PpIX
accumulation (Utsuki et al., 2006). Conversely, because of the presence of reactive astrocytes
and macrophages and leakage of PpIX into the extracellular matrix, false-positive (i.e., the area
fluoresced, but no tumor was seen histologically) results in weakly fluorescing normal-
appearing tissue are also common (Utsuki et al., 2007). Therefore, more objective and quanti‐
tative indicators need to be established for neurosurgeons to improve intraoperative
identification of tumor margins. Recently, a quantitative method involving spectroscopic
analysis for determining the amount of fluorescence present has been developed, which allows
more precise visualization of quantitative fluorescence from tumor tissues (Utsuki et al.,
2006; Valdes et al., 2011).
5. 5–ALA mediated-PDT
PDT is a tool for the treatment of certain cancerous and pre-cancerous conditions, especially
in the field of dermatology (Buytaert et al., 2007). Among the many kinds of photosensitizers,
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5-ALA has become widely accepted. 5-ALA-PDT is a novel treatment modality for early or
superficial cancers, as well as a palliative treatment to a certain extent, that triggers a photo‐
dynamic effect similar to that of light in the visible range to produce a rapid PDT response in
the targeted tissue. Three types of mechanisms have been identified in the literature as
contributing to the rapid PDT response in vivo: (1) PDT can directly damage and kill the
malignant tumor cells, either by apoptosis or a non-apoptotic mechanism; (2) PDT may
produce profound changes in the tumor vasculature, including blood flow stasis, vascular
collapse, and/or vascular leakage, that can result in indirect killing of malignant cells; and (3)
PDT can promote the release of cytokines and other inflammatory mediators from target cells
that induce an inflammatory response and recruit additional host cells to the tumor (Mac‐
Donald & Dougherty, 2001; Oleinick et al., 2002). Recent studies have shown that 5-ALA-PDT-
induced photodamage causes mitochondrial and nuclear DNA damage. As a result, massive
apoptosis occurs owing to mitochondrial release of cytochrome c and activation of caspase-3
and caspase-9 in glioma cells (Inoue et al., 2007; Karmakar et al., 2007). These results indicate
that 5-ALA-PDT triggers apoptosis through a mitochondrial pathway.
Compared to the other modalities, 5-ALA-PDT has the advantage of better specificity and
lower complication rates, and it is also a good alternative in tumor patients not eligible for
surgery. Unfortunately, current 5-ALA-PDT protocols have yet to be widely established in
clinical treatment for glioma. This may be partly due to limitations in current PDT regimens
and partly due to the therapeutic efficacy of 5-ALA-PDT in preclinical settings (Teng et al.,
2011). The reason for 5-ALA-PDT not being standard treatment in malignant glioma may be
multifactorial, including the lack of randomized controlled trials and an optimal 5-ALA-PDT
regimen. Generally, PDT efficacy depends on parameters such as the photosensitizing agent,
irradiance and timing, oxygen, photosensitizer concentration, and different pathologic grade
glioma tissue sensitivity to the PDT effect (Teng et al., 2011). Optimizing these parameters is
difficult, expensive, and time consuming. The efficacy of 5-ALA-PDT may also be limited by
reduced penetration of appropriate light through the target tissue and local acute phototoxicity
to normal surrounding brain tissue (Norum et al., 2009). In addition, post-treatment edema
and long-lasting skin photosensitivity after PDT of brain tumors are potentially challenging
side effects that neurosurgeons have to deal with. Regarding the specificity of PDD for glioma
surgery, new techniques allowing more specific accumulation of PpIX in target tumor cells
need to be developed. Further studies are required for screening available and specific glioma
antigens that are strongly expressed in glioma tissues, but not in normal brain tissues. 5-ALA
labeled with antibodies against glioma-specific antigens may be useful in increasing the
accumulation of PpIX and the specificity of PDD in glioma tissues. If the specificity and
selectivity of 5-ALA-PDT could be improved in glioma tissue, 5-ALA-PDT would certainly be
regarded as a promising and competitive alternative in glioma treatment.
6. Perspective
In this review, we focused on the 5-ALA agent as a potential treatment modality for patients
with malignant glioma. 5-ALA-induced fluorescence is a useful intraoperative tool for the
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al., 1998c). In 1998, Stummer et al. first presented a detailed description of the technical
principles for 5-ALA fluorescence-guided microsurgical resection of malignant glioma tissue
(Stummer et al., 1998a). Subsequently, they performed a prospective study in 52 glioblastoma
patients and identified the usefulness of 5-ALA-induced tumor fluorescence for guiding tumor
resection. Recent controlled Phase III clinical trials have demonstrated that compared to
conventional microsurgery, 5-ALA fluorescence-guided microsurgical resection enables more
complete resection of contrast-enhancing lesions and improves progression-free survival in
patients with malignant glioma (Pichlmeier et al., 2008; Stummer et al., 2006). After the rapid
development of the neurosurgical fluorescence operation microscope, several investigators
have recently demonstrated the feasibility of 5-ALA fluorescence-guided resection in patients
with glioma (Kuroiwa et al., 1998; Kuroiwa et al., 2001; Sherman et al., 2011). Widhalm et al.
also indicated that 5-ALA is a promising marker for intraoperative visualization of anaplastic
foci in diffusely infiltrating gliomas without contrast enhancement and showed that the
positive predictive value (PVV) of focal 5-ALA fluorescence for World Health Organization
(WHO) grade III glioma was 100% (sensitivity 89%) (Widhalm et al., 2010). In addition,
Nabavi’s group investigated the feasibility and selectivity of 5-ALA-induced fluorescence to
guide resection in recurrent gliomas (WHO grade III/IV) and found that 5-ALA fluorescence
(weak and strong) had a high PPV (97.2%) in all pathological-appearing tissues obtained from
354 biopsies performed in 36 patients (Nabavi et al., 2009). Based on these findings, they
suggested that 5-ALA fluorescence guidance is an effective surgical adjunct in the surgery of
recurrent malignant gliomas, and many other trials have displayed similar successful results
using 5-ALA fluorescence-guided resection in meningiomas to achieve optimal resection
(Coluccia et al., 2010; Kajimoto et al., 2007).
Despite the advantages of 5-ALA fluorescence, successful glioma resection often depends on
the neurosurgeon’s ability to distinguish residual tumor tissue from surrounding brain tissue
even with the assistance of PpIX fluorescence (Teng et al., 2011). The marginal area containing
infiltrating glioma cells shows vague fluorescence because the density of the glioma cells in
these areas is low and heterogeneous, resulting in insufficient 5-ALA uptake and PpIX
accumulation (Utsuki et al., 2006). Conversely, because of the presence of reactive astrocytes
and macrophages and leakage of PpIX into the extracellular matrix, false-positive (i.e., the area
fluoresced, but no tumor was seen histologically) results in weakly fluorescing normal-
appearing tissue are also common (Utsuki et al., 2007). Therefore, more objective and quanti‐
tative indicators need to be established for neurosurgeons to improve intraoperative
identification of tumor margins. Recently, a quantitative method involving spectroscopic
analysis for determining the amount of fluorescence present has been developed, which allows
more precise visualization of quantitative fluorescence from tumor tissues (Utsuki et al.,
2006; Valdes et al., 2011).
5. 5–ALA mediated-PDT
PDT is a tool for the treatment of certain cancerous and pre-cancerous conditions, especially
in the field of dermatology (Buytaert et al., 2007). Among the many kinds of photosensitizers,
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5-ALA has become widely accepted. 5-ALA-PDT is a novel treatment modality for early or
superficial cancers, as well as a palliative treatment to a certain extent, that triggers a photo‐
dynamic effect similar to that of light in the visible range to produce a rapid PDT response in
the targeted tissue. Three types of mechanisms have been identified in the literature as
contributing to the rapid PDT response in vivo: (1) PDT can directly damage and kill the
malignant tumor cells, either by apoptosis or a non-apoptotic mechanism; (2) PDT may
produce profound changes in the tumor vasculature, including blood flow stasis, vascular
collapse, and/or vascular leakage, that can result in indirect killing of malignant cells; and (3)
PDT can promote the release of cytokines and other inflammatory mediators from target cells
that induce an inflammatory response and recruit additional host cells to the tumor (Mac‐
Donald & Dougherty, 2001; Oleinick et al., 2002). Recent studies have shown that 5-ALA-PDT-
induced photodamage causes mitochondrial and nuclear DNA damage. As a result, massive
apoptosis occurs owing to mitochondrial release of cytochrome c and activation of caspase-3
and caspase-9 in glioma cells (Inoue et al., 2007; Karmakar et al., 2007). These results indicate
that 5-ALA-PDT triggers apoptosis through a mitochondrial pathway.
Compared to the other modalities, 5-ALA-PDT has the advantage of better specificity and
lower complication rates, and it is also a good alternative in tumor patients not eligible for
surgery. Unfortunately, current 5-ALA-PDT protocols have yet to be widely established in
clinical treatment for glioma. This may be partly due to limitations in current PDT regimens
and partly due to the therapeutic efficacy of 5-ALA-PDT in preclinical settings (Teng et al.,
2011). The reason for 5-ALA-PDT not being standard treatment in malignant glioma may be
multifactorial, including the lack of randomized controlled trials and an optimal 5-ALA-PDT
regimen. Generally, PDT efficacy depends on parameters such as the photosensitizing agent,
irradiance and timing, oxygen, photosensitizer concentration, and different pathologic grade
glioma tissue sensitivity to the PDT effect (Teng et al., 2011). Optimizing these parameters is
difficult, expensive, and time consuming. The efficacy of 5-ALA-PDT may also be limited by
reduced penetration of appropriate light through the target tissue and local acute phototoxicity
to normal surrounding brain tissue (Norum et al., 2009). In addition, post-treatment edema
and long-lasting skin photosensitivity after PDT of brain tumors are potentially challenging
side effects that neurosurgeons have to deal with. Regarding the specificity of PDD for glioma
surgery, new techniques allowing more specific accumulation of PpIX in target tumor cells
need to be developed. Further studies are required for screening available and specific glioma
antigens that are strongly expressed in glioma tissues, but not in normal brain tissues. 5-ALA
labeled with antibodies against glioma-specific antigens may be useful in increasing the
accumulation of PpIX and the specificity of PDD in glioma tissues. If the specificity and
selectivity of 5-ALA-PDT could be improved in glioma tissue, 5-ALA-PDT would certainly be
regarded as a promising and competitive alternative in glioma treatment.
6. Perspective
In this review, we focused on the 5-ALA agent as a potential treatment modality for patients
with malignant glioma. 5-ALA-induced fluorescence is a useful intraoperative tool for the
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visualization of glioma tissue, and 5-ALA-PDT is a promising and alternative adjuvant therapy
for photokilling residual neoplastic cells. Although impressive advances in the application of
5-ALA to glioma have been made from many clinical trials, this evolving field still faces
important challenges. For example, single imaging in solid malignant glioma tissue with all
of these features is not sufficient. Judgment of the extent of resection may still be treacherous
within infiltrating parts of brain tumors, where the ratio of background noise of normal brain
tissue to signal intensity of PpIX-saturated malignant glioma cells is less pronounced (Hefti et
al., 2012; Liao et al., 2012). Recent efforts to boost target-to-background ratios have used a
combination of intraoperative 5-ALA-induced fluorescence and 3D MRI imaging or neurona‐
vigation imaging with some success (Liao et al., 2008; Panciani et al., 2012). Furthermore, more
objective indicators to measure quantitative PpIX concentrations intraoperatively in the brain
tumor margin need to be established. In the future, laboratory and clinical studies should be
devoted to 5-ALA-PDT in conjunction with the use of other therapies, which will have maximal
effect on the residual tumor after resection. This multiple adjuvant therapy should enhance
specificity and allow lowering of the total PDT dose, while still increasing the therapeutic
efficacy of PDT. Other proposals should adjust the current PDT treatment regimens, modify
the existing photosensitizer, or develop new and more specific photosensitizers. Further
studies are needed to elucidate possible mechanisms of 5-ALA uptake that could explain the
diversity of intraoperative findings.
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devoted to 5-ALA-PDT in conjunction with the use of other therapies, which will have maximal
effect on the residual tumor after resection. This multiple adjuvant therapy should enhance
specificity and allow lowering of the total PDT dose, while still increasing the therapeutic
efficacy of PDT. Other proposals should adjust the current PDT treatment regimens, modify
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studies are needed to elucidate possible mechanisms of 5-ALA uptake that could explain the
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Author details
Lei Teng1,2, Mitsutoshi Nakada1*, Yutaka Hayashi1, Takeshi Yoneyama3, Shi-Guang Zhao2 and
Jun-Ichiro Hamada1
*Address all correspondence to: mnakada@med.kanazawa-u.ac.jp
1 Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University,
Kanazawa,, Japan
2 Department of Neurosurgery, The First Clinical College of Harbin Medical University,
Harbin,, China
3 College of Science and Engineering, Kanazawa University, Kanazawa,, Japan
References
[1] Aydin, H, Sillenberg, I, & Von Lieven, H. (2001). Patterns of failure following CT-
based 3-D irradiation for malignant glioma. Strahlenther Onkol. 0179-7158, 177(8),
424-431.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors256
[2] Babu, R, & Adamson, C. (2012). Fluorescence-Guided Malignant Glioma Resections.
Curr Drug Discov Technol. Vol. No. pp. 1875-6220, 1875-6220.
[3] Blake, E, & Curnow, A. (2010). The hydroxypyridinone iron chelator CP94 can en‐
hance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol.
1751-1097, 86(5), 1154-1160.
[4] Bottomley, S. S, & Muller-eberhard, U. (1988). Pathophysiology of heme synthesis.
Seminars in hematology. 0037-1963, 25(4), 282-302.
[5] Buytaert, E, Dewaele, M, & Agostinis, P. (2007). Molecular effectors of multiple cell
death pathways initiated by photodynamic therapy. Biochim Biophys Acta.
0006-3002, 1776(1), 86-107.
[6] Castano, A. P, Mroz, P, & Hamblin, M. R. (2006). Photodynamic therapy and anti-tu‐
mour immunity. Nature reviews Cancer. 0147-4175X, 6(7), 535-545.
[7] Coluccia, D, Fandino, J, Fujioka, M, Cordovi, S, Muroi, C, & Landolt, H. (2010). Intra‐
operative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neuro‐
chir (Wien). 0942-0940, 152(10), 1711-1719.
[8] Hallewin, D, Vanherzeele, M. A, & Baert, H. L. ((1998). Fluorescence detection of flat
transitional cell carcinoma after intravesical instillation of aminolevulinic acid. Amer‐
ican journal of clinical oncology. 0277-3732, 21(3), 223-225.
[9] Eljamel, M. S, Goodman, C, & Moseley, H. (2008). ALA and Photofrin fluorescence-
guided resection and repetitive PDT in glioblastoma multiforme: a single centre
Phase III randomised controlled trial. Lasers in medical science. 0268-8921, 23(4),
361-367.
[10] Ferreira, G. C, Franco, R, Lloyd, S. G, Moura, I, Moura, J. J, & Huynh, B. H. (1995).
Structure and function of ferrochelatase. J Bioenerg Biomembr. 0014-5479X, 27(2),
221-229.
[11] Gossner, L, Stolte, M, Sroka, R, Rick, K, May, A, Hahn, E. G, & Ell, C. (1998). Photo‐
dynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by
means of 5-aminolevulinic acid. Gastroenterology. 0016-5085, 114(3), 448-455.
[12] Guyon, L, Ascencio, M, Collinet, P, & Mordon, S. (2012). Photodiagnosis and photo‐
dynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagnosis Photo‐
dyn Ther. 1873-1597, 9(1), 16-31.
[13] Hefti, M, Albert, I, & Luginbuehl, V. (2012). Phenytoin reduces 5-aminolevulinic
acid-induced protoporphyrin IX accumulation in malignant glioma cells. J Neuroon‐
col. 1573-7373, 108(3), 443-450.
[14] Iacob, G, & Dinca, E. B. (2009). Current data and strategy in glioblastoma multiforme.
J Med Life. 0184-4122X, 2(4), 386-393.
[15] Inoue, H, Kajimoto, Y, Shibata, M. A, Miyoshi, N, Ogawa, N, Miyatake, S, Otsuki, Y,
& Kuroiwa, T. (2007). Massive apoptotic cell death of human glioma cells via a mito‐
Current Applications of 5–ALA in Glioma Diagnostics and Therapy
http://dx.doi.org/10.5772/52428
257
chondrial pathway following 5-aminolevulinic acid-mediated photodynamic thera‐
py. J Neurooncol. 0016-7594X, 83(3), 223-231.
[16] Kajimoto, Y, Kuroiwa, T, Miyatake, S. I, Ichioka, T, Miyashita, M, Tanaka, H, & Tsuji,
M. (2007). Use of 5-aminolevulinic acid in fluorescence-guided resection of meningio‐
ma with high risk of recurrence- Case report. Journal of Neurosurgery. 0022-3085,
106(6), 1070-1074.
[17] Karmakar, S, Banik, N. L, Patel, S. J, & Ray, S. K. (2007). Aminolevulinic acid-based
photodynamic therapy suppressed survival factors and activated proteases for apop‐
tosis in human glioblastoma U87MG cells. Neurosci Lett. 0304-3940, 415(3), 242-247.
[18] Kemmner, W, Wan, K, Ruttinger, S, Ebert, B, Macdonald, R, Klamm, U, & Moesta, K.
T. (2008). Silencing of human ferrochelatase causes abundant protoporphyrin-IX ac‐
cumulation in colon cancer. FASEB J. 1530-6860, 22(2), 500-509.
[19] Kennedy, J. C, & Pottier, R. H. (1992). Endogenous protoporphyrin IX, a clinically
useful photosensitizer for photodynamic therapy. J Photochem Photobiol B.
1011-1344, 14(4), 275-292.
[20] Kuroiwa, T, Kajimoto, Y, & Ohta, T. (1998). Development of a fluorescein operative
microscope for use during malignant glioma surgery- A technical note and prelimi‐
nary report. Surgical Neurology. 0090-3019, 50(1), 41-48.
[21] Kuroiwa, T, Kajimoto, Y, & Ohta, T. (2001). Development and clinical application of
near-infrared surgical microscope: preliminary report. Minim Invasive Neurosurg.
0946-7211, 44(4), 240-242.
[22] Lefranc, F, Sadeghi, N, Camby, I, Metens, T, Dewitte, O, & Kiss, R. (2006). Present
and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther.
1744-8328, 6(5), 719-732.
[23] Liao, H, Shimaya, K, Wang, K, Maruyama, T, Noguchi, M, Muragaki, Y, Kobayashi,
E, Iseki, H, & Sakuma, I. (2008). Combination of intraoperative 5-aminolevulinic acid-
induced fluorescence and 3-D MR imaging for guidance of robotic laser ablation for
precision neurosurgery. Med Image Comput Comput Assist Interv. No. Pt 2, ISSN:,
11, 373-380.
[24] Liao, H. E, Noguchi, M, Maruyama, T, Muragaki, Y, Kobayashi, E, Iseki, H, & Saku‐
ma, I. (2012). An integrated diagnosis and therapeutic system using intra-operative 5-
aminolevulinic-acid-induced fluorescence guided robotic laser ablation for precision
neurosurgery. Med Image Anal. 1361-8415, 16(3), 754-766.
[25] Loh, C. S, & Vernon, D. MacRobert, A.J., Bedwell, J., Bown, S.G. & Brown, S.B.
((1993). Endogenous porphyrin distribution induced by 5-aminolaevulinic acid in the
tissue layers of the gastrointestinal tract. J Photochem Photobiol B. 1011-1344, 20(1),
47-54.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors258
[26] Loning, M, Diddens, H, Kupker, W, Diedrich, K, & Huttmann, G. (2004). Laparo‐
scopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulin‐
ic acid-induced protoporphyrin IX. Cancer. 0000-8543X, 100(8), 1650-1656.
[27] MacDonaldI.J. & Dougherty, T.J. ((2001). Basic principles of photodynamic therapy. J
Porphyr Phthalocya. 1088-4246, 5(2), 105-129.
[28] Nabavi, A, Thurm, H, Zountsas, B, Pietsch, T, Lanfermann, H, Pichlmeier, U, Meh‐
dorn, M, & Glioma, A. L. A. R. (2009). Five-Aminolevulinic Acid for Fluorescence-
Guided Resection of Recurrent Malignant Gliomas: A Phase Ii Study. Neurosurgery.
0014-8396X, 65(6), 1070-1076.
[29] Norum, O. J, Selbo, P. K, Weyergang, A, Giercksky, K. E, & Berg, K. (2009). Photo‐
chemical internalization (PCI) in cancer therapy: from bench towards bedside medi‐
cine. J Photochem Photobiol B. 1873-2682, 96(2), 83-92.
[30] Oleinick, N. L, Morris, R. L, & Belichenko, T. (2002). The role of apoptosis in response
to photodynamic therapy: what, where, why, and how. Photoch Photobio Sci.
0147-4905X, 1(1), 1-21.
[31] Panciani, P. P, Fontanella, M, Garbossa, D, Agnoletti, A, Ducati, A, & Lanotte, M.
(2012). aminolevulinic acid and neuronavigation in high-grade glioma surgery: re‐
sults of a combined approach. Neurocirugia. 1130-1473, 23(1), 23-28.
[32] Peng, Q, Warloe, T, Berg, K, Moan, J, Kongshaug, M, Giercksky, K. E, & Nesland, J.
M. (1997). Aminolevulinic acid-based photodynamic therapy. Clinical research and
future challenges. Cancer. 0000-8543X, 79(12), 2282-2308.
[33] Pichlmeier, U, Bink, A, Schackert, G, & Stummer, W. (2008). Resection and survival
in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study
patients. Neuro Oncol. 1522-8517, 10(6), 1025-1034.
[34] Piotrowski, W. J, Marczak, J, Nawrocka, A, Antczak, A, & Gorski, P. (2004). Inhala‐
tions of 5-ALA in photodynamic diagnosis of bronchial cancer. Monaldi Arch Chest
Dis. 1122-0643, 61(2), 86-93.
[35] Sherman, J. H, Hoes, K, Marcus, J, Komotar, R. J, Brennan, C. W, & Gutin, P. H.
(2011). Neurosurgery for brain tumors: update on recent technical advances. Current
neurology and neuroscience reports. 1534-6293, 11(3), 313-319.
[36] Stummer, W, Novotny, A, Stepp, H, Goetz, C, Bise, K, & Reulen, H. J. (2000). Fluores‐
cence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-
induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg.
0022-3085, 93(6), 1003-1013.
[37] Stummer, W, Pichlmeier, U, Meinel, T, Wiestler, O. D, Zanella, F, Reulen, H. J,
Group, A. L, & Fluorescence-guided, G. S. surgery with 5-aminolevulinic acid for re‐
section of malignant glioma: a randomised controlled multicentre phase III trial. Lan‐
cet Oncol. 1470-2045, 7(5), 392-401.
Current Applications of 5–ALA in Glioma Diagnostics and Therapy
http://dx.doi.org/10.5772/52428
259
chondrial pathway following 5-aminolevulinic acid-mediated photodynamic thera‐
py. J Neurooncol. 0016-7594X, 83(3), 223-231.
[16] Kajimoto, Y, Kuroiwa, T, Miyatake, S. I, Ichioka, T, Miyashita, M, Tanaka, H, & Tsuji,
M. (2007). Use of 5-aminolevulinic acid in fluorescence-guided resection of meningio‐
ma with high risk of recurrence- Case report. Journal of Neurosurgery. 0022-3085,
106(6), 1070-1074.
[17] Karmakar, S, Banik, N. L, Patel, S. J, & Ray, S. K. (2007). Aminolevulinic acid-based
photodynamic therapy suppressed survival factors and activated proteases for apop‐
tosis in human glioblastoma U87MG cells. Neurosci Lett. 0304-3940, 415(3), 242-247.
[18] Kemmner, W, Wan, K, Ruttinger, S, Ebert, B, Macdonald, R, Klamm, U, & Moesta, K.
T. (2008). Silencing of human ferrochelatase causes abundant protoporphyrin-IX ac‐
cumulation in colon cancer. FASEB J. 1530-6860, 22(2), 500-509.
[19] Kennedy, J. C, & Pottier, R. H. (1992). Endogenous protoporphyrin IX, a clinically
useful photosensitizer for photodynamic therapy. J Photochem Photobiol B.
1011-1344, 14(4), 275-292.
[20] Kuroiwa, T, Kajimoto, Y, & Ohta, T. (1998). Development of a fluorescein operative
microscope for use during malignant glioma surgery- A technical note and prelimi‐
nary report. Surgical Neurology. 0090-3019, 50(1), 41-48.
[21] Kuroiwa, T, Kajimoto, Y, & Ohta, T. (2001). Development and clinical application of
near-infrared surgical microscope: preliminary report. Minim Invasive Neurosurg.
0946-7211, 44(4), 240-242.
[22] Lefranc, F, Sadeghi, N, Camby, I, Metens, T, Dewitte, O, & Kiss, R. (2006). Present
and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther.
1744-8328, 6(5), 719-732.
[23] Liao, H, Shimaya, K, Wang, K, Maruyama, T, Noguchi, M, Muragaki, Y, Kobayashi,
E, Iseki, H, & Sakuma, I. (2008). Combination of intraoperative 5-aminolevulinic acid-
induced fluorescence and 3-D MR imaging for guidance of robotic laser ablation for
precision neurosurgery. Med Image Comput Comput Assist Interv. No. Pt 2, ISSN:,
11, 373-380.
[24] Liao, H. E, Noguchi, M, Maruyama, T, Muragaki, Y, Kobayashi, E, Iseki, H, & Saku‐
ma, I. (2012). An integrated diagnosis and therapeutic system using intra-operative 5-
aminolevulinic-acid-induced fluorescence guided robotic laser ablation for precision
neurosurgery. Med Image Anal. 1361-8415, 16(3), 754-766.
[25] Loh, C. S, & Vernon, D. MacRobert, A.J., Bedwell, J., Bown, S.G. & Brown, S.B.
((1993). Endogenous porphyrin distribution induced by 5-aminolaevulinic acid in the
tissue layers of the gastrointestinal tract. J Photochem Photobiol B. 1011-1344, 20(1),
47-54.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors258
[26] Loning, M, Diddens, H, Kupker, W, Diedrich, K, & Huttmann, G. (2004). Laparo‐
scopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulin‐
ic acid-induced protoporphyrin IX. Cancer. 0000-8543X, 100(8), 1650-1656.
[27] MacDonaldI.J. & Dougherty, T.J. ((2001). Basic principles of photodynamic therapy. J
Porphyr Phthalocya. 1088-4246, 5(2), 105-129.
[28] Nabavi, A, Thurm, H, Zountsas, B, Pietsch, T, Lanfermann, H, Pichlmeier, U, Meh‐
dorn, M, & Glioma, A. L. A. R. (2009). Five-Aminolevulinic Acid for Fluorescence-
Guided Resection of Recurrent Malignant Gliomas: A Phase Ii Study. Neurosurgery.
0014-8396X, 65(6), 1070-1076.
[29] Norum, O. J, Selbo, P. K, Weyergang, A, Giercksky, K. E, & Berg, K. (2009). Photo‐
chemical internalization (PCI) in cancer therapy: from bench towards bedside medi‐
cine. J Photochem Photobiol B. 1873-2682, 96(2), 83-92.
[30] Oleinick, N. L, Morris, R. L, & Belichenko, T. (2002). The role of apoptosis in response
to photodynamic therapy: what, where, why, and how. Photoch Photobio Sci.
0147-4905X, 1(1), 1-21.
[31] Panciani, P. P, Fontanella, M, Garbossa, D, Agnoletti, A, Ducati, A, & Lanotte, M.
(2012). aminolevulinic acid and neuronavigation in high-grade glioma surgery: re‐
sults of a combined approach. Neurocirugia. 1130-1473, 23(1), 23-28.
[32] Peng, Q, Warloe, T, Berg, K, Moan, J, Kongshaug, M, Giercksky, K. E, & Nesland, J.
M. (1997). Aminolevulinic acid-based photodynamic therapy. Clinical research and
future challenges. Cancer. 0000-8543X, 79(12), 2282-2308.
[33] Pichlmeier, U, Bink, A, Schackert, G, & Stummer, W. (2008). Resection and survival
in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study
patients. Neuro Oncol. 1522-8517, 10(6), 1025-1034.
[34] Piotrowski, W. J, Marczak, J, Nawrocka, A, Antczak, A, & Gorski, P. (2004). Inhala‐
tions of 5-ALA in photodynamic diagnosis of bronchial cancer. Monaldi Arch Chest
Dis. 1122-0643, 61(2), 86-93.
[35] Sherman, J. H, Hoes, K, Marcus, J, Komotar, R. J, Brennan, C. W, & Gutin, P. H.
(2011). Neurosurgery for brain tumors: update on recent technical advances. Current
neurology and neuroscience reports. 1534-6293, 11(3), 313-319.
[36] Stummer, W, Novotny, A, Stepp, H, Goetz, C, Bise, K, & Reulen, H. J. (2000). Fluores‐
cence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-
induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg.
0022-3085, 93(6), 1003-1013.
[37] Stummer, W, Pichlmeier, U, Meinel, T, Wiestler, O. D, Zanella, F, Reulen, H. J,
Group, A. L, & Fluorescence-guided, G. S. surgery with 5-aminolevulinic acid for re‐
section of malignant glioma: a randomised controlled multicentre phase III trial. Lan‐
cet Oncol. 1470-2045, 7(5), 392-401.
Current Applications of 5–ALA in Glioma Diagnostics and Therapy
http://dx.doi.org/10.5772/52428
259
[38] Stummer, W, Reulen, H. J, Novotny, A, Stepp, H, & Tonn, J. C. (2003). Fluorescence-
guided resections of malignant gliomas--an overview. Acta Neurochir Suppl. No.
0065-1419, 88, 9-12.
[39] Stummer, W, Stepp, H, Moller, G, Ehrhardt, A, Leonhard, M, & Reulen, H. J. (1998a).
Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resec‐
tion of malignant glioma tissue. Acta Neurochir (Wien). 0001-6268, 140(10), 995-1000.
[40] Stummer, W, Stocker, S, Novotny, A, Heimann, A, Sauer, O, Kempski, O, Plesnila, N,
Wietzorrek, J, & Reulen, H. J. (1998b). In vitro and in vivo porphyrin accumulation
by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B.
1011-1344, 45(2-3), 160-169.
[41] Stummer, W, Stocker, S, Wagner, S, Stepp, H, Fritsch, C, Goetz, C, Goetz, A. E, Kief‐
mann, R, & Reulen, H. J. (1998c). Intraoperative detection of malignant gliomas by 5-
aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. discussion
525-526, 0014-8396X, 42(3), 518-525.
[42] Takahashi, K, Ikeda, N, Nonoguchi, N, Kajimoto, Y, Miyatake, S, Hagiya, Y, Ogura,
S, Nakagawa, H, Ishikawa, T, & Kuroiwa, T. (2011). Enhanced expression of copro‐
porphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-in‐
duced fluorescence. Neuro Oncol. 1523-5866, 13(11), 1234-1243.
[43] Teng, L, Nakada, M, Zhao, S. G, Endo, Y, Furuyama, N, Nambu, E, Pyko, I. V, Haya‐
shi, Y, & Hamada, J. I. (2011). Silencing of ferrochelatase enhances 5-aminolevulinic
acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer. 1532-1827,
104(5), 798-807.
[44] Toda, M. (2008). Intraoperative navigation and fluorescence imagings in malignant
glioma surgery. The Keio journal of medicine. 1880-1293, 57(3), 155-161.
[45] Utsuki, S, Oka, H, Sato, S, Shimizu, S, Suzuki, S, Tanizaki, Y, Kondo, K, Miyajima, Y,
& Fujii, K. (2007). Histological examination of false positive tissue resection using 5-
aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo).
0470-8105, 47(5), 210-213.
[46] Utsuki, S, Oka, H, Sato, S, Suzuki, S, Shimizu, S, Tanaka, S, & Fujii, K. (2006). Possi‐
bility of using laser spectroscopy for the intraoperative detection of nonfluorescing
brain tumors and the boundaries of brain tumor infiltrates. Technical note. J Neuro‐
surg. 0022-3085, 104(4), 618-620.
[47] Valdes, P. A, Leblond, F, Kim, A, Harris, B. T, Wilson, B. C, Fan, X. Y, Tosteson, T. D,
Hartov, A, Ji, S. B, Erkmen, K, Simmons, N. E, Paulsen, K. D, & Roberts, D. W. (2011).
Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX
as an intraoperative biomarker. Journal of Neurosurgery. 0022-3085, 115(1), 11-17.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors260
[48] Wallner, K. E, Galicich, J. H, Krol, G, Arbit, E, & Malkin, M. G. (1989). Patterns of fail‐
ure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int
J Radiat Oncol Biol Phys. 0360-3016, 16(6), 1405-1409.
[49] Widhalm, G, Wolfsberger, S, Minchev, G, Woehrer, A, Krssak, M, Czech, T, Prayer,
D, Asenbaum, S, Hainfellner, J. A, & Knosp, E. (2010). Aminolevulinic Acid Is a
Promising Marker for Detection of Anaplastic Foci in Diffusely Infiltrating Gliomas
With Nonsignificant Contrast Enhancement. Cancer. 0000-8543X, 116(6), 1545-1552.
[50] Zhao, S. G, Chen, X. F, Wang, L. G, Yang, G, Han, D. Y, Teng, L, Yang, M. C, Wang,
D. Y, Shi, C, Liu, Y. H, Zheng, B. J, Shi, C. B, Gao, X, & Rainov, N. G. (2012). In‐
creased Expression of ABCB6 Enhances Protoporphyrin IX Accumulation and Photo‐
dynamic Effect in Human Glioma. Annals of surgical oncology. Vol. No. pp.
1534-4681, 1534-4681.
Current Applications of 5–ALA in Glioma Diagnostics and Therapy
http://dx.doi.org/10.5772/52428
261
[38] Stummer, W, Reulen, H. J, Novotny, A, Stepp, H, & Tonn, J. C. (2003). Fluorescence-
guided resections of malignant gliomas--an overview. Acta Neurochir Suppl. No.
0065-1419, 88, 9-12.
[39] Stummer, W, Stepp, H, Moller, G, Ehrhardt, A, Leonhard, M, & Reulen, H. J. (1998a).
Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resec‐
tion of malignant glioma tissue. Acta Neurochir (Wien). 0001-6268, 140(10), 995-1000.
[40] Stummer, W, Stocker, S, Novotny, A, Heimann, A, Sauer, O, Kempski, O, Plesnila, N,
Wietzorrek, J, & Reulen, H. J. (1998b). In vitro and in vivo porphyrin accumulation
by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B.
1011-1344, 45(2-3), 160-169.
[41] Stummer, W, Stocker, S, Wagner, S, Stepp, H, Fritsch, C, Goetz, C, Goetz, A. E, Kief‐
mann, R, & Reulen, H. J. (1998c). Intraoperative detection of malignant gliomas by 5-
aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. discussion
525-526, 0014-8396X, 42(3), 518-525.
[42] Takahashi, K, Ikeda, N, Nonoguchi, N, Kajimoto, Y, Miyatake, S, Hagiya, Y, Ogura,
S, Nakagawa, H, Ishikawa, T, & Kuroiwa, T. (2011). Enhanced expression of copro‐
porphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-in‐
duced fluorescence. Neuro Oncol. 1523-5866, 13(11), 1234-1243.
[43] Teng, L, Nakada, M, Zhao, S. G, Endo, Y, Furuyama, N, Nambu, E, Pyko, I. V, Haya‐
shi, Y, & Hamada, J. I. (2011). Silencing of ferrochelatase enhances 5-aminolevulinic
acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer. 1532-1827,
104(5), 798-807.
[44] Toda, M. (2008). Intraoperative navigation and fluorescence imagings in malignant
glioma surgery. The Keio journal of medicine. 1880-1293, 57(3), 155-161.
[45] Utsuki, S, Oka, H, Sato, S, Shimizu, S, Suzuki, S, Tanizaki, Y, Kondo, K, Miyajima, Y,
& Fujii, K. (2007). Histological examination of false positive tissue resection using 5-
aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo).
0470-8105, 47(5), 210-213.
[46] Utsuki, S, Oka, H, Sato, S, Suzuki, S, Shimizu, S, Tanaka, S, & Fujii, K. (2006). Possi‐
bility of using laser spectroscopy for the intraoperative detection of nonfluorescing
brain tumors and the boundaries of brain tumor infiltrates. Technical note. J Neuro‐
surg. 0022-3085, 104(4), 618-620.
[47] Valdes, P. A, Leblond, F, Kim, A, Harris, B. T, Wilson, B. C, Fan, X. Y, Tosteson, T. D,
Hartov, A, Ji, S. B, Erkmen, K, Simmons, N. E, Paulsen, K. D, & Roberts, D. W. (2011).
Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX
as an intraoperative biomarker. Journal of Neurosurgery. 0022-3085, 115(1), 11-17.
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors260
[48] Wallner, K. E, Galicich, J. H, Krol, G, Arbit, E, & Malkin, M. G. (1989). Patterns of fail‐
ure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int
J Radiat Oncol Biol Phys. 0360-3016, 16(6), 1405-1409.
[49] Widhalm, G, Wolfsberger, S, Minchev, G, Woehrer, A, Krssak, M, Czech, T, Prayer,
D, Asenbaum, S, Hainfellner, J. A, & Knosp, E. (2010). Aminolevulinic Acid Is a
Promising Marker for Detection of Anaplastic Foci in Diffusely Infiltrating Gliomas
With Nonsignificant Contrast Enhancement. Cancer. 0000-8543X, 116(6), 1545-1552.
[50] Zhao, S. G, Chen, X. F, Wang, L. G, Yang, G, Han, D. Y, Teng, L, Yang, M. C, Wang,
D. Y, Shi, C, Liu, Y. H, Zheng, B. J, Shi, C. B, Gao, X, & Rainov, N. G. (2012). In‐
creased Expression of ABCB6 Enhances Protoporphyrin IX Accumulation and Photo‐
dynamic Effect in Human Glioma. Annals of surgical oncology. Vol. No. pp.
1534-4681, 1534-4681.




Photodynamic Therapy Using Talaporfin Sodium and
Diode Laser for Newly Diagnosed Malignant Gliomas
Jiro Akimoto
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53485
1. Introduction
Wilson et al. [1] investigated the progression of glioblastoma (Grade 4) at the cellular level
and showed that cells from tumors of 4 cm or greater in diameter on diagnostic imaging are
considered to be present in both normal and affected brain tissues, with a distribution of
92% of tumor cells in the tumor bulk, 6% in areas within a 2-cm margin around the tumor,
and 1.8% within an additional 2-cm area surrounding this margin. The majority of recurrent
malignant gliomas develop in this marginal area, and therefore, controlling infiltrating cells
in this region while protecting normal brain cells is critical to inhibit tumor recurrence.
In photodynamic therapy (PDT), a photosensitizer taken up in tumor tissues and neovascular‐
ized tumor vessels is administered to cancer patients. Tumor tissues are then later irradiated
using a laser to induce a photochemical reaction in the photosensitizer, thereby selectively
causing tumor cell apoptosis and necrosis. This tumor cell apoptosis and necrosis result from
the strong oxidative effect of singlet oxygen (active oxygen) produced by the photochemical re‐
action in the photosensitizer, induced by a laser at a specific wavelength [2].
We previously reported that PDT using talaporfin sodium (TS), a second-generation photo‐
sensitizer, induced tumor coagulation necrosis and tumor cell-selective apoptosis in rats in
which C6 glioma cells had been transplanted into the brain [3]. In the present study, we
evaluated the safety and efficacy of PDT in areas with tumor invasion following tumor re‐
moval in patients with malignant glioma.
2. Materials
Eligible subjects were patients with a first time diagnosis of adult intracranial malignant
glioma (Grade 3 or 4) based on preoperative diagnostic imaging and with a tumor bulk adja‐
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causing tumor cell apoptosis and necrosis. This tumor cell apoptosis and necrosis result from
the strong oxidative effect of singlet oxygen (active oxygen) produced by the photochemical re‐
action in the photosensitizer, induced by a laser at a specific wavelength [2].
We previously reported that PDT using talaporfin sodium (TS), a second-generation photo‐
sensitizer, induced tumor coagulation necrosis and tumor cell-selective apoptosis in rats in
which C6 glioma cells had been transplanted into the brain [3]. In the present study, we
evaluated the safety and efficacy of PDT in areas with tumor invasion following tumor re‐
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cent to the eloquent areas of the brain associated with language, motor, sensation and vi‐
sion, for which a wide resection of the tumor much larger than the tumor bulk was
impossible. Selective treatment of the infiltrating tumor cells by PDT was considered neces‐
sary because of tumor invasion into the eloquent areas, despite the fact that the tumor bulk
had been removed as extensively as possible. PDT was performed after a rapid intraopera‐
tive pathological diagnosis confirmed malignant glioma. We excluded patients who had re‐
ceived radiotherapy or chemotherapy within 3 weeks prior to the surgery, patients with
bleeding or abnormal coagulation test results, and patients with porphyria or porphyrin hy‐
persensitivity. This clinical study was approved by the Institutional Review Board of our in‐
stitution. All subjects provided written informed consent. The subjects were consecutive 8
patients (7 men and 1 woman) treated at our hospital between May 2006 and Mar 2009 and
aged 48 to 82 years (median, 58 years). The tumors were localized in the frontal lobe in 4
patients, temporal lobe in 2 patients, insular gyrus in 1 patient and parietal lobe in 1 patient.
Preoperative Karnofsky Performance Scale (KPS) was 50 to 80 (median 60). The extent of tu‐
mor resection was subtotal in 7 patients and partial in 1 patient. The final pathological diag‐
nosis was Grade 3 in 3 patients, and Grade 4 glioblastoma in 5 patients. As postoperative
adjuvant therapy, 4 patients received irradiation in combination with temozolomide (TMZ)
and 2 patients received irradiation and ACNU-based multidrug chemotherapy.
3. Methods
3.1. Talaporfin sodium and diode laser
Talaporfin  sodium  (TS:  Laserphyrin®,  Meiji  Seika  Pharma  Co.,  Ltd.,  Tokyo,  Japan)  is  a
photosensitizer  utilized  in  PDT which  was  approved for  use  in  Japan in  2003  as  treat‐
ment for early-stage lung cancer, in conjunction with a diode laser (PD Laser®, Panasonic
HealthCare Co., Ltd., Ehime, Japan) at a wavelength of 664 nm [4]. (Fig. 1A and B) Tala‐
porfin sodium is a second-generation photosensitizer which is more quickly excreted from
the body than the first-generation porfimer sodium (Photofrin®,  Pfizer  Japan Inc.,Tokyo,
Japan). It is characterized by the rapid resolution of a skin photosensitive reaction, which
is  important  with  the  use  of  photosensitizers.  This  has  enabled the  period of  necessary
light shielding in a room with measurement of < 500 lux to be reduced to 2 weeks for ta‐
laporfin sodium, whereas porfimer sodium requires patients to stay in a semi-dark(< 300
lux) room for 1 month after administration. The diode laser instrument is a compact sys‐
tem weighing 14 kg, has low power consumption, and can be easily maintained without
the need for dye exchange. (Fig. 2A).
3.2. Operating microscope equipped with diode laser
The PD Laser® (Panasonic HealthCare Co., Ltd.), installed in the MM30 microscope (Mitaka
Kohki Co., Ltd., Tokyo, Japan), is combined into a system which provides laser irradiation
from the operating microscope from a plane nearly coaxial to the surgical view. The laser is
introduced into the microscope by a quartz fiber, and providing a laser transmission path
close to an observation light path using a conventional halogen light. This allows surgeons
to accurately identify an irradiation target area during surgery. (Fig. 2A, B)
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Figure 1. Second-generation photosensitizer, Talaporfin sodium. A:Chemical structures of talaporfin sodium (mono-L-
aspartyl chlorine e6, NPe6) N-[[(2S,3S)-18-carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dibydro-3,7,12,17-tetramethyl-8-vi‐
nylporphyrin-20-yl]-L-asparatic acid. B:Absorption spectrum of talaporfin sodium and change in absorption
wavelength following conjugation with albumin (solid line; talaporfin sodium and phosphate buffer solution, dotted
line; talaporfin sodium conjugated with albumin) talaporfin sodium has absorption peaks in the Soret band (398nm)
and Q bands (502, 530, 620 and 654nm) in pH 7.4 phosphate buffer solution (PBS). When it conjugates with albumin,
its absorption band wavelength becomes approximately 10nm longer (bathochromic shift).
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cent to the eloquent areas of the brain associated with language, motor, sensation and vi‐
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impossible. Selective treatment of the infiltrating tumor cells by PDT was considered neces‐
sary because of tumor invasion into the eloquent areas, despite the fact that the tumor bulk
had been removed as extensively as possible. PDT was performed after a rapid intraopera‐
tive pathological diagnosis confirmed malignant glioma. We excluded patients who had re‐
ceived radiotherapy or chemotherapy within 3 weeks prior to the surgery, patients with
bleeding or abnormal coagulation test results, and patients with porphyria or porphyrin hy‐
persensitivity. This clinical study was approved by the Institutional Review Board of our in‐
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3.2. Operating microscope equipped with diode laser 
The PD Laser® (Panasonic HealthCare Co., Ltd.), installed in the MM30 microscope (Mitaka Kohki Co., Ltd., Tokyo, Japan), is 
combined into a system which provides laser irradiation from the operating microscope from a plane nearly coaxial to the surgical 
view. The laser is introduced into the microscope by a quartz fiber, and providing a laser transmission path close to an observation 
light path using a conventional halogen light. This allows surgeons to accurately identify an irradiation target area during surgery. 
(Figs. 2 A, B) 
 
Figure 2. Diode laser with a neurosurgical operating microscope. A: MM80® microscope (Mitaka Kohki Co., Ltd.) equipped with a compact-size 
diode laser (PD Laser®, Panasonic Health Care Ltd.). B: From the operating microscope, the diode laser irradiates the surgical field with an 
irradiation diameter of 1.0 cm2. 
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Figure 2. Diode laser with a neurosurgical operating microscope. A: MM80® microscope (Mitaka Kohki Co., Ltd.)
equipped with a compact-size diode laser (PD Laser®, Panasonic Health Care Ltd., arrow). B: From the operating micro‐
scope, the diode laser irradiates the surgical field with an irradiation diameter of 1.5 cm2.
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3.3. Photodynamic therapy (PDT)
TS was administered bolus intravenously at a dose of 40mg/m2 in shielded conditions 24
hours prior to surgery. At surgery, maximal resection of the tumor was performed usually
utilizing optical navigation system and electrophysiological monitoring leaving a tumor bed
area to be irradiated. The surface area of tumor bed was observed under operative micro‐
scope and optimal navigation system, and identified the optimal target for PDT. PDT cover‐
ing an area of 1.5 cm2 diameter was used for any tumor growth in these area. When 2 sites
were to be irradiated, we took care to avoid overlapping the irradiated areas under opera‐
tive microscope. Irradiation energy density of 27 J/cm2 (power density of 150mW/cm2, irradi‐
ation time of 180 seconds) of 664nm diode laser for PDT was irradiated superficially to one
or two targets of tumor bed.
3.4. Skin photosensitive reaction test
The administration of TS enhances sensitivity to light, and which may produce a photosen‐
sitive reaction. Patients should therefore avoid direct sunlight immediately after the admin‐
istration of talaporfin sodium and stay in a room where the illumination intensity is
adjusted to < 500 lux using a shading curtain. After surgery, patients were required to ex‐
pose the back of the palm of the hand to direct sunlight for 5minutes every day between
11:00 and 14:00 to evaluate the development of erythema. However, even when the result of
this skin photosensitivity test confirmed the resolution of a photosensitive reaction (defined
by the absence of evident erythema) and the restriction for shading at < 500 lux could be re‐
moved, patients were advised to avoid further direct sunlight for 2 weeks after the adminis‐
tration of talaporfin sodium. In particular, we recommended that special shading eye
goggles should be used worn 7 days after the administration of talaporfin sodium to avoid
exposing the retinas to direct sunlight.
4. Results
4.1. Selected case
A 65-year-old man presented with 2 months history of headache and gradually worsened.
Head MRI showed a tumor in the right frontal lobe, and edema extending as far as the pre-
motor area at the posterior edge of the tumor bulk. On a sagittal view, part of the posterior
edge of the tumor bulk extended posteriorly, and this part was determined to have invaded
the supplemental motor area(SMA) (Fig. 3A and B). Using optical navigation system and
motor evoked potential (MEP) monioring, we performed craniotomy in order to resect the
tumor, and rapid pathological diagnosis confirmed that the tumor was a glioblastoma. From
the optical navigation images, the posterior margin of the tumor bulk was confirmed to
have reached the pre-motor area (SMA-proper) (Fig.3C), and a single session of PDT at 27
J/cm2 (diameter of the irradiated area: 1.5 cm2) was performed at this site (Fig 3.D and E).
Under a pathological diagnosis of glioblastoma, the patient given postoperative irradiation
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equipped with a compact-size diode laser (PD Laser®, Panasonic Health Care Ltd., arrow). B: From the operating micro‐
scope, the diode laser irradiates the surgical field with an irradiation diameter of 1.5 cm2.
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A 65-year-old man presented with 2 months history of headache and gradually worsened.
Head MRI showed a tumor in the right frontal lobe, and edema extending as far as the pre-
motor area at the posterior edge of the tumor bulk. On a sagittal view, part of the posterior
edge of the tumor bulk extended posteriorly, and this part was determined to have invaded
the supplemental motor area(SMA) (Fig. 3A and B). Using optical navigation system and
motor evoked potential (MEP) monioring, we performed craniotomy in order to resect the
tumor, and rapid pathological diagnosis confirmed that the tumor was a glioblastoma. From
the optical navigation images, the posterior margin of the tumor bulk was confirmed to
have reached the pre-motor area (SMA-proper) (Fig.3C), and a single session of PDT at 27
J/cm2 (diameter of the irradiated area: 1.5 cm2) was performed at this site (Fig 3.D and E).
Under a pathological diagnosis of glioblastoma, the patient given postoperative irradiation
Photodynamic Therapy Using Talaporfin Sodium and Diode Laser for Newly Diagnosed Malignant Gliomas
http://dx.doi.org/10.5772/53485
267
and chemotherapy with oral TMZ. On day 3 after surgery, MRI showed remaining contrast-
enhanced tumor growth in the pre-motor area, but by the end of radiotherapy (on day 51
after surgery, Fig. 3F), complete response was confirmed at this site. His headache was dis‐
appeared and he enjoyed a play of weekly golf until 3 years after operation.
(a) (b) 
(c) 
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Figure 3. PDT and changes over time on postoperative magnetic resonance imaging (MRI) in Case 3. A: Preoperative
axial FLAIR image showed the right frontal tumor and the peri-tumoral edema extending to the right pre-motor cor‐
tex. B: Preoperative gadolinium-enhanced T1-weighted sagittal imaging showed a heterogeneously enhanced tumor
was present in the right superior frontal gyrus to supplementary motor cortex. C: Based on intra-operative optical nav‐
igation images, it was determined that the tumor had reached a portion adjacent to the ambulatory motor area
(green cross). D: The tumor was remained in this area (arrow). E: PDT at 150 mW/cm2 and 27 J/cm2 (diameter of the
irradiation area: 1.5 cm2) was performed for tumor infiltration into this area. (aluminum foil protected the anterior
cerebral arteries, arrow). F: Gadolinium-enhanced T1-weighted sagittal imaging on days 51 after surgery showed that
gadolinium-enhancement at the site of PDT had disappeared.
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In the evaluation of patients, of the 6 patients who were assessable after surgery, 3 achieved
complete response, 2 achieved partial response, and 1 had progressive disease. The response
rate was high at 83.3%. Regarding adverse events associated with PDT, brain edema involv‐
ing a large part of the middle cerebral artery perforator region occurred during PDT after
insular glioma resection in Case 1. While it remains uncertain whether this was associated
with the surgical procedure or PDT, the effect on normal capillary vessels should be closely
monitored. No other obvious adverse events were observed. In most patients, postoperative
chemo-radiation therapy was initiated, but recurrence was observed at the site of PDT in 7
patients. Despite recurrence, the progression-free survival time was 1 to 34 months (median:
22 months), and in cases receiving treatment after recurrence, 5 patients had a survival time
of 6 to 14 months (median: 6 months). A further 3 patients of Grade 3 were alive during a
follow-up period of 42 to 74 months (median: 50 months). An evaluation of 5 patients with
glioblastoma also showed a median progression-free survival time of 14 months and a me‐
dian survival time of 26 months.
While it was possibly an adverse event associated with the surgical procedure, a causal rela‐
tionship with the PDT could not be excluded. In terms of photosensitivity, the photosensi‐
tive reaction resolved within 3 days after surgery (within 4 days after the intravenous
injection) in all patients, at which point light shading at 500 lux was discontinued.
5. Discussion
The objective of PDT is to selectively kill infiltrating tumor cells via a photochemical reac‐
tion, and this selectivity facilitates optimal local control therapy [2], making it possible to
maintain brain function. PDT is designed to cause damage at the cellular level in the form of
apoptosis [2]. There are numerous studies which have reported that the main mechanism of
PDT is the induction of vascular occlusion from fibrin thrombus formation due to vascular
endothelial cell damage [5]. In particular, it has been assumed that the main mechanism on
cellular damage induced by PDT using TS in conjunction with a diode laser irradiation is
indirect damage in the form of coagulation necrosis by tumor vascular occlusion [5]. In our
basic experimental study, C6 glioma tissue showed coagulation necrosis in tissues located in
a portion near the tumor surface that was laser irradiated, and cellular death in the distal
portion [3]. However, in the actual area of tissue damage, 80% of the area was considered to
be tissue damage caused by the coagulation necrosis. Yamamoto et al. [5] reported that fac‐
tor XIII was activated by vascular endothelial cell damage within 20 seconds following PDT
of cancer tissue. A fibrin thrombus formed as a consequence, which appeared to be the main
mechanism of PDT.
Our strategy was to optimally reduce vascular damage caused by PDT, and to ensure safety
to avoid ischemic damage to normal brain tissues. Madsen et al. [6] reported that the factors
which influence the effects of PDT were tissue factors and irradiation laser factors. The tis‐
sue factors included the tissue concentrations of the photosensitizer, the level of tissue oxy‐
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genation, and the depth from the site of laser irradiation. The irradiation laser factors
included irradiation level and duration. How the cytotoxic effects can be enhanced while
minimizing the vascular effects, and how ischemic damage to normal brain tissues can be
minimized may well be the keys to determining whether or not PDT can be developed for
the treatment of malignant glioma.
In the present study, we selected a dose of 40 mg/m2 of TS and performed PDT approxi‐
mately 24 hours after the administration of TS. The practice of the PDT was performed on
the diode laser (664nm) irradiation at a power density of 150 mW/cm2 for 180 seconds (27
J/cm2). We previously reported that this PDT protocol was considered safe in terms of the
protection of early vascular endothelial cell damage and normal brain tissues, and could in‐
duce the selective tumor cell damage by singlet oxygen [7].
Although there were only consecutive 8 patients of newly diagnosed malignant glioma in
this series, PDT achieved a response rate of 83.3% and a median progression-free survival
time of 14 months, a median survival time of 26 months in the glioblastoma patients who
eventually died, and all 3 cases of Grade 3 patients were survived for 50 months median fol‐
low up period. In the 5 patients who achieved complete or partial response, preoperative
KPS was improved. None of the patients had adverse events unequivocally attributable to
PDT. The brain edema observed in Case 1 was possibly due to the surgical procedure, but
the possibility of direct laser irradiation of brain blood vessels inducing vascular occlusion
due to PDT could not be completely excluded. Therefore, normal blood vessels should be
covered with aluminum foil whenever possible.






NE 60Gy ACNU/VCR/IFN 50 (+) 22 mon. Dead: 36 mon.
CR 60Gy IFN 70 (+) 24 mon. Alive: 74 mon.
CR 60Gy TMZ 90 (+) 34 mon. Dead: 40 mon.
PR 60Gy TMZ 90 (+) 14 mon. Dead: 26 mon.
PR 60Gy (-) 50 (+) 24 mon. Alive: 50 mon.
PD (-) TMZ 40 (+) 1 mon. Dead: 7 mon.
CR 60Gy PCZ/ACNU/VCR 80 (+) 6mon. Dead: 12mon.
NE 60Gy TMZ 90 (-) Alive: 42mon.
KPS: Karnofsky Performance Scale, PDT: photodynamic therapy, RTx: radiation therapy, Chemo Tx: chemo‐
therapy, PFS: progression-free survival, Rt: right, Lt: left, Bil: bilateral, Anapl: anaplastic, CR: complete re‐
sponse, PR: partial response, PD: progression disease, NE: not evaluable, TMZ: temozolomide, VCR:
vincristine, IFN: interferon-beta, PCZ: procarbazine, mon. months
Table 1. Clinical summary of patients with newly diagnosed malignant glioma who received photodynamic therapy
(PDT)
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The present study of PDT using talaporfin sodium in conjunction with diode laser irradiation
for malignant glioma supports the validity of PDT for malignant glioma in Japan. Laser irra‐
diation used to activate TS has a longer wavelength (664 nm) than that used with other photo‐
sensitizers,  such  as  Porfimer  sodium  [8-11],  5-ALA  [12-14]  and  m-THPC  [15,  16],  and
theoretically, it can penetrate brain tissue to a greater depth. We believe that our strategy will
demonstrate a therapeutic effect not to be inferior to those of previous reports [17] using other
photosensitizers.  In future, it  is necessary to perform the larger-scale prospective clinical
study to confirm the clinical feasibility of this novel therapeutic option to malignant gliomas.
6. Conclusions
We performed PDT using TS in conjunction with diode laser irradiation in areas of tumor
invasion, following resection of adult malignant glioma which had infiltrated the eloquent
areas. We selected a 24 hours interval after the administration of TS before commencing
PDT and reduced irradiation energy intensity of the diode laser to 27 J/cm2 to preserve nor‐
mal brain function. The therapy achieved with no adversed event directly attributable to
PDT and a response rate of 83.3% in patients with a newly diagnosed malignant gliomas.
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The present study of PDT using talaporfin sodium in conjunction with diode laser irradiation
for malignant glioma supports the validity of PDT for malignant glioma in Japan. Laser irra‐
diation used to activate TS has a longer wavelength (664 nm) than that used with other photo‐
sensitizers,  such  as  Porfimer  sodium  [8-11],  5-ALA  [12-14]  and  m-THPC  [15,  16],  and
theoretically, it can penetrate brain tissue to a greater depth. We believe that our strategy will
demonstrate a therapeutic effect not to be inferior to those of previous reports [17] using other
photosensitizers.  In future, it  is necessary to perform the larger-scale prospective clinical
study to confirm the clinical feasibility of this novel therapeutic option to malignant gliomas.
6. Conclusions
We performed PDT using TS in conjunction with diode laser irradiation in areas of tumor
invasion, following resection of adult malignant glioma which had infiltrated the eloquent
areas. We selected a 24 hours interval after the administration of TS before commencing
PDT and reduced irradiation energy intensity of the diode laser to 27 J/cm2 to preserve nor‐
mal brain function. The therapy achieved with no adversed event directly attributable to
PDT and a response rate of 83.3% in patients with a newly diagnosed malignant gliomas.
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1. Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor among adults.
Rapid tumor progression and diffuse invasion of brain tissue restrict the therapeutic options
and result in poor prognosis despite advances in the understanding of this tumor’s molecular
biology and pathophysiology [1-4]. Current standard therapy consists of a combination of
tumor resection, irradiation and temozolomide. Advances in the field of molecular biology
have led to the development of targeted therapy, and the epidermal growth factor receptor
(EGFR) has been introduced as one potential therapeutic target [5]. Although pre-clinical
studies have shown promising effects, clinical applications yielded no significant benefit in
comparison with standard therapy. This fact encouraged extensive investigations studying the
molecular mechanisms underlying GBM resistance to EGFR-targeted therapy. Epithelial to
mesenchymal transition (EMT) is considered an important factor contributing to resistance
towards this therapy by diminishing the molecular target [1-6].
Epithelial to mesenchymal transition is a common process, taking part in organ development,
wound healing, tissue remodelling, cancer progression and metastasis. The main features
accompanying this mechanism are the loss of epithelial characteristics of cells and the acquis‐
ition of mesenchymal markers such as fibronectin, vimentin and N-cadherin. As a result, tumor
cells develop increasing invasive and migratory potential. The loss of epithelial features
mounts the resistance of tumor cells against targeted therapy directed towards the EGFR.
Mesenchymal transition leads to disorganisation of the cytoskeleton, disruption of intercellu‐
lar adhesions and changes in expression of transcriptional factors, resulting in the development
of a more malignant cellular phenotype [1, 2, 7].
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In embryogenesis, epithelial to mesenchymal transition appears during gastrulation and
activates the formation of the mesodermal layer as the third germ layer after ectoderm and
endoderm are built. In addition, EMT is involved in the development of neural crest cells,
arising from the dorsal part of the neural tube [7]. This requires a highly specialised program
that is necessary to allow the normal development of cells. On the other hand, under patho‐
logical conditions, EMT increases the invasiveness and migratory potential of tumor cells,
supports their malignant transformation and may lead to resistance of tumor cells towards
various therapeutic agents, especially in malignant gliomas.
2. EGFR
The EGFR is a transmembraneous glycoprotein belonging to the human EGFR (HER) family,
which includes four members (HER 1-4) that share a similar structure. The EGFR/HER1
consists of external and internal domains. The extracellular part possesses a binding sequence
for ligands such as EGF, hepatocyte growth factor (HGF), fibroblast growth factor (FGF),
insulin-like growth factor-1 (IGF-1) or tumor growth factor-α (TGF-α). The internal domain
contains a tyrosine kinase (TK), capable of phosphorylation and activation of a variety of
downstream pathways such as phospholipase Cγ, phosphatidylinositol-3-kinase (PI3-K),
Janus-activated kinase 2 (JAK-2) and mitogen-activated kinase (MAPK). Human epidermal
growth factor family receptors are expressed on many cell types and mediate signal transduc‐
tion to intracellular compartments and hereby regulate various functions of cells such as
proliferation or differentiation [1, 5, 8, 9].
Phosphorylation and dephosphorylation are crucial pathophysiological events within
intracellular interactions. A dysregulation of their balance contributes to the development of
an invasive cellular phenotype. Upon activation, receptor tyrosine kinases dimerise and
autophosphorylate on tyrosine residues, which in turn create complexes with proteins
possessing SH2 domains such as GRB2, SHC or signalling proteins PI3-K and SRC [9].
Pathological activation of RAS occurs in numerous cancers. This signalling pathway inte‐
grates various diverse stimuli promoting cell transformation, gene expression and tumor
progression. RAS is a small guanine triphosphate-binding protein that activates the serine-
threonine kinase RAF. RAF phosphorylates the dual specificity kinase MEK, which in turn
activates MAPK (ERK). The latter translocate into the nucleus and activate various tran‐
scription factors such as the ETS family factors FOS, JUN or SLUG (SNAI-2). Thereby RAS
propagates the activation of EMT. Moreover, RAS is able to promote EMT by downstream
activation of PI3-K or RHO/RAC. PI3-K is involved in cell cycle regulation via phosphory‐
lation of cyclin-dependent kinase inhibitors. In addition, it controls the phosphorylation of
proapoptotic proteins and survival of the cell. PI3-K can be activated either via RAS or di‐
rectly via TK receptors. PI3-K is a lipide kinase, and its activation generates phosphatidyli‐
nositol-3,4,5-triphosphate (PIP3) at the inner side of plasma membrane, which furthermore
mediates the signalling via the serine-threonine kinase AKT that is able to translocate into
the nucleus and take part in gene regulation through phosphatidylinositol-dependent pro‐
tein kinase-1 (PDK-1) [8, 9, 10].
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Epidermal growth factor overexpression and/or mutational activation is the most common
molecular alteration in primary GBM and can be detected in far more than 50% of glioblastoma
cells [5]. There are several mechanisms that may cause dysfunction of the receptor. Epidermal
growth factor receptor gene amplification is the most common reason leading to protein
overexpression. Other mechanisms include constitutive receptor activation by deletion-
mutation (EGFRvIII) or autocrine overproduction of EGFR ligands [5, 6, 9]. The presence of
EGFRvIII is associated with EGFR gene amplification.
3. Therapeutic EGFR inhibitors
Several drugs that target EGFR have been introduced. The TK inhibitors erlotinib and gefitinib
compete with adenosine triphosphate to bind to the intracellular TK domain and dissolve
further signalling involving PI3-K/AKT and MAPK pathways. Erlotinib was approved in the
treatment of metastatic non-small cell lung carcinoma (NSCLC) and in combination with
gemcitabine for metastasized pancreatic cancer or pancreatic cancer without the possibility of
gross total resection [11, 12]. Gefitinib is used for metastatic NSCLC. Another small molecule
EGFR-TK inhibitor represents lapatinib, which affords dual inhibition of EGFR and HER-2
and has been approved for the treatment of advanced or metastatic breast cancer. Unfortu‐
nately, the clinical application in gliomas had shown no benefit in comparison to standard
therapy [1, 5, 6, 8].
Another possibility to inhibit EGFR signalling consists in the prevention of ligand binding.
Monoclonal antibodies such as cetuximab have been introduced and investigated for this
purpose. However, their molecular weight impairs their penetration of the blood brain barrier.
Often the concentration of the agent is insufficient to yield a significant therapeutic effect
within the targeted tissue [13].
Antisense RNA has been introduced as an option to inhibit the EGFR pathway as well. Sense
RNA hybridizes to antisense RNA which leads to inhibition of translation. Another strategy
to switch off the EGFR cascade is the application of small interfering RNAs. These suppress
the homolog genes and result in sequence-specific degradation of mRNA. Furthermore,
ribozymes are small RNA molecules that are able to bind and cleave complementary RNA
substrates. EGFRvIII-targeted ribozymes have been reported to reverse malignant phenotype
of transformed fibroblasts and glioblastoma cells [14, 15]. However, the potential clinical value
of these methods remains unknown [16].
4. Molecular principles of EMT
Tumor progression represents an integrated multistep complex of molecular changes that
ultimately result in local invasion and dissemination of malignant cells.  The cells invade
the epithelial basement membrane, infiltrate the surrounding tissue, access the blood circu‐
lation and may create new tumor seeds.  This dynamic and aggressive process demands
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cell-to-cell and cell-to-matrix interactions, degradation and remodelling of extracellular ma‐
trix, cytoskeleton reorganisation and gain of migratory behaviour of tumor cells. Epithelial
to mesenchymal transition is a differentiation switch which promotes the loss of the epithe‐
lial phenotype and facilitates cell motility and invasiveness. One of the crucial steps pro‐
moting EMT is  the  repression of  the  epithelial  marker  E-cadherin,  a  transmembraneous
calcium-dependent glycoprotein responsible for cell-cell adhesion, which plays a key role
in embryonic development and homeostasis. The intracellular domain of E-cadherin asso‐
ciates with a protein complex involving α-catenin, β-catenin and p120-catenin. Actin pro‐
teins bind α-catenin and hereby allow the connection between E-cadherin and the actin
microfilament network of the cytoskeleton that forms the shape of the cell. Epithelial cells
are typically characterized by apicobasal difference. Thus, the apical compartment faces the
lumen, whereas the basolateral surface is located on a basement membrane. Epithelial cells
are anchored by specialized cell-to-cell connections, i.e. tight junctions, adherens junction
and desmosomes. E-cadherin acts as a tumor suppressor by linking the epithelial cells and
keeping them in a stationary rigid state [1, 2, 7, 8, 9, 17].
During EMT, tumor cells loose junctional contact and epithelial cell polarity and acquire typical
properties of mesenchymal cells. E-cadherin is a central regulator of the epithelial phenotype,
and its downregulation results in the destabilisation of the epithelial architecture. Dysregula‐
tion of E-cadherin may be located at various levels, and hypermethylation of the E-cadherin
promoter is among the molecular mechanisms [1, 2, 8-10, 17].
Under normal physiological conditions, epithelial cells are separated from the extracellular
matrix (ECM) by basement membranes. This barrier prevents the interaction between epithe‐
lial cells and their microenvironment. The destabilisation of the basement membrane enables
contact between various signalling proteins of the ECM and epithelial cells. The resulting
cellular signalling may enhance the progression of EMT by activating different intracellular
signalling pathways [17]. Gene transcription regulated by transcription factors is an important
mechanism involved in gene regulation. Some transcriptional repressors such as SNAI-1/2,
zinc finger E-box binding homeobox-1 (ZEB-1) and ZEB-2 are able to bind directly to the E-
cadherin promoter and repress its transcription. Overexpression of these proteins supports
mesenchymal transformation and the change of behavioural characteristics and promotes the
continuous acquisition of malignant features by tumor cells [18, 19]. Crucial transcription
factors involved in EMT are TWIST-1 and signal transducers and activators of transcrip‐
tion-3/-5 (STAT-3/-5). TWIST-1 is a basic helix-loop-helix protein that forms heterodimers
binding on DNA, hereby regulating the development and differentiation of cells. For instance,
TWIST-1 inhibits p53-mediated apoptosis in rodent fibroblasts or stops normal skeletal muscle
development by creating heterodimers with myogenic basic helix-loop-helix proteins (MyoD
and myogen). Its function within EMT is repression of the epithelial marker E-cadherin,
activation of N-cadherin and hereby promotion of mesenchymal transformation, resulting in
a more aggressive phenotype and progression of glioblastoma. TWIST-1 is reported to be an
important EMT regulator in other malignancies as well, such as breast, gastric, hepatocellular
and prostate cancer. There is significant evidence that TWIST-1 is involved in regulation of
programmed cell death and induction of apoptosis. Through inhibition of p53-mediated
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apoptosis, TWIST-1 enables cell survival by preventing growth arrest and promotes invasive‐
ness of tumor cells [3, 4]. Moreover, this process may result in increased resistance to various
chemotherapeutic agents.
Sex determining region Y-box-2, also known as SOX-2, is another transcription factor that is
co-expressed with TWIST-1, playing an important role during the development of the nervous
system and tumor progression. Knockdown of SOX-2 results in reduced expression of TWIST-1
[4], promoting EMT and potentially being essential for tumor progression and the develop‐
ment of tumor resistance to EGFR-targeted therapies.
Signal transducer and activator of transcription-3 activation is associated with more malig‐
nant tumors and poor prognosis. Its overexpression has been detected in malignant glio‐
mas,  and  its  activation  correlates  with  glioma  grade.  The  STAT  protein  family  is
phosphorylated  by  receptor-associated  kinases  and  builds  homo-  or  heterodimers  that
translocate to the cell nucleus and play a crucial role in cell cycle progression, EMT, anti-
apoptosis and metastasis. Signal transducer and activator of transcription-3 is hereby con‐
sidered an important factor mediating and converging many cellular pathways. Therefore,
either direct or indirect inhibition of STAT-3 may represent an optional therapeutic target
in gliomas. Moreover, STAT-3 interacts with EGFR and mediates TWIST-1 expression and
TWIST-1-mediated EMT. In addition, there seems to be a correlation between EGFR/EGFR‐
vIII expression, activation of STAT-3 and glioma grade. Noteworthy, a nuclear interaction
between EGFRvIII and STAT-3 leads to malignant transformation of glioma cells [20].
Another interesting point is a recent discovery, described by Lo. He found increased expression
of the pro-inflammatory gene cyclooxygenase-2 (COX-2) activated by EGFR-EGFRvIII and
STAT-3 cooperation [21]. These interactions represent potential factors contributing to
increased resistance of GBM to EGFR-targeted therapy. The important inflammatory enzyme
COX-2 is overexpressed in various malignancies. In NSCLC, it has been reported that increased
levels of COX-2 contribute to apoptosis resistance, angiogenesis and invasiveness of tumor
cells. The effector of COX-2 is prostaglandin E-2 (PGE-2) which is produced by tumorous
stromal cells and reduces the expression of E-cadherin via ZEB-1 and SNAI-1. Prostaglandin
E-2 activates four G-protein coupled receptors, also known as E-prostanoid receptors-1 to -4
(EP-1 to EP-4), and promotes signalling via the MAPK/ERK cascade, which finally upregulates
SNAI-1 and ZEB-1 expression [1, 21, 23]. This loop enhances signalling in the same pathway
that is activated by EGFR. In addition, low levels of E-cadherin have been reported to be
associated with increased resistance to EGFR-TK inhibitors in NSCLC [21, 23].
Signal transducer and activator of transcription-5 represents an important transcription fac‐
tor which is involved in the regulation of many genes, facilitating cellular growth, migra‐
tion and motility. Dimers of STAT-5 bind to specific DNA promoter regions and mediate
cellular gene responses. Dysregulation of STAT-5 has been recently described in many ma‐
lignancies  such  as  prostate,  breast  and  squamous  cell  cancer  of  the  head  and  neck
(SCCHN). In SCCHN, the activity of STAT-5 results in increased resistance of tumor cells
to erlotinib. Moreover, it confers decreased apoptosis following treatment with cisplatin, fi‐
nally diminishing the clinical effect [19].
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cell-to-cell and cell-to-matrix interactions, degradation and remodelling of extracellular ma‐
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teins bind α-catenin and hereby allow the connection between E-cadherin and the actin
microfilament network of the cytoskeleton that forms the shape of the cell. Epithelial cells
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a more aggressive phenotype and progression of glioblastoma. TWIST-1 is reported to be an
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and prostate cancer. There is significant evidence that TWIST-1 is involved in regulation of
programmed cell death and induction of apoptosis. Through inhibition of p53-mediated
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors280
apoptosis, TWIST-1 enables cell survival by preventing growth arrest and promotes invasive‐
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The SNAI family members (SNAI-1-3) are related transcriptional repressors. Their SNAG
domain at the N-terminal region is responsible for their activity, and their zinc-finger C-
terminal region enables the attachment to specific DNA sequences. The main role of SNAI
genes is the regulation and promotion of E-cadherin expression. It has been reported that
knockdown of SNAI-1 results in decreased invasion and migration of glioma cells. Moreover,
SNAI-1 induces expression of matrix metalloprotease-2 (MMP-2), another contributor to EMT
progression [18].
Zinc finger E-box binding homeobox-1 regulates transcription of E-cadherin by binding of two
zinc finger domains to two E-boxes located in the E-cadherin promoter region. It has been
shown that low levels of ZEB-1 improve the sensitivity of cells to erlotinib in head and neck
squamous cell carcinoma cell lines [21].
Figure 1. Signal transduction pathways associated with EMT. Abbreviations: APC – adenomatous polyposis coli, EMT -
epithelial to mesenchymal transition, TGF-β – transforming growth factor β, EGF – epidermal growth factor, EGFR -
epidermal growth factor receptor, FGF – fibroblast growth factor, GSK 3 – glycogen synthase kinase, HGF – hepatocyte
growth factor, IGF – insulin-like growth factor, ILK – integrin-linked kinase, MAPK - mitogen-activated protein kinase,
MEK - mitogen-activated protein kinase kinase, MMPs - matrix metalloproteases, PI3K – phosphoinositide 3-kinase,
RTK – receptor tyrosine kinase.
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Activator protein-1 (AP-1) is a protein complex consisting of JUN and FOS heterodimers or
JUN homodimers. It plays an important role in the regulation of a variety of genes, resulting
in the progression of EMT. Induction of AP-1 correlates with MAPK-activation and phos‐
phorylation of the ETS family transcription factors such as E twenty-six-like transcription
factor (ELK-1) which furthermore induces the transcription of FOS. Phosphorylated ETS
factors result ultimately into the repression of E-cadherin and up-regulation of genes that lead
to the transcription of MMPs [2].
As a result of downregulation of E-cadherin, loss of cell-to-cell adhesions and reorganisation
of the actin cytoskeleton during EMT, cells acquire a mesenchymal identity. The expression of
mesenchymal cytoskeleton proteins such as vimentin and the deposition of ECM proteins such
as collagen or fibronectin become dominant and stimulate the activation of integrins and their
signalling pathways that promote the migratory potential of cells. Moreover, it has been
reported that the level of E-cadherin depends on the phosphorylation state of β-catenin.
Tyrosine phosphorylation of β-catenin prevents the binding to E-cadherin and favours the loss
of intercellular contact [1, 2, 17].
Endocytosis and proteolytic cleavage of the extracellular domain of E-cadherin are other
factors contributing to destabilisation of intercellular adhesion complexes, cell dissociation
and EMT. In addition, integrins together with TK receptor activity contribute to the acquisition
of an invasive phenotype via SRC. SRC is a non-receptor, SH2-containing cytoplasmic TK
which participates in the control of adhesion and migration. SRC signalling contributes to the
alteration of the balance between the adhesive and migratory states of cells. SRC stimulates
focal adhesion kinase (FAK) that in turn mediates MAPK signalling, leading to the phosphor‐
ylation of light chain kinase which ultimately creates phosphomyosin, resulting in increased
cell motility and the disorganisation of cell-to-cell adhesions. In addition, SRC is involved in
the regulation of numerous proteins of the ECM such as vinculin or paxillin [2, 17].
5. Cancer stem cells
Cancer stem cells have been introduced as cell colonies able to self-renew, proliferate and
produce heterogeneous lineages of cancer cells. Hereby they are playing a crucial role in tu‐
mor initiation, growth, invasion and recurrence. Epithelial to mesenchymal transition pro‐
motes the development of cancer stem-like cells that exhibit mesenchymal phenotypes and
acquire multipotent features.  Recent studies have provided the evidence of  glioma stem
cells or brain tumor stem cells [22]. These exhibit a similar phenotype as neural stem cells
and in the majority of cases are characterized by surface proteins such as CD133 or nestin
[23, 24]. This type of cells exhibits radio-resistance and an abnormal growth pattern. Tumor
recurrence is the primary consequence of treatment failure and cause of death in patients
suffering from malignant gliomas. Glioma stem cells possess the potential to stimulate the
survival of transformed cells and thereby may become a useful therapeutic target [23, 24].
However,  a profound understanding of the biological features of these cells will  require
many more studies.
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factor (ELK-1) which furthermore induces the transcription of FOS. Phosphorylated ETS
factors result ultimately into the repression of E-cadherin and up-regulation of genes that lead
to the transcription of MMPs [2].
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of the actin cytoskeleton during EMT, cells acquire a mesenchymal identity. The expression of
mesenchymal cytoskeleton proteins such as vimentin and the deposition of ECM proteins such
as collagen or fibronectin become dominant and stimulate the activation of integrins and their
signalling pathways that promote the migratory potential of cells. Moreover, it has been
reported that the level of E-cadherin depends on the phosphorylation state of β-catenin.
Tyrosine phosphorylation of β-catenin prevents the binding to E-cadherin and favours the loss
of intercellular contact [1, 2, 17].
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of an invasive phenotype via SRC. SRC is a non-receptor, SH2-containing cytoplasmic TK
which participates in the control of adhesion and migration. SRC signalling contributes to the
alteration of the balance between the adhesive and migratory states of cells. SRC stimulates
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the regulation of numerous proteins of the ECM such as vinculin or paxillin [2, 17].
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cells or brain tumor stem cells [22]. These exhibit a similar phenotype as neural stem cells
and in the majority of cases are characterized by surface proteins such as CD133 or nestin
[23, 24]. This type of cells exhibits radio-resistance and an abnormal growth pattern. Tumor
recurrence is the primary consequence of treatment failure and cause of death in patients
suffering from malignant gliomas. Glioma stem cells possess the potential to stimulate the
survival of transformed cells and thereby may become a useful therapeutic target [23, 24].
However,  a profound understanding of the biological features of these cells will  require
many more studies.
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6. Extracellular matrix and EMT
Tumor cells express matrix metalloproteases (MMPs) which are able to dissolve the ECM and
thereby promote tumor invasion, migration and metastasis. Matrix metaloproteases are a
group of zinc-dependent endoproteases. Matrix metalloprotease-2 (MMP-2) and MMP-9 are
regulated by SNAI-1 and SNAI-2 (SLUG). Epithelial to mesenchymal transition-mediated
dysregulation of SNAI-1 and SLUG in turn promotes the activity of MMP-2 and MMP-9 and
thereby increases the invasive and migratory activity of tumor cells. Thus, cancer cells
undergoing EMT enhance the initiation of metastasis, often involving transforming growth
factor-β (TGF-β) and SMAD, and represent a phenotypic subpopulation of cancer cells which
promote the dissemination of the malignant disease. Stromelysin, known as MMP-3, promotes
EMT through the induction of reactive oxygen species (ROS) that, in turn, results in overex‐
pression of SNAI [2, 8-10, 17].
7. TGF–β
Transforming growth factor-β has been reported as a strong inducer of EMT. This protein
belongs to the TGF-β superfamily and exhibits three isoforms, i.e. TGF-β1, TGF-β2 and TGF-
β3, all of which are involved in cell proliferation and differentiation. Transforming growth
factor-β is able to induce apoptosis in numerous cell types via the Smad pathway. In addition,
TGF-β may recruit non-Smad signalling, for instance the MMP cascade, to promote the
malignant transformation of cells. The TGF-β response results in Smad 2 and Smad 3 activation
through C-terminal phosphorylation [7, 8].
Transforming growth factor-β signalling finally regulates the expression of SNAI, ZEB and
TWIST proteins that, in turn, influence the expression of proteins such as claudin, desmo‐
plakin, MMPs or fibronectin. In this context, TGF-β functions as an important regulator of
EMT [7, 8].
Promoted by TGF-β, SNAI-1 and SNAI-2 (SLUG) levels are increased during EMT. Hepatocyte
growth factor, FGF and EGF induce the RAS-MAPK or PI3K-AKT pathways that lead to the
activation of SNAI expression. The increased expression of SNAI-1 or SNAI-2 enhances the
expression of vimentin and fibronectin, reduces E-cadherin and plakoglobin levels and hereby
switches on mesenchymal transformation. During embryological development, this process
takes care of mesodermal layer and neural crest development. In addition, SNAI proteins
inactivate a variety of epithelial proteins such as occludin and claudin. SNAI-1 represses the
expression of claudin 3, claudin 4 and claudin 7 and regulates the expression of desmosome
proteins such as desmoplakin. SNAI-1 and SNAI-2 decrease the expression level of claudin 1
and occludin. Furthermore, increased SNAI protein activity stimulates the expression of
mesenchymal proteins such as Rho-like GTPases which are composed of RHO, RAC and
CDC-42 proteins that influence cytoskeleton architecture and cell motility. RHO and RAC
regulate E-cadherin activity and adhesiveness of cells, and their activity is among the impor‐
tant determinants of EMT. TGF-β activates the signalling cascade downstream of RHO. The
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main RHO effector in TGF-β response is ROCK activity which regulates different processes
involved in cell migration such as cytoskeleton reorganisation [1, 2, 7, 8, 17, 18].
Transforming growth factor-β activates TK receptors via PI3-K that, in turn, controls AKT
in diverse cells. AKT is an important regulator of various signalling cascades, controlling
cell survival, migration and proliferation. Activation of the PI3K-AKT cascade plays a cru‐
cial role in EMT.
The WNT protein plays a significant role in the process of mesenchymal transformation as
well. WNT is connected downstream to β-catenin, builds adherens junctions and connects E-
cadherin to the cytoskeleton through α-catenin. The WNT glycoprotein binds to the trans‐
membraneous Frizzled receptor that activates Dishevelled, which in turn prevents
phosphorylation of β-catenin by inhibition of glycogen synthase kinase-3β (GSK-3β) and
hereby stops its ubiquitination and degradation. This step increases the level of cytoplasmic
β-catenin that ultimately translocates into the nucleus and builds complexes with T-Cell factor
(TCF) and lymphoid enhancer factor-1 (LEF-1). These related transcription factors mediate the
gene response by activating genes required for EMT such as SLUG, ETS and JUN or fibronectin
and vimentin. In addition, the basic feature of EMT, downregulation of E-cadherin, increases
the level of cytosolic free β-catenin itself. Similarly, the activation of PI3K-AKT and integrin-
linked kinase (ILK) inhibits GSK-3β and leads to the accumulation of β-catenin. This inhibitory
effect is responsible for the upregulation of SNAI, which normally is negatively regulated by
the activation of GSK-3β. The process contributes significantly to the destabilisation of
epithelial adhesiveness and promotes the acquisition of the mesenchymal phenotype with
increased cell motility and invasiveness [2, 27].
8. Nuclear factor–κB
Nuclear factor-κB (NF-κB) belongs to a family of transcriptional factors, whose activity is
important for the maintenance and promotion of the invasive phenotype in cancer cells.
Nuclear factor-κB binds DNA sequences as hetero- or homodimers and consequently regulates
various cellular processes. Several genes encoding proteins that are involved in the cell cycle
(Cyclin D1, c-MYC), cell adhesion (vascular cell adhesion protein) or inflammation (interleu‐
kin-2, interleukin-6, interleukin-8) are regulated in this way. Even if NF-κB is ubiquitous, its
activity is detected mostly in mature B-lymphocytes [28, 29].
The inhibitor protein IκB plays a crucial role in the degradation of NF-κB and has been
discovered  in  breast  cancer.  Signalling  via  NF-κB  results  in  increased  expression  of
SNAI-1 and hereby contributes to EMT progression. Moreover, the activity of NF-κB cor‐
relates with the expression of ZEB-1, ZEB-2 and TWIST, which are other strong inducers
of EMT [28].
Vimentin,  a  56-kDa intermediate  filament  protein,  contributes  to  mesenchymal  transfor‐
mation  of  the  cell.  Cells  acquire  a  spindle-shape  form  and  loosen  their  connections  to
neighbouring  cells.  Studies  of  vimentin-knockdown  mice  have  shown  significantly  re‐
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main RHO effector in TGF-β response is ROCK activity which regulates different processes
involved in cell migration such as cytoskeleton reorganisation [1, 2, 7, 8, 17, 18].
Transforming growth factor-β activates TK receptors via PI3-K that, in turn, controls AKT
in diverse cells. AKT is an important regulator of various signalling cascades, controlling
cell survival, migration and proliferation. Activation of the PI3K-AKT cascade plays a cru‐
cial role in EMT.
The WNT protein plays a significant role in the process of mesenchymal transformation as
well. WNT is connected downstream to β-catenin, builds adherens junctions and connects E-
cadherin to the cytoskeleton through α-catenin. The WNT glycoprotein binds to the trans‐
membraneous Frizzled receptor that activates Dishevelled, which in turn prevents
phosphorylation of β-catenin by inhibition of glycogen synthase kinase-3β (GSK-3β) and
hereby stops its ubiquitination and degradation. This step increases the level of cytoplasmic
β-catenin that ultimately translocates into the nucleus and builds complexes with T-Cell factor
(TCF) and lymphoid enhancer factor-1 (LEF-1). These related transcription factors mediate the
gene response by activating genes required for EMT such as SLUG, ETS and JUN or fibronectin
and vimentin. In addition, the basic feature of EMT, downregulation of E-cadherin, increases
the level of cytosolic free β-catenin itself. Similarly, the activation of PI3K-AKT and integrin-
linked kinase (ILK) inhibits GSK-3β and leads to the accumulation of β-catenin. This inhibitory
effect is responsible for the upregulation of SNAI, which normally is negatively regulated by
the activation of GSK-3β. The process contributes significantly to the destabilisation of
epithelial adhesiveness and promotes the acquisition of the mesenchymal phenotype with
increased cell motility and invasiveness [2, 27].
8. Nuclear factor–κB
Nuclear factor-κB (NF-κB) belongs to a family of transcriptional factors, whose activity is
important for the maintenance and promotion of the invasive phenotype in cancer cells.
Nuclear factor-κB binds DNA sequences as hetero- or homodimers and consequently regulates
various cellular processes. Several genes encoding proteins that are involved in the cell cycle
(Cyclin D1, c-MYC), cell adhesion (vascular cell adhesion protein) or inflammation (interleu‐
kin-2, interleukin-6, interleukin-8) are regulated in this way. Even if NF-κB is ubiquitous, its
activity is detected mostly in mature B-lymphocytes [28, 29].
The inhibitor protein IκB plays a crucial role in the degradation of NF-κB and has been
discovered  in  breast  cancer.  Signalling  via  NF-κB  results  in  increased  expression  of
SNAI-1 and hereby contributes to EMT progression. Moreover, the activity of NF-κB cor‐
relates with the expression of ZEB-1, ZEB-2 and TWIST, which are other strong inducers
of EMT [28].
Vimentin,  a  56-kDa intermediate  filament  protein,  contributes  to  mesenchymal  transfor‐
mation  of  the  cell.  Cells  acquire  a  spindle-shape  form  and  loosen  their  connections  to
neighbouring  cells.  Studies  of  vimentin-knockdown  mice  have  shown  significantly  re‐
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duced wound healing abilities.  In addition,  vimentin expression promotes the migration
of cancer cells. Nuclear factor-κB activates the vimentin promoter and thus increases the
expression of vimentin [28].
9. Resistance to EGFR–targeted therapy
Epithelial to mesenchymal transition is considered an important factor contributing to the
resistance of glioma cells against EGFR-targeted therapy. On the other hand, alternative
potential explanations of this phenomenon have been suggested.
Glioblastomas exhibit a high degree of intrinsic heterogeneity with a variety of signalling
pathways that mediate the subcellular actions. In the case of EGFR inhibition, alternative
downstream pathways may be activated and potentiated. A functional-switch could lead to
the survival of the cells and, by clonal selection, to the acquisition of resistance to specific
therapeutic agents that inhibit one specific signalling pathway.
Phosphatase and tensin homolog is a tumor suppressor protein which dephosphorylates
phosphatidylinositol (3, 4, 5)-triphosphate and hereby negatively regulates the AKT signalling
axis. Phosphatase and tensin homolog is often mutated in GBM cells which promotes the
activity of mTOR resulting in tumor progression. The inhibition of this dominant pathway
may lead to alteration of the hierarchy in TKs such as platelet-derived growth factor receptor
(PDGFR), JAK2 or cellular mesenchymal-epithelial transition factor (c-MET) [9, 29]. Platelet-
derived growth factor receptor is the second most common TK receptor amplified in GBMs.
Moreover, MET is also amplified in some GBMs. Concomitant presence of gene amplifications
within GBMs may activate and potentiate alternative signalling pathways during inhibitory
targeting of EGFR and hereby contribute to increased resistance of glioma cells to erlotinib or
other TK-inhibitors [29].
10. Conclusion
The EGFR has been introduced as a therapeutic target in some malignancies. Unfortunately,
in GBM, there has been no demonstrable benefit of this approach in comparison to standard
therapy. Epithelial to mesenchymal transition is considered an important factor contributing
to failure of this therapy by diminishing the molecular target. This phenomenon leads to the
loss of epithelial characteristics of cells and to the expression of mesenchymal features. The
acquisition of increased motility and invasiveness by glioma cells represents an essential
prerequisite for subsequent tumor recurrence and malignant progression. Epithelial to
mesenchymal transition is primarily regulated through signalling pathways affecting E-
cadherin, a transmembraneous protein responsible for intercellular cell contact. Molecular
changes are promoted by a variety of external stimuli. The identification and better under‐
standing of these processes may enable the development of new therapeutic strategies
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duced wound healing abilities.  In addition,  vimentin expression promotes the migration
of cancer cells. Nuclear factor-κB activates the vimentin promoter and thus increases the
expression of vimentin [28].
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the survival of the cells and, by clonal selection, to the acquisition of resistance to specific
therapeutic agents that inhibit one specific signalling pathway.
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(PDGFR), JAK2 or cellular mesenchymal-epithelial transition factor (c-MET) [9, 29]. Platelet-
derived growth factor receptor is the second most common TK receptor amplified in GBMs.
Moreover, MET is also amplified in some GBMs. Concomitant presence of gene amplifications
within GBMs may activate and potentiate alternative signalling pathways during inhibitory
targeting of EGFR and hereby contribute to increased resistance of glioma cells to erlotinib or
other TK-inhibitors [29].
10. Conclusion
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therapy. Epithelial to mesenchymal transition is considered an important factor contributing
to failure of this therapy by diminishing the molecular target. This phenomenon leads to the
loss of epithelial characteristics of cells and to the expression of mesenchymal features. The
acquisition of increased motility and invasiveness by glioma cells represents an essential
prerequisite for subsequent tumor recurrence and malignant progression. Epithelial to
mesenchymal transition is primarily regulated through signalling pathways affecting E-
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1. Introduction
Gliomas are the most common tumors of the brain. Normal glia includes astrocytes, oligo‐
dendrocytes, and ependyma. Gliomas are analogously designated as astrocytomas, oligo‐
dendrogliomas, and ependymomas to reflect the non-neoplastic cell types that they most
closely resemble.
Gliomas can also be classified histologically as astrocytomas, oligodendrogliomas, or tumors
with morphological features of both astrocytes and oligodendrocytes. The 2007 World
Health Organization (WHO) classification recognizes three main histologic types of low
grade diffuse glioma grade II: diffuse astrocytoma, oligoastrocytoma, and oligodendroglio‐
ma [1]. Diffuse astrocytomas account for approximately 40% of primary intracranial tumors.
Their gross, microscopic, and biologic characteristics vary to a considerable degree accord‐
ing to their site. They occur at all ages, although the median age is 30 to 40 for astrocytoma
(grade II), 40 to 50 for anaplastic astrocytoma (grade III), and 50 to 60 years for glioblastoma
multiforme (grade IV). Diffuse astrocytomas tend to progress to more malignant histologic
types, such as anaplastic astrocytoma (WHO grade III) and sometimes secondary glioblasto‐
ma (WHO grade IV). Oligodendrogliomas account for approximately 5% of intracranial
gliomas. They are most often found in the cerebral hemispheres, where they usually involve
the cortex and the white matter. Traditionally the prognosis of oligodendrogliomas has been
regarded as relatively favorable, but in practice no valid correlation has been established be‐
tween the microscopic appearances of these tumors and their clinical evolution. Progression
of oligodendrogliomas to anaplastic oligodendrogliomas can be unpredictable. Glioblasto‐
mas are malignant, rapidly fatal, astrocytic neoplasms. Glioblastomamultiforme (GBM), ac‐
count for 30% of primary brain tumors in adults [2, 3]. Patients with
glioblastomamultiforme have a mean survival of about 12 months. They may occur in any
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Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 15
Laboratory Testing for Prognostic and Predictive
Markers in Gliomas
Milena Cankovic
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52670
1. Introduction
Gliomas are the most common tumors of the brain. Normal glia includes astrocytes, oligo‐
dendrocytes, and ependyma. Gliomas are analogously designated as astrocytomas, oligo‐
dendrogliomas, and ependymomas to reflect the non-neoplastic cell types that they most
closely resemble.
Gliomas can also be classified histologically as astrocytomas, oligodendrogliomas, or tumors
with morphological features of both astrocytes and oligodendrocytes. The 2007 World
Health Organization (WHO) classification recognizes three main histologic types of low
grade diffuse glioma grade II: diffuse astrocytoma, oligoastrocytoma, and oligodendroglio‐
ma [1]. Diffuse astrocytomas account for approximately 40% of primary intracranial tumors.
Their gross, microscopic, and biologic characteristics vary to a considerable degree accord‐
ing to their site. They occur at all ages, although the median age is 30 to 40 for astrocytoma
(grade II), 40 to 50 for anaplastic astrocytoma (grade III), and 50 to 60 years for glioblastoma
multiforme (grade IV). Diffuse astrocytomas tend to progress to more malignant histologic
types, such as anaplastic astrocytoma (WHO grade III) and sometimes secondary glioblasto‐
ma (WHO grade IV). Oligodendrogliomas account for approximately 5% of intracranial
gliomas. They are most often found in the cerebral hemispheres, where they usually involve
the cortex and the white matter. Traditionally the prognosis of oligodendrogliomas has been
regarded as relatively favorable, but in practice no valid correlation has been established be‐
tween the microscopic appearances of these tumors and their clinical evolution. Progression
of oligodendrogliomas to anaplastic oligodendrogliomas can be unpredictable. Glioblasto‐
mas are malignant, rapidly fatal, astrocytic neoplasms. Glioblastomamultiforme (GBM), ac‐
count for 30% of primary brain tumors in adults [2, 3]. Patients with
glioblastomamultiforme have a mean survival of about 12 months. They may occur in any
© 2013 Cankovic; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
region of the central nervous system, however, the cerebral hemispheres, in particular the
frontal lobes or temporal lobes, the basal ganglia, and the commissural pathways are sites of
predilection. Most GBMs are diagnosed as de novo or primary tumors and are more com‐
mon in males. A subset of about 5% of GBM tumors, termed secondary GBM, progress from
lower-grade tumors (grade II/III), are seen in younger patients, are more evenly distributed
among the sexes, and exhibit longer survival times [4]. Depending on the grade and mor‐
phologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resec‐
tion, radiotherapy, or chemotherapy, or some combination of these therapies.
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments [5, 6]. Temozolomide is a novel alkylating agent
that has demonstrated activity in recurrent gliomas [7-9]. Regardless of therapy, most pa‐
tients will progress and have a high risk of mortality and reduced quality of life. For these
reasons there has been a great deal of interest in understanding the biology and genetics of
gliomas, to provide better diagnostic tools and new therapeutic approaches [10]. Molecular
pathology markers are being identified that have been or will soon prove to be clinically
useful in treatment of glioma patients.
Molecular genomic-based laboratory assays are often used for detection of prognostic and pre‐
dictive markers in gliomas. Research efforts have identified a number of cytogenetic and mo‐
lecular  genetic  alterations  in  gliomas  [11]  that  may  be  exploited  to  facilitate  glioma
classification, especially in cases that exhibit inconclusive or borderline histologic features.
This chapter will focus on those molecular biomarkers that have been established in glioma di‐
agnostics, namely MGMT promoter methylation, 1p/19q Loss of Heterozygosity (LOH), IDH1
and IDH2 mutations, and epidermal growth factor variant III (EGFRvIII) mutations. Emphasis
will be placed on clinical applications, most frequently used methods of detection, as well as is‐
sues involved in assay validation, specimen selection, and clinical laboratory oversight.
1.1. MGMT promoter methylation
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments. Temozolomide is a novel alkylating agent that
has demonstrated activity in recurrent gliomas. Alkylating agents cause cell death by form‐
ing cross-links between adjacent strands of DNA due to alkylation of the O6 position of gua‐
nine. The O6-methylguanine-DNA methyltransferase (MGMT) gene produces the cellular
DNA repair protein O6-alkylguanine DNA alkyltransferase (AGT) which is a key factor in
resistance to alkylating agents. It functions as a DNA repair enzyme that removes the muta‐
genic alkyl-adducts from the O6-poasition of guanine, and this transfer of alkyl groups to
AGT prevents the formation of lethal cross links in DNA. Tumors appear to be heterogene‐
ous with respect to MGMT expression, and in a subset of cancer cells, its expression is si‐
lenced due to abnormal promoter methylation. Aberrant methylation of CpG islands located
in the promoter region of MGMT gene is associated with transcriptional inactivation of this
gene, and consequent low levels of the MGMT DNA repair enzyme. Studies have shown
that patients with low levels of this DNA repair enzyme are more likely to experience re‐
sponse to therapy and prolonged overall and disease free survival [12-15].
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DNA methylation (for more detailed description and references please see [16]) is a mecha‐
nism by which the cell regulates gene expression. Methylation is an enzyme mediated modi‐
fication that adds a methyl (-CH3) group at a selected site on DNA or RNA. In humans,
methylation occurs only at cytosine (C) bases followed by a guanosine (G), also known as
CpGdinucleotides. The CpG dinucleotides are prone to spontaneous mutations and have
been selectively depleted from mammalian genome. However, some regions of DNA have
retained CpGdinucleotides and are referred to as CpG islands. The CpG islands are found
primarily in the 5' region of expressed genes, often in association with promoters. When the
promoter CpG island is methylated, the corresponding gene is silenced and transcription
does not occur. Aberrant CpG island methylation of tumor suppressor genes is frequent in
cancer and appears to be an important mechanism of neoplastic transformation.
Quantitative evaluation on methylated MGMT in tumors suggests that not all cells in a tu‐
mor positive for promoter methylation carry a methylated MGMT allele. This raises the
question of what level of promoter methylation has clinical significance. A recent study [17]
investigated the degree and pattern of MGMT promoter methylation in paired samples of
glioblastoma tissue and glioblastoma-derived spheres. The degree and density of MGMT
methylation was then compared with the chromatin structure of MGMT, gene dosage, gene
expression and enzyme activity, and the tumor cell content of the patient samples. Ten
paired samples were evaluated for the extent and density of methylation by clone sequenc‐
ing 28 of 97 CpGs in the CpGisland of the MGMT promoter. This region of the promoter en‐
compasses the enhancer element and, according to reporter assays, is associated with
complete silencing of the gene when fully methylated [18]. Most assays interrogate CpG
methylation in this region. For all glioblastomas with MGMT methylation, a band for unme‐
thylated alleles was also detectable, which is expected since benign cells will always be
present in the specimen. Sequencing of the original glioblastoma tissue revealed that 10% to
90% of all clones sequenced showed dense methylation, arbitrarily defined as at least 4 con‐
secutive CpGs methylated in a given interrogated clone. The density of MGMT promoter
methylation, defined as the number of methylated CpGs over 28 interrogated CPGs, ranged
from 25% to 90%, never reaching 100%, and showing a characteristic pattern for each tumor.
The study [17] further showed that MGMT methylation is associated with no or low MGMT
expression and closed chromatin structure. MGMT activity was below the limit of detection
in glioblastoma spheres of completely methylated cases. Moderate activity was measured in
the case with one unmethylated allele, and the unmethylated case showed the highest activi‐
ty. MGMT activity was measurable in all respective original tissues likely due to contami‐
nating normal cells. In accordance with lack of MGMT expression and MGMT activity, the
closed chromatin pattern was also observed. Marks of active and inactive chromatin pattern
were observed for unmethylated and partially methylated cases.
As combined chemoradiotherapy comprising the alkylating agent temozolomide has be‐
come the new standard of care [19], there has been growing interest to use MGMT promoter
methylation status for individual patient management, and for patient stratification or selec‐
tion in clinical trials. Knowledge of MGMT promoter methylation status is relevant for both
prognostic and predictive considerations. Furthermore, MGMT promoter methylation status
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region of the central nervous system, however, the cerebral hemispheres, in particular the
frontal lobes or temporal lobes, the basal ganglia, and the commissural pathways are sites of
predilection. Most GBMs are diagnosed as de novo or primary tumors and are more com‐
mon in males. A subset of about 5% of GBM tumors, termed secondary GBM, progress from
lower-grade tumors (grade II/III), are seen in younger patients, are more evenly distributed
among the sexes, and exhibit longer survival times [4]. Depending on the grade and mor‐
phologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resec‐
tion, radiotherapy, or chemotherapy, or some combination of these therapies.
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments [5, 6]. Temozolomide is a novel alkylating agent
that has demonstrated activity in recurrent gliomas [7-9]. Regardless of therapy, most pa‐
tients will progress and have a high risk of mortality and reduced quality of life. For these
reasons there has been a great deal of interest in understanding the biology and genetics of
gliomas, to provide better diagnostic tools and new therapeutic approaches [10]. Molecular
pathology markers are being identified that have been or will soon prove to be clinically
useful in treatment of glioma patients.
Molecular genomic-based laboratory assays are often used for detection of prognostic and pre‐
dictive markers in gliomas. Research efforts have identified a number of cytogenetic and mo‐
lecular  genetic  alterations  in  gliomas  [11]  that  may  be  exploited  to  facilitate  glioma
classification, especially in cases that exhibit inconclusive or borderline histologic features.
This chapter will focus on those molecular biomarkers that have been established in glioma di‐
agnostics, namely MGMT promoter methylation, 1p/19q Loss of Heterozygosity (LOH), IDH1
and IDH2 mutations, and epidermal growth factor variant III (EGFRvIII) mutations. Emphasis
will be placed on clinical applications, most frequently used methods of detection, as well as is‐
sues involved in assay validation, specimen selection, and clinical laboratory oversight.
1.1. MGMT promoter methylation
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments. Temozolomide is a novel alkylating agent that
has demonstrated activity in recurrent gliomas. Alkylating agents cause cell death by form‐
ing cross-links between adjacent strands of DNA due to alkylation of the O6 position of gua‐
nine. The O6-methylguanine-DNA methyltransferase (MGMT) gene produces the cellular
DNA repair protein O6-alkylguanine DNA alkyltransferase (AGT) which is a key factor in
resistance to alkylating agents. It functions as a DNA repair enzyme that removes the muta‐
genic alkyl-adducts from the O6-poasition of guanine, and this transfer of alkyl groups to
AGT prevents the formation of lethal cross links in DNA. Tumors appear to be heterogene‐
ous with respect to MGMT expression, and in a subset of cancer cells, its expression is si‐
lenced due to abnormal promoter methylation. Aberrant methylation of CpG islands located
in the promoter region of MGMT gene is associated with transcriptional inactivation of this
gene, and consequent low levels of the MGMT DNA repair enzyme. Studies have shown
that patients with low levels of this DNA repair enzyme are more likely to experience re‐
sponse to therapy and prolonged overall and disease free survival [12-15].
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DNA methylation (for more detailed description and references please see [16]) is a mecha‐
nism by which the cell regulates gene expression. Methylation is an enzyme mediated modi‐
fication that adds a methyl (-CH3) group at a selected site on DNA or RNA. In humans,
methylation occurs only at cytosine (C) bases followed by a guanosine (G), also known as
CpGdinucleotides. The CpG dinucleotides are prone to spontaneous mutations and have
been selectively depleted from mammalian genome. However, some regions of DNA have
retained CpGdinucleotides and are referred to as CpG islands. The CpG islands are found
primarily in the 5' region of expressed genes, often in association with promoters. When the
promoter CpG island is methylated, the corresponding gene is silenced and transcription
does not occur. Aberrant CpG island methylation of tumor suppressor genes is frequent in
cancer and appears to be an important mechanism of neoplastic transformation.
Quantitative evaluation on methylated MGMT in tumors suggests that not all cells in a tu‐
mor positive for promoter methylation carry a methylated MGMT allele. This raises the
question of what level of promoter methylation has clinical significance. A recent study [17]
investigated the degree and pattern of MGMT promoter methylation in paired samples of
glioblastoma tissue and glioblastoma-derived spheres. The degree and density of MGMT
methylation was then compared with the chromatin structure of MGMT, gene dosage, gene
expression and enzyme activity, and the tumor cell content of the patient samples. Ten
paired samples were evaluated for the extent and density of methylation by clone sequenc‐
ing 28 of 97 CpGs in the CpGisland of the MGMT promoter. This region of the promoter en‐
compasses the enhancer element and, according to reporter assays, is associated with
complete silencing of the gene when fully methylated [18]. Most assays interrogate CpG
methylation in this region. For all glioblastomas with MGMT methylation, a band for unme‐
thylated alleles was also detectable, which is expected since benign cells will always be
present in the specimen. Sequencing of the original glioblastoma tissue revealed that 10% to
90% of all clones sequenced showed dense methylation, arbitrarily defined as at least 4 con‐
secutive CpGs methylated in a given interrogated clone. The density of MGMT promoter
methylation, defined as the number of methylated CpGs over 28 interrogated CPGs, ranged
from 25% to 90%, never reaching 100%, and showing a characteristic pattern for each tumor.
The study [17] further showed that MGMT methylation is associated with no or low MGMT
expression and closed chromatin structure. MGMT activity was below the limit of detection
in glioblastoma spheres of completely methylated cases. Moderate activity was measured in
the case with one unmethylated allele, and the unmethylated case showed the highest activi‐
ty. MGMT activity was measurable in all respective original tissues likely due to contami‐
nating normal cells. In accordance with lack of MGMT expression and MGMT activity, the
closed chromatin pattern was also observed. Marks of active and inactive chromatin pattern
were observed for unmethylated and partially methylated cases.
As combined chemoradiotherapy comprising the alkylating agent temozolomide has be‐
come the new standard of care [19], there has been growing interest to use MGMT promoter
methylation status for individual patient management, and for patient stratification or selec‐
tion in clinical trials. Knowledge of MGMT promoter methylation status is relevant for both
prognostic and predictive considerations. Furthermore, MGMT promoter methylation status
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has been used as a stratifying factor or eligibility criterion in ongoing and accruing clinical
trials [20].
Aberrant methylation of CpG islands in the promoter region of many genes has been recog‐
nized as an important epigenetic mechanism for gene silencing [21-24]. Inactivation of mul‐
tiple tumor suppressor genes by aberrant hypermethylation is a fundamental process
involved in the development of many malignant tumors [25, 26]. Mapping of methylation
patterns in CpG islands has become an important tool in understanding tissue-specific gene
expression in both normal and pathologic situations, and several protocols have been pub‐
lished for evaluating methylation status by methylation-specific PCR (MSP). Most of these
protocols are based on bisulfite treatment of isolated DNA [27, 28]. Bisulfite treatment chem‐
ically changes unmethylated, but not methylated, cytosines to uracil. Methylated DNA can
be distinguished from unmethylated DNA using sodium bisulfate treatment of DNA, which
converts unmethylated C to uracil (U) but leaves methylated C intact. Detection of methyla‐
tion or lack of it involves analysis of bisulfite-treated DNA using primer pairs that specifi‐
cally identify either methylated or unmethylated DNA.
The methylated and unmethylated sequences are detected through the use of methylation-
specific primers.
Figure 1. MGMT promoter methylation detection by methylation specific PCR. Methylated bands (M) can be seen in
samples S1 and S2 and in methylated control (M). Unmethylated bands (U) are seen in S1, S2, S3, and in negative (un‐
methylated) control
Methylation Specific PCR (MSP): Methylation is a chemical modification that adds methyl
(CH3) groups at selected sites on protein, DNA and RNA. In humans, DNA methylation only
affects the cytosine base (C) when it is followed by a guanine (G). Most CpG islands have been
observed in the 5’ promoter regions of genes. When promoter CpG islands become methylat‐
ed, the associated gene is silenced. Small amount of DNA, including those from paraffin em‐
bedded tissue, can be used for testing. DNA is first treated with bisulfite which converts
unmethylated, but not methylated, cytosine to uracil. This modified DNA is then used as a
template for PCR. The sequence differences between methylated and unmethylated DNA af‐
ter bisulfite treatment allow the designing of PCR primers that are specific for each type. The
primers are intended to amplify the identified region of the promoter mentioned above. PCR
products are detected by gel electrophoresis or by capillary electrophoresis.
Methylight Protocol: The MethyLight assay utilizes the TaqMan PCR principle which re‐
quires forward and reverse primers as well as an oligomeric probe which emits fluorescence
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only after it is degraded by the 5’-3’ exonuclease activity of Taq polymerase. MethyLight
protocol is a simple, real-time PCR method to determine the methylation status of CpG is‐
lands. Collagen 2A1 (COL2A1) gene is used as the internal reference (amplification control)
to assess the quality and quantity of input DNA.
Pyrosequencing: This is a method of DNA synthesis based on sequencing by synthesis prin‐
ciple. The procedure involves taking a single strand of the DNA to be sequenced and then
synthesizing its complementary strand enzymatically. The pyrosequencing method is based
on detecting the activity of DNA polymerase with another chemiluminescent enzyme [29,
30]. The pyrosequencing reaction occurs in 5 steps. In step 1, a sequencing primer is hybri‐
dized to a single-stranded amplicon that serves as a template, and incubated with the en‐
zymes DNA polymerase, ATP sulfurylase, luciferase, and apyrase, as well as substrates
adenosine 5' phosphosulfate and luciferin. In subsequent steps triphosphates are added to
reaction and each incorporation event is accompanied by release of pyrophosphate PPi). The
PPi is subsequently converted to ATP which then drives conversion of luciferin to oxyluci‐
ferin that generates visible light. Addition of dNTPs is performed sequentially. As the proc‐
ess continues, the complementary DNA stand is built up and the nucleotide sequence is
determined from the signal peaks in the pyrogram trace.
Methylation-Specific MLPA (MS-MLPA): The multiplex ligation-dependent probe amplifi‐
cation (MLPA) method allows for multiplex detection of gene copy number aberrations in a
routine laboratory. The methylation-specific MLPA (MS-MLPA) can detect changes in both
CpG methylation as well as copy number of up to 40 chromosomal sequences in a simple
reaction. In MS-MLPA, the ligation of MLPA probe oligonucleotides is combined with di‐
gestion of the genomic DNA-probe hybrid complexes with methylation-sensitive endonu‐
cleases [31, 32]. MS-MLPA is not based on bisulfite conversion of unmethylatedcytosines,
can provide methylation status, is semiquantitative, and can be used to evaluate methyla‐
tion status of multiple sequences simultaneously. Furthermore, it allows for a combined
copy number detection and methylation-specific analysis.
1.2. 1p/19q Loss of heterozygosity(LOH)
Among the major subtypes of gliomas, oligodendrogliomas are distinguished by their remark‐
able sensitivity to chemotherapy, with approximately 70% of anaplastic (malignant) oligoden‐
drogliomas  responding  dramatically  to  treatment  with  procarbazine,  lomustine,  and
vincristine (termed PCV) [33]. Unfortunately, no clinical or pathologic feature allows accurate
prediction of chemotherapeutic response. The prognosis for grade II oligodendrogliomas is
significantly better than that for grade II astrocytomas, with average survival times of 10 to 15
years. As with astrocytomas, there is considerable individual variability in time to progres‐
sion and overall survival. The average survival for anaplastic grade III oligodendrogliomas is 3
to 5 years, although some patients with genetically favorable subset may survive 10 years or
longer. The histologic distinction between oligodendroglioma and astrocytoma is often highly
subjective, and there has been significant interobserver variation.
Patients with oligodendroglial tumors are often stratified into therapeutic groups according
to age, extent of resection, tumor grade, and 1p/19q status. The current national Comprehen‐
Laboratory Testing for Prognostic and Predictive Markers in Gliomas
http://dx.doi.org/10.5772/52670
295
has been used as a stratifying factor or eligibility criterion in ongoing and accruing clinical
trials [20].
Aberrant methylation of CpG islands in the promoter region of many genes has been recog‐
nized as an important epigenetic mechanism for gene silencing [21-24]. Inactivation of mul‐
tiple tumor suppressor genes by aberrant hypermethylation is a fundamental process
involved in the development of many malignant tumors [25, 26]. Mapping of methylation
patterns in CpG islands has become an important tool in understanding tissue-specific gene
expression in both normal and pathologic situations, and several protocols have been pub‐
lished for evaluating methylation status by methylation-specific PCR (MSP). Most of these
protocols are based on bisulfite treatment of isolated DNA [27, 28]. Bisulfite treatment chem‐
ically changes unmethylated, but not methylated, cytosines to uracil. Methylated DNA can
be distinguished from unmethylated DNA using sodium bisulfate treatment of DNA, which
converts unmethylated C to uracil (U) but leaves methylated C intact. Detection of methyla‐
tion or lack of it involves analysis of bisulfite-treated DNA using primer pairs that specifi‐
cally identify either methylated or unmethylated DNA.
The methylated and unmethylated sequences are detected through the use of methylation-
specific primers.
Figure 1. MGMT promoter methylation detection by methylation specific PCR. Methylated bands (M) can be seen in
samples S1 and S2 and in methylated control (M). Unmethylated bands (U) are seen in S1, S2, S3, and in negative (un‐
methylated) control
Methylation Specific PCR (MSP): Methylation is a chemical modification that adds methyl
(CH3) groups at selected sites on protein, DNA and RNA. In humans, DNA methylation only
affects the cytosine base (C) when it is followed by a guanine (G). Most CpG islands have been
observed in the 5’ promoter regions of genes. When promoter CpG islands become methylat‐
ed, the associated gene is silenced. Small amount of DNA, including those from paraffin em‐
bedded tissue, can be used for testing. DNA is first treated with bisulfite which converts
unmethylated, but not methylated, cytosine to uracil. This modified DNA is then used as a
template for PCR. The sequence differences between methylated and unmethylated DNA af‐
ter bisulfite treatment allow the designing of PCR primers that are specific for each type. The
primers are intended to amplify the identified region of the promoter mentioned above. PCR
products are detected by gel electrophoresis or by capillary electrophoresis.
Methylight Protocol: The MethyLight assay utilizes the TaqMan PCR principle which re‐
quires forward and reverse primers as well as an oligomeric probe which emits fluorescence
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only after it is degraded by the 5’-3’ exonuclease activity of Taq polymerase. MethyLight
protocol is a simple, real-time PCR method to determine the methylation status of CpG is‐
lands. Collagen 2A1 (COL2A1) gene is used as the internal reference (amplification control)
to assess the quality and quantity of input DNA.
Pyrosequencing: This is a method of DNA synthesis based on sequencing by synthesis prin‐
ciple. The procedure involves taking a single strand of the DNA to be sequenced and then
synthesizing its complementary strand enzymatically. The pyrosequencing method is based
on detecting the activity of DNA polymerase with another chemiluminescent enzyme [29,
30]. The pyrosequencing reaction occurs in 5 steps. In step 1, a sequencing primer is hybri‐
dized to a single-stranded amplicon that serves as a template, and incubated with the en‐
zymes DNA polymerase, ATP sulfurylase, luciferase, and apyrase, as well as substrates
adenosine 5' phosphosulfate and luciferin. In subsequent steps triphosphates are added to
reaction and each incorporation event is accompanied by release of pyrophosphate PPi). The
PPi is subsequently converted to ATP which then drives conversion of luciferin to oxyluci‐
ferin that generates visible light. Addition of dNTPs is performed sequentially. As the proc‐
ess continues, the complementary DNA stand is built up and the nucleotide sequence is
determined from the signal peaks in the pyrogram trace.
Methylation-Specific MLPA (MS-MLPA): The multiplex ligation-dependent probe amplifi‐
cation (MLPA) method allows for multiplex detection of gene copy number aberrations in a
routine laboratory. The methylation-specific MLPA (MS-MLPA) can detect changes in both
CpG methylation as well as copy number of up to 40 chromosomal sequences in a simple
reaction. In MS-MLPA, the ligation of MLPA probe oligonucleotides is combined with di‐
gestion of the genomic DNA-probe hybrid complexes with methylation-sensitive endonu‐
cleases [31, 32]. MS-MLPA is not based on bisulfite conversion of unmethylatedcytosines,
can provide methylation status, is semiquantitative, and can be used to evaluate methyla‐
tion status of multiple sequences simultaneously. Furthermore, it allows for a combined
copy number detection and methylation-specific analysis.
1.2. 1p/19q Loss of heterozygosity(LOH)
Among the major subtypes of gliomas, oligodendrogliomas are distinguished by their remark‐
able sensitivity to chemotherapy, with approximately 70% of anaplastic (malignant) oligoden‐
drogliomas  responding  dramatically  to  treatment  with  procarbazine,  lomustine,  and
vincristine (termed PCV) [33]. Unfortunately, no clinical or pathologic feature allows accurate
prediction of chemotherapeutic response. The prognosis for grade II oligodendrogliomas is
significantly better than that for grade II astrocytomas, with average survival times of 10 to 15
years. As with astrocytomas, there is considerable individual variability in time to progres‐
sion and overall survival. The average survival for anaplastic grade III oligodendrogliomas is 3
to 5 years, although some patients with genetically favorable subset may survive 10 years or
longer. The histologic distinction between oligodendroglioma and astrocytoma is often highly
subjective, and there has been significant interobserver variation.
Patients with oligodendroglial tumors are often stratified into therapeutic groups according
to age, extent of resection, tumor grade, and 1p/19q status. The current national Comprehen‐
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sive Cancer Network (NCCN) guidelines for central nervous tumor cancers recommend
testing for 1p/19q codeletion or unbalanced translocation, for cases of suspected oligoden‐
droglioma. The test is also recommended to distinguish anaplastic oligodendroglioma from
anaplastic astrocytomas and glioblastomas. Recent studies [34-36] have shown that: (1) - al‐
lelic loss (loss of heterozygosity) of chromosome arm 1p is a statistically significant and cur‐
rently the best predictor of chemosensitivity; (2) combined loss involving chromosome arms
1p and 19q predicts both chemotherapeutic response and longer survival in patients with
oligodendrogliomas; and (3) combined allelic loss of chromosomes 1p and 19q can be con‐
sidered a molecular signature of oligodendroglioma (present in approximately 70-80% of
oligodendroglial tumors and in only 10% of astrocytomas). Anaplastic oligodendrogliomas
with loss on 1p, or combined loss on 1p and 19q usually respond favorably to chemothera‐
py, with about half of such tumors showing complete neuroradiological response. Owing to
the major prognostic significance of the 1p/19q status in patients with anaplastic gliomas
treated with radio and/or chemotherapy, ongoing prospective trials are no longer stratifying
anaplastic glioma patients according to histological types but according to the 1p/19q dele‐
tion status [37]. Detection methods for 1p and 19q deletion include polymerase chain reac‐
tion (PCR), fluorescent in situ hybridization (FISH), array comparative genomic
hybridization, and multiplex ligation-dependent probe amplification (MPLA) [38-40].
Primary Markers Back up markers
Microsatellite Locus Abbreviation Microsatellite Locus Abbreviation
D1S548 1-1 D1S468 1-2
D1S592 1-3 D1S1612 1-5
D1S552 1-4 D1S496 1-6
D19S219 19-1
D19S412 19-2 D19S606 19-3
PLA2G4C 19-5 D19S1182 19-4
Table 1. Primary and back up microsatellite markers for detection 1p and 19q deletion
1.3. 1p/19q LOH - Microsatellite-based method of detection
Allelic loss is assessed by PCR assay in normal DNA / tumor DNA pairs using markers at
both 1p and 19q. For this type of testing, a patient's blood sample is needed to accurately
assess patient's genotype and establish the normal DNA baseline. Because there might be
partial as well as complete deletions, any reductions in tumor peaks can then accurately be
interpreted as deletions. The 6 markers on 1p and the 5 markers on 19q are microsatellites (2
or 4 nucleotide repeats) except PLA2G4C which is a minisatellite (26 nucleotide repeat)
polymorphism. The markers were selected based on heterozygosity score, amplicon size,
and ease of interpretation. LOH at all informative loci on each chromosomal arm represents
the typical finding in oligodendrogliomas with 1p and 19q deletion. To streamline the work
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flow process, a set of primary markers in tested first. If at least two markers for 1p and two
marker for 19q show either no deletion or clear deletion, the results can be considered valid.
If the results with primary markers are not clear, either because the markers are not infor‐
mative (homozygosity), or they did not amplify, then the back up markers are used in sub‐
sequent PCR reaction.
Figure 2. The tumor sample on the left demonstrates 1p deletion. Normal DNA baseline is on the top.
Figure 3. Sample on the left demonstrates two alleles both in base line sample and in tumor sample. The sample on
the right has a non-informative microsatellite marker.
Array Comparative Genomic Hybridization (aCGH) - aCGH is a technique to detect genom‐
ic copy number variations at a higher resolution level than chromosome-based comparative
genomic hybridization (CGH). DNA from a test sample and normal sample are labeled dif‐
ferentially, using different fluorophores, and hybridized to several thousand probes. The
probes are derived from known genomic sequences and are printed on glass slides. The flu‐
orescence intensity of the test and of the reference DNA is then measured to calculate the
ratio between them and subsequently the copy number changes for a particular location in
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sive Cancer Network (NCCN) guidelines for central nervous tumor cancers recommend
testing for 1p/19q codeletion or unbalanced translocation, for cases of suspected oligoden‐
droglioma. The test is also recommended to distinguish anaplastic oligodendroglioma from
anaplastic astrocytomas and glioblastomas. Recent studies [34-36] have shown that: (1) - al‐
lelic loss (loss of heterozygosity) of chromosome arm 1p is a statistically significant and cur‐
rently the best predictor of chemosensitivity; (2) combined loss involving chromosome arms
1p and 19q predicts both chemotherapeutic response and longer survival in patients with
oligodendrogliomas; and (3) combined allelic loss of chromosomes 1p and 19q can be con‐
sidered a molecular signature of oligodendroglioma (present in approximately 70-80% of
oligodendroglial tumors and in only 10% of astrocytomas). Anaplastic oligodendrogliomas
with loss on 1p, or combined loss on 1p and 19q usually respond favorably to chemothera‐
py, with about half of such tumors showing complete neuroradiological response. Owing to
the major prognostic significance of the 1p/19q status in patients with anaplastic gliomas
treated with radio and/or chemotherapy, ongoing prospective trials are no longer stratifying
anaplastic glioma patients according to histological types but according to the 1p/19q dele‐
tion status [37]. Detection methods for 1p and 19q deletion include polymerase chain reac‐
tion (PCR), fluorescent in situ hybridization (FISH), array comparative genomic
hybridization, and multiplex ligation-dependent probe amplification (MPLA) [38-40].
Primary Markers Back up markers
Microsatellite Locus Abbreviation Microsatellite Locus Abbreviation
D1S548 1-1 D1S468 1-2
D1S592 1-3 D1S1612 1-5
D1S552 1-4 D1S496 1-6
D19S219 19-1
D19S412 19-2 D19S606 19-3
PLA2G4C 19-5 D19S1182 19-4
Table 1. Primary and back up microsatellite markers for detection 1p and 19q deletion
1.3. 1p/19q LOH - Microsatellite-based method of detection
Allelic loss is assessed by PCR assay in normal DNA / tumor DNA pairs using markers at
both 1p and 19q. For this type of testing, a patient's blood sample is needed to accurately
assess patient's genotype and establish the normal DNA baseline. Because there might be
partial as well as complete deletions, any reductions in tumor peaks can then accurately be
interpreted as deletions. The 6 markers on 1p and the 5 markers on 19q are microsatellites (2
or 4 nucleotide repeats) except PLA2G4C which is a minisatellite (26 nucleotide repeat)
polymorphism. The markers were selected based on heterozygosity score, amplicon size,
and ease of interpretation. LOH at all informative loci on each chromosomal arm represents
the typical finding in oligodendrogliomas with 1p and 19q deletion. To streamline the work
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors296
flow process, a set of primary markers in tested first. If at least two markers for 1p and two
marker for 19q show either no deletion or clear deletion, the results can be considered valid.
If the results with primary markers are not clear, either because the markers are not infor‐
mative (homozygosity), or they did not amplify, then the back up markers are used in sub‐
sequent PCR reaction.
Figure 2. The tumor sample on the left demonstrates 1p deletion. Normal DNA baseline is on the top.
Figure 3. Sample on the left demonstrates two alleles both in base line sample and in tumor sample. The sample on
the right has a non-informative microsatellite marker.
Array Comparative Genomic Hybridization (aCGH) - aCGH is a technique to detect genom‐
ic copy number variations at a higher resolution level than chromosome-based comparative
genomic hybridization (CGH). DNA from a test sample and normal sample are labeled dif‐
ferentially, using different fluorophores, and hybridized to several thousand probes. The
probes are derived from known genomic sequences and are printed on glass slides. The flu‐
orescence intensity of the test and of the reference DNA is then measured to calculate the
ratio between them and subsequently the copy number changes for a particular location in
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the genome. This method allows one to detect microdeletions and chromosomal duplica‐
tions and is used with increasing frequency for loss of heterozygosity detection [41].
1.4. IDH1 and IDH2 mutations
Point mutations in the cytosolic isocitrate dehydrogenase enzyme gene (IDH1) or the mito‐
chondrial version of the same gene (IDH2) are frequently detected in low grade astrocyto‐
mas, oligodendrogliomas and in secondary glioblastomas. IDH1 is involved in the metabolic
conversion of isocitrate to alpha-ketoglutarate, which reduces NADP to NADPH. In glio‐
mas, mutations in this gene were discovered through large scale DNA sequencing of tumor
samples [42]. Among WHO grade II and grade III gliomas, 50% to 80% have mutated IDH1,
whereas 5% to 10% of WHO grade IV gliomas carry IDH1 mutation. Studies of clinical trial
samples of low grade gliomas showed that mutated IDH1 may be both prognostic and pre‐
dictive, because it was associated with longer survival times and better response to temozo‐
lomide therapy [43, 44]. Another study with astrocytoma showed an association with
improved survival but not with response to temozolomide [45]. Further clarification of the
correlation of chemotherapy response and IDH1 mutational status will be needed for this
marker to receive broad clinical use. At present, lack of IDH1 mutation can not be consid‐
ered strong enough evidence to alter therapy.
Because the presence of an IDH mutation is considered tumor specific, it has a role as a diag‐
nostic marker when morphologic features are inconclusive and a non neoplastic (reactive)
condition is possible.





































Table 2. IDH 1 and IDH2 mutations and resulting amino acid changes
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Sanger Sequencing - The ability to sequence DNA has been essential to the field of molecu‐
lar pathology because sequence information is needed for primer design in PCR-based as‐
says, for determination of target sequence, and for detection of any changes such as
mutations, insertions and deletions in DNA sequence. The method for DNA sequencing de‐
veloped by Sanger [46] is the basis for most DNA sequencing currently performed in clinical
molecular laboratories. The Sanger sequencing reaction (for more detailed description see
[16]) uses a single DNA primer and DNA polymerase with linear amplification rather than
the exponential amplification of PCR. Components essential to the Sanger sequencing reac‐
tion include: (1) an electrophoresis technique capable of clearly distinguishing single nucleo‐
tide length differences in DNA strands dozens or hundreds nucleotides in length, (2)
sequence-specific complementary primers, with one primer used in the forward reaction
and the other used in reverse reaction for each DNA template strand, and (3) the addition of
small proportions of dideoxynucleoside triphosphates (ddNTPs) in addition to the conven‐
tional deoxyribonucleoside triphosphates (dNTPs) used in polymerase chain reaction. Di‐
deoxynucleotides differ from deoxynucleotides by having a hydrogen atom attached to the
3' carbon rather than an OH group, which is present on the deoxynucleotide. Because the
ddNTPs lack a 3'-hydroxyl group, elongation of the newly polymerized chain cannot occur
once a ddNTP has been incorporated. The end result is a set of fragments of different
lengths complementary to the parent DNA strand. The sequencing reaction products are
most frequently detected by capillary electrophoresis on a DNA sequencing instrument.
Figure 4. Sanger sequencing for IDH1 mutation detection: IDH1 wild type sequence (top) and CGT>CAT, p.R132H mu‐
tant (bottom)
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the genome. This method allows one to detect microdeletions and chromosomal duplica‐
tions and is used with increasing frequency for loss of heterozygosity detection [41].
1.4. IDH1 and IDH2 mutations
Point mutations in the cytosolic isocitrate dehydrogenase enzyme gene (IDH1) or the mito‐
chondrial version of the same gene (IDH2) are frequently detected in low grade astrocyto‐
mas, oligodendrogliomas and in secondary glioblastomas. IDH1 is involved in the metabolic
conversion of isocitrate to alpha-ketoglutarate, which reduces NADP to NADPH. In glio‐
mas, mutations in this gene were discovered through large scale DNA sequencing of tumor
samples [42]. Among WHO grade II and grade III gliomas, 50% to 80% have mutated IDH1,
whereas 5% to 10% of WHO grade IV gliomas carry IDH1 mutation. Studies of clinical trial
samples of low grade gliomas showed that mutated IDH1 may be both prognostic and pre‐
dictive, because it was associated with longer survival times and better response to temozo‐
lomide therapy [43, 44]. Another study with astrocytoma showed an association with
improved survival but not with response to temozolomide [45]. Further clarification of the
correlation of chemotherapy response and IDH1 mutational status will be needed for this
marker to receive broad clinical use. At present, lack of IDH1 mutation can not be consid‐
ered strong enough evidence to alter therapy.
Because the presence of an IDH mutation is considered tumor specific, it has a role as a diag‐
nostic marker when morphologic features are inconclusive and a non neoplastic (reactive)
condition is possible.
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Sanger Sequencing - The ability to sequence DNA has been essential to the field of molecu‐
lar pathology because sequence information is needed for primer design in PCR-based as‐
says, for determination of target sequence, and for detection of any changes such as
mutations, insertions and deletions in DNA sequence. The method for DNA sequencing de‐
veloped by Sanger [46] is the basis for most DNA sequencing currently performed in clinical
molecular laboratories. The Sanger sequencing reaction (for more detailed description see
[16]) uses a single DNA primer and DNA polymerase with linear amplification rather than
the exponential amplification of PCR. Components essential to the Sanger sequencing reac‐
tion include: (1) an electrophoresis technique capable of clearly distinguishing single nucleo‐
tide length differences in DNA strands dozens or hundreds nucleotides in length, (2)
sequence-specific complementary primers, with one primer used in the forward reaction
and the other used in reverse reaction for each DNA template strand, and (3) the addition of
small proportions of dideoxynucleoside triphosphates (ddNTPs) in addition to the conven‐
tional deoxyribonucleoside triphosphates (dNTPs) used in polymerase chain reaction. Di‐
deoxynucleotides differ from deoxynucleotides by having a hydrogen atom attached to the
3' carbon rather than an OH group, which is present on the deoxynucleotide. Because the
ddNTPs lack a 3'-hydroxyl group, elongation of the newly polymerized chain cannot occur
once a ddNTP has been incorporated. The end result is a set of fragments of different
lengths complementary to the parent DNA strand. The sequencing reaction products are
most frequently detected by capillary electrophoresis on a DNA sequencing instrument.
Figure 4. Sanger sequencing for IDH1 mutation detection: IDH1 wild type sequence (top) and CGT>CAT, p.R132H mu‐
tant (bottom)
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Immunohistochemistry: Approximately 90% of IDH1 mutated proteins can be detected by
using immunohistochemistry with a monoclonal antibody that detects p.R132H, the most
common IDH1 mutation [47].
1.5. EGFRvIII mutation detection in glioblastomamultiforme
The epidermal growth factor receptor (EGFR) is an attractive molecular target in glioblasto‐
ma because it is amplified, overexpressed, and/or mutated in up to 40% to 50% of patients.
EGFR variant III (EGFRvIII) is an oncogenic, constitutively active mutant form of EGFR that
is commonly expressed in glioblastoma. EGFRvIII is generated by in-frame genomic dele‐
tion of 801bp from exons 2 to 7 of the coding region of EGFR which produces a truncated
receptor lacking a portion of extracellular ligand binding domain. EGFRvIII mutations in
gliomas typically lead to unique signal transduction properties to the receptor, particularly
enhanced downstream activation of a phosphatidylinositol 3'-kinase (PI3K) signaling path‐
way with concurrent loss of PTEN. Cell culture and in vivo models of glioblastoma have
demonstrated EGFRvIII as defining prognostically distinct subgroups of glioblastomas. Ad‐
ditionally, the presence of EGFRvIII has been shown to sensitize tumors to EGFR tyrosine
kinase inhibitors when the tumor suppressor protein PTEN is intact [48, 49].
Expression of EGFRvIII is associated with favorable clinical response to the EGFR kinase in‐
hibitors gefitinib and erlotinib when the tumor suppressor protein PTEN is intact
EGFRvIII also presents a unique antigenetic target on tumor cells that is currently being
therapeutically used with anti- EGFRvIII vaccines as a molecularly targeted treatment ap‐
proach. In addition to its recently shown relevance for defining prognostically distinct sub‐
groups, EGFRvIII detection is likely to be increasingly important for determining treatment
decisions for patients with glioblastoma and potentially for those with other types of cancer.
RT-PCR-Based Detection - Reverse transcription-polymerase chain reaction (RT-PCR) is an
RNA-based PCR assay [50]. Reverse transcriptase catalyzes DNA synthesis using RNA as
the template, producing a DNA strand complementary to the RNA template, called comple‐
mentary DNA (cDNA). Because cDNA is not subject to RNase degradation, it is much more
stable in laboratory environment than corresponding RNA. For EGFRvIII detection, RNA is
extracted from FFPE tissue and reverse transcribed into cDNA. PCR is performed and PCR
products are detected by gel electrophoresis. PCR primers are designed to detect EGFRvIII
sequences but not unmutated sequences. A portion of a control gene is amplified in parallel
to test for RNA/cDNA yield and integrity.
2. Testing and quality control issues
2.1. Specimen types
Formalin-fixed paraffin-embedded tissue - most frequently used in clinical testing, both for
DNA-based and RNA-based analysis. Fresh and frozen tissue can be used to extract DNA or
RNA, however it is less frequently used in clinical molecular laboratories.
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groups, EGFRvIII detection is likely to be increasingly important for determining treatment
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RT-PCR-Based Detection - Reverse transcription-polymerase chain reaction (RT-PCR) is an
RNA-based PCR assay [50]. Reverse transcriptase catalyzes DNA synthesis using RNA as
the template, producing a DNA strand complementary to the RNA template, called comple‐
mentary DNA (cDNA). Because cDNA is not subject to RNase degradation, it is much more
stable in laboratory environment than corresponding RNA. For EGFRvIII detection, RNA is
extracted from FFPE tissue and reverse transcribed into cDNA. PCR is performed and PCR
products are detected by gel electrophoresis. PCR primers are designed to detect EGFRvIII
sequences but not unmutated sequences. A portion of a control gene is amplified in parallel
to test for RNA/cDNA yield and integrity.
2. Testing and quality control issues
2.1. Specimen types
Formalin-fixed paraffin-embedded tissue - most frequently used in clinical testing, both for
DNA-based and RNA-based analysis. Fresh and frozen tissue can be used to extract DNA or
RNA, however it is less frequently used in clinical molecular laboratories.
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Figure 5. Gliosarcoma, WHO grade IV. (A and B) Sections show a moderately pleomorphic, biphasic glial tumor. Tu‐
mor tissue tested positive for MGMT promoter methylation (C) and negative for IDH1 mutation (D).
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Microdissection may need to be performed to enrich for tumor content. If a specimen contains
too few tumor cells or too many background reactive cell types, the sensitivity of the test may
be diminished. In the past 15 years, various techniques of microdissection have been em‐
ployed to isolate cells of interest in order to increase test sensitivity. Most frequently, a pathol‐
ogist will examine an H&E stained tissue section and mark areas of tumor involvement.
Tissues from tumor rich areas are then manually scrapped off the slides and used for nucleic
acid extraction. Less frequently, laser capture microdissection might be performed, however
this method is not practical for use in routine clinical molecular laboratories.
2.2. Nucleic acid extraction
Nucleic acid purification begins with lysis of the cells in the sample. Cell lysis liberates cellu‐
lar macromolecules including proteins, lipids, and nucleic acids. Cell lysis can be accom‐
plished using a detergent solution to break cell membranes and remove lipids. Proteins are
enzymatically degraded with protease, usually proteinase K, or selectively precipitated. Pro‐
tein digestion is performed at about 56oC and will permanently denature many proteins but
does not affect nucleic acids. This process is followed by selective extraction that takes ad‐
vantage of the physical and chemical differences between nucleic acids and other cellular
molecules, forming the basis for their isolation. The nucleic acid is then purified from the
soluble contaminants produced in the extraction process by precipitation in an ethanol-salt
solution. The isolated nucleic acid is then resuspended in a dilute salt buffer.
2.3. DNA
PCR-based genetic analyses most frequently require isolated genomic DNA. Molecular anal‐
yses of nucleic acids have traditionally required DNA derived from blood, bone marrow as‐
pirate, and fresh or frozen tissues. New developments in DNA extraction methods now
make it possible to also use DNA extracted from formalin-fixed, paraffin-embedded (FFPE)
tissues. The purpose of DNA isolation/extraction procedures is to obtain useful samples of
DNA that are free of contaminating molecules which could hinder downstream DNA analy‐
sis. DNA is a hardy molecule present at stable cellular levels. It is relatively easy to isolate
and store because deoxyribonucleases (DNases) that could potenitially degrade isolated
DNA are easily denatured by heating or inhibited by sequestration of divalent cations.
2.4. RNA
Gene expression protocols (RT-PCR based genetic analyses) require isolated human RNA.
RNA analysis depends on successful RNA isolation and preservation. Total RNA is purified
with the use of RNA purification kits by first adding the white blood cells or tissue samples to a
detergent/salt solution to lyse and homogenize the cells and eliminate endogenous RNase ac‐
tivity. Homogenization disrupts the cell membranes releasing RNA into the lysing solution,
and shears the genomic DNA to reduce its ability to bind to the purification column with the
RNA. The lysates are then passed through a purification column to bind the RNA and wash
away proteins, DNA and other contaminants. Residual DNA is removed by an on-column
DNase treatment. Finally, the purified RNA is eluted with DEPC-treated water.
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ployed to isolate cells of interest in order to increase test sensitivity. Most frequently, a pathol‐
ogist will examine an H&E stained tissue section and mark areas of tumor involvement.
Tissues from tumor rich areas are then manually scrapped off the slides and used for nucleic
acid extraction. Less frequently, laser capture microdissection might be performed, however
this method is not practical for use in routine clinical molecular laboratories.
2.2. Nucleic acid extraction
Nucleic acid purification begins with lysis of the cells in the sample. Cell lysis liberates cellu‐
lar macromolecules including proteins, lipids, and nucleic acids. Cell lysis can be accom‐
plished using a detergent solution to break cell membranes and remove lipids. Proteins are
enzymatically degraded with protease, usually proteinase K, or selectively precipitated. Pro‐
tein digestion is performed at about 56oC and will permanently denature many proteins but
does not affect nucleic acids. This process is followed by selective extraction that takes ad‐
vantage of the physical and chemical differences between nucleic acids and other cellular
molecules, forming the basis for their isolation. The nucleic acid is then purified from the
soluble contaminants produced in the extraction process by precipitation in an ethanol-salt
solution. The isolated nucleic acid is then resuspended in a dilute salt buffer.
2.3. DNA
PCR-based genetic analyses most frequently require isolated genomic DNA. Molecular anal‐
yses of nucleic acids have traditionally required DNA derived from blood, bone marrow as‐
pirate, and fresh or frozen tissues. New developments in DNA extraction methods now
make it possible to also use DNA extracted from formalin-fixed, paraffin-embedded (FFPE)
tissues. The purpose of DNA isolation/extraction procedures is to obtain useful samples of
DNA that are free of contaminating molecules which could hinder downstream DNA analy‐
sis. DNA is a hardy molecule present at stable cellular levels. It is relatively easy to isolate
and store because deoxyribonucleases (DNases) that could potenitially degrade isolated
DNA are easily denatured by heating or inhibited by sequestration of divalent cations.
2.4. RNA
Gene expression protocols (RT-PCR based genetic analyses) require isolated human RNA.
RNA analysis depends on successful RNA isolation and preservation. Total RNA is purified
with the use of RNA purification kits by first adding the white blood cells or tissue samples to a
detergent/salt solution to lyse and homogenize the cells and eliminate endogenous RNase ac‐
tivity. Homogenization disrupts the cell membranes releasing RNA into the lysing solution,
and shears the genomic DNA to reduce its ability to bind to the purification column with the
RNA. The lysates are then passed through a purification column to bind the RNA and wash
away proteins, DNA and other contaminants. Residual DNA is removed by an on-column
DNase treatment. Finally, the purified RNA is eluted with DEPC-treated water.
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2.5. Limitations of nucleic acid-based procedures
The following can affect the quality of lab results and should ideally be addressed during
assay validation:
1. The accumulation of normal cells in the tumor, including infiltrating lymphocytes, may
complicate accurate assessment of MGMT promoter methylation. Review of tissue mor‐
phology by a pathologist prior to testing will ensure that best suited tissue block are ex‐
amined.
2. Excessive necrosis of tumor tissue will complicate analysis; a different tissue block
needs to be selected, when available.
3. Bisulfite treatment of DNA is technically the most challenging part of this protocol.
Since DNA loss routinely occurs during bisulfite treatment; it is important to select cas‐
es with minimal necrosis to ensure adequate yield of DNA. In order to control for bisul‐
fite effect, methylated and unmethylated controls must be treated in parallel to patient
samples to ensure that complete conversion occurred.
Appropriate specimen handling is critical to ensure specimen integrity and the accuracy of
quantitative and qualitative nucleic acid detection. Inappropriate specimen handling can re‐
sult in nucleic acid degradation, which can lead to erroneous quantitation of target from the
patient. For example, RNA is rapidly degraded by a variety of ribonuclease (RNase) en‐
zymes that are abundantly present within cells, on the skin surfaces, and possibly laboratory
bench tops and equipment. RNases are very stable, active in virtually any aqueous environ‐
ment, and can regain their activity after denaturation, and steps need to be developed to
prevent RNA degradation by exposure to contaminating RNases.
2.6. Contamination prevention measures in a PCR laboratory
Millions of copies of target DNA are generated when PCR and other in vitro nucleic acid
amplification techniques are used. If precautions are not taken, amplicons from previous re‐
actions can be introduced into new amplification reactions and act as substrates for new
DNA synthesis. The contaminating amplicons, amplified along with the patient samples
will produce false positive results. Clinical molecular laboratories must have strict policies
regarding contamination prevention and unidirectional work flow. Amplicon contamination
and false positive results are prevented by using physical barriers and chemical and ultra‐
violet (UV) techniques to destroy amplicons or make them unsuitable for amplification. The
physical barriers involve doing separate procedure steps in specially designated areas. For
example, DNA isolation and PCR set-up are done in areas, separated by a wall, from areas
used in downstream processing (thermal cycling, data analysis). This is also known as uni‐
directional work flow. Each area must have designated equipment and supplies to avoid
cross contamination. Laminar flow hoods and other biological containment boxes equipped
with UV light must be available in pre-PCR areas. Small scale physical separation techni‐
ques also include the use of barrier pipette tips, frequent glove changes, designated lab
coats, and PCR tube openers or careful, slow opening of tubes to prevent aerosolization of
contents. Chemical techniques include daily cleansing with bleach and other specialized de‐
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contaminants of work areas before and after use. Use of UV light will further degrade any
residual nucleic acids on work surfaces. A no template PCR reaction must be included with
every assay as a quality control check for amplicon contamination.
3. Assay validation
For a test to become generally useful, it must have demonstrated analytic validity and clini‐
cal utility. Analytic validation focuses on determining how accurately and reliably the assay
measures the molecular event of interest. The assay must be reliable in routine laboratory
setting using a variety of specimen types. Even assays that are routinely performed in the
laboratory require analytic validation within the clinical setting of each laboratory when test
results are used for clinical decisions. To ensure reproducible findings, clinical laboratories
need to understand the impact that preanalytic variables and specimen processing have on
assay performance. Analytic validation ensures that the same answer will be produced for
the same sample within predefined technical variation. In recognition of the critical impor‐
tance of analytic validation for biomarkers, multiple groups have developed recommenda‐
tions and frameworks with which to standardize the assessment.
Clinical validation assesses the strength of association between the assay results and the
clinical outcome of interest, whether it is diagnostic, prognostic, or predictive. A large num‐
ber of measures are used to assess these associations. These analyses address whether one
can be sure the clinical state is positive if the test is positive (positive predictive power) and
that the clinical state is negative if the test is negative (negative predictive power).
Evaluation of new biomarkers can be aided if tumor biomarker studies and the journals re‐
porting them adhere to the Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK). These guidelines were produced by a working group convened as part
of the NCI-EORTC joint meeting on Cancer Diagnostics in Nyborg, Denmark, in 2000 [51].
REMARK criteria include specifications of patient populations, biological specimen under
study, assay methods, study design, and statistical methods, and detailed guidelines for
analysis and presentation of data. This reporting standard is now requested for manuscripts
being submitted to many journals. Although the tissue sources are not always available to
allow the most rigorous validation of assays, providing a standardized means to communi‐
cate the level of clinical validation is critical to biomarker development. Using the above re‐
porting standards should help establish the clinical validity of new biomarkers being used
in cancer research and treatment.
An emerging standard for the adoption of new molecular tests is the demonstration of clini‐
cal utility. Clinical utility refers to the ability of the assay to improve clinical decision mak‐
ing and patient outcomes. Clinical utility depends on the clinical situation, availability of
effective therapies, magnitude of clinical benefit, and relative value the patient, caregiver,
and society place on the differences in benefits and risks in these separate groups. For exam‐
ple, if a marker clearly distinguishes differences between positive and negative results but
the evidence for differential treatment is not available, there is no reason to test for the
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the same sample within predefined technical variation. In recognition of the critical impor‐
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study, assay methods, study design, and statistical methods, and detailed guidelines for
analysis and presentation of data. This reporting standard is now requested for manuscripts
being submitted to many journals. Although the tissue sources are not always available to
allow the most rigorous validation of assays, providing a standardized means to communi‐
cate the level of clinical validation is critical to biomarker development. Using the above re‐
porting standards should help establish the clinical validity of new biomarkers being used
in cancer research and treatment.
An emerging standard for the adoption of new molecular tests is the demonstration of clini‐
cal utility. Clinical utility refers to the ability of the assay to improve clinical decision mak‐
ing and patient outcomes. Clinical utility depends on the clinical situation, availability of
effective therapies, magnitude of clinical benefit, and relative value the patient, caregiver,
and society place on the differences in benefits and risks in these separate groups. For exam‐
ple, if a marker clearly distinguishes differences between positive and negative results but
the evidence for differential treatment is not available, there is no reason to test for the
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marker. Likewise, if therapy is effective regardless whether the patient tests positive or neg‐
ative, the marker does not have clinical utility. Additionally, a novel assay might have out‐
standing analytic validity and proven clinical validity but there is already an established
method to test for the same parameters, which makes the new assay unnecessary.
Associations such as Clinical Laboratory Standards Institute (CLSI) have published several
guidelines dealing with molecular genomic testing in clinical laboratories. As more molecu‐
lar tests are being introduced for patient management, CLSI will likely continue to publish
new and expanded guidelines addressing current and possibly future considerations and
best practices.
3.1. Issues with MGMT assay validation
Molecular markers in general are developed to address a variety of indications [52]. Diag‐
nostic markers are a large category of molecular tests that aid in the diagnosis or subclassifi‐
cation of a particular disease state. Diagnostic subclassification may result in different
management of the disease, but the marker is used primarily to establish the particular dis‐
ease that is present in the patient sample. An example of a diagnostic marker is BCR/ABL
t(9;22) translocation in chronic myelogenous leukemia. Prognostic markers have an associa‐
tion with some clinical outcomes, such as overall survival or recurrence-free survival, inde‐
pendent of the treatment rendered. An example of a prognostic marker is the FLT3 IDT
mutation in acute myeloid leukemia, which identifies a subset of patients who will have a
more aggressive disease course regardless of current treatment options. Predictive markers
predict the activity of a specific class or type of therapy, and are used to help make more
specific treatment decisions. They are used as indicators of the likely benefit of a specific
treatment to a specific patient. Human epidermal growth factor receptor (EGFR) is an exam‐
ple of a predictive marker. Patients with lung cancers whose tumors exhibit adenocarcinoma
histology and carry one of the sensitizing EGFR mutations are likely to respond well to
treatment with tyrosine kinase inhibitors erlotinib and gefitinib. Some of these markers may
also be used as companion markers to identify a subgroup of patients that are likely to re‐
spond to a specific therapy. One example of a companion diagnostic is the BRAF V600E mu‐
tation test which is coapproved with the kinase inhibitor vemurafenib. BRAF mutations are
found in 30% to 60% of melanomas, and the kinase activating BRAF V600E mutation confers
sensitivity to vemurafenib, a small molecule inhibitor.
The clinical utility of the MGMT methylation status as a biomarker for benefit from alkylat‐
ing agent therapy in gliomas is still being evaluated and there is no consensus as to which
procedure is most suitable for routine clinical testing. While most protocols measure the lev‐
el of methylation accurately, presence of contaminating normal cells in every specimen
makes it difficult to set up a consistent cut off point between low positive and negative test
results. The extent of methylation required and the sets of CpGs that are crucial for complete
silencing are still under investigation. Given the complexity of the biological relationship be‐
tween promoter methylation and gene silencing and the difficulties to integrate these fea‐
tures into a test that is in addition complicated by presence of nontumoral tissue, there are
unavoidable drawbacks for any technology attempting to predict loss of MGMT expression
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for potential benefit from alkylating agent therapy. Key to introducing tests for diagnostics
is their careful prospective validation.
3.2. MGMT methylight assay validation - A one lab experience
Epigenetic silencing of the MGMT gene through promoter hypermethylation and resulting
transcriptional inactivation is now routinely used as a prognostic and possibly predictive bi‐
omarker in evaluating treatment choices in patients diagnosed with glioma. Patients enroll‐
ing in clinical trials are also evaluated for the MGMT promoter methylation status. For that
reason, a sensitive, clinically validated assay for detection of MGMT promoter methylation
can be of great help in patient management.We previously developed a simplified MGMT
MSP protocol [53] that utilized formalin fixed paraffin embedded specimens. This MSP pro‐
tocol proved reliable with majority of glioma patients, however, result interpretation was
sometimes challenging when evaluating specimens with few malignant cells and/or exten‐
sive necrosis, both of which gave faint bands on agarose gels.To further enhance our ability
to accurately assess methylation status of the MGMT promoter region in glioma specimens,
we investigated the use of real-time PCR technology as a way of enhancing assay sensitivity.
Our ultimate goal was to develop a more sensitive detection method that would give relia‐
ble, semi-quantitative results, even with suboptimal specimens. Previous studies have
shown sodium bisulfite conversion to be a reproducible method, with subsequent quantita‐
tive real-time PCR methylation assays having acceptable precision for clinical work [54].
The goal of this study was to evaluate the MethyLight protocol, as compared to the MGMT-
MSP protocol, and appropriateness of the MethyLight protocol for use in MGMT promoter
methylation detection in routine clinical testing of glioma cases.
3.3. Materials and methods
3.3.1. Tumor samples
Thirty archival brain resection cases were selected for the study: glioblastomamultiforme
(18), oligodendroglioma (3), anaplastic oligodendroglioma (3), and astrocytoma (6). For all
tumor samples, histology was reviewed to confirm diagnosis and select blocks with greatest
tumor involvement. Microdissection was performed on all samples showing an estimated
tumor cell content of less than 50% except in cases where infiltrative pattern of tumor
growth made this step unreliable.
3.3.2. DNA extraction and bisulfite treatment
Genomic DNA was isolated from 2 to 3 twenty micrometer thick paraffin sections after con‐
firmation of the histology. DNA from formalin fixed, paraffin embedded tissue was extract‐
ed using Puregene kit (Gentra Systems, Minneapolis, MN). MGMT promoter methylation
status was assessed using a two step approach. The first step involved bisulfite conversion
of isolated DNA (200-500 ng) which was done using EZ DNA Methylation Gold kit (Zymo
Research, Orange, CA). The second step involved detection of methylated and unmethylat‐
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marker. Likewise, if therapy is effective regardless whether the patient tests positive or neg‐
ative, the marker does not have clinical utility. Additionally, a novel assay might have out‐
standing analytic validity and proven clinical validity but there is already an established
method to test for the same parameters, which makes the new assay unnecessary.
Associations such as Clinical Laboratory Standards Institute (CLSI) have published several
guidelines dealing with molecular genomic testing in clinical laboratories. As more molecu‐
lar tests are being introduced for patient management, CLSI will likely continue to publish
new and expanded guidelines addressing current and possibly future considerations and
best practices.
3.1. Issues with MGMT assay validation
Molecular markers in general are developed to address a variety of indications [52]. Diag‐
nostic markers are a large category of molecular tests that aid in the diagnosis or subclassifi‐
cation of a particular disease state. Diagnostic subclassification may result in different
management of the disease, but the marker is used primarily to establish the particular dis‐
ease that is present in the patient sample. An example of a diagnostic marker is BCR/ABL
t(9;22) translocation in chronic myelogenous leukemia. Prognostic markers have an associa‐
tion with some clinical outcomes, such as overall survival or recurrence-free survival, inde‐
pendent of the treatment rendered. An example of a prognostic marker is the FLT3 IDT
mutation in acute myeloid leukemia, which identifies a subset of patients who will have a
more aggressive disease course regardless of current treatment options. Predictive markers
predict the activity of a specific class or type of therapy, and are used to help make more
specific treatment decisions. They are used as indicators of the likely benefit of a specific
treatment to a specific patient. Human epidermal growth factor receptor (EGFR) is an exam‐
ple of a predictive marker. Patients with lung cancers whose tumors exhibit adenocarcinoma
histology and carry one of the sensitizing EGFR mutations are likely to respond well to
treatment with tyrosine kinase inhibitors erlotinib and gefitinib. Some of these markers may
also be used as companion markers to identify a subgroup of patients that are likely to re‐
spond to a specific therapy. One example of a companion diagnostic is the BRAF V600E mu‐
tation test which is coapproved with the kinase inhibitor vemurafenib. BRAF mutations are
found in 30% to 60% of melanomas, and the kinase activating BRAF V600E mutation confers
sensitivity to vemurafenib, a small molecule inhibitor.
The clinical utility of the MGMT methylation status as a biomarker for benefit from alkylat‐
ing agent therapy in gliomas is still being evaluated and there is no consensus as to which
procedure is most suitable for routine clinical testing. While most protocols measure the lev‐
el of methylation accurately, presence of contaminating normal cells in every specimen
makes it difficult to set up a consistent cut off point between low positive and negative test
results. The extent of methylation required and the sets of CpGs that are crucial for complete
silencing are still under investigation. Given the complexity of the biological relationship be‐
tween promoter methylation and gene silencing and the difficulties to integrate these fea‐
tures into a test that is in addition complicated by presence of nontumoral tissue, there are
unavoidable drawbacks for any technology attempting to predict loss of MGMT expression
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for potential benefit from alkylating agent therapy. Key to introducing tests for diagnostics
is their careful prospective validation.
3.2. MGMT methylight assay validation - A one lab experience
Epigenetic silencing of the MGMT gene through promoter hypermethylation and resulting
transcriptional inactivation is now routinely used as a prognostic and possibly predictive bi‐
omarker in evaluating treatment choices in patients diagnosed with glioma. Patients enroll‐
ing in clinical trials are also evaluated for the MGMT promoter methylation status. For that
reason, a sensitive, clinically validated assay for detection of MGMT promoter methylation
can be of great help in patient management.We previously developed a simplified MGMT
MSP protocol [53] that utilized formalin fixed paraffin embedded specimens. This MSP pro‐
tocol proved reliable with majority of glioma patients, however, result interpretation was
sometimes challenging when evaluating specimens with few malignant cells and/or exten‐
sive necrosis, both of which gave faint bands on agarose gels.To further enhance our ability
to accurately assess methylation status of the MGMT promoter region in glioma specimens,
we investigated the use of real-time PCR technology as a way of enhancing assay sensitivity.
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tive real-time PCR methylation assays having acceptable precision for clinical work [54].
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MSP protocol, and appropriateness of the MethyLight protocol for use in MGMT promoter
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tumor samples, histology was reviewed to confirm diagnosis and select blocks with greatest
tumor involvement. Microdissection was performed on all samples showing an estimated
tumor cell content of less than 50% except in cases where infiltrative pattern of tumor
growth made this step unreliable.
3.3.2. DNA extraction and bisulfite treatment
Genomic DNA was isolated from 2 to 3 twenty micrometer thick paraffin sections after con‐
firmation of the histology. DNA from formalin fixed, paraffin embedded tissue was extract‐
ed using Puregene kit (Gentra Systems, Minneapolis, MN). MGMT promoter methylation
status was assessed using a two step approach. The first step involved bisulfite conversion
of isolated DNA (200-500 ng) which was done using EZ DNA Methylation Gold kit (Zymo
Research, Orange, CA). The second step involved detection of methylated and unmethylat‐
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ed DNA sequences, and was done using the following methods: 1) Methylation specific PCR
(MSP) and 2) Real-time PCR amplification (MethyLight).
3.3.3. Methylation-specific PCR
MGMT MSP amplification was performed as previously reported [53] with specific primers
designed to distinguish methylated from unmethylated DNA. Methylated and unmethylat‐
ed DNA sequences were detected on 2.5% agarose gels. Samples giving signals approxi‐
mately equivalent to the positive methylated control were designated as methylated.
Samples giving no signals with positive methylated control, but demonstrating presence of
unmethylated DNA, similar to the negative control, were designated as unmethylated.
3.3.4. Quantitative real-time PCR (MethyLight)
Real-time PCR assays were set-up in parallel to measure MGMT methylation. Two sets of
primers and probes designed specifically for bisulfite-converted DNAwere used [55]: a set
for MGMT gene and a set for collagen 2A1 (COL2A1) to normalize for the amount of input
DNA. The MGMT forward primer is 5’-GCG TTT CGA CGT TCG TAG GT-3’, the MGMT
reverse primer is 5’-CAC TCT TCC GAA AAC GAA ACG-3’, and the MGMT probe is
6FAM-5’-CGC AAA CGA TAC GCA CCG CGA-3’BHQ1. COL2A1 forward primer is 5’-TCT
AAC AAT TAT AAA CTC CAA CCA CCA A-3’, the COL2A1 reverse primer is 5’-GGG
AAG ATG GGA TAG AAG GGA ATA T-3’, and the COL2A1 probe is 6FAM-5’-CCT TCA
TTC TAA CCC AAT ACC TAT CCC ACC TCT AAA-3’BHQ1. We used Rotor Gene 3000 re‐
al-time PCR instrument (Qiagen, Germantown, MD, USA). The PCR conditions were as pre‐
viously described [56, 57]. Briefly, PCR amplification was performed in 0.2 ml PCR tubes
with a final reaction mixture of 25 µl consisting of 12.5 µl of TaqMan Universal Master mix
without uracil DNA glycosylase (Applied Biosystems, Foster City, CA), 3 µl of respective
forward and reverse primers (10 µM) for either MGMT or COL2A1, 1 µl of probe, 5 µl
(about 50 ng) of bisulfite-modified DNA, and water. PCR conditions were as follows: 95ºC
for 10 min, followed by 50 cycles at 95ºC for 15 s and 60ºC for 1 min.
3.3.5. Assay controls
For assay controls, methylated DNA and unmethylated DNA were purchased from Chemi‐
con International, Temecula, CA, and used as positive and negative controls for methylated
sequences. The control DNA was subjected to bisulfite treatment and PCR amplification in
parallel with patient samples for every run. Controls without DNA were also performed for
each set of reactions. Additionally, for the MethyLight protocol, collagen 2A1 (COL2A1)
gene was used as the internal reference to assess the quality and quantity of input DNA.
3.3.6. Results
To determine the limit of detection of the MehtyLight protocol, bisulfite treated methylated
control DNA was serially diluted into bisulfite treated unmethylated control DNA. DNA
mixing study with methylated and unmethylated DNA showed good linearity. The limit of
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detection of the MethyLight assay was determined to be 1% of methylated DNA in the back‐
ground of unmethylated DNA. The MSP protocol was shown to be slightly less sensitive,
with the limit of detection of 5% of methylated DNA in unmethylated background [53].
Tube No. % of Methylated DNA % of Unmethylated DNA
Cycle Threshold
(Ct)
1 100 0 28.80
2 50 50 29.77
3 20 80 30.77
4 10 90 31.83
5 5 95 32.74
6 1 99 35.22
7 0 100 0
8 0 0 0
Table 3. Cycle threshold values of serial dilution of methylated DNA into unmethylated control DNA
To evaluate run-to-run variations, we tested the reproducibility of the MethyLight assay by
performing eight independent runs of the serially diluted methylated control in the negative
control background. Acceptable reproducibility was demonstrated between runs.
Of the 30 tumor specimens in the study group, we were able to extract DNA of sufficient
quantity and quality to allow us to determine MGMT promoter methylation status for all
samples. There was a complete concordance in test results between the two methods for
25/30 cases (83%). Overall, methylation specific PCR (MSP) identified 16 (53%) specimens as
positive (methylated MGMT promoter was present) and 14 (47%) of tumors as negative
(having unmethylatedMGMT promoter). The MethyLight protocol identified 15 specimens
(50%) as positive for MGMT promoter methylation. Among the discordant cases, two sam‐
ples tested negative by MSP and were low positive by MethyLight; low DNA recovery was
observed for both of these samples, and the small amount of bisulfite treated DNA that was
available for analysis might have contributed to the discordance in results. The other three
discordant cases tested as weak positive with MSP and were negative by MethyLight; all
three of these cases had significant amount of necrotic tissue, which complicated interpreta‐
tion of the MSP results.
As regards assay controls, in the MSP protocol, MGMT promoter hypermethylation was al‐
ways accompanied by amplification in the unmethylated reaction as well. This is to be ex‐
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con International, Temecula, CA, and used as positive and negative controls for methylated
sequences. The control DNA was subjected to bisulfite treatment and PCR amplification in
parallel with patient samples for every run. Controls without DNA were also performed for
each set of reactions. Additionally, for the MethyLight protocol, collagen 2A1 (COL2A1)
gene was used as the internal reference to assess the quality and quantity of input DNA.
3.3.6. Results
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detection of the MethyLight assay was determined to be 1% of methylated DNA in the back‐
ground of unmethylated DNA. The MSP protocol was shown to be slightly less sensitive,
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Table 3. Cycle threshold values of serial dilution of methylated DNA into unmethylated control DNA
To evaluate run-to-run variations, we tested the reproducibility of the MethyLight assay by
performing eight independent runs of the serially diluted methylated control in the negative
control background. Acceptable reproducibility was demonstrated between runs.
Of the 30 tumor specimens in the study group, we were able to extract DNA of sufficient
quantity and quality to allow us to determine MGMT promoter methylation status for all
samples. There was a complete concordance in test results between the two methods for
25/30 cases (83%). Overall, methylation specific PCR (MSP) identified 16 (53%) specimens as
positive (methylated MGMT promoter was present) and 14 (47%) of tumors as negative
(having unmethylatedMGMT promoter). The MethyLight protocol identified 15 specimens
(50%) as positive for MGMT promoter methylation. Among the discordant cases, two sam‐
ples tested negative by MSP and were low positive by MethyLight; low DNA recovery was
observed for both of these samples, and the small amount of bisulfite treated DNA that was
available for analysis might have contributed to the discordance in results. The other three
discordant cases tested as weak positive with MSP and were negative by MethyLight; all
three of these cases had significant amount of necrotic tissue, which complicated interpreta‐
tion of the MSP results.
As regards assay controls, in the MSP protocol, MGMT promoter hypermethylation was al‐
ways accompanied by amplification in the unmethylated reaction as well. This is to be ex‐
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pected since the original tissue sections contained a mixture of tumor and non-malignant
tissue. The presence of unmethylated promoter served as an internal amplification control
that confirmed that the quality and quantity of bisulfite treated DNA was acceptable for
clinical testing. Only tumor samples that contained a clearly visible methylated signal, with
or without an additional unmethylated signal, were interpreted as positive for the MGMT
promoter methylation. All the samples that only amplified with unmethylated primers were
interpreted as negative. COL2A1 internal control was used with the MethyLight protocol to
assess the quality and quantity of DNA. All samples demonstrated positive signals with the
COL2A1 PCR amplification.
In comparing the two quality control methods, we observed 100% concordance between the
two systems, with both methods indicating that all samples in the study group contained
sufficient amount of bisulfite converted DNA for clinical testing. The gel signals observed
with unmethylated DNA as an indicator of DNA quantity with the MSP protocol, and the
expression of COL2A1 as an internal control standard in the MethyLight protocol proved to
be equivalent and reliable indicators of quality of input DNA.
This study reports an improvement on our previously published MSP protocol for the detec‐
tion of MGMT promoter methylation in glioma specimens. MethyLight protocol, a real-time
PCR based approach, was used in a number of application [54, 55-57]. In our laboratory, the
MethyLight assay proved to be easy to perform, reproducible, and sensitive in detecting the
amount of methylated DNA sequences in formalin fixed, paraffin embedded brain tumor
specimens. Furthermore, with the use of the real-time PCR approach, we were able to elimi‐
nate post PCR processing that is integral to the MSP protocol.
Recently Ogino and colleagues [54] performed an in-depth investigation of critical parame‐
ters that influence the success of quantitative DNA methylation analysis after sodium bisul‐
fite conversion of DNA samples from archived formalin-fixed paraffin-embedded tumor
specimens, demonstrating the value of percentage of methylated reference (PMR) estima‐
tion. Our system, however, proved impractical for measurement of PMR.To obtain PMR
measurement in their study, the investigators microdissected tumor tissue to obtain pure
populations of tumor cells. Exclusion of normal tissue allowed for precise calculation of
PMR values, and consequently quantitation of the amount of methylation in each tumor
sample. This approach proved to be impractical for some of the samples in our study due to
the pattern of growth of gliomas, particularly GBM tumors, which grow in an infiltrating
pattern, with many benign cells surrounding a few infiltrating tumor cells. Consequently,
sections of these tumors contain both malignant and normal cells, with no easy way of dis‐
secting out a pure tumor population, unless one performs laser capture microdissection.
Since our aim was to optimize a simple MGMT promoter methylation detection assay for
routine clinical use, we continued our practice of histology review and preselecting tissue
blocks with greatest amount of tumor involvement and smallest amount of necrosis prior to
analysis. Using the entire tissue block section proved to be a practical approach for routine
testing in our laboratory, even when microdissection was not possible. At 1% sensitivity, we
were able to detect MGMT promoter methylation even when tumor cells were in minority,
as assessed by review of histology.
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While this study group consisted of a relatively small number of samples, we were able to
develop a testing protocol using MethyLighttechnique, that proved to be reliable and repro‐
ducible in a clinical setting. When applying this method to clinical use, it is important that
proper controls be included with every assay run.After bisulfite treatment of isolated DNA,
patient samples are tested in duplicates for the evidence of MGMT promoter, and for the ex‐
pression of COL2A1 internal control sequences to normalize for input DNA. Additionally,
three different concentrations (100%, 10% and 1%) of methylated DNA in unmethylated
background are run as reference standards. This approach allows clear distinction between
positive and negative signals. The assay results are interpreted as positive or negative for
MGMT promoter methylation. In terms of patient management, temozolomide is give to all
patients, regardless of MGMT promoter methylation status. It has been established that
strongly positive patients will respond to temozolomide, however it is less clear how low
positive patients will respond. When very low positive results are reported for a glioma
specimen, the amount of tumor involvement in that particular sample, as assessed by re‐
view of histology, can serve as an additional guide for the clinical care provider.
In summary, while both MSP and MethyLight detection methods proved acceptable for clin‐
ical testing, with 83% concordance between the two methods, the MethyLight method
proved superior in several different areas. It allowed easier interpretation of low positive re‐
sults, because there was a clear distinction between positive and negative signals. This real-
time, quantitative approach also allowed for reduced turn around time and high throughput
specimen processing, because post PCR gel analysis steps were eliminated. Finally, the
MethyLight method appeared to be more sensitive, even though the significance of very low
positive results is unknown. The limit of detection of the MethyLight assay was determined
to be 1% of methylated DNA in the background of unmethylated DNA, compared to 5%
with the MSP assay.
3.4. Regulation of molecular genomic testing
Molecular testing falls under high complexity testing and is highly regulated. In the United
States two federal agencies, the Food and Drug Administration (FDA) and the Centers for
Medicare and Medicaid Services (CMS) have jurisdiction over this type of testing. The laws
and policies concerning the development and implementation of molecular tests continue to
evolve. Medical tests are regulated by the Center for devices and Radiologic Health, a
branch of FDA. Devices are divided into 3 classes based primarily on the risks associated
with their intended use. Class I tests are low risk, usually of a simple design. Class II tests
pose moderate risks, are evaluated by the FDA through review of a 510(k) premarket notifi‐
cation, and are cleared for marketing once they are found to be substantially equivalent to a
legally marketed device that was previously cleared by the FDA. Class III tests are those as‐
sociated with the highest clinical risk. Each Class III test is reviewed through application for
premarket approval (PMA). A demonstration of safety and effectiveness is needed to gain
FDA approval. The FDA approval/clearance process provides reasonable assurance of safety
and effectiveness, and that the test will provide clinically significant results.
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Figure 6. Oligodendroglioma, WHO grade II. (A) Sections show moderately cellular glial neoplastic proliferation. Tu‐
mor tissue tested positive for MGMT promoter methylation and 1p19q codeletion. (B) The IDH1 R132H is positive.
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The rapid transition of new scientific knowledge to medical practice has led to development
and use of diagnostic tests that are often called laboratory developed tests (LTDs). The FDA
retains jurisdiction over this category of tests and until recently the oversight was basically
directed towards critical reagents used to build these tests. With LTDs being used more
widely in clinical decision making it is likely the FDA will develop clinical guidelines on
Companion Diagnostics or molecular tests which directly impact the use of a pharmaceuti‐
cal or biologic drug.
Clinical laboratories are governed through the Clinical Laboratory Improvement Amendment
(CLIA) of 1988 administered by CMS. CLIA certification is a descriptor which is frequently as‐
sociated with analytically valid assays performed in a clinical laboratory or a laboratory that
has received a CLIA certification. CLIA certification requires that a laboratory adopt specific
practices and perform prescribed measures of analytic validation while performing specific as‐
says. Assays must be performed in CLIA certified laboratories if the results of the assays are
going to be used to guide patient management. Key components of the regulation and over‐
sight of CLIA accredited laboratories are inspections and proficiency tests. In most hospitals
these are provided by the College of American Pathologists (CAP). CAP inspection guidelines
essentially set the standards for overall biomarker laboratory operation, including assay vali‐
dation, quality control, and quality assurance activities. The guidelines mandate regular profi‐
ciency  testing  for  every  clinical  assay,  and  CAP  runs  an  extensive  program  providing
proficiency testing samples for all commonly used clinical assays.
4. Prognostic and predictive relevance of glioma biomarkers
Cancer-specific DNA methylation changes are hallmarks of human cancers, in which global
hypomethylation is often seen concomitantly with hypermethylation of CpG islands. Pro‐
moter CpG island hypermethylation generally results in transcriptional silencing of the as‐
sociated gene [58]. There have been several reports of promoter-associated CpG island
hypermethylator phenotype in human GBM and other glioma subtypes [59-61]. Several
studies have reported differences between primary and secondary GBMs with respect to ep‐
igenetic changes. Overall, secondary GBMs have a higher frequency of promoter methyla‐
tion than primary GBMs [62]. Analysis of epigenetic changes from The Cancer Genome
Atlas study [63] identified the existence of a proportion of GBM tumors with highly con‐
cordant DNA methylation of a subset of loci, indicative of a CpG island methylator pheno‐
type (G-CIMP). G-CIMP positive samples were associated with secondary or recurrent
(treated) tumors and tightly associated with IDH1 mutation. G-CIPM tumors also showed a
relative lack of copy number variation commonly observed in GBM. Integration of the DNA
methylation data with gene expression data showed that G-CIMP tumors represent a subset
of proneural tumors. G-CIMP -positive tumors showed a favorable prognosis with GBMs as
a whole and also with the proneural subset. These data suggest that G-CIMP-positive status
may confer favorable outcome. When lower grade tumors were examined, nearly 10-fold
more G-CIMP-positive gliomas were detected among grade II tumors as compared to grade
IV GBMs. The study suggests that the improved survival of G-CIMP gliomas at all tumor
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Figure 6. Oligodendroglioma, WHO grade II. (A) Sections show moderately cellular glial neoplastic proliferation. Tu‐
mor tissue tested positive for MGMT promoter methylation and 1p19q codeletion. (B) The IDH1 R132H is positive.
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The rapid transition of new scientific knowledge to medical practice has led to development
and use of diagnostic tests that are often called laboratory developed tests (LTDs). The FDA
retains jurisdiction over this category of tests and until recently the oversight was basically
directed towards critical reagents used to build these tests. With LTDs being used more
widely in clinical decision making it is likely the FDA will develop clinical guidelines on
Companion Diagnostics or molecular tests which directly impact the use of a pharmaceuti‐
cal or biologic drug.
Clinical laboratories are governed through the Clinical Laboratory Improvement Amendment
(CLIA) of 1988 administered by CMS. CLIA certification is a descriptor which is frequently as‐
sociated with analytically valid assays performed in a clinical laboratory or a laboratory that
has received a CLIA certification. CLIA certification requires that a laboratory adopt specific
practices and perform prescribed measures of analytic validation while performing specific as‐
says. Assays must be performed in CLIA certified laboratories if the results of the assays are
going to be used to guide patient management. Key components of the regulation and over‐
sight of CLIA accredited laboratories are inspections and proficiency tests. In most hospitals
these are provided by the College of American Pathologists (CAP). CAP inspection guidelines
essentially set the standards for overall biomarker laboratory operation, including assay vali‐
dation, quality control, and quality assurance activities. The guidelines mandate regular profi‐
ciency  testing  for  every  clinical  assay,  and  CAP  runs  an  extensive  program  providing
proficiency testing samples for all commonly used clinical assays.
4. Prognostic and predictive relevance of glioma biomarkers
Cancer-specific DNA methylation changes are hallmarks of human cancers, in which global
hypomethylation is often seen concomitantly with hypermethylation of CpG islands. Pro‐
moter CpG island hypermethylation generally results in transcriptional silencing of the as‐
sociated gene [58]. There have been several reports of promoter-associated CpG island
hypermethylator phenotype in human GBM and other glioma subtypes [59-61]. Several
studies have reported differences between primary and secondary GBMs with respect to ep‐
igenetic changes. Overall, secondary GBMs have a higher frequency of promoter methyla‐
tion than primary GBMs [62]. Analysis of epigenetic changes from The Cancer Genome
Atlas study [63] identified the existence of a proportion of GBM tumors with highly con‐
cordant DNA methylation of a subset of loci, indicative of a CpG island methylator pheno‐
type (G-CIMP). G-CIMP positive samples were associated with secondary or recurrent
(treated) tumors and tightly associated with IDH1 mutation. G-CIPM tumors also showed a
relative lack of copy number variation commonly observed in GBM. Integration of the DNA
methylation data with gene expression data showed that G-CIMP tumors represent a subset
of proneural tumors. G-CIMP -positive tumors showed a favorable prognosis with GBMs as
a whole and also with the proneural subset. These data suggest that G-CIMP-positive status
may confer favorable outcome. When lower grade tumors were examined, nearly 10-fold
more G-CIMP-positive gliomas were detected among grade II tumors as compared to grade
IV GBMs. The study suggests that the improved survival of G-CIMP gliomas at all tumor
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grades might be due to certain molecular features within the G-CIMP gliomas that encour‐
age a less aggressive tumor phenotype.
Low grade diffuse gliomas WHO grade II (diffuse astrocytoma, oligoastrocytoma, oligoden‐
droglioma) are characterized by frequent IDH1/2 mutations (>80%) that occur at a very early
stage. In addition, the majority of diffuse astrocytomas (about 60%) carry TP53 mutations,
which constitute a prognostic marker for shorter survival. Limited data exists correlating
IDH1/2 mutations with loss of heterozygosity (LOH) on chromosome arms 1p and 19q,
methylation of the promoter region of DNA repair enzyme O-6-Methylguanine DNA meth‐
yl transferase (M-MGMT) rendering sensitivity to DNA alkylating agents, and epidermal
growth factor receptor variant III (EGFRvIII), a constitutively active mutant form of EGFR













GBM IV 5/20 0/20 0/20 10/20 3/20 nd
0 II 5/14 12/14 1/14 10/13 0/3 10/13
AO III 0/2 2/2 0/2 1/2 0/1 1/1
A II 2/6 2/6 0/6 3/6 0/4 0/2
AA III 0/6 0/6 0/6 3/6 0/4 0/2
OA II/III 3/8 8/8 0/8 6/7 0/4 2/8
AOA III 1/6 1/6 0/6 3/5 0/3 3/3
Table 4. Biomarker distribution among different glioma types
High throughput profiling techniques in conjunction with sophisticated bioinformatics inte‐
grative tools are emerging to revolutionize our knowledge about the complexity of the dis‐
ease. Development of novel array-based profiling techniques and next generation
sequencing techniques has facilitated development of sophisticated tumor-specific genomic
and transcriptional signatures. Integrative analysis of DNA copy number, gene expression
and DNA methylation profiling indicate that molecular alterations may impact future treat‐
ment strategies. For example, as PIK3R1 encodes the regulatory protein p85a subunit, re‐
sponse to PI3K inhibitors may depend on whether the tumors bear mutations in this specific
gene or not. Also, in predicting sensitivity and the development of resistance to temozolo‐
mide the Cancer Genome Atlas network added further support for a role of the DNA mis‐
match repair system. MGMT methylation in conjunction with temozolomide treatment may
lead to a loss of mismatch repair function by introduction of mutations in mismatch repair
genes [64, 65]. Thus patients who initially respond to front line therapy may evolve treat‐
ment resistance by developing a hypermutator phenotype. As a consequence, selective strat‐
egies targeting mismatch repair deficient cells might have to be used in combination with
alkylating agent therapy to prevent or minimize resistance to temozolomide.
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5. Conclusion
The list of clinically useful biomarkers in gliomas is expected to expand as novel markers are
validated in large scale clinical trials [52]. MGMT promoter methylation is now routinely
performed in many institutions. Alkylating agents cause cell death by forming cross-links
between adjacent strands of DNA due to alkylation of the O6 position of guanine. The cellu‐
lar DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) functions as a
DNA repair enzyme that removes the mutagenic alkyl-adducts from the O6-poasition of
guanine and thereby causes resistance to alkylating drugs [66-68]. 1p/19q LOH has shown
clinical utility, and is a part of guidelines for all oligodendroglioma and mixed tumor man‐
agement. Some of the newer markers, such as IDH1/2 mutations and EGFRvIII mutations
still need further evaluation, and are being used with increasing frequency to provide fur‐
ther definition of tumor stage and possibly subsequent behavior. Molecular laboratories are
likely to evolve also, as clinical care providers continue to rely on genomic-type assays for
guiding patient treatment.
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1. Introduction
Brain tumors are a large and heterogeneous group of neoplasms affecting the central nervous
system that, despite the progress of the modern medicine, still represent a great challenge for
physicians all over the world. The annual global age-standardized incidence of primary
malignant brain tumors is ~3.7 per 100,000 for males and 2.6 per 100,000 for females. Rates
appear to be higher in more developed countries (males 5.8, and females 4.1 per 100,000) than
in less developed countries (males 3.0 and females 2.1 per 100,000). Conversely, the incidence
of both primary malignant and non-malignant brain tumors is about 10 - 14 cases per 100,000/
year all over the world, with white males having the highest rate. Males also generally have
higher rates of primary malignant brain tumors while females have higher rates of non-
malignant tumors, primarily meningiomas. Worldwide age-standardized mortality for
primary malignant brain tumors is ~2.8 for male and 2.0 for females per 100,000. Mortality
rates differ significantly by histology and age. For example, glioblastoma multiforme (GBM)
has a 5-year survival rate of 3.3%, low grade gliomas, such as pilocytic astrocytomas, oligo‐
dendrogliomas, and ependymomas have 5-year survival rates of over 70%, while anaplastic
astrocytoma, malignant gliomas and lymphomas have 5-year survival rates less than 40% [1].
Due to these dramatic epidemiological data, in the past decades we assisted to the birth of an in‐
tensifying interest in understanding the causes of brain tumors among the scientific communi‐
ty.  Despite  notable  advances  achieved during recent  years  in  both surgical  and chemo/
radiotherapeutic approaches, an improved survival has not been clearly documented, especial‐
ly for primary malignant brain tumors. This is partially due to the tumors’ intrinsic clinical and
molecular heterogeneity. As a matter of fact, choice of initial treatment, prediction of survival,
stratification of patients, prediction and monitoring of response to therapy, still represent some
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of the greatest challenges in the management of patients affected by brain tumors. In these set‐
tings, different studies have been performed to better understand the pathophysiology of cere‐
bral neoplasms, with the aim to identify new molecular prognostic markers and therapeutic
targets. However, until now, molecular biomarkers that effectively predict response to therapy
and/or survival outcomes in brain tumors are limited. Consequently, there is a strong need to
develop novel and independent markers of prognosis for these neoplasms. One of the cellular
structure candidate to accomplish this role is represented by telomeres.
Telomeres consist of long tandem arrays of TTAGGG repeats, bound by proteins, placed at
the end of linear chromosomes, which are involved in several essential biological functions [2,
3]. These non-coding telomeric repeats represent a buffer zone preventing the adjacent coding
region of the genome from erosion. In normal human cells, the telomeres decreases by some
5-20 repeats with every cell division [4]. Therefore telomere shortening limits the number of
times a cell can divide.[5] Hence, they can be considered the mitotic clock by which cells count
their divisions and regulate the onset of replicative senescence in somatic cells [6-8]. The
alteration of telomere length homeostasis affects telomere structure and leads to genomic
instability by generating chromosome end-to end fusion and chromosomal abnormalities [9].
It has been demonstrated that telomeres shortening could initiate successive events, such as
aberrant fusions or recombination of the end of chromosomes, genomic instability, loss of cell
growth control, and finally cancer development [10, 11]. Hence, cells exhibiting critical
telomeres shortening and genomic instability present an increased capacity of dicentric
chromosomes formation and susceptibility to oncogenic transformation [5, 12, 13]. Several
studies showed the presence of an hypervariability of telomere length in different human solid
tumors, including brain tumors, suggesting for telomeres and proteins involved in the
modulation of their length a possible clinical role as diagnostic/prognostic marker or thera‐
peutic target for cancer treatment.
2. Telomeres
Human telomeres are regions of 4-15 kilobases of repetitive hexameric (TTAGGG)n guanine-
rich DNA sequences at the ends of each chromosome [14]. They end with a single-stranded 3'-
overhang that folds back and invades its complementary strand to form a T-loop [15].
Formation of this structure is presumed to involve the insertion of the 3’-telomeric overhang
into duplex telomeric DNA, its hybridization with the cytosine-rich strand, and dislodgment
of the guanine-rich strand into a displacement loop (D-loop) [16]. It has been demonstrated
that T-loops are especially well-adapted to shield the ends of chromosomes from DNA repair
and DNA damage-sensing mechanisms [15, 17]. Moreover, a complex of telomere-specific
proteins, named shelterin complex, binds and caps telomeres, further preventing chromoso‐
mal ends from being recognized as DNA double strand breaks (DSB) by the DNA damage
response (DDR) machinery [18, 19]. As the lagging strands of telomeres are incapable of being
fully replicated during each round of cell division, telomeres undergo progressive shortening
during normal cellular proliferation. Eventually, they become so short that they trigger the
DDR, causing cell crisis [4, 18, 20]. This normally results in replicative senescence and even‐
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tually checkpoint-driven cell death and apoptosis, defining cellular lifespan and safeguarding
an organism against unlimited cellular proliferation and cancer [19, 21, 22].
Shelterin complex proteins interact selectively with telomeric DNA and localize to telomeres.
In its most abundant form, the complex is composed of six core components: TRF1, TRF2,
POT1, TIN2, TPP1 and RAP1[16]. TRF1 and TRF2 (Telomeric Repeat Factors 1 and 2) recognize
duplex telomeric DNA whereas POT1 (Protection of Telomere 1) associates with the single-
strand telomeric DNA present at the 3′-overhang [23, 24]. The scaffolding subunit TIN2 (TRF1-
interacting nuclear protein 2) binds simultaneously to TRF1, TRF2 and TPP1, whereas TPP1
(previously known as TINT 1 [25] ) connects POT1 with TIN2 [25-31]. A sixth component,
RAP1 (Repressor Activator Protein 1), is a TRF2-associated factor [32]. Via protein–protein
interactions, these DNA binding factors bring a number of other proteins to telomeres, where
they localize to form a variety of complexes [33, 34], playing a key role in telomere capping
and length regulation (see Figure 1).
Figure 1. Schematic representation of the six subunits of the Shelterin complex on the telomeric DNA and of their
molecular structure, including domains, protein interactions and DNA binding sites.
In addition to this 6-member complex, Shelterin may also be present in the form of sub-
complexes that lack either TRF1 or TRF2/RAP1[30, 34-41]. While the importance of these
different sub-complexes remains unclear, the particular function of each of the three DNA
binding subunits (TRF1, TRF2 and POT1) is well-understood.
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TRF1 has a key role in the modulation of telomere length. Its ADP-ribosylation, allow telo‐
merase to bind telomeres and start their elongation.
TRF2 serves to block recognition of telomeres as double-strand DNA breaks. Loss of TRF2
function leads to the activation of the ATM kinase (Ataxia telangiectasia mutated kinase),
formation of telomere dysfunction-induced foci (TIFs), and induction of either senescence or
apoptosis [21, 36, 42-45]. Moreover, in cells lacking functional checkpoints, telomeres devoid
of TRF2 serve as substrates for the NHEJ (non-homologous end-joining) repair mechanism
and give rise to interchromosomal fusions [41, 46]. TRF2 also appears to protect telomeres, at
least in part, through its ability to promote T-loop formation and maintenance [15, 17].
POT1 serves to hide the 3′-telomeric overhang from telomerase and from DNA damage
sensing mechanisms. Hence, the loss of POT1 leads to the activation of the ATR kinase (ATM
and Rad3-related kinase), formation of TIFs, and induction of either apoptosis or cell cycle
arrest [38, 42, 47, 48]. In cells that lack functional checkpoints, POT1 dysfunction leads to a loss
of telomerase regulation that results in longer telomeres [31, 39].
Therefore, through the interaction with the shelterin complex proteins, telomeres protect
chromosomes from recombination, end-to-end fusion, and recognition as damaged DNA,
providing a means for complete replication of chromosomes.
In summary, telomeres serve as a molecular clock that controls the replicative capacity of hu‐
man cells and their entry into senescence, but they also contribute to the functional organization
of chromosomes within the nucleus and participate in the regulation of gene expression [49, 50].
2.1. Telomere length modulation
During a process of DNA synthesis and cell division, telomeres shorten as a result of the
incomplete replication of linear chromosomes. This progressive shortening represent the so-
called ‘end-replication problem’.
As previously described, in order to prevent degradation by exonucleases or processing as
damaged DNA, the telomere 3’ single-strand overhang folds back into the D-loop of duplex
telomeric DNA to form a protective ‘T-loop’, which is reinforced with TRF2 and other telomeric
DNA-binding proteins that constitute the shelterin complex [51]. These proteins have a
fundamental role in the modulation of telomere length, allowing telomeres elongation or
conversely promoting their attrition.
In human cells, several pathways regulating telomeres length have been identified.
The most important mechanism is represented by telomerase, a highly specialized ribonuclear
reverse transcriptase enzyme that catalyzes extension of 5’-ends of the lagging DNA strand
by adding TTAGGG repeats onto the telomeres using its intrinsic RNA as a template for reverse
transcription [52]. Two major subunits of the human telomerase core complex have been
identified, named h-TERC and h-TERT. The former serves as a template for telomeres
elongation; instead, the latter subunit (h-TERT) contains a reverse transcriptase domain that
catalyzes this reaction [53] (see Figure 2).
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Figure 2. Schematic representation of telomere elongation by telomerase
However, the length and structure of telomeres are also controlled by a variety of proteins,
working exclusively at the telomere or contemporarily participating in DNA repair process.
Collectively, these telomeric proteins may function to protect telomere integrity and function,
to connect the DNA damage/repair network with the controls of cellular senescence, to monitor
telomere homeostasis and modify the access of telomerase to telomeres. Two major proteins
are the TRF1 and TRF 2 that are localized at telomeres [54]. These proteins play key roles in
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transcription [52]. Two major subunits of the human telomerase core complex have been
identified, named h-TERC and h-TERT. The former serves as a template for telomeres
elongation; instead, the latter subunit (h-TERT) contains a reverse transcriptase domain that
catalyzes this reaction [53] (see Figure 2).
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Figure 2. Schematic representation of telomere elongation by telomerase
However, the length and structure of telomeres are also controlled by a variety of proteins,
working exclusively at the telomere or contemporarily participating in DNA repair process.
Collectively, these telomeric proteins may function to protect telomere integrity and function,
to connect the DNA damage/repair network with the controls of cellular senescence, to monitor
telomere homeostasis and modify the access of telomerase to telomeres. Two major proteins
are the TRF1 and TRF 2 that are localized at telomeres [54]. These proteins play key roles in
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the maintenance of telomere function and structure modifying telomerase activity [41, 55, 56].
Moreover, a recent evidence shows that TRF1 interacts with other telomere-binding molecules
and is integrated into the functional telomere structure [57]. TRF1 accepts adenosine diphos‐
phate (ADP)-ribosylation catalyzed by the tankyrase-poli-ADP-ribose polymerase (TANKs-
PARP) complex. The ADP-ribosylation of TRF1 reduces its ability to bind telomeric DNA,
allowing telomerase to elongate telomeres and extending the cellular life span [58-60].
In most somatic cells telomerase is produced at very low levels. In contrast, many malignant
cells are able to upregulate this enzyme and extend their survival through continuous
telomeric elongation [61].
The vast majority of tumor cells use telomerase as preferred mechanism for telomere mainte‐
nance, whereas only 10-15% of all cancer lose the functional activity of telomerase and use the
telomerase-independent Alternative Lengthening of Telomeres pathway (ALT) that operates
via DNA repair and recombination processes [22].
ALT was first deduced in human cell lines from the fact that some telomerase-deficient lines
were able to be maintained in culture for many hundreds of population doubling times [62].
Later phenotypic studies revealed that, unlike telomerase-positive cells, ALT-dependent cells
almost always contain heterogeneous telomere length distribution and form ALT-associated
promyelocytic leukemia (PML) bodies or APBs. [63, 64] These phenotypes are either unde‐
tectable or have very low levels of activity in normal somatic cells. [22]
Several characteristic features are associated with ALT activity [65]. First, telomere length
distribution is highly heterogeneous and ranges from less than 3 kb to more than 50 kb [66].
In contrast, in human telomerase-positive cells all telomeres typically have a similar length of
around 10 kb. Second, ALT-positive cells have been described to contain several classes of
extrachromosomal telomeric repeats (ECTRs) in the nucleus. ECTRs comprise double- and
single-stranded circular molecules, linear telomeric DNA, and t-complex molecules that
consist of high molecular weight DNA with highly branched structures [67-70]. These DNA
fragments might be products of t-loop resolution by recombination enzymes. The function of
ECTRs in the telomere lengthening process is unknown but the amount of partially single-
stranded telomeric (CCCTAA)n DNA circles (C-circles) appears to correlate with ALT activity
[71]. Third, the occurrence of telomere sister chromatid exchanges (T-SCE) is generally
increased in ALT cells [72, 73]. Fourth, in ALT cells promyelocytic leukemia nuclear bodies
(PML-NBs) associate with some telomeres [64, 74]. These complexes are called ALT-associated
PML-NBs (APBs) [64, 65].
Which type of telomere maintenance mechanism is active seems to depend on the origin of
the tumor. ALT is rarely found in carcinomas but frequently activated in tumors of mesen‐
chymal and neuroepithelial origin like osteosarcomas, liposarcomas or astrocytomas [75, 76].
Therefore, at least two mechanisms of telomere maintenance, telomerase activity and the
recombination-based ALT, may be more or less prevalent in different tissues undergoing
tumour formation, leading to the aforementioned features [77, 78]. The activation of such a
mechanisms causes the alteration of telomere length that is reflected by a hypervariability of
telomere length already observed in different human solid tumors [79-81], and also in brain
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tumors [82-87]. Hence, analysis of telomere length variations and of length modulation
mechanisms may provide promising information for their potential role as prognostic marker
or therapeutic target in cancer.
3. Telomere in aging and disease
Aging can be defined as the progressive decline of tissue function that eventually results in
mortality [88]. Aging is a natural occurring process and not a disease state. While aging is
inevitable for all humans, the speed of age-related functional deterioration varies considerably
amongst individuals. Why some individuals reach frailty earlier than others is not understood
and genetic factors as well as environmental exposures are believed to modulate the senescence
process. Currently, aging is viewed as a generalized process occurring in all organ systems in
a parallel fashion [88]. However, recent studies point towards a much higher degree of
complexity in the aging process and accumulating data support the notion that diseases
incurred during life may accelerate the aging of certain organ systems [89].
Telomeres shorten as we age. Consequently, telomere length has been postulated as a marker
of “genetic age” (mitotic clock), as a fundamental explanation for the aging process, and has
been marketed as a simple predictor of longevity. Telomere length indeed reflects the cell’s
past proliferative history and future propensity to apoptosis, senescence, and transformation.
However, cellular aging is not equivalent to organ or organismal aging. Studies in humans
have attempted to relate short telomeres to longevity. In a provocative initial publication from
the University of Utah, individuals around 60 years of age who had the longest telomeres lived
longer than did subjects with the shortest telomeres, but the most associated cause of death in
the latter group was, inexplicably, infection, and those with shorter telomeres did not have a
higher rate of cancer deaths [90]. Heart disease as the cause of death was also more common
in subjects with the shortest telomeres. Subsequent studies have produced conflicting findings.
The Cardiovascular Health Study of subjects over 65 years of age found that individuals in the
shortest quartile for telomere length were 60% more likely to die than those in the longest
quartile [91]. Causes of death related to short telomeres were infectious. Two twin studies at
older age also correlated shorter telomeres with poorer survival [92, 93]. Finally, a cohort study
that looked at participants at time zero and after 10 years found that death within 10 years was
significantly more common in those with shorter telomeres [94]. In contrast, these associations
have not been confirmed in other studies of older subjects. Njajou and collegues reported that
telomere length failed to predict survival, but correlated with years of healthy life [95]. In a
Danish study of people aged 73 to 101 years, telomeres correlated with life expectancy in simple
univariate analysis but, when corrected for age, did not predict longevity [96]. In Dutch men
with a mean age of 78 years, telomere length eroded with aging but failed to correlate with
mortality [97]. In a Finnish investigation, telomere length did not predict overall mortality [98].
Finally, in an analysis from California, short telomere length predicted death from cardiovas‐
cular disease in women but not in men, where the rate of shortening predicted mortality rather
than length itself [99]. Collectively, data on association between telomere length and aging are
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the maintenance of telomere function and structure modifying telomerase activity [41, 55, 56].
Moreover, a recent evidence shows that TRF1 interacts with other telomere-binding molecules
and is integrated into the functional telomere structure [57]. TRF1 accepts adenosine diphos‐
phate (ADP)-ribosylation catalyzed by the tankyrase-poli-ADP-ribose polymerase (TANKs-
PARP) complex. The ADP-ribosylation of TRF1 reduces its ability to bind telomeric DNA,
allowing telomerase to elongate telomeres and extending the cellular life span [58-60].
In most somatic cells telomerase is produced at very low levels. In contrast, many malignant
cells are able to upregulate this enzyme and extend their survival through continuous
telomeric elongation [61].
The vast majority of tumor cells use telomerase as preferred mechanism for telomere mainte‐
nance, whereas only 10-15% of all cancer lose the functional activity of telomerase and use the
telomerase-independent Alternative Lengthening of Telomeres pathway (ALT) that operates
via DNA repair and recombination processes [22].
ALT was first deduced in human cell lines from the fact that some telomerase-deficient lines
were able to be maintained in culture for many hundreds of population doubling times [62].
Later phenotypic studies revealed that, unlike telomerase-positive cells, ALT-dependent cells
almost always contain heterogeneous telomere length distribution and form ALT-associated
promyelocytic leukemia (PML) bodies or APBs. [63, 64] These phenotypes are either unde‐
tectable or have very low levels of activity in normal somatic cells. [22]
Several characteristic features are associated with ALT activity [65]. First, telomere length
distribution is highly heterogeneous and ranges from less than 3 kb to more than 50 kb [66].
In contrast, in human telomerase-positive cells all telomeres typically have a similar length of
around 10 kb. Second, ALT-positive cells have been described to contain several classes of
extrachromosomal telomeric repeats (ECTRs) in the nucleus. ECTRs comprise double- and
single-stranded circular molecules, linear telomeric DNA, and t-complex molecules that
consist of high molecular weight DNA with highly branched structures [67-70]. These DNA
fragments might be products of t-loop resolution by recombination enzymes. The function of
ECTRs in the telomere lengthening process is unknown but the amount of partially single-
stranded telomeric (CCCTAA)n DNA circles (C-circles) appears to correlate with ALT activity
[71]. Third, the occurrence of telomere sister chromatid exchanges (T-SCE) is generally
increased in ALT cells [72, 73]. Fourth, in ALT cells promyelocytic leukemia nuclear bodies
(PML-NBs) associate with some telomeres [64, 74]. These complexes are called ALT-associated
PML-NBs (APBs) [64, 65].
Which type of telomere maintenance mechanism is active seems to depend on the origin of
the tumor. ALT is rarely found in carcinomas but frequently activated in tumors of mesen‐
chymal and neuroepithelial origin like osteosarcomas, liposarcomas or astrocytomas [75, 76].
Therefore, at least two mechanisms of telomere maintenance, telomerase activity and the
recombination-based ALT, may be more or less prevalent in different tissues undergoing
tumour formation, leading to the aforementioned features [77, 78]. The activation of such a
mechanisms causes the alteration of telomere length that is reflected by a hypervariability of
telomere length already observed in different human solid tumors [79-81], and also in brain
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tumors [82-87]. Hence, analysis of telomere length variations and of length modulation
mechanisms may provide promising information for their potential role as prognostic marker
or therapeutic target in cancer.
3. Telomere in aging and disease
Aging can be defined as the progressive decline of tissue function that eventually results in
mortality [88]. Aging is a natural occurring process and not a disease state. While aging is
inevitable for all humans, the speed of age-related functional deterioration varies considerably
amongst individuals. Why some individuals reach frailty earlier than others is not understood
and genetic factors as well as environmental exposures are believed to modulate the senescence
process. Currently, aging is viewed as a generalized process occurring in all organ systems in
a parallel fashion [88]. However, recent studies point towards a much higher degree of
complexity in the aging process and accumulating data support the notion that diseases
incurred during life may accelerate the aging of certain organ systems [89].
Telomeres shorten as we age. Consequently, telomere length has been postulated as a marker
of “genetic age” (mitotic clock), as a fundamental explanation for the aging process, and has
been marketed as a simple predictor of longevity. Telomere length indeed reflects the cell’s
past proliferative history and future propensity to apoptosis, senescence, and transformation.
However, cellular aging is not equivalent to organ or organismal aging. Studies in humans
have attempted to relate short telomeres to longevity. In a provocative initial publication from
the University of Utah, individuals around 60 years of age who had the longest telomeres lived
longer than did subjects with the shortest telomeres, but the most associated cause of death in
the latter group was, inexplicably, infection, and those with shorter telomeres did not have a
higher rate of cancer deaths [90]. Heart disease as the cause of death was also more common
in subjects with the shortest telomeres. Subsequent studies have produced conflicting findings.
The Cardiovascular Health Study of subjects over 65 years of age found that individuals in the
shortest quartile for telomere length were 60% more likely to die than those in the longest
quartile [91]. Causes of death related to short telomeres were infectious. Two twin studies at
older age also correlated shorter telomeres with poorer survival [92, 93]. Finally, a cohort study
that looked at participants at time zero and after 10 years found that death within 10 years was
significantly more common in those with shorter telomeres [94]. In contrast, these associations
have not been confirmed in other studies of older subjects. Njajou and collegues reported that
telomere length failed to predict survival, but correlated with years of healthy life [95]. In a
Danish study of people aged 73 to 101 years, telomeres correlated with life expectancy in simple
univariate analysis but, when corrected for age, did not predict longevity [96]. In Dutch men
with a mean age of 78 years, telomere length eroded with aging but failed to correlate with
mortality [97]. In a Finnish investigation, telomere length did not predict overall mortality [98].
Finally, in an analysis from California, short telomere length predicted death from cardiovas‐
cular disease in women but not in men, where the rate of shortening predicted mortality rather
than length itself [99]. Collectively, data on association between telomere length and aging are
Telomeres and Brain Tumors
http://dx.doi.org/10.5772/52426
327
quite inhomogeneous and contradictory, whereas data on the role of telomere length in human
disease are more consistent.
Telomere dysfunction and telomere length alterations have been reported as responsible of
various human pathologies, ranging from neurodegenerative to inherited genetic diseases. In
the last decade, several studies elucidated telomere’s role in the pathophysiology of different
diseases at a molecular level. For this reason, measuring of telomeres in peripheral mononu‐
clear cells or in whole blood samples has been applied to patients with a multitude of disease
states [100].
Dyskeratosis congenital (DC), is a rare inherited bone marrow failure disease, and can be con‐
sidered the classic “telomere disease”. The inherited defect in X-linked dyskeratosis congenital
was identified in a gene named DKC1 [101]. DKC1 encodes dyskerin, a protein that binds to the
RNA component of telomerase and stabilizes the telomerase complex. Inheritance is X-linked
recessive, autosomal dominant, or autosomal recessive. In addition to the diagnostic triad of
nail dystrophy, lacey reticular pigmentation, and oral leukoplakia, patients with DC are at very
high risk of bone marrow failure (BMF), cancer, pulmonary and liver disease, and multiple oth‐
er medical problems [102, 103]. Several studies demonstrated that patients with dyskeratosis
congenita have accelerated telomere shortening and that telomere length measurement by flow
fluorescence in situ hybridization in peripheral blood lymphocytes is an important diagnostic
test for DC: in particular, age-adjusted values provide a quantitative measure of disease severi‐
ty, with shortest telomeres associated to severe variants of DC [104, 105].
Much attention has been given to individuals with atherosclerotic disease and, as a common
rule, telomeric length of peripheral mononuclear cells seems to be a strong predictor for disease
progression. In particular, leukocyte telomere length is associated with measures of subclinical
atherosclerosis [106] and with HDL cholesterol levels [107]. Moreover, cellular aging reflected
by shorter leukocyte telomere length is a predictor for advanced atherosclerosis and cardio‐
vascular disease risk [108]. Patients with myocardial infarction have shorter telomeres as
compared to controls [109], and reduced leukocyte telomere length has been linked to
increased coronary artery calcium [110] and reduction in left ventricular mass.[111] Shortened
telomeres have been observed also in white blood cells of patients affected by diabetes type I
and II,[112-114] neurodegenerative disease including dementia and Alzheimer disease
[115-119], ischemic stroke [120]. All these results suggest an important role of telomere and of
its length modulation mechanisms in the pathophysiology of several common diseases, often
age-related, encouraging new researches to improve the knowledge about telomere biology
and to translate these new informations in the clinical practice for a better patient’s manage‐
ment in terms of diagnosis, treatment and prognostic stratification.
4. Telomeres and cancer
Functional telomeres protect chromosome ends from recombination and fusion, and are
therefore essential for maintenance of chromosomal stability [3, 121, 122]. The alteration of
telomere length homeostasis affects telomere structure and leads to genomic instability by
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generating chromosome end-to-end fusion and chromosomal abnormalities [9]. It has been
demonstrated that telomeres shortening could initiate successive events, such as aberrant
fusion or recombination of the end of chromosomes, genomic instability, loss of cell growth
control, and finally cancer development [10, 11]. Cells exhibiting critical telomeres shortening
and genomic instability thus present an increased capacity of dicentric chromosomes forma‐
tion and susceptibility to oncogenic transformation [5, 12, 13].
The phenomenon of telomeres alteration during carcinogenesis and cancer progression is well
known and established at the molecular level [123-125]. Several studies demonstrated the
presence of telomere length alterations in different human solid tumors, such as prostate,
breast, colorectal, head and neck cancer [81]. These alterations are widely variable, resulting
in both telomere attrition and elongation as compared to adjacent normal tissues. In the
majority of cases, telomere length seems to be reduced in human tumors [126-131], even if it
tends to increase along with malignancy of tumors [79, 132, 133].
In particular, telomere dysfunction has been extensively studied in the most common solid
tumors. These studies demonstrated telomere length modification in different histologies as
compared to normal tissue due to the alteration of telomere length modulation mechanisms
[81]. This differences have been widely analysed in order to identify new cancer biomarkers,
to investigate the eventual correlation with patient’s prognosis and to discover new targeted
molecular therapies.
In breast cancer, multiple studies have showed that telomere shortening is associated with
increased risk and poor outcome, and can thus be used as a prognostic factor to predict the
course of disease. The first report describing the use of telomere length as a possible prognostic
marker in breast cancer was published by Odagiri and collegues [130]. In this study, telomere
length analysis was performed in a cohort of 41 patients diagnosed with breast cancer and
showed that telomere length was significantly reduced in tumor tissues (8.1 ± 0.6 kb) as
compared to that of the adjacent normal breast tissues (9.7 ± 0.5 kb) in 18 of 22 patients (p >
0.05). Subsequent studies confirmed the potential role of telomere length as clinical biomarker
in breast cancer, including Fordyce et al. [127] who reported measurements of telomere length
in 2 independent sets of breast tumors containing a total of 140 samples. This study showed
that telomere alterations include both telomere attrition and elongation. In fact, only 50% of
all tumors had telomere values in the normal range. Moreover, in this study telomere length
was associated with tumor size (p = 0.02), TNM stage (p = 0.004), 5-year overall survival (p =
0.0001) and 5-year disease-free survival (p = 0.0004) and, in particular, reduced telomere length
was associated with nodal involvement (p < 0.0001).
Recent investigations concerning prostate cancer suggest that reduced telomere length is
associated with poor clinical outcome and markers of disease progression [126, 128]. The first
reported study was performed by Donaldson and colleagues in 1999 and represented a
retrospective investigation of the relationship between clinical outcomes in patients with
organ-confined prostate adenocarcinoma and telomere length [128]. In this archival case-
controlled study, association analysis for telomere length and survival and telomere length
and biochemical recurrence indicated by PSA levels of > 2.5ng/ml, revealed that reduced
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quite inhomogeneous and contradictory, whereas data on the role of telomere length in human
disease are more consistent.
Telomere dysfunction and telomere length alterations have been reported as responsible of
various human pathologies, ranging from neurodegenerative to inherited genetic diseases. In
the last decade, several studies elucidated telomere’s role in the pathophysiology of different
diseases at a molecular level. For this reason, measuring of telomeres in peripheral mononu‐
clear cells or in whole blood samples has been applied to patients with a multitude of disease
states [100].
Dyskeratosis congenital (DC), is a rare inherited bone marrow failure disease, and can be con‐
sidered the classic “telomere disease”. The inherited defect in X-linked dyskeratosis congenital
was identified in a gene named DKC1 [101]. DKC1 encodes dyskerin, a protein that binds to the
RNA component of telomerase and stabilizes the telomerase complex. Inheritance is X-linked
recessive, autosomal dominant, or autosomal recessive. In addition to the diagnostic triad of
nail dystrophy, lacey reticular pigmentation, and oral leukoplakia, patients with DC are at very
high risk of bone marrow failure (BMF), cancer, pulmonary and liver disease, and multiple oth‐
er medical problems [102, 103]. Several studies demonstrated that patients with dyskeratosis
congenita have accelerated telomere shortening and that telomere length measurement by flow
fluorescence in situ hybridization in peripheral blood lymphocytes is an important diagnostic
test for DC: in particular, age-adjusted values provide a quantitative measure of disease severi‐
ty, with shortest telomeres associated to severe variants of DC [104, 105].
Much attention has been given to individuals with atherosclerotic disease and, as a common
rule, telomeric length of peripheral mononuclear cells seems to be a strong predictor for disease
progression. In particular, leukocyte telomere length is associated with measures of subclinical
atherosclerosis [106] and with HDL cholesterol levels [107]. Moreover, cellular aging reflected
by shorter leukocyte telomere length is a predictor for advanced atherosclerosis and cardio‐
vascular disease risk [108]. Patients with myocardial infarction have shorter telomeres as
compared to controls [109], and reduced leukocyte telomere length has been linked to
increased coronary artery calcium [110] and reduction in left ventricular mass.[111] Shortened
telomeres have been observed also in white blood cells of patients affected by diabetes type I
and II,[112-114] neurodegenerative disease including dementia and Alzheimer disease
[115-119], ischemic stroke [120]. All these results suggest an important role of telomere and of
its length modulation mechanisms in the pathophysiology of several common diseases, often
age-related, encouraging new researches to improve the knowledge about telomere biology
and to translate these new informations in the clinical practice for a better patient’s manage‐
ment in terms of diagnosis, treatment and prognostic stratification.
4. Telomeres and cancer
Functional telomeres protect chromosome ends from recombination and fusion, and are
therefore essential for maintenance of chromosomal stability [3, 121, 122]. The alteration of
telomere length homeostasis affects telomere structure and leads to genomic instability by
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generating chromosome end-to-end fusion and chromosomal abnormalities [9]. It has been
demonstrated that telomeres shortening could initiate successive events, such as aberrant
fusion or recombination of the end of chromosomes, genomic instability, loss of cell growth
control, and finally cancer development [10, 11]. Cells exhibiting critical telomeres shortening
and genomic instability thus present an increased capacity of dicentric chromosomes forma‐
tion and susceptibility to oncogenic transformation [5, 12, 13].
The phenomenon of telomeres alteration during carcinogenesis and cancer progression is well
known and established at the molecular level [123-125]. Several studies demonstrated the
presence of telomere length alterations in different human solid tumors, such as prostate,
breast, colorectal, head and neck cancer [81]. These alterations are widely variable, resulting
in both telomere attrition and elongation as compared to adjacent normal tissues. In the
majority of cases, telomere length seems to be reduced in human tumors [126-131], even if it
tends to increase along with malignancy of tumors [79, 132, 133].
In particular, telomere dysfunction has been extensively studied in the most common solid
tumors. These studies demonstrated telomere length modification in different histologies as
compared to normal tissue due to the alteration of telomere length modulation mechanisms
[81]. This differences have been widely analysed in order to identify new cancer biomarkers,
to investigate the eventual correlation with patient’s prognosis and to discover new targeted
molecular therapies.
In breast cancer, multiple studies have showed that telomere shortening is associated with
increased risk and poor outcome, and can thus be used as a prognostic factor to predict the
course of disease. The first report describing the use of telomere length as a possible prognostic
marker in breast cancer was published by Odagiri and collegues [130]. In this study, telomere
length analysis was performed in a cohort of 41 patients diagnosed with breast cancer and
showed that telomere length was significantly reduced in tumor tissues (8.1 ± 0.6 kb) as
compared to that of the adjacent normal breast tissues (9.7 ± 0.5 kb) in 18 of 22 patients (p >
0.05). Subsequent studies confirmed the potential role of telomere length as clinical biomarker
in breast cancer, including Fordyce et al. [127] who reported measurements of telomere length
in 2 independent sets of breast tumors containing a total of 140 samples. This study showed
that telomere alterations include both telomere attrition and elongation. In fact, only 50% of
all tumors had telomere values in the normal range. Moreover, in this study telomere length
was associated with tumor size (p = 0.02), TNM stage (p = 0.004), 5-year overall survival (p =
0.0001) and 5-year disease-free survival (p = 0.0004) and, in particular, reduced telomere length
was associated with nodal involvement (p < 0.0001).
Recent investigations concerning prostate cancer suggest that reduced telomere length is
associated with poor clinical outcome and markers of disease progression [126, 128]. The first
reported study was performed by Donaldson and colleagues in 1999 and represented a
retrospective investigation of the relationship between clinical outcomes in patients with
organ-confined prostate adenocarcinoma and telomere length [128]. In this archival case-
controlled study, association analysis for telomere length and survival and telomere length
and biochemical recurrence indicated by PSA levels of > 2.5ng/ml, revealed that reduced
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telomere length correlated with death (p < 0.0001) and disease recurrence (p < 0.0001), even if
there was no statistical association with patients’ ages at diagnosis, nodal statuses, pathological
grades or Gleason sum scores. This finding was recently confirmed in a larger retrospective
population-based study comprising 77 men who underwent prostatectomy between 1982 and
1995 [126]. In this cohort, telomere length was a predictor of time to recurrence when adjusted
for age at diagnosis, Gleason sum score and pelvic node involvement.
Although relatively rare, researches on the role of telomeres in lung cancer showed that
telomerase expression and activity can be considered important contributors to the malignant
phenotype in lung epithelial cells, and have been proposed to be of potential prognostic value
[134]. Conversely, reports on the use of telomere length to predict lung cancer progression are
scarce. Shirotani et al. investigated the relationship between telomere length and various
characteristics of tumor cells in 46 lung cancer specimens, comprising 40 primary and 6
metastatic lesions [135]. In partial accordance with recent studies in breast and prostate cancers
[126, 127], the authors observed both elongation (2 cases) and reduction of telomere length (13
cases) in the 16 small cell carcinomas of the sample set. The 2 cases with telomere elongation
were associated with a poor prognosis. Similarly, in the adenocarcinoma samples of this study,
both telomere reduction and elongation were observed, but a clear association with patients
prognosis was not reported. Hirashima et al. evaluated the prognostic significance of telomere
length alterations in cancer and normal lung tissues obtained from 72 patients with histolog‐
ically confirmed pathological stage I-IIIA non-small cell lung cancer (NSCLC) [136]. In this
study, the 25 patients (34.7%) with alterations in telomere length, elongation or attrition, had
significantly shorter survival durations than those of the others.
The use of telomeres as prognostic factors in colorectal carcinoma has been suggested in several
studies performed by the groups led by Siewert and coworkers[132, 137] and by Iniesta and
collegues [133]. It is interesting that these studies showed an opposite relationship as compared
to studies in other cancer types [126-129, 131], with longer telomeres associated with poor
prognosis. This difference may be explained considering the different regulation of telomerase
expression in colorectal epithelial cells. Normal colorectal epithelium, in fact, has been showed
to contain cells of possible stem cell origin that are telomerase-positive and presumably
counteract telomere attrition due to physiologically high cell proliferation rates, and total cell
loss due to physiological shedding in this specialized cell compartment [138]. Consequently,
it is possible that the existing high telomerase activity may affect cells undergoing tumor
initiation and results in elongated telomeres in cells of colorectal cancer.
Studies indicating the prognostic potential of telomeres have also been reported for head and
neck cancer. Patel et al. studied telomere alterations in tumor and adjacent normal tissues in
110 patients with head and neck cancer (squamous cell carcinomas of the oral cavity, larynx
and pharynx) and 40 patients with precancerous and benign conditions (leukoplakia, submu‐
cous fibrosis, erythroplakia, hemangioma) [79]. Telomere lengths in this sample set were
significantly lower in malignant tissues as compared with the tumor adjacent normal tissues.
In addition, 2-year disease-free survival analysis showed that patients with longer telomeres
in malignant tissues had poor disease-free survival. These findings are in agreement with that
reported for colorectal carcinoma and lung [132, 133, 135, 137], and in contrast to other cancer
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histologies [126-129]. A possible explanation for these interesting discrepancies in head and
neck cancer is the fact that telomerase activity was observed in over half of the adjacent normal
tissues. As before discussed for colorectal carcinoma, altered regulation of telomerase expres‐
sion in cells undergoing transformation may explain the elongated telomeres in the tumors.
Collectively, these findings suggest that hypervariability of telomere length in various human
solid tumors probably reflects the differential regulation of telomerase expression in cancer
cells and depends on the different stages of carcinogenesis and tumor progression. Therefore,
analysis of telomere length may have a clinical relevance as a prognostic marker in human
solid tumors, whereas analysis of the mechanisms of length modulation, such as telomerase
and ALT, can suggest new molecular target for advanced therapeutic strategies.
5. Telomeres and brain tumors
Brain tumors research is being performed worldwide at a remarkable pace, with some of the
more recent promising studies focused on identification of aberrant genetic events and
signalling pathways, tumor stem cell identification and characterization, modulation of tumor
immunological responses, combination therapies, and understanding of the rare long-term
survivors. Identification of additional indicators will enable better patients’ stratification and
individualization of treatment is needed to more accurately determine patient’s prognosis and
to identify novel therapeutic approaches that can optimize patient’s outcome. A growing body
of knowledge suggests a potential role of telomere length measurement in different tumors.
Nevertheless, even if its clinical use is not completely established, a number of studies
demonstrated that it can be helpful to patients stratification, to provide useful information
about patient’s prognosis and, in some case, to suggest new therapeutic strategies in cancer.
Although not entirely consistent in the type of telomere alteration, i.e., attrition vs. elongation,
and unclear on the underlying mechanisms, multiple studies have showed that telomere
dysfunctions are associated with parameters of clinical outcome in patients with brain tumors.
A possible explanation for these interesting discrepancies in brain tumors is the fact that
different expression and/or altered regulation of telomerase expression in tumor cells may
reflects the underlying biology of telomere maintenance and its dysfunction over time. In
telomerase positive tumor cells, telomere length is balanced by telomere shortening due to cell
division and telomere elongation by telomerase. Therefore, telomere length is maintained by
telomerase activity that can be influenced in different ways and by various factors. This
mechanism keeps tumour cells proliferating and growing by the stabilization of their telomeres
which is essential to maintain the unlimited dividing potential and to escape from ‘crisis’ [49,
123, 139]. As well as in almost all malignant tumors, World Health Organization (WHO) high
grade brain tumors are associated to higher telomerase activity than benign tumors, such as
schwannomas, meningiomas [140] or normal brain tissue [141]. Increased telomerase expres‐
sion has been also associated with higher proliferative index, tumor grading, age, vascular and
endothelial proliferation [142], poor outcome [83, 143, 144], and it increases with malignancy
from low-grade to high-grade brain tumors [83, 145].
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telomere length correlated with death (p < 0.0001) and disease recurrence (p < 0.0001), even if
there was no statistical association with patients’ ages at diagnosis, nodal statuses, pathological
grades or Gleason sum scores. This finding was recently confirmed in a larger retrospective
population-based study comprising 77 men who underwent prostatectomy between 1982 and
1995 [126]. In this cohort, telomere length was a predictor of time to recurrence when adjusted
for age at diagnosis, Gleason sum score and pelvic node involvement.
Although relatively rare, researches on the role of telomeres in lung cancer showed that
telomerase expression and activity can be considered important contributors to the malignant
phenotype in lung epithelial cells, and have been proposed to be of potential prognostic value
[134]. Conversely, reports on the use of telomere length to predict lung cancer progression are
scarce. Shirotani et al. investigated the relationship between telomere length and various
characteristics of tumor cells in 46 lung cancer specimens, comprising 40 primary and 6
metastatic lesions [135]. In partial accordance with recent studies in breast and prostate cancers
[126, 127], the authors observed both elongation (2 cases) and reduction of telomere length (13
cases) in the 16 small cell carcinomas of the sample set. The 2 cases with telomere elongation
were associated with a poor prognosis. Similarly, in the adenocarcinoma samples of this study,
both telomere reduction and elongation were observed, but a clear association with patients
prognosis was not reported. Hirashima et al. evaluated the prognostic significance of telomere
length alterations in cancer and normal lung tissues obtained from 72 patients with histolog‐
ically confirmed pathological stage I-IIIA non-small cell lung cancer (NSCLC) [136]. In this
study, the 25 patients (34.7%) with alterations in telomere length, elongation or attrition, had
significantly shorter survival durations than those of the others.
The use of telomeres as prognostic factors in colorectal carcinoma has been suggested in several
studies performed by the groups led by Siewert and coworkers[132, 137] and by Iniesta and
collegues [133]. It is interesting that these studies showed an opposite relationship as compared
to studies in other cancer types [126-129, 131], with longer telomeres associated with poor
prognosis. This difference may be explained considering the different regulation of telomerase
expression in colorectal epithelial cells. Normal colorectal epithelium, in fact, has been showed
to contain cells of possible stem cell origin that are telomerase-positive and presumably
counteract telomere attrition due to physiologically high cell proliferation rates, and total cell
loss due to physiological shedding in this specialized cell compartment [138]. Consequently,
it is possible that the existing high telomerase activity may affect cells undergoing tumor
initiation and results in elongated telomeres in cells of colorectal cancer.
Studies indicating the prognostic potential of telomeres have also been reported for head and
neck cancer. Patel et al. studied telomere alterations in tumor and adjacent normal tissues in
110 patients with head and neck cancer (squamous cell carcinomas of the oral cavity, larynx
and pharynx) and 40 patients with precancerous and benign conditions (leukoplakia, submu‐
cous fibrosis, erythroplakia, hemangioma) [79]. Telomere lengths in this sample set were
significantly lower in malignant tissues as compared with the tumor adjacent normal tissues.
In addition, 2-year disease-free survival analysis showed that patients with longer telomeres
in malignant tissues had poor disease-free survival. These findings are in agreement with that
reported for colorectal carcinoma and lung [132, 133, 135, 137], and in contrast to other cancer
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histologies [126-129]. A possible explanation for these interesting discrepancies in head and
neck cancer is the fact that telomerase activity was observed in over half of the adjacent normal
tissues. As before discussed for colorectal carcinoma, altered regulation of telomerase expres‐
sion in cells undergoing transformation may explain the elongated telomeres in the tumors.
Collectively, these findings suggest that hypervariability of telomere length in various human
solid tumors probably reflects the differential regulation of telomerase expression in cancer
cells and depends on the different stages of carcinogenesis and tumor progression. Therefore,
analysis of telomere length may have a clinical relevance as a prognostic marker in human
solid tumors, whereas analysis of the mechanisms of length modulation, such as telomerase
and ALT, can suggest new molecular target for advanced therapeutic strategies.
5. Telomeres and brain tumors
Brain tumors research is being performed worldwide at a remarkable pace, with some of the
more recent promising studies focused on identification of aberrant genetic events and
signalling pathways, tumor stem cell identification and characterization, modulation of tumor
immunological responses, combination therapies, and understanding of the rare long-term
survivors. Identification of additional indicators will enable better patients’ stratification and
individualization of treatment is needed to more accurately determine patient’s prognosis and
to identify novel therapeutic approaches that can optimize patient’s outcome. A growing body
of knowledge suggests a potential role of telomere length measurement in different tumors.
Nevertheless, even if its clinical use is not completely established, a number of studies
demonstrated that it can be helpful to patients stratification, to provide useful information
about patient’s prognosis and, in some case, to suggest new therapeutic strategies in cancer.
Although not entirely consistent in the type of telomere alteration, i.e., attrition vs. elongation,
and unclear on the underlying mechanisms, multiple studies have showed that telomere
dysfunctions are associated with parameters of clinical outcome in patients with brain tumors.
A possible explanation for these interesting discrepancies in brain tumors is the fact that
different expression and/or altered regulation of telomerase expression in tumor cells may
reflects the underlying biology of telomere maintenance and its dysfunction over time. In
telomerase positive tumor cells, telomere length is balanced by telomere shortening due to cell
division and telomere elongation by telomerase. Therefore, telomere length is maintained by
telomerase activity that can be influenced in different ways and by various factors. This
mechanism keeps tumour cells proliferating and growing by the stabilization of their telomeres
which is essential to maintain the unlimited dividing potential and to escape from ‘crisis’ [49,
123, 139]. As well as in almost all malignant tumors, World Health Organization (WHO) high
grade brain tumors are associated to higher telomerase activity than benign tumors, such as
schwannomas, meningiomas [140] or normal brain tissue [141]. Increased telomerase expres‐
sion has been also associated with higher proliferative index, tumor grading, age, vascular and
endothelial proliferation [142], poor outcome [83, 143, 144], and it increases with malignancy
from low-grade to high-grade brain tumors [83, 145].
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Therefore, understanding the context and mechanisms by which telomeres length contribute
to cancer development is the next logical research step and may represent an interesting
research field in order to elucidate brain tumors biology. Moving toward the study of molec‐
ular mechanisms controlling telomere length, included telomerase and ALT, will not only
provide insight into the complex etiology of brain tumors but also promises to provide novel
targets for cancer therapy.
In these settings, several studies have been performed to analyze telomere biology in brain
tumors, with the aim to better understand the patophysiology of these tumors for improving
prognosis of patients affected by such terrible neoplasms.
5.1. Astrocytic gliomas
Astrocytic tumors represent about the 23% of primary brain and CNS tumours and, in
particular, astrocytomas and glioblastomas (GBMs) account for 76% of all gliomas. The
incidence of such tumours tends to increase with age, although some histological variants are
more frequent in specific age ranges. For example, pilocytic astrocytomas affect exclusively
childhood, being the most common brain tumor between 5 and 14 years old. Conversely, the
incidence of glioblastomas increases with age, with the highest rates in the 75 to 84 years old.
The prognosis can be different according to histology. For low grade astrocytomas (grade I
and II), prognosis is usually good and a gross total surgical excision alone represents a
sufficient therapeutic strategy. Conversely, for high grade astrocytomas (i.e. glioblastomas
WHO IV), although a multimodal therapeutic strategy consisting of radical surgical removal,
chemotherapy and radiotherapy, prognosis remains poor. For example, five–year survival
rates are 94% for pilocytic astrocytomas but are less than 5% for glioblastomas. Survival
generally decreases with older age at diagnosis. Children and young adults have better
survival for most histologies [146].
Several studies focused on astrocytomas showed an association between telomerase activity
and reduced telomeres length in high grade tumors. Liu et al. analyzed telomere length in a
series of astrocytic tumors. Telomere length measurement was performed using a telomere
specific restriction enzyme and Southern blot analysis. The authors observed a progressive
shortening of the telomere restriction fragments (TRFs) in astrocytomas from WHO grade I to
IV as compared to TRFs of normal brain tissue, with no significant differences between primary
and recurrent GBMs [87]. These findings support the hypothesis that telomere shortening is
one of the important genetic events during transformation of astrocytomas and progression
to higher grades.
Subsequent studies were focused on the analysis of the relationship between telomere length
and telomerase activity, suggesting new interesting hypothesis about telomere maintenance
mechanisms during the neoplastic transformation and progression of astrocytic tumors. In
1997, Morii and colleagues, analysed telomere length and telomerase activity in a series of 20
gliomas (WHO grade I to IV), including 1 pilocytic astrocytomas, 7 oligoastrocytomas, 1
anaplastic astrocytoma (AA) and 11 GBMs. In their series, telomerase-positive samples had a
mean TRF length of <10 kb, whereas telomerase-negative samples all had long heterogeneous
TRFs which exhibited an increased signal peak from 10 to 20 kb. The authors concluded that
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telomerase-negative gliomas had longer TRFs compared with telomerase positive ones,
suggesting that, in addition to the telomerase-dependent mechanism, an alternative telomer‐
ase-independent mechanism (ALT) for telomere maintenance may be present in human
gliomas [86]. Hiraga et al, in 1998, performed the most complete analysis of telomere length
in human brain tumors, comparing TRFs length and telomerase activity in 160 neuroepithelial
and non-neuroepithelial brain tumors. Among grade I-IV astrocytomas, the authors compared
telomere length between telomerase-positive and telomerase-negative samples vs normal
brain tissue (NBT). TRFs were shorter in tumors with telomerase activity than telomerase-
negative samples and NBT samples. Specifically, the detection rates of telomerase activity were
widely different for different histopathological entities. Telomerase activity was detected in
none of pilocytic astrocytomas, in 20.0% (3 of 15) of grade II astrocytomas, 40% (6 of 15) of
anaplastic astrocytomas and 72.3% (34 of 47) of glioblastomas, suggesting that telomerase
activity tend to increase with the malignancy of astrocytic tumors. In particular, all pilocytic
astrocytomas (3 of 3) were telomerase negative and showed longer TRFs as compared to
normal brain tissue. TRFs in grade II astrocytomas and anaplastic astrocytomas with telomer‐
ase activity were shorter as compared to the same tumors without telomerase activity. Lastly,
80% of the progression GBMs exhibited reduced mean TRF length (7.747 kb) compared with
NBT and origin tumors, and telomerase was reactivated in 100% (10 of 10) of cases. In
summary, the mean TRF length of tumors with telomerase activity was significantly shorter
than that of tumors with undetectable telomerase activity for each tumor entity [139].
These results suggest that telomerase activity strongly correlates with malignancy and
potential progression of the astrocytic tumors, being often associated with reduced telomere
length.
These findings were confirmed by Le et collegues, in 1998 [83]. The authors performed an
analysis of telomere length and telomerase activity in a series of 69 grade I-IV gliomas. From
the analysis of all series, the authors concluded that telomerase activity is present in most
glioma samples (72%), but that the frequency of such activity increases with malignancy, being
higher in high grade gliomas (HGGs) than in low grade gliomas (LGGs), and is often associated
with telomeres shortening. This can be explained with the relative low replicative rate of LGG
tumor cells. When the proliferative activity increases, such as during the progression to HGGs,
the increased mitotic activity causes a progressive telomeres shortening. In this condition, the
activation of telomerase activity represents the only way to escape from cell crisis and
apoptosis. This can explain the presence of high telomerase activity and reduced TRFs only in
a small percentage of LGGs that probably presents a more aggressive behavior than the
telomerase negative LGGs with normal or elongated telomeres. This demonstrates an increas‐
ing telomerase activity with the more malignancy of gliomas samples, underlying the role of
telomerase and TRFs length as marker of malignancy.
Similar findings were found by Maes and collegues in 2007 [145]. They conducted a study
focusing on the relationship between telomerase activity and telomere length in a series of 53
intracranial tumors, including 2 low grade astrocytomas, 1 anaplastic astrocytomas, and 11
GBMs. Again, in this study the authors demonstrated that telomere length was reduced in
high-grade tumours, whereas it was compatible or elongated as compared to normal brain
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Therefore, understanding the context and mechanisms by which telomeres length contribute
to cancer development is the next logical research step and may represent an interesting
research field in order to elucidate brain tumors biology. Moving toward the study of molec‐
ular mechanisms controlling telomere length, included telomerase and ALT, will not only
provide insight into the complex etiology of brain tumors but also promises to provide novel
targets for cancer therapy.
In these settings, several studies have been performed to analyze telomere biology in brain
tumors, with the aim to better understand the patophysiology of these tumors for improving
prognosis of patients affected by such terrible neoplasms.
5.1. Astrocytic gliomas
Astrocytic tumors represent about the 23% of primary brain and CNS tumours and, in
particular, astrocytomas and glioblastomas (GBMs) account for 76% of all gliomas. The
incidence of such tumours tends to increase with age, although some histological variants are
more frequent in specific age ranges. For example, pilocytic astrocytomas affect exclusively
childhood, being the most common brain tumor between 5 and 14 years old. Conversely, the
incidence of glioblastomas increases with age, with the highest rates in the 75 to 84 years old.
The prognosis can be different according to histology. For low grade astrocytomas (grade I
and II), prognosis is usually good and a gross total surgical excision alone represents a
sufficient therapeutic strategy. Conversely, for high grade astrocytomas (i.e. glioblastomas
WHO IV), although a multimodal therapeutic strategy consisting of radical surgical removal,
chemotherapy and radiotherapy, prognosis remains poor. For example, five–year survival
rates are 94% for pilocytic astrocytomas but are less than 5% for glioblastomas. Survival
generally decreases with older age at diagnosis. Children and young adults have better
survival for most histologies [146].
Several studies focused on astrocytomas showed an association between telomerase activity
and reduced telomeres length in high grade tumors. Liu et al. analyzed telomere length in a
series of astrocytic tumors. Telomere length measurement was performed using a telomere
specific restriction enzyme and Southern blot analysis. The authors observed a progressive
shortening of the telomere restriction fragments (TRFs) in astrocytomas from WHO grade I to
IV as compared to TRFs of normal brain tissue, with no significant differences between primary
and recurrent GBMs [87]. These findings support the hypothesis that telomere shortening is
one of the important genetic events during transformation of astrocytomas and progression
to higher grades.
Subsequent studies were focused on the analysis of the relationship between telomere length
and telomerase activity, suggesting new interesting hypothesis about telomere maintenance
mechanisms during the neoplastic transformation and progression of astrocytic tumors. In
1997, Morii and colleagues, analysed telomere length and telomerase activity in a series of 20
gliomas (WHO grade I to IV), including 1 pilocytic astrocytomas, 7 oligoastrocytomas, 1
anaplastic astrocytoma (AA) and 11 GBMs. In their series, telomerase-positive samples had a
mean TRF length of <10 kb, whereas telomerase-negative samples all had long heterogeneous
TRFs which exhibited an increased signal peak from 10 to 20 kb. The authors concluded that
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telomerase-negative gliomas had longer TRFs compared with telomerase positive ones,
suggesting that, in addition to the telomerase-dependent mechanism, an alternative telomer‐
ase-independent mechanism (ALT) for telomere maintenance may be present in human
gliomas [86]. Hiraga et al, in 1998, performed the most complete analysis of telomere length
in human brain tumors, comparing TRFs length and telomerase activity in 160 neuroepithelial
and non-neuroepithelial brain tumors. Among grade I-IV astrocytomas, the authors compared
telomere length between telomerase-positive and telomerase-negative samples vs normal
brain tissue (NBT). TRFs were shorter in tumors with telomerase activity than telomerase-
negative samples and NBT samples. Specifically, the detection rates of telomerase activity were
widely different for different histopathological entities. Telomerase activity was detected in
none of pilocytic astrocytomas, in 20.0% (3 of 15) of grade II astrocytomas, 40% (6 of 15) of
anaplastic astrocytomas and 72.3% (34 of 47) of glioblastomas, suggesting that telomerase
activity tend to increase with the malignancy of astrocytic tumors. In particular, all pilocytic
astrocytomas (3 of 3) were telomerase negative and showed longer TRFs as compared to
normal brain tissue. TRFs in grade II astrocytomas and anaplastic astrocytomas with telomer‐
ase activity were shorter as compared to the same tumors without telomerase activity. Lastly,
80% of the progression GBMs exhibited reduced mean TRF length (7.747 kb) compared with
NBT and origin tumors, and telomerase was reactivated in 100% (10 of 10) of cases. In
summary, the mean TRF length of tumors with telomerase activity was significantly shorter
than that of tumors with undetectable telomerase activity for each tumor entity [139].
These results suggest that telomerase activity strongly correlates with malignancy and
potential progression of the astrocytic tumors, being often associated with reduced telomere
length.
These findings were confirmed by Le et collegues, in 1998 [83]. The authors performed an
analysis of telomere length and telomerase activity in a series of 69 grade I-IV gliomas. From
the analysis of all series, the authors concluded that telomerase activity is present in most
glioma samples (72%), but that the frequency of such activity increases with malignancy, being
higher in high grade gliomas (HGGs) than in low grade gliomas (LGGs), and is often associated
with telomeres shortening. This can be explained with the relative low replicative rate of LGG
tumor cells. When the proliferative activity increases, such as during the progression to HGGs,
the increased mitotic activity causes a progressive telomeres shortening. In this condition, the
activation of telomerase activity represents the only way to escape from cell crisis and
apoptosis. This can explain the presence of high telomerase activity and reduced TRFs only in
a small percentage of LGGs that probably presents a more aggressive behavior than the
telomerase negative LGGs with normal or elongated telomeres. This demonstrates an increas‐
ing telomerase activity with the more malignancy of gliomas samples, underlying the role of
telomerase and TRFs length as marker of malignancy.
Similar findings were found by Maes and collegues in 2007 [145]. They conducted a study
focusing on the relationship between telomerase activity and telomere length in a series of 53
intracranial tumors, including 2 low grade astrocytomas, 1 anaplastic astrocytomas, and 11
GBMs. Again, in this study the authors demonstrated that telomere length was reduced in
high-grade tumours, whereas it was compatible or elongated as compared to normal brain
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tissues in low-grade astrocytomas, suggesting that telomerase activity with shortened
telomeres correlates with the aggressive growth of high-grade gliomas.
Harada and colleagues [147] analyzed possible differences of telomerase activity and telomere
length among primary and secondary GBMs. Summarizing their findings, TRFs were always
shorter than NBT samples, but not statistically significant differences between primary and
secondary GBMs were found. Interestingly, although the latter presented significantly higher
levels of telomerase activity and hTERT expression than the former, telomere length was
anyway shorter than normal brain tissue. The authors explained this apparent discrepancy
suggesting that telomerase activation occurs late in carcinogenesis, when the high replication
rate of tumor cells already caused telomeres shortening. At this point, activation of telomerase
represents the principal mechanism to escape from apoptosis and cell death. Conversely, in
primary GBMs, shorter telomere length can be explained by a reduced telomerase activity that
might have less influence on carcinogenesis and, hence, other unknown factors might facilitate
their cellular immortality.
Although the vast majority of the researches have been performed focusing their attention to
telomere length and telomerase expression in astrocytic gliomas, recently several studies
showed an increasing interest also to the analysis of the relation between ALT mechanism,
telomere length and patients prognosis.
The presence of elongated telomeres and of an alternative mechanism of telomere length
maintenance (ALT) was demonstrated to be associated to a better prognosis in patients affected
by GBMs by Hakin-Smith et al. in 2003 [148]. Their work represents the first report describing
the relationship among ALT pattern, telomere length, and prognosis in human GBMs. In this
study, the authors analyzed telomerase activity and telomere lengths in 77 GBM patients. ALT
phenotype patients had a median survival of 542 days compared with 247 days in those
without the ALT phenotype. Moreover, ALT phenotype was associated with elongated
telomeres, benign biology and better prognosis. Therefore, the presence of ALT could be a
positive prognostic marker in glioblastoma multiforme.
The first study that analyzed the ALT prevalence among different grades of astrocytic tumors
was performed by Henson and coworkers in 2005. In their study, the authors analyzed the
prevalence of ALT phenotype and telomerase activity in a series of 40 astrocytomas, composed
by 7 WHO grade II-III astrocytomas and 33 GBMs. This study showed for the first time that
the prevalence of ALT associated to elongated telomeres is significantly higher in grade II to
III astrocytomas as compared to GBMs.
On the basis of Henson’s results, in 2010 Slatter and collegues conducted a study focusing on
the analysis of ALT prevalence in a series of 48 astrocytic tumors from grade I to IV. In
agreement with previous studies by Hakin-Smith and Henson [148, 149], ALT phenotype was
more frequent in low grade astrocityc tumors, whereas telomerase activity was prevalent in
the higher grades.
Collectively, these studies demonstrated that telomerase activity correlates with malignancy of
astrocytic tumors, being higher with the increasing WHO grading [83, 86, 87, 139, 145, 147, 150].
Therefore, telomerase activity and reduced telomeres should be considered a potential bio‐
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marker of aggressive behaviour of these neoplasms. Conversely, low grade astrocytomas are
usually telomerase-negative and have compatible or elongated telomeres as compared to nor‐
mal brain tissue [83, 86, 139, 145, 149]. In these tumors, the only telomere length maintenance
mechanism is represented by ALT [149, 150]. Henson et al [149] and Slatter and collegues [150]
documented that ALT phenotype is associated to elongated telomeres and it is more frequent in
low grade astrocityc tumors as compared to GBMs. Moreover, Hakin-Smith and collegues [148]
demonstrated that, despite the ALT phenotype associated to elongated telomeres is rarely
documented in GBMs, when present it is associated to a longer survival, suggesting its possible
role as a positive prognostic markers in GBMs. These findings can be explained considering the
biological role of telomeres. In normal tissues as in neoplastic cells, telomeres undergo progres‐
sive shortening during each cell replication. When telomeres are critically shortened, the cell
cannot preserve anymore its own chromosomic ends and goes toward cell crisis and subse‐
quent apoptosis. Therefore, telomeres represent the biologic clock of cells and constitute one of
the most important structure that can preserve cells from senescence. This is the reason why tu‐
mor cells need a robust telomere maintenance mechanism to allow an high replicative activity,
escaping from cell death. It is well known that high grade brain tumors are malignant neo‐
plasms with an high replicative activity. Consequently, they need a mechanism of telomere
maintenance that allows cell division avoiding excessive telomere shortening that can deter‐
mine cell death. Telomerase seems to accomplish this role with success, especially in high grade
tumors. This can be the explanation of the higher telomerase activity found in brain tumors with
the increasing of WHO grading. Hence, the highest levels of telomerase expression are found in
GBMs. Conversely, low grade astrocytic tumor have a slow replication rate and thus they does
not need telomerase. According to the aforementioned studies, in these tumors the slow grow‐
ing rate is accompanied by a sluggish cell division rate. This can be the reason why the most part
of the studies in the literature documents elongated telomeres in low grade tumors. In these ne‐
oplasms, the main telomere length maintenance mechanism is represented by ALT. Being spe‐
cific of benign or slightly aggressive tumors, ALT and elongated telomere are associated to a
better survival [149, 150] even if these features are found in a low percentage of high grade brain
tumors, such as GBMs [148]. When low grade tumors progress to higher grade, the increasing
replicative activity causes a progressive telomere shortening. In this condition, the only way to
escape from cell death is the activation of telomerase activity. This is typically observed in pro‐
gression GBMs [139].
In summary, high telomerase activity and reduced telomere seem to be features of high grade
astrocytic tumors, whereas elongated telomeres and ALT phenotype are specific of low grade
ones and, therefore, correlates with a better prognosis.
Different studies have also been performed to analyze the role of the Shelterin proteins in the
pathophysiology of several neoplasms, including brain tumors. Telomere-specific DNA-
binding proteins, such as TRF1, have been put forward as additional candidates for the role
of molecules modifying telomerase activity, and they have been suggested to play key roles
in the maintenance of telomere function [41, 55, 56]. It has been demonstrated that overex‐
pression of TRF1 inhibits telomere elongation in telomerase-positive cells [151], resulting in
gradual and progressive telomeres shortening to the “mortality stages,” the proliferative
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tissues in low-grade astrocytomas, suggesting that telomerase activity with shortened
telomeres correlates with the aggressive growth of high-grade gliomas.
Harada and colleagues [147] analyzed possible differences of telomerase activity and telomere
length among primary and secondary GBMs. Summarizing their findings, TRFs were always
shorter than NBT samples, but not statistically significant differences between primary and
secondary GBMs were found. Interestingly, although the latter presented significantly higher
levels of telomerase activity and hTERT expression than the former, telomere length was
anyway shorter than normal brain tissue. The authors explained this apparent discrepancy
suggesting that telomerase activation occurs late in carcinogenesis, when the high replication
rate of tumor cells already caused telomeres shortening. At this point, activation of telomerase
represents the principal mechanism to escape from apoptosis and cell death. Conversely, in
primary GBMs, shorter telomere length can be explained by a reduced telomerase activity that
might have less influence on carcinogenesis and, hence, other unknown factors might facilitate
their cellular immortality.
Although the vast majority of the researches have been performed focusing their attention to
telomere length and telomerase expression in astrocytic gliomas, recently several studies
showed an increasing interest also to the analysis of the relation between ALT mechanism,
telomere length and patients prognosis.
The presence of elongated telomeres and of an alternative mechanism of telomere length
maintenance (ALT) was demonstrated to be associated to a better prognosis in patients affected
by GBMs by Hakin-Smith et al. in 2003 [148]. Their work represents the first report describing
the relationship among ALT pattern, telomere length, and prognosis in human GBMs. In this
study, the authors analyzed telomerase activity and telomere lengths in 77 GBM patients. ALT
phenotype patients had a median survival of 542 days compared with 247 days in those
without the ALT phenotype. Moreover, ALT phenotype was associated with elongated
telomeres, benign biology and better prognosis. Therefore, the presence of ALT could be a
positive prognostic marker in glioblastoma multiforme.
The first study that analyzed the ALT prevalence among different grades of astrocytic tumors
was performed by Henson and coworkers in 2005. In their study, the authors analyzed the
prevalence of ALT phenotype and telomerase activity in a series of 40 astrocytomas, composed
by 7 WHO grade II-III astrocytomas and 33 GBMs. This study showed for the first time that
the prevalence of ALT associated to elongated telomeres is significantly higher in grade II to
III astrocytomas as compared to GBMs.
On the basis of Henson’s results, in 2010 Slatter and collegues conducted a study focusing on
the analysis of ALT prevalence in a series of 48 astrocytic tumors from grade I to IV. In
agreement with previous studies by Hakin-Smith and Henson [148, 149], ALT phenotype was
more frequent in low grade astrocityc tumors, whereas telomerase activity was prevalent in
the higher grades.
Collectively, these studies demonstrated that telomerase activity correlates with malignancy of
astrocytic tumors, being higher with the increasing WHO grading [83, 86, 87, 139, 145, 147, 150].
Therefore, telomerase activity and reduced telomeres should be considered a potential bio‐
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marker of aggressive behaviour of these neoplasms. Conversely, low grade astrocytomas are
usually telomerase-negative and have compatible or elongated telomeres as compared to nor‐
mal brain tissue [83, 86, 139, 145, 149]. In these tumors, the only telomere length maintenance
mechanism is represented by ALT [149, 150]. Henson et al [149] and Slatter and collegues [150]
documented that ALT phenotype is associated to elongated telomeres and it is more frequent in
low grade astrocityc tumors as compared to GBMs. Moreover, Hakin-Smith and collegues [148]
demonstrated that, despite the ALT phenotype associated to elongated telomeres is rarely
documented in GBMs, when present it is associated to a longer survival, suggesting its possible
role as a positive prognostic markers in GBMs. These findings can be explained considering the
biological role of telomeres. In normal tissues as in neoplastic cells, telomeres undergo progres‐
sive shortening during each cell replication. When telomeres are critically shortened, the cell
cannot preserve anymore its own chromosomic ends and goes toward cell crisis and subse‐
quent apoptosis. Therefore, telomeres represent the biologic clock of cells and constitute one of
the most important structure that can preserve cells from senescence. This is the reason why tu‐
mor cells need a robust telomere maintenance mechanism to allow an high replicative activity,
escaping from cell death. It is well known that high grade brain tumors are malignant neo‐
plasms with an high replicative activity. Consequently, they need a mechanism of telomere
maintenance that allows cell division avoiding excessive telomere shortening that can deter‐
mine cell death. Telomerase seems to accomplish this role with success, especially in high grade
tumors. This can be the explanation of the higher telomerase activity found in brain tumors with
the increasing of WHO grading. Hence, the highest levels of telomerase expression are found in
GBMs. Conversely, low grade astrocytic tumor have a slow replication rate and thus they does
not need telomerase. According to the aforementioned studies, in these tumors the slow grow‐
ing rate is accompanied by a sluggish cell division rate. This can be the reason why the most part
of the studies in the literature documents elongated telomeres in low grade tumors. In these ne‐
oplasms, the main telomere length maintenance mechanism is represented by ALT. Being spe‐
cific of benign or slightly aggressive tumors, ALT and elongated telomere are associated to a
better survival [149, 150] even if these features are found in a low percentage of high grade brain
tumors, such as GBMs [148]. When low grade tumors progress to higher grade, the increasing
replicative activity causes a progressive telomere shortening. In this condition, the only way to
escape from cell death is the activation of telomerase activity. This is typically observed in pro‐
gression GBMs [139].
In summary, high telomerase activity and reduced telomere seem to be features of high grade
astrocytic tumors, whereas elongated telomeres and ALT phenotype are specific of low grade
ones and, therefore, correlates with a better prognosis.
Different studies have also been performed to analyze the role of the Shelterin proteins in the
pathophysiology of several neoplasms, including brain tumors. Telomere-specific DNA-
binding proteins, such as TRF1, have been put forward as additional candidates for the role
of molecules modifying telomerase activity, and they have been suggested to play key roles
in the maintenance of telomere function [41, 55, 56]. It has been demonstrated that overex‐
pression of TRF1 inhibits telomere elongation in telomerase-positive cells [151], resulting in
gradual and progressive telomeres shortening to the “mortality stages,” the proliferative
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barriers that lead to a non-dividing state and cell death [24, 151, 152]. The mutation or deletion
of TRF1 can result in telomere elongation and extend cell survival [151]. Overexpression of a
dominant negative TRF1, which removes endogenous TRF1 from telomeres, results in
telomere lengthening in telomerase-positive cells [151] [153]. Therefore, the expression of TRF1
is considered a physiological homeostatic mechanism that controls the proliferative potential
of normal cells by inhibiting the activity of telomerase [151].
It has been demonstrated that TRF1 is expressed in astroglial brain tumors of different grades,
whereas it is not expressed in normal brain tissue. Such expression decreases from low-grade
through high grade astrocytomas [123]. This finding may suggest that the loss of TRF1
expression capability, being the result of down- regulation of TRF1 expression in malignant
gliomas cells, may play a role in the cell immortalization of astroglial brain tumors.
Furthermore, according to the role of telomerase in the elongation of telomeres in high grade
astrocytic tumors, several studies suggested its possible role as molecular target for new
therapeutic strategies. Marian et al demonstrated that the telomerase antagonist Imetelstat
efficiently targets glioblastoma tumor-initiating cells leading to a decreased proliferation and
tumor growth [154]. Gurung and collegues showed that Thymoquinone induces telomere
attrition, DNA damage, cell cycle arrest and apoptosis in the glioblastoma cells by inhibiting
the activity of telomerase [155]. Lin et al documented that Butylidenephthalide (BP) inhibits
proliferation and induces senescence in human glioblastomas by downregulating hTERT
expression and consequently telomerase activity [156]. From this perspective, telomerase
represent a promising target for new specific therapeutic approaches for the personalized
treatment of telomerase-positive high grade astrocytic tumors.
5.2. Ependymomas, oligodendrogliomas and mixed tumors
Ependymomas are tumors that arise from ependymal cells lining the cerebral ventricles and
the central canal of the spinal cord. They represent the 5-6% of intracranial gliomas ( 69% occur
in children) and 60% of spinal cord gliomas ( 96% occur in adult) [157]. In pediatrics they are
usually intracranial (the most common localization is the posterior fossa), whereas in adults
they tend to be spinal. The treatment of choice is the radical surgical excission followed by
radiotherapy (XRT), whereas the role of chemotherapy is very limited. The operative mortality
is 5-8%, the 5 year survival is 20-30% in pediatrics and 80% in adults [158, 159].
Data on telomeric alterations in adult and pediatric intracranial ependymomas are slightly
inhomogeneous. In 2008 Ridely et al. performed an analysis of telomere length in a series of
21 primary and recurrent pediatric intracranial ependimomas from 7 patients (6 primary
tumors and 15 recurrences) [84]. Telomerase activity was detected in 19 tumors (86%), and
particularly it was evident in 11 of 14 primary tumors and in all recurrent tumors. Mean
telomere length ranged from 7.3 to 16.7 kb, with telomere maintenance observed in five of
seven patients (71%). Of these five cases, four showed telomere lengthening and one had
compatible TRFs in relapsed tumors as compared to the primary tumor. Conversely, telomere
shortening occurred in two of seven recurrent cases (29%).
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The authors concluded that variable TRFs length and evidence for telomerase-mediated
telomere maintenance were present in the majority of pediatric ependymoma recurrent cases
(71%), whereas TRFs shortening was evident in a minority (29%). These results implicate
telomerasemediated telomere maintenance as a key mechanism facilitating tumor progression
in pediatric ependymoma.
This was demonstrated by the fact that all recurrent tumors analyzed were telomerase positive,
although telomere length was reduced only in small percentage of cases.
In the same year, Tabori et al evaluated TRFs length in a series of 26 pediatric intracranial
ependymomas (grade II and III), analyzing an eventual correlation with patients’ prognosis
[85]. Telomerase activity was detected in 73% of tumor samples but TRFs length was widely
variable (mean 6.5 kb,range 3.6–9.1 kb). Based on these findings, although ependymomas rely
predominantly on telomerase activity to maintain their telomere length, the authors concluded
that there was no correlation between telomere length and telomerase expression or survival.
Although it seems to emerge that the majority of intracranial ependymomas (especially in
children) shows telomerase activity, telomere length appears to be widely variable. Therefore,
there is a lack of a firm correlation of telomere length with telomerase expression that do not
allows to get definitive conclusions about their possible role as prognostic marker in these
neoplasms. It is more probable that these findings reflect an high molecular variability of
intracranial ependymomas.
Oligodendrogliomas arise from oligodendroglia cells. They represent 25-33% of glial tumors
[160, 161] and have an incidence peak at 40 years, with a smaller earlier peak in childhood
between 6-12 years [162]. They show a slight preference for male, with a male-female ratio of
3:2. In 90% of cases they are supratentorial. Surgery is the treatment of choice; chemotherapy
is recommended, whereas XRT is suggested only for anaplastic variants [163]. The median
survival for surgically treated lesions is 35 months [164], although the ten-year survival is
about 10-30% [165]. According to Nurnberg [82] and Hiraga [139], oligodendrogliomas seem
to have compatible or longer telomeres than normal brain tissues and detectable telomerase
activity. The lack of reduced telomeres in telomerase positive tumor samples can be consid‐
ered a marker of the less aggressive behavior of such tumors.
Different results have been reported for oligoastrocytomas, that show shorter telomeres than
normal brain tissue associated to high telomerase activity [86]. This pattern is more frequent
in the anaplastic variant, confirming the role of telomerase activity associated to reduced te‐
lomeres as markers of aggressive behavior in these neoplasms as in astrocytic gliomas[139].
5.3. Meningiomas
Meningiomas are extra-axial, usually benign tumors with a slow growing rate that arise from
arachnoid cells. They account for 34% of all primary brain and CNS tumors [146]. The incidence
peak is at 45 years with a male-female ratio of 1:2,2. About 1.5% occur in childhood and
adolescence between 10-20-yeras age [166]. Surgery is the treatment of choice for symptomatic
meningiomas and the five-year survival is 91.3% [167].
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barriers that lead to a non-dividing state and cell death [24, 151, 152]. The mutation or deletion
of TRF1 can result in telomere elongation and extend cell survival [151]. Overexpression of a
dominant negative TRF1, which removes endogenous TRF1 from telomeres, results in
telomere lengthening in telomerase-positive cells [151] [153]. Therefore, the expression of TRF1
is considered a physiological homeostatic mechanism that controls the proliferative potential
of normal cells by inhibiting the activity of telomerase [151].
It has been demonstrated that TRF1 is expressed in astroglial brain tumors of different grades,
whereas it is not expressed in normal brain tissue. Such expression decreases from low-grade
through high grade astrocytomas [123]. This finding may suggest that the loss of TRF1
expression capability, being the result of down- regulation of TRF1 expression in malignant
gliomas cells, may play a role in the cell immortalization of astroglial brain tumors.
Furthermore, according to the role of telomerase in the elongation of telomeres in high grade
astrocytic tumors, several studies suggested its possible role as molecular target for new
therapeutic strategies. Marian et al demonstrated that the telomerase antagonist Imetelstat
efficiently targets glioblastoma tumor-initiating cells leading to a decreased proliferation and
tumor growth [154]. Gurung and collegues showed that Thymoquinone induces telomere
attrition, DNA damage, cell cycle arrest and apoptosis in the glioblastoma cells by inhibiting
the activity of telomerase [155]. Lin et al documented that Butylidenephthalide (BP) inhibits
proliferation and induces senescence in human glioblastomas by downregulating hTERT
expression and consequently telomerase activity [156]. From this perspective, telomerase
represent a promising target for new specific therapeutic approaches for the personalized
treatment of telomerase-positive high grade astrocytic tumors.
5.2. Ependymomas, oligodendrogliomas and mixed tumors
Ependymomas are tumors that arise from ependymal cells lining the cerebral ventricles and
the central canal of the spinal cord. They represent the 5-6% of intracranial gliomas ( 69% occur
in children) and 60% of spinal cord gliomas ( 96% occur in adult) [157]. In pediatrics they are
usually intracranial (the most common localization is the posterior fossa), whereas in adults
they tend to be spinal. The treatment of choice is the radical surgical excission followed by
radiotherapy (XRT), whereas the role of chemotherapy is very limited. The operative mortality
is 5-8%, the 5 year survival is 20-30% in pediatrics and 80% in adults [158, 159].
Data on telomeric alterations in adult and pediatric intracranial ependymomas are slightly
inhomogeneous. In 2008 Ridely et al. performed an analysis of telomere length in a series of
21 primary and recurrent pediatric intracranial ependimomas from 7 patients (6 primary
tumors and 15 recurrences) [84]. Telomerase activity was detected in 19 tumors (86%), and
particularly it was evident in 11 of 14 primary tumors and in all recurrent tumors. Mean
telomere length ranged from 7.3 to 16.7 kb, with telomere maintenance observed in five of
seven patients (71%). Of these five cases, four showed telomere lengthening and one had
compatible TRFs in relapsed tumors as compared to the primary tumor. Conversely, telomere
shortening occurred in two of seven recurrent cases (29%).
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The authors concluded that variable TRFs length and evidence for telomerase-mediated
telomere maintenance were present in the majority of pediatric ependymoma recurrent cases
(71%), whereas TRFs shortening was evident in a minority (29%). These results implicate
telomerasemediated telomere maintenance as a key mechanism facilitating tumor progression
in pediatric ependymoma.
This was demonstrated by the fact that all recurrent tumors analyzed were telomerase positive,
although telomere length was reduced only in small percentage of cases.
In the same year, Tabori et al evaluated TRFs length in a series of 26 pediatric intracranial
ependymomas (grade II and III), analyzing an eventual correlation with patients’ prognosis
[85]. Telomerase activity was detected in 73% of tumor samples but TRFs length was widely
variable (mean 6.5 kb,range 3.6–9.1 kb). Based on these findings, although ependymomas rely
predominantly on telomerase activity to maintain their telomere length, the authors concluded
that there was no correlation between telomere length and telomerase expression or survival.
Although it seems to emerge that the majority of intracranial ependymomas (especially in
children) shows telomerase activity, telomere length appears to be widely variable. Therefore,
there is a lack of a firm correlation of telomere length with telomerase expression that do not
allows to get definitive conclusions about their possible role as prognostic marker in these
neoplasms. It is more probable that these findings reflect an high molecular variability of
intracranial ependymomas.
Oligodendrogliomas arise from oligodendroglia cells. They represent 25-33% of glial tumors
[160, 161] and have an incidence peak at 40 years, with a smaller earlier peak in childhood
between 6-12 years [162]. They show a slight preference for male, with a male-female ratio of
3:2. In 90% of cases they are supratentorial. Surgery is the treatment of choice; chemotherapy
is recommended, whereas XRT is suggested only for anaplastic variants [163]. The median
survival for surgically treated lesions is 35 months [164], although the ten-year survival is
about 10-30% [165]. According to Nurnberg [82] and Hiraga [139], oligodendrogliomas seem
to have compatible or longer telomeres than normal brain tissues and detectable telomerase
activity. The lack of reduced telomeres in telomerase positive tumor samples can be consid‐
ered a marker of the less aggressive behavior of such tumors.
Different results have been reported for oligoastrocytomas, that show shorter telomeres than
normal brain tissue associated to high telomerase activity [86]. This pattern is more frequent
in the anaplastic variant, confirming the role of telomerase activity associated to reduced te‐
lomeres as markers of aggressive behavior in these neoplasms as in astrocytic gliomas[139].
5.3. Meningiomas
Meningiomas are extra-axial, usually benign tumors with a slow growing rate that arise from
arachnoid cells. They account for 34% of all primary brain and CNS tumors [146]. The incidence
peak is at 45 years with a male-female ratio of 1:2,2. About 1.5% occur in childhood and
adolescence between 10-20-yeras age [166]. Surgery is the treatment of choice for symptomatic
meningiomas and the five-year survival is 91.3% [167].
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Benign mengiomas (WHO grade I) show a variable telomere length [82, 139, 168], sometimes
slightly shorter than normal meningeal tissue [145], whereas atypical and anaplastic menin‐
giomas show telomerase activity associated with a significant telomere length shortening [169].
This can be explained considering that the slow growth of benign meningiomas and the
absence of telomerase activity cause an equally slow shortening of telomeres, whereas the
higher replicative capacity of atypical and especially of malignant meningiomas determines a
more evident reduction of telomere length. In these settings, the activation of telomerase
activity can give to the cell the capacity to escape from senescence and, consequently, an high
proliferative strength. Therefore detectable telomerase activity and shortened telomere length
suggest that the tumor contains a cell population with the capacity for unlimited proliferation.
These results indicate that telomere shortening together with telomerase activity may be a
critical step in pathogenesis of atypical and malignant meningiomas and may correlate with
their malignant behavior. Indeed, as previously discussed for astrocytic tumors, the association
of telomerase activity with reduced telomeres length may be considered a marker of an
aggressive behavior also in meingiomas, being more frequent in atypical and malignant
meningiomas.
5.4. Schwannomas
Schwannomas are benign, usually encapsulated, peripheral nerve sheath tumor composed of
neoplastic Schwann cells that can have an intracranial or spinal localization. They account for
about 8-10% of intracranial and 25-30% of spinal tumors. The peak of incidence is between the
4th and 6th decades [146]. The vast majority of intracranial Schwannomas develops from
vestibular nerve. Tumors of trigeminal or facial nerve are far less common. Management
includes many options: surgery, wait and see strategy for little or no growth tumors, radiation
therapy alone or in conjunction with surgery, chemotherapy, radiosurgery [170].
Schwannomas usually show reduced telomeres, benign pathological features, low prolifera‐
tive indices and a lack of telomerase activity [169, 171]. These peculiarities allows such tumors
to have a benign clinical course. Conversely, rarely they can assume an aggressive behaviour
that is characterized by malignant pathological features and high replicative potential that are
usually associated to elongated telomeres. This can be explained considering that long
telomeres allow tumor cells to maintain an high proliferative capacity without the need of
telomerase activity. When the length of the telomere is long enough for proliferation, the
telomerase activity subsides.
For these reasons, telomeres elongation, even in absence of telomerase activity, can be
considered a marker of aggressive clinicopathological behaviour in schwannomas [169, 171].
5.5. Primitive Neuroectodermal Tumors (PNETS)
Primary neuroectodermal tumors (PNETs), also called embryonal tumors, represent 1 % of all
primary central nervous system (CNS) tumors. They are frequent especially in children, repre‐
senting the most frequent brain and CNS tumor in the range between 0 and 4 years old [146].
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They are highly malignant lesions and can disseminate via CSF spontaneously or iatrogenically
[172]. Extraneural metastases can also occur. Radical surgical excision is the treatment of
choice. XRT is indicated following surgical removal, but it should be avoided at all if possible
before 3 years of age to avoid intellectual impairment and growth retardation. Overall survival
rate for PNETs is substantially poor with an expected 3 year progression free survival of
approximately 50% for localized supratentorial PNETs [173].
PNETs usually show telomerase activity even if there is not a clear association with telomere
length. Despite Hiraga [139] and Rahman [174] reported reduced telomeres in the most part
of tumor samples, data from Didiano [175] document a wide variability of telomeres length.
Interestingly, Rahman reported shorter telomere length in PNETs cells than GBMs, suggesting
an higher replicative activity in the former as compared to the latter. These results underline
and explain the aggressive behaviour of neuroectodermal tumors. The same author, reported
a minority of cases with elongated telomeres and undetectable telomerase activity, suggesting
ALT as alternative mechanism of telomere maintenance in these tumors [174].
In summary, telomerase activity can be considered a marker of PNETs and can explain the
malignancy of these tumors, although there is not an evident correlation with telomere length.
Moreover, in a little percentage of cases without telomerase activity, the aggressive behaviour
of PNETs is due to ALT and is associated to elongated telomeres, that allow tumour cells to
actively replicate [175].
5.6. Pituitary adenomas
Pituitary adenomas are usually benign tumors that arise from anterior pituitary cells (adenohy‐
pophysis). They represent about 13% of primary brain and CNS tumors with an incidence peak
on 3th and 4th decades of life [146]. Treatment of pituitary adenomas include medical treatment
(dopamine agonists, somatostatin, etc), surgery (transcranial or transsphenoidal approach) or
XRT (in case of recurrence that cannot be surgically removed or treated medically).
Their usually benign behaviour can be explained with the lack of telomerase activity, although
telomere length is slightly reduced as compared to normal brain tissue [139]. Sometimes they
can recur or, rarely, they can progress to pituitary adenocarcinomas. As demonstrated by
Harada and colleagues, during progression to carcinoma, the replicative activity of tumor cells
causes a progressive shortening of telomeres and the reactivation of telomerase [176]. There‐
fore, also in pituitary adenomas, telomerase activity and reduced telomere length can be
considered marker of aggressive behaviour and can be used to predict the progression to
carcinomas.
5.7. Primary Central Nervous System Lymphomas (PCNSLs)
Primary central nervous system lymphomas (PCNSL) also known as primary brain lympho‐
mas are a primary intracranial tumors appearing mostly in patients with severe immunosop‐
pression (typically patients with AIDS). They represent the 0.5-1.2% of intracranial tumours
and less than 1 % of extranodal non-Hodgkin lymphomas (NHL), although in the last years
there was a progressive increase of incidence also in immunocompetent patients. They affect
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Benign mengiomas (WHO grade I) show a variable telomere length [82, 139, 168], sometimes
slightly shorter than normal meningeal tissue [145], whereas atypical and anaplastic menin‐
giomas show telomerase activity associated with a significant telomere length shortening [169].
This can be explained considering that the slow growth of benign meningiomas and the
absence of telomerase activity cause an equally slow shortening of telomeres, whereas the
higher replicative capacity of atypical and especially of malignant meningiomas determines a
more evident reduction of telomere length. In these settings, the activation of telomerase
activity can give to the cell the capacity to escape from senescence and, consequently, an high
proliferative strength. Therefore detectable telomerase activity and shortened telomere length
suggest that the tumor contains a cell population with the capacity for unlimited proliferation.
These results indicate that telomere shortening together with telomerase activity may be a
critical step in pathogenesis of atypical and malignant meningiomas and may correlate with
their malignant behavior. Indeed, as previously discussed for astrocytic tumors, the association
of telomerase activity with reduced telomeres length may be considered a marker of an
aggressive behavior also in meingiomas, being more frequent in atypical and malignant
meningiomas.
5.4. Schwannomas
Schwannomas are benign, usually encapsulated, peripheral nerve sheath tumor composed of
neoplastic Schwann cells that can have an intracranial or spinal localization. They account for
about 8-10% of intracranial and 25-30% of spinal tumors. The peak of incidence is between the
4th and 6th decades [146]. The vast majority of intracranial Schwannomas develops from
vestibular nerve. Tumors of trigeminal or facial nerve are far less common. Management
includes many options: surgery, wait and see strategy for little or no growth tumors, radiation
therapy alone or in conjunction with surgery, chemotherapy, radiosurgery [170].
Schwannomas usually show reduced telomeres, benign pathological features, low prolifera‐
tive indices and a lack of telomerase activity [169, 171]. These peculiarities allows such tumors
to have a benign clinical course. Conversely, rarely they can assume an aggressive behaviour
that is characterized by malignant pathological features and high replicative potential that are
usually associated to elongated telomeres. This can be explained considering that long
telomeres allow tumor cells to maintain an high proliferative capacity without the need of
telomerase activity. When the length of the telomere is long enough for proliferation, the
telomerase activity subsides.
For these reasons, telomeres elongation, even in absence of telomerase activity, can be
considered a marker of aggressive clinicopathological behaviour in schwannomas [169, 171].
5.5. Primitive Neuroectodermal Tumors (PNETS)
Primary neuroectodermal tumors (PNETs), also called embryonal tumors, represent 1 % of all
primary central nervous system (CNS) tumors. They are frequent especially in children, repre‐
senting the most frequent brain and CNS tumor in the range between 0 and 4 years old [146].
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They are highly malignant lesions and can disseminate via CSF spontaneously or iatrogenically
[172]. Extraneural metastases can also occur. Radical surgical excision is the treatment of
choice. XRT is indicated following surgical removal, but it should be avoided at all if possible
before 3 years of age to avoid intellectual impairment and growth retardation. Overall survival
rate for PNETs is substantially poor with an expected 3 year progression free survival of
approximately 50% for localized supratentorial PNETs [173].
PNETs usually show telomerase activity even if there is not a clear association with telomere
length. Despite Hiraga [139] and Rahman [174] reported reduced telomeres in the most part
of tumor samples, data from Didiano [175] document a wide variability of telomeres length.
Interestingly, Rahman reported shorter telomere length in PNETs cells than GBMs, suggesting
an higher replicative activity in the former as compared to the latter. These results underline
and explain the aggressive behaviour of neuroectodermal tumors. The same author, reported
a minority of cases with elongated telomeres and undetectable telomerase activity, suggesting
ALT as alternative mechanism of telomere maintenance in these tumors [174].
In summary, telomerase activity can be considered a marker of PNETs and can explain the
malignancy of these tumors, although there is not an evident correlation with telomere length.
Moreover, in a little percentage of cases without telomerase activity, the aggressive behaviour
of PNETs is due to ALT and is associated to elongated telomeres, that allow tumour cells to
actively replicate [175].
5.6. Pituitary adenomas
Pituitary adenomas are usually benign tumors that arise from anterior pituitary cells (adenohy‐
pophysis). They represent about 13% of primary brain and CNS tumors with an incidence peak
on 3th and 4th decades of life [146]. Treatment of pituitary adenomas include medical treatment
(dopamine agonists, somatostatin, etc), surgery (transcranial or transsphenoidal approach) or
XRT (in case of recurrence that cannot be surgically removed or treated medically).
Their usually benign behaviour can be explained with the lack of telomerase activity, although
telomere length is slightly reduced as compared to normal brain tissue [139]. Sometimes they
can recur or, rarely, they can progress to pituitary adenocarcinomas. As demonstrated by
Harada and colleagues, during progression to carcinoma, the replicative activity of tumor cells
causes a progressive shortening of telomeres and the reactivation of telomerase [176]. There‐
fore, also in pituitary adenomas, telomerase activity and reduced telomere length can be
considered marker of aggressive behaviour and can be used to predict the progression to
carcinomas.
5.7. Primary Central Nervous System Lymphomas (PCNSLs)
Primary central nervous system lymphomas (PCNSL) also known as primary brain lympho‐
mas are a primary intracranial tumors appearing mostly in patients with severe immunosop‐
pression (typically patients with AIDS). They represent the 0.5-1.2% of intracranial tumours
and less than 1 % of extranodal non-Hodgkin lymphomas (NHL), although in the last years
there was a progressive increase of incidence also in immunocompetent patients. They affect
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all age groups, but are most commonly diagnosed in people who are over 50 years of age.
Histologically they are a form of extranodal, high-grade non-Hodgkin lymphoma. Most
PCNSLs (about 90%) are diffuse large B-cell lymphomas (DLBCLs); the remaining 10% are
poorly characterized low-grade lymphomas, Burkitt lymphomas, and T-cell lymphomas [177].
PCNSLs originate inside the CNS and typically remain confined, rarely spreading outside the
nervous system. Although the origin cells are lymphocytes, PCNSLs can be assimilated to brain
tumors for their intracranial localization and relationship with brain parenchyma and brain
blood barrier that gives PCNSLs the same therapeutic challenges (i.e. in terms of drug delivery
through the blood brain barrier) of the other brain tumors.
Data from the literature demonstrate that in PCNSLs have variable telomere length, usually
reduced as compared with normal brain tissue, and show high telomerase activity [139, 178].
Harada et al demonstrated a statistically significant correlation between telomerase activity
and the survival period of patients with PCNSL. In particular, patients with high telomerase
activity had poor prognosis and short survival, regardless of telomere length [178].
These findings suggest that telomerase activity represents a common features in PCNSLs and
can be considered by itself a marker for predicting a poor prognosis, regardless of telomeres
length, the age at onset and the KPS score before the initial treatment. Nevertheless, telomeres
are usually shortened in these tumors and this can explain the aggressive behavior of such
tumors, even if the association with patients’ survival has not been demonstrated.
5.8. Other intracranial tumors
Only few studies have been performed focusing on the analysis of telomere length and
telomerase activity among less common non-neuroepithelial tumors, such as hemangioblas‐
tomas, hemangioperycitomas and germ cell tumors.
Hemangioblastomas are benign tumors that usually show normal telomere length and
undetectable telomerase activity. Nevertheless, the rare cases of hemangioblastomas with
aggressive behavior show shorter telomeres than normal brain tumors and are telomerase-
positive [139].
Conversely, malignant non-neuroepithelial tumors such as hemangioperycitomas and germ
cell tumors, usually show high telomerase activity associated to an important shortening of
telomere length [139].
This suggest that, also for these rare non-neuroepithelial brain tumors, telomerase activity
associated to reduced telomere length can be considered a marker of malignancy.
6. Conclusions
There is a desperate need for developing innovative diagnostic tools and therapies for brain
tumors.
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According to their role in the regulation of cell replication and senescence, telomeres and
telomeric proteins represent a new interesting research field to better understand the altera‐
tions responsible of carcinogenesis and malignant progression of human brain tumors. In these
settings, elucidation of telomeres biology represents the new frontier of cancer research.
Although a lot of studies have already been focused on this promising field, further studies
should be performed to better understand the pathways involved in the telomeres length
maintenance and, consequently, in the process of carcinogenesis and malignant progression
of human brain tumors, in order to discover new diagnostic/prognostic tools or new thera‐
peutic strategies for improving prognosis of patients affected by these terrible neoplasms.
Acknowledgements
The study was financed by COFIN 2008 prot. 2008979M8K-001 by Italian Ministry of Univer‐
sity and Research
Author details
Domenico La Torre1*, Giovanni Raffa1, Chiara Tomasello2, M’Hammed Aguennouz1 and
Antonino Germanò1
*Address all correspondence to: dlatorre@unime.it
1 Department of Neurosciences, University of Messina, Messina, Italy
2 Department of Medical Oncology, University of Messina School of Medicine, Messina, Italy
References
[1] Bondy, M. L, Scheurer, M. E, Malmer, B, Barnholtz-sloan, J. S, & Davis, F. G. Il’yaso‐
va D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiolo‐
gy Consortium. Cancer (2008). Suppl) , 1953-68.
[2] Blackburn, E. H. Structure and function of telomeres. Nature (1991). , 350(6319),
569-73.
[3] Wright, W. E, & Shay, J. W. Time, telomeres and tumours: is cellular senescence more
than an anticancer mechanism? Trends in cell biology (1995). , 5(8), 293-7.
[4] Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? Mutation research
(1991).
Telomeres and Brain Tumors
http://dx.doi.org/10.5772/52426
341
all age groups, but are most commonly diagnosed in people who are over 50 years of age.
Histologically they are a form of extranodal, high-grade non-Hodgkin lymphoma. Most
PCNSLs (about 90%) are diffuse large B-cell lymphomas (DLBCLs); the remaining 10% are
poorly characterized low-grade lymphomas, Burkitt lymphomas, and T-cell lymphomas [177].
PCNSLs originate inside the CNS and typically remain confined, rarely spreading outside the
nervous system. Although the origin cells are lymphocytes, PCNSLs can be assimilated to brain
tumors for their intracranial localization and relationship with brain parenchyma and brain
blood barrier that gives PCNSLs the same therapeutic challenges (i.e. in terms of drug delivery
through the blood brain barrier) of the other brain tumors.
Data from the literature demonstrate that in PCNSLs have variable telomere length, usually
reduced as compared with normal brain tissue, and show high telomerase activity [139, 178].
Harada et al demonstrated a statistically significant correlation between telomerase activity
and the survival period of patients with PCNSL. In particular, patients with high telomerase
activity had poor prognosis and short survival, regardless of telomere length [178].
These findings suggest that telomerase activity represents a common features in PCNSLs and
can be considered by itself a marker for predicting a poor prognosis, regardless of telomeres
length, the age at onset and the KPS score before the initial treatment. Nevertheless, telomeres
are usually shortened in these tumors and this can explain the aggressive behavior of such
tumors, even if the association with patients’ survival has not been demonstrated.
5.8. Other intracranial tumors
Only few studies have been performed focusing on the analysis of telomere length and
telomerase activity among less common non-neuroepithelial tumors, such as hemangioblas‐
tomas, hemangioperycitomas and germ cell tumors.
Hemangioblastomas are benign tumors that usually show normal telomere length and
undetectable telomerase activity. Nevertheless, the rare cases of hemangioblastomas with
aggressive behavior show shorter telomeres than normal brain tumors and are telomerase-
positive [139].
Conversely, malignant non-neuroepithelial tumors such as hemangioperycitomas and germ
cell tumors, usually show high telomerase activity associated to an important shortening of
telomere length [139].
This suggest that, also for these rare non-neuroepithelial brain tumors, telomerase activity
associated to reduced telomere length can be considered a marker of malignancy.
6. Conclusions
There is a desperate need for developing innovative diagnostic tools and therapies for brain
tumors.
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According to their role in the regulation of cell replication and senescence, telomeres and
telomeric proteins represent a new interesting research field to better understand the altera‐
tions responsible of carcinogenesis and malignant progression of human brain tumors. In these
settings, elucidation of telomeres biology represents the new frontier of cancer research.
Although a lot of studies have already been focused on this promising field, further studies
should be performed to better understand the pathways involved in the telomeres length
maintenance and, consequently, in the process of carcinogenesis and malignant progression
of human brain tumors, in order to discover new diagnostic/prognostic tools or new thera‐
peutic strategies for improving prognosis of patients affected by these terrible neoplasms.
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1. Introduction
Cytogenetics is the branch of genetics that studies the cell activity focusing mainly on the
chromosome structure, organization and function, isolated or as the whole karyotype, in order
to understand aspects of cell biology, evolution or implicated diseases. The behavior of DNA
and genes is greatly constrained by the fact that they are incorporated into chromosomes. The
DNA is associated with proteins that control and catalyze the processes of transcription and
replication. Gene expression is controlled by modifications in histones and by chromatin
remodeling complexes. It can also be influenced by the position of the gene in the chromosome.
Hence, errors in chromosome behavior are an important cause of ill-health. The presence of
chromosomal abnormalities is usual in cancer, and specific chromosome abnormality may
often be one of the first events in the development of cancer [1]. The importance of cytogenetic
analysis in oncology is demonstrated by the number of researches made on this area since the
discovery of the Philadelphia chromosome, a 9/22 translocation, which is seen in chronic
myelogenous leukemia (CML) patients [2]. The focus of these studies is the relation between
specific chromosome alterations to prognosis, drug resistance and diagnosis for some tumors
entities. Moreover, DNA repair problems and others genomic stability pathways defects may
lead to genome-wide genetic instability, which can drive further cancer progression [3].
Although chromosome rearrangements are mainly used as markers in hematologic cancers,
these alterations have been increasingly studied in solid tumors (90% of all human malignan‐
cies), showing that chromosomal numerical/structural aberrations are common in this kind of
neoplasia.
Brain cancers are very diverse solid tumors that demonstrate a wide range of complex
karyotypes. The chromosomal features of each tumor can provide information that helps in
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clinical decisions, stratifying it in low and high risk in complementation to the grading aspects
usually considered to the central nervous system (CNS) cancers [4]. On this chapter we will
consider the implications of the presence of some chromosome mutations for specifics brain
tumors. How can these specific alterations help in risk stratification? How these aberrations
influence on the choice of treatment? What these rearranged chromosomes indicate about
recurrence, metastasis, overall survival or resistance? Obviously, chromosomal mutations
have many implications to the cell behavior, affecting the gene dosage by a deletion or
amplification, or driving the formation of chimerical transcripts because of chromosomal
translocations, etc. Each chromosomal rearrangement has an effect in gene expression or global
metabolic equilibrium of the cells. The variety of chromosomal rearrangements is great,
involving numerical and structural, and also including very specific types found mainly in
cancer, such as double minutes (DMs) and homogeneously staining regions (HSRs), which
correspond to gene amplifications (Figure 1).
The importance of chromosomal studies in brain tumors is highlighted by the fact that the
most recent World Health Organization’s (WHO) book of the CNS neoplasm classification [4]
has improved the knowledge about the tumors entities with molecular and cytogenetic
markers that, together with the histopathology features, helps in identifying, stratifying or
understanding the behavior of tumors.
Figure 1. Amplification represents one of the major molecular pathways through which the oncogenic potential of
proto-oncogenes is activated during tumorigenesis. In the example, MYCN (a MYC family gene) on 2p24.3 is showed
amplified by two different mechanisms: extra-chromosomal amplifications (double minutes – DM), and intrachromo‐
somal amplifications (Homogeneously Staining Region (HSR).
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2. Cytogenetics and cancer
The idea that chromosomal rearrangements might be causally involved in early stages of
carcinogenesis is not new. The first reports hypothesizing that karyotypic aberrations, typical
of tumor cells, may possibly be involved in the transformation of normal cells into malignant
ones was published more than a century ago by Theodor Boveri [5] in 1914. Although limited
by the poor techniques and the restricted knowledge of cell biology, those early findings
allowed him to formulate what is now known as the somatic mutation theory of cancer, which
still holds the central stage of cancer research [6]. Because cancer cells usually exhibit abnormal
karyotypes, a number of questions have emerged: are these abnormal chromosomes a cause
or a consequence of tumorigenesis? Can a single gene mutation drive the neoplastic transfor‐
mation? One assumption is correct: Some cytogenetic alterations have demonstrated that they
are directly linked to tumor formation, progression or metastases, as they are found since the
very beginning of tumorigenesis. The observation that some genes affected by chromosomal
rearrangements were involved in critical stages in cell growth, development, or survival has
focused the interest on how these rearrangements alter the function of target genes. These
studies have led to a better understanding of origin of chromosomal alterations and their role
in cancer development.
It is widely accepted that the process of tumorigenesis is initiated by an acquired muta‐
tion that  confers  a  selective advantage on a  dividing cell.  This  mutated cell  will  be  ex‐
posed  to  new  mutations  and  each  new  mutation  will  be  passible  of  a  new  round  of
Darwinian selection [7]. The cell genome is far from stable, with intrinsic errors in repli‐
cation,  checkpoint,  repair,  apoptosis,  chromosome segregation,  recombination,  etc.  Some
of these mutations can guide to chromosomal instability (CIN) and consequently to high‐
er  tendency  to  cancer  formation  [8],  a  situation  well  illustrated  in  patients  with  repair
process mutation syndromes, such as Xeroderma Pigmentosum and Fanconi anemia, which
are associated with an increased risk of cancer.
Albertson and coworkers [9] affirmed that the importance of chromosomal aberrations to
tumor development varies substantially between tumors. While there are some tumors with
marked chromosome rearrangements, others may evolve by mechanisms that result in little
chromosomal change. The difference resides on tumor initiation or the manner in which
genome instability is formed. In the same way, the ratio of chromosome rearrangement is
accompanied by the malignant stage evolution of a neoplasm, and those pre-malignant tumors
show few chromosomal aberrations, which are substantially increased on the malignant ones,
supporting a role in chromosomal aberration acquisition in tumor progression. An important
advance in the study of chromosomal rearrangements, especially aneuploidy, was the
discovery that many cancer cell lines exhibit CIN, a phenotype in which cell division is
accompanied by an abnormally high rate of chromosome loss and gain. Thus, CIN can be
considered as one form of genomic instability, along with elevated rates of mutation, errors in
DNA repair and somatic hyperrecombination [10, 11].
Many studies have also focused on the elucidation of the differential response to treatment of
cancers from the same histological classification. Because resistance for multiple drugs cannot
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be explained solely in the light of gene mutation, Duesberg and coworkers [12] developed a
theory in which they affirm that the dynamic evolution of karyotypes in cancers cells can be
responsible for resistance acquisition to most drugs utilized on treatments of cancers. This
karyotype evolution is derived by rounds of chromosome mutations facilitated by CIN,
followed by Darwinian selection which increases oncogenic functions in cells. It can explain
the rapid evolution of a tumor to gain resistance to drugs administrated on the chemotherapy
transforming itself autocatalytically. The natural selection drives the constitution of some
chromosome mutation to give a selective advantage to cell not only in growth but also in
resistance to drugs and other features of the cancer environment. It is not surprising that the
presence of chromosomal abnormalities in malignancies has been pivotal in the discovery of
targeted therapy against cancer cells, or in discriminating patients sensitive or insensitive to
traditional or new therapies [8]. Today we can say that chromosome abnormalities can be used
as markers in many different types of malignancy in the cases when it is observed that specific
rearrangements are found in tumors with a certain behavior or grade. In many different kinds
of tumors, the presence of a specific chromosomal abnormality has improved the quality of
the diagnosis, allowing a clearer definition of the prognosis and permitting the definition of
new targets on cancer therapy.
The origin and progression of cancer always were unsolved questions to majority of tumor
types. Li and coworkers [13] accompanied the chromosomal alterations in human cell lineages
for many generations after transformation by SV40 aneuploidogenics genes. They proposed a
theory in which cancer-causing karyotypes represent chromosomal equilibria between
destabilizing aneuploidy and stabilizing selection for oncogenic function. Furthermore, they
concluded that karyotypes are more likely to initiate and maintain cancers than specific gene
mutations (Figure 2). One of the great questions concerns the quasi-stable karyotype observed
in different passages of a long time cultured cell lineage or between different samples of the
same tumor type versus de CIN observed on cancer cells. The answer comes from the Dar‐
winian selection to give oncogenic function to cell, much like new species. Thus, this tumor
karyotype increases and maintains the CIN and can form nonneoplastic and nonviable
karyotypic compositions which will be eliminated (Figure 2: B, C and D); however, it can evolve
to a karyotype that provides new capability to cells such as drug-resistance or metastasis
(Figure 2: C, D and E). So, they defined two steps to cancer initiation: 1) the chromosomal
instability initiation by carcinogens that generate random aneuploidy and 2) the karyotype
Darwinian selection to give oncogenic function, that emerge from unstable randomly aneu‐
ploid karyotypes. In our opinion, Li’s theory of cancer-causing karyotypes is very concise and
is supported by different studies. Routine cancer cell culture experience demonstrates easily
that tumor samples show different karyotypic compositions, with clonal structural or numer‐
ical chromosomal abnormalities, which are examples of CIN with the so called selection for
oncogenic function. In complementation, oncogenic chromosomal compositions can be
maintained quasi-stable in distant passages of a cancer cell culture.
The recognition of the importance of cytogenetic science to cancer surveillance has accompa‐
nied the technological development of microscopy, computer image acquisition’s software
and fluorochrome applications. Although chromosome-banding is still the gold standard for
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all routine techniques of clinical and tumor cytogenetics, the technical restrictions of this
methodology are well known. Only changes that affect the normal pattern such as size var‐
iations or position in a chromosomal band or the chromosome itself can be detected, and the
origin of additional material or gain/loss of small amounts in a structurally altered chromo‐
some often remains questionable. To overcome such limitations, fluorescence in situ hybridi‐
zation (FISH) approaches were introduced into cytogenetics. FISH is a technique based on
the probe-sample hybrid formation labeled with a detectable fluorescent dye. It is a reliable
technique that has made a revolution to chromosome mutation detection. Many other tech‐
niques have derived from FISH: Interphase FISH, chromosome region specific FISH (telo‐
mere, centromere, etc.), multicolor FISH, SKY, Multiplex-FISH, CGH, array-CGH,
microarray-CGH, FISH banding, etc. In general, these techniques are very informative and
can be utilized in complementation to those classical clinical histopathology diagnostic pro‐
cedures.
Figure 2. Li's theory of cancer-causing karyotypes. (A) Cells with CIN (gray cells) generate karyotypes with oncogenic
functions (dark gray cell). (B) Cells with oncogenic functions will develop and grow forming nonneoplastic and nonvia‐
ble cells (pink cells), which will be continually generated and eliminated (C and D). However, some karyotypes evolve
to more aggressive behavior, like metastatic or drug-resistance cells (blue cells) which can migrate to others sites (C, D
and E).
Some of these techniques, such as SKY, M-FISH or CGH-based methodologies (Figure 3), are
able to show all chromosomal alterations of a sample in a single experiment, each respecting
its limitation, of course. SKY and M-FISH (Figure 3A) can differently dye every chromosome
pair in a metaphase spread of a tumor sample, using five different fluorochromes in 24 distinct
combinations (22 autosomes, X and Y). These techniques allow the definition of the origin of
each chromosome segment involved in rearrangement, but cannot indicate microdeletions or
the gain/loss of specific loci. The CGH-based methodologies (Figure 3B) use only two different
fluorochromes, for cancer and negative control, showing all losses, gains and amplifications
in a tumor sample. These technological advances had led to an exponential increase on the
number of patients cytogenetically analyzed. After decades of cancer genome and karyotype
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analysis, is estimated that 14% (about 3000) of the human genes are involved on cancer
formation and progression [8], and the quantity of chromosome alterations involved is equally
large. Therefore, some web tools were created to permit a faster search of these genic and
chromosomal mutations on cancer for specific entities, as for example the “Mitelman Catalog
of chromosomal alterations” [14].
Figure 3. Whole-genome analysis of a tumor cell can be obtained by (A) M-FISH, SKY or (B) CGH methodologies. (A)
SKY or M-FISH utilizes a pool with 24 differently labeled chromosomes with a combination of five distinct fluoro‐
chromes to show all chromosomal rearrangements in a metaphase, including structural and numerical rearrange‐
ments and markers chromosome. (B) CGH utilizes two different DNA probes, from tumor and from a control
nonneoplastic sample, to hybridize onto a spread metaphase, or more recently in a slide array, to demonstrate DNA
loss, gain or amplification in the tumor sample.
Further down we will list some of the new and well established correlations between brain
tumors entities clinical behavior and some specific chromosome abnormalities. Some of the
imbalances were correlated with particular pathways or genic imbalances, others have no well-
established correlation with a specific gene function disturbance or cell pathways modifica‐
tions, although are systematically found in some brain tumor types.
3. Brain tumors
Brain tumors are the second most common type of cancer in children and are associated with
poor survival both in infants and adults, representing, therefore, a heavy burden for the
patients and their relatives [15]. These tumors can be devastating because they are difficult to
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treat, and frequently cause mental impairment or death. The incidence of brain tumors has
increased during the past three decades for all age and gender groups as a result of imaging
with computed tomography (CT) and magnetic resonance imaging (MRI), lymphomas
secondary to HIV/AIDS, and changes in coding and classification [16]. With the exception of
meningiomas and pituitary adenomas, women are less likely than men to be diagnosed with
a brain tumor, particularly glioblastoma multiforme and anaplastic astrocytoma, as well as
medulloblastomas. The lifetime risk of contracting a primary malignant brain tumor is 0.52%
for women and 0.67% for men. Similarly, the chance of dying from a malignant brain tumor
is 0.40% for women and 0.49% for men. There have been growing amount of studies dedicated
to detecting chromosomal imbalances and intercellular genomic variations both in benign and
malign brain tumors. Currently, it is suggested that almost all the chromosomes are involved
in aberrations associated with brain tumorigenesis [17]. Moreover, some specifics chromosome
structures can differentiate the tumor grades, in accordance to WHO classification, simply by
determining its proliferative potential, it is the case of Nucleolar Organizer Region (NOR),
which can be analyzed by AgNOR to discriminate benign and malignant brain tumors [18].
Nevertheless, there are a number of chromosomal regions that are recurrently rearranged in
brain tumors.
In order to illustrate the importance of cytogenetic studies and the relation of some recurrent
rearrangements and tumor behavior/classification, we are going to describe the most common
chromosomal rearrangements in some brain tumors.
4. Gliomas
The most common malignant primary brain tumors are gliomas, corresponding to more than
70% of the total primary brain tumors. They include a variety of malignant grades and
histological tumor types. Gliomas can be classified in Astrocytic tumors, oligodendrogliomas
and Ependymal tumors in accordance with the WHO classification of the tumors [4]. The most
common gliomas are astrocytic tumors in which the most malignant entity is the glioblastoma
(WHO grade IV). Gliomas are characterized as non-curable tumors. Today histopathology is
still the gold standard for diagnosis and grading of gliomas tumors. However some markers
have emerged and have important applications to their classification and prognosis.
4.1. Astrocytic tumors
The Astrocytic tumors are very diverse and represent the largest and most common group of
brain tumors. The Astrocytomas, Anaplastic Astrocytomas and the secondary Glioblastomas
(GBMs) are examples of tumors that show linear progression from benign to malignant
neoplasms [4]. This progression is driven by some specific genetic events including chromo‐
somal mutations. The most common cytogenetic observation is an increased complexity of the
karyotype, both structural and numerically, concurrent with the progression in malignancy.
Amplifications of EGFR locus on 7p12 and PTEN mutations on 10q23.3 are the best known
genetic markers that distinguish the de novo GBM from GBM that has a progression from a low
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analysis, is estimated that 14% (about 3000) of the human genes are involved on cancer
formation and progression [8], and the quantity of chromosome alterations involved is equally
large. Therefore, some web tools were created to permit a faster search of these genic and
chromosomal mutations on cancer for specific entities, as for example the “Mitelman Catalog
of chromosomal alterations” [14].
Figure 3. Whole-genome analysis of a tumor cell can be obtained by (A) M-FISH, SKY or (B) CGH methodologies. (A)
SKY or M-FISH utilizes a pool with 24 differently labeled chromosomes with a combination of five distinct fluoro‐
chromes to show all chromosomal rearrangements in a metaphase, including structural and numerical rearrange‐
ments and markers chromosome. (B) CGH utilizes two different DNA probes, from tumor and from a control
nonneoplastic sample, to hybridize onto a spread metaphase, or more recently in a slide array, to demonstrate DNA
loss, gain or amplification in the tumor sample.
Further down we will list some of the new and well established correlations between brain
tumors entities clinical behavior and some specific chromosome abnormalities. Some of the
imbalances were correlated with particular pathways or genic imbalances, others have no well-
established correlation with a specific gene function disturbance or cell pathways modifica‐
tions, although are systematically found in some brain tumor types.
3. Brain tumors
Brain tumors are the second most common type of cancer in children and are associated with
poor survival both in infants and adults, representing, therefore, a heavy burden for the
patients and their relatives [15]. These tumors can be devastating because they are difficult to
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treat, and frequently cause mental impairment or death. The incidence of brain tumors has
increased during the past three decades for all age and gender groups as a result of imaging
with computed tomography (CT) and magnetic resonance imaging (MRI), lymphomas
secondary to HIV/AIDS, and changes in coding and classification [16]. With the exception of
meningiomas and pituitary adenomas, women are less likely than men to be diagnosed with
a brain tumor, particularly glioblastoma multiforme and anaplastic astrocytoma, as well as
medulloblastomas. The lifetime risk of contracting a primary malignant brain tumor is 0.52%
for women and 0.67% for men. Similarly, the chance of dying from a malignant brain tumor
is 0.40% for women and 0.49% for men. There have been growing amount of studies dedicated
to detecting chromosomal imbalances and intercellular genomic variations both in benign and
malign brain tumors. Currently, it is suggested that almost all the chromosomes are involved
in aberrations associated with brain tumorigenesis [17]. Moreover, some specifics chromosome
structures can differentiate the tumor grades, in accordance to WHO classification, simply by
determining its proliferative potential, it is the case of Nucleolar Organizer Region (NOR),
which can be analyzed by AgNOR to discriminate benign and malignant brain tumors [18].
Nevertheless, there are a number of chromosomal regions that are recurrently rearranged in
brain tumors.
In order to illustrate the importance of cytogenetic studies and the relation of some recurrent
rearrangements and tumor behavior/classification, we are going to describe the most common
chromosomal rearrangements in some brain tumors.
4. Gliomas
The most common malignant primary brain tumors are gliomas, corresponding to more than
70% of the total primary brain tumors. They include a variety of malignant grades and
histological tumor types. Gliomas can be classified in Astrocytic tumors, oligodendrogliomas
and Ependymal tumors in accordance with the WHO classification of the tumors [4]. The most
common gliomas are astrocytic tumors in which the most malignant entity is the glioblastoma
(WHO grade IV). Gliomas are characterized as non-curable tumors. Today histopathology is
still the gold standard for diagnosis and grading of gliomas tumors. However some markers
have emerged and have important applications to their classification and prognosis.
4.1. Astrocytic tumors
The Astrocytic tumors are very diverse and represent the largest and most common group of
brain tumors. The Astrocytomas, Anaplastic Astrocytomas and the secondary Glioblastomas
(GBMs) are examples of tumors that show linear progression from benign to malignant
neoplasms [4]. This progression is driven by some specific genetic events including chromo‐
somal mutations. The most common cytogenetic observation is an increased complexity of the
karyotype, both structural and numerically, concurrent with the progression in malignancy.
Amplifications of EGFR locus on 7p12 and PTEN mutations on 10q23.3 are the best known
genetic markers that distinguish the de novo GBM from GBM that has a progression from a low
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grade astrocytic tumor, which is frequently associated with TP53 and IDH1 gene mutations
[19-21]. Trisomy of 7 and monosomy of 10 as well as frequent gains of 12p, 19q, and 20q differ
primary from secondary glioblastomas [22]. Despite of these cytogenetic differences, primary
or secondary glioblastomas can be assigned to a common set of functional pathways [23].
EGFR-mediated signaling is up regulated in about 30% of malignant gliomas and 60% of GBM
[24-26]. In GBM the overexpression generally is driven by EGFR gene amplification [27, 28].
Several contradictory studies have been made in prognostic value determination of EGFR
amplification [29]. Erlotinib and gefitinib are two drugs that target the EGFR amplification/
overexpression positive patients. These drugs presented unclear results up to date, with
different researches demonstrating contradictory results. However, a recent study showed that
co-expression of PTEN and EGFRvIII (a mutant form of EGFR molecules that constitutively
activates the EGFR-phosphoinositide 3-kinase pathway) was associated with an increased
sensitivity to erlotinib, whereas tumors without PTEN expression did not respond to erlotinib
[30]. In another study, glioblastoma patients treated with these drugs did not show major
response or survival improvement [31, 32]. On the other hand, a mixed result was obtained by
the combined use of erlotinib with temozolomide and radiotherapy [33, 34]: a group with no
overall benefit that did not help to identify a subgroup of tumors that might respond to therapy
[33], and other group suggested that this regime might be useful for patients with tumors with
MGMT promoter methylation and intact PTEN [34]. There is no consensus about use of these
drugs in gliomas and glioblastomas patients to date, but new drugs and new molecularly
targeted drugs reached clinical trials [35].
A more informative scenery is obtained by the simultaneous analyses of EGFR gene amplifi‐
cation and EGFRvIII in gliomas. An estimative of 50-60% of the amplified EGFR patients
presents the EGFRvIII mutation. This condition is considered both diagnostic and prognosti‐
cally informative, indicating a high grade malignancy. It is suggested that anaplastic or low-
grade gliomas with this combination are more malignant than indicated by their
histopathology and an unfavorable impact on the prognosis has been described for these
patients [36]. To high grade gliomas, like primary glioblastomas, the EGFR amplification/
EGFRvIII poor prognosis is less obvious [37] but some studies have reported a poor prognosis
association [38-41].
In glioblastomas, EGFR amplification mostly occurs as double-minutes (DM), which are small
fragments of extra-chromosomal DNA. FISH assessment of this amplification is an accessible
technique to be made in conventional pathology laboratories, which can be made in interphasic
nuclei of a paraffin-embeded section [42, 43]. Quantitative PCR or reverse transcriptase PCR
can be used to detect EGFR amplification as well [44]. Immunohistochemistry is used, but its
value is less clear [45].
Some alterations in astrocytomas can indicate an increased risk of dying, independently of its
histological grade, such as the presence of +7q and -10q chromosomal alterations detected by
the CGH analysis of astrocytomas [46]. Misra and coworkers [47] identified three groups in
GBM patients: those with both 7 gain and 10 loss, some with 10 loss without gain of 7 and the
group without these two alterations. In clinical evaluation, the patients with 7 gain and 10 loss
showed typical characteristic of GBM short-term survivors. In contrast, patients who had none
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of these alterations showed characteristics of typical and long-term survivors. In this research
it was showed that EGFR is amplified on 7 gain 10 loss group of primary GBM. In a review
using interphase-based FISH to chromosomes 7 and 10, it was found that 75% of the astrocy‐
tomas grade II and 100% of the grade III and IV exhibited cells with polysomy of chromosome
7 and that 75% of the grades II and III or 100% of the GBM samples showed cells with loss of
chromosome 10 [20].
A gene expression profile (GEP) in a series of gliomas was associated with the cytogenetic of
the glioblastomas and with the histopathology of gliomas [48]. When low-grades versus high-
grades gliomas were compared, divergent profiles both cytogenetic and GEP were exhibited.
High grades gliomas demonstrated higher intratumoral cytogenetic heterogeneity (demon‐
strated by a higher number of cell clones). The authors correlated this with the genomic
instability or with the ancestral tumor cell clone chromosomal alterations in which karyotype
composition led to an increased CIN. According to this study, three distinct glioblastomas GEP
groups were formed: GEP1 with EGFR amplification, GEP2 with isolated trisomy 7 and GEP3
demonstrating more complex karyotype. All these three groups were formed after analysis of
ancestral tumor cell clone and further cytogenetic evolution of the tumor cells of GEP1, GEP2
and GEP3 glioblastomas were related with 7 gain, 9p and 10q deletions, suggesting a simul‐
taneous occurrence of EGFR activation (normal or mutant variants) and loss of both Ink4A/Arf
and PTEN tumor suppressor genes.
4.2. Oligodendroglial tumors
Oligodendroglial  tumors  are  diffusely  infiltrating,  well  differentiated  gliomas,  typically
located in  cerebral  hemispheres  in  adults,  composed of  neoplastic  cells  morphologically
resembling oligodendroglia [4]. In oligodendrogliomas (WHO grade II) 80-90% are corre‐
lated to  simultaneous  deletion of  1p  and 19q,  whereas  more  malignant  tumors  demon‐
strate  lower  frequencies  of  this  same  alteration.  The  anaplastic  oligodendrogliomas
(WHO grade III) present 1p/19q co-deletions in approximately 50-60%, oligoastrocytomas
in 30-50%, anaplastic oligoastrocytomas in 20-30%, and diffuse astrocytic gliomas in less
than 10%, including glioblastomas. Currently, loss of 1p and 19q is the genetic hallmark
of  oligodendroglial  tumors  [4,  49].  Theses  deletions  were  firstly  associated  with  PVC
(Procarbazine,  CCNU and vincristine)  sensitivity,  demonstrating a  favorable  outcome in
contrast with patients who don’t show these chromosomal deletions, simultaneously [50].
Nowadays,  this  substantially  improved survival  times was correlated with others  drugs
(like temozolomide) or procedures (like radiotherapy) sensitivity,  suggesting that 1p/19q
co-deletion is an indicator of tumor vulnerability to a broad range of therapeutic options
than as a specific predictor of chemosensitivity [35].
Interestingly, although the 1p and 19q regions have been extensively mapped, no tumorigenic
gene was implicated. Another observation is that 1p/19q co-deletion tumors generally present
a classical histology [51-53] and is correlated with IDH1 and IDH2 mutations [54]. On the other
hand, TP53 mutation, 10q deletions and EGFR amplifications were inversely correlated with
1p/19q co-deletion tumors [53]. Another association is obtained from tumor location: when
anaplastic oligodendrogliomas and low grade oligodendrogliomas occur in the frontal,
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grade astrocytic tumor, which is frequently associated with TP53 and IDH1 gene mutations
[19-21]. Trisomy of 7 and monosomy of 10 as well as frequent gains of 12p, 19q, and 20q differ
primary from secondary glioblastomas [22]. Despite of these cytogenetic differences, primary
or secondary glioblastomas can be assigned to a common set of functional pathways [23].
EGFR-mediated signaling is up regulated in about 30% of malignant gliomas and 60% of GBM
[24-26]. In GBM the overexpression generally is driven by EGFR gene amplification [27, 28].
Several contradictory studies have been made in prognostic value determination of EGFR
amplification [29]. Erlotinib and gefitinib are two drugs that target the EGFR amplification/
overexpression positive patients. These drugs presented unclear results up to date, with
different researches demonstrating contradictory results. However, a recent study showed that
co-expression of PTEN and EGFRvIII (a mutant form of EGFR molecules that constitutively
activates the EGFR-phosphoinositide 3-kinase pathway) was associated with an increased
sensitivity to erlotinib, whereas tumors without PTEN expression did not respond to erlotinib
[30]. In another study, glioblastoma patients treated with these drugs did not show major
response or survival improvement [31, 32]. On the other hand, a mixed result was obtained by
the combined use of erlotinib with temozolomide and radiotherapy [33, 34]: a group with no
overall benefit that did not help to identify a subgroup of tumors that might respond to therapy
[33], and other group suggested that this regime might be useful for patients with tumors with
MGMT promoter methylation and intact PTEN [34]. There is no consensus about use of these
drugs in gliomas and glioblastomas patients to date, but new drugs and new molecularly
targeted drugs reached clinical trials [35].
A more informative scenery is obtained by the simultaneous analyses of EGFR gene amplifi‐
cation and EGFRvIII in gliomas. An estimative of 50-60% of the amplified EGFR patients
presents the EGFRvIII mutation. This condition is considered both diagnostic and prognosti‐
cally informative, indicating a high grade malignancy. It is suggested that anaplastic or low-
grade gliomas with this combination are more malignant than indicated by their
histopathology and an unfavorable impact on the prognosis has been described for these
patients [36]. To high grade gliomas, like primary glioblastomas, the EGFR amplification/
EGFRvIII poor prognosis is less obvious [37] but some studies have reported a poor prognosis
association [38-41].
In glioblastomas, EGFR amplification mostly occurs as double-minutes (DM), which are small
fragments of extra-chromosomal DNA. FISH assessment of this amplification is an accessible
technique to be made in conventional pathology laboratories, which can be made in interphasic
nuclei of a paraffin-embeded section [42, 43]. Quantitative PCR or reverse transcriptase PCR
can be used to detect EGFR amplification as well [44]. Immunohistochemistry is used, but its
value is less clear [45].
Some alterations in astrocytomas can indicate an increased risk of dying, independently of its
histological grade, such as the presence of +7q and -10q chromosomal alterations detected by
the CGH analysis of astrocytomas [46]. Misra and coworkers [47] identified three groups in
GBM patients: those with both 7 gain and 10 loss, some with 10 loss without gain of 7 and the
group without these two alterations. In clinical evaluation, the patients with 7 gain and 10 loss
showed typical characteristic of GBM short-term survivors. In contrast, patients who had none
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of these alterations showed characteristics of typical and long-term survivors. In this research
it was showed that EGFR is amplified on 7 gain 10 loss group of primary GBM. In a review
using interphase-based FISH to chromosomes 7 and 10, it was found that 75% of the astrocy‐
tomas grade II and 100% of the grade III and IV exhibited cells with polysomy of chromosome
7 and that 75% of the grades II and III or 100% of the GBM samples showed cells with loss of
chromosome 10 [20].
A gene expression profile (GEP) in a series of gliomas was associated with the cytogenetic of
the glioblastomas and with the histopathology of gliomas [48]. When low-grades versus high-
grades gliomas were compared, divergent profiles both cytogenetic and GEP were exhibited.
High grades gliomas demonstrated higher intratumoral cytogenetic heterogeneity (demon‐
strated by a higher number of cell clones). The authors correlated this with the genomic
instability or with the ancestral tumor cell clone chromosomal alterations in which karyotype
composition led to an increased CIN. According to this study, three distinct glioblastomas GEP
groups were formed: GEP1 with EGFR amplification, GEP2 with isolated trisomy 7 and GEP3
demonstrating more complex karyotype. All these three groups were formed after analysis of
ancestral tumor cell clone and further cytogenetic evolution of the tumor cells of GEP1, GEP2
and GEP3 glioblastomas were related with 7 gain, 9p and 10q deletions, suggesting a simul‐
taneous occurrence of EGFR activation (normal or mutant variants) and loss of both Ink4A/Arf
and PTEN tumor suppressor genes.
4.2. Oligodendroglial tumors
Oligodendroglial  tumors  are  diffusely  infiltrating,  well  differentiated  gliomas,  typically
located in  cerebral  hemispheres  in  adults,  composed of  neoplastic  cells  morphologically
resembling oligodendroglia [4]. In oligodendrogliomas (WHO grade II) 80-90% are corre‐
lated to  simultaneous  deletion of  1p  and 19q,  whereas  more  malignant  tumors  demon‐
strate  lower  frequencies  of  this  same  alteration.  The  anaplastic  oligodendrogliomas
(WHO grade III) present 1p/19q co-deletions in approximately 50-60%, oligoastrocytomas
in 30-50%, anaplastic oligoastrocytomas in 20-30%, and diffuse astrocytic gliomas in less
than 10%, including glioblastomas. Currently, loss of 1p and 19q is the genetic hallmark
of  oligodendroglial  tumors  [4,  49].  Theses  deletions  were  firstly  associated  with  PVC
(Procarbazine,  CCNU and vincristine)  sensitivity,  demonstrating a  favorable  outcome in
contrast with patients who don’t show these chromosomal deletions, simultaneously [50].
Nowadays,  this  substantially  improved survival  times was correlated with others  drugs
(like temozolomide) or procedures (like radiotherapy) sensitivity,  suggesting that 1p/19q
co-deletion is an indicator of tumor vulnerability to a broad range of therapeutic options
than as a specific predictor of chemosensitivity [35].
Interestingly, although the 1p and 19q regions have been extensively mapped, no tumorigenic
gene was implicated. Another observation is that 1p/19q co-deletion tumors generally present
a classical histology [51-53] and is correlated with IDH1 and IDH2 mutations [54]. On the other
hand, TP53 mutation, 10q deletions and EGFR amplifications were inversely correlated with
1p/19q co-deletion tumors [53]. Another association is obtained from tumor location: when
anaplastic oligodendrogliomas and low grade oligodendrogliomas occur in the frontal,
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parietal, and occipital lobes, they are generally related to 1p/19q co-deletions [55-57]. In
glioblastomas 1p/19q co-deletion is uncommon, however, when it is detected, the results
observed are opposite, predicting shortened survival [52]. Thus, this cytogenetic marker
denotes a clinically distinct tumor, with progression, prognosis, and treatment responses that
are different of others gliomas. Therefore detection of 1p/19q alterations in oligodendroglio‐
mas has become a useful and common test procedure [35]. FISH is the most reliable procedure
to detect this marker in the laboratories, which can be substituted by array CGH in the next
future when this technique may become less expensive.
By contrast, when the short arm of chromosome 1 is deleted alone, which is a rare cytogenetic
finding in gliomas, it is associated with a poorer prognosis. On the other hand, in glioblasto‐
mas, primary or secondary, loss of heterozygosity (LOH) of 1p (other rare observation) is
associated with longer survival [50]. In contrast, the oligodendroglial tumors are associated
with poorer outcome when 8q gains are observed [20].
4.3. Pediatric gliomas
Pilocytic astrocytomas commonly present a characteristic BRAF proto-oncogene activation at
7q34, mainly by gene fusion or duplication, which is infrequent in diffusely infiltrating
astrocytic gliomas [58-61]. Therefore, difficult diferential diagnosis between pilocytic astrocy‐
toma and low-grade diffuse astrocytoma could be improved by the detection of BRAF
activation. BRAF is target of a new therapy that inhibits the MAPK pathway, as showed in a
case report [62]. The detection of BRAF fusion can be made by specific FISH probes or by
specialized RT-PCR assays.
5. CNS Embryonal tumors
Embryonal tumors of the CNS form by far the largest group of malignant brain tumors in
childhood. They are characterized by a mass of cells that begins its growth in the embryonic
tissue in the brain. Despite the progress in the knowledge of these tumors, few studies were
translated on clinical improvement. The WHO classification divides embryonal tumors into
three entities: Medulloblastomas, CNS Primitive Neuroectodermal tumors (PNETs) and
Atypical teratoid/rhabdoid tumor (AT/RT) [4].
5.1. Medulloblastomas
Medulloblastomas (MBs) are the most frequent embryonal tumors and the most frequent CNS
tumor in childhood. They affect the cerebellum and are defined as grade IV in the WHO
classification. Histopathological classification differentiates five distinct medulloblastoma
variants: the classic MB, desmoplastic/nodular MB, MB with extensive nodularity, anaplastic
MB and large cell MB [4].
In  a  recent  comprehension  made  by  [63],  MB  comprises  four  distinct  molecular  sub‐
groups: WNT, SHH, group C and group D. This subgroup classification was made in ac‐
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors366
cordance with its GEP of important genes in medulloblastoma disease. The authors also
created an immunohistochemistry (an easier  methodology to install  on the conventional
histopathology laboratories) four-antibody approach to discriminate the medulloblastoma
patients into the four distinct molecular variants. Children patients classified as group C
demonstrate a marked reduction in survival regardless of it  metastatic stage. After a re‐
cent discussion about the classification of MB in the light of its transcriptome, involving
researchers  of  different  laboratories  and  countries,  these  subgroup  were  renamed,  to
WNT, SHH, Group 3 and Group 4 [64].
Analyzing the somatic copy number aberrations (SCNA) of the MB, Northcott and coworkers
[65] concluded that SCNA in MB are common and are predominantly subgroup-enriched.
Only the WNT subgroup demonstrated no significant deletions and a small subset of focal
gains, which were found in a proportional frequency in non-WNT tumors, concluding that
there are no frequent, targetable SCNA on this subgroup. SHH tumors, however, exhibit
multiple focal SCNAs restricted/enriched on this group and have important clinical implica‐
tions [65]. Group 3 and Group 4, which were generically named because less is known about
its biology [64], presented important SCNAs restricted/enriched on them. MYC amplification
(Figure 4A) mutually with OTX2 oncogene demonstrated that are largely restricted to Group
3, and were extremely prognostic. Furthermore, TGF-β signaling is the unique restricted
pathway involved in group 3 tumors, which may indicating a new therapy for Group 3 patients
that present a dismal prognosis. In group 4 MB patients, the NF-kB pathway could represent
a rational therapeutic target, because NFKBIA (14q13) and USP4 (3p21.3), regulators of NF-kB,
were consistently deleted on this group [65]
The  most  frequent  chromosomal  abnormality  in  MB  is  the  isochromosome  17q  (i17q),
found in approximately 30%-50% of patients [66,  67].  The i17q structure consists of  two
centromeres,  two  very  centromeric  “17p”  region  that  are  fused  together,  mainly  in  the
Smith-Magenis region, and two copies of 17 long arm. It was observed in increased lev‐
els  of  recurrent  meduloblastomas  compared  with  the  initials  ones,  suggesting  a  role  in
progression  of  medulloblastomas  [68].  But,  although  there  are  well-known  tumor  sup‐
pressor  genes  and  oncogenes  on  chromosome  17,  the  tumor  suppressor  genes  on  the
17p  or  the  oncogenes  in  the  17q  directly  involved  on  MB disease  were  not  yet  identi‐
fied,  however  the  tumor  growth  advantage  may  occur  by  haploinsufficiency  for  genes
on 17p and an increased expression of genes on 17q driven by the copy number altera‐
tions.  For this  reason,  17q gain,  17p loss  or  both represent  the same biological  effect  of
an i17q  (Figure  4C),  which is  an  alteration commonly seen in  MB patients  [63,  68,  69].
The presence of  this  abnormality was the unique chromosomal alteration that  occurs  at
a high frequency in [63]  and was significantly prominent in Group D (Group 4)  molec‐
ular  subgroup of  MBs (65.7%).  The  others  chromosomal  alterations  were  seen at  a  low
frequency [63].  The monossomy 6 in the same study and others was detected exclusive‐
ly in WNT tumors [63, 70-73],  while the 9q loss was detected only in SHH tumors [72].
These  and others  chromosomal  markers  presents  on  the  four  molecular  subgroups  will
be shown in Table 1.
Chromosomal Analysis: Clinical Applicability to Brain Cancers
http://dx.doi.org/10.5772/52354
367
parietal, and occipital lobes, they are generally related to 1p/19q co-deletions [55-57]. In
glioblastomas 1p/19q co-deletion is uncommon, however, when it is detected, the results
observed are opposite, predicting shortened survival [52]. Thus, this cytogenetic marker
denotes a clinically distinct tumor, with progression, prognosis, and treatment responses that
are different of others gliomas. Therefore detection of 1p/19q alterations in oligodendroglio‐
mas has become a useful and common test procedure [35]. FISH is the most reliable procedure
to detect this marker in the laboratories, which can be substituted by array CGH in the next
future when this technique may become less expensive.
By contrast, when the short arm of chromosome 1 is deleted alone, which is a rare cytogenetic
finding in gliomas, it is associated with a poorer prognosis. On the other hand, in glioblasto‐
mas, primary or secondary, loss of heterozygosity (LOH) of 1p (other rare observation) is
associated with longer survival [50]. In contrast, the oligodendroglial tumors are associated
with poorer outcome when 8q gains are observed [20].
4.3. Pediatric gliomas
Pilocytic astrocytomas commonly present a characteristic BRAF proto-oncogene activation at
7q34, mainly by gene fusion or duplication, which is infrequent in diffusely infiltrating
astrocytic gliomas [58-61]. Therefore, difficult diferential diagnosis between pilocytic astrocy‐
toma and low-grade diffuse astrocytoma could be improved by the detection of BRAF
activation. BRAF is target of a new therapy that inhibits the MAPK pathway, as showed in a
case report [62]. The detection of BRAF fusion can be made by specific FISH probes or by
specialized RT-PCR assays.
5. CNS Embryonal tumors
Embryonal tumors of the CNS form by far the largest group of malignant brain tumors in
childhood. They are characterized by a mass of cells that begins its growth in the embryonic
tissue in the brain. Despite the progress in the knowledge of these tumors, few studies were
translated on clinical improvement. The WHO classification divides embryonal tumors into
three entities: Medulloblastomas, CNS Primitive Neuroectodermal tumors (PNETs) and
Atypical teratoid/rhabdoid tumor (AT/RT) [4].
5.1. Medulloblastomas
Medulloblastomas (MBs) are the most frequent embryonal tumors and the most frequent CNS
tumor in childhood. They affect the cerebellum and are defined as grade IV in the WHO
classification. Histopathological classification differentiates five distinct medulloblastoma
variants: the classic MB, desmoplastic/nodular MB, MB with extensive nodularity, anaplastic
MB and large cell MB [4].
In  a  recent  comprehension  made  by  [63],  MB  comprises  four  distinct  molecular  sub‐
groups: WNT, SHH, group C and group D. This subgroup classification was made in ac‐
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cordance with its GEP of important genes in medulloblastoma disease. The authors also
created an immunohistochemistry (an easier  methodology to install  on the conventional
histopathology laboratories) four-antibody approach to discriminate the medulloblastoma
patients into the four distinct molecular variants. Children patients classified as group C
demonstrate a marked reduction in survival regardless of it  metastatic stage. After a re‐
cent discussion about the classification of MB in the light of its transcriptome, involving
researchers  of  different  laboratories  and  countries,  these  subgroup  were  renamed,  to
WNT, SHH, Group 3 and Group 4 [64].
Analyzing the somatic copy number aberrations (SCNA) of the MB, Northcott and coworkers
[65] concluded that SCNA in MB are common and are predominantly subgroup-enriched.
Only the WNT subgroup demonstrated no significant deletions and a small subset of focal
gains, which were found in a proportional frequency in non-WNT tumors, concluding that
there are no frequent, targetable SCNA on this subgroup. SHH tumors, however, exhibit
multiple focal SCNAs restricted/enriched on this group and have important clinical implica‐
tions [65]. Group 3 and Group 4, which were generically named because less is known about
its biology [64], presented important SCNAs restricted/enriched on them. MYC amplification
(Figure 4A) mutually with OTX2 oncogene demonstrated that are largely restricted to Group
3, and were extremely prognostic. Furthermore, TGF-β signaling is the unique restricted
pathway involved in group 3 tumors, which may indicating a new therapy for Group 3 patients
that present a dismal prognosis. In group 4 MB patients, the NF-kB pathway could represent
a rational therapeutic target, because NFKBIA (14q13) and USP4 (3p21.3), regulators of NF-kB,
were consistently deleted on this group [65]
The  most  frequent  chromosomal  abnormality  in  MB  is  the  isochromosome  17q  (i17q),
found in approximately 30%-50% of patients [66,  67].  The i17q structure consists of  two
centromeres,  two  very  centromeric  “17p”  region  that  are  fused  together,  mainly  in  the
Smith-Magenis region, and two copies of 17 long arm. It was observed in increased lev‐
els  of  recurrent  meduloblastomas  compared  with  the  initials  ones,  suggesting  a  role  in
progression  of  medulloblastomas  [68].  But,  although  there  are  well-known  tumor  sup‐
pressor  genes  and  oncogenes  on  chromosome  17,  the  tumor  suppressor  genes  on  the
17p  or  the  oncogenes  in  the  17q  directly  involved  on  MB disease  were  not  yet  identi‐
fied,  however  the  tumor  growth  advantage  may  occur  by  haploinsufficiency  for  genes
on 17p and an increased expression of genes on 17q driven by the copy number altera‐
tions.  For this  reason,  17q gain,  17p loss  or  both represent  the same biological  effect  of
an i17q  (Figure  4C),  which is  an  alteration commonly seen in  MB patients  [63,  68,  69].
The presence of  this  abnormality was the unique chromosomal alteration that  occurs  at
a high frequency in [63]  and was significantly prominent in Group D (Group 4)  molec‐
ular  subgroup of  MBs (65.7%).  The  others  chromosomal  alterations  were  seen at  a  low
frequency [63].  The monossomy 6 in the same study and others was detected exclusive‐
ly in WNT tumors [63, 70-73],  while the 9q loss was detected only in SHH tumors [72].
These  and others  chromosomal  markers  presents  on  the  four  molecular  subgroups  will
be shown in Table 1.
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Figure 4. Somatic Copy Number Aberrations (SCNA) in medulloblastomas involving chromosomes (A) 8, (B) 2 and (C)
17. The colors represent the inferred copy number for each chromosome locus, in which red spectrum represent
gains/amplification and blue spectrum represent loss/deletions, normal SCNA is represented in white. (A) Chromo‐
some 8 SCNA exhibiting amplification on the MYC locus on 8q24.21. (B) Chromosome 2 SCNA showing amplification
on MYCN locus on 2p24.3. (C) Chromosome 17 SCNA demonstrating 17q gain and both 17p loss and 17q gain (repre‐
senting i17q). Courtesy of Dubuc AM, Taylor MD, Northcott PA and Shih D. See [65] for details.
The investigation of MYC and MYCN locus provided consistent prognostic information to
medulloblastoma patients [66, 74-79], and can be accessed by FISH or CGH experiments
(Figure 4A and 4B), being related mutated in up to 10% of medulloblastomas. MYC amplifi‐
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cation is associated with poor prognosis and with the large cell/anaplastic medulloblastoma
variants, but histologically aggressive cases diagnosed, like large cell/anaplastic MB without
amplification of MYC, were not significantly associated with worse outcome [68]. MYCN
amplification (Figure 4B) is associated with poor prognosis and correlated with large cell/
anaplastic variants, but is clinically more heterogeneous than MYC. The MYC family was
considered in Northcott molecular stratification of MBs [63, 65], and MYC amplification on
8q24 (Figure 4A) was detected exclusively on Group C (Group 3) patients. MYCN was
demonstrated amplified (Figure 4B) both in SHH and Group D (Group 4) MB patients [63, 65].
Losses Gains Others
WNT - - Monossomy 6
SHH 9q, 10q, 14 2, 3q, 9p, 20q, 21q
Group C 5q, 8p, 10q, 11p, 16q 1q, 17q, 18 i17q,
Group D X, 8p, 8q, 11p 17q, 18 i17q,
Table 1. Significant chromosomal abnormalities observed on the four distinct molecular variants of the Northcott
study.
For adult Medulloblastomas, different genetic and cytogenetic changes were observed in
relation to pediatric ones, with profiles of chromosomal abnormalities greatly differing from
childhood. CDK6 amplification, 17q gain and 10q loss were strongly associated with shortened
survival. The WNT signaling pathway activation does not demonstrate the excellent prognosis
seen in pediatrics MB [80].
5.2. Atypical teratoid/rhabdoid tumor
Atypical teratoid/rhabdoid tumors (AT/RT) are very malignant embryonal neoplasms (WHO
grade IV) that occur in very young children [4]. Very constant alterations in SMARCB1 locus
on 22q11 were published. These alterations can be detected like deletions, loss of heterozygos‐
ity (LOH) or gene mutation in all the exons of this gene. SMARCB1 protein immunohisto‐
chemistry search has demonstrated great utility in diagnosis of AT/RT or in determinate
patients with poor therapy response and aggressive clinical course, even in the absence of AT/
RT cell [81, 82]. When combined FISH, genomic sequencing, MLPA and SNP-based oligonu‐
cleotide arrays were used to diagnosis AT/RT in 36 patients, all demonstrated biallelic
alteration in SMARCB1 locus [83]. The molecular diagnostic became yet more important when
it is possible to determinate adult carriers, to genetic counseling finalities.
5.3. Ependymoblastomas
Ependymoblastoma and ETANTR (Embryonal Tumor with Abundant Neuropil and True
Rosettes) are rare and very aggressive Primitive Neuroectodermal Tumors (PNETs) charac‐
terized by the presence of multilayred rosette [4]. They were recently associated with focal
amplification of 19q13.42 that contains a cluster of mi-RNA-coding gene. This amplification
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survival. The WNT signaling pathway activation does not demonstrate the excellent prognosis
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5.2. Atypical teratoid/rhabdoid tumor
Atypical teratoid/rhabdoid tumors (AT/RT) are very malignant embryonal neoplasms (WHO
grade IV) that occur in very young children [4]. Very constant alterations in SMARCB1 locus
on 22q11 were published. These alterations can be detected like deletions, loss of heterozygos‐
ity (LOH) or gene mutation in all the exons of this gene. SMARCB1 protein immunohisto‐
chemistry search has demonstrated great utility in diagnosis of AT/RT or in determinate
patients with poor therapy response and aggressive clinical course, even in the absence of AT/
RT cell [81, 82]. When combined FISH, genomic sequencing, MLPA and SNP-based oligonu‐
cleotide arrays were used to diagnosis AT/RT in 36 patients, all demonstrated biallelic
alteration in SMARCB1 locus [83]. The molecular diagnostic became yet more important when
it is possible to determinate adult carriers, to genetic counseling finalities.
5.3. Ependymoblastomas
Ependymoblastoma and ETANTR (Embryonal Tumor with Abundant Neuropil and True
Rosettes) are rare and very aggressive Primitive Neuroectodermal Tumors (PNETs) charac‐
terized by the presence of multilayred rosette [4]. They were recently associated with focal
amplification of 19q13.42 that contains a cluster of mi-RNA-coding gene. This amplification
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was seen in virtually all the embryonal brain tumor with true multilayered rosettes [84-86].
These results indicate that they may represent a single biological entity that can be diagnosed
by the detection of 19q13.42 amplification. The term Embryonal Tumor with Multilayered
Rosettes (ETMR) was proposed to designate these entities that apparently affect only children
and have a very poor prognosis.
6. Ependymal tumors
Ependymomas form a group of heterogeneous tumors anywhere along the craniospinal axis
that can occur in adult or childhood. They can originate from the radial glial cells [87, 88] which
originate the ependymal cells during normal cellular development. The WHO classification
[4] designates ependymal tumors in different histology entities, as hereafter: Subependymo‐
mas and myxopapillary ependymomas (WHO grade I); Classic ependymomas (WHO grade
II); anaplastic ependymomas (WHO grade III). The classic ependymoma was subdivided in
four variant cellular, papillary, clear cell and tanycytic [89]. For these tumors the WHO grading
was the most powerful prognostic factor in adult population. In the same way, the tumor
location has been demonstrated as having potential prognostic value, with those in the
supratentorial regions demonstrating poor prognosis and with higher risk of recurrence.
The chromosomal abnormalities reflect the heterogeneity of topology and age of Ependymo‐
mas. A study made by Korshunov and coworkers [90] has presented a comprehensive work
that subdivides the ependymomas in three groups:
a. Group 1: five years of Overall survival of 100% - tumors with gain of chromosomes 9, 15q,
or 18, or loss of chromosome 6, without 1q gain or CDKN2A deletion.
b. Group 2: five years of Overall survival of 78% - tumors balanced for chromosome 1q, 6,
9, 15q, and 18, without a homozygous deletion of CDKN2A.
c. Group 3: five years of Overall survival of 32% - tumors with 1q gain or homozygous
deletions of CDKN2A.
Group 1 demonstrates an excellent response to standard therapy protocols, demonstrating an
excellent prognosis. Group 3 demonstrates a propensity to generate metastasis and generally
show an aggressive clinical behavior, having its chromosomal composition associated with a
poor prognosis. Another possibility for this group is the association of 1q21.1-32.1 gain
correlated with an increased propensity to recurrence.
Some chromosome alterations remain unclear between the groups. The 6q23 loss in group 1
can be correlated with a decreased progression-free survival, while 6q25.3 loss in anaplastic
ependymomas has been correlated with an improved overall survival. The 9q gain in pediatric
group 1 patients was correlated with a frequent recurrence.
Yang and coworkers [91] conclude that diagnosis based only in the light of histologic proce‐
dures may be insufficient to assign an appropriate risk stratification strategy. In our opinion
the enlargement of cytogenetic analysis could generate a map of chromosomal alterations on
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ependymomas that would help in creating a personalized treatment for these tumors and
indicate targets to avoid growth, recurrence or metastasis.
7. Meningiomas
Meningiomas are the second most common tumor of the CNS in adults. They are classified as
benign, atypical or anaplastic corresponding to 80%, 15-20% and 1-3%, respectively, and
stratified in grades I, II and III, respectively [92]. Even the grade I meningiomas, with a
favorable prognosis under the classical treatment with surgical resection, radiation and
chemotherapy, presents an aggressive remaining group which needs molecular or cytogenetic
markers to distinct its diagnosis and treatment.
The karyotypes of meningiomas show diversity among the WHO grades. The WHO grade I
benign meningiomas rarely exhibit chromosomal aberrations beyond 22q losses. More
complex karyotype compositions are seen in higher grade meningiomas with more aggressive
behavior. The losses are common to 1p, 10q, 14q and less frequent on 6q and 18q in Atypical
and Anaplastic meningiomas. Higher grade meningiomas are characterized by gains on 1q,
9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas have demonstrated losses on 9p with
amplification on 17q23 in a higher frequency. Alterations on chromosome 1 always represent
important alterations on CNS tumors. In meningioma losses on 1p can be related as a strong
indicator of recurrence: only 4.3% of the meningiomas with recurrence are seen with an intact
1p. The presence of deletions of 1p can be related to a strong propensity to recur. LOH on 1p,
10q and 9p are also associated with recurrence propensity. At the same way, 9p losses are
associated with anaplastic meningiomas (grade III) with p14ARF (encoding p14), CDKN2B/
p15ARF (encoding p15), and CDKN2A/p16INKa (encoding p16) tumor suppressor genes losses.
The most important is the CDKN2A impairment causing poorer outcome when compared to
patients with intact CDKN2A genes. Losses in 14q also are found in meningiomas, and are
associated with a worse prognosis. 14q deletions serve as a powerful and reliable prognostic
factor indicating tumor recurrence [93].
8. Others brain tumors
Less well understood involvement of chromosome abnormalities are reported for some
infrequent tumors of the CNS. The low frequency can explain the low number of cytogenetic
studies, but the involvement of a multigroup work to understand them could provide a
solution to compile these patients. However, some works have made a suggestive involvement
of specific chromosomal alterations in the genesis, development, aggressiveness or response
to therapies. For these, a brief description will be made here.
An example is the Olfactory Neuroblastoma (also named Esthesioneuroblastoma), that
originate from the olfactory epithelium, that form a group of neoplasm less studied at the
cytogenetic point of view, but the first comprehensive study has suggested that the prevalence
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c. Group 3: five years of Overall survival of 32% - tumors with 1q gain or homozygous
deletions of CDKN2A.
Group 1 demonstrates an excellent response to standard therapy protocols, demonstrating an
excellent prognosis. Group 3 demonstrates a propensity to generate metastasis and generally
show an aggressive clinical behavior, having its chromosomal composition associated with a
poor prognosis. Another possibility for this group is the association of 1q21.1-32.1 gain
correlated with an increased propensity to recurrence.
Some chromosome alterations remain unclear between the groups. The 6q23 loss in group 1
can be correlated with a decreased progression-free survival, while 6q25.3 loss in anaplastic
ependymomas has been correlated with an improved overall survival. The 9q gain in pediatric
group 1 patients was correlated with a frequent recurrence.
Yang and coworkers [91] conclude that diagnosis based only in the light of histologic proce‐
dures may be insufficient to assign an appropriate risk stratification strategy. In our opinion
the enlargement of cytogenetic analysis could generate a map of chromosomal alterations on
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The karyotypes of meningiomas show diversity among the WHO grades. The WHO grade I
benign meningiomas rarely exhibit chromosomal aberrations beyond 22q losses. More
complex karyotype compositions are seen in higher grade meningiomas with more aggressive
behavior. The losses are common to 1p, 10q, 14q and less frequent on 6q and 18q in Atypical
and Anaplastic meningiomas. Higher grade meningiomas are characterized by gains on 1q,
9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas have demonstrated losses on 9p with
amplification on 17q23 in a higher frequency. Alterations on chromosome 1 always represent
important alterations on CNS tumors. In meningioma losses on 1p can be related as a strong
indicator of recurrence: only 4.3% of the meningiomas with recurrence are seen with an intact
1p. The presence of deletions of 1p can be related to a strong propensity to recur. LOH on 1p,
10q and 9p are also associated with recurrence propensity. At the same way, 9p losses are
associated with anaplastic meningiomas (grade III) with p14ARF (encoding p14), CDKN2B/
p15ARF (encoding p15), and CDKN2A/p16INKa (encoding p16) tumor suppressor genes losses.
The most important is the CDKN2A impairment causing poorer outcome when compared to
patients with intact CDKN2A genes. Losses in 14q also are found in meningiomas, and are
associated with a worse prognosis. 14q deletions serve as a powerful and reliable prognostic
factor indicating tumor recurrence [93].
8. Others brain tumors
Less well understood involvement of chromosome abnormalities are reported for some
infrequent tumors of the CNS. The low frequency can explain the low number of cytogenetic
studies, but the involvement of a multigroup work to understand them could provide a
solution to compile these patients. However, some works have made a suggestive involvement
of specific chromosomal alterations in the genesis, development, aggressiveness or response
to therapies. For these, a brief description will be made here.
An example is the Olfactory Neuroblastoma (also named Esthesioneuroblastoma), that
originate from the olfactory epithelium, that form a group of neoplasm less studied at the
cytogenetic point of view, but the first comprehensive study has suggested that the prevalence
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of 3q deletion demonstrates that it can be adopted as an early genetic event in Esthesioneur‐
oblastoma and the involvement of deletion on chromosomes 5, 6q, 7q, 11p/q, 15q21 as well as
gains of 1p32-34, 1q12, and 2p22-24 can be associated with a metastatic phenotype and a worse
prognosis [94].
Rickert and coworkers [95] in a study applying CGH in choroid plexus papillomas and choroid
plexus carcinomas made the follow correlation: patients with choroid plexus carcinomas were
associated to have a significantly longer survival when +9p and -10q alterations were present.
9. Brain metastases
Brain metastases are tumors that originate outside the CNS and secondarily spread to the CNS
via the haematogenous route (metastasis) or by direct invasion from adjacent tissues [4].
Metastatic tumors form a heterogeneous group, in which primary site can be from any location
in body. But the frequencies of tumors that metastasize to brain are non-random, because there
is an organ tropism to each tumor. However, brain metastases can occur in up to 40% of the
cancer patients and represent a major cause of mortality and morbidity in cancer patients; some
authors indicate that there are under notification of brain metastases [96]. The most commons
primary sites that metastasize to brain are the lung, breast and melanoma with frequencies of
40-50%, 15-25% and 5-20%, respectively. However, melanoma will be not considered here since
the BRAF gene mutation, it the main molecular marker, can’t be detected by cytogenetic
procedures.
A consensus is that up to date the role of current chemotherapy with cytotoxic drugs is limited
to palliation, and the efficacy depends on the chemosensitivity of the primary tumor [97]. A
new possibility is to create a therapy that prevents brain metastasis; it will be possible when
targeted therapies to known molecular pathways to brain colonization become clear. This
possibility could become a common strategy to those tumors that frequently form brain
metastases.
On established brain metastases the therapy mainly consists on the use of whole brain radiation
therapy (WBRT). Less frequently targeted agents, either alone or in combination with WBRT,
have been investigated in newly diagnosed brain metastases [98].
A correlation can be made to Non-small Cell Lung Cancer (NSCLC). NSCLC patients show
activating epidermal growth factor receptor (EGFR) mutations in 10-25% of the cases, with the
highest prevalence in never-smoking women from East Asia, in up to 55%. Erlotinib and
gefitinib, EGFR tyrosine kinase inhibitors, have been demonstrated to be useful in patients
with brain metastases from NSCLC [99-106]. Nevertheless, Brain metastasis from NSCLC
patients with mutant EGFR confronted with those wild type EGFR have demonstrated an
improved overall survival, when receiving EGFR inhibitors [107]. Another molecular marker
in NSCLC patient, a FISH detectable rearrangement in 2p23 in 4% of patients, the ALK
rearrangement can be treated with crizotinib (a specific ALK inhibitor) demonstrating
objective response or stabilization of the malignancy [108]. A speculation about a brain barrier
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to crizotinib agent could permit a poorer penetration into the brain leading to a lower efficacy,
but no data about any treatment with crizotinib to brain metastasis exist to date [109].
The most informative molecular marker on brain metastases of breast cancer came from
HER2. Breast tumors positive for HER2, triple negative lacking expression of HER2, estrogen
and progesterone receptors, or the basal-like subtype form the high risk group that can
metastasize to brain. The HER2 breast cancer patients represent 25% of overall population, and
have the highest risk of brain metastases development, especially if estrogen/progesterone
negative [110]. A recent work analyzed alterations on chromosome 17 in metastatic brain
tumors from breast cancers using a dual color experiment with CEP17 and TP53 locus specific
probe. The result was a high incidence of chromosome 17p deletion in these neoplasms,
suggesting a role of 17p loss in the metastatic capability acquisition for breast tumor cells [111].
When breast cancer patients are treated with trastuzumab, a monoclonal antibody that target
HER2, 25-40% tend to present brain metastasis [112-116], which can increase when compared
with trastuzumab-no treated patients [117]. An explanation is that trastuzumab efficiently
controls the systemic disease spread [118], associated with a HER2 propensity to brain
colonization [119, 120] and with the trastuzumab decreases penetration through the blood-
brain barrier [118]. Recent works have demonstrated that a higher penetrance of trastuzumab
into the brain, which could be provided by lesion in blood-brain barrier or increased vascular
permeability driven by tumor activity or by radiation therapy, have revealed an improved
prognosis to HER2-positive patients with brain metastases [116, 121-124].
The HER2 gene, a member of EGFR gene family, is located on 17q21.1 and the amplification
can be detected by a FISH experiment. HER2 protein overexpression can be detected by an
immunohistochemistry method. Both, FISH or immunohistochemistry, can be made in
paraffin-embedded tissues. The higher cost and longer time required to cell scoring in FISH
experiments make the immunohistochemistry the most utilized procedure in laboratories, but
FISH was demonstrated as more efficient and accurate scoring systems to determine HER2
amplification than immunohistochemistry [125, 126]. More recently, a study aimed to deter‐
mine a relationship between HER2 protein expression level or HER2 gene amplification ratio
(by FISH with a HER2 gene probe and CEP17 probe in a dual color experiment) correlated
with the time to brain metastases formation in HER2+ advanced breast cancer patients. It
showed that HER2 protein expression level detection demonstrated a more sensitive method
to determinate the time to brain metastases, shown a shorter time to brain metastases in higher
level of HER2 protein expression [127].
10. Conclusions
After analyzing all these cumulative information, one can conclude that chromosomal analysis
of brain tumors can strongly improve the clinical diagnostic and prognostic in clinical practice
and the knowledge about the biology of brain tumors. This information has helped in the choice
of the best therapy in widely studied tumor types, and could help even more. Also, the great
number of chromosome abnormalities associated to specific tumor entities improves the search
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the BRAF gene mutation, it the main molecular marker, can’t be detected by cytogenetic
procedures.
A consensus is that up to date the role of current chemotherapy with cytotoxic drugs is limited
to palliation, and the efficacy depends on the chemosensitivity of the primary tumor [97]. A
new possibility is to create a therapy that prevents brain metastasis; it will be possible when
targeted therapies to known molecular pathways to brain colonization become clear. This
possibility could become a common strategy to those tumors that frequently form brain
metastases.
On established brain metastases the therapy mainly consists on the use of whole brain radiation
therapy (WBRT). Less frequently targeted agents, either alone or in combination with WBRT,
have been investigated in newly diagnosed brain metastases [98].
A correlation can be made to Non-small Cell Lung Cancer (NSCLC). NSCLC patients show
activating epidermal growth factor receptor (EGFR) mutations in 10-25% of the cases, with the
highest prevalence in never-smoking women from East Asia, in up to 55%. Erlotinib and
gefitinib, EGFR tyrosine kinase inhibitors, have been demonstrated to be useful in patients
with brain metastases from NSCLC [99-106]. Nevertheless, Brain metastasis from NSCLC
patients with mutant EGFR confronted with those wild type EGFR have demonstrated an
improved overall survival, when receiving EGFR inhibitors [107]. Another molecular marker
in NSCLC patient, a FISH detectable rearrangement in 2p23 in 4% of patients, the ALK
rearrangement can be treated with crizotinib (a specific ALK inhibitor) demonstrating
objective response or stabilization of the malignancy [108]. A speculation about a brain barrier
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to crizotinib agent could permit a poorer penetration into the brain leading to a lower efficacy,
but no data about any treatment with crizotinib to brain metastasis exist to date [109].
The most informative molecular marker on brain metastases of breast cancer came from
HER2. Breast tumors positive for HER2, triple negative lacking expression of HER2, estrogen
and progesterone receptors, or the basal-like subtype form the high risk group that can
metastasize to brain. The HER2 breast cancer patients represent 25% of overall population, and
have the highest risk of brain metastases development, especially if estrogen/progesterone
negative [110]. A recent work analyzed alterations on chromosome 17 in metastatic brain
tumors from breast cancers using a dual color experiment with CEP17 and TP53 locus specific
probe. The result was a high incidence of chromosome 17p deletion in these neoplasms,
suggesting a role of 17p loss in the metastatic capability acquisition for breast tumor cells [111].
When breast cancer patients are treated with trastuzumab, a monoclonal antibody that target
HER2, 25-40% tend to present brain metastasis [112-116], which can increase when compared
with trastuzumab-no treated patients [117]. An explanation is that trastuzumab efficiently
controls the systemic disease spread [118], associated with a HER2 propensity to brain
colonization [119, 120] and with the trastuzumab decreases penetration through the blood-
brain barrier [118]. Recent works have demonstrated that a higher penetrance of trastuzumab
into the brain, which could be provided by lesion in blood-brain barrier or increased vascular
permeability driven by tumor activity or by radiation therapy, have revealed an improved
prognosis to HER2-positive patients with brain metastases [116, 121-124].
The HER2 gene, a member of EGFR gene family, is located on 17q21.1 and the amplification
can be detected by a FISH experiment. HER2 protein overexpression can be detected by an
immunohistochemistry method. Both, FISH or immunohistochemistry, can be made in
paraffin-embedded tissues. The higher cost and longer time required to cell scoring in FISH
experiments make the immunohistochemistry the most utilized procedure in laboratories, but
FISH was demonstrated as more efficient and accurate scoring systems to determine HER2
amplification than immunohistochemistry [125, 126]. More recently, a study aimed to deter‐
mine a relationship between HER2 protein expression level or HER2 gene amplification ratio
(by FISH with a HER2 gene probe and CEP17 probe in a dual color experiment) correlated
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10. Conclusions
After analyzing all these cumulative information, one can conclude that chromosomal analysis
of brain tumors can strongly improve the clinical diagnostic and prognostic in clinical practice
and the knowledge about the biology of brain tumors. This information has helped in the choice
of the best therapy in widely studied tumor types, and could help even more. Also, the great
number of chromosome abnormalities associated to specific tumor entities improves the search
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for target genes or cell pathways that direct or indirect act in tumorigenesis or tumor progres‐
sion. On the other hand, if Li’s theory [13] is true and the tumors are generated by aneuploi‐
dogenics carcinogens or mutations, targeted preventions to avoid aneuploidy/aneuploidy cells
or a methodology that enhances genomic stability/cell defense mechanisms against cells with
CIN could provide an effective approach.
Similarly, it is clear that some chromosomal alterations are more important to a wide range of
brain tumor, participating in the genesis, progression, metastases and others hallmarks of
cancer than to a specific entity. Alterations on chromosome 1, 7, 8, 10, 17 and 22 appear to be
important to a variety of tumors of the brain. 1q gain is an example of alteration that leads to
a worse prognosis, correlated with tumor recurrence or progression. At the same way, 17q
gains and 17p losses almost always represent a poor prognosis. The presence of important
tumor suppressor genes or oncogenes in these loci can explain its higher participation on the
evolution of tumors cells to achieve the malignancy. Gain of chromosome 7q could be related
with EGFR amplification, which is implicated with a large number of brain tumors entities.
Likewise 17q gain could be related to HER2 amplification, or 17p losses could be associated
with the selective advantage of TP53 pathways inactivation.
Obviously, as molecular markers, locus amplifications/deletions, structural abnormal chro‐
mosomes or aneuploidies are important genetic mutations that confer to tumors different
clinical and biological behavior. These markers can be applied in clinical routine to determine
prognostic, a better diagnostic or indicate alternative chemotherapy to brain tumor patient
treatment.
Nomenclature
AT/RT Atypical Teratoid/Rhabdoid Tumors
BRAF v-raf murine sarcoma viral oncogene homolog B1
CDK6 cyclin-dependent kinase 6
CDKN2A cyclin-dependent kinase inhibitor 2A
CDKN2A/p16INKa cyclin-dependent kinase inhibitor 2A (encoding p16)
CDKN2B/p15ARF cyclin-dependent kinase inhibitor 2B (encoding p15)
CGH Comparative Genomic Hybridization
CIN Chromosomal Instability
CML Chronic Myelogenous Leukemia
CNS Central Nervous System
DM Double-minutes
EGFR Epidermal Growth Factor Receptor
ETANTR Embryonal Tumors with Abundant Neuropil and True Rosettes
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ETMR Embryonal Tumors with Multilayered Rosettes
FISH Fluorescence in situ Hybridization
GBM Glioblastomas
GEP Gene Expression Profile
HER2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog
HSR Homogeneously Staining Region
IDH1 isocitrate dehydrogenase 1
IDH2 isocitrate dehydrogenase 2
Ink4A/Arf cyclin-dependent kinase inhibitor 2A




MYC v-myc myelocytomatosis viral oncogene homolog
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
NF-kB Nuclear Factor kappa B
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
NSCLC Non-small Cell Lung Cancer
OTX2 orthodenticle homeobox 2
P14ARF cyclin-dependent kinase inhibitor 2A (encoding p14)
PCR Polymerase Chain Reaction
PNET Primitive Neuroectodermal Tumors
PTEN phosphatase and tensin homolog
SCNA Somatic Copy Number Aberrations
SHH Sonic Hedgehog
SKY Spectral Karyotyping
SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily
b, member 1.
TGF-β transforming growth factor, beta
TP53 tumor protein p53
USP4 ubiquitin specific peptidase 4
WBRT Whole Brain Radiation Therapy
WHO World Health Organization
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1. Introduction
Brainstem gliomas are a heterogeneous group of tumors occurring in the brainstem and
cervicomedullary junction.  They occur  more  often in  children than in  adults.  Brainstem
tumors,  according  to  data  prior  to  early  1980s,  represent  10-20% of  all  central  nervous
system neoplasms in the pediatric population [1-3]. Approximately 90% of brainstem tu‐
mors are gliomas in origin [4].
Diffuse intrinsic pontine glioma (DIPG) is the most common type representing approximate‐
ly 80% of brainstem gliomas [5, 6]. They have a dismal prognosis with a median survival of
only a year. Their natural history is often compared to but worse than that of supratentorial
glioblastoma seen primarily in the adult population. Nondiffuse brainstem gliomas, includ‐
ing focal, dorsal exophytic and cervicomedullary gliomas, are encountered less often and
have a better prognosis. However, if untreated, they could also lead to progressive brain‐
stem dysfunction and ultimately death.
2. Epidemiology
True incidence studies of brainstem gliomas are lacking. According to the Central Brain Tu‐
mor Registry of the United States, there were 400-450 cases of brainstem gliomas in children
per year in the U.S. during 2004-2008, representing 10.7% of primary central nervous system
tumors [7]. This number is higher than those previously estimated for the period between
1970s-1990s [8]. The increase is thought primarily to be a result of increased detection by the
use of magnetic resonance imaging (MRI) and better data reporting as opposed to a true in‐
crease in the incidence of these tumors.
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The most common age at diagnosis for DIPG is 5-9 years old with a median of 6.5 years, but
cases have been seen in all age groups from infants to adults [5, 9]. Nondiffuse brainstem
gliomas have roughly the same age distribution.
Neurofibromatosis type 1 (NF1) patients have higher incidence of brainstem gliomas. These
tumors, whether diffuse or nondiffuse, appear to have a more benign course compared with
tumors from patients without NF1 [10].
There does not appear to be a sex predilection in any of the brainstem tumor subgroups [5,
9]. Because of the low incidence and lack of diagnosis in less developed countries, there is
not sufficient data to determine if there is a geographic propensity. No specific risk factors,
either environmental or infectious, have been described to be related to the incidence of
brainstem gliomas.
3. Classification
Brainstem gliomas are classified based on their location, focality and growth patterns. Clas‐
sification systems were created using the current form of imaging available. Brainstem glio‐
mas can be broadly categorized as diffuse intrinsic pontin glioma (DIPG) and nondiffuse
brainstem gliomas. Nondiffuse brainstem gliomas can be further classified into three
groups: focal gliomas (tectal and other locations), dorsal exophytic gliomas and cervicome‐
dullary gliomas.
DIPG accounts for approximately 80% of brainstem gliomas in children [5, 6]. Surgical resec‐
tion is not possible due to the location and infiltrative nature of the tumor. The standard of
care for DIPG is radiation therapy. They have a median survival of about 10-12 months [6].
Focal gliomas account for about 5% of brainstem gliomas in children. They may be located
anywhere within the brainstem but are typically not in the ventral pons. Most focal gliomas
occur in the midbrain, especially the tectum of the midbrain. Focal gliomas in other areas of
the brainstem, such as medulla, are less often seen. As a result, some discussions about focal
gliomas may focus on tectal gliomas. Focal gliomas have well defined margins. They usually
have an indolent course, and depending on location, are often amenable to surgical resec‐
tion. The majority of tectal glioma patients have non-communicating hydrocephalus at ini‐
tial presentation due to compression of cerebral aqueduct. Focal gliomas have a good
prognosis [11].
Dorsal exophytic gliomas account for 10-15% of brainstem gliomas in children. They present
insidiously with a long history of nonspecific headache and vomiting. They are amenable to
surgical resection. These tumors have a good outcome after surgical resection [12].
Cervicomedullary gliomas account for 5-10% of brainstem gliomas in childrens. They arise
from the lower medulla or the upper cervical spinal cord. They are amenable to surgical re‐
section. Long-term tumor control can be achieved in most patients with surgical resection
alone [13, 14].
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4. Pathology and pathophysiology
Brainstem gliomas are typically astrocytomas. Focal, dorsal exophytic and cervicomedullary
gliomas are usually pilocytic astrocytoma (WHO grade I) and fibrillary astrocytoma (WHO
grade II). Other low-grade gliomas with indolent growth such as ganglioglioma are also
seen. DIPGs are typically anaplastic astrocytoma (WHO grade III) and glioblastoma multi‐
forme (WHO grade IV). Growth of low-grade gliomas typically respect fiber tracts and pial
borders. In contrast, high-grade gliomas grow and expand without respecting anatomic
boundaries of these surrounding tissues.
70-90% of DIPGs are anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme
(WHO grade IV) if biopsied before radiation therapy is given [15-17]. The remainders are
mainly fibrillary astrocytoma (WHO grade II). At a later stage, invasion of adjacent levels of
the brainstem and cerebellar peduncles is common. At autopsy, the vast majority of DIPGs
are high-grade and more than 50% have disseminated within the neuraxis [18].
Most focal gliomas are low-grade [11, 19]. Low-grade gliomas seen in this subgroup include
pilocytic astrocytoma, fibrillary astrocytoma and ganglioglioma. Most tectal gliomas cause
hydrocephalus at an early stage due to its compression on the cerebral aqueduct.
Dorsal exophytic gliomas arise from subependymal glial tissue. Over 90% of these tumors
are pilocytic astrocytomas [20] that grow along the path of least resistance. As a result, most
of the tumor extends into the fourth ventricle rather than infiltrating the brainstem ventrally.
Tumors that extend laterally and/or ventrally into the brainstem are usually more aggressive
and of higher grade on pathological examination.
Cervicomedullary  gliomas  arise  from either  the  lower  medulla  or  upper  cervical  spinal
cord.  Most  of  them are  low-grade astrocytomas,  but  gangliogliomas and ependymomas
are also seen [14,  21].  Tumors with epicenters  in the upper cervical  cord grow dorsally
into the cisterna magna.  Those with epicenters  in the lower medulla  grow centrifugally
as focal nodules.
5. Molecular genetics
Partially because of the low incidence of brainstem gliomas, their molecular genetics is less
studied compared with some more common primary central nervous system tumors. How‐
ever, there are some significant advances in the last a few years concerning both DIPG and
focal brainstem gliomas.
DIPGs are genetically complex and distinct from both adult and pediatric supratentorial
high-grade gliomas (HGG). Recent evidence points to platelet-derived growth factor (PDGF)
and its receptors (PDGFR) as among the major driving forces of tumorigenesis in the majori‐
ty of cases [22-26]. Another type of growth factor receptors involved in DIPG is epidermal
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grade and less than 20% of low grade DIPG by immunohistochemistry staining [27]. The
same study also reported that 25% of grade III and 50% of grade IV tumors had EGFR gene
amplification. Recent data show that strong EGFR immunohistochemistry staining was seen
in about 27% cases [23], lower than in the earlier report, and that amplification rate of the
EGFR gene is also much lower (about 7-9%) [23, 25]. Unlike the case in pediatric supratento‐
rial HGG, CDKN2A deletion is non-existent in DIPG [25, 28] and amplification of CDK4 and
CDK6 only occurs at a low rate [25]. Approximately 50% of DIPG had p53 mutation [29, 30]
and three groups reported loss of a region of 17p containing the p53 gene in 31%, 57% and
64% cases, respectively [23, 28, 31]. In approximately 50% of DIPG patients, allelic loss of a
region of 10q where PTEN is located was observed [31-33].
There  have been fewer  molecular  genetics  studies  of  nondiffuse  brainstem gliomas.  Re‐
cently  it  was  reported that  BRAF gene  duplication and mutation are  often  observed in
pediatric  pilocytic  astrocytomas  and  fibrillary  astrocytomas,  including  those  located  in
the brainstem [34-36].
6. Clinical presentation
The clinical behavior and presentation of brainstem gliomas are highly variable, depending
on the anatomic location and growth pattern of the tumor, age of the patient and certain oth‐
er factors. Symptom evolution reflects aggressiveness of the tumor. Low-grade tumors typi‐
cally present with an insidious course over several months of gradual symptom progression.
By comparison, a shorter and more abrupt onset of symptoms is indicative of higher-grade
tumors.
Nondiffuse gliomas are often low-grade lesions with expectedly slow growth. Symptoms
are insidious in onset and may not be readily appreciated. Careful history taking, including
comparison to photographs, may be necessary to evaluate subtle changes associated with
cranial nerve dysfunction in these slow-growing tumors. DIPGs, in comparison, typically
present with a short prodrome of symptoms (usually 1-2 months or shorter) [9].
In brainstem gliomas, the pattern of symptoms reflects the extent of the tumor. Diffusely
growing tumors are associated with multiple and bilateral cranial neuropathies, long tract
signs and ataxia. Hydrocephalus in these tumors is uncommon at initial presentation. Non‐
diffuse gliomas often present with isolated cranial neuropathies, signs and symptoms of in‐
creased intracranial pressure, and ataxia. Rarely, hemiparesis may be part of the clinical
presentation.
Brainstem glioma patients can have a combination of the following at presentation.
Cranial neuropathies are common in most tumors of the brainstem. Simultaneous involve‐
ment of multiple cranial nerves is more frequently encountered with diffuse lesions. Focal
lesions, in contrast, are often associated with more limited cranial nerve involvement. Upper
brainstem involvement is often associated with oculomotor deficits, and lesions of the lower
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brainstem are frequently found to have lower cranial nerve involvement resulting in
changes in voice, dysphagia and/or aspiration pneumonias.
Long tract signs, including motor dysfunction and hyperreflexia, are most often associated
with diffusely growing tumors or focal tumors of the cervicomedullary junction. Long tract
signs are often conspicuously absent with dorsal exophytic gliomas [12].
In brainstem glioma patients, ataxia can be a result of loss of proprioceptive sensation, CN
VIII involvement and/or invasion of cerebellar peduncles by the tumor. Ataxia is frequently
seen in DIPG patients.
Obstructive hydrocephalus is usually the first sign seen in focal tectal gliomas as a result of
the tumor compressing cerebral aqueduct. Hydrocephalus and its associated signs and
symptoms are also often seen in dorsal exophytic gliomas which grow dorsally into the
fourth ventricle resulting in the obstruction of normal cerebrospinal fluid (CSF) flow.
Failure to thrive is commonly encountered in infants with tumors of the cervicomedullary
junction due to lower cranial nerve dysfunction resulting in swallowing difficulties.
6.1. Diffuse intrinsic pontine gliomas
DIPG patients usually have an acute onset and present with a history of rapid deterioration
of 1-2 months or even shorter. Physical examination reveals classic brainstem signs: cranial
nerve deficits, long tract signs and ataxia, or combinations of the three. At least two of the
triad need to be present along with MRI evidence to establish the diagnosis of DIPG.
Bilateral and multiple cranial nerve involvement is frequent in DIPG. Abducens (CN VI)
palsy is the most frequent cranial neuropathy at presentation [5]. Facial palsy is also fre‐
quently seen at initial presentation. Involvement of CN VIII causes deadness and contrib‐
utes to ataxia. Lower cranial nerve involvement causes aspiration, and difficulty in speech,
swallowing and maintaining normal head positions.
These  children  often  present  with  severe  limb weakness  and hyperreflexia,  resulting  in
their  difficulty  to  walk  and  sometimes  even  to  sit.  Long  tract  involvement  also  causes
loss  of  tactile,  nociceptive  and proprioceptive  sensations,  causing  numbness  and contri‐
buting to ataxia.
In DIPG patients, both CN VIII involvement and loss of proprioceptive sensation contribute
to ataxia. Invasion of cerebellar peduncles is also common in DIPG, which is another factor
contributing to ataxia.
DIPG patients may also have other symptoms including headache, nausea and vomiting etc.
indicating increased intracranial pressure from edema or hydrocephalus. Approximately
10% of DIPG patients have hydrocephalus at initial presentation [5].
6.2. Focal gliomas
Focal gliomas can occur anywhere in the brainstem, but usually not in the vental pons. Their
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Focal tectal gliomas have an insidious clinical course and often compress on cerebral aque‐
duct to cause a non-communicating hydrocephalus [11, 37]. As a result the initial presenta‐
tion is usually those signs reflecting increased intracranial pressure: headache, vomiting,
diplopia and papilledema.
Focal gliomas in the midbrain tegmentum and the medulla are usually larger than tectal
gliomas and presents with cranial nerve dysfunction, long tract signs and ataxia [11, 38].
6.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas grow into the fourth ventricle and typically present with signs
and symptoms of increased intracranial pressure including headache, nausea and/or vomit‐
ing, lethargy, downward gaze preference, changes in vision and cranial nerve palsies (in‐
cluding abducens palsy). Infants with these tumors may present primarily with failure to
thrive. Long tract signs are rare with these tumors [12].
6.4. Cervicomedullary gliomas
Cervicomedullary gliomas usually have an indolent course because the majority of these tu‐
mors are slow growing low-grade lesions. Two presenting syndromes have been described
based on the epicenter of these tumors [39]. Medullary syndrome often presents as a failure
to thrive secondary to nausea, vomiting or dysphagia. Also seen with this syndrome are
sleep apnea, dysarthria and recurrent upper respiratory tract infections. Cervical cord syn‐
drome presents with chronic neck pain and/or progressive myelopathy with spasticity and
weakness. Hydrocephalus is unusual in cervicomedullary gliomas.
7. Imaging studies
Diagnosis of brainstem gliomas is based on clinical presentations and imaging studies. MRI
is the imaging method of choice because of its high resolution and ability to differentiate the
natures of lesions (tumor vs. inflammation etc.), which is especially important in the diagno‐
sis of DIPG. MRI enables identification of important anatomic features and localization of
tumors with multi-planar views. It allows a precise evaluation of the growth pattern and ac‐
curate preoperative diagnosis in most cases. Both T1- and T2-weighted axial and sagittal se‐
quences should be obtained for the basic studies. Other useful sequences include fluid
attenuated inversion recovery (FLAIR), diffusion tensor imaging (DTI), gradient echo (GRE)
and susceptibility weighted imaging (SWI). DTI tractography may be useful in evaluating
the relationship between the tumor and white matter tracts [40], which can be a part of the
preoperative planning for nondiffuse brainstem gliomas.
7.1. Diffuse intrinsic pontine gliomas
DIPGs are diagnosed with clinical presentation and magnetic resonance imaging. Since the
publication of the Children's Cancer Group (CCG) report in 1993 [41], when a brainstem tu‐
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mor presents with typical symptoms and radiological appearance, it is usually considered
that these findings are diagnostic and a biopsy is rarely performed. If, however, the clinical
or radiological presentation is not typical, where brainstem encephalitis or an inflammatory
process of the pons cannot be ruled out, a stereotactic biopsy would be needed before initiat‐
ing radiation therapy and/or chemotherapy.
DIPGs infiltrate widely. MRI scans show infiltrative expansion of the pons that is typical‐
ly  hypointense  on  T1-weighted,  hyperintense  on  T2-weighted  and  FLAIR  images,  and
has  no  significant  dorsal  exophytic  component.  Involvement  of  adjacent  levels  of  the
brainstem and/or  cerebellar  peduncles  is  common.  Envelopment  of  the  basilar  artery  is
commonly present  in  DIPG showing the  tumor growing ventrally  outside  of  the  boun‐
dary  of  the  brainstem.  Contrast  enhancement  with  gadolinium is  variable,  with  no  en‐
hancement  being  common  [42].  Enhancement,  if  present,  is  usually  patchy,  without
known prognostic  significance.  Neuraxis  dissemination of  DIPG can be seen on MRI in
more than 50% of patients during progression [18].  In some cases the tumor may show
atypical  features  including  prominent  enhancement  and/or  hypointense  T2-weighted/
FLAIR signals.
Magnetic resonance spectroscopy (MRS) is helpful in differential diagnosis when the tumor
shows atypical features. Increased Cho/NAA (choline/N-acetyl aspartate) and Cho/Cr (chol‐
ine/creatine) ratios in DIPG are useful in differentiating it from brainstem encephalitis, de‐
myelination and other inflammatory processes when clinical and MRI presentations are
atypical [43, 44]. However, the differentiating power of MRS is limited in NF1-associated
DIPG [43].
7.2. Focal gliomas
Before the availability of computed tomography (CT) and MRI for the diagnosis of intracra‐
nial lesions, focal tectal gliomas could only be found in autopsy evaluations. In the 1950s,
when CSF diversion procedures were not as universally successful as of today, Kernohan
and Sayre stated that tectal gliomas were “in all probability the smallest tumors in the hu‐
man body that lead to the death of the patient [45].”
Focal gliomas show as focal lesions on MRI. Focal tectal gliomas are usually isointense on
MRI and show as thickened tectal plate. Tectal gliomas rarely enhance with gadolinium [11,
37]. Central calcification may be noted rarely [46]. Hydrocephalus is seen in the vast majori‐
ty of tectal gliomas, causing symptoms for which the patients are seeking medical attention.
Focal gliomas in other areas of the brainstem are usually hypointense on T1-weighted and
hyperintense on T2-weighted images. The margins are well defined in focal tegmentum and
medullary gliomas, and most are more or less round or spherical. They are frequently cystic
with an intense rim enhancement after intravenous contrast agent administration. Most
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7.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas typically erupt through the pia/ependyma early in their growth,
so imaging will show that the bulk of tumor outside of the brainstem. Imaging of patients
suspected of dorsal exophytic gliomas should include MRI studies with and without intra‐
venous gadolinium of the brain to differentiate this type of tumor from tumors in the fourth
ventricle such as primitive neuroectodermal tumors (PNETs). On MRI, dorsal exophytic
gliomas appear as a dorsal exophytic expansion into the fourth ventricle or below the cere‐
bellum. They usually show as sharply demarcated hypointense signals on T1-weighted and
hyperintense on T2-weighted images. Bright homogeneous contrast enhancement and hy‐
drocephalus are common MRI findings [20].
7.4. Cervicomedullary gliomas
Imaging of patients suspected cervicomedullary gliomas should include MRI studies with
and without intravenous gadolinium of the brain and cervical spine to determine the extent
of tumor growth and involvement.
Cervicomedullary gliomas arise from either the lower medulla or upper cervical spinal cord.
Growth pattern of the tumor will give some hints as to their epicenters and what structures
are being placed at risk by tumor growth. Tumors with epicenters in the upper cervical cord
will have their rostral growth blocked by the decussating fibers of the sensory and motor
pathways. Instead, the tumor curves dorsally to grow into the cisterna magna at the cervico‐
medullary junction. Tumors with epicenters in the lower medulla grow centrifugally as focal
nodules pushing the surrounding fibers to their side [21].
Cervicomedullary gliomas appear as solid masses within the above-described areas. They
are hypointense on T1-weighted and hyperintense on T2-weighted images. They typically
enhance homogeneously upon gadolinium injection.
8. Diagnosis and differential diagnosis
Diagnosis of brainstem gliomas is based on clinical presentations and imaging studies and
needs to address the location and nature of the lesion.
It is expected that the patient's clinical course, examination and imaging studies be in agree‐
ment. With nondiffuse brainstem gliomas this congruence often prompts surgical interven‐
tion (resection and/or relief of hydrocephalus), particularly for those located at the
cervicomedullary junction or dorsal exophytic in growth.
Incongruence between presentation and clinical studies suggests the need for biopsy prior
to definitive treatment. In cases with disagreement between the imaging findings and clini‐
cal course (i.e. rapidly progressive course with imaging consistent with a focal or low-grade
lesion), frozen sections should be obtained at the time of surgery prior to progressing to an
aggressive resection. These instances may be representative of a more malignant tumor in
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which case the potential for iatrogenic injury during resection outweighs the potential bene‐
fit of an extensive resection.
Differential diagnosis includes other tumors in the brainstem and adjacent regions and le‐
sions of other natures. Other tumors include lymphoma, metastatic tumors, germinoma and
nongerminomatous germ cell tumors, PNET, hemangioblastoma, lipoma, acoustic neuroma,
etc. Some of these tumors typically arise from nearby regions and may encroach into the
brainstem, e.g., primary intracranial germ cell tumors usually occur in the pineal region and
can invade the brainstem. The majority of nongerminomatous germ cell tumors can be dif‐
ferentiated by testing for secreted markers in the blood such as α-fetoprotein and β-human
chorionic growth hormone. PNET occurring in the brainstem, even though relatively rare,
can appear similar to DIPG or nondiffuse brainstem gliomas. Because of the difference in
treatment options from those for brainstem gliomas, it should be carefully differentiated
when suspected. Lesions of other natures include infectious, autoimmune, other inflamma‐
tory, vascular and metabolic lesions etc.
The role of biopsy in the diagnosis of DIPG remains intensely debated [47, 48]. Before the
wide adoption of MRI in the diagnosis of brainstem gliomas, biopsy was performed to con‐
firm diagnosis and provide information on prognosis. However, biopsy has been only per‐
formed infrequently since mid-1990s. Of note is that since the Children's Cancer Group
(CCG) report in 1993 [41], MRI has superseded biopsy as the main method of diagnosing
DIPG. As better methods to characterize tumors become available and more molecularly tar‐
geted therapies have become available or are under development in recent years, there are
increasing calls to perform biopsy more frequently in clinically diagnosed DIPGs. Brainstem
biopsy is safe with low morbidity and mortality rates [49-51]. Survey showed that parents of
children with DIPG are generally amenable to biopsy, even if the results may not benefit the
patient [52]. Various focus groups have been holding discussions on criteria of recommend‐
ing biopsy. Some investigational protocols of DIPG have included biopsy and molecular
characterization as mandatory components in stratifying subjects for experimental therapy.
9. Treatment
Treatment of brainstem gliomas includes management of pain, bulbar symptoms and motor
impairment, relief of hydrocephalus and general support. Brainstem glioma patients should
be cared for by a multidisciplinary team including neurosurgeons, non-surgical specialists
and other therapists.
Surgical intervention is indicated for certain nondiffuse brainstem gliomas. Tectal gliomas
are usually indolent and present with hydrocephalus. Hydrocephalus is relieved by endo‐
scopic third ventriculostomy (ETV) or ventricular shunt placement. Early resection of tectal
gliomas is controversial. Dorsal exophytic gliomas are the most amenable to surgical resec‐
tion in brainstem gliomas. The goal is to remove the exophytic component, and when safe,
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mended early for cervicomedullary gliomas. Subtotal resection can be safely performed in
most cases.
Adjuvant therapy for brainstem gliomas depends on the tumor location, pathological diag‐
nosis and extent of previous surgical resection. Radiation therapy is the standard of care for
DIPG, but it is not recommended as an early treatment for nondiffuse brainstem gliomas if
pathology shows a low-grade glioma. It is usually used in patients with high-grade patholo‐
gy, upon clinical and imaging evidence of progression, or late in the disease course [5, 38].
Stereotactic radiosurgery is also used in nondiffuse brainstem gliomas. Chemotherapy has
limited use in the management of brainstem gliomas. It is mainly used for high-grade path‐
ology or at late stage of the disease.
9.1. Diffuse intrinsic pontine glioma
Surgical resection of DIPG is not safe because of its location and infiltrative nature. Biopsy is
not indicated for patients with typical clinical presentation and MRI findings. Hydrocepha‐
lus, if present, should be treated with either an ETV or a shunt. A histological confirmation
might be needed if imaging or clinical history is not typical for a DIPG, or if an investiga‐
tional protocol requests it.
The standard of care for DIPG is involved field external beam radiation therapy, typical‐
ly delivered at 1.8Gy/fraction for 30-33 fractions in the North America. Significant clinical
improvement occurs in 85% of patients receiving radiation therapy, but the improvement
is usually transient,  lasting only 3-4 months,  before progressive decline in clinical status
returns [6].
Various chemotherapeutic regimens have been studied either alone or in combination with
radiation therapy. However, up to date, no chemotherapeutic agent, either alone or in com‐
bination, or in conjunction with radiation therapy, has altered the natural history of DIPG.
Many patients are enrolled in clinical trials of new agents or previously used agents in pre‐
viously untested combinations.
9.2. Focal gliomas
Most tectal gliomas in children have indolent growth with few symptoms except those
caused by hydrocephalus. Early resection of focal tectal gliomas is controversial and infre‐
quently done. Often, these tumors are managed by relief of hydrocephalus, followed by clin‐
ical observation and periodic MRI scans [53, 54]. Treatment of the hydrocephalus typically
includes ETV to restore CSF flow. Shunting is an alternative or can be considered for pa‐
tients who fail ETV. Surgical resection may be considered on rare occasions.
Focal gliomas in other areas of the brainstem, including tegmentum and medulla, are usual‐
ly indicated for surgical resection. Tissue diagnosis before radical resection is indicated for
lesions with atypical clinical and imaging findings. For those patients initially put on obser‐
vation, when tumor progression is observed, biopsy or sometimes radical resection is indi‐
cated. Transventricular endoscopic biopsy may be performed with or without CSF diversion
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when the tumor is adjacent to a ventricle’s walls [55]. Stereotactic biopsies may be consid‐
ered for lesions that cannot be approached with endoscopy where accurate histological diag‐
nosis is warranted but more aggressive surgical resection is deemed unsafe. Surgical
resection of focal, well-circumscribed lesions provides not only a tissue diagnosis but also a
prolonged event-free survival in many cases.
Conventional radiation therapy has demonstrated limited efficacy in patients with focal
gliomas. Tumors with high-grade features should be treated with radiation therapy after re‐
covery from surgery or when surgery is not indicated, while low-grade tumors may be ob‐
served and treated only if there is subsequent tumor progression [5, 38]. Implantation of
iodine-129 (I-129) or iodine-125 (I-125) seeds has been used in some patients with acceptable
tumor control. I-125 is an alternative to resection, external beam radiation therapy and che‐
motherapy in children with progressively symptomatic low-grade gliomas in deep and elo‐
quent areas where high postoperative morbidity would be expected with open surgery [56].
Stereotactic radiosurgery has been used as an alternative means for managing focal brain‐
stem gliomas [57]. Its use has been reported in patients with progressive tumor growth or
worsening neurological deficits.
The role of chemotherapy has not been well evaluated for focal brainstem gliomas. In gener‐
al, for tumors that total or subtotal resection has been performed on and subsequently prog‐
ress, chemotherapy may be considered with or without radiation therapy. In children
younger than 3 years old, chemotherapy may be used alone in attempts to delay the need
for radiation therapy.
9.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas are the group most amenable to surgical resection among brain‐
stem gliomas and total or near total resection alone usually results in a good prognosis [12,
20]. Long-term event-free survival is expected when these tumors are simply shaven down
to the level of the floor of the fourth ventricle. They should not be aggressively "chased" into
the brainstem. In patients with findings consistent with an obstructive hydrocephalus who
have not previously undergone a CSF diversion procedure (e.g. ETV or shunting), place‐
ment of an external ventricular drain may be considered. Tumor specimens should be sent
early for frozen sections. A high-grade lesion is an indication to halt the surgery, as there is
no proven long-term benefit to debulking aggressive lesions. Resection of the tumor takes
place primarily within the fourth ventricle on the extra-axial part. In instances where there is
a large intramedullary component to the tumor or if it is felt that damage to the functional
tissues of the brainstem would be unavoidable, subtotal resection should be attempted.
Some have advocated that resection carried to the level of the floor of the fourth ventricle
confers a sufficient balance between disease control and preservation of neurological func‐
tion by minimizing the risk of injuring functional brainstem tissues.
Radiation therapy is used for inoperable tumors or recurrent disease not amenable to re-re‐
section [5, 38]. Treatment primarily consists of conventional external beam radiation therapy
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no proven long-term benefit to debulking aggressive lesions. Resection of the tumor takes
place primarily within the fourth ventricle on the extra-axial part. In instances where there is
a large intramedullary component to the tumor or if it is felt that damage to the functional
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Some have advocated that resection carried to the level of the floor of the fourth ventricle
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Radiation therapy is used for inoperable tumors or recurrent disease not amenable to re-re‐
section [5, 38]. Treatment primarily consists of conventional external beam radiation therapy




and radiosurgery has also been examined in small cohorts. Chemotherapy has no proven ef‐
ficacy in the treatment of dorsal exophytic gliomas [61].
9.4. Cervicomedullary gliomas
Cervicomedullary  gliomas  are  treated  in  a  fashion  similar  to  that  of  an  intramedullary
spinal  cord  glioma  or  a  focal  glioma  of  the  medulla  depending  on  the  location  of  the
epicenter.  Specimens  should  be  sent  early  for  frozen  sections.  Identification  of  a  high-
grade lesion is an indication to halt the surgery, as there is no proven long-term benefit
to debulking aggressive lesions.  Surgical  resection should begin with internal  debulking
from the center to periphery.
As the majority of these tumors are low grade, surgery is typically the initial treatment mo‐
dality. Radiation therapy should be reserved for advanced or recurrent diseases not amena‐
ble to surgical resection [5, 38]. Treatment primarily consists of conventional fractionated
external beam radiation given at 1.8Gy/fraction for 30-33 fractions [58-60]. The use of stereo‐
tactic radiation therapy and radiosurgery has also been examined in small cohorts. Al‐
though a number of trials have examined the efficacy of chemotherapy in the treatment of
DIPG, no role has been defined for its use in the treatment of cervicomedullary tumors [61].
10. Outcomes
The outcome of brainstem gliomas depends on the location and pathological grade of the
tumor. Focal, dorsal exophytic and cervicomedullary gliomas typically have a fairly good
prognosis. In contrast, the median survival of DIPG patients is only about one year despite
numerous investigational therapies. In both DIPG and nondiffuse brainstem gliomas, pa‐
tients with neurofibromatosis, older age, and longer duration of symptoms before diagnosis
are thought to have a more favorable outcome [10].
10.1. Diffuse intrinsic pontine gliomas
External beam radiation therapy transiently improves the neurological condition in 85% of
DIPG patients, but the disease usually progresses within 3-4 months. No treatment has been
shown to be effective at the time of progression. Clinical deterioration is usually fast once
progression is detected. Median survival is 10-12 months. Only 10% of patients survive be‐
yond two years after diagnosis [6]. Children under the age of 3 years, young adults over 18
and those with NF1 may have a better prognosis.
10.2. Focal gliomas
Lesions typical of tectal gliomas on imaging studies usually need treatment for hydrocepha‐
lus only and rarely progress over many years. Hydrocephalus can be well managed in tectal
gliomas. ETV for tectal gliomas has a success rate exceeding 70% and as high as 90%. Focal
gliomas in other areas of the brainstem, especially if the pathology is pilocytic astrosytoma,
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can be cured by gross total resection but long-term follow-up is necessary. One study noted
a 4-year progression-free survival rate of 94% and an overall 4-year survival rate of 100% in
17 patients with focal midbrain gliomas, which included tectal gliomas [11]. Stereotactic ra‐
diosurgery may be an effective primary treatment or adjunct to open surgery for focal brain‐
stem gliomas. After gamma knife radiosurgery, most patients improved or stabilized but
some worsened [57].
10.3. Dorsal exophytic gliomas
Dorsal exophytic gliomas are amenable to surgical resection. Gross total or subtotal resec‐
tion can be achieved in most cases. They have a good outcome after surgical resection.
Among 18 patients who underwent surgery, 17 survived and only four showed evidence of
radiological progression after a median follow-up of 113 months [12]. Subsequent progres‐
sion may require re-resection or radiation therapy.
10.4. Cervicomedullary gliomas
Tumor control can be achieved by surgical resection in most patients with cervicomedullary
gliomas. 5-year progression-free survival rate is 60% and overall 5-year survival rate about
90% after surgical resection alone [14].
11. Recent advances and future directions
Because of the dismal prognosis of DIPG and the lack of therapeutic efficacy of current che‐
motherapies, innovative approach is urgently needed for the disease. One promising drug
delivery method that may improve the outcome of DIPG patients is convection-enhanced
delivery (CED). Another recent advance is the molecular characterization of DIPG, which
may provide guidance for developing new therapies.
11.1. Convection-enhanced delivery
The blood-brain barrier (BBB) presents a significant obstacle to achieving therapeutic con‐
centrations of systemically delivered agents in brain tumors. Convection-enhanced delivery
(CED) is a method of local delivery that bypasses the BBB [62]. CED is typically accomplish‐
ed by inserting a small-bore cannula directly into a tumor followed by drug infusion
through the cannula. Experimental studies have led to the recognition that CED can be char‐
acterized by several common features:
• Local drug concentration can exceed that achieved with systemic administration by sever‐
al thousand times.
• Systemic exposure by efflux into the vasculature is minimal.
• Tissue penetration by CED is well beyond that achieved by other local delivery methods
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• Distribution is preferentially along white matter tracts, a pattern reminiscent of glioma
cell invasion.
• CED can be used to deliver macromolecules such as monoclonal antibodies or recombi‐
nant toxins, which is not possible by systemic administration in the brain parenchyma or
tumor.
It is hypothesized that CED is ideally suited for the treatment of DIPG based on several fea‐
tures particular to this disease such as the tumor’s relative compact growth pattern, its ten‐
dency to migrate along white matter fibers, the rarity of tumor related cysts and the lack of
cavitary changes from radiation therapy.
The safety of CED in the brainstem has been well established in rodents and non-human pri‐
mates [63-71]. The tolerability of several therapeutic agents delivered using CED into the
brainstem has also been investigated and most of them proven to be safe at high concentra‐
tions [72-78]. This approach has been safely used on a limited clinical basis.
Although it is clear that certain limitations exist in the application of CED for the treatment
of DIPG, currently existing preclinical data are sufficient to guide the design of clinical stud‐
ies. Decisions in the design of these studies include the selection of an appropriate agent or
agents, surgical technique, parameters of infusion, timing of treatment and methods of as‐
sessing distribution, local concentration, safety and therapeutic efficacy. These questions,
however, should not be a barrier for clinical implementation, but rather as goals for early
phase clinical studies. Based on current preclinical data, CED may serve as the basis for a
new approach in the treatment of DIPG.
11.2. Molecular characterization of diffuse intrinsic pontine gliomas
A promising advance that may aid the development of therapeutic agents for the treatment
of DIPG is the recent molecular characterization of this tumor. Four groups independently
discovered that platelet-derived growth factor (PDGF) and its receptors (PDGFR) are ampli‐
fied or over-expressed in the majority of these tumors [22-26]. Another type of growth factor
receptors involved in DIPG is epidermal growth factor receptor (EGFR). Expression of EGFR
was reported in the majority of high grade and less than 20% of low grade DIPG by immu‐
nohistochemistry staining [27]. The same study also reported that 25% of grade III and 50%
of grade IV tumors had EGFR gene amplification. Recent data show that strong EGFR im‐
munohistochemistry staining was seen in about 27% cases [23], lower than in the earlier re‐
port, and that amplification rate of the EGFR gene is also much lower (about 7-9%) [23, 25].
Unlike the case in pediatric supratentorial HGG, CDKN2A deletion is non-existent in DIPG
[25, 28] and amplification of CDK4 and CDK6 only occurs at a low rate [25]. Approximately
50% of DIPG had p53 mutation [29, 30] and three groups reported loss of a region of 17p
containing the p53 gene in 31%, 57% and 64% cases, respectively [23, 28, 31]. In approxi‐
mately 50% of DIPG patients, allelic loss of a region of 10q where PTEN is located was ob‐
served [31-33]. Like in adult malignant gliomas, the interleukin-13 receptor subtype
IL-13Rα2 is highly expressed in DIPG [79].
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Some of these genetic aberrations have been the basis for DIPG animal models that could be
powerful tools for studying the disease, e.g., Becher et al. designed a mouse model of DIPG
based on PDGF overexpression [22]. Some of the molecular abnormalities have already been
used as therapeutic targets. There are therapeutic monoclonal antibodies targeting PDGFR,
namely IMC-3G3 (ImClone) and MEDI-575 (MedImmune), that need to be tested for efficacy
in treating DIPG, preferably delivered through CED into the tumor since they are macromo‐
lecules unable to cross the BBB. There are numerous small molecule tyrosine kinase inhibi‐
tors with strong inhibitory effects on PDGFR and/or EGFR kinases, and inhibitors of
downstream signaling molecules such as AKT and mTOR, that are undergoing clinical trials
for the treatment of DIPG. There are also targeted recombinant toxins, e.g. IL13-PE38QQR,
utilizing IL-13 as the targeting moiety to target tumor cells overexpressing IL-13 receptors.
Even though biopsy of DIPG is far from being routine, when these molecularly targeted
therapies come to clinical use, it would be ideal for the tumor to be pre-screened for specific
targets of those agents.
12. Conclusion
Brainstem gliomas are a heterogeneous group of neoplasms with considerably diverse natu‐
ral histories and prognoses. They are classified into four groups based on their location, fo‐
cality and growth patterns. Diffuse intrinsic pontine gliomas (DIPG) account for
approximately 80% of brainstem gliomas. The overwhelming majority of them is high grade.
They are not resectable and the standard of care is involved field external beam radiation
therapy. They have a dismal prognosis. The vast majority of focal, dorsal exophytic and cer‐
vicomedullary gliomas is low grade, often amenable to surgical resection and has a more fa‐
vorable outcome.
Developing effective  therapy for  DIPG is  so  far  frustrating as  neither  new schedules  of
radiation therapy nor chemotherapeutic regimens being studied have improved survival
of  these  patients.  As  better  molecular  characterization  methods  become available,  there
are increasing calls to perform biopsy and tissue diagnosis in clinically diagnosed DIPGs.
Recent molecular characterization of DIPG identified some genetic aberrations that could
be used as effective therapeutic targets,  including PDGF and PDGF receptors.  There are
both large  and small  molecule  agents  targeting these  genetic  aberrations  that  are  either
available or under development.  However,  most of  these agents are unable to cross the
blood-brain  barrier  (BBB)  to  reach the  tumor.  Convection-enhanced delivery  (CED)  is  a
drug delivery method to  bypass  the  BBB.  It  has  proven capability  to  deliver  high local
drug  concentrations  and  the  safety  of  its  use  in  the  brainstem  has  been  established  in
small  and large  animals  and a  small  number  of  patients.  CED,  combined with  conven‐
tional chemotherapeutic drugs and novel targeted agents, has the potential to produce an
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1. Introduction
Glioma is the most common primary tumors of the central nervous system, accounting ap‐
proximately for 30% of entire CNS tumors, and classified into four clinical grades as I to IV.
The most aggressive and lethal tumors is glioblastoma multiforme (GBM) with median sur‐
vival of only 14.6 months, mainly because of limited effects of conventional post-surgical
chemotherapeutic agents and irradiation [1]. In this chapter, we summarize chemotherapeu‐
tic agents for glioma focusing on their mechanism of anti-tumor action and the acquisition
of resistance to the agents.
2. Temozolomide
2.1. Mechanism of action
Temozolomide (TMZ) is an alkylating agent which is applied to the treatment of malignant
glioma including GBM. TMZ induces DNA methylation of guanine at O6 position (O6-MG;
6% of adducts formed), as well as 7-methylguanine (N7-MG; 70% of adducts formed), and 3-
methyladenine (N3-MA; 9% of adducts formed) [2]. O6-MG incorrectly pairs with thymine
and triggers the mismatch repair (MMR) system leading to double strand break of the ge‐
nome that result in the arrest of cell cycle and induction of apoptosis. N7-MG and N3-MA
are removed by the methylpurine glycosylase followed by AP endonuclease which are the
first two enzymes in the base excision repair (BER) pathway. Efficient BER system functions
and repairs DNA lesions in normal and tumor cells. 573 patients with newly diagnosed as
GBM were randomly assigned to be treated by radiotherapy alone or by radiotherapy plus
continuous daily medication of temozolomide [3]. At a median follow-up of 28 months, the
median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months
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with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-te‐
mozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-
rank test). The two-year survival rate was 26.5 percent with radiotherapy plus
temozolomide and 10.4 percent with radiotherapy alone.
2.2. MGMT – a key molecule for TMZ resistance
MGMT specifically removes the methyl/alkyl group from the O6-position of guanine and re‐
store the guanine to its normal form escaping from DNA strand breaks (Fig. 1). Thus, the ex‐
pression of MGMT in tumors has a protective effect against alkylating agents-dependent cell
death correlating between MGMT activity and TMZ resistance. MGMT expressing tumor cells
exhibit 4- to 10-folds increase of resistance to TMZ, BCNU, and their related compounds [4].
MGMT-mediated repair is unique compared with other DNA repair pathways because : (a) it
acts alone without relying on any other proteins or cofactors; (b) it transfers the alkyl group to
an internal cysteine residue in the protein, acting as both a transferase and an acceptor of the al‐
kyl-group; (c) it inactivates itself after receiving the alkyl-group from guanine, and thus, it is a
suicidal protein; (d) it repairs in a stoichiometric fashion. As one molecule of MGMT removes
one alkyl molecule, an excess of DNA adducts at the O6-position could completely deplete
MGMT. MGMT is ubiquitously expressed in normal human tissues [5] but is overexpressed in
all types of human tumors, including colon cancer, glioma, lung cancer, breast cancer, leuke‐
mia, lymphomas, and myeloma. These properties make MGMT as an important drug resist‐
ance factor and an ideal target for suppression of drug resistance [2].
2.3. Regulation of MGMT
2.3.1. Promoter methylation
It is well known that MGMT expression levels vary widely in tumor cells [6; 7]. Hyperme‐
thylation of CpG islands within the promoter region is associated with epigenetic inactiva‐
tion of the MGMT. In the EORTC trial with 206 GBM patients, MGMT promoter
methylation was observed in 45% cases [8]. In cases with methylated MGMT promoter
which means negative of MGMT expression, TMZ was effective as median survival was 21.7
months treated with TMZ and RT compared with 15.3 months with only RT (P = 0.007). A
study of German Glioma Network (GGN) also showed that MGMT promoter methylation
was associated with prolonged progression-free survival (PFS) and OS in patients receiving
TMZ [9]. Several other studies have also shown predictive and prognostic significance of
MGMT promoter methylation in GBM [10].
2.3.2. Transcriptional regulation
In the MGMT promoter region, there are several specific sequences for the binding of tran‐
scription factors including SP1, GRE, AP-1, and NF-κB, thus MGMT can be induced by glu‐
cocorticoids, cyclic AMP, protein kinase C activators, and NF-κB [11; 12; 13; 14]. p53 is also
reported to suppress MGMT expression by directly binding to the MGMT or by suppressing
the transcription factor of SP1 [15; 16]. In addition, MGMT expression can be induced by ra‐
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diation or other forms of DNA damages [17]. However, physiological roles and regulation
of MGMT induction is not elucidated.
Figure 1. MGMT and other DNA repair mechanisms deal with DNA damage produced by the methylating ther‐
apeutic drug, temozolomide (TMZ), in human cells. TMZ and related drugs cause potentially cytotoxic DNA lesions
such as O6-methylguanine (O6-MG, orange circle) and N7-methylguanine (N7-MG, brown circle). (i), MGMT (O6-MG
DNA methyltransferase) removes the O6-alkylguanine DNA adduct through covalent transfer of the alkyl group to the
conserved active-site cysteine and restores the guanine to normal. After receiving a methyl-group from O6-MG,
MGMT is inactivated, and subject to ubiquitin-mediated degradation. A similar suicidal enzyme reaction occurs when
MGMT transfers and accepts an alkyl-group from O6-benzylguanine (O6-BG), a therapeutic strategies. (ii), if an O6-MG
DNA adduct escapes MGMT repair, it would form a base pair with thymine (blue circle) during DNA replication. The
mismatched base pair of the persistent O6-MG with thymine is recognized by the mismatch repair pathway, resulting
in futile cycles of repair leading to cell death. (iii), N7-MG DNA adducts ( > 70% of total DNA adducts formed by TMZ)
are efficiently repaired by the base excision repair (BER) pathway, and normally they contribute little to the cytotoxici‐
ty of TMZ. Methoxyamine binds to AP sites produced by methylpurine glycosylase (MPG), the first step in BER process‐
ing. Methoxyamine-bound AP sites are refractory to AP endonuclease (APE, green circle) cleavage, resulting in the
blockage of the BER pathway. This leads to strand breaks, disrupted replication, and increased cytotoxicity of TMZ. Fig‐
ure 1 is adapted from L. Liu et al. Clin Cancer Res. 2006;12(2):328-331.
2.3.3. Post-transcriptional regulation
MGMT protein was reported to be degraded via the ubiquitin proteolytic pathway [18]. Ac‐
cording to the recent study, the correlation between MGMT promoter methylation and
MGMT protein expression was poor (p = 0.27) [19]. In silico analysis predicted potential
binding sites for several miRNAs within the 3'UTR of MGMT, suggesting a mechanism for
post-transcriptional regulation of MGMT.
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2.4. Candidate drugs for combination with TMZ
Strategies to potentiate the effecacy of TMZ by suppressing MGMT or BER pathway have
been examined. Pseudosubstrates of MGMT such as O6-benzylguanine were expected to
suppress drug resistance by depleting MGMT [20; 21; 22]. However, clinical trials did not
show significant restoration of TMZ sensitivity in patients with TMZ-resistant GBM [23].
IFN-β down-regulates the expression of MGMT and sensitizes resistant glioma to TMZ and
phase II study has been started [15; 24].
We discovered post-transcriptional regulation of MGMT by signal transducer and activator
of transcription-3 (STAT3) and demonstrated that STAT3 inhibitor or STAT3 knockdown
potentiated TMZ efficacy in TMZ-resistant GBM cell lines [25] (Fig 2). Furthermore, immu‐
nohistochemical analysis of 44 malignant glioma specimens demonstrated significant posi‐
tive correlation between expression levels of MGMT and phosphorylated STAT3 (pSTAT3)
(p<0.001, r=0.58) (Fig 2). Therefore, STAT3 inhibitor might be one of the candidate reagents
for combination therapy with TMZ for TMZ-resistant GBM patients.
2.5. Other molecules involving TMZ resistance
In spite of the correlation between promoter methylation of MGMT and temozolomide sen‐
sitivity, survival time of the patients who have methylated promoters of MGMT is still short
and this suggests the involvement of other mechanism in TMZ resistance. Especially, key
molecules of MMR, BER, and Fanconi anemia repair pathway such as MSH6 [26; 27], N-
methyl purine DNA glycosylase (MPG) [28], DNA polymerase β (Polβ) [28], alkylpurine-
DNA-N-glycosylase (APNG) [29] and FANCD1/BRCA2 [30] have been reported to affect to
TMZ resistance. The unfolded protein response regulator GRP78/BiP was shown to act as a
novel target for increased chemosensitivity in malignant gliomas [31]. Inhibition of Y-box
binding protein-1 (YB-1) slows the increased growth of GBM and sensitizes to temozolo‐
mide independent of MGMT [32]. High levels of HOXA9/HOXA10 gene expression were as‐
sociated with a shorter survival in pediatric high-grade glioma patient samples. [33].
Phosphatase and tensin homologue (PTEN) deficiency in GBM confers resistance to radia‐
tion and temozolomide that is reversed by the protease inhibitor nelfinavir [34].
Table 1. Candidate drugs for combiunation with TMZ. STAT3 indicates signal transducer and activator of
transcription-3; PARP, poly(ADP-ribose) polymerase; BER, base excision repair.
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Figure 2. Correlation between expression levels of MGMT and phosphorylated STAT3. (A) Immunoblot analysis
of MGMT in T98G treated with 200 mM of STAT3 inhibitor VI. Duration of the treatment is indicated at the top as 0 to
48hr. Medium change indicated removal of STAT3 inhibitor. The level of pSTAT3 was also evaluated (middle panel).
Actin is shown as a loading control (bottom panel). (B) Correlation between pSTAT3 and MGMT in 44 cases of malig‐
nant glioma specimens. x and y axes indicate score of positivity of pSTAT3 and MGMT, respectively. z axis indicates the
number of cases. n=44, correlation coefficient r=0.58, p<0.001. (A) Immunoblot analysis of MGMT in T98G treated
with 200 mM of STAT3 inhibitor VI. Duration of the treatment is indicated at the top as 0 to 48hr. Medium change
indicated removal of STAT3 inhibitor. The level of pSTAT3 was also evaluated (middle panel). Actin is shown as a load‐
ing control (bottom panel). (B) Correlation between pSTAT3 and MGMT in 44 cases of malignant glioma specimens. x
and y axes indicate score of positivity of pSTAT3 and MGMT, respectively. z axis indicates the number of cases. n=44,
correlation coefficient r=0.58, p<0.001.
3. Targeted molecular agents
3.1. Therapeutic targets in GBM
Identification of biological mechanisms contributing to GBM oncogenesis contributes to pro‐
vide appropriate targeted therapies to improve patient outcomes. In a large-scale multidi‐
mensional analysis performed by the Cancer Genome Atlas involving, the most frequent
gene amplifications were: epidermal growth factor receptor (EGFR) and platelet-derived
growth factor receptor α (PDGFRα), 2 transmembrane receptors with tyrosine kinase activi‐
ty; cyclin-dependent kinase 4 (CDK4), and murine double minute (MDM)2 and MDM4
which are suppressors for p53 [35]. The most frequent homozygous gene deletions were
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CDKN2A, CDKN2B, and CDKN2C, which encode tumor suppressor proteins that suppress
CDK4 and CDK6, phosphatase and tensin homolog (PTEN), a tumor suppressor that inhib‐
its phosphatidylinositol-3 kinase (PI3K) signaling such as retinoblastoma (RB1), a cell-cycle
inhibitor as PARK2, a regulator of dopaminergic cell death, and neurofibromin 1 (NF1), a
negative regulator of the RAS signal transduction pathway. The most frequently mutated
genes were p53, PTEN, NF1, EGFR, human epidermal growth factor receptor 2 (HER2), RB1,
and PIK3R1 and PIK3CA-2 components/regulators of the PI3K signaling pathway. This
study shows that several genes encoding proteins which are involved in signaling pathways
of receptor tyrosine kinases/PI3K, and p53 and the cyclin/RB1, are considerably altered in
GBM (Fig. 3). Another study has identified characteristic mutations in the active site of isoci‐
trate dehydrogenase 1 (IDH1) in 12% of patients with GBM. IDH1 mutations occurred in a
high proportion of young patients and in the majority of secondary GBM cases and were as‐
sociated with increased OS (3.8 years), compared with wild-type IDH1 (1.1 years) [36]. This
may be due to increased tumor sensitivity to chemotherapy, although a large controlled ser‐
ies in the German Glioma Network did not find any association between prolonged survival
of patients with tumors with IDH1 mutations and administration of a specific therapy [9].
Mutation of the IDH1 active site prevents conversion of isocitrate to α-ketoglutarate but al‐
lows the mutated enzyme to catalyze the nicotinamide dinucleotide phosphate-dependent
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG) [37]. Accumulated 2HG ap‐
pears to act as an oncometabolite that contributes to glioma formation and malignant pro‐
gression. This observation is supported by data from patients with inherited 2-
hydroxyglutaric aciduria, in whom deficient 2HG dehydrogenase causes an accumulation of
brain 2HG. These patients have an increased risk of developing brain tumors, possibly be‐
cause of increased production of reactive oxygen species [38].
3.1.1. EGFR
EGFR is one of the most attractive therapeutic targets in GBM. Approximately 50% of GBM
overexpress EGFR and 25% express a constitutively active mutated form of EGFR known as
EGFRvIII, which has a large deletion in the extracellular domain and renders the receptor
ligand independent for signaling [39]. Overexpression of EGFR is more common in primary
tumors than in secondary GBM [40]. The deletion also renders a unique codon, which is not
found in the wild-type receptor, thereby creating a tumor-specific epitope that can be ex‐
ploited for therapeutic targeting. Increased EGFR signaling drives tumor cell proliferation,
invasiveness, motility, angiogenesis, and inhibition of apoptosis.
3.1.1.1. Gefitinib, Erlotinib, Lapatinib and Cetuximab
Small-molecules of EGFR inhibitor such as gefitinib and erlotinib are well tolerated in pa‐
tients with malignant gliomas, phase II trials have so far shown limited clinical benefit of er‐
lotinib in patients with either recurrent or newly diagnosed GBM, either in combination
regimens [41; 42; 43; 44] or as monotherapy [45]. Neither the EGFR/HER-2 inhibitor lapati‐
nib [46], nor the monoclonal antibody against EGFR, cetuximab [47], have proven to be ef‐
fective. Attempts to identify biomarkers to predict response to EGFR inhibitors have yielded
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conflicting results. There is no convincing evidence of a correlation between the drug effica‐
cy and the expression levels of EGFR in tumor tissue. In a phase I study, patients with glio‐
mas expressing high levels of EGFR and low levels of activated AKT had better responses to
erlotinib than did those with low EGFR expression and high levels of activated AKT [48].
Another study have shown significant correlation of therapeutic response of erlotinib and
the presence of EGFR deletion mutant variant III [49]. However, not all studies confirmed
these initial observations to predict the sensitivity to EGFR inhibitors [45].
3.1.2. PDGFR
PDGFR is a receptor tyrosine kinase with α and β isoforms. Overexpression of PDGFRα has
been demonstrated in astrocytoma and GBM, indicating a potential role in tumor develop‐
Figure 3. Genetic Alterations in Glioblastoma Occur Frequently in 3 Cellular Signaling Pathways. DNA altera‐
tions and copy number changes in the following signaling pathways are indicated in (a) receptor tyrosine kinase (RTK),
RAS, and phosphoinositol–3–kinase (PI3K); (b) p53 tumor suppressor; and (c)retinoblastoma (Rb) tumor suppressor.
Activating genetic alterations are shown in red. Genetic alterations that lead to a loss of function are indicated in blue.
In each pathway, the altered components, the type of alteration, and the percentage of tumors carrying each altera‐
tion are shown. Blue boxes contain the total percentages of glioblastomas with alterations in at least 1 known compo‐
nent gene of the designated pathway. Figure 3 is adapted from The Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature
2008;455(7216):1061–1068.
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ment [50]. Several PDGFR-targeting agents have been developed that may have therapeutic
potential against tumors with elevated PDGFR expression.
3.1.2.1. Sorafenib, Imatinib and Tandutinib
Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth and pro‐
liferation by blocking the action of intracellular and receptor kinases, including PDGFR,
RAF kinase, VEGFR2, and c-KIT [51]. In human GBM cell lines, sorafenib inhibited prolifera‐
tion synergistically in combination with bortezomib, a proteosome inhibitor [52], and rot‐
tlerin, an experimental inhibitor of protein kinase C [53]. A phase II trial found that first-line
TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients with
GBM, although preliminary efficacy data for this regimen (median PFS duration, 6 months;
12-month PFS rate, 16%) were similar to data for standard therapy.
Imatinib mesylate, a small-molecule inhibitor for PDGFR, ABL, and c-KIT, was reported to
have significant antitumor activity both in vitro and in vivo as orthotopic glioma models (Kil‐
ic et al 2000). Especially, preclinical trials suggested that Imatinib have shows growth inhibi‐
tion in a subpopulation of CXCL12-expressing GBM cells [54] and radiosensitizes them [55].
However, in phase II trials involving recurrent GBM, imatinib alone or combined with hy‐
droxyurea had limited antitumor activity [56; 57; 58; 59; 60].
Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase activity.
Although no preclinical data was available for tandutinib in GBM, 2 early-phase trials are
assessing tandutinib in recurrent/progressive GBM as monotherapy or combined with beva‐
cizumab. As correlation between increased gene expression levels of PDGFR and preclinical
data for therapeutic efficacy was reported, PDGFR may be a promising target for treating
GBM. However, the available clinical data suggest otherwise. Trial data of combination regi‐
mens involving PDGFR inhibitors are awaited [61].
3.1.3. VEGFR
There are multiple reasons for adapting anti-angiogenic drugs to the treatment of malignant
gliomas. Malignant glioma exhibits higher vascularization which is one of the pathological
hallmarks of GBM. One of the difficulties of developing effective treatments for gliomas has
been poor drug penetration through the blood-brain barrier. The dense network of angio‐
genic vessels in GBM typically display structural, functional, and biochemical abnormalities,
including large endothelial cell fenestrae, deficient basement membrane, decreased pericytes
and smooth muscle cells, haphazard interconnections with saccular blind-ended extensions,
complex tortuosity, and dysregulated transport pathways [62; 63; 64; 65; 66; 67]. Therefore,
by targeting the tumor vasculature, it is possible to bypass this dependence on drugs to pass
the blood-brain barrier to reach their targets. Further, there is also both experimental [68]
and clinical [69; 70] evidence that anti-angiogenic drugs can decrease vasogenic edema and
patients' requirement for corticosteroids which contributes to morbidity in this population.
The VEGF family of growth factors and their respective receptors are the best characterized
proangiogenic proteins in glioma. The VEGF family includes 6 secreted glycoproteins
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(VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor [PlGF]). VEGF-
A, the best characterized member, typically localizes adjacent to pseudopalisading necrosis
in GBM [71], and the levels of VEGF-A is increased in higher grade of glioma [72; 73], and is
associated with poor prognosis [74]. The VEGF receptor (VEGFR) family includes VEGFR-1
(Flt-1), VEGFR-2 (KDR), VEGFR-3, neuropilin-1 (NRP-1), and NRP-2, which exhibit different
binding affinities of the VEGF homologs. VEGFR-1 and VEGFR-2 regulate angiogenesis,
whereas VEGFR-3 regulates lymphangiogenesis. Vascular endothelial growth factor produc‐
tion and secretion by tumor cells is stimulated mainly by hypoxia, and malignant gliomas
are rapidly growing and innately hypoxic tumors. More specifically, VEGF-A binds to
VEGFR-2 expressed in blood vessels, which promotes endothelial cell migration and prolif‐
eration results in new blood vessel formation in a manner of paracrine signaling loop.
3.1.3.1. Bevacizumab
Bevacizumab, a recombinant humanized monoclonal antibody composed of human immu‐
noglobulin G1 (IgG1; 93%) and murine VEGF-binding complementarity-determining re‐
gions (7%), binds all isoforms of VEGF with high affinity and specificity [75]. Despite initial
reluctance to evaluate bevacizumab in patients with brain tumors owing to concerns of in‐
tracranial hemorrhage, a series of 29 patients with recurrent malignant glioma treated with
bevacizumab and irinotecan showed no significant hemorrhage with remarkable tumor re‐
gression as radiographic response rate of 66% compared with ordinal chemotherapeutic re‐
agents as rates of 9% [76; 77]. These results led rigorous prospective clinical trials of
bevacizumab in recurrent malignant gliomas. The combination of bevacizumab and irinote‐
can was studied in single-arm phase 2 trials for recurrent malignant glioma (n = 33) and
GBM (n = 35), showing response rates as 61% and 57%, and progression-free survival (PFS)
at 6 months as 55% and 46% [78; 79], respectively. These results were compared with previ‐
ous rates of PFS at 6 months as 9% to 15% for recurrent GBM and 17% to 31% for recurrent
malignant gliomas [80]. A large phase 2 trial randomized 167 patients of recurrent GBM to
analyze efficacy of combination of either bevacizumab or bevacizumab with irinotecan. This
noncomparative randomized study showed radiographic response rates as 28% and 38%,
and a PFS at 6 months of 43% and 50%, respectively [69]. In addition, patients treated with
bevacizumab often exhibit less vasogenic edema and decreased corticosteroid dependence
secondary to neutralization of VEGF, a known vascular permeability factor. Another phase 2
trial involved bevacizumab monotherapy in 48 heavily pretreated patients with recurrent
GBM [70]. The radiographic response rate was 35%, and the PFS6 rate was 29%. Ongoing
phase 3 studies are evaluating the combination of bevacizumab with temozolomide and ra‐
diotherapy. The results will be of great interest because of the uncertainty regarding the im‐
pact of bevacizumab on overall survival. Combinations of bevacizumab and other
chemotherapeutics or targeted molecular drugs are also currently in clinical trials.
3.1.3.2. Aflibercept
VEGF Trap (aflibercept) sequesters all isoforms of VEGF-A and PDGF as a soluble, recombi‐
nant, decoy receptor, composed of the second Ig domain of VEGFR-1 and the third Ig do‐
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phase 3 studies are evaluating the combination of bevacizumab with temozolomide and ra‐
diotherapy. The results will be of great interest because of the uncertainty regarding the im‐
pact of bevacizumab on overall survival. Combinations of bevacizumab and other
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main of VEGFR-2 bound to the hinge region of the Fc portion of human IgG1 [81]. Single
arm phase II study of aflibercept in recurrent malignant glioma was proceeded [82]. 42 pa‐
tients with GBM and 16 patients with malignant glioma who had received concurrent radia‐
tion and temozolomide therapies, and adjuvant temozolomide were enrolled at first relapse.
The 6-month progression-free survival rate was 7.7% for GBM cohort and 25% for patients
with malignant glioma. Overall radiographic response rate was 24% (18% for GBM and 44%
for malignant glioma). The median PFS was 24 weeks for patients with malignant glioma
(95% CI, 5 to 31 weeks) and 12 weeks for patients with GBM (95% CI, 8 to 16 weeks). A total
of 14 patients (25%) were removed from the study for toxicity, on average less than 2
months from treatment initiation. This study suggested Aflibercept monotherapy had mod‐
erate toxicity and minimal evidence of single-agent activity in unselected patients with re‐
current malignant glioma.
3.1.3.3. Cediranib
Several inhibitors for VEGFR tyrosine kinase have shown significant antiangiogenic and an‐
titumor activity in preclinical GBM models [83; 84; 85; 86; 87; 88], which may also enhance
cytotoxic therapy [89; 90; 91]. In addition, several these agents are undergoing evaluation in
phase I/II clinical trials, but only cediranib has advanced to phase III investigation. In an ini‐
tial phase II study of single-agent cediranib (45 mg/d), 27% of patients with recurrent malig‐
nant glioma exhibited a radiographic response and a 6-month PFS was 26%. In addition,
cediranib induced rapid normalization of tumor vasculature, including decreased diameter
of microvessels and diminished permeability, which reversed after cediranib interruption.
Adverse events including hypertension and fatigue were observed, and nearly half of the
patients required a dose reduction or interruption of therapy because of its toxicity [92].
3.1.3.4. Mechanisms of resistance to antiangiogenic therapy
Although antiangiogenic therapies prolong PFS of GBM patients, further progression of dis‐
ease is inevitable. Progression of tumors under antiangiogenic therapy cannot often be treat‐
ed successfully thereafter, and most patients die of the disease within a few months. In the
cediranib study, serum levels of the proangiogenic factors bFGF, stromal-derived factor 1
(SDF1), and soluble VEGFR2 increased at the time of failure [93]. The alternative proangio‐
genic pathways depends on these angiogenic factors may drive angiogenesis in the setting
of VEGFR inhibition. Furthermore, for many gliomas, particularly malignant gliomas, there
is often little evidence for vascular proliferation. As the individual infiltrating tumor cell
tends to grow along normal cerebral vasculature, and thus there is no need for tumor-associ‐
ated angiogenesis. Indeed, there is at least a theoretical concern that inhibition of angiogene‐
sis in malignant glioma may prevent the formation bulky tumor but has little effect on
sparsely infiltrative GBM cells results in little impact on OS of patients. Early clinical and
radiographic observations of patients treated with bevacizumab suggest that this may be the
case [94; 95]. Another concern is recent laboratory evidence that suggests that inhibition of
VEGF may actually increase invasiveness of tumor cells [96]. The infiltrative tumor cells are
often responsible for relapse leading to the death of patients.
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Combination of antiangiogenic and anti-invasion therapy may delay disease progression.
Studies of co-administration of cediranib (pan-VEGFR inhibitor) with cilengitide (integrin
inhibitor) and bevacizumab (neutralizing VEGF antibody) with dasatinib (PDGFRβ inhibi‐
tor) are ongoing. Another potential mechanism of resistance to antiangiogenic therapies in‐
volves increased PDGF signaling. PDGF stabilizes neovasculature by recruiting pericytes
and facilitating pericyte-endothelial cell interactions [97]. Preclinical data suggest that dual
VEGFR/PDGFR inhibition potentiates antiangiogenic efficacy and reduces resistance to ther‐
apy [98], and this approach is currently being evaluated in clinical trials.
3.1.4. c-MET
Aberrant signaling by hepatocyte growth factor (HGF) and its receptor MET has been ob‐
served in various tumors including GBM, and potential involvement in tumorigenesis and
metastasis has been reported [99]. Recently c-MET overexpression was detected in 18 (29%)
of 62 GBM with shorter median survival durations than those of little or no expression of c-
MET (median durations of survival, 11.7 vs 14.3 months) [100].
3.1.4.1. AMG102 and PF02341066
Inhibitors of HGF or c-MET have shown preclinical activity against GBM cell lines [99]. The
anti-HGF antibody AMG102 enhanced TMZ-induced inhibition of growth of GBM cell line
in vitro and in vivo as xenografts [101]. However, phase II trial suggests AMG 102 monother‐
apy did not significantly suppress tumor growth of recurrent GBM [102]. PF02341066, an or‐
ally available ATP-competitive inhibitor of c-MET inhibited growth and c-MET
phosphorylation of GBM in preclinical studies [103]. This molecule is currently under clini‐
cal investigation in patients with advanced cancers.
3.1.5. PI3K and related pathways
PI3K plays a role in intracellular signaling pathways regulating in cell  survival,  growth,
and  proliferation.  Activated  PI3K  is  recruited  to  the  cell  membrane  where  it  mediates
signaling after  activation of  receptor  tyrosine kinases.  Downstream targets  include AKT
for cell proliferation and survival; glycogen synthase kinase-3 (GSK-3) for regulation of c-
MYC;  and  mammalian  target  of  rapamycin  (mTOR)  for  regulation  of  protein  synthesis
and  negative  regulator  of  PI3K.  In  malignant  glioma,  PI3K/Akt/mTOR  signaling  is  fre‐
quently  activated  because  of  the  stimulation  of  receptor  tyrosine  kinases  as  EGFR,
PDGFR, and mesenchymal-epithelial transition factor (MET), mutation of oncogenic PI3K
subunits,  and/or  loss  of  PTEN tumor  suppressor  activity.  Therefore  inhibiting  the  PI3K
pathway may have therapeutic potential.
3.1.5.1. NVP-BEZ235 and Enzastaurin
NVP-BEZ235, an orally available kinase inhibitor for PDK1, mTOR, and PI3K, induced G1
arrest of a GBM cell line in vitro and enhanced TMZ efficacy in vivo [104]. NVP-BEZ235 treat‐
ment is currently in phase I trials involving patients with solid tumors.
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Although antiangiogenic therapies prolong PFS of GBM patients, further progression of dis‐
ease is inevitable. Progression of tumors under antiangiogenic therapy cannot often be treat‐
ed successfully thereafter, and most patients die of the disease within a few months. In the
cediranib study, serum levels of the proangiogenic factors bFGF, stromal-derived factor 1
(SDF1), and soluble VEGFR2 increased at the time of failure [93]. The alternative proangio‐
genic pathways depends on these angiogenic factors may drive angiogenesis in the setting
of VEGFR inhibition. Furthermore, for many gliomas, particularly malignant gliomas, there
is often little evidence for vascular proliferation. As the individual infiltrating tumor cell
tends to grow along normal cerebral vasculature, and thus there is no need for tumor-associ‐
ated angiogenesis. Indeed, there is at least a theoretical concern that inhibition of angiogene‐
sis in malignant glioma may prevent the formation bulky tumor but has little effect on
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radiographic observations of patients treated with bevacizumab suggest that this may be the
case [94; 95]. Another concern is recent laboratory evidence that suggests that inhibition of
VEGF may actually increase invasiveness of tumor cells [96]. The infiltrative tumor cells are
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NVP-BEZ235, an orally available kinase inhibitor for PDK1, mTOR, and PI3K, induced G1
arrest of a GBM cell line in vitro and enhanced TMZ efficacy in vivo [104]. NVP-BEZ235 treat‐
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Enzastaurin,  a  PKC/PI3K/AKT inhibitor,  suppressed proliferation and induced apoptosis
via  a  caspase-dependent mechanism in GBM cells  in vitro [105].  In vivo  models showed
that enzastaurin combined with radiotherapy synergistically reduced tumor volume, radi‐
ation-induced satellite  tumor formation,  upregulation of  VEGF expression,  neovasculari‐
zation,  and GSK-3β  phosphorylation  [106].  In  phase  II  study  of  enzastaurin  in  patients
with recurrent heavily pretreated GBM showed that objective radiographic responses oc‐
curred in 25% of patients [107]. The subsequent phase III trial comparing lomustine and
enzastaurin at first or second recurrence was the first phase III trial to evaluate a target‐
ed therapy for recurrent GBM. Enzastaurin was well tolerated and had a better hemato‐
logic  toxicity  profile  but  did  not  have  superior  efficacy  compared  with  lomustine  in
patients with recurrent GBM [108].
3.1.6. SRC and SRC-Family kinases
SRC and SRC-Family Kinases (SFKs) are frequently activated in GBM [109] frequently due
to their overexpression [110]. SRC and SFKs are promiscuous regulators of multiple signal‐
ing pathways for cell proliferation, adhesion, migration, and invasion, which are important
processes in tumor invasion and metastasis.
3.1.6.1. Dasatinib
Dasatinib  is  a  potent  inhibitor  of  SRC and  SFKs  and  has  been  approved  for  the  treat‐
ment of certain types of leukemia on the basis of inactivation of BCR-ABL [111]. Dasati‐
nib also inhibits c-KIT and PDGFR [112]. In GBM cells, dasatinib inhibited migration and
induced  autophagy,  resulted  in  cell  death  which  was  enhanced  by  combination  with
TMZ [111; 113]. Dasatinib inhibited invasion, promoted tumor regression, induced apop‐
tosis  in  EGFRvIII-expressing  GBM,  and  enhanced  the  activity  of  anti-EGFR  antibodies
[111]. Trials of dasatinib are ongoing in GBM and several solid tumors. A phase I/II trial
involving patients with newly diagnosed GBM is assessing dasatinib combined with ra‐
diotherapy  and  concomitant  TMZ,  followed  by  adjuvant  dasatinib  plus  TMZ.  Trials  of
dasatinib for treatment of recurrent GBM include a phase II trial of dasatinib monothera‐
py,  a  phase  I  trial  of  dasatinib  in  combination  with  erlotinib,  and a  randomized phase
I/II  trial  of dasatinib in combination with CCNU that has started its phase I  component
with patients who have recurrent GBM.
3.1.7. Integrin
Integrin  plays  key  roles  regulating  cell  adhesion,  migration,  and  invasion.  In  addition
to  a  role  for  matrix-cell  contact,  integrin  also  activate  intracellular  signals  including
SRC-dependent  pathway.  In  various  tumors,  integrin  has  an  established  role  in  meta‐
stasis  and  angiogenesis  [114].  Therefore,  targeting  integrin  function  may  have  potential
for  treating GBM.
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Table 2. Targeted molecular agents currently in clinical development for high-grade glioma TKI indicates tyrosine
kinase inhibitor; SAHA, suberoylanilide hydroxamic acid; RGD, arginine-glycine-aspartate; STKI. serine-threnoine
kinase inhibitor; PKC, protein kinase C.
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Table 2. Targeted molecular agents currently in clinical development for high-grade glioma TKI indicates tyrosine
kinase inhibitor; SAHA, suberoylanilide hydroxamic acid; RGD, arginine-glycine-aspartate; STKI. serine-threnoine
kinase inhibitor; PKC, protein kinase C.




Cilengitide is a specific αV integrin inhibitor in clinical development. In a phase I/IIa tri‐
al,  cilengitide combined with the current standard of therapy in patients with newly di‐
agnosed GBM was well tolerated, with 6-month PFS as 69%. Methylation of promoter of
O6-methylguanine-DNA methyltransferase  (MGMT) predicts  a  higher  likelihood of  ach‐
ieving  6-month  PFS,  as  shown  by  increases  in  the  durations  of  PFS  and  OS  to  13.4
months  and 23.2  months,  respectively,  compared with  3.4  and 13.1  months  for  patients
without MGMT promoter methylation [115]. On the basis of these findings, a similar reg‐
imen is being compared with radiotherapy/TMZ alone in the phase III CENTRIC trial in
patients with newly diagnosed GBM with hypermethylated MGMT promoter. In a phase
IIa study of recurrent GBM, cilengitide monotherapy was well tolerated but was largely
inactive (6-month PFS rate, 15%); long-term disease stabilization was seen in a small sub‐
set of patients:  10% were progression free for 12 months,  and 5% were progression free
for 24 months [116].
3.1.8. Histone deacetylase inhibitor
Histone deacetylases (HDACs) are involved in multiple processes to lead malignant pheno‐
type of glioma including maintanance of stemness, angiogenesis, and resistance to DNA
damage.
3.1.8.1. Vorinostat
Vorinostat is an orally available inhibitor of class I and II HDAC approved for advance cuta‐
neous T cell lymphoma. In a phase II study of recurrent GBM, vorinostat monotherapy was
well tolerated and had modest clinical activity (6-month PFS rate, 15.2%; median OS dura‐
tion, 5.7 months) [117]. Vorinostat is currently being evaluated for use in newly diagnosed
and recurrent GBM as a combination therapy.
4. Conclusion
Although TMZ prolonged the survival of GBM patients, GBM are still immortal disease
with extremely poor prognosis because of acquisition of TMZ resistance. Therefore, other
therapeutic agents which suppress MGMT expression or attenuate TMZ resistance are high‐
ly desired. As the efficacy of single agent of targeted molecular therapy seems to be limited,
combination therapy should be evaluated since multi-pathway is involved in the chemore‐
sistance in GBM. An ‘tailor-made’ selection of chemotherapeutic agents for each GBM pa‐
tients based on molecular analysis is essential to obtain maximum efficacy of
chemotherapeutic agents.
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1. Introduction
The treatment of brain tumors remains a challenge for modern medicine and care. Therapy for
these patients is often complicated by site accessibility and the risk of damage to surrounding
tissue. The ability of chemotherapies to cross the blood brain barrier has also limited their use
as compared with surgical resections and radiation therapy. (Groothuis, 2000) For these
reasons, malignant gliomas of the central nervous system (CNS) have a poor prognosis. In fact,
the majority of patients with high grade gliomas (glioblastomas) will die within the first couple
of years after the diagnosis.(McLendon, 2003) The 5 year survival rate for these patients with
glioblastoma is less than 4% with the majority of deaths in the first two years post-diagnosis.
( Grossman, 2004; CBTRUS, 2012) This devastating impact has been the impetus behind much
of the research that is ongoing into effective therapies to combat these tumors. Over the years
many therapies have been studied, but in recent times the increased investigation into specific
molecular pathways has led to targeting specific tumor expression patterns and cellular
attributes. The enhanced understanding of cell division, including aspects of DNA replication
are now being used to target tumor replication and treat many cancers from various tissues.
In this fashion, tumors of the CNS should be more specifically targeted so that damage to the
surrounding normal tissue is minimized.
2. Epidemiology
Even after treatment, the median survival after the primary diagnosis remains poor. Many
multimodal treatment approaches are considered, but few patients have been reported to have
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long term survival greater than three years. In a recent study, analysis of 34,664 patients,
diagnosed with GBM over the age of 20 from 1972-2008 in the Surveillance, Epidemiology, and
End Results (SEER) NCI database, evaluated specific prognostic factors known to influence
survival in these patients. (Thumma, 2012) This analysis included racial/ethnic characteristics
in the description of specific subpopulations and found that Asian/Pacific Islanders had a
better survival compared to the white population (P<0.001). Patients diagnosed with GBM
during the years of 2000 to 2008 had a superior survival rate when compared with earlier
decades (P<0.001). Statistically significant improvements in overall survival were also found
for patients who received surgical resections, and adjuvant radiation treatment versus no
radiation (P values <0.001). Young age was also found to be highly predictive of improved
overall survival rates when separated into age groups as well as when studied as a continuous
variable. (Thumma, 2012) Thus, there are subpopulations with varied genomic and environ‐
mental attributes that may affect survival of CNS tumors. Although these studies did not
specifically identify the critical factors that dictate these differences, future studies may
capitalize on differences that enhance efficacy.
Despite aggressive therapy for malignant gliomas, recurrence rate is quite high and the
prognosis for most patients is extremely poor. The standard approach for high grade gliomas
is radiation therapy combined with temozolomide. (Stupp, 2005) Temozolomide added to
cranial radiation therapy improved Two year survival to 26.5% vs 10.4% to radiation therapy
alone. Toxicity of temozolomide and radiation therapy was minimal. Despite the improved
two-year survival with the addition of temozolomide to standard radiation therapy, the vast
majority of patients progress and die of their disease. Thus, more effective drugs and ap‐
proaches are definitely needed. Newer drugs being investigated include topoisomerase I
inhibitors. This chapter will review topoisomerase I inhibitors in the treatment of malignant
gliomas. Novel approaches using this class of compounds will also be discussed.
3. Current therapies
The DNA topoisomerases are a family of important enzymes involved in different stages of
the cell cycle. They are essential nuclear enzymes important in DNA topology, repair, and
replication by breaking and rejoining of the DNA double helix. The breakage that they induce
in essence unwinds the DNA structure and releases the molecule from its wound configura‐
tion. In this configuration, DNA replication as well as transcription can occur in the cell
nucleus. Two significant topoisomerase molecules are named topoisomerase I and topoiso‐
merase II. Although these molecules are in the same family, they work in different steps to
bind and cause the eventual unwinding of the helical DNA structure. Topoisomerase I is a
monomeric protein that induces single stranded breaks in DNA, one strand at a time.(Redinbo,
1998) Topoisomerase II brings about double stranded breaks in DNA since it is a dimer in
which each homologous monomer can cleave a strand of DNA.(Wang, 1996) These differences
have lead to the development of specific inhibitors to these topoisomerase enzymes. Since these
inhibitors actually damage DNA, they are sometimes referred to as poisons in the literature.
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4. Topotecan
Topotecan (TPT) is an analogue of camptothecin, an FDA approved chemotherapy for many
types of cancer.(Bookman, 1998; tenBukkel, 2004) TPT is water soluble, and inhibits an essential
role of topoisomerase I, depleting it in tumor cells and resulting in DNA strand breaks that are
not utilized or repaired.(Yamashita, 2007) Cells are then stopped in the G2 phase of the cell
cycle, and the progression of replication does not occur eventually leading to programmed cell
death through apoptotic processes. In subcutaneous xenograft models and in vitro, TPT
therapy has shown significant activity against glioblastoma (GBM) which is the most common
and malignant type of primary brain tumor.(Ciusani, 2005; Rapisarda, 2004) Topotecan
treatment showed some efficacy in preclinical studies, and TPT was found to be distributed
in the cerebrospinal fluid after systemic administration, leading to the initiation of clinical trials
evaluating the efficacy of TPT monotherapy on patients with GBM. (Ciusani, 2005; Baker,
1996) Data from phase II clinical trials with TPT treatment of both newly diagnosed and
recurrent GBM revealed modest tumor responses. It is proposed that the lack of efficacy in
treatment may be due to rapid clearance of TPT from the CSF, and rapid inactivation in plasma.
(Mi, 1995) Both of these processes provide a survival advantage to the tumors since drug
concentrations may not be significant around the tumor site. In order to address this and other
mechanisms, the approach to TPT therapy has changed from monotherapy to use in combi‐
nation with different agents targeting alternate pathways.(MacDonald,1996; Blaney,1996;
Reveiz,2012) These combinations may vary in the sequence of drug delivery or may be
simultaneous depending on the protocol used.
Topotecan is being studied as a component of combination therapies in primary brain tumors
as well as in the efficacy it may have in the treatment of brain metastases. In one recent large
scale literature review, approximately 10% to 18% of patients presented with brain metastases
(BM) at the time of initial diagnosis of small cell lung cancer (SCLC), and an additional 40% to
50% will develop brain metastases during the course of their disease. To evaluate the effec‐
tiveness and toxicity of systemic chemotherapy for the treatment of these types of brain
metastases from SCLC, the large scale systematic literature review was conducted for publi‐
cations up to July 2011.(Reveiz,2012) The literature searched included randomized controlled
trials comparing systemic chemotherapy (single agent or combination chemotherapy) vs
another chemotherapy regimen, palliative care, whole brain radiotherapy or any combination
of these interventions for the treatment of brain metastases as the sole site of progression.
(Reveiz,2012) After this extensive search, no significant differences for overall survival (OS)
were reported from randomized controlled trials with whole brain radiation therapy, and no
significant difference was found between those treated with topotecan and those not treated
with topotecan. Hence the treatment efficacy was not established in that review. A second trial
found that patients receiving teponoside plus whole brain radiotherapy had a higher complete
response rate than those receiving only the topoisomerase inhibitor. Hence, available evidence
is insufficient to judge the effectiveness and safety of chemotherapy for the treatment of brain
metastasis from small cell lung cancer. This may depend on the characteristics of the primary
tumor and the activated mechanisms of metastasis. Future research may better address the
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mental attributes that may affect survival of CNS tumors. Although these studies did not
specifically identify the critical factors that dictate these differences, future studies may
capitalize on differences that enhance efficacy.
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alone. Toxicity of temozolomide and radiation therapy was minimal. Despite the improved
two-year survival with the addition of temozolomide to standard radiation therapy, the vast
majority of patients progress and die of their disease. Thus, more effective drugs and ap‐
proaches are definitely needed. Newer drugs being investigated include topoisomerase I
inhibitors. This chapter will review topoisomerase I inhibitors in the treatment of malignant
gliomas. Novel approaches using this class of compounds will also be discussed.
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replication by breaking and rejoining of the DNA double helix. The breakage that they induce
in essence unwinds the DNA structure and releases the molecule from its wound configura‐
tion. In this configuration, DNA replication as well as transcription can occur in the cell
nucleus. Two significant topoisomerase molecules are named topoisomerase I and topoiso‐
merase II. Although these molecules are in the same family, they work in different steps to
bind and cause the eventual unwinding of the helical DNA structure. Topoisomerase I is a
monomeric protein that induces single stranded breaks in DNA, one strand at a time.(Redinbo,
1998) Topoisomerase II brings about double stranded breaks in DNA since it is a dimer in
which each homologous monomer can cleave a strand of DNA.(Wang, 1996) These differences
have lead to the development of specific inhibitors to these topoisomerase enzymes. Since these
inhibitors actually damage DNA, they are sometimes referred to as poisons in the literature.
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treatment showed some efficacy in preclinical studies, and TPT was found to be distributed
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as well as in the efficacy it may have in the treatment of brain metastases. In one recent large
scale literature review, approximately 10% to 18% of patients presented with brain metastases
(BM) at the time of initial diagnosis of small cell lung cancer (SCLC), and an additional 40% to
50% will develop brain metastases during the course of their disease. To evaluate the effec‐
tiveness and toxicity of systemic chemotherapy for the treatment of these types of brain
metastases from SCLC, the large scale systematic literature review was conducted for publi‐
cations up to July 2011.(Reveiz,2012) The literature searched included randomized controlled
trials comparing systemic chemotherapy (single agent or combination chemotherapy) vs
another chemotherapy regimen, palliative care, whole brain radiotherapy or any combination
of these interventions for the treatment of brain metastases as the sole site of progression.
(Reveiz,2012) After this extensive search, no significant differences for overall survival (OS)
were reported from randomized controlled trials with whole brain radiation therapy, and no
significant difference was found between those treated with topotecan and those not treated
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response rate than those receiving only the topoisomerase inhibitor. Hence, available evidence
is insufficient to judge the effectiveness and safety of chemotherapy for the treatment of brain
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different combination therapies as well as monotherapies in head to head comparisons and
trials in populations with primary tumors and metastatic tumors.
Liposomes are microscopic phospholipid particles with a bilayer membrane structure, and are
used to encapsulate various anticancer drugs.(Allen, 2004; Drummond,1999,2005) Liposomes
have been used to encapsulate TPT, while free TPT was found to be less active against
subcutaneous xenografts of cancers than injection of nano-liposomal TPT.(Drummond,
2005;Tardi,2001) Liposomal encapsulation may improve the efficacy of TPT by increasing
increasing drug circulatory half-life and by providing the appropriate pH to maintain drug
activity.(Tardi, 2001;Burke, 1994) In either case, the effect may be an increased amount of active
drug present at the tumor site. In orthotopic, intracranial xenograft models of GBM, nanoli‐
posomal TPT demonstrated superior efficacy when administered directly into the tumor by
convection-enhanced delivery (CED).(Tardi, 2001;Saito,2006) CED of nano-liposomal TPT
increased TPT half-life in the brain vs free TPT, and conferred a highly significant survival
advantage. In a recent study, systemically administered nano-liposomal TPT had enhanced
efficacy in 3 orthotopic xenograft models of GBM.(Serwer,2011) Bioluminescence monitoring
of tumor growth and therapeutic response, survival benefit to animal subjects, and immune-
histochemical analysis of tumor apoptotic response to therapy were used to assess efficacy.
Although these results were promising, data from clinical trials would be more significant and
applicable to the demonstration of efficacy. Consistent with the inhibitor function, increased
DNA strand breaks in TPT-treated tumors, and an increase in activated caspase-3 (marker of
programmed cell death) were observed in this study.(Serwer,2011) Delivery of liposomal
packaged TPT to tumors increased both of these molecular events, leading to cell death.
Nano-liposomal topotecan (nLS-TPT) has anti-tumor activity when administered directly to
brain tumors by convection-enhanced delivery (CED).(Serwer,2011 poster) As a topoisomer‐
ase I inhibitor, topotecan (TPT) must be internalized in order to have a cytotoxic effect, hence
increasing cellular internalization may increase the anti-tumor activity of nLS-TPT. Attaching
an epidermal growth factor (EGFR)-specific antibody to the nLS-TPT surface increased EGFR-
targeting. EGFR activation is considered a proliferative event leading to more cell replication.
This receptor is commonly found on cell membranes in order to increase accessibility to ligand
binding, hence the antibody used for targeting in this study may increase specific binding to
cells that have increased expression of the receptor. Improved targeting rates of TPT-nLS
internalization in vitro, and secondly nLS-TPT-EGFR offered superior efficacy compared to
nLS-TPT in vivo.(Serwer,2011 poster) When coupled to the antibody, the internalization of the
inhibitor was highly and significantly increased as was the rate of internalization of nLS-TPT-
EGFR when compared to nLS-TPT in all cells that express EGFR. In vivo studies in both EGFR-
expressing mouse models of glioblastoma models showed a substantial dose dependent
benefit of nLS-TPT-EGFR treatment compared to nLS-TPT treatment.(Serwer, 2011 and poster)
The use of nLS-TPT-EGFR against glioblastomas that overexpress EGFR increases targeting
and improves internalization. This may ultimately increase survival by delaying tumor
growth.
The prognosis for newly-diagnosed GBM remains poor, and one of the reasons for this is that
GBM’s have the highest levels of vascular endothelial growth factor (VEGF) and hypoxia
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors442
inducing factor-1 alpha (HIF-1 alpha), an important regulator of VEGF. Topotecan therapy
may play a role in this signalling pathway by inhibiting HIF-1 alpha in treated tumor cells,
limiting tumor vascularization. (Vredenburgh, 2011) A phase II trial in newly diagnosed GBM
added bevacizumab and topotecan to standard therapy. 80 newly diagnosed GBM patients
received standard radiation therapy and temozolomide with bevacizumab at 10 mg/kg every
14 days was added a minimum of 4 weeks post-op. Two weeks after radiation therapy was
completed, 12 monthly cycles of temozolomide, and oral topotecan were given for patients not
on an enzyme inducing anti-epileptic drug.(Vredenburgh, 2011) The addition of bevacizumab
to temozolomide and radiation followed by temozolomide, bevacizumab and oral topotecan
was tolerable and safe. Six patients came off the study with recurrent grade IV thrombocyto‐
penia, one each with grade 2 CNS hemorrhage, wound dehiscence requiring surgery and a GI
perforation. Median PFS and OS were not reached at a median follow-up of 8 months but the
6 month EFS was 83%. Hence in this case, multifactorial combination therapies for DNA
replication as well as vascularization may aid in treatment efficacy.
5. Irinotecan
Irinotecan is another water soluble topoisomerase inhibitor that is being used clinically for the
treatment of tumors. (Hsiang, 1985) A recent prospective, phase II study evaluated the efficacy
of irinotecan and bevacizumab in the treatment of recurrent glioblastoma multiforme (GBM).
(Møller,2012) In the evaluation of 85 patients with different brain tumors, the investigators
used response rate and progression free survival (PFS) in patients who received intravenous
bevacizumab (10 mg/kg), and irinotecan (125/340 mg/m2 ) every 14 days until progression. The
median treatment that these patients received was four cycles. At 8 week intervals, the patients
underwent MRI imaging and were evaluated based on the Macdonald response criteria. The
following histologies were studied among the 85 patients: GBM (n = 32), glioma WHO gr. III
(n = 33), glioma WHO gr. II (n = 12), others (n = 8). For glioblastoma, ORR (overall response
rate) was 25%, with 59% achieving stable disease. The median PFS in this study was 5.2 months.
Upon evaluating the other types of tumors, for grade III gliomas ORR was 21% and 45% had
SD with a median PFS of 3.7 months. Objective responses were not found for any grade II
gliomas in this study. (Møller,2012) Since the study included a non-glioma population, the
investigators reported that they observed several long PFS times. Bevacizumab and irinotecan
combination therapy was well tolerated and moderately efficacious in glioblastoma and
glioma of WHO grade III with the majority of patients achieving some disease stabilization.
(Møller, 2012) The current studies have evaluated irinotecan alone or in combination (ex:bev‐
acizumab). (Table 1) Future studies should expand on these findings in larger cohorts since
progression-free survival was prolonged in non-glioma patients.
6. Safety, adverse effects, and methods to minimize toxicity
Malignant gliomas are highly proliferative, resistant to therapy and often recurrent post
radiation and chemotherapy. Lack of adequately tumoricidal concentrations of chemothera‐
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different combination therapies as well as monotherapies in head to head comparisons and
trials in populations with primary tumors and metastatic tumors.
Liposomes are microscopic phospholipid particles with a bilayer membrane structure, and are
used to encapsulate various anticancer drugs.(Allen, 2004; Drummond,1999,2005) Liposomes
have been used to encapsulate TPT, while free TPT was found to be less active against
subcutaneous xenografts of cancers than injection of nano-liposomal TPT.(Drummond,
2005;Tardi,2001) Liposomal encapsulation may improve the efficacy of TPT by increasing
increasing drug circulatory half-life and by providing the appropriate pH to maintain drug
activity.(Tardi, 2001;Burke, 1994) In either case, the effect may be an increased amount of active
drug present at the tumor site. In orthotopic, intracranial xenograft models of GBM, nanoli‐
posomal TPT demonstrated superior efficacy when administered directly into the tumor by
convection-enhanced delivery (CED).(Tardi, 2001;Saito,2006) CED of nano-liposomal TPT
increased TPT half-life in the brain vs free TPT, and conferred a highly significant survival
advantage. In a recent study, systemically administered nano-liposomal TPT had enhanced
efficacy in 3 orthotopic xenograft models of GBM.(Serwer,2011) Bioluminescence monitoring
of tumor growth and therapeutic response, survival benefit to animal subjects, and immune-
histochemical analysis of tumor apoptotic response to therapy were used to assess efficacy.
Although these results were promising, data from clinical trials would be more significant and
applicable to the demonstration of efficacy. Consistent with the inhibitor function, increased
DNA strand breaks in TPT-treated tumors, and an increase in activated caspase-3 (marker of
programmed cell death) were observed in this study.(Serwer,2011) Delivery of liposomal
packaged TPT to tumors increased both of these molecular events, leading to cell death.
Nano-liposomal topotecan (nLS-TPT) has anti-tumor activity when administered directly to
brain tumors by convection-enhanced delivery (CED).(Serwer,2011 poster) As a topoisomer‐
ase I inhibitor, topotecan (TPT) must be internalized in order to have a cytotoxic effect, hence
increasing cellular internalization may increase the anti-tumor activity of nLS-TPT. Attaching
an epidermal growth factor (EGFR)-specific antibody to the nLS-TPT surface increased EGFR-
targeting. EGFR activation is considered a proliferative event leading to more cell replication.
This receptor is commonly found on cell membranes in order to increase accessibility to ligand
binding, hence the antibody used for targeting in this study may increase specific binding to
cells that have increased expression of the receptor. Improved targeting rates of TPT-nLS
internalization in vitro, and secondly nLS-TPT-EGFR offered superior efficacy compared to
nLS-TPT in vivo.(Serwer,2011 poster) When coupled to the antibody, the internalization of the
inhibitor was highly and significantly increased as was the rate of internalization of nLS-TPT-
EGFR when compared to nLS-TPT in all cells that express EGFR. In vivo studies in both EGFR-
expressing mouse models of glioblastoma models showed a substantial dose dependent
benefit of nLS-TPT-EGFR treatment compared to nLS-TPT treatment.(Serwer, 2011 and poster)
The use of nLS-TPT-EGFR against glioblastomas that overexpress EGFR increases targeting
and improves internalization. This may ultimately increase survival by delaying tumor
growth.
The prognosis for newly-diagnosed GBM remains poor, and one of the reasons for this is that
GBM’s have the highest levels of vascular endothelial growth factor (VEGF) and hypoxia
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inducing factor-1 alpha (HIF-1 alpha), an important regulator of VEGF. Topotecan therapy
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14 days was added a minimum of 4 weeks post-op. Two weeks after radiation therapy was
completed, 12 monthly cycles of temozolomide, and oral topotecan were given for patients not
on an enzyme inducing anti-epileptic drug.(Vredenburgh, 2011) The addition of bevacizumab
to temozolomide and radiation followed by temozolomide, bevacizumab and oral topotecan
was tolerable and safe. Six patients came off the study with recurrent grade IV thrombocyto‐
penia, one each with grade 2 CNS hemorrhage, wound dehiscence requiring surgery and a GI
perforation. Median PFS and OS were not reached at a median follow-up of 8 months but the
6 month EFS was 83%. Hence in this case, multifactorial combination therapies for DNA
replication as well as vascularization may aid in treatment efficacy.
5. Irinotecan
Irinotecan is another water soluble topoisomerase inhibitor that is being used clinically for the
treatment of tumors. (Hsiang, 1985) A recent prospective, phase II study evaluated the efficacy
of irinotecan and bevacizumab in the treatment of recurrent glioblastoma multiforme (GBM).
(Møller,2012) In the evaluation of 85 patients with different brain tumors, the investigators
used response rate and progression free survival (PFS) in patients who received intravenous
bevacizumab (10 mg/kg), and irinotecan (125/340 mg/m2 ) every 14 days until progression. The
median treatment that these patients received was four cycles. At 8 week intervals, the patients
underwent MRI imaging and were evaluated based on the Macdonald response criteria. The
following histologies were studied among the 85 patients: GBM (n = 32), glioma WHO gr. III
(n = 33), glioma WHO gr. II (n = 12), others (n = 8). For glioblastoma, ORR (overall response
rate) was 25%, with 59% achieving stable disease. The median PFS in this study was 5.2 months.
Upon evaluating the other types of tumors, for grade III gliomas ORR was 21% and 45% had
SD with a median PFS of 3.7 months. Objective responses were not found for any grade II
gliomas in this study. (Møller,2012) Since the study included a non-glioma population, the
investigators reported that they observed several long PFS times. Bevacizumab and irinotecan
combination therapy was well tolerated and moderately efficacious in glioblastoma and
glioma of WHO grade III with the majority of patients achieving some disease stabilization.
(Møller, 2012) The current studies have evaluated irinotecan alone or in combination (ex:bev‐
acizumab). (Table 1) Future studies should expand on these findings in larger cohorts since
progression-free survival was prolonged in non-glioma patients.
6. Safety, adverse effects, and methods to minimize toxicity
Malignant gliomas are highly proliferative, resistant to therapy and often recurrent post
radiation and chemotherapy. Lack of adequately tumoricidal concentrations of chemothera‐
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peutic drugs in tumor cells may be be one of the primary causes of treatment failure in solid
tumors. The blood-brain barrier (BBB) restricts the concentrations of chemotherapeutic drugs
that may reach the tumor site. Methods that deliver drugs in a systemic fashion may increase
toxicity and create off target site complications. Convection-enhanced delivery (CED) is a
method that may provide drugs to the tumor in a more targeted fashion through the interstitial
space.(Barker,1998; Bobo,1994) This approach results into more drug being delivered into
tumors and surrounding brain through stereo-tactically placed catheters connected to pumps.
(Barker,1998; Bobo,1994) By providing a continuous, low grade positive-pressure microinfu‐
sion that distributes drugs by bulk flow, CED may result in high local concentrations and
reduce systemic toxicity. (Bruce,2011)
Topotecan, a topoisomerase I inhibitor, is cytotoxic to glioma cells and nontoxic to normal
brain, and its levels are higher in glioma cells and tumor tissue than in normal brain. Topotecan
is a natural-product drug with high molecular weight which allows it to minimally traverse
the BBB from the brain to the systemic circulation. (Kaiser,2000;Bruce,2000;Borris,1998,
Matsumoto, 1999) Now there is evidence that in colon tumors topotecan treatment results in
the downregulation of hypoxia-inducible factor-1α (HIF1A) target genes along with an
inhibition of HIF1A protein accumulation. (Guerin, 2012) Hence, topoisomerase I inhibitors
may also influence the tumor environment by decreasing tumor angiogenesis leading to tumor
size stabilization, although clinical trials of topotecan delivered intravenously had minimal
effects on tumors. (Fridman,1999) In other studies, CED in rat in vivo models prolonged
survival and had significant antitumor efficacy. (Kaiser,2000; Bruce,2000)
Recently, a prospective, dose-escalation phase Ib study of CED of topoisomerase-I was
conducted in sixteen patients with recurrent malignant gliomas with a median age of 50 years.
Ten patients had glioblastoma multiforme, and the other 6 had World Health Organization
grade III glial tumors with an average enhancing volume of 16.1 cm3. (Bruce,2011) Standard
MRI/CT-guided stereotactic biopsy was used to histologically confirm the presence of
recurrent malignant glioma. In this study, the investigators evaluated toxicity and quality of
life (QOL) effects and confirmed antitumor activity radiographically. The change in contrast-
enhancing volume of tumor on MRI was used to assess tumor response to treatment. Three
response categories were used to characterize the tumors: early response; as a decrease in
contrast-enhancing volume of >50% through the first 3 to 6 months after therapy, progressive
disease; as increasing contrast-enhancing volume (>25%) at ≥1 month after therapy until
surgical resection or death, and pseudoprogression; an increase in the contrast-enhancing
volume of >50% followed by regression of enhancement and edema (changes had to be
sustained for at least 4 weeks with patients on a stable or decreasing dose of steroids).(Bruce,
2011) The investigators noted significant antitumor activity in these tumors through radio‐
graphic changes, and treatment with CED topotecan prolonged overall survival. The maxi‐
mum tolerated dose that can be used for phase II studies was determined in this trial. Drug-
associated toxicity was minimal and topotecan convection-enhanced delivery had activity at
concentrations that were nontoxic to normal brain. (Bruce,2011)
CED locally administered topotecan treatment was tested on a rat model of glioblastoma that
is induced by intracerebral injection of PDGF (platelet-derived growth factor)-IRES (internal
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ribosome entry site) expressing retrovirus. (Lopez, 2011) Glial progenitor cells recruited to the
tumor and the transformed tumor cells were analyzed by histopathology. Glial progenitor cells
are proliferate within gliomas and contribute to the growth of the tumor. (Appolloni, 2009
OGDEN) This pro-growth process is influenced via PDGF signaling, another common
proliferative pathway. (Assanah, 2006 Assanah, 2009) The transformed cell population was
reduced about 10-fold and recruited progenitors by about 80-fold. A significant survival
advantage was found in treated animals and this improved with greater treatment duration.
(Lopez, 2011) In addition, the distribution of topotecan was traced with MRI of a tracer
molecule and corresponded with regions of glial progenitor ablation. The decrease in progen‐
itor recruitment was most likely due to the ablation of recruitable progenitor cells. These results
showed that in a model of growth factor influenced gliomas, tumor cells and the induced
progenitor cells are eradicated by topoisomerase inhibition based treatments. Hence, future
characterization of tumors through these methods may enhance the efficacy of treatments in
specific subpopulations. Topotecan administration by convection-enhanced delivery has
significant antitumor activity at concentrations that are nontoxic to normal brain. The potential
for use of this therapy as a generally effective treatment option for malignant gliomas will be
tested in subsequent phase II and III trials. (Bruce, 2011)
Topoisomerase II (epipodophyllotoxin) has been implicated in the pathogenesis of treatment-
related myelodysplastic syndrome/ treatment-related acute myelogenous leukemia (t-MDS/t-
AML). (Baehring, 2012) Once patients develop these t-MDS/t-AML disorders they are treated
with supportive care, including transfusion of blood products and administration of antibiot‐
ics; 5-azacytidine, decitabine, and lenalidomide are approved for the treatment of selected
patients with MDS in the United States. Hence, some of the side effects of topoisomerase
inhibition therapy for CNS tumors must be further investigated in additional head to head
clinical studies with other monotherapies or combinations that may alleviate adverse effects.
Additional ways to reduce or minimize toxicity include close monitoring of blood counts and
limiting long term usage of the drug.
7. Emerging topoisomerase therapies and combinations
Genz-644282 is a new a non-camptothecin topoisomerase I inhibitor (Kurtzberg, 2011) in
clinical  development.  Efficacy  for  this  novel  agent  was  tested  and  compared  with  the
standard anticancer drugs; irinotecan, docetaxel, and dacarbazine in human tumor xeno‐
grafts  of  colon cancer,  renal  cell  carcinoma,  non-small  cell  lung cancer,  and melanoma.
Genz-644282 had superior  or  equal  antitumor activity than the standard drug compara‐
tors, although brain tumor models were not utilized. (Kurtzberg) Genz-644282 and its me‐
tabolites induce Top1 cleavage at similar, as well as unique genomic positions, compared
with camptothecin which traps topoisomerase I (Top1)-DNA cleavage complexes. Protein-
linked DNA breaks are induced by Genz-644282,  and cleavage complexes persist  longer
after  compound  removal  than  camptothecin  treatment.  (Sooryakumar,  2011)  The  agent
was tested against the pediatric preclinical testing program (PPTP) panel as well as in vivo
using at its maximum tolerated dose (MTD) of 4 mg/kg (3 times per week × 2 schedule re‐
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peutic drugs in tumor cells may be be one of the primary causes of treatment failure in solid
tumors. The blood-brain barrier (BBB) restricts the concentrations of chemotherapeutic drugs
that may reach the tumor site. Methods that deliver drugs in a systemic fashion may increase
toxicity and create off target site complications. Convection-enhanced delivery (CED) is a
method that may provide drugs to the tumor in a more targeted fashion through the interstitial
space.(Barker,1998; Bobo,1994) This approach results into more drug being delivered into
tumors and surrounding brain through stereo-tactically placed catheters connected to pumps.
(Barker,1998; Bobo,1994) By providing a continuous, low grade positive-pressure microinfu‐
sion that distributes drugs by bulk flow, CED may result in high local concentrations and
reduce systemic toxicity. (Bruce,2011)
Topotecan, a topoisomerase I inhibitor, is cytotoxic to glioma cells and nontoxic to normal
brain, and its levels are higher in glioma cells and tumor tissue than in normal brain. Topotecan
is a natural-product drug with high molecular weight which allows it to minimally traverse
the BBB from the brain to the systemic circulation. (Kaiser,2000;Bruce,2000;Borris,1998,
Matsumoto, 1999) Now there is evidence that in colon tumors topotecan treatment results in
the downregulation of hypoxia-inducible factor-1α (HIF1A) target genes along with an
inhibition of HIF1A protein accumulation. (Guerin, 2012) Hence, topoisomerase I inhibitors
may also influence the tumor environment by decreasing tumor angiogenesis leading to tumor
size stabilization, although clinical trials of topotecan delivered intravenously had minimal
effects on tumors. (Fridman,1999) In other studies, CED in rat in vivo models prolonged
survival and had significant antitumor efficacy. (Kaiser,2000; Bruce,2000)
Recently, a prospective, dose-escalation phase Ib study of CED of topoisomerase-I was
conducted in sixteen patients with recurrent malignant gliomas with a median age of 50 years.
Ten patients had glioblastoma multiforme, and the other 6 had World Health Organization
grade III glial tumors with an average enhancing volume of 16.1 cm3. (Bruce,2011) Standard
MRI/CT-guided stereotactic biopsy was used to histologically confirm the presence of
recurrent malignant glioma. In this study, the investigators evaluated toxicity and quality of
life (QOL) effects and confirmed antitumor activity radiographically. The change in contrast-
enhancing volume of tumor on MRI was used to assess tumor response to treatment. Three
response categories were used to characterize the tumors: early response; as a decrease in
contrast-enhancing volume of >50% through the first 3 to 6 months after therapy, progressive
disease; as increasing contrast-enhancing volume (>25%) at ≥1 month after therapy until
surgical resection or death, and pseudoprogression; an increase in the contrast-enhancing
volume of >50% followed by regression of enhancement and edema (changes had to be
sustained for at least 4 weeks with patients on a stable or decreasing dose of steroids).(Bruce,
2011) The investigators noted significant antitumor activity in these tumors through radio‐
graphic changes, and treatment with CED topotecan prolonged overall survival. The maxi‐
mum tolerated dose that can be used for phase II studies was determined in this trial. Drug-
associated toxicity was minimal and topotecan convection-enhanced delivery had activity at
concentrations that were nontoxic to normal brain. (Bruce,2011)
CED locally administered topotecan treatment was tested on a rat model of glioblastoma that
is induced by intracerebral injection of PDGF (platelet-derived growth factor)-IRES (internal
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ribosome entry site) expressing retrovirus. (Lopez, 2011) Glial progenitor cells recruited to the
tumor and the transformed tumor cells were analyzed by histopathology. Glial progenitor cells
are proliferate within gliomas and contribute to the growth of the tumor. (Appolloni, 2009
OGDEN) This pro-growth process is influenced via PDGF signaling, another common
proliferative pathway. (Assanah, 2006 Assanah, 2009) The transformed cell population was
reduced about 10-fold and recruited progenitors by about 80-fold. A significant survival
advantage was found in treated animals and this improved with greater treatment duration.
(Lopez, 2011) In addition, the distribution of topotecan was traced with MRI of a tracer
molecule and corresponded with regions of glial progenitor ablation. The decrease in progen‐
itor recruitment was most likely due to the ablation of recruitable progenitor cells. These results
showed that in a model of growth factor influenced gliomas, tumor cells and the induced
progenitor cells are eradicated by topoisomerase inhibition based treatments. Hence, future
characterization of tumors through these methods may enhance the efficacy of treatments in
specific subpopulations. Topotecan administration by convection-enhanced delivery has
significant antitumor activity at concentrations that are nontoxic to normal brain. The potential
for use of this therapy as a generally effective treatment option for malignant gliomas will be
tested in subsequent phase II and III trials. (Bruce, 2011)
Topoisomerase II (epipodophyllotoxin) has been implicated in the pathogenesis of treatment-
related myelodysplastic syndrome/ treatment-related acute myelogenous leukemia (t-MDS/t-
AML). (Baehring, 2012) Once patients develop these t-MDS/t-AML disorders they are treated
with supportive care, including transfusion of blood products and administration of antibiot‐
ics; 5-azacytidine, decitabine, and lenalidomide are approved for the treatment of selected
patients with MDS in the United States. Hence, some of the side effects of topoisomerase
inhibition therapy for CNS tumors must be further investigated in additional head to head
clinical studies with other monotherapies or combinations that may alleviate adverse effects.
Additional ways to reduce or minimize toxicity include close monitoring of blood counts and
limiting long term usage of the drug.
7. Emerging topoisomerase therapies and combinations
Genz-644282 is a new a non-camptothecin topoisomerase I inhibitor (Kurtzberg, 2011) in
clinical  development.  Efficacy  for  this  novel  agent  was  tested  and  compared  with  the
standard anticancer drugs; irinotecan, docetaxel, and dacarbazine in human tumor xeno‐
grafts  of  colon cancer,  renal  cell  carcinoma,  non-small  cell  lung cancer,  and melanoma.
Genz-644282 had superior  or  equal  antitumor activity than the standard drug compara‐
tors, although brain tumor models were not utilized. (Kurtzberg) Genz-644282 and its me‐
tabolites induce Top1 cleavage at similar, as well as unique genomic positions, compared
with camptothecin which traps topoisomerase I (Top1)-DNA cleavage complexes. Protein-
linked DNA breaks are induced by Genz-644282,  and cleavage complexes persist  longer
after  compound  removal  than  camptothecin  treatment.  (Sooryakumar,  2011)  The  agent
was tested against the pediatric preclinical testing program (PPTP) panel as well as in vivo
using at its maximum tolerated dose (MTD) of 4 mg/kg (3 times per week × 2 schedule re‐
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peated at day 21).(Houghton, 2012) Testing was also conducted in model systems in or‐
der to determine a dose regulated response. Treatment exhibited potent cytotoxic activity
in vitro models, and in vivo it induced and maintained complete responses in all 6 solid
tumor  models  at  MTD.  At  lower  doses  of  2 mg/kg  it  induced  complete  responses  and
maintained  complete  responses  in  tumor  models  relatively  insensitive  to  Topotecan  al‐
though responses were not observed at lower doses. A significant correlation was found
between predictive response scores in baseline mRNA tumor gene expression profiles and
the observed in vivo responses to Genz-644282. Future research on clinical activity in chil‐
dren impacted by CNS tumors will depend on tolerated drug exposures and safety pro‐
files. (Houghton, 2012)
Topotecan has been studied in combination with other therapies that may increase treatment
efficacy in brain tumors. In a recent study, the combination of nanoliposomal topotecan (nLs-
TPT) and pegylated liposomal doxorubicin (PLD) was delivered with CED as treatment for
malignant brain tumors. (Yamashita, 2007) Both drugs decreased proteins and enzymes with
roles in cell replication in vitro, with some synergistic effects. Doxorubicin is also used to inhibit
topoisomerase II, and although these studies used implantation of tumor cells in animals, the
investigators conducted a survival study in which animals in the control group and the single
agent groups had a median survival that was less than the median survival of the combination
group. In this study combination therapy use two agents that were both encapsulated in
liposomes. Furthermore, the use of CED was promoted as an enhanced drug delivery method,
increasing drug availability at the brain tumor site and leading to tumor death.
New phase III randomized control trials incorporating the addition of bevacizumab for newly
diagnosed GBM patients may be informative and increase treatment efficacy. (Vredenburg,
2011) In combination with the use of specific molecular biomarkers, data from these trials may
clarify the role of anti-angiogenesis agents such as bevacizumab in combination therapy with
topoisomerase inhibitors. The incorporation of molecular signatures elicited by therapies such
as irinotecan will create a more descriptive situation of the tumor microenvironment, and lead
to the elucidation of additional therapeutic targets. (Guerin, 2012 )
Additional research into the use of low-dose etoposide (topoII inhibitor) with an oncolytic
herpes simplex virus increased survival of mice-bearing intracranial human GSC–derived
tumors. (Cheema) These results were found without adverse side effects, possibly leading to
this as an effective combination strategy to treat resistant and recurrent GBM in the future.
(Cheema)
In a recent study of both a neuroblastoma and astrocytoma cell line that were resistant to
chemotherapy  (eg.  temozolomide)  and  radiation  treatment,  investigators  found  that  a
novel cytotoxic compound was toxic to these these cells but not to human primary astro‐
cytes. This compound is an analog of thiobarbituric acid and is effective in subcutaneous
and intracranial mouse tumor models with a good safety profile. (Lee, 2011) The mecha‐
nism of  action of  the lead compound has topoisomerase IIa  inhibition activity but  does
not inhibit topoisomerase I activity. These types of studies may lead to the development
of new agents that can overcome some of the tumor resistance mechanisms in temozolo‐
mide and radiation resistant astrocytomas.
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8. Predictive biomarkers and tests
The development of molecular markers which predict response to chemotherapy is an
important aspect of current neuro-oncology research. The studies and subsequent tests that
may assess the status of these biomarkers are ongoing, but few molecules are being tested at
this time. O 6-methylguanine-DNA methyltransferase MGMT promoter methylation is the
only proved marker of glioblastoma. (Weller,2010) This DNA repair enzyme antagonizes the
genotoxic effects of alkylating agents. The expression of MGMT in tumor cells is a marker for
significant resistance to temozolomide therapy and other treatments. (Liu, 2006; Donson,
2007; Hegi, 2005) MGMT promoter methylation is the key mechanism of MGMT gene silencing
and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating
agent chemotherapy. (Weller,2010) The predictive or prognostic value of MGMT promoter
methylation may differ depending on glioma subtypes, and the extent to which testing should
be incorporated into routine clinical practice is still under investigation.
A recent study assessed the effect of topoisomerase expression on glioblastoma survival and
the mechanisms involved. (Arivazhagan,2012) In an effort to correlate outcome with gene
expression, the transcript levels of all isoforms of the topoisomerase family in all grades of
diffuse astrocytoma were assessed in this prospective study of patients with glioblastoma
treated by a uniform treatment procedure. Transcript levels of TOP2A, TOP2B, and TOP3A
were up regulated significantly in GBM in comparison with lower grades of astrocytoma and
normal brain samples. The mRNA levels of TOP2A correlated significantly with survival of
the patients, and better prognosis in GBM patients. Temozolomide (Arivazhagan,2012) was
also a TOP2A inhibitor, and TOP2A transcript levels determined the chemosensitivity of
glioblastoma to temozolomide therapy. Very high levels of TOP2A were considered a good
prognostic indicator in GBM patients receiving temozolomide chemotherapy. Methylation of
the MGMT promoter was found to be the strongest predictor of outcome and benefit from
temozolomide chemotherapy. (Stupp,2009) Analysis of progression free survival revealed an
advantage solely for patients whose tumor had a methylated MGMT promoter and who were
treated with temozolomide and radiotherapy. Hence, in this patient analysis relied on
combination therapy was as opposed to monotherapy. These types of results may serve as the
impetus for the identification of new genetic biomarkers for GBM and the development of
therapies targeting new molecular targets.
9. Conclusions
The treatment of primary malignancies of the CNS continues to be a challenging problem since
their treatment is complicated due to anatomical site and the intricacy of the blood brain
barrier. Topoisomerase I (topo I) inhibitors, in addition to temozolomide and nitrosourea
compounds, represent one promising one treatment option. While preclinical studies in glioma
models were promising, clinical trials with topo I inhibitors with topotecan and CPT-11
showed only modest benefit in phase II clinical trials. Children with anaplastic astrocytoma
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peated at day 21).(Houghton, 2012) Testing was also conducted in model systems in or‐
der to determine a dose regulated response. Treatment exhibited potent cytotoxic activity
in vitro models, and in vivo it induced and maintained complete responses in all 6 solid
tumor  models  at  MTD.  At  lower  doses  of  2 mg/kg  it  induced  complete  responses  and
maintained  complete  responses  in  tumor  models  relatively  insensitive  to  Topotecan  al‐
though responses were not observed at lower doses. A significant correlation was found
between predictive response scores in baseline mRNA tumor gene expression profiles and
the observed in vivo responses to Genz-644282. Future research on clinical activity in chil‐
dren impacted by CNS tumors will depend on tolerated drug exposures and safety pro‐
files. (Houghton, 2012)
Topotecan has been studied in combination with other therapies that may increase treatment
efficacy in brain tumors. In a recent study, the combination of nanoliposomal topotecan (nLs-
TPT) and pegylated liposomal doxorubicin (PLD) was delivered with CED as treatment for
malignant brain tumors. (Yamashita, 2007) Both drugs decreased proteins and enzymes with
roles in cell replication in vitro, with some synergistic effects. Doxorubicin is also used to inhibit
topoisomerase II, and although these studies used implantation of tumor cells in animals, the
investigators conducted a survival study in which animals in the control group and the single
agent groups had a median survival that was less than the median survival of the combination
group. In this study combination therapy use two agents that were both encapsulated in
liposomes. Furthermore, the use of CED was promoted as an enhanced drug delivery method,
increasing drug availability at the brain tumor site and leading to tumor death.
New phase III randomized control trials incorporating the addition of bevacizumab for newly
diagnosed GBM patients may be informative and increase treatment efficacy. (Vredenburg,
2011) In combination with the use of specific molecular biomarkers, data from these trials may
clarify the role of anti-angiogenesis agents such as bevacizumab in combination therapy with
topoisomerase inhibitors. The incorporation of molecular signatures elicited by therapies such
as irinotecan will create a more descriptive situation of the tumor microenvironment, and lead
to the elucidation of additional therapeutic targets. (Guerin, 2012 )
Additional research into the use of low-dose etoposide (topoII inhibitor) with an oncolytic
herpes simplex virus increased survival of mice-bearing intracranial human GSC–derived
tumors. (Cheema) These results were found without adverse side effects, possibly leading to
this as an effective combination strategy to treat resistant and recurrent GBM in the future.
(Cheema)
In a recent study of both a neuroblastoma and astrocytoma cell line that were resistant to
chemotherapy  (eg.  temozolomide)  and  radiation  treatment,  investigators  found  that  a
novel cytotoxic compound was toxic to these these cells but not to human primary astro‐
cytes. This compound is an analog of thiobarbituric acid and is effective in subcutaneous
and intracranial mouse tumor models with a good safety profile. (Lee, 2011) The mecha‐
nism of  action of  the lead compound has topoisomerase IIa  inhibition activity but  does
not inhibit topoisomerase I activity. These types of studies may lead to the development
of new agents that can overcome some of the tumor resistance mechanisms in temozolo‐
mide and radiation resistant astrocytomas.
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8. Predictive biomarkers and tests
The development of molecular markers which predict response to chemotherapy is an
important aspect of current neuro-oncology research. The studies and subsequent tests that
may assess the status of these biomarkers are ongoing, but few molecules are being tested at
this time. O 6-methylguanine-DNA methyltransferase MGMT promoter methylation is the
only proved marker of glioblastoma. (Weller,2010) This DNA repair enzyme antagonizes the
genotoxic effects of alkylating agents. The expression of MGMT in tumor cells is a marker for
significant resistance to temozolomide therapy and other treatments. (Liu, 2006; Donson,
2007; Hegi, 2005) MGMT promoter methylation is the key mechanism of MGMT gene silencing
and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating
agent chemotherapy. (Weller,2010) The predictive or prognostic value of MGMT promoter
methylation may differ depending on glioma subtypes, and the extent to which testing should
be incorporated into routine clinical practice is still under investigation.
A recent study assessed the effect of topoisomerase expression on glioblastoma survival and
the mechanisms involved. (Arivazhagan,2012) In an effort to correlate outcome with gene
expression, the transcript levels of all isoforms of the topoisomerase family in all grades of
diffuse astrocytoma were assessed in this prospective study of patients with glioblastoma
treated by a uniform treatment procedure. Transcript levels of TOP2A, TOP2B, and TOP3A
were up regulated significantly in GBM in comparison with lower grades of astrocytoma and
normal brain samples. The mRNA levels of TOP2A correlated significantly with survival of
the patients, and better prognosis in GBM patients. Temozolomide (Arivazhagan,2012) was
also a TOP2A inhibitor, and TOP2A transcript levels determined the chemosensitivity of
glioblastoma to temozolomide therapy. Very high levels of TOP2A were considered a good
prognostic indicator in GBM patients receiving temozolomide chemotherapy. Methylation of
the MGMT promoter was found to be the strongest predictor of outcome and benefit from
temozolomide chemotherapy. (Stupp,2009) Analysis of progression free survival revealed an
advantage solely for patients whose tumor had a methylated MGMT promoter and who were
treated with temozolomide and radiotherapy. Hence, in this patient analysis relied on
combination therapy was as opposed to monotherapy. These types of results may serve as the
impetus for the identification of new genetic biomarkers for GBM and the development of
therapies targeting new molecular targets.
9. Conclusions
The treatment of primary malignancies of the CNS continues to be a challenging problem since
their treatment is complicated due to anatomical site and the intricacy of the blood brain
barrier. Topoisomerase I (topo I) inhibitors, in addition to temozolomide and nitrosourea
compounds, represent one promising one treatment option. While preclinical studies in glioma
models were promising, clinical trials with topo I inhibitors with topotecan and CPT-11
showed only modest benefit in phase II clinical trials. Children with anaplastic astrocytoma
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or glioblastoma (Turner, 2002) appear to benefit more with higher response rates than adults
with the same tumors. (Friedman,1999; Batchelor, 2004)
The combination of topo I inhibitors with drugs that block angiogenesis including VEGF
appear promising, and further studies are needed in the establishment of efficacy, and the
development of treatment strategy. However, serious toxicity such as CNS hemorrhage and
leukoencephalopathy may occur with these agents. (Ozcan,2006) Further clinical trials are
needed to better define the patients at risk for these major side effects.
Another future approach is combining topo I inhibitors together with targeted agents and
antiangiogenesis drugs. For example, NF-қB activation in glioma cells may be induced by
campothecins leading to inhibition of apoptosis in these cells. It has been shown that over‐
production of IL-1Β can sustain NF-қB activation (Morandi,2006) and agents that inhibit NF-
қB activation may increase the susceptibility of glioma cells y to apoptosis induced by
campothecin. (Weaver,2003)
Other agents that may increase the efficacy of topo I drugs include the new chemotherapy
drug, irofulven. (Woo,2005) PKC inhibitors in combination with CPT-11 have also shown
promise in laboratory studies. (Chen TC, 2003) These studies demonstrated an increase in
apoptosis and decrease in proliferation in glioma cell lines when exposed to both agents. A
decrease in the antiapoptotic protein bcl-2 and an increase in the proapoptotic bax protein may
be propagate this mechanism of apoptosis.
Other novel approaches include the use of agents to increase penetration of topotecan into
glioma cells. (Carcaboso, 2010) It is possible that one mechanism of drug resistance to topotecan
is increased pumping of drug out of the cell. It is known that topotecan is a substrate of the
ATP-binding cassette (ABC) transporters P-glycoprotein and breast cancer resistance protein
(BCRP/ABCG2). In mice it has been shown that the epidermal growth factor receptor tyrosine
kinase inhibitor, Gefitinib, can increase intracellular drug penetration into glioma cells. Similar
approaches in the treatment of brain tumors may increase drug availability to the tumor
environment.
Immunotherapy for treatment of malignant gliomas has usually been unsuccessful. One new
approach is to add topotecan to enhance immune clearance of gliomas. (Wei J,2009) Preclinical
studies with the human glioma cell line U-87 using topotecan showed that the drug can
upregulate functional Fas receptors and the resulting upregulated Fas expression can increase
susceptibility to cytotoxic T cell killing. These findings will have to be substantiated through
additional clinical studies and testing.
Another novel approach is to increase drug delivery across the blood brain barrier. Liposomes
incorporating Tamoxifen and wheat germ agglutinin have improved the transport of topote‐
can across the blood brain barrier in brain tumor-bearing rats. (Du 2009) In these studies,
improved survival may be related to the enhanced effect of Tamoxifen by inhibiting efflux of
multidrug resistant proteins in the blood brain barrier and/or an enhanced effect by the wheat
germ agglutinin via endocytosis in the blood brain barrier and in the brain tumor.
Another method to deliver more drug into brain tumors is by a convection-delivery system.
This approach may be advantageous by potentially increasing drug delivery into the brain
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tumor while reducing systemic side effects. Regression of malignant gliomas by this convec‐
tion-enhanced delivery system has been reported recently. (Bruce, 2011) Future phase II trials
are being planned with this technique since the maximum tolerated dose has been established.
Finally, there are newer generations of topo I inhibitors being evaluated and several have
entered into clinical trials in human patients. These newer topo I inhibitors include Diflomo‐
tecan, Karenitecin, Silatecan, PEG-camptothecin, Rubitecan, 9-aminocamptothecin, Exatecan
mesylate, Lurtotecan, and Gimatecan. (Pommier, 2006) A phase II trial of Rubitecan in patients
with glioblastoma showed disappointing results. (Raymond,2002) A phase I and pharmaco‐
kinetic study of Karenitecin in patients with recurrent malignant gliomas was recently
reported. (Grossman, 2008)
Since the vast majority of patients with malignant gliomas die of their disease, it is clear that
newer and more effective drugs are needed. There has been renewed interest in topoisomerase
I inhibitors in brain tumors using innovative drug carriers or drug delivery systems. In
addition, novel topoisomerase I inhibitors are promising and are currently being explored and
investigated.
Investigator n Treatment Response Rate Ref.
Møller et al. 85 IV bevacizumab (10 mg/kg),
irinotecan (125/340 mg/m2 ) every
14d until progression
ORR (overall response rate) was
25%, with 59% achieving stable
disease; median PFS of 5.2 months
Møller, 2012
Bruce et al. 16 Dose escalation of Ib study of CED of
topotecan
Significant antitumor activity by
radiographic changes, and




80 Add. bevacizumab to temozolomide
and radiation followed by temozolo-
mide, bevacizumab, topotecan
Median PFS and OS not reached at a
median follow-up of 8 months but





25 After combined treatment with
bevacizumab and
itinotecandetermine the
independent prognostic value of
(FDG)-PET on PFS and OS of recurrent
histologically proven high grade
glioma, compared with other
documented prognostic variables.
Imaging was performed within 6
weeks of starting chemotherapy
Median PFS and OS were 4 months
(range, 0.9-10.4 months) and 7.2
months (range, 1.2-41.7 months),
respectively. At 6 months, PFS and
OS rate were 16.0% and 72.0%.
FDG uptake was the most powerful
predictor of both PFS and OS
Colavolpe,
2012
Paldino et al. 15 Determine the prognostic
significance of changes in parameters
derived from diffusion tensor
imaging (DTI) that occur in response
to treatment with bevacizumab and
DTI detected a change in Apparent
diffusion coefficient (ADC) within
FLAIR signal abnormality (FSA).
Patients with a change in ADC
within FSA had significantly shorter
Paldino, 2012
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or glioblastoma (Turner, 2002) appear to benefit more with higher response rates than adults
with the same tumors. (Friedman,1999; Batchelor, 2004)
The combination of topo I inhibitors with drugs that block angiogenesis including VEGF
appear promising, and further studies are needed in the establishment of efficacy, and the
development of treatment strategy. However, serious toxicity such as CNS hemorrhage and
leukoencephalopathy may occur with these agents. (Ozcan,2006) Further clinical trials are
needed to better define the patients at risk for these major side effects.
Another future approach is combining topo I inhibitors together with targeted agents and
antiangiogenesis drugs. For example, NF-қB activation in glioma cells may be induced by
campothecins leading to inhibition of apoptosis in these cells. It has been shown that over‐
production of IL-1Β can sustain NF-қB activation (Morandi,2006) and agents that inhibit NF-
қB activation may increase the susceptibility of glioma cells y to apoptosis induced by
campothecin. (Weaver,2003)
Other agents that may increase the efficacy of topo I drugs include the new chemotherapy
drug, irofulven. (Woo,2005) PKC inhibitors in combination with CPT-11 have also shown
promise in laboratory studies. (Chen TC, 2003) These studies demonstrated an increase in
apoptosis and decrease in proliferation in glioma cell lines when exposed to both agents. A
decrease in the antiapoptotic protein bcl-2 and an increase in the proapoptotic bax protein may
be propagate this mechanism of apoptosis.
Other novel approaches include the use of agents to increase penetration of topotecan into
glioma cells. (Carcaboso, 2010) It is possible that one mechanism of drug resistance to topotecan
is increased pumping of drug out of the cell. It is known that topotecan is a substrate of the
ATP-binding cassette (ABC) transporters P-glycoprotein and breast cancer resistance protein
(BCRP/ABCG2). In mice it has been shown that the epidermal growth factor receptor tyrosine
kinase inhibitor, Gefitinib, can increase intracellular drug penetration into glioma cells. Similar
approaches in the treatment of brain tumors may increase drug availability to the tumor
environment.
Immunotherapy for treatment of malignant gliomas has usually been unsuccessful. One new
approach is to add topotecan to enhance immune clearance of gliomas. (Wei J,2009) Preclinical
studies with the human glioma cell line U-87 using topotecan showed that the drug can
upregulate functional Fas receptors and the resulting upregulated Fas expression can increase
susceptibility to cytotoxic T cell killing. These findings will have to be substantiated through
additional clinical studies and testing.
Another novel approach is to increase drug delivery across the blood brain barrier. Liposomes
incorporating Tamoxifen and wheat germ agglutinin have improved the transport of topote‐
can across the blood brain barrier in brain tumor-bearing rats. (Du 2009) In these studies,
improved survival may be related to the enhanced effect of Tamoxifen by inhibiting efflux of
multidrug resistant proteins in the blood brain barrier and/or an enhanced effect by the wheat
germ agglutinin via endocytosis in the blood brain barrier and in the brain tumor.
Another method to deliver more drug into brain tumors is by a convection-delivery system.
This approach may be advantageous by potentially increasing drug delivery into the brain
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tumor while reducing systemic side effects. Regression of malignant gliomas by this convec‐
tion-enhanced delivery system has been reported recently. (Bruce, 2011) Future phase II trials
are being planned with this technique since the maximum tolerated dose has been established.
Finally, there are newer generations of topo I inhibitors being evaluated and several have
entered into clinical trials in human patients. These newer topo I inhibitors include Diflomo‐
tecan, Karenitecin, Silatecan, PEG-camptothecin, Rubitecan, 9-aminocamptothecin, Exatecan
mesylate, Lurtotecan, and Gimatecan. (Pommier, 2006) A phase II trial of Rubitecan in patients
with glioblastoma showed disappointing results. (Raymond,2002) A phase I and pharmaco‐
kinetic study of Karenitecin in patients with recurrent malignant gliomas was recently
reported. (Grossman, 2008)
Since the vast majority of patients with malignant gliomas die of their disease, it is clear that
newer and more effective drugs are needed. There has been renewed interest in topoisomerase
I inhibitors in brain tumors using innovative drug carriers or drug delivery systems. In
addition, novel topoisomerase I inhibitors are promising and are currently being explored and
investigated.
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Investigator n Treatment Response Rate Ref.
irinotecan in patients with recurrent
GM through serial 1.5 T MRI. Axial
single-shot echo planar DTI was
obtained on scans performed 3 days
and 1 day prior to and 6 wks. after
initiation of therapy.
overall survival (p=0.032) and
progression free survival (p=0.046)
than those with no change.
Desjardins et
al.
32 PII trial of combined protracted daily
temozolomide 50 mg/m(2) and
biweekly bevacizumab (10mg/kg) IV
for patients with recurrent
glioblastoma who had previously
received radiation therapy and
temozolomide. Underwent physical
examination and brain MRI every 8
weeks.
6month PFS rate 18.8% (95% [CI],
7.6%-33.7%), median PFS 15.8 wks.
Median OS of 37 wks.,6-m OS rate
of 62.5% (95% CI, 43.5%-76.7%),
12-m OS rate of 31.3% (95% CI,
16.4%-47.3%). Patients progressed;
locally (52%), diffuse pattern (38%),
distant (10%). Regimen had some
activity and was well tolerated but
results obtained were inferior to
those observed in studies of
bevacizumab monotherapy and of
combination with irinotecan.
Patient population was more
heterogeneous and pretreated






40 Phase II, open, label, single arm trial




carboplatin (area under the plasma
curve [AUC] 4 mg/ml-min) on day
one, while bevacizumab (10 mg/kg)
and irinotecan (340 mg/m(2) for
patients on CYP3A-enzyme-inducing
anti-epileptics [EIAEDs] and 125 mg/
m(2) for patients not on EIAEDs)
administered on days 1 and 14 of
every 28-day cycle. Evaluated after
each of the first 2 cycles and then
after every other cycle. Treatment
continued until progressive disease,
unacceptable toxicity, non-
compliance, or voluntary withdrawal.
All patients had progression after
standard therapy, patients (40%)
had a KPS of 90-100, while 68%
were at first progression. PFS-6 rate
was 46.5% (95% CI: 30.4, 61.0%)
and median OS of 8.3 months [95%
CI: 5.9, and 10.7 months]. Addition
of carboplatin and irinotecan to
bevacizumab significantly increases
toxicity but does not improve anti-
tumor activity to that achieved
historically with single-agent
bevacizumab among bevacizumab-
naïve, recurrent GBM patients.
Reardon, 2012
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Investigator n Treatment Response Rate Ref.
Reardon, et
al.
Phase II, open, label, single arm trial
on efficacy of carboplatin, irinotecan,
and bevacizumab among recurrent
glioblastoma (GBM) patients after
prior progression on bevacizumab
therapy. Received carboplatin (area
under the plasma curve [AUC] 4
mg/ml-min) on day 1, bevacizumab
(10 mg/kg) and irinotecan (340 mg/
m(2) for patients on CYP3A enzyme-
inducing anti-epileptics [EIAEDs] and
125 mg/m(2) for patients not on
EIAEDs) were administered on days 1
and 14 of every 28-day cycle. Patients
were evaluated after each of the first
2 cycles and then after every other
cycle. Treatment continued until
progressive disease, unacceptable
toxicity, noncompliance, or voluntary
withdrawal.
All patients had progression on at
least 1 prior bevacizumab regimen
and 56% enrolled after either 2nd or
3rd overall progression. Median OS
was 5.8 months (95% [CI], 4.0-7.0
months) and PFS-6 rate was 16%
(95% CI, 5.0%-32.5%). Carboplatin,
irinotecan, and bevacizumab was
associated with modest activity and
adequate safety among these
patients.
Reardon, 2011
Parekh et al. 8 Retrospectively reviewed the records
of patients <21 yrs. of age with
recurrent or progressive WHO grade
3-4 gliomas who were treated with




bevacizumab, one patient received
irinotecan and bevacizumab, and one
patient received CCNU and
bevacizumab.
3 patients had stable disease for
30-93 weeks, 5 patients progressed
within 17 wks., median PFS was 15
weeks, 6-m PFS was 38%. Contrast
enhancing disease responded or
remained stable in 5/7 patients, and
non-enhancing disease progressed
in 3/4 patients. Bevacizumab was
well tolerated when used in
combination with conventional
chemotherapy (irinotecan in most
cases). PFS in cohort was much
shorter and the response rate was
inferior in this small cohort of
patients when compared with
published adult data, but
bevacizumab regimens may have




Pope et al. 85 Evaluated patterns of tumor
progression in patients with recurrent
79% treated with single-agent BEV
and 70% of patients treated with
Pope, 2011
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Investigator n Treatment Response Rate Ref.
glioblastoma who were treated with
bevacizumab (BEV) alone or in
combination with irinotecan (CPT-11)
while participating in the BRAIN
study. Iindependent neuroradiologist
reviewed MRI scans in patients who
received BEV or BEV+CPT-11 while on
BRAIN. 28% of patients who
participated had nonlocal disease at
baseline.
BEV+CPT-11 experienced disease
progression while on BRAIN. Most
patients did not have a change in
radiographic pattern (i.e., "no shift")
at the time of progression. 82% of
BEV patients had no shift and BEV
+CPT-11 patients (53%, χ(2) p =
0.0004), and a greater proportion of
BEV+CPT-11 (39%) compared with
BEV (16%) experienced local-to-
diffuse tumor pattern at
progression (χ(2) p = 0.002).
Patients treated with BEV or BEV
+CPT-11 who had local-to-local or
local-to-diffuse progression patterns
had similar efficacy outcomes,
including objective response, PFS,
and OS.
Table 1. Recent studies of topoisomerase inhibitors as monotherapies or in combination with other
chemotherapeutics for the treatment of brain tumors
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at the time of progression. 82% of
BEV patients had no shift and BEV
+CPT-11 patients (53%, χ(2) p =
0.0004), and a greater proportion of
BEV+CPT-11 (39%) compared with
BEV (16%) experienced local-to-
diffuse tumor pattern at
progression (χ(2) p = 0.002).
Patients treated with BEV or BEV
+CPT-11 who had local-to-local or
local-to-diffuse progression patterns
had similar efficacy outcomes,
including objective response, PFS,
and OS.
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1. Introduction
A primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodg‐
kin’s lymphoma arising in the craniospinal axis. For many years, PCNSLs were reported to
represent 3–5% of all primary central nervous system (CNS) tumors [1]. However, PCNSL
appears to be increasing in incidence [2-4]. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-
fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the
same registries over the same time periods [2]. The increase is evident in all age groups and
in both genders [2]. The tumor manifestation is often diffuse and multifocal, and most fre‐
quently affects the supratentorial brain parenchyma. The absence of systemic lymphadeno‐
pathies and other extracranial localizations of disease should be confirmed. Most PCNSLs
belong to the diffuse large B-cell lymphomas (DLBCLs), but differ from systemic DLBCLs by
their less favorable prognosis. The systemic use of high-dose methotrexate (HD-MTX)-based
chemotherapy with radiation therapy for newly diagnosed PCNSL has improved the me‐
dian overall survival (OS) from 20 to 36 months [5-8]. However, more intense efforts are re‐
quired to improve the outcome of the patients and to identify novel therapeutic strategies.
In this article, we will review the recent developments of basic and clinical research on
PCNSL.
2. Clinical characteristics
PCNSL has been described at all ages, but usually arise in the fifty to sixty years, with a
male to female ratio of 1.5 [9]. The symptoms are focal neurological deficits, mental disturb‐
ance and increased intracranial pressure. The characteristics of radiographic findings of
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PCNSL are homogenous contrast enhancement on MRI with gadolinium at least 15 mm in
contact with the subarachnoid space [10], periventricular lesions involving the corpus callos‐
um, basal ganglia, or thalamus. The eye is involved in about 20% of patients [11]. Leptome‐
ningeal involvement is seen in about 18% [12]. The tumor is single in 60% of patients and
multiple in the remainder [10]. Diffusion-weighted MRI (DW-MRI) and proton-MR-spectro‐
scopy (1H-MRS) usually reveal a uniformly pathologic pattern of metabolite concentrations
[10]. The absence of systemic lymphadenopathies and other extracranial localizations of dis‐
ease should be confirmed. Corticosteroids can temporaly cause regression of the tumor in
40-85% of patients [13]. Diagnosis requires histologic conformation. Molecular analysis of
the rearrangement of immunoglobulin heavy chain genes by means of polymerase chain re‐
action (PCR) and Southern blotting may be acceptable [14]. Most PCNSLs belongs to diffuse
large B cell and phenotypically express pan-B-cell markers such as CD19, CD20, CD22 and
CD79a. The majority of PCNSL express BCL-6, a marker of GCB (germinal center B-cell-like)
cells, and MUM1, a marker of late GCB cells.
3. Treatment
PCNSL is sensitive to radiation therapy, however patients treated with radiotherapy alone
had 5-year over all survivals of 3-4%, more than 80% patients relapsed within 10-14 months
[15]. Standard radiotherapy for patients consists of 40 Gy to whole brain with an additional
boost of 10-20 Gy on the tumor bed [16]. Shibamoto et al. [17] reported the recent improved
results of radiation monotherapy, 5-year survival was 25% for patients 63 years old or
younger, and 9.8% for those older than 63 years. Since total irradiation dose is an important
predictor of delayed neurotoxicity, a decrease in the incidence of this complication should
be expected if the total irradiation dose is reduced. Several studies have demonstrated that
HD-MTX, with or without other chemotherapeutic agents, yielded high response rates with
33-45 months over all survival. These results are better than the results of radiotherapy
alone. HD-MTX is widely recognized as the single most effective chemotherapeutic agent
for PCNSL [18-23]. MTX is usually administered at high doses with various schedules. Re‐
cently, randomized trials for PCNSLs are reported. Ferreri et al. [6] assessed the effect of
adding high-dose cytarabine to methotrexate in patients with newly diagnosed PCNSL in
randomised phase 2 trial. Seventy-nine patients with PCNSLs were randomly divided to re‐
ceive four courses of either methotrexate 3.5 g/m2 on day 1 (n=40) or methotrexate 3.5 g/m2
on day 1 plus cytarabine 2 g/m2 twice a day on days 2-3 (n=39). Both regimens were admin‐
istered every 3 weeks and were followed by whole-brain radiotherapy (WBRT). After che‐
motherapy, seven patients given methotrexate and 18 given methotrexate plus cytarabine
achieved a complete remission, with a complete remission rate of 18% and 46% (p=0.006),
and a 3-year OS of 32% and 46% (p=0.07) respectively. In patients aged 75 years and young‐
er with PCNSL, the addition of high-dose cytarabine to high-dose methotrexate provides
improved outcome with acceptable toxicity compared with high-dose methotrexate alone.
Thiel et al. [8] aimed to investigate whether first-line chemotherapy based on high-dose me‐
thotrexate was non-inferior to the same chemotherapy regimen followed by WBRT for over‐
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all survival. Patients received high-dose methotrexate (4 g/m2) on day 1 of six 14-day cycles;
thereafter, patients received high-dose methotrexate plus ifosfamide (1.5 g/m2) on days 3-5
of six 14-day cycles. In those assigned to receive first-line chemotherapy followed by radio‐
therapy, WBRT was given to a total dose of 45 Gy. 551 patients (median age 63 years) were
enrolled and randomised, of whom 318 were treated per protocol. In the per-protocol popu‐
lation, median OS was 32.4 months in patients receiving WBRT (n=154), and 37.1 months in
those not receiving WBRT (n=164), hazard ratio 1.06 (p=0.71). Median progression-free sur‐
vival (PFS) was 18.3 months in patients receiving WBRT, and 11.9 months (p=0.14) in those
not receiving WBRT. Treatment-related neurotoxicity in patients with sustained complete
response was more common in patients receiving WBRT than in those who did not. No sig‐
nificant difference in OS was recorded when WBRT was omitted from first-line chemothera‐
py in patients with newly diagnosed PCNSL. The PFS benefit afforded by WBRT has to be
weighed against the increased risk of neurotoxicity in long-term survivors. The results of
this trial may indicate that WBRT can be omitted from first-line treatment of PCNSL.
4. Neurological toxicity
As survival of patients with PCNSL becoming long, the quality o life and mental function is
now very important. Neurotoxicity typically is associated with significant cognitive, motor
and autonomic dysfunction, and has a negative impact on quality of life. Delayed neurologic
toxicity is a serious complication, especially occurring in patients older than 60 years [24].
MTX is a known neurotoxin and has the potential of producing leukoenceohalopathy as
well as other types of neurotoxicities such as microangiopathy [25]. MTX is a folate antago‐
nist inhibiting nucleic acid and methioine synthesis. Methionine is necessary for CNS myeli‐
nation. The presence of a risk haplotype defined by polymorphisms influencing methionine
metabolism referred a relative risk for CNS white matter changes [26]. MTX in combination
with WBRT relates to its potential for causing delayed leukoencephalopathy. Radiation ther‐
apy prior to MTX administration increase the risk of leukoencephalopathy. While intrathe‐
cal, intravenous MTX and WBRT have the potential for producing leukoencephalopathy
independently, when two or three of them are combined the risk will increase [27]. Nguyen
et al. [28] reported late treatment-associated neurotoxicity in 15% of patients and was signifi‐
cantly associated with total radiation doses greater than 36 Gy. O`Brien et al. [29] reported
30% of neurotoxicity risk who were treated with MTX (1g/m2) followed by WBRT. For pa‐
tients aged>60 years the risk of neurotoxicity at 7 years was 58%. Correa et al. [30] reported
the neuropsychological evaluation of 28 patients. These were of sufficient severity to reduce
quality of life in half of the patient sample. Patients treated with WBRT+/- chemotherapy re‐
vealed more pronounced cognitive impairement, particularly in the memory and attention/
executive domain. Extent of white matter disease correlated with attention/executive, mem‐
ory, and language impairment. PCNSL survivors treated with WBRT+/- chemotherapy dis‐
played more pronounced cognitive dysfunction than patients treated with MTX-based
chemotherapy alone. Omuro et al. [31] described delayed neurotoxicity, analyzing 185
PCNSL patients. The 5-year cumulative incidence of neurotoxicity was 24%. Neurotoxicity
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presented as a rapidly progressive subcortical dementia characterized by psychomotor
slowing, executive and memory dysfunction, behavioral changes, gait ataxia, and inconti‐
nence. Imaging findings revealed diffuse white matter disease and cortical-subcortical atro‐
phy. Available autopsy data showed white matter damage with gliosis, thicking of small
vessels, and demyelination. Older age, mental status changes at diagnosis, female sex, and
radiotherapy predicted neurotoxicity on univariate analysis, but only radiotherapy re‐
mained significant in the multivariate setting. They conclude that the core pathophysiologi‐
cal mechanism is the interruption of frontal-subcortical circuits mediated by radiation
damage, possibly caused by microvascular alterations, loss of oligodendrocyte progenitors,
or oxidative stress. Fliessbach et al. [32] reported the impact of HD-MTX based chemothera‐
py alone on long term cognition and quality of life in patients with PCNSL. The median fol‐
low-up period was 44 months after diagnosis. In long-term follow-up 22 (95%) of 23 patients
showed either preserved or improved cognitive functions as compared with pretreatment
and immediate posttreatment baseline assessment. Eleven (48%) of 23 patients displayed at
least mild cognitive deficits at long-term follow-up not related to therapy. Nineteen (83%) of
23 patients reported a good quality of life (QOL). They conclude that in patients with
PCNSL treated with MTX-based chemotherapy alone, no gross cognitive decline has to be
expected as a long-term treatment effect. Finally, formal neuropsychological examination
guideline in PCNSL clinical trial should be established in the future.
5. Molecular biomarker
There are still many individual variations within the diagnostic and prognostic categories,
resulting in a need for additional molecular biomarkers, partly because of the inability to
recognize these patients prospectively. Although the clinical scoring model using age, Kar‐
nofsky Performance Status (KPS), and lactate dehydrogenase (LDH) level has prognostic
value for PCNSL [33-35], it has not been used successfully to stratify patients for therapeutic
trials. Molecular markers could improve the outcome prediction, discover potential targets
for therapeutic intervention, and elucidate mechanisms that result in resistance to chemo‐
therapy. The reason little progress in molecular analyses of PCNSL has been achieved so far
is the very tiny sample amounts obtained for genetic analyses. A better understanding of
PCNSL biology is crucial to improve its prognosis. However, only a few studies have been
reported on gene expression profiles of PCNSLs. Rubenstein et al. [36] compared the gene
expression signature of 23 PCNSL patients with that of nine nodal large B-cell lymphoma
patients. They showed that individual cases of PCNSL were classified as GCB cell, ABC (ac‐
tivated B-cell-like) cell, or type 3 large B-cell lymphoma based on the cell-of-origin classifica‐
tion described by Alizadeh et al [37]. In addition, PCNSLs were distinguished from nodal B-
cell lymphoma by high expression of regulators of the unfolded protein response signaling
pathway by c-Myc and Pim-1. The IL-4 signaling pathway is associated with tumorigenesis
and adverse prognosis in PCNSL patients [36]. Montesinos-Rongen et al. [38] reported the
gene expression profile of 21 PCNSLs. They showed that PCNSLs resembled late GCB cells
in their gene expression pattern, and that PCNSLs were distributed among the spectrum of
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systemic DLBCLs. Tun et al. [39] reported a gene expression comparison between 13
PCNSLs and 30 non-CNS DLBCLs. PCNSL was characterized by significant expression of
multiple extracellular matrix- and adhesion-related pathways. Sung et al. [40] evaluated 12
PCNSL patients by comparative genomic hybridization and 7 out of the 12 patients by ex‐
pression profiling. They selected eight candidate genes in which expression changes were
associated with copy number changes.
Systemic DLBCLs comprise several diseases that differ in responsiveness to chemotherapy
[41,42]. The GCB cell-like subgroup expressed genes characteristic of normal GCB cells and
were associated with a good outcome, whereas the ABC cell-like subgroup expressed genes
characteristic of activated B cells and were associated with a poor outcome. Gene expression
analyses of PCNSLs have largely focused on normal lymphocyte development, and the cell-
of-origin classification method was investigated so far. Kawaguchi et al. [43] developed a
novel scoring system based on molecular markers. Expression profiling was performed on
32 PCNSLs. A gene classifier with 23 genes was developed using the random survival for‐
ests model. Based on this, Prognosis Prediction Score using immunohistochemical analysis
is also developed and validated in another data set. Among the genes, BRCA1 protein ex‐
pression was most strongly associated with patient survival. They have identified gene ex‐
pression signatures that can accurately predict survival in patients with PCNSL.
6. Conclusion
Much more aggressive therapies, such as high-dose chemotherapy with stem cell implanta‐
tion [44] or molecular targeted therapies that specifically target disabled pathways, might be
tailored in those patients with a poor prognosis. In this regard, molecular biomarkers might
not only predict the likelihood of short-term survival, but also yield clues on individual
genes involved in tumor development, progression, and response to therapy. Moreover, the
ability to distinguish PCNSLs will enable appropriate therapies to be tailored to specific tu‐
mor subtypes. Class prediction models based on defined molecular profiles allow classifica‐
tion of PCNSLs in a manner that will be better correlated with clinical outcomes. Therefore,
identification of these molecular subclasses of PCNSLs could greatly facilitate prognosis pre‐
diction and ability to develop effective treatment protocols.
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expression signature of 23 PCNSL patients with that of nine nodal large B-cell lymphoma
patients. They showed that individual cases of PCNSL were classified as GCB cell, ABC (ac‐
tivated B-cell-like) cell, or type 3 large B-cell lymphoma based on the cell-of-origin classifica‐
tion described by Alizadeh et al [37]. In addition, PCNSLs were distinguished from nodal B-
cell lymphoma by high expression of regulators of the unfolded protein response signaling
pathway by c-Myc and Pim-1. The IL-4 signaling pathway is associated with tumorigenesis
and adverse prognosis in PCNSL patients [36]. Montesinos-Rongen et al. [38] reported the
gene expression profile of 21 PCNSLs. They showed that PCNSLs resembled late GCB cells
in their gene expression pattern, and that PCNSLs were distributed among the spectrum of
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systemic DLBCLs. Tun et al. [39] reported a gene expression comparison between 13
PCNSLs and 30 non-CNS DLBCLs. PCNSL was characterized by significant expression of
multiple extracellular matrix- and adhesion-related pathways. Sung et al. [40] evaluated 12
PCNSL patients by comparative genomic hybridization and 7 out of the 12 patients by ex‐
pression profiling. They selected eight candidate genes in which expression changes were
associated with copy number changes.
Systemic DLBCLs comprise several diseases that differ in responsiveness to chemotherapy
[41,42]. The GCB cell-like subgroup expressed genes characteristic of normal GCB cells and
were associated with a good outcome, whereas the ABC cell-like subgroup expressed genes
characteristic of activated B cells and were associated with a poor outcome. Gene expression
analyses of PCNSLs have largely focused on normal lymphocyte development, and the cell-
of-origin classification method was investigated so far. Kawaguchi et al. [43] developed a
novel scoring system based on molecular markers. Expression profiling was performed on
32 PCNSLs. A gene classifier with 23 genes was developed using the random survival for‐
ests model. Based on this, Prognosis Prediction Score using immunohistochemical analysis
is also developed and validated in another data set. Among the genes, BRCA1 protein ex‐
pression was most strongly associated with patient survival. They have identified gene ex‐
pression signatures that can accurately predict survival in patients with PCNSL.
6. Conclusion
Much more aggressive therapies, such as high-dose chemotherapy with stem cell implanta‐
tion [44] or molecular targeted therapies that specifically target disabled pathways, might be
tailored in those patients with a poor prognosis. In this regard, molecular biomarkers might
not only predict the likelihood of short-term survival, but also yield clues on individual
genes involved in tumor development, progression, and response to therapy. Moreover, the
ability to distinguish PCNSLs will enable appropriate therapies to be tailored to specific tu‐
mor subtypes. Class prediction models based on defined molecular profiles allow classifica‐
tion of PCNSLs in a manner that will be better correlated with clinical outcomes. Therefore,
identification of these molecular subclasses of PCNSLs could greatly facilitate prognosis pre‐
diction and ability to develop effective treatment protocols.
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1. Introduction
Perhaps no concept is as difficult to define and understand as human consciousness. Its nature
has been intensively debated for centuries by philosophers [1], for decades by psychologists
[2], and by neuroscientists [3] as knowledge and techniques have advanced to the point where
an experimental approach to such a complex issue is finally possible [4].
The cognitive revolution in psychology was paralleled by the development of the field of
cognitive science, whose practitioners included neuroscientists, behavioral biologists, neuro‐
surgeons, psychologists, psychiatrists, philosophers, linguists, sociologists, anthropologists
and even physicists.
Over many centuries, philosophers and physicians, poets and priests have debated and written
at great length on how mind may relate to brain.
And it is not surprising that neurosurgeons, from their unrivaled vantage point of dealing with
the human brain, sometimes in conscious patients (as during epilepsy surgery), should seek
answers to this seductive enigma.
There is no accepted definition of consciousness. While some take consciousness to be a unique
substance, others say it is a special property, and still others claim it to be nothing more than
the operation of the brain [5]. Other authors have shown that consciousness includes “what it
is like” to be something. So, the role of subjectivity should be one component, if not the essential
one in any definition of consciousness [6].
Consciousness has been also called “the last surviving mystery” [7]. Crick considered con‐
sciousness the central problem of biology [8]. According to [5], understanding consciousness
implies to produce the quintessence of philosophy, psychology, neuroscience and several other
fields of study.
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Consciousness may be also defined as our awareness of our environment, our bodies and
ourselves [9]. Awareness of ourselves implies an awareness of awareness, that is the conscious
of being. Awareness of ourselves implies meta-cognition [9, 10]. Some authors emphasize
consciousness as a momentary creation of a neural pattern which describes a relation between
the organism and an object or event [11]. According to [12], consciousness is, quite literally,
mind-boggling.
We consider that consciousness is an universal set of neurologic and mental or spiritual
processes produced by the brain in awake state, which allows people to understand the mind
of others (mind reading); it also allows an optimal social living to perform any kind of high
normal behavior activity (social, political, professional, moral, ethic, religious, etc.) related to
the self and the environment (family, society).
So, the two separate forms of consciousness are neurologic on one hand and mental or spiritual
on the other. Although many theorists treat consciousness as single, all-or-nothing phenom‐
enon, others distinguish between first-order consciousness and a meta-level of consciousness.
For example, they may distinguish between consciousness and metaconsciousness [13],
primary consciousness and higher-order consciousness [14], or core consciousness and
extended consciousness [15]. Animals possess primary (core) consciousness which comprises
sensory awareness, attention, perception, memory (or learning), emotion and action [12, 16].
In [16] it is also shown that every organism, even bacteria, would possess some degree of
consciousness.
However, animals have got an inferior consciousness function. It is, of course, unclear at what
phylogenetic level this assumption - about self-awareness and the environment - falls below
the definition of consciousness as we noted it. According to [9], what differentiates humans
from their fellow mammals, and gives humans what Edelman defines as secondary conscious‐
ness, depends upon language and the associated enrichment of cognition that allow humans
to develop and to use verbal and numeric abstraction. Spoken and written language are human
specializations. These mental capacities contribute to our sense of self as agents and as creative
beings. This fact also determines the awareness of awareness that we assume our animal
“collaborators” do not possess [9].
Many factors are involved in establishing the levels of consciousness commonly referred to as
wakefulness and sleep. Such factors include the enormous driving of the cerebral cortex over
the ascending activating and inhibiting systems and the influence of cyclic limbic activation
of cerebral cortical areas. There are complex interconnections between these areas of the
nervous system. But, the brain is such a complex structure that even now we know only a tiny
portion of what is to be known about it. By dividing consciousness into various attributes -
self-reflection, attention, memory, perception emotion, arousal, thoughts - and ordering these
into a functional hierarchy, we can link anatomy and function. So, consciousness must be a
function of numerous interacting systems. No single neural structure is necessary and
sufficient for consciousness. Not all areas of the brain contribute equally to consciousness.
Our state of consciousness also includes accompanying autonomic responses such as changes
in respiration, heart rate, or body temperature. Injuries that involve a considerable part of
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tegmentum of the midbrain result in a profound coma because of the interruption of ascending
multisynaptic activating system as well as descending hypothalamotegmental and dorsal
longitudinal fasciculus path.
In humans, the complex system of mental and spiritual processes depends on, and is produced
by the highest psychical activities, i.e. depends on, and is produced by the brain, making people
to: use symbolic representation and language; reflect on the past and anticipate and plan for
the future; transform thought into speech and action; logically record the personal experience
and transmit it orally by writing and/or by drawing; participate in the progress and civilization;
read other people’s thoughts, judge correctly their intentions and act consequently; use
abstractization and generalization to make new discoveries; know, spread and protect the
ethical, moral and religious standards in order to live an optimal social life; organize behavior
and extrapolate it in time; deal with cognitive novelty.
The prediction and comprehension of others’ behavior are, evidently, very important aspects
of social functioning.
The consciousness processes belong, in essence, to people who act by control mechanisms of
psychological activities, generalization and abstractization mechanisms, exploring and
handling of mental images to solve all the problems man is facing with.
In humans, the level of consciousness depends on the complexity of the brain ontogenetic
evolution; the human brain makes culture and technology possible. We believe that the
cerebral cortex is absolutely necessary for this function; machines that are responsive to
sensory events and are capable of complex movements are not conscious. Some philosophers
stress that the two defining characteristics of consciousness are: intentionality and subjectivity.
In [17] is pointed out that computers are not conscious because they lack intentionality.
Computers have no clue about what exactly it is they are computing. In this respect, Searle [18]
rebuts those who imagine that present-day computers (because their operations, in some ways,
resemble mental processes) can already be considered to have the rudiments of consciousness.
Searle emphasized that meaningful output from a computer, however sophisticated, cannot
provide evidence for consciousness or self-awareness within it. Despite this argument,
deflating simplistic assertions that extant machines exhibit rudimentary form of consciousness,
Searle does not dispute the idea that in the future it is possible to construct conscious entities.
Anyhow, machines that are responsive to sensory events and are capable of complex move‐
ments do not possess consciousness.
They do not refer to anything in the real world. Human mental computations are about
something; they are grounded in reality. According to this point of view, the brainstem
occupies the bottom of the totem pole, providing the basic arousal mechanism without which
the higher brain regions cannot operate.
On the other hand, consciousness must be a function of numerous interacting systems. The
major structures supposed to play a key role in the neural correlates of consciousness are: the
brainstem, the midbrain, the cerebellum, the diencephalon (especially the hypothalamus and
thalamus), the limbic system, and the cerebral cortex. There is the idea of being conscious
versus unconscious.
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Thus, the brain “language” can be conceptualized as the transmission of neural signals [19].
The “grammar” of the brain’s language system concerns the proper timing of neuronal
impulses. Neuronal impulse timing is based upon proper integration and balance of excitatory
and inhibitory processes [20].
Consciousness is a product of all cortical areas, but it exists only in association with the passage
of the impulses through ever-changing circuits of the higher brainstem, mesencephal, dience‐
phal, cortex and their cognitive operations.
So, consciousness is a function of numerous interacting systems. Certainly, without higher
brain stem and diencephalic integration it cannot exist.
In fact, consciousness is not a single process but a collection of many processes, such as those
associated with language, thinking, memory, emotion, feelings, seeing, executive function and
so on.
In sum, there are: consciousness of the self; consciousness of the environment; and social
cognition. Social cognition is a learned consciousness that allows us to make sense of another
person’s actions and intentions.
Certainly, some anatomical formations and functional processes are much more important for
consciousness than others.
Consciousness is not always the same. A person at different ages of his/her life is not thought
to be equally conscious: young children are usually not considered to experience the same type
of consciousness as healthy adults do. Indeed, part of the process of maturation is becoming
fully conscious. Conscious state varies across the spam of a day as we pass through various
states of sleep and waking [21].
The sleep is intrinsically reversible; sufficient stimulation will return the individual to a normal
waking state.
2. Patients and methods
In our attempt to demonstrate the presence of the ascending inhibitory system, the conscious‐
ness disorders and its modular aspect, a group of fifteen patients has been subjected to
evaluation or surgery within National Institute of Neurology and Neurovascular Diseases in
Bucharest. Thirteen of them have been diagnosed, respectively, with brain tumor, one patient
with limbic encephalitis, and another one with brain cysticercosis. Patients’ average age was
41.5 years, the youngest being 21 and the oldest 73.
Ten (66.6%) of the patients were male. In 14 patients, the main examination was computed
tomography (CT) and magnetic resonance imaging (MRI).
In the following, we will present the clinical symptomatology of every patient.
Case 1. A 21-year-old man presented himself with a sudden onset coma. MRI-scan revealed a
bilateral ponto-mesencephalic hemorrhage triggered by a cavernoma. After total resection of
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the cavernoma and hematoma, patient’s status has improved significantly, presenting only a
remaining minimal right side weakness and hemisensory deficit. Now the patient is a student,
and his state is excellent.
Case 2. A 38-year-old woman was admitted with a history of logorrhea syndrome, with
hyperkinesia, hyperwakefulness and hyperprosexia. The patient could sleep for only a short
time, and then awake and was unable to fall back asleep. MRI-scan revealed a left petroclival
meningioma which significantly compresses the superior part of the brainstem.
The postoperative evolution was very good. She remained for five weeks with mild hypoes‐
thesia on the left face but logorrhea syndrome with hyperkinesia disappeared.
Case 3. A 36-year-old man presented with intermittent increased intracranial pressure,
paralysis of the conjugate upward gaze (Parinaud’s sign), pseudo-Argyll-Robertson pupil and
arousal disorders. A contrast-enhanced CT-scan revealed a tumor of the pineal area. Only 15%
of the patients with tumors of the pineal area, which are compressing the dorsal part of the
mesencephalon, also experienced arousal disorders. Postoperative, the patient remained
clinically intact and arousal disorders disappeared.
Case 4. A 27-year-old man was admitted in the department of neurosurgery with headache,
memory impairment, endocrinopathy (gonadal insufficiency, loss of libido and reduced
masculine hair growth) and bitemporal hemianopsia. Neurobehavioral abnormalities mani‐
fested with intermittent hypersomnia, apathy, depression, and flatting of affect. Preoperative
MRI demonstrates a large supraselar, paraselar and intraselar mass with a few calcifications
(craniopharingiomas). Symptoms reflect the tumor’s close proximity to hypothalamic region,
pituitary gland, optic apparatus, third ventricle and intracranial vessels.
The hypothalamus and its surrounding structures are especially important for the ascending
activatory and inhibitory system and for the anatomy, physiology and pathology of the
consciousness. Upward grown into the region of the hypothalamus, this tumor affected overall
endocrine control.
After radical subfrontal resection, the patient remained in an excellent state and returned to
full activity.
Case 5. A 29-year-old woman presented with left hemiparesis by compression of the adjacent
internal capsule, palsies of vertical and lateral gaze, absence of convergence, retraction
nystagmus, and mild sensory deficit in the opposite side of the body, including the trunk. Pain
and thermal sensation were more affected than touch, vibration and position.
Involvement of ventral posterolateral and posteromedial nuclei of the thalamus causes loss or
diminution of all forms of sensation on the opposite side of the body. Contrast medium-
enhanced coronal and axial MRI shows a big right thalamic tumor.
The tumor was fully resected and thirty-five days after surgery was started radiation therapy
using a 10 MeV linear accelerator. The clinical examination performed thirteen month after
surgery, demonstrated a good health condition of the patient. However she remained with a
mild sensory deficit and a hemiparesis, but she returned to an independent life.
Contributions to the Understanding of the Neural Bases of the Consciousness
http://dx.doi.org/10.5772/52688
477
Thus, the brain “language” can be conceptualized as the transmission of neural signals [19].
The “grammar” of the brain’s language system concerns the proper timing of neuronal
impulses. Neuronal impulse timing is based upon proper integration and balance of excitatory
and inhibitory processes [20].
Consciousness is a product of all cortical areas, but it exists only in association with the passage
of the impulses through ever-changing circuits of the higher brainstem, mesencephal, dience‐
phal, cortex and their cognitive operations.
So, consciousness is a function of numerous interacting systems. Certainly, without higher
brain stem and diencephalic integration it cannot exist.
In fact, consciousness is not a single process but a collection of many processes, such as those
associated with language, thinking, memory, emotion, feelings, seeing, executive function and
so on.
In sum, there are: consciousness of the self; consciousness of the environment; and social
cognition. Social cognition is a learned consciousness that allows us to make sense of another
person’s actions and intentions.
Certainly, some anatomical formations and functional processes are much more important for
consciousness than others.
Consciousness is not always the same. A person at different ages of his/her life is not thought
to be equally conscious: young children are usually not considered to experience the same type
of consciousness as healthy adults do. Indeed, part of the process of maturation is becoming
fully conscious. Conscious state varies across the spam of a day as we pass through various
states of sleep and waking [21].
The sleep is intrinsically reversible; sufficient stimulation will return the individual to a normal
waking state.
2. Patients and methods
In our attempt to demonstrate the presence of the ascending inhibitory system, the conscious‐
ness disorders and its modular aspect, a group of fifteen patients has been subjected to
evaluation or surgery within National Institute of Neurology and Neurovascular Diseases in
Bucharest. Thirteen of them have been diagnosed, respectively, with brain tumor, one patient
with limbic encephalitis, and another one with brain cysticercosis. Patients’ average age was
41.5 years, the youngest being 21 and the oldest 73.
Ten (66.6%) of the patients were male. In 14 patients, the main examination was computed
tomography (CT) and magnetic resonance imaging (MRI).
In the following, we will present the clinical symptomatology of every patient.
Case 1. A 21-year-old man presented himself with a sudden onset coma. MRI-scan revealed a
bilateral ponto-mesencephalic hemorrhage triggered by a cavernoma. After total resection of
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors476
the cavernoma and hematoma, patient’s status has improved significantly, presenting only a
remaining minimal right side weakness and hemisensory deficit. Now the patient is a student,
and his state is excellent.
Case 2. A 38-year-old woman was admitted with a history of logorrhea syndrome, with
hyperkinesia, hyperwakefulness and hyperprosexia. The patient could sleep for only a short
time, and then awake and was unable to fall back asleep. MRI-scan revealed a left petroclival
meningioma which significantly compresses the superior part of the brainstem.
The postoperative evolution was very good. She remained for five weeks with mild hypoes‐
thesia on the left face but logorrhea syndrome with hyperkinesia disappeared.
Case 3. A 36-year-old man presented with intermittent increased intracranial pressure,
paralysis of the conjugate upward gaze (Parinaud’s sign), pseudo-Argyll-Robertson pupil and
arousal disorders. A contrast-enhanced CT-scan revealed a tumor of the pineal area. Only 15%
of the patients with tumors of the pineal area, which are compressing the dorsal part of the
mesencephalon, also experienced arousal disorders. Postoperative, the patient remained
clinically intact and arousal disorders disappeared.
Case 4. A 27-year-old man was admitted in the department of neurosurgery with headache,
memory impairment, endocrinopathy (gonadal insufficiency, loss of libido and reduced
masculine hair growth) and bitemporal hemianopsia. Neurobehavioral abnormalities mani‐
fested with intermittent hypersomnia, apathy, depression, and flatting of affect. Preoperative
MRI demonstrates a large supraselar, paraselar and intraselar mass with a few calcifications
(craniopharingiomas). Symptoms reflect the tumor’s close proximity to hypothalamic region,
pituitary gland, optic apparatus, third ventricle and intracranial vessels.
The hypothalamus and its surrounding structures are especially important for the ascending
activatory and inhibitory system and for the anatomy, physiology and pathology of the
consciousness. Upward grown into the region of the hypothalamus, this tumor affected overall
endocrine control.
After radical subfrontal resection, the patient remained in an excellent state and returned to
full activity.
Case 5. A 29-year-old woman presented with left hemiparesis by compression of the adjacent
internal capsule, palsies of vertical and lateral gaze, absence of convergence, retraction
nystagmus, and mild sensory deficit in the opposite side of the body, including the trunk. Pain
and thermal sensation were more affected than touch, vibration and position.
Involvement of ventral posterolateral and posteromedial nuclei of the thalamus causes loss or
diminution of all forms of sensation on the opposite side of the body. Contrast medium-
enhanced coronal and axial MRI shows a big right thalamic tumor.
The tumor was fully resected and thirty-five days after surgery was started radiation therapy
using a 10 MeV linear accelerator. The clinical examination performed thirteen month after
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Case 6. A 27-year-old woman complained of headaches which progressed to double vision,
nausea and vomiting. At the neurologic examination, the presence of a slight Parinaud’s
syndrome was discovered.
Contrast-enhanced Tl-weighted magnetic resonance images show a well-demarcated and
homogeneously enhanced pineal body tumor. After its surgical resection, the final histological
diagnose was of pineocytoma. Immunohistochemistry for neurofilament (68 kDa) showed
numerous positive cell processes.
Immunohistochemistry of GFAP showed strong positivity in interstitial cells. Post-surgical
evolution was excellent.
Case 7. A 56-year-old man presented with a sudden onset of coma and fever. Coronal and axial
Tl-weighted MRI scans revealed edematous, demyelination symmetrical infra- and supraten‐
torial changes which involved the entire midbrain, both thalamic formations, bilateral basal
ganglia, two-side temporo-occipital convolution and hippocampus; these were determined by
encephalitis (limbic encephalitis). After 9 days of coma the patient died.
Case 8. A 56-year-old man, with a history of severe headaches, presented with taste and smell
disorder, excessive euphoria accompanied by peculiar kind of compulsive, shallow and
childish humor (moria), irritability, hypomania and puerilism.
The patient also shown disorders of attention and motility, distractibility, hyperreactivity,
hyperkinesia, perseveration, emotional lability, cognitive dysfunction that impede the
initiation and temporal organization of actions, and lack of initiative, wrong decision and
instinctual disinhibition (sociopathy).
Contrast-enhanced computed tomography (CT) scan shows a giant size olfactory groove
meningioma and displacement of anterior brain. Post-surgery, after complete resection of the
tumor, the orbitofrontal syndrome disappeared almost completely.
Case 9. A 35-year-old woman was admitted to the department of neurosurgery with a bilateral
meningioma of the anterior falx which compressed dorsolateral premotor and prefrontal
cortex (Brodmann’s areas 6, 8, 9, 10, and 46).
As symptoms, she had attention disorder directed to a particular item of sensorium or inner
experience, and the capacity to suppress from inner experience items that can interfere with
what is currently on focus. She was apathetic, disinterested in herself and in the world around
her. Visuospatial neglect along with gaze abnormalities were also present because the lesion
encroaches on area 8.
According to our experience, the apathy is present in all lateral-damage conditions, and is
mostly apparent after large bilateral lesions of the frontal convexity.
Perseveration, dysexecutive syndrome with attention, working-memory and planning
disorders were among the symptoms. Language disorders were directly linked to failure of
temporal integration.
In this patient, depression was secondary to cognitive disorder. Postoperative, the frontal
syndrome disappeared.
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Case 10. A 42-year-old man presented with a 2-year history of subtle but progressive sensory
aphasia, the inability to designate or name the different fingers of the two hands, and the
inability to calculate and write (an incomplete Gerstmann’s syndrome). The patient also
showed constructional apraxia, alexia and misdirected and dissymmetric movement of the
opposite limbs. MRI prior to surgery showed a left side parietal cystic astrocytoma. After
extirpation of the tumor, all symptoms disappeared.
Case 11. A 39-year-old man was admitted with progressive left hemiparesis, tactile inattention,
constructional apraxia, dressing apraxia, dysprosody, and anosodiaphoria. Preoperative CT-
scan showed a tumor in the right parietal region.
Post-surgery, the patient improved his motor strength and was discharged after 3 weeks in a
very good state, while the CT-scan demonstrates the complete removal of the tumor (fibrillary
astrocytoma).
Case 12. A 46-year-old man was admitted with olfactory hallucination (“uncinate fits”) often
accompanied by a dreamy state of mind, auditory elementary hallucination when the patient
heard the sound of running water, impaired recognition of melodies in the absence of words,
and the usual tendency for the patient to report the current date as an earlier one. Coronal Tl-
weighted, gadolinium-enhanced MRI prior to surgery showed a large right-sided temporo‐
basal tumor (astrocytoma).
After complete removal of the tumor, the patient remained in a very good state. The patient
improved very much and was discharged after 2 weeks.
Case 13. A 42-year-old woman was admitted to the department of neurosurgery with a failure
to precisely grasp or touch an object under visual guidance (optic ataxia). This optic ataxia was
detected when she tried to reach for an object. Patients with such unilateral lesions typically
demonstrate greater impairment when reaching for items located in the hemispace, that is
contralateral to the lesion, using the contralateral hand. Another symptom was visual inat‐
tention (simultanagnosia) which affected mainly the periphery of the visual field. Simulta‐
nagnosia was considered to be a disruption in spatial attention, which was associated with the
inability to direct one’s attention to more than one or to a few objects at the time.
The presence of simultanagnosia was tested by asking the patient to carry out tasks such as
looking at a series of objects, and connecting a series of dots by a line or to examine and describe
the events depicted in a complex visual image. Once he focused on one object in his visual
field, the patient ignored or neglected all the other objects.
Therefore, optic apraxia and visual inattention have been described within a single visual field
contralateral to the right parieto-occipital lesion (areas 7 and 19) (incomplete Balint’s syn‐
drome). Generally, patients with Balint’s syndrome display three classic symptoms including
simultanagnosia (visual inattention), optic ataxia, and ocular apraxia, but this patient had only
two symptoms, so an incomplete Balint’s syndrome. After total extirpation of the tumor, the
patient Balint’s syndrome disappeared.
Case 14. A 73-year-old man was admitted with a coma and deceased within 18 hours. On
autopsy, more than 110 bilateral cortical and intracerebral metastases have been discovered,
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originating from a melanocarcinoma situated in the right abdominal area, subject to surgery
7 months earlier.
Case 15. A 56-year-old man complained of headache, nausea, vomiting, cognitive dysfunction
and drowsiness. The disease onset was sudden and progressive, with attention deficit (3
months before), memory disorder, disorientation, difficult walking and loss of continence. A
magnetic resonance image showed multiple cysts in the parenchyma depicted as round
hypointense lesions, sized at 5 mm at most. The respective lesions are disseminated bilaterally
in the cortex and cerebral mass, surrounded by hyperintense areas with slight brain edema.
The histopathology examination based on a brain biopsy sample reported neurocysticercosis.
The overall and neurological state of the patient deteriorated, and he deceased in the fifth day
following in-hospital admission.
3. Results
From the analysis of the 15 presented cases, and also of those previously published in [22 -
24], we had ascertained several important results with reference to the state of consciousness






Figure 1. A 21-year-old man who presented with a history of sudden onset of coma. Sagittal (a), axial (b) and coronal
(c) T1-weighted magnetic resonance imaging (MRI) scans revealed a gross pontine hemorrhage (1.9 cm) from a caver‐
nous malformation that reached the surface of the floor of the fourth ventricle and in the cerebelopontine angle. The
lesion was resected through a suboccipital approach. Sagittal (d), axial (e), and coronal (f) MRI scans, one year later,
reveal no rest of the malformation. Two months after surgery, the patient presented with minimal right sided weak‐
ness and hemisensory deficits. (surgeon Leon Dănăilă) (case 1).
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Hence, we had reasoned clinically that the existence of the ascending reticular activating
system (ARAS, further called AAS) and of the ascending reticular inhibitory system (ARIS,
further called AIS), which are functioning interdependently, are essential for the functioning
of the Central Nervous System (CNS).
In Fig. 1 (case 1), the pontomesencephalic hemorrhage caused the development of coma, and
in case 2 the extra-axial pontomesencephalic compression led to the development of the
logorrhea syndrome with hyperkinesia.
The respective compression has induced the reduction or the abolition of the function of the
ascending reticular activating system and the diminution, to a greater or lesser extent, of its
influence on the cerebral and especially on the cortical functions.
Hereinafter we shall reproduce comments concerning the existence and the functioning of the
2 ascending activating and inhibiting systems.
3.1. The brainstem
The brainstem is the portion of the central nervous system rostral to the spinal cord and caudal
to the cerebral hemispheres.
The net-like appearance of the brainstem neurons led to the designation as “reticular forma‐
tion”, a term that was originally used in a purely descriptive anatomical sense.
3.1.1. The reticular formation
The reticular formation (RF), beginning in the medulla and extending to the midbrain, plays
a major role in the sleep-wakefulness cycles of animals and humans. It occupies a significant
portion of the dorsal brainstem and forms a network of reticular fibers that synapse with, and
modulate many ascending and descending fiber tracts.
Nuclei of RF receive afferent information from all sensory (visual, auditory, etc.) and motor
systems as well as from other major structures of the brain, and project their axons upwards
and downwards to virtually all parts of the nervous system. Through their connections with
the thalamus, hypothalamus and directly to the cerebral cortex they can send information to,
and receive it from all areas of the cortex. There are ascending (or forward) and descending
(or backward) connections between them.
The RF is also known as the reticular activating system and the reticular inhibitory system [22,
23, 25]. The role of reticular formation is to awake or to get to sleep the cerebral cortex.
After waking, the cortex allows all modes of sensory processing (sight, hearing, touch, etc.) to
combine with conscious thought and experience, in order to focus on some inputs and suppress
others. Neuroscientists now recognize that the various nuclei within the brainstem serve many
functions and that only a few participate in waking and sleeping.
Instead of being used in a descriptive analogical way, the reticular formation was promoted
to a functional concept, a brainstem system, which, by virtue of its nonspecific connectivity,
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could act as a kind of volume control for the degree of conscious arousal and sleeping and as
a homeostatic system.
3.1.2. Ascending (reticular) Activating System (AAS)
In [26] is reported the innovation of the electroencephalogram (EEG), which is closely corre‐
lated with the level of consciousness of the patients. Since Berger’s first observation, the various
ongoing brain oscillations have been used successfully to characterize mental status such as
sleep, waking state or vigilance and mental pathologies such as epilepsy. Sensory evoked
potentials (EEG signals triggered by an external stimulation) have demonstrated that such
mental factors as sensation, attention, intellectual activity, and planning of movement, have
distinctive electrical correlates at the surface of the skull [27]. Afterwards, in [28, 29] were
examined the EEG waveforms in cats into which the lesions of the brainstem were placed. It
was found that after a transection between the medulla and the spinal cord, a preparation that
he called the encephale isolé, or isolated brain, animals showed a desynchronized (low-voltage,
fast-wave) EEG pattern and appeared to be fully awake [27 – 29]. When the neuraxis between
the superior and inferior colliculus was transected, a preparation called the cerveau isolé, or
isolated cerebrum, the EEG showed a synchronized, or high-voltage, slow-wave pattern
indicative of deep sleep and the animals were behaviorally unresponsive. Bremer concluded
that the forebrain fell asleep due to the lack of somatosensory and auditory sensory inputs.
The reticular activating system obtained this designation in [30] were one reported that it was
stimulated electrically in anesthetized cats and that it was found that the stimulation produced
a waking pattern of electrical activity in cat’s cortex. When the lesions were placed in the
paramedian reticular formation of the midbrain, the animals showed cortical-evoked respons‐
es to somatosensory or auditory stimuli, but the background EEG was synchronized and the
animals were behaviorally unresponsive. These observations emphasized the midbrain
reticular core as relaying important arousing influences to the cerebral cortex and this pathway
was labeled the ascending reticular activating system (today named AAS).
The most important reticular nuclei for arousal and consciousness are the raphe nuclei and the
central nuclei. These groups receive significant converging sensory input from all sensory
modalities and project to the thalamus (i.e., intralaminar nuclei), cholinergic basal forebrain
nuclei, and the entire cerebral cortex. An important component of the central reticular
activating system is thought to be the noradrenergic nuclei, particularly the locus coeruleus,
at the pontomesencephalic junction.
The centromedian and parafascicular nuclei, two of the intralaminar nuclei of the thalamus
representing the rostral extent of the AAS, receive inputs from the spinothalamic, trigemino‐
thalamic and multisynaptic ascending pathways (of the reticular formation) relaying pain
sensation. As a result of their diffuse cortical connections, they are involved in the maintenance
of arousal.
The neurons of the locus coeruleus project to the thalamus, hypothalamus, basal cholinergic
nuclei, and the neocortex [31, 32]. Immediate coma results from the destruction of the central
reticular nuclei at or above the upper pontine level.
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Anyhow, AAS acts on the cerebral cortex through the thalamus, directly, and through the
arousal caudal hypothalamic neurons (tuberomammillary nucleus) which are connected with




Figure 2. The Ascending Reticular Activating System (AAS) is found in the brainstem (1), and sends projections
throughout the cortex: directly (2), through the thalamus (3), or through the hypothalamus (4), tuberomammillary
neurons (5), which receive influence from suprachiasmatic nucleus (6).
As a result, the reticular formation comes to be known as the reticular activating system to
maintain general arousal, and as the reticular inhibitory system for sleeping.
However, an exact physiologic role of the reticular activating system in consciousness is
unclear. The awake condition, as well as the sleep, has many phases: a quick short phase, which
is determined by the direct action of AAS on the cerebral cortex, a longer phase, during 24
hours, determined by indirect action of AAS on the cortex through the thalamus, and a
rhythmical phase, determined by the AAS action on the cerebral cortex through the hypothal‐
amus awaking system under the influence of the suprachiasmatic nucleus. These nuclei are
serially interconnected with AAS not only in the forward, but also in the reverse direction
(backward).
It is generally agreed that a key component of the reticular activating system is a group of
cholinergic nuclei near the pons-midbrain junction that project to the thalamocortical neurons.
The relevant neurons in the nuclei are characterized by high discharge rates during the waking.
When stimulated, these nuclei cause “desynchronization” of the electroencephalogram (that
is, a shift of EEG activity, from high-amplitude, synchronized waves to lower amplitude,
higher-frequency, desynchronized ones).
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In [33] it has been concluded that the intralaminar nuclei act not only as a thalamic pacemaker
and as a relay for cortical arousal, but they are characterized also by the presence of cells
responding to visual auditory and somesthetic stimuli. In [34] it is written “cortical and
subcortical innervations of the intralaminar nuclei place them in a central position to influence
distributed networks underlying arousal, attention, intention, working memory and sensori‐
motor integration, including gaze control”. Thus, there are three main types of thalamic
projections: the specific (for vision, audition), the diffuse, and the projection to striatum
(essentially, all from intralaminar nuclei). Diffuse intralaminar nuclei efferents are widely,
though sparsely, distributed to most of neocortex: this is the diffuse projection that has to do
with consciousness. One can understand how intralaminar nuclei could directly influence
ideation, as ideation is a function of cortex [35].
Activity of these neurons is not, however, the only neuronal basis of wakefulness: the nora‐
drenergic neurons of the locus coeruleus; the serotoninergic neurons of the raphe nuclei; and
histamine-containing neurons in the tuberomammillary nucleus (TMN) of the hypothalamus
are also involved. The locus coeruleus and raphe nuclei are modulated by the TMN neurons
located near the tuberal region that synthesize the peptide orexin (also called hypocretin).
Orexin promotes waking, and thus may have useful applications in jobs where operators need
to stay alert. On the other hand, antihistamines inhibit the histamine-containing TMN network,
and thus tend to make people drowsy [36].
Arousal systems are regulated not only by external stimuli, but also by control systems of the
brain. For example, the frontal cortex, particularly the orbitofrontal area, regulates the thalamic
reticular nucleus and the cholinergic basal forebrain structures. Patients with lesions in this
area show deficits in arousal [37]. Cortical control is not limited to cholinergic modulation. In
a work on the norepinephrine system [32], it is demonstrated the role of locus coeruleus -
norepinephrine system in the prefrontal cortex function and cognitive control.
The frontal cortex also exerts an influence on the limbic system, which regulates emotional
arousal. The anterior cingulate region is important in the self-regulation of arousal through its
connections with the cholinergic basal forebrain [37].
In sum, AAS can exert both direct and indirect action on the cerebral cortex. However, the
reticular formation which appears to be responsible for maintaining cortical arousal is not the
same with consciousness.
3.1.3. Ascending (reticular) Inhibitory System (AIS)
According to case 2, it is impossible that the two important functions of the central nervous
system, arousal and sleep, or activation and inhibition, depend only on AAS. The two
compulsory conditions (arousal and sleep) cannot be determined or explained by the AAS
activity or inactivity only.
In [22, 23, 25] is clinically demonstrated that, besides the AAS, there is an ascending reticular
inhibitory system (AIS) as well, whose lesion leads to the appearance of the logorrhea
syndrome with hyperkinesia, hyperwakefulness, and hyperprosexia.
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Normally, during the 24 daily hours, after arousal follows sleep, which is based on AIS. The
two reticular systems (AAS and AIS) are under the influence of the suprachiasmatic nucleus
and of the awake and sleep centers in the hypothalamus.
As much as awake is determined by AAS, sleep, considered the most profound natural
alteration of consciousness, is determined by AIS. It acts on the cerebral cortex directly, through
the thalamus, through the ventrolateral preoptic (VLPO) nucleus of the hypothalamus, which,
in its turn, is under the influence of the suprachiasmatic nucleus, and through the basal ganglia.
The lateral group of the reticular formation, localized in the pons and rostral part of the
brainstem, gives origin to AIS. When AIS is activated, the cerebral cortex becomes inactive and
the person is asleep. This system receives inhibitory signals from the cerebellum and sends
output signals to the thalamus, to the hypothalamic sleeping center, and directly to the cerebral
cortex (Fig. 3).
The raphe nuclei, in the midline of the brainstem, use serotonin as their primary neurotrans‐
mitter and have diffuse connections to the cerebral cortex and subcortical gray matter [38].
Thus, the correlated activity between reticular neurons leads to a strengthened connection,
both excitatory and inhibitory. In the absence of inhibition, any external input, weak or strong,
would generate more or less the same one-way pattern, an avalanche of excitatory stimuli
involving the whole population [39]. Cortical networks gain their nonlinearity and functional
complexity primarily from the inhibitory interneuronal system [40]. The specific firing patterns
of principal cells in a network depend on the temporal and spatial distribution of inhibition.
Without inhibition, and dedicated neural formation, excitatory circuits cannot accomplish
anything useful [41]. Fast coupling of the excitatory and inhibitory influences can bring about
a submillisecond precision of spike timing [40].
Anyhow, reticular nucleus efferents terminate in the immediately underlying thalamic nuclei
and the reticular nuclei efferents are GABA-ergic (the neurons in reticular nuclei are exclu‐
sively inhibitory, using GABA as their transmitter) [35, 42]. Thus, thalamocortical communi‐
cation can be simultaneously inhibited by this reticular nucleus efferents that terminate in the
underlying thalamic nuclei. In the brain, and particularly in the cerebral cortex, there are
multiple influences, both inhibitory and facilitatory. When a performance has been lost because
the competence has lost some facilitation, the re-emergence of the performance can result
simply from the subsidence of inhibition [43, 44]. The main point is that a loss of performance
is not necessarily the result of damage to the competence for that performance; it may result
from unbalanced or excessive inhibition of the competence [42].
Generally, the reticular formation of the brainstem is, in turn, influenced by circadian clocks
located in the suprachiasmatic nuclei and the arousal (tuberomammillary nucleus) and
sleeping (ventrolateral preoptic nucleus) centers of the hypothalamus. The clock adjusts
periods of sleep and wakefulness to appropriate duration along the 24-hours cycle of light and
darkness. So, in all structures of the nervous system, inhibition plays a pivotal role.
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Figure 3. The Ascending Reticular Inhibitory System (AIS) is found in the brainstem, and sends projections throughout
the cortex: directly (1), through the thalamus (2), or through the hypothalamus; ventrolateral preoptic nucleus - VLPO,
(3), which receives influence from suprachiasmatic nucleus.
Thus, brain uses not only excitation, but also inhibition during its normal operations and
behaviors. With no inhibitory cells in a network, depending on the temporal and spatial
distribution and dedicated interneurons, excitatory circuits cannot accomplish anything useful
[41]. Excitatory potentials dominate on the dendrites of principal cells, whereas only inhibitory
postsynaptic potentials impinge upon the cell body (soma). Interneurons provide autonomy
and independence to neighboring principal cells but they offer, at the same time, useful
temporal coordination. The functional diversity of principal cells is enhanced by the domain-
specific actions of GABA-ergic interneurons which can dynamically alter the qualities of the
principal cells [41]. The separation of inputs in a network with only excitatory connections and
circuits is not possible. Like all somatic functions, at all levels of the system, executive functions,
beginning with attention, make use of inhibition for focus, contrast suppression of interference,
order, and timeliness [45]. Inhibition enhances saliency and contrast. Inhibition appears
essential for the control of impulsivity and a wide array of instinctual drives.
So, there are two opposing active processes that could summate, algebraically, a control
excitatory reticular system and a control inhibitory one. Thus, the brain uses not only excita‐
tion, but also inhibition during its normal function.
Ascending output of the brainstem reticular formation not only subserves arousal and sleep
but also contains information about other bodily states and other neural formation outside the
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reticular formation. This is why ARAS and ARIS might be named ascending activatory system
(AAS) and, respectively, ascending inhibitory system (AIS).
3.1.4. Clinical aspects
It is important to distinguish between alertness and impairment of the wakeful state. It is
possible to be awake and not conscious, but it is impossible to be conscious and not awake. A
combination of clinical lesion studies and animal data has identified the following major
mechanisms through which alterations in consciousness are produced: disturbance of the
ascending reticular system; bilateral lesions of the midbrain and diencephalon; and bilateral
involvement of the cerebral cortex (hemispheres). To which degree the same damage will
render unconsciousness to a person or another, remains to be clarified.
3.1.4.1. Coma
Destructive lesions of the brainstem may occur as a result of vascular disease, tumor, infection,
or trauma. Unlike compressive lesions, which can often be reversed by removing a mass,
destructive lesions cannot be reversed. Between the conscious state of mind and coma there
are multiple intermediary stages that manifest through: confusion or lethargy, drowsiness,
stupor, semicoma (light coma), locked-in syndrome persistent vegetative state, loss of
consciousness in concussion (diffuse axonal injury).
We will shortly discuss below the most important of them.
3.1.4.2. Persistent vegetative state
The term persistent vegetative state was introduced in [46] to describe the state of preservation
of autonomic function and primitive reflexes, without the ability to interact meaningfully with
external environment.
The vegetative state has been differentiated from the newly introduced category of minimally
conscious state (MCS) [47, 48]. In MCS, patients may show islands of relatively preserved brain
response [49, 50], as well as fragments of behavior interpretable as signs of perception and
voluntary movement that preclude the diagnosis of vegetative state [27]. Both, the vegetative
and minimally conscious states need to be distinguished from the locked-in syndrome in which
the patient is fully conscious but, due to a circumscribed brainstem lesion, is unable to
communicate in any way other than by the lid closure and the vertical eye movements.
Overall, brain metabolism is less reduced in locked-in patients [51].
3.1.4.3. Diffuse axonal injury (loss of consciousness in concussion)
The mechanism of the loss of consciousness with a blow to the head is not completely under‐
stood.
Brief loss of consciousness, which in humans is not usually associated with any changes in CT
and MRI scan, may be due to the shearing forces transiently applied to the ascending arousal
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system at the mesodiencephalic junction. Physiologically, the concussion causes abrupt neural
depolarization and promotes release of excitatory neurotransmitters. There is an efflux of
potassium from cells with calcium influx into cells and sequestration in mitochondria leading
to impaired oxidative metabolism. There are also alterations in the cerebral blood flow and in
the glucose metabolism, all of which impair neuronal and axonal functions [52].
Concussion or hemorrhage into the dorsolateral mesopontine tegmentum may be visible
on MRI, but diffuse axonal injury is generally not. Magnetic resonance spectroscopy may
be useful  in evaluating patients with diffuse axonal  injury,  who typically have a reduc‐
tion in N-acetylaspartate  as  well  as  elevation of  glutamate/glutamine and choline/creati‐
nine ratio [53 - 55].
3.1.4.4. Logorrhea syndrome with hyperkinesia
The activity in the reticular formation is the mechanism that induces the sleep, awakens one
from sleep and brings one back to full consciousness.
Thus, damage in the reticular formation typically sends a person into coma because this is an
on/off switch for all higher brain centers or determines the logorrhea syndrome with hyper‐
kinesia [22, 23, 25]. In a study on the behavior of patients with brainstem tumors and another
neurosurgical conditions, reported in [22, 23], it was observed that, apart from the locked-in
syndrome, persistent vegetative state or coma, the patients may also manifest various other
states, especially logorrhea syndrome with hyperkinesia, hyperwakefulness and hyperpro‐
sexia (Fig. 4, Case 2). In our opinion, the logorrhea syndrome with hyperkinesia, hyperwake‐
fulness and hyperprosexia reflect a hyperconsciousness or, in other words, a super-arousal
determined by the release of the AAS from the influence of AIS which is damaged.
Thus, the logorrhea syndrome with hyperkinesia is produced by the lesion of the AIS and is
an argument in favor of the existence of AIS. The lesions found in our cases (pons, rostral part
of the brainstem) mark the location of the AIS. In [56] is described a syndrome of hemiballism
and logorrhea determined by a hematome of the left subthalamic nucleus. The right hemibal‐
lism is explained by the influence on the subthalamic nucleus, but not the logorrhea. In our
opinion, the image given in figure 1 of their article shows multiple subthalamic lesions which
affect zona incerta; one knows that zona incerta has an inhibitory role [57].
So, we consider that in this case the logorrhea syndrome is given by the lesion produced to the
zona incerta which is located in the immediate neighborhood of the subthalamic nucleus. AIS
passes through zona incerta.
In sum, besides the other homeostatic systems, the reticular system (AAS and AIS) represents
an actual regulator system of the entire neuraxis, as proven by its participation in the regulation
of all the psychical processes (attention, memory, reasoning, behavior, etc.), speech, muscular
tonus, and the physiognomy of movement.
In case 3, in spite of the presence of an important compression on the mesencephal, the
respective patient has shown only a dorsal mesencephalic syndrome, without the alteration
of the state of consciousness.




Figure 4. MRI studies of a petroclival meningioma (a) which compresses from outside the Brainstem and provokes
logorrhea syndrome with hyperkinezia and hyperwakefulness. Postsurgery (b) this syndrome disappears (surgeon
Leon Dănăilă) (case 2).
When the tumor is bigger and it exerts a higher compression on this upper part of the brain‐
stem, we are also faced with the development of coma, besides the above mentioned syndrome.
3.2. The midbrain (Mesencephalon)
The midbrain is the short portion of the brain between the pons and the cerebral hemispheres.
It consists of tectum, contains the four corpora quadrigemina and two cerebral peduncles with
tegmentum and crus cerebri.
The cerebral aqueduct, surrounded by the central gray matter, separates the tectum from the
tegmentum. The cerebral peduncle consists of two parts: (1) a dorsal part, the tegmentum, and
(2) a ventral part, the crus cerebri. These two parts are separated from each other by substantia
nigra.
The midbrain tegmentum contains the trochlear and oculomotor nuclei, neural structures
concerned with ocular and visual reflexes, the mesencephalic reticular formation, the red
nuclei and many scattered collections of cells.
3.2.1. Dorsal midbrain syndrome
The midbrain may be forced downward through the tentorial opening by a mass lesion
impinging upon it from the dorsal surface (Fig. 5, case 3).
The most common causes are masses in the pineal gland, in the posterior thalamus, or in
upward transtentorial herniation which kinks the midbrain.
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Figure 5. a) A contrast-enhanced axial CT-scan of a 36-year-old man with hydrocephalus and a large pineal region
tumor, that was totally resected. Post-surgery, the patient remains clinically intact. (b) Axial CT-scan, 3 months postsur‐
gery, confirming total removal of the tumor (germinoma) (surgeon Leon Dănăilă) (case 3).
Primary midbrain hemorrhages, which may be of either type, are rare. Most of such patients
present themselves with acute headache, alteration of consciousness and abnormal eye signs.
Most of them recover completely from bleeds from cavernous angiomas, but some remain with
mild neurologic deficit.
Pressure from this direction produces the characteristic dorsal midbrain syndrome manifested
first by limited upgaze. In severe cases, the eyes may be fixed in forced, downward position.
There may be also a deficit of convergent eye movements and associated pupilloconstriction.
The presence of retractory nystagmus, in which all of the eye muscle contracts simultaneously
to pull the globe back into the orbit, is characteristic.
Motor responses are difficult to obtain or result in extensor posturing. Motor tone and tendon
reflexes may be heightened, and plantar responses are in extension.
If the cerebral aqueduct is compressed sufficiently to cause acute hydrocephalus, however, an
acute increase in supratentorial pressure may ensue. This may cause an acute increase in
downward pressure on the midbrain, resulting in sudden lapse into deep coma [58]. Most
patients in whom the herniation can be reversed suffer chronic neurologic disability [59 - 60].
After the midbrain stage becomes complete, it is rare for patients to fully recover.
3.3. Diencephalon
The diencephalon contains: hypothalamus, thalamus, subthalamus (substantia nigra, zona
incerta, the nucleus of the tegmental fields of Forel, ansa lenticularis, Forel’s field H1 -thalamic
fasciculus - Forel’s field H2 – lenticular fasciculus –, and subthalamic fasciculus), metathalamus
(medial geniculate body, and lateral geniculate body), and epithalamus (pineal body, habe‐
nular trigones, stria medullaris, and roof of the third ventricle).
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In the following, we shall deal only with the role of the hypothalamus and thalamus in sleep,
arousal, and circadian rhythm.
3.3.1. Hypothalamus
Fig. 6 (Case 4) is considered important because in it the hypothalamus was affected. The
compression of this important part of the brain led to the appearance of several specific
hormonal disorders and also to the alteration of the state of consciousness manifested by
apathy, depression, flattened affectations, hyposomnia, as well as the development of confu‐
sional states.
In this case it has been affected the tuberomammillary nucleus in the caudal hypothalamus,
as well as the connections of the hypothalamus with the suprachiasmatic nucleus, causing the




Figure 6. Preoperative T1-weighted coronal (a), and sagittal (b) magnetic resonance imaging (MRI)-scan demon‐
strates a large supraselar, paraselar, and intraselar mass. T2-weighted MRI-scan illustrates a few calcifications. MRI-
scan (c and d) six months after radical subfrontal resection of the craniopharingiomas (surgeon Leon Dănăilă) (case 4).
We shall further present hereinafter several details concerning sleep and the hypothalamus
function.
The hypothalamus is composed of about 22 small nuclei, the fiber system that passes through
it and the pituitary gland. Although the hypothalamus comprises only about 0.3% of the brain
weight, it takes part in nearly all aspects of motivated behavior, including sleeping, arousal,
temperature regulation, emotional behavior, endocrine function, metabolism, sexual behavior,
and movement [61, 62].
From our point of view, the ventrolateral preoptic nucleus (sleeping system), the tuberomam‐
millary nucleus (arousal system), and the suprachiasmatic nucleus (day-night cycle system)
are important.
The sleep is a circadian function, and although the suprachiasmatic nuclei are not essential for
its generation, they are responsible for consolidation of sleep in cycles that occur within a
circadian framework.
According to the results reported in [9], when humans go to sleep, they rapidly become less
conscious. The initial loss of awareness of the external world that may occur when we are
reading in bed is associated with the slowing of the EEG that is called Stage I. At sleep onset,
although awareness of the outside world is lost, subject may continue to have visual imagery






Figure 5. a) A contrast-enhanced axial CT-scan of a 36-year-old man with hydrocephalus and a large pineal region
tumor, that was totally resected. Post-surgery, the patient remains clinically intact. (b) Axial CT-scan, 3 months postsur‐
gery, confirming total removal of the tumor (germinoma) (surgeon Leon Dănăilă) (case 3).
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In the following, we shall deal only with the role of the hypothalamus and thalamus in sleep,
arousal, and circadian rhythm.
3.3.1. Hypothalamus
Fig. 6 (Case 4) is considered important because in it the hypothalamus was affected. The
compression of this important part of the brain led to the appearance of several specific
hormonal disorders and also to the alteration of the state of consciousness manifested by
apathy, depression, flattened affectations, hyposomnia, as well as the development of confu‐
sional states.
In this case it has been affected the tuberomammillary nucleus in the caudal hypothalamus,
as well as the connections of the hypothalamus with the suprachiasmatic nucleus, causing the
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and associated reflective consciousness. Even in the depths of non-REM stage IV sleep, when
consciousness appears to be largely obliterated, the brain remains highly active and it is still
capable of processing its own information. From PET and single neuron studies, it can safely
be concluded that the brain remains about 80% active in the depths of sleep. Most of the brain
activity is not associated with consciousness. Non-REM, stage IV is characterized by low-
frequency, high-amplitude EEG, in which subjects may report not only some thought-like
mentation but also movie-like dreams [63].
The circuitry through which AIS influences the sleep is localized in the upper pons and rostral
parts of the brainstem and includes the hypothalamic ventrolateral preoptic nuclei, supra‐
chiasmatic nuclei, the thalamus, and the cerebral cortex. In [64] very good arguments are
provided regarding the sleep and arousal. Nevertheless, in our opinion, the explanation of the
sleep/wakefulness given by them as due to a flip-flop switch, to the influence of suprachias‐
matic nucleus, to the homeostatic mechanism and to the allostatic mechanism is not enough.
We believe that the explanation should also include the existence of the AAS and AIS, which
are working also under the influence of the suprachiasmatic nucleus, homeostatic mechanisms,
and allostatic mechanism, and which control the sleep.
The arousal, like sleep, exhibits more steps: a rapid one, which has a short lifetime and which
is determined by the direct action of the AAS on the cerebral cortex; another, with a longer
lifetime within the 24 hours, which is caused by indirect action of AAS on the cerebral cortex
via thalamus; and the third, which is rhythmic and it is determined by the AAS action on the
cerebral cortex via the hypothalamic arousal system that, in its turn, is found under the
influence of the suprachiasmatic nucleus.
Some studies have demonstrated that the influence of the hypothalamus on arousal is not
restricted to the tuberomammillary neurons in caudal hypothalamus. In particular, a promi‐
nent group of neurons confined to the lateral hypothalamus has been implicated in the sleep
disorder known as narcolepsy [65].
These neurons express novel neuropeptides known as hypocretins or orexins and are differ‐
entially concentrated within the perifornical nucleus that surrounds the fornix in the tuberal
hypothalamus. Mapping studies have shown that hypocretin (orexin) neurons are similar to
tuberomammillary neurons in that they are confined to the hypothalamus and give rise to
extensive projections throughout the neuraxis [66].
Human sleep occurs with circadian periodicity. Thus, humans have an internal “free-running
clock” that operates even in the absence of information about the period of 24 hours [67 - 69].
This clock is controlled by the suprachiasmatic nucleus.
So, circadian rhythms provide temporal organization and coordination for physiological,
biochemical, and behavioral variables in all eukaryotic organisms and in some prokaryotes.
Circadian rhythms that are genetically determined, not learned [70- 72], are generated by an
endogenous self-sustained pacemaker.
The pineal body synthesizes the sleep-promoting neurohormone melatonin and secretes it into
the bloodstream where it modulates the sleep.
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3.3.2. Thalamus
Although the thalamus is the first neurological structure at whose level begins the process of
awareness, the result of the ablation of a single thalamus demonstrated that the female patient
in Fig. 7 (case 5) has shown postoperatively only moderate sensitivity disorders on the opposite
part of the body and a slight hemiparesis.
Nevertheless, the concomitant involvement of the right and left thalamus leads to the loss of
consciousness and coma.
Although the thalamic physiology has been scarcely studied, and therefore limitedly under‐
stood, we present below several data concerning the extremely important and complex




Figure 7. Contrast medium-enhanced coronal (a) and axial (b) magnetic resonance imaging showing a big right thala‐
mic tumor that proved to be an astrocytoma. Thirteen months following resection and radiotherapy, coronal (c) and
axial (d) magnetic resonance imaging demonstrates the absence of tumor. The patient was conscious and in good
state (surgeon Leon Dănăilă) (case 5).
The fundamental function of the thalamus is that of relay and it modulates peripheral
information to the cerebral cortex and to the basal ganglia, keeping the somatosensory, mental,
and emotional activity of a living individual in harmony.
With the exception of the thalamic reticular nucleus, all thalamic subnuclei possess thalamic
projection neurons that relay processed information to the cerebral cortex. In addition, the
thalamic subnuclei also have inhibitory GABA-ergic interneurons whose cell bodies and
processes are confined to a single subnucleus. The reticular nucleus of the thalamus is a
continuation into the diencephalon of the reticular formation of the brainstem. It receives
inputs from the cerebral cortex and thalamic nuclei. The former are collaterals of corticotha‐
lamic projections, and the latter are collateral of thalamocortical projections. The reticular
nucleus projects to other thalamic nuclei. The inhibitory neurotransmitter of this projection is
GABA. The reticular nucleus is unique amongst the thalamic nuclei because its axons do not
leave the thalamus. Based on its connections, the reticular nucleus plays a role in integrating
and gating activities of the thalamic nuclei.
As the termination site for the reticular ascending system is considered, it is not surprising that
the thalamus has an important arousal and sleep-producing function [52, 73 – 75] and that it
alerts, activates or inhibits a specific processing and response system. Its involvement in
attention shows up in diminished awareness of stimuli impinging on the opposite side the
lesion (unilateral inattention) [22, 23, 76 - 78].
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The ascending input to intralaminar nuclei can help explain consciousness of primitive
percepts (non-cognitive component). So, ascending output of the brainstem reticular formation
not only subserves arousal but also contains information about other states. Thus, other input
to reticular formation comes from the spinothalamic system, trigeminal complex, and dentate
nuclei in the cerebellum conveying proprioceptive signals. There are also ascending inputs to
intralaminar nuclei from deep layers of the periaqueductal gray, substantia nigra and amyg‐
dala with affective information, and from the vestibular nuclei with information about body
position [33, 52, 79, 80].
Intralaminar nuclei. These nuclei, embedded in the internal medullary lamina, consist of
centralis, lateralis, paracentralis, central medial nuclei (anterior group), and centromedial and
parafasciculus nuclei (posterior group) (Ohye, 2002). The latter are often called the centrome‐
dian-parafascicular complex.
The anterior group receives different projections from the spinothalamic tract, deep cerebellar
nucleus, brainstem reticular formation, etc. The posterior group has a reciprocal connection
with the basal ganglia. The efferent connection with the cerebral cortex is very wide and it was
thought to be a diffuse projection. The intralaminar nuclei were classified as representatives
of the “nonspecific system” rather than of the “specific system”, such as the thalamic station
for the visual, auditory, or somatosensory system with definite modality - specific peripheral
input.
3.3.3. Reticular nucleus
This nucleus is considered to be related to arousal, attention, cognitive function, etc. It plays a
role in maintaining cortical activity in a disease state of epilepsy [52, 81, 82]. In [83] it was
studied the human thalamus using microrecordings during stereotactic thalamotomy for
dyskinesia and it was found verbal command neurons in this nucleus and in the adjacent area.
Surround-type inhibition mediated by thalamic reticular nuclei may selectively gate out
extraneous stimuli while allowing focused relay important sensory data to the thalamocortical
circuits, which endow a given neural activity pattern with the property of conscious perception
[84]. But how is this neurophysiologic activity coordinated in time to produce a somewhat
unified conscious stream? Data suggest the answer may lie in the acquisition of gamma
synchrony, most commonly at approximately 40 Hz [85].
Gamma synchrony has also been hypothesized to “bind” disparate features of a given object,
such as color, size, texture, and motion, into a temporally unified sensory stimulus [86].
On the other hand, thalamocortical neurons receive ascending projections from the locus
coeruleus (noradrenergic), raphe nuclei (serotoninergic), reticular junction (cholinergic), TMN
(histaminergic) and project to cortical pyramidal cells. In the tonic firing state, thalamocortical
neurons transmit information to the cortex that is correlated with the spike trains encoding
peripheral stimuli [87, 88]).
In brief, the control of sleep and wakefulness depends on the brainstem and hypothalamic
modulation of the thalamus and cortex.
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3.3.4. Epithalamus
Fig. 8 (Case 6) did not confirm the presence of the sleep/vigil rhythm disorder as we should





Figure 8. Sagittal (a) gadolinium-enhanced magnetic resonance images show a pineal body tumor (pineocytoma) be‐
fore, and complete removal of it (b),(surgeon Leon Dănăilă) (case 6).
The function of the epithalamus is not well understood. The production of the pineal hormone
melatonin is cyclic with high levels of synthesis occurring at night and low levels during the
day.
3.3.5. A destructive disease of the diencephalon
Unilateral thalamic or diencephalic lesions (tumors, hemorrhage, etc.) do not determine coma.
Bilateral destructive lesions of the diencephalic region result in deep coma and death, despite
an intact cortex.
Occasional inflammatory and infectious disorders may have a predilection for the diencepha‐
lon. Fatal familial insomnia, a prion disorder, is reported to affect the thalamus selectively, and
this has been proposed as a cause of the sleep disorder although this produces hyperwake‐
fulness, not coma [89]. Humans with bilateral damage to the region of the dorsal pons,
midbrain, and thalamus (by trauma, brain tumor, viral or bacterial infection, ischemic or
hemorrhagic stroke) may exhibit an impaired state of alertness, possibly becoming stuporose
or comatose.
3.4. The limbic system and hippocampus
The bilateral limbic encephalitis lesions in Fig. 9 (case 7) where the cerebral cortex has remained
unaffected by the above mentioned pathological process has led in a very short time to the
development of coma and the death of the patient.
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Broca first described and named the limbic lobe [90]. In a subsequent phase in speculation on
the limbic lobe it was suggested that, in humans, this lobe is partially olfactory and is mainly
concerned with emotional behavior. In addition, the amygdala was seen as part of limbic lobe
[91, 92]. Finally, it was shown that the hippocampus projects via the fornix back to the
hypothalamus [91]. This concept was developed further, insisting on the functional importance
of certain regions of the neural axis, such as the septum, cingulate gyrus, orbitofrontal cortex,
preoptic area, “limbic striatum” (including the nucleus accumbens, mesolimbic dopaminergic
tract), nonspecific thalamic nuclei, hypothalamus and midbrain tegmental area, regions closely
related to the amygdala and hippocampus [93]. These regions form a ring, or “limbus”, around
the base of the brain. Anterior cingulate cortex (ACC) is part of a neural circuit that mediates
outcome-contingent changes in behavior [94 - 96] and processes fictive information in humans
[97]. The ACC is interconnected with the orbitofrontal cortex which mediates fictive thinking




Figure 9. Coronal (a) and axial (b) T1-weighted magnetic resonance imaging scans revealed edematous, demyelina‐
tion symmetrical changes infra- and supratentorial, which involve the entire midbrain, both thalamic formations, bilat‐
eral basal ganglia, two-side temporo-occipital convolution and hippocampus, determined by encephalitis (limbic
encephalitis). After 9 days of coma, the patient died (case 7).
It was also hypothesized that neurons in the ACC, which monitors the consequences of actions
and mediates subsequent changes in behavior, would respond to fictive reward information
[100].
Generally, the hypothalamus allows to consider that the link between the limbic and endocrine
system reasonable. The limbic system is now considered to be a functional unit. Areas around
the limbic system are called paralimbic and have a more complex histologic structure.
Anyhow, the limbic system makes a link between the external and the internal world.
3.4.1. Hippocampus
The hippocampus occupies the medial part of the floor of the temporal horn and is divided
into three parts: head, body and tail. The hippocampus is bilaminar, consisting of the cornu
Ammonis (or hippocampus proper) and the gyrus dentatus (or fascia dentata), with one lamina
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rolled up inside the other. The possible functions of the hippocampus are divided into four
categories: (1) learning and memory, (2) regulation of emotional behavior, (3) certain aspects
of motor control, and (4) regulation of hypothalamic functions [101]. The hippocampus and
related diencephalic structures form and consolidate declarative memories that are ultimately
stored elsewhere.
The hippocampus is also involved in the regulation of the hypothalamo-hypophyseal axis.
Through its projections to the paraventricular hypothalamic nucleus, it may inhibit the
hypophyseal secretion of adrenocorticotrophic hormone (ACTH)[102 – 105].
3.4.2. Amygdala
The amygdala is a complex mass of gray matter buried in the anterior-medial portion of the
temporal lobe, just rostral to the hippocampus. The amygdala and its interconnections with
an array of neocortical areas in the prefrontal cortex and anterior temporal lobe, as well as
several subcortical structures, appear to be especially important in the higher order processing
of emotion.
The amygdala links cortical regions that process sensory information with hypothalamic and
brainstem effector systems. In a review of the role of the amygdala in emotional processing,
there were identified five areas in which there is evidence coming out from studies regarding
the cognition-emotion interactions involving the amygdala: implicit emotional learning and
memory; emotional modulation of memory; emotional influences on perception and attention;
emotion and social behavior; emotion, inhibition and regulation [106].
3.5. The cerebral cortex
We consider that the most important logical scheme to shape and analyze the consciousness
has a modular structure. The inner structure of all our behavior acts is multimodular and it is
subordinated to a main module, in agreement with [107]: “ In the brain everything is connected
to everything”. In our opinion the module is one morphofunctional cortical specific unit
(column, area, circumvolution, etc) related to selfconsciousness (physical, psychic), or to the
structure and content of the external, objective environment (social, political, religious,
physical, etc).
From the analysis of cases 8 - 15 it results that the injury of a part of the cerebral cortex or of a
cerebral lobe leads to the partial alteration of certain components, or better said modules, of
the state of consciousness. Thus, in Fig. 10 (case 8), where the orbital prefrontal region is
compressed by the meningioma, there has been administered or has disappeared certain
emotional functions such as response inhibition, stimulus significance, perception, memory
and thought.
The reactivating process and the immediate memory has been the most affected. The moriatic
orbitofrontal syndrome has asserted itself through emotional lability, impulsive behavior,
sexual disinhibition, reduction of criticism, puerile euphoria, logorrhea, excessive joviality,
urinary and stercoral gatism [108]. It has been shown that this region has a significant role in
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Figure 9. Coronal (a) and axial (b) T1-weighted magnetic resonance imaging scans revealed edematous, demyelina‐
tion symmetrical changes infra- and supratentorial, which involve the entire midbrain, both thalamic formations, bilat‐
eral basal ganglia, two-side temporo-occipital convolution and hippocampus, determined by encephalitis (limbic
encephalitis). After 9 days of coma, the patient died (case 7).
It was also hypothesized that neurons in the ACC, which monitors the consequences of actions
and mediates subsequent changes in behavior, would respond to fictive reward information
[100].
Generally, the hypothalamus allows to consider that the link between the limbic and endocrine
system reasonable. The limbic system is now considered to be a functional unit. Areas around
the limbic system are called paralimbic and have a more complex histologic structure.
Anyhow, the limbic system makes a link between the external and the internal world.
3.4.1. Hippocampus
The hippocampus occupies the medial part of the floor of the temporal horn and is divided
into three parts: head, body and tail. The hippocampus is bilaminar, consisting of the cornu
Ammonis (or hippocampus proper) and the gyrus dentatus (or fascia dentata), with one lamina
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rolled up inside the other. The possible functions of the hippocampus are divided into four
categories: (1) learning and memory, (2) regulation of emotional behavior, (3) certain aspects
of motor control, and (4) regulation of hypothalamic functions [101]. The hippocampus and
related diencephalic structures form and consolidate declarative memories that are ultimately
stored elsewhere.
The hippocampus is also involved in the regulation of the hypothalamo-hypophyseal axis.
Through its projections to the paraventricular hypothalamic nucleus, it may inhibit the
hypophyseal secretion of adrenocorticotrophic hormone (ACTH)[102 – 105].
3.4.2. Amygdala
The amygdala is a complex mass of gray matter buried in the anterior-medial portion of the
temporal lobe, just rostral to the hippocampus. The amygdala and its interconnections with
an array of neocortical areas in the prefrontal cortex and anterior temporal lobe, as well as
several subcortical structures, appear to be especially important in the higher order processing
of emotion.
The amygdala links cortical regions that process sensory information with hypothalamic and
brainstem effector systems. In a review of the role of the amygdala in emotional processing,
there were identified five areas in which there is evidence coming out from studies regarding
the cognition-emotion interactions involving the amygdala: implicit emotional learning and
memory; emotional modulation of memory; emotional influences on perception and attention;
emotion and social behavior; emotion, inhibition and regulation [106].
3.5. The cerebral cortex
We consider that the most important logical scheme to shape and analyze the consciousness
has a modular structure. The inner structure of all our behavior acts is multimodular and it is
subordinated to a main module, in agreement with [107]: “ In the brain everything is connected
to everything”. In our opinion the module is one morphofunctional cortical specific unit
(column, area, circumvolution, etc) related to selfconsciousness (physical, psychic), or to the
structure and content of the external, objective environment (social, political, religious,
physical, etc).
From the analysis of cases 8 - 15 it results that the injury of a part of the cerebral cortex or of a
cerebral lobe leads to the partial alteration of certain components, or better said modules, of
the state of consciousness. Thus, in Fig. 10 (case 8), where the orbital prefrontal region is
compressed by the meningioma, there has been administered or has disappeared certain
emotional functions such as response inhibition, stimulus significance, perception, memory
and thought.
The reactivating process and the immediate memory has been the most affected. The moriatic
orbitofrontal syndrome has asserted itself through emotional lability, impulsive behavior,
sexual disinhibition, reduction of criticism, puerile euphoria, logorrhea, excessive joviality,
urinary and stercoral gatism [108]. It has been shown that this region has a significant role in
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the social and emotional behavior, as well as in the build-up of the new memory data [ 45, 109,
110]. The orbitofrontal module of the state of consciousness has an extremely important role




Figure 10. A preoperative contrast-enhanced computed tomographic (CT)-scan of a 56-year-old man shows a giant
size olfactory groove meningioma, and displacement of anterior brain (a). The patient presented an orbitofrontal syn‐
drome. Postoperative contrast-enhanced CT-scan showing no residual tumor (b) and the fact that the orbitofrontal
syndrome disappeared (surgeon Leon Dănăilă) (case 8).
The patient with lesions of the orbitofrontal cortex does not have adequate social abilities, in
spite of the fact that he shows an intact cognitive processing of multiple tasks which are
performed with great difficulty. Occasionally, the behavioral syndrome is so severely affected
that it has been introduced the term of “acquired sociopathy” [111, 112].
Fig. 11 (Case 9) demonstrates the loss of another consciousness module relative to the func‐




Figure 11. A preoperative contrast-enhanced computed tomographic (CT) scan of a 35-year-old woman shows a bilo‐
bed meningioma of the anterior falx (a). She has a dorsolateral frontal syndrome. Postoperative contrast-enhanced CT
scan showing no residual tumor (b) and the fact that the frontal syndrome disappeared (surgeon Leon Dănăilă) (case 9).
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors498
The injury of these areas leads to the alteration of a wide range of cognitive processes, such as
the sustained and concentrated attention, the fluency and flexibility of thought in generating
solutions for new circumstances, and the purpose-oriented adjustment of the adaptive
behavior [45, 112, 113].
In Fig. 12 (case 10), the left parietal cistic astrocytoma has led to the development of Gerst‐




Figure 12. T1- enhanced sagital MRI (a) demonstrates a large parietal cystic tumor in a 42-year-old man, presented
with a 3 months history of a subtle sensory aphasia and Gerstmann’s syndrome (incompletely). Postoperative sagittal
MRI (b) demonstrates total tumor removal of a cystic astrocytoma and Gerstmann’s syndrome disappeared (surgeon
Leon Dănăilă) (case 10).
If we consider the anterior (somatosensory) and posterior parietal zones as functionally distinct
regions, we can identify two independent contributions of the parietal lobes. The anterior zone
processes somatic sensations and perceptions; the posterior zone is specialized primarily for
integrating sensory input from the somatic and visual regions and, to a lesser extent, from
other sensory regions, mostly for the control of movement [21]. In 1924, Gerstmann described
a patient with an unusual disorder subsequent to a left parietal stroke. Gerstmann’s syndrome
(left - right confusion, acalculia, and agraphia) provides the striking example of bilateral
asomatognosia and is due to a left, or dominant parietal lesion [114].
The results of the examination of Fig. 13 (case 11) highlighted the right parietal module whose
alteration leads to the occurrence of a series of symptoms which has been very well summar‐
ized by [115 - 117]. Tactile perseveration and hallucination of touch, cortical sensory loss,
impaired recognition of objects, texture, two-point discrimination, stimulus localization,
barognosis, vibratory sensation, position, sense, graphesthesia, hemianesthesia, tactile
inattention, altered sensory adaptation time, anaesthoagnosia, asymboly for pain, pseudotha‐
lamic pain syndrome, unilateral asomatognosia (Anton Babinski syndrome), anosognosia,
amorphosynthesis, ideomotor and ideational apraxia, dressing apraxia, stereoanesthesia,
astereognosias tactile agnosia etc.
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Figure 13. Preoperative CT-scan (a) of a 39-year-old man shows a tumor in the right parietal region. The patient was
noted to have a left hemiparesis, tactile inattention and constructional apraxia, dysprosody, apraxia for dressing, and
anosodiaphoria. Postoperative CT-scan (b) demonstrates the complete removal of the tumor (astrocytoma). Parietal
syndrome disappeared (surgeon Leon Dănăilă) (case 11).
So, patient’s appreciation of self in relation to the environment is distributed. Some disorder
occurs in the state of continuous consciousness of parts of the body, which depends on the
influx of sensations and their association with past memories, the stream-of-life experiences,
and the feelings that keep us continuously aware of ourselves [116]. The patients have an
altered way of feeling and experiencing. It is tempting to view all these elusive clinical
phenomena as manifestations of more general disturbances of the body-environmental
schemata, but the evidence to support this view is insufficient [116].
In Fig. 14 (Case 12), the right temporal tumor demonstrates the presence of another modular
appearance of the state of consciousness. The temporal lobes do not have a unitary function,
in that they house the primary auditory cortex (Heschl’s gyrus with aria 41), the auditory
association cortex, the visual cortex, the limbic cortex, and the amygdala and hippocampus.
Left temporal lesions are associated with deficits in processing speech sounds, whereas right
temporal lesions are associated with deficits in processing certain aspects of music.
Right, but not left, temporal-lobe lesions lead to impairments in the recognition of face and
facial expression. The temporal lobe is the great integrator of sensations, emotions, and
behaviors and it is continuously active throughout life. So, the two sides play different roles
in social recognition and have different effects on personality and consciousness.
The temporal lobe seems to be the site where all sensory modalities are integrated into ultimate
self-awareness. The stream of thinking requires both language and memory function and both
these functions involve the temporal lobes.
Long-term memory depends on the entire visual stream as well as on the paralimbic cortex of
the medial temporal region.




Figure 14. Preoperative coronal T1-weighted, gadolinium-enhanced magnetic resonance images (a) were obtained
from a 46-year-old man and demonstrated a large right-sided temporo-basal astrocytoma; (b). image obtained after
complete removal of the tumor. (surgeon Leon Dănăilă) (case 12).
Patients with left posterior temporal lesions may show dysphasic symptoms in which they can
recognize the broader categorization but have difficulty with the more specific ones.
The amygdala contributes to normal and abnormal emotional responses and experiences [112,
118, 119]. Epilepsy is not an unitary phenomenon and there is no reason to expect patients with
epilepsy to have a specific personality type.
So, psychomotor symptoms may be defined as a “state of clouding of consciousness” [120].
The results of the examination of Fig. 15 (case 13) have revealed the absence of another module
of the state of consciousness known as Balint’s syndrome. However, at the level of each lobe
we can find several modules of the state of consciousness.
Their numbering and statistical assessment might lead to the calculation or estimation of the
state of consciousness of each individual, in both normal and pathological states.
Hereinafter we shall underline the modular functions of the occipital lobe.
Extrastriate cortical areas are organized into two largely separate systems that eventually feed
information into cortical association areas in the temporal and parietal lobe. Thus, the dorsal
stream leads from the striate cortex into the parietal lobe. This system is responsible for spatial
aspects of vision and for the speed of movement [121]. The ventral stream includes area V4
and leads from the striate cortex into the inferior part of the temporal lobe. This system is
responsible for high-resolution form vision and object recognition, such as selectivity for shape,
color, texture, and faces [121]. Some neuroimaging studies have implicated ventral occipito‐
temporal cortex in the nearly area, but distinct from fusiform face area, in the analysis of visual
world form.
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Figure 15. Preoperative contrast-enhanced CT-scan (a), showing a right side parasagittal parietooccipital meningioma
in a 42-year-old woman who presented Balint’s syndrome. Postoperative CT-scan demonstrates total removal of the
tumor (b). After two months, Balint’s syndrome disappeared (surgeon Leon Dănăilă) (case 13).
Primary visual cortex, also known as striate cortex (V1) is within, and adjacent to, the calcarine
sulcus. V1 sends feedforward signals to many higher visual areas such as V2, V3, V4 and
motion-sensitive area MT, to name a few [122].
So, in clinical description, a patient who suffered a stroke that damage the extrastriate region,
thought to be comparable to area MT (middle temporal area) in the monkey, is unable to
estimate the motion of objects.
Another example of a specific visual deficit as a result to extrastriate cortex is cerebral
achromatopsia.
However, different cortical areas and neurons involved in processing specific kind of visual
stimuli (color, orientation, motion, faces, objects, etc.), together with other cortical areas and
subcortical structures (thalamus, hypothalamus, reticular formation, etc.) seem to play
different roles in our conscious visual experience [123].
Combination of feedforward-feedback signals is important for awareness, because higher
areas need to check the signals in nearly areas and confirm if they are getting the right message,
or perhaps to link neural representation of an object to the specific features that make up the
object [124].
Visual field deficits, visual agnosis, associative agnosia, apperceptive agnosia, simultanagno‐
sia, prosopagnosia, visual object agnosia, disorder of reading, disorder of color processing,
achromatopsia, color anomia, color agnosia, visual neglect, polyopsia, oscillopsia, cortical
blindness (Anton’s syndrome), topografical disorientation, defects in constructional skills,
visual illusions (metamorphosias), visual hallucination, etc. are symptoms known by the
neurologists for more than ninety years.
Brain lesions studies are important for understanding what brain areas may be necessary for
certain kind of visual awareness - awareness of color, motion, faces, objects, or the capacity to
be aware of seeing anything at all [124].
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The results arising from the analysis of Fig. 16 (case 14) and of Fig. 17 (case 15) demonstrate




Figure 16. Bilateral, cortical and subcortical, showing more than 110 cerebral metastases (a) and (b). The primitive
tumor was a melanocarcinoma (case 14).
The patients with catastrophic diseases and panhemispheric syndromes who are associated
with intractable seizures, determined by Rasmussen’s encephalitis, hemimegaencephalopaty,
tuberous sclerosis, hamartomas, Sturge-Weber syndrome, and congenital hemiplegia or




Figure 17. Fast spin-echo TI-weighted axial (a) and sagittal (b) images with enhanced contrast, reveal round, multiple
parenchymal cysts in the acute encephalitic stage that are T2 hyperintense and TI hypointense. These lesions were as‐
sociated with central nervous system cysticercosis. Scolex are rarely visible as a small point in the interior of certain
cysts.
After hemispherectomy, the respective patients remain conscious, but with more or less
important deficits, depending on the excised hemisphere.
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As a conclusion, the involvement of a single hemisphere leads to the disappearance of some
of the consciousness modules, but not to its total loss.
The cerebral cortex of the cerebral hemispheres, the convoluted outer layer of gray matter
composed of tens of billions of neurons and their synaptic connections, is the most highly
organized correlation center of the brain, but the specific of cortical structures in mediating
behavior is neither clear-cut nor circumscribed [126, 127]. This multitude of neurons sends a
large number of axons in all directions, covered by supportive myelin. This forms the white
matter of the cortex fills the large subcortical space.
The cerebral cortex receives sensory information from internal/external environment of the
organism, processes this information and then decides on and carries out the response to it.
In general, the cerebral cortex supply much of the content and registration function of
consciousness, including language, abstract reasoning, somatosensory visual and spatial
abilities, map of the physical dimensions of the self, executive function, complex emotion,
feelings, memory and ability to read other’s mind. While the cortex is vital for cognitive
functions, it interacts constantly with major satellite organs, notably the thalamus, basal
ganglia, hypothalamus, cerebellum, brainstem, and limbic regions, among others.
In order to be conscious, to operate at normal parameters, to record and potentiate the internal
and external sensory data and to correctly process them based on the previous individual
experience, and to answer adequately, it is necessary that the cerebral cortex should be integer
and aroused by the ascending activating system.
These considerations suggest that there might be multiple conscious awareness systems each
of them supporting conscious awareness in different mental domains.
3.5.1. Unilateral and diffuse, bilateral cortical destruction
Different regions of the cerebral cortex have modular specific functions (somatic sensory and
motor, visceral sensory and motor, integrative cognitive functions, speech functions, etc.)
responsible for the high-order cognitive processing or conscious mind. These correspond to
the Brodmann areas, as well as to each of the four cerebral lobes.
Being aware of the somatic and visceral ego refers to the ability of being conscious of the
components of one’s body, concrete activities and their status. Thus, a lesion of the parietal
lobe leads to a destruction of the ego, which manifests through agnosia, such as asomatognosia
(denial of one’s own body part), finger agnosia, tactile agnosia, hemiosomatognosia.
The ideational consciousness refers to the ability of one person to be aware of their concrete
activities, ideas and thoughts that are expressed through spoken or written words. A lesion of
the frontal, parietal, occipital, temporal lobe and of the callous body leads to apraxia, Gerst‐
man’s syndrome, Balint’s syndrome, akinetic mutism, aphasia and agraphia. Emotional
consciousness refers to the ability of being aware of emotions. The frontal lobe and the left
parietal lobe coordinate positive emotions, whereas the ones on the right side coordinate
negative emotions.
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We stress on the existence of the same discrete modules in the brain for each possible neuro‐
psychological capacity. Adjacent modules communicate with each other more than do non-
adjacent modules. So, the term of modular or functional localization of consciousness is used
to indicate that certain functions can be localized to particular areas of the cerebral cortex. The
mapping of cortical functions began with the inference made from the deficits produced by
cortical lesions in humans.
As we have noticed, partial lesion of some Brodmann specialized areas or of one of the lobes,
leads to the modular loss of consciousness. When the entire cerebral cortex is destroyed as well
as the white matter of the two hemispheres, that globally depress neuronal activity, the
consciousness level decreases and coma is produced. These causes of diseases include cortical
and subcortical tumors, hypoxia, sedatives, hypnotics, neurotransmitter receptor antagonists,
neural toxins, infectious diseases and metabolic diseases. Careful studies of split-brain patients
make it clear that the right hemisphere has a consciousness of its own, even if it lacks the ability
to communicate its experiences verbally.
4. Discussion
The consciousness processes belong to people who act by control mechanisms of psychological
activities, generalization and abstractization mechanisms, as well as by exploring and handling
of mental images to solve all the problems man is facing with. The consciousness level depends
on the complexity of the brain ontogenetic evolution. It must be a function of numerous
interacting systems.
Data based on our experience support this statement. In Table 1 we present a synthesis of the
lesions produced to the brain modules for the patients/cases analyzed in this paper. All the
damaged modules or circuits have as direct consequences modifications of the respective
consciousness state of the patients as described in detail in the chapter Results.
According to Tononi and Laureys, consciousness can be dissociated from other brain functions,
such as responsiveness to sensorial inputs, motor control, attention, language, memory,
reflection, spatial frames of reference, the body and perhaps even the self [128]. We consider
this point of view to be incorrect because consciousness cannot appear without these functions.
It cannot be dissociated from them. The respective functions represent modules of the
consciousness. The consciousness results from the respective cerebral activities. Lesions of
some functions lead to modular disorder of the consciousness.
The major structures supposed to play a key role in the neural correlates of consciousness are:
the brainstem, the diencephalon (the hypothalamus and thalamus), the limbic system (espe‐
cially the hippocampus and amygdala), basal ganglia, cerebellum, and the cerebral cortex. The
brainstem is the source of massive reticular formation pathways that activate or inhibit higher
and lower brain centers. They are the core of the basic arousal and sleeping cycle.
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These considerations suggest that there might be multiple conscious awareness systems each
of them supporting conscious awareness in different mental domains.
3.5.1. Unilateral and diffuse, bilateral cortical destruction
Different regions of the cerebral cortex have modular specific functions (somatic sensory and
motor, visceral sensory and motor, integrative cognitive functions, speech functions, etc.)
responsible for the high-order cognitive processing or conscious mind. These correspond to
the Brodmann areas, as well as to each of the four cerebral lobes.
Being aware of the somatic and visceral ego refers to the ability of being conscious of the
components of one’s body, concrete activities and their status. Thus, a lesion of the parietal
lobe leads to a destruction of the ego, which manifests through agnosia, such as asomatognosia
(denial of one’s own body part), finger agnosia, tactile agnosia, hemiosomatognosia.
The ideational consciousness refers to the ability of one person to be aware of their concrete
activities, ideas and thoughts that are expressed through spoken or written words. A lesion of
the frontal, parietal, occipital, temporal lobe and of the callous body leads to apraxia, Gerst‐
man’s syndrome, Balint’s syndrome, akinetic mutism, aphasia and agraphia. Emotional
consciousness refers to the ability of being aware of emotions. The frontal lobe and the left
parietal lobe coordinate positive emotions, whereas the ones on the right side coordinate
negative emotions.
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We stress on the existence of the same discrete modules in the brain for each possible neuro‐
psychological capacity. Adjacent modules communicate with each other more than do non-
adjacent modules. So, the term of modular or functional localization of consciousness is used
to indicate that certain functions can be localized to particular areas of the cerebral cortex. The
mapping of cortical functions began with the inference made from the deficits produced by
cortical lesions in humans.
As we have noticed, partial lesion of some Brodmann specialized areas or of one of the lobes,
leads to the modular loss of consciousness. When the entire cerebral cortex is destroyed as well
as the white matter of the two hemispheres, that globally depress neuronal activity, the
consciousness level decreases and coma is produced. These causes of diseases include cortical
and subcortical tumors, hypoxia, sedatives, hypnotics, neurotransmitter receptor antagonists,
neural toxins, infectious diseases and metabolic diseases. Careful studies of split-brain patients
make it clear that the right hemisphere has a consciousness of its own, even if it lacks the ability
to communicate its experiences verbally.
4. Discussion
The consciousness processes belong to people who act by control mechanisms of psychological
activities, generalization and abstractization mechanisms, as well as by exploring and handling
of mental images to solve all the problems man is facing with. The consciousness level depends
on the complexity of the brain ontogenetic evolution. It must be a function of numerous
interacting systems.
Data based on our experience support this statement. In Table 1 we present a synthesis of the
lesions produced to the brain modules for the patients/cases analyzed in this paper. All the
damaged modules or circuits have as direct consequences modifications of the respective
consciousness state of the patients as described in detail in the chapter Results.
According to Tononi and Laureys, consciousness can be dissociated from other brain functions,
such as responsiveness to sensorial inputs, motor control, attention, language, memory,
reflection, spatial frames of reference, the body and perhaps even the self [128]. We consider
this point of view to be incorrect because consciousness cannot appear without these functions.
It cannot be dissociated from them. The respective functions represent modules of the
consciousness. The consciousness results from the respective cerebral activities. Lesions of
some functions lead to modular disorder of the consciousness.
The major structures supposed to play a key role in the neural correlates of consciousness are:
the brainstem, the diencephalon (the hypothalamus and thalamus), the limbic system (espe‐
cially the hippocampus and amygdala), basal ganglia, cerebellum, and the cerebral cortex. The
brainstem is the source of massive reticular formation pathways that activate or inhibit higher
and lower brain centers. They are the core of the basic arousal and sleeping cycle.
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The hypothalamus, the thalamus and the cerebral cortex are likely closely intertwined with
RF which plays a key role in consciousness. In general, there are an ascending activating system
(AAS) and an ascending inhibitory system (AIS).
However, AAS which appears to be responsible for maintaining cortical arousal is not the same
with consciousness.
Sleep is based on ascending reticular inhibitory system. The two reticular systems (AAS and
AIS) are under the influence of the suprachiasmatic nucleus and of the awake and sleep centers
in the hypothalamus. So, as much as awake is determined by AAS, sleep, considered the most
profound natural alteration of consciousness, is determined by AIS. AAS and AIS are not the
neurological basis of consciousness but they rather constitute the necessary substrate for
consciousness to emerge.
Lesions of AIS produced the logorrhea syndrome with hyperkinesia, hyperwakefulness and
hyperprosexia. Bilateral lesions/destructions of the neurological formations (brainstem,
midbrain, diencephalon, limbic system and cerebral cortex) lead to the loss of consciousness.
The ascending inhibitory system is important in explaining the sleep and many other behavior
aspects.
On the other side, the cerebral cortex and consciousness have a modular structure. AAS and
AIS reach the cerebral cortex directly, through the thalamus and the hypothalamus. In order
to be conscious, it is necessary that the cerebral cortex should be integer and aroused. Thus, to
be conscious is equivalent of having access to information about the self and the environment
and to have the capacity to read another individual’s intention. The consciousness is the most
developed form of expressing the personality. The self, similar to the ego, the spirit, the soul
is the main expert in primary knowledge. So, consciousness is not equal to the awakened state
of mind, as it involves functions of almost the entire brain. But different brain structures and
functions have a certain role in generating consciousness. The consciousness, as a result of
functions from almost entire brain, is composed by modules which have different important
values and features.
Injuring one module only leads to partial modification of the conscious state. Thus, attention,
memory, sensorial input, motor output, language, introspection/reflection, space, body and
self, perception, imagination, gnosia, etc. are necessary prerequisite of consciousness. The
measurement scale of the (actual) level of consciousness of a person in the awakened state of
mind and under ordinary life condition is composed of several modules such as: being aware
of the somatic, visceral, cognitive, emotional and spiritual ego, and being aware of the physical,
spatial, social, socio-relational extra ego.
In the following we will analyse a few data about the implication of the cerebellum in the
consciousness.
Throughout the lifespan, the cerebellum plays an essential and fundamental role in organiza‐
tion and expression of higher-level cognitive functions and consciousness. Cerebello-cortical
and cortico-cerebellar circuits represent the neuroanatomic substrate. So, the feed forward
connections from cortex to cerebellum and the feedback connections from cerebellum to cortex
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are developed very early in life [129]. However, there is a topographical organization of the
cerebellum, along antero-posterior and medial-lateral gradients. Thus, sensori-motor func‐
tions are primarily mapped in anterior regions of the cerebellum. Cognitive functions are
primarily mapped in posterior and inferior cerebellar regions [130]. Lesions in the anterior
lobes should generate motor deficits, and lesions in posterior lobes should result in cognitive
impairment [131].
CASE / FIGURE IN
THE TEXT
DAMAGED CIRCUITS OR MODULES
LESIONS OF AREA OR BRAIN CIRCUITS BETWEEN BRAINSTEM AND CEREBRAL CORTEX
Case 1; Fig.1 Via the Ascending (reticular) activating system (AAS)
Case 2; Fig.4 Via the Ascending (reticular) inhibitory system (AIS)
LESIONS OF SOME SUBCORTICAL CENTERS
Case 3; Fig.5 Pineal gland
Case 4; Fig.6 Hypothalamus
Case 5; Fig.7 Thalamus
Case 6; Fig.8 Pineal gland
Case 7; Fig.9 Limbic encephalitis
LESIONS OF BROADMANN CORTICAL CEREBRAL AREAS
Case 8; Fig.10 Olfactory meningioma; lesions produced on cortical areas: 10; 11; 13; 14; 34; 35; 47.
Case 9; Fig.11 Bi-lobed meningioma of the anterior falx; lesions produced on cortical areas: 8; 9; 10; 46.
Case 10; Fig.12 Left parietal cystic astrocytoma; lesions produced on cortical areas: 7a, 7b and 5 which project
the frontal areas 6, 8, 9.
Case 11; Fig.13 Right parietal fibrillary astrocytoma; lesions produced on cortical areas: 1; 2; 3a; 3b; 5; 7; 40.
Case 12; Fig.14 Right-sided temporobasal astrocytoma; lesions produced on cortical areas: 20; 28; 34; 36; 38.
Case 13; Fig.15 Right parieto-occipital meningioma producing lesions of the cortical areas: 7; 19.
Case 14; Fig.16 Cortical and intracerebral metastases producing lesions of all the cortical areas.
Case 15; Fig.17 Neurocysticercosis metastases producing lesions of all the cortical areas.
Table 1. Lesions produced in the brain modules shown by the reported cases
In addition, the medial-lateral gradient predicts that lesions within the vermal area should
generate changes in affective/emotional functioning, while lesions in lateral region should
result in cognitive deficits. Cognitive deficits include impairment in attention, planning,
abstract thinking, and memory.
Children with involvement of the vermis, or “limbic cerebellum”, develop changes in person‐
ality functioning, such as irritability, emotional lability, and even autistic-like cognitive and
behavioral features [132].
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generate changes in affective/emotional functioning, while lesions in lateral region should
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So, the cerebellum contributes to consciousness.
The cerebellar cognitive affective syndrome with his group of cognitive, emotional, and
behavioral symptoms is a module of consciousness [133]. The picture of cognitive and affective
characteristics of this syndrome is impaired in patients with posterior involvement of the
cerebellum and in patients demonstrating pathology within the vermis.
The type and level of impairment that these patients demonstrated was undistinguishable
from that observed in individuals demonstrating pathology within the cerebral cortex, because
the cerebellum regulates neural signals in these regions of the brain [129].
Disturbances have been identified in executive functioning, like impaired planning, set-
shifting, verbal fluency, abstract reasoning, visuospatial organization, working memory,
episodic memory, and attention. Blunting of affect or desinhibited and inappropriate behavior,
are characteristic of patients with midline cerebellar involvement.
General intellectual functioning was also affected.
Visuospatial deficits are characteristic of patients with left cerebellar lesions and verbal
memory difficulty, with particular problems in working memory and are also characteristic
of patients with right cerebellar infarcts [134]. Deficiencies in the performance of non-verbal
tasks and deficits in prosody follow left cerebellar lesions. Impairment in verbal intelligence
and higher-level language skills typically follow right cerebellar lesions. In addition, the
language deficit observed with right cerebellar involvement does not occur in isolation. It is
accompanied by cognitive deficits such as impairment in the shifting of attention and thinking
or persevering behavior, as well as impairment in problem-solving. Residual functional
deficits are common [135, 136].
So, there were visuospatial deficits and dysprosodia with left cerebellar hemispheric infarct
and language difficulties and executive function deficit with right cerebellar hemisphere
infarct. These localizations of the previous phenomena have been reported in [133 – 135, 137,
138].
The left lateral cerebellum is more active in procedural learning through the ipsilateral hand,
but the right lateral cerebellum is activated in procedural learning regardless of hand [139,
140]. The role of the right cerebellum has been related to the refinement or timing of signals
within the left dorsolateral prefrontal cortex. Patients with either focal or atrophic cerebellar
damage have also been described as demonstrating impairment in cognitive sequence learning
[141, 142].
On the other hand, the discovery of the existence and functions of the mirror-neurons, reported
in [143, 144] led to the explanation of the learning by imitation, of the empathy, of the reading
of other people’s thoughts and to the understanding of the connection between the individual
and universal consciousness. The development of the multitude of the specific human abilities
took place only when the mirror-neurons multiplied and became concentrated in well localized
zones within the cerebral cortex and in particular in the pre-frontal lobes.
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5. Conclusions
According to our results, two reticular systems: ascending activating system – AAS and
ascending inhibitory system – AIS, may be introduced as functional units that seem to play an
important role in consciousness. Observing and correlating the status of the “hardware” of the
brain whose subunits are affected by neurological diseases/accidents and by related neuro‐
surgical interventions in humans with the induced modifications of the consciousness in the
respective patients, we have been led to the conclusion: besides the already reported and
accepted ascending activating system (AAS, formerly called ARAS) that has an important role
in the consciousness state, an ascending inhibitory system (AIS) should be defined which acts
so that in interaction with AAS the consciousness state may be controlled and kept under
functional equilibrium. By points, our main conclusions are:
• The bilateral destruction of the reticular activating nuclei at the rostral pons and midbrain
lead to loss of consciousness and the induction of coma.
• The damage of the ascending reticular inhibitory system leads to the appearance of the
logorrhea syndrome with hyperkinesia, hyperwakefulness, and hyperprosexia.
• The ascending inhibitory system is very important in explaining the sleep and many other
behaviors.
• AAS and AIS reach the cerebral cortex by three distinct ways: directly, through the thalamus,
and through the hypothalamus.
• The sleep is controlled by the action of the AAS-AIS dipole.
• With respect to its functioning, the cerebral cortex may be compared to a continuous chess
game between of the two systems, AAS and AIS, which act in perfect equilibrium, in order
to perform all functions and behaviors of the individual.
• The cerebral cortex and consciousness have a modular structure.
Related to our conclusions, in Table 2 we present a more detailed synthesis of the relations
between the lesions produced in the brain by the tumors operated neurosurgically and the
modifications of the consciousness observed before and after operations. In this table are
shown the specific connections between the brain (AAS and AIS included) lesions/tumors and
the consciousness alterations, for each of the operated cases. The connections are made
between the brain modules numbers (as generally known) [24, 25], the modules of the
consciousness and their denominations on one hand (first two columns). On the other hand,
are presented in the columns 3, 4 and 5, respectively, the case number and the corresponding
figure, the modules of the consciousness that suffered modifications due to the lesions
produced in the brain modules (in each operated case), and the coma/disease cases. As for the
brain modules 9 and 10, in Table 2 no operated cases were shown by us in this chapter.
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Values and Individual Character
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Case 6; Fig.8 9; 10 -
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about the Self and the Environment
Case 7; Fig.9 All modules Coma and
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***Lesions of all modules lead to coma with or without decease. Unless specified, coma/decease are not produced.
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From the data and the analysis dedicated to the description and understanding of the neuro‐
logical bases of the consciousness it became obvious for us that this subject is not completely
elucidated and there is still the need to further develop systematic and systemic research on
this topic.
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1. Introduction
The incidence of brain tumors and other types of cancer have been evidently increasing during
the last few decades. Due to the well documented fact that the cancer cells are under high levels
of oxidative stress, the relevance between oxidative stress and cancer has been the main topic
of intense discourse (Powis & Baker, 1997; Pervaiz & Clement, 2004). Elevated levels of intrinsic
oxidative stress has been emphasized in different types of tumors, possibly due to the
clustering of factors such as enhanced metabolism, mitochondrial mutation, inflammation and
cytokines (Mumper, 2009). Cellular damage on account of oxidative stress has been indicated
in a range of disorders such as cancer (Floyd, 1990) diabetes mellitus (Dandona, et al.,1996),
atherosclerosis (Valko, et al., 2007), neurodegenerative disorders such as Alzheimer’s disease
and Parkinson’s disease (Jenner, 1997) autoimmune disorders such as arthritis and has also
been indicated to be involved in aging (Ames & Shigenaga, 1992)
Oxidation is a natural process of cellular metabolism, but oxidation is what creates these
destructive reactive oxygen species (ROS). ROS are constantly produced during oxidative
metabolism and can  have  deleterious  effects  on  cell  function  and viability  due  to  their
ability to induce damage to the cells.  The formation of ROS is a consequence of aerobic
metabolism (Castro,  2001).  ROS are generated in many compartments and by numerous
enzymes in cells (Fig. 1).
In normal conditions, the countenance in the intracellular ROS levels is maintained with the
contribution of antioxidant scavenging systems and defense components. Yet, in some
disorders such as cancer, the balance between the ROS and the antioxidant status falls off.
Brain tissue also displays higher susceptibility to oxygen and glucose necessity, which are
required to support normal function through glycolysis and oxidative phosphorylation thus
the brain is particularly susceptible to oxidative damage since does not have much antioxidant
storage. Additionally, the brain has a high amount of fatty acids. All these attributes lead to
© 2013 Atukeren and Yigitoglu; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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brain cell damage. Thereby human brain encounters intense percentage of oxygen consump‐
tion, eventually generates an excessive amount of reactive oxygen species (ROS) when
compared with other tissues.
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Figure 1. Sources of reactive oxygen species in the human body
Oxidative stress can be defined as the disturbance in the oxidant-antioxidant balance
(Chandra, et al., 2000). The cancer cells exposed to oxidative stress tend to heavily interpret
adaptation mechanisms and may deplete cellular antioxidant capacity. The generated exces‐
sive ROS cannot be neutralized by cellular antioxidants and oxidative stress endures (Pervaiz,
2006). The redox status related to the production of intracellular ROS in cancer cells has also
been denoted to control the aggression of cancer cells. The reason of the induced oxidative
stress in cancer cells is a result of the lower levels of antioxidant enzymes such as SOD,
glutathione peroxidase, glutathione reductase, and catalase (Anshul, 2009). The reduced ROS
combout is known in conjunction with tumor growth and metastasis.
The enhanced oxidative stress can lead to modification of cellular targets and induce cell
damage and death. Nuclear and mitochondrial DNA single strand breaks, mitochondrial
inner membrane damage resulting with the loss of cellular ATP storage and initiation of
lipid peroxidation in membrane phospholipids can be seen (Farber, et al.,  1990). The cell
damage and the following deficiency in cellular repair processes due to the constant oxi‐
dative damage are correlated with carcinogenesis( Behrend, et al.,  2003; Federico, et al.,
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2007;  Nair & Nair,  2007).  Such as,  guanine nucleotide base oxidation in DNA results  in
the formation of 8- hydroxy-2-deoxyguanosine (8-OHdG), which alters DNA and eventu‐
ates  as  mutagenesis  and  cause  carcinogenesis  (Gate,  et  al.,  1999).  ROS  interaction  with
DNA results in fragmentation with the loss of bases and causes DNA strand breaks (Im‐
lay,  1988;  Farber,  et  al.,  1990;  Farber,  1994).  When  DNA  strand  breaks  accumulates  in
cells, this can lead oncogenic transformation depending on the intensity of cellular repair
processes  (Federico,  et  al.,  2007).  At  this  level,  cells  exposed to  excessive ROS stress  ei‐
ther undergo apoptosis or in some cases the cells start to proliferate and thus are irrever‐
sibly  turn  into  malignant  cells  (Fruehauf  &  Meyskens,  1997)  and  maintain  excessive
oxidative  stress  compared to  normal  cells.  Thus  the  strategy  of  producing  further  ROS
stress in malignant cells could be a successful anti-cancer strategy (Anshul, 2009).
On the other hand, ROS also subserve for the regulation of cellular functions and normal
metabolism (Poli,  et  al.,  2004).  Adversely,  low concentrations  of  ROS serve a  variety  of
important  cellular  functions  such  as  the  activation  and  modulation  of  the  signal  trans‐
duction  pathways  (Monteino  &  Stern,  1996),  modulation  of  the  activities  of  the  redox
sensitive  transcription  factors  (Li,  et  al.,  1998;  Oberley,  2002)  regulation  of  apoptosis
(Nulton-Persson,  2001;  Fang  &  Iyer,  2007)  and  the  regulation  of  mitochondrial  enzyme
activities  (Nulton-Persson,  2001;  Oberley,  2002).  Increased  ROS  production  is  well  dis‐
played in transformed cells (Toyokuni, et al., 1995; Burdon, 1995; Storz, 2005; Kryston, et
al.,  2011) and growing evidence suggests that ROS act as second messengers in intracel‐
lular signaling pathways (Liou & Storz, 2010).
Recently, oxidative stress has been related with the etiology and the prospective treatment of
cancer (Powis & Baker, 1997; Pervaiz & Clement, 2004). Cells have developed a number of
antioxidant defense systems to confront the hazardous effects of endogenous ROS production
and accumulation to protect against cellular oxidative damage. Antioxidants in the cells form
a heterogeneous group including low molecular weight substances which are water or lipid
soluble, being inclusive in the body through nutrition, also a number of endogenous metabo‐
lites own antioxidant activities.
Malignant gliomas account for the most diagnosed primary brain cancers (Behrend, et al.,
2003). Despite of exquisite treatment approaches the prognosis remains poor. There is a well-
documented association between increased consumption of antioxidants and decreased
incidence of cancer. Antioxidant supplements are recommended as part of a cancer prevention
diet. Even though cells have endogenous antioxidant enzymes, most human cancer cells have
decreased antioxidant enzyme levels compared to their normal tissue counterparts. It is found
that; cruciferous vegetables such as broccoli, horseradish, brussels, decreased the risk of
anaplastic astrocytomas which is a type of aggressively growing brain tumor. One of the
important functions of apoptosis is disposing of preneoplastic and neoplastic cells which
appears when a damage or malfunction is recognized and signaling cascades are initiated so
caspases and endonucleases that kill the cell are activated. In cell suicide, the signaling cascade
avails ROS as messenger molecules. Thats why antioxidants are ascendant in the inhibition of
apoptosis. So, the removal of antioxidants from the diet can be suggested as this may enhance
apoptosis and inhibit tumor growth. The tumor cell survives in an ROS rich environment
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brain cell damage. Thereby human brain encounters intense percentage of oxygen consump‐
tion, eventually generates an excessive amount of reactive oxygen species (ROS) when
compared with other tissues.
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Figure 1. Sources of reactive oxygen species in the human body
Oxidative stress can be defined as the disturbance in the oxidant-antioxidant balance
(Chandra, et al., 2000). The cancer cells exposed to oxidative stress tend to heavily interpret
adaptation mechanisms and may deplete cellular antioxidant capacity. The generated exces‐
sive ROS cannot be neutralized by cellular antioxidants and oxidative stress endures (Pervaiz,
2006). The redox status related to the production of intracellular ROS in cancer cells has also
been denoted to control the aggression of cancer cells. The reason of the induced oxidative
stress in cancer cells is a result of the lower levels of antioxidant enzymes such as SOD,
glutathione peroxidase, glutathione reductase, and catalase (Anshul, 2009). The reduced ROS
combout is known in conjunction with tumor growth and metastasis.
The enhanced oxidative stress can lead to modification of cellular targets and induce cell
damage and death. Nuclear and mitochondrial DNA single strand breaks, mitochondrial
inner membrane damage resulting with the loss of cellular ATP storage and initiation of
lipid peroxidation in membrane phospholipids can be seen (Farber, et al.,  1990). The cell
damage and the following deficiency in cellular repair processes due to the constant oxi‐
dative damage are correlated with carcinogenesis( Behrend, et al.,  2003; Federico, et al.,
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2007;  Nair & Nair,  2007).  Such as,  guanine nucleotide base oxidation in DNA results  in
the formation of 8- hydroxy-2-deoxyguanosine (8-OHdG), which alters DNA and eventu‐
ates  as  mutagenesis  and  cause  carcinogenesis  (Gate,  et  al.,  1999).  ROS  interaction  with
DNA results in fragmentation with the loss of bases and causes DNA strand breaks (Im‐
lay,  1988;  Farber,  et  al.,  1990;  Farber,  1994).  When  DNA  strand  breaks  accumulates  in
cells, this can lead oncogenic transformation depending on the intensity of cellular repair
processes  (Federico,  et  al.,  2007).  At  this  level,  cells  exposed to  excessive ROS stress  ei‐
ther undergo apoptosis or in some cases the cells start to proliferate and thus are irrever‐
sibly  turn  into  malignant  cells  (Fruehauf  &  Meyskens,  1997)  and  maintain  excessive
oxidative  stress  compared to  normal  cells.  Thus  the  strategy  of  producing  further  ROS
stress in malignant cells could be a successful anti-cancer strategy (Anshul, 2009).
On the other hand, ROS also subserve for the regulation of cellular functions and normal
metabolism (Poli,  et  al.,  2004).  Adversely,  low concentrations  of  ROS serve a  variety  of
important  cellular  functions  such  as  the  activation  and  modulation  of  the  signal  trans‐
duction  pathways  (Monteino  &  Stern,  1996),  modulation  of  the  activities  of  the  redox
sensitive  transcription  factors  (Li,  et  al.,  1998;  Oberley,  2002)  regulation  of  apoptosis
(Nulton-Persson,  2001;  Fang  &  Iyer,  2007)  and  the  regulation  of  mitochondrial  enzyme
activities  (Nulton-Persson,  2001;  Oberley,  2002).  Increased  ROS  production  is  well  dis‐
played in transformed cells (Toyokuni, et al., 1995; Burdon, 1995; Storz, 2005; Kryston, et
al.,  2011) and growing evidence suggests that ROS act as second messengers in intracel‐
lular signaling pathways (Liou & Storz, 2010).
Recently, oxidative stress has been related with the etiology and the prospective treatment of
cancer (Powis & Baker, 1997; Pervaiz & Clement, 2004). Cells have developed a number of
antioxidant defense systems to confront the hazardous effects of endogenous ROS production
and accumulation to protect against cellular oxidative damage. Antioxidants in the cells form
a heterogeneous group including low molecular weight substances which are water or lipid
soluble, being inclusive in the body through nutrition, also a number of endogenous metabo‐
lites own antioxidant activities.
Malignant gliomas account for the most diagnosed primary brain cancers (Behrend, et al.,
2003). Despite of exquisite treatment approaches the prognosis remains poor. There is a well-
documented association between increased consumption of antioxidants and decreased
incidence of cancer. Antioxidant supplements are recommended as part of a cancer prevention
diet. Even though cells have endogenous antioxidant enzymes, most human cancer cells have
decreased antioxidant enzyme levels compared to their normal tissue counterparts. It is found
that; cruciferous vegetables such as broccoli, horseradish, brussels, decreased the risk of
anaplastic astrocytomas which is a type of aggressively growing brain tumor. One of the
important functions of apoptosis is disposing of preneoplastic and neoplastic cells which
appears when a damage or malfunction is recognized and signaling cascades are initiated so
caspases and endonucleases that kill the cell are activated. In cell suicide, the signaling cascade
avails ROS as messenger molecules. Thats why antioxidants are ascendant in the inhibition of
apoptosis. So, the removal of antioxidants from the diet can be suggested as this may enhance
apoptosis and inhibit tumor growth. The tumor cell survives in an ROS rich environment
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depending on the overexpression of antioxidant enzymes and the excessive levels of nonen‐
zymatic antioxidant scavengers. A range of complementary and alternative therapies can be
inclusive for the treatment of brain cancer. Nutrients and herbs are believed to protect against
side effects of conventional therapies, they may also enhance chemotherapy and support
anticancer activities. At that, normal cells protect themselves when exposed to high doses of
antioxidants while cancer cells can not adapt and they suffer damage caused by the antioxi‐
dants. Thus, high doses of antioxidants may be toxic to cancer cells but not to normal cells.
Antioxidants which are active in the brain tissue, can cross the blood brain barrier and prevent
oxidative damage, so this can also be taken into consideration as a good treatment and
prevention strategy of brain cancer.
2. The redox status of the brain
Brain is considered enormously vulnerable to oxidative damage so is the target for oxidative
stress damaging effects than the other tissues. One of the reasons is its having high oxygen
consumption (Sah, et al., 2002) and this is around 20% of the total metabolic activity (Dal-Pizzol,
et al., 2000). Also, the brain tissue contains much amounts of polyunsaturated fatty acids, which
are particularly sensitive to free radical attacks and prooxidative transition metals such as high
levels of iron which is a triggering factor in lipid peroxidation of the cell membranes and also
the brain has a comparatively low antioxidant capacity (Sies, 1993; Bellissimo, et al. 2001;
Freitas, et al., 2004) and glucose deprivation, which are needed to support normal metabolic
functions through glycolysis and oxidative phosphorylation.
Massive neuronal death is the outcome of the secondary injury response, creating an excessive
pool of ROS, which triggers a cascade of reactive oxygen chain reactions. The free metal
concentrations are also controlled in the nervous system by transport proteins such as ferritin
(Sies, 1993) and this limits the non-enzymatic catalysis of hydroxyl radical formation. The
nervous system contains antioxidant enzymes; including Cu/Zn- and Mn dependent SOD and
GPx which are expressed in higher quantities than CAT (Shivakumar et al., 1991; Hussain et
al., 1995). It was shown that the zinc, iron and selenium concentrations were found significantly
lower in cancer patients and the copper concentrations were found to be either elevated or
significantly elevated, as 2-3 fold, when compared to age matched samples of normal tissues
(Kuo, et al., 2002; Zuo, et al., 2006). It has been also shown that the Cu/Zn, Cu/Se and Cu/Fe
ratios were found higher in cancer patients when compared to normal subjects.
Cancer  cells  display  increased glycolysis  rate  combined with  a  reduced respiration  rate
(Spitz, 2000). The enhanced requirements for ATP; generates oxygen free radicals and this
causes oxidative stress conditions to come out which eventually promotes cell death. Neu‐
rons and cancer cells consume glucose as energy source to respond this issue and glycolyt‐
ic  metabolism rules  over  in  tumor  cells.  The  release  of  cytochrome c  couples  with  the
pentose phosphate pathway and this initiates cytochrome c mediated apoptosis (Vaughn
&Deshmukh, 2008). Caspase activation is initiated by cytochrome c when released from mi‐
tochondria during apoptosis.  So,  the cancer cells  and neurons control apoptosis through
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regulation of cytochrome c release,  while utilizing glucose as a source of energy (Dajas,
2012). This marked changes in metabolism have been shown to be related with increased
oxidative stress which is emphasized to be due to increased mitochondrial superoxide radi‐
cal production (Oberley, et al.,  1981). A more oxidizing redox status of the transforming
cell occurs and this streamlines immortalization, increases cell proliferation and supports
development of the malignant cell (Spitz, et al., 2000). In the initial steps of carcinogenesis,
a relatively prooxidant intracellular environment is developed and entails the mutation of
tumor suppression genes and the activation of the oncogenes. Thus, the loss of normal re‐
dox control in cell growth and development occurs (Blackburn, et al., 1999).
Oxidative stress in the brain is known to increase the glutamate release in the hippocampus,
and this affects ionic homeostasis and neurotransmission (Costa, 2004). The glutamate
receptors are activated subsequently so acidification occurs in neurons because of Ca2+ entry
and this can be associated with the death of central neurons (Reynolds & Hastings, 1995;
Bellisimo, et al., 2001). This countenance can be altered by increased ROS production or
decreased intracellular antioxidant defense systems (Tejada, et al., 2006).
Studies have been done to evaluate antioxidant enzyme activities in different types of brain
tumors. However, most studies have emphasized decreased levels of antioxidant enzymes and
vitamins in diverse malignancies (Rao, et al., 2000; Manju, et al., 2002; Gromadzinska, et al.,
2003) but still the results are inconsistent (Hennekens, et al., 1996).
2.1. Mitochondrial changes in tumor cells
Mitochondrial DNA is more vulnerable to mutation when compared with nuclear DNA.
Conversely to nuclear DNA, mitochondrial DNA is in close proximity to the electron transport
system where ROS are produced, and it doesn’t have any protective histones and chromatin
structure, also its repair capabilities are limited, and it doesn’t have any introns (Copeland, et
al., 2002). Many studies have established mitochondrial DNA changes in different cancer types
related to these features (Lu, et al., 1992; Savre-Train, et al., 1992; Polyak, et al., 1998; Modica,
et al., 2002; Modica, et al., 2007). Cancer specific mitochondrial DNA mutations have been
identified. Recent studies, associating the alterations in mitochondrial DNA and cancer risk,
suggest mitochondrial DNA changes during cancer development are more complicated than
estimated (Ebner, et al., 2011; Lam, et al. 2012).
Mitochondria are highly prospered with antioxidants such as GSH and antioxidant enzymes
such as superoxide dismutase and GPx, which exist on both sides of their membranes to
minimise oxidative stress in the organelle because mitochondria are the major zone of free
radical generation (Cadenas & Davies, 2000). Superoxide radicals are ascendantly detoxified
into hydrogen peroxide and into water by Cu/ZnSOD and MnSOD. The redox components of
the cell comprises mitochondrial redox indicators which are glutathione (GSH/GSSG),
thioredoxin (Trx/TrxR), glutaredoxin (Grx) and peroxiredoxin (Prx) systems dependent
merely on NADPH generation via reduction of NADP+ by mitochondria.
In some apparent cases, when mitochondrial oxidative stress increases, over generation of the
antioxidant defences above a certain threshold may lead to cell death. In normal cells, the same
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depending on the overexpression of antioxidant enzymes and the excessive levels of nonen‐
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anticancer activities. At that, normal cells protect themselves when exposed to high doses of
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dants. Thus, high doses of antioxidants may be toxic to cancer cells but not to normal cells.
Antioxidants which are active in the brain tissue, can cross the blood brain barrier and prevent
oxidative damage, so this can also be taken into consideration as a good treatment and
prevention strategy of brain cancer.
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consumption (Sah, et al., 2002) and this is around 20% of the total metabolic activity (Dal-Pizzol,
et al., 2000). Also, the brain tissue contains much amounts of polyunsaturated fatty acids, which
are particularly sensitive to free radical attacks and prooxidative transition metals such as high
levels of iron which is a triggering factor in lipid peroxidation of the cell membranes and also
the brain has a comparatively low antioxidant capacity (Sies, 1993; Bellissimo, et al. 2001;
Freitas, et al., 2004) and glucose deprivation, which are needed to support normal metabolic
functions through glycolysis and oxidative phosphorylation.
Massive neuronal death is the outcome of the secondary injury response, creating an excessive
pool of ROS, which triggers a cascade of reactive oxygen chain reactions. The free metal
concentrations are also controlled in the nervous system by transport proteins such as ferritin
(Sies, 1993) and this limits the non-enzymatic catalysis of hydroxyl radical formation. The
nervous system contains antioxidant enzymes; including Cu/Zn- and Mn dependent SOD and
GPx which are expressed in higher quantities than CAT (Shivakumar et al., 1991; Hussain et
al., 1995). It was shown that the zinc, iron and selenium concentrations were found significantly
lower in cancer patients and the copper concentrations were found to be either elevated or
significantly elevated, as 2-3 fold, when compared to age matched samples of normal tissues
(Kuo, et al., 2002; Zuo, et al., 2006). It has been also shown that the Cu/Zn, Cu/Se and Cu/Fe
ratios were found higher in cancer patients when compared to normal subjects.
Cancer  cells  display  increased glycolysis  rate  combined with  a  reduced respiration  rate
(Spitz, 2000). The enhanced requirements for ATP; generates oxygen free radicals and this
causes oxidative stress conditions to come out which eventually promotes cell death. Neu‐
rons and cancer cells consume glucose as energy source to respond this issue and glycolyt‐
ic  metabolism rules  over  in  tumor  cells.  The  release  of  cytochrome c  couples  with  the
pentose phosphate pathway and this initiates cytochrome c mediated apoptosis (Vaughn
&Deshmukh, 2008). Caspase activation is initiated by cytochrome c when released from mi‐
tochondria during apoptosis.  So,  the cancer cells  and neurons control apoptosis through
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regulation of cytochrome c release,  while utilizing glucose as a source of energy (Dajas,
2012). This marked changes in metabolism have been shown to be related with increased
oxidative stress which is emphasized to be due to increased mitochondrial superoxide radi‐
cal production (Oberley, et al.,  1981). A more oxidizing redox status of the transforming
cell occurs and this streamlines immortalization, increases cell proliferation and supports
development of the malignant cell (Spitz, et al., 2000). In the initial steps of carcinogenesis,
a relatively prooxidant intracellular environment is developed and entails the mutation of
tumor suppression genes and the activation of the oncogenes. Thus, the loss of normal re‐
dox control in cell growth and development occurs (Blackburn, et al., 1999).
Oxidative stress in the brain is known to increase the glutamate release in the hippocampus,
and this affects ionic homeostasis and neurotransmission (Costa, 2004). The glutamate
receptors are activated subsequently so acidification occurs in neurons because of Ca2+ entry
and this can be associated with the death of central neurons (Reynolds & Hastings, 1995;
Bellisimo, et al., 2001). This countenance can be altered by increased ROS production or
decreased intracellular antioxidant defense systems (Tejada, et al., 2006).
Studies have been done to evaluate antioxidant enzyme activities in different types of brain
tumors. However, most studies have emphasized decreased levels of antioxidant enzymes and
vitamins in diverse malignancies (Rao, et al., 2000; Manju, et al., 2002; Gromadzinska, et al.,
2003) but still the results are inconsistent (Hennekens, et al., 1996).
2.1. Mitochondrial changes in tumor cells
Mitochondrial DNA is more vulnerable to mutation when compared with nuclear DNA.
Conversely to nuclear DNA, mitochondrial DNA is in close proximity to the electron transport
system where ROS are produced, and it doesn’t have any protective histones and chromatin
structure, also its repair capabilities are limited, and it doesn’t have any introns (Copeland, et
al., 2002). Many studies have established mitochondrial DNA changes in different cancer types
related to these features (Lu, et al., 1992; Savre-Train, et al., 1992; Polyak, et al., 1998; Modica,
et al., 2002; Modica, et al., 2007). Cancer specific mitochondrial DNA mutations have been
identified. Recent studies, associating the alterations in mitochondrial DNA and cancer risk,
suggest mitochondrial DNA changes during cancer development are more complicated than
estimated (Ebner, et al., 2011; Lam, et al. 2012).
Mitochondria are highly prospered with antioxidants such as GSH and antioxidant enzymes
such as superoxide dismutase and GPx, which exist on both sides of their membranes to
minimise oxidative stress in the organelle because mitochondria are the major zone of free
radical generation (Cadenas & Davies, 2000). Superoxide radicals are ascendantly detoxified
into hydrogen peroxide and into water by Cu/ZnSOD and MnSOD. The redox components of
the cell comprises mitochondrial redox indicators which are glutathione (GSH/GSSG),
thioredoxin (Trx/TrxR), glutaredoxin (Grx) and peroxiredoxin (Prx) systems dependent
merely on NADPH generation via reduction of NADP+ by mitochondria.
In some apparent cases, when mitochondrial oxidative stress increases, over generation of the
antioxidant defences above a certain threshold may lead to cell death. In normal cells, the same
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process would take longer to happen as mitochondrial oxidative stress would be in basal levels
and lower. Indeed, most of the anti tumor agents are known to act as prooxidant agents and
they disturb the mitochondrial respiratory chain and this leads to an increase in mitochondrial
oxidative stress levels (Chou, et al., 2004).
Relying on glycolysis other than oxidative phosphorylation for glucose oxidation and en‐
hanced usage of  glutamine as  an energy source  are  the  the  two common metabolic  re‐
programming  processes  in  cancer.  Excessive  upregulation  in  glutamine  consumption  is
seen in tumor cells which is a second shift  in energy metabolism (Barbosa,  et  al.,  2012).
Mitochondria  are  the  the  main  energy  producers  via  oxidative  phosphorylation  in  nor‐
mal  cells  and  they  produce  various  metabolic  intermediates,  and  they  mediate  various
apoptotic  pathways  (Weinberg  &  Chandel,  2009).  Mitochondria  exhibits  same  essential
roles  in  cancer  cells,  too.  Though,  mitochondria  undergo massive changes  during onco‐
genesis,  and this  mostly  result  with a  change in  the energy metabolism,  a  resistance to
apoptosis and enhanced ROS production.
Because the cancer cells have different metabolic and mitochondrial needs other than their
normal counterparts, metabolic and mitochondrial changes in cancer cells may suggest an
efficient and selective anti cancer therapy opportunity. This fact can be taken into consideration
when targeting tumor mitochondria in terms of therapy.
3. Antioxidant defence systems
ROS are detoxified by exhaustive antioxidant defence systems. When the balance between ROS
and antioxidant status is disturbed, cellular defences can be reeled causing an abnormal cell
growth and this leads in turn to tumor cell forming (Wang, et al., 2011). Mammalian cells have
developed a number of antioxidant defense systems to withstand the detrimental effects of
ROS and they protect against cellular oxidative damage (Aoyama, et al., 2008). Antioxidants
comprise of a highly heterogeneous group. They involve water or lipid soluble low molecular
weight substances and enzymes such as CAT, SOD, GPx and GR. Also, a number of endoge‐
nous metabolites have antioxidant activities (Table 1).
Superoxide dismutase enzyme decomposes superoxide radicals into H2O2 and O2. The most
important H2O2 scavenging enzymes and concerned proteins having antioxidant capacity
comprise CAT, GPx, GR enzymes associated with the synthesis of reduced GSH (Halliwell &
Gutteridge, 1996) and a group of cysteine containing proteins known as thioredoxins, thiore‐
doxin peroxidases (peroxiredoxins), and glutaredoxins (Kumar & Holmgren, 1999; Rhee, et
al., 1999; Powis, et al., 2000; Holmgren, 2000). When ROS production is enhanced, the antiox‐
idant scavenging capacity is disturbed and this results in the development of oxidative stress
which leads to tissue injury and apoptosis activation (Todorova, et al., 2004).
GSH is a low molecular weight thiol and it has a key role in maintaining the intracellu‐
lar  redox  balance.  Cellular  glutathione  appears  mainly  in  the  reduced  form  as  GSH,
while some of the total GSH exists in its oxidized disulfide form as GSSG. Depletion of
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GSH and an eventual  decrease in the GSH/GSSG ratio may be seen in oxidizing condi‐
tions,  yet  peroxidise  coupled  reactions  can  mediate  its  antioxidant  activity.  GSH  also
amends signaling pathways and some cellular events. In oxidative stress, GSH is deplet‐
ed hereby the GSH pool is  affected (Dickinson & Forman, 2002;  Circu & Aw, 2008; Bis‐
was & Rahman, 2009; Forman et al., 2009; Yuan & Kaplowitz, 2009).
Table 1. Antioxidants
Vitamin E, vitamin C and carotenoids can be defined as traditional antioxidant nutrients when
consumed with diet, also they have antioxidant and anti inflammatory properties along with
multiple other bioactive phytochemicals. The phytochemicals that includes phenolic acids and
their derivatives, flavonoids and different types of coumarins and tannins consist of a large
and heterogeneous group (Liu, 2004).
The phenolic compounds have recently been attracting attention conversely to antioxidant
vitamins and carotenoids (Gescher, et al., 2001) and still most have not been tested in placebo
controlled cancer prevention strudies. Curcumin, a phenolic acid derivative obtained from the
spice turmeric; resveratrol, a polyhydroxylated stilbene found in grapes ; and genistein, an
isoflavone readily isolated from soy have been pointed out for future studies (Gullet, et al.,
2010). These compounds are known to have antioxidant and anti inflammatory features
(Djuric, et al., 2001; Leu, et al., 2006; Brisdelli, et al., 2009), and they are implied as promising
in cancer prevention depending on in vitro and in vivo animal experiments (Sarkar, et al.,
2006; Sarkar, et al., 2010; Kelkel, et al., 2010; Patel, et al., 2010; Slusarz, et al., 2010). Resveratrol;
having a hydroxylated structure, is a well identified antioxidant. It can act both as free radical
scavenger and as metal chelator. Moreover, it also amends many enzymes in the regulation of
redox status which are CAT, SOD, GR, NADPH oxidase, xanthine oxidase and (Delmas et al.,
2005; Pervaiz & Holme, 2009). Flavonoids are polyphenols and isoflavones and anthocyani‐
dines as the subclasses of flavonoids. They have a strong antioxidant activity because of their
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process would take longer to happen as mitochondrial oxidative stress would be in basal levels
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mal  cells  and  they  produce  various  metabolic  intermediates,  and  they  mediate  various
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roles  in  cancer  cells,  too.  Though,  mitochondria  undergo massive changes  during onco‐
genesis,  and this  mostly  result  with a  change in  the energy metabolism,  a  resistance to
apoptosis and enhanced ROS production.
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normal counterparts, metabolic and mitochondrial changes in cancer cells may suggest an
efficient and selective anti cancer therapy opportunity. This fact can be taken into consideration
when targeting tumor mitochondria in terms of therapy.
3. Antioxidant defence systems
ROS are detoxified by exhaustive antioxidant defence systems. When the balance between ROS
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growth and this leads in turn to tumor cell forming (Wang, et al., 2011). Mammalian cells have
developed a number of antioxidant defense systems to withstand the detrimental effects of
ROS and they protect against cellular oxidative damage (Aoyama, et al., 2008). Antioxidants
comprise of a highly heterogeneous group. They involve water or lipid soluble low molecular
weight substances and enzymes such as CAT, SOD, GPx and GR. Also, a number of endoge‐
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Superoxide dismutase enzyme decomposes superoxide radicals into H2O2 and O2. The most
important H2O2 scavenging enzymes and concerned proteins having antioxidant capacity
comprise CAT, GPx, GR enzymes associated with the synthesis of reduced GSH (Halliwell &
Gutteridge, 1996) and a group of cysteine containing proteins known as thioredoxins, thiore‐
doxin peroxidases (peroxiredoxins), and glutaredoxins (Kumar & Holmgren, 1999; Rhee, et
al., 1999; Powis, et al., 2000; Holmgren, 2000). When ROS production is enhanced, the antiox‐
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which leads to tissue injury and apoptosis activation (Todorova, et al., 2004).
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lar  redox  balance.  Cellular  glutathione  appears  mainly  in  the  reduced  form  as  GSH,
while some of the total GSH exists in its oxidized disulfide form as GSSG. Depletion of
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GSH and an eventual  decrease in the GSH/GSSG ratio may be seen in oxidizing condi‐
tions,  yet  peroxidise  coupled  reactions  can  mediate  its  antioxidant  activity.  GSH  also
amends signaling pathways and some cellular events. In oxidative stress, GSH is deplet‐
ed hereby the GSH pool is  affected (Dickinson & Forman, 2002;  Circu & Aw, 2008; Bis‐
was & Rahman, 2009; Forman et al., 2009; Yuan & Kaplowitz, 2009).
Table 1. Antioxidants
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controlled cancer prevention strudies. Curcumin, a phenolic acid derivative obtained from the
spice turmeric; resveratrol, a polyhydroxylated stilbene found in grapes ; and genistein, an
isoflavone readily isolated from soy have been pointed out for future studies (Gullet, et al.,
2010). These compounds are known to have antioxidant and anti inflammatory features
(Djuric, et al., 2001; Leu, et al., 2006; Brisdelli, et al., 2009), and they are implied as promising
in cancer prevention depending on in vitro and in vivo animal experiments (Sarkar, et al.,
2006; Sarkar, et al., 2010; Kelkel, et al., 2010; Patel, et al., 2010; Slusarz, et al., 2010). Resveratrol;
having a hydroxylated structure, is a well identified antioxidant. It can act both as free radical
scavenger and as metal chelator. Moreover, it also amends many enzymes in the regulation of
redox status which are CAT, SOD, GR, NADPH oxidase, xanthine oxidase and (Delmas et al.,
2005; Pervaiz & Holme, 2009). Flavonoids are polyphenols and isoflavones and anthocyani‐
dines as the subclasses of flavonoids. They have a strong antioxidant activity because of their
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free radical scavenging and metal chelating features, also they can interact with enzymatic and
non enzymatic mechanisms of the regulation of redox status (Heim et al., 2002; Laguerre et al.,
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Figure 2. Antioxidant defence systems
Antioxidant molecules has been known as also beneficial in the induction of endogenous
protective antioxidant enzymes and in the modulation of various of cellular signaling path‐
ways (Valko et al., 2007). They can quickly oxidize spontaneously or induced by the biological
microenvironment.
Antioxidant enzymes can antagonize initiation and promotion steps of carcinogenesis and they
are reduced in cancer. Mitochondrial Mn-SOD is the most frequently decreasing enzyme and
this suggests that MnSOD may be a new type of tumour suppressor gene. On the other hand,
studies also suggest that the deficiency of the MnSOD enzyme activity depends on a defect in
the expression of the related gene. Transition metal ions such as Mn and Fe have been found
to be significantly lower in some tumours. It can be thought that, an impairment in the signal
transduction may cause the defect in the MnSOD gene expression in the early stage of
carcinogenesis (Mates, et al., 2000).
Studies are present implying low antioxidant status and enhanced oxidative stress in cancer pa‐
tients, even before chemotherapy starts. Low activities of Cu, Zn-SOD, MnSOD, CAT, and GPx
are shown in different types of tumor cells when compared with their normal counterparts
(Sykes, et al., 1978). Some studies show that administration of antineoplastic agents during can‐
cer therapy results in a higher level of oxidative stress rather than the stress induced by cancer it‐
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self (Conklin, 2000). Chemotherapeutic agents are thought to cause increase in ROS generation
by affecting mitochondrial respiration chain (Carew, et al., 2003; Pelicano, et al., 2003).
In chemotherapy, an increase in lipid peroxidation products and a significant decrease in some
plasma antioxidants such as Vitamin E, Vitamin C and carotenes are shown (Jeanne, et al.,
2003). The increase in oxidative stress during chemotherapy may exceed the oxidative defense
in cancer cells and this may initiate lipid peroxidation. Enhanced lipid peroxidation inhibits
cancer cell proliferation and intervenes chemotherapy. Thus, the antioxidant status in cancer
may play an important role in response to chemotherapy (Papageorgiou, et al., 2005).
3.1. Antioxidant status of the brain
Tumor cells frequently demonstrate a change in redox status. The alterations in the redox
environment enhancing oxidation can induce some of the factors that cause cell proliferation
and malignant transformation.
Elevated MnSOD levels were shown in the serum samples of neuroblastoma patients in a study
(Kawamura, et al., 1992). In recent studies, MnSOD was found to be associated with loss of
differentiation and increased clinical malignancy in neuroepithelial origined brain tumors
(Landriscina, et al., 1996; Ria, et al., 2001). MnSOD was found significantly positive in Grade
IV astrocytomas and medulloblastomas and negative in normal brain samples (Cobbs, et al.,
1996). It can be said that MnSOD is overexpressed in most brain tumor types and enhanced
MnSOD expression is related with a poor prognosis. MnSOD seems to be a tumor suppressor
in the proliferative stage. When tumor progresses more aggressive, MnSOD is upregulated.
MnSOD level positively correlates with increased metastasis so MnSOD has an oncogene role
(Hempel, et al., 2011; Dhar, et al., 2011). Increase in MnSOD level was seen during the
progression of different types of tumors, including brain, to the metastatic stage. Tumorigen‐
esis and metastasis are dependent on the levels of ROS. A cell having low levels of MnSOD is
vulnerable to oxidative stress then it may turn its progression to a tumor cell (Miriyala, et al.,
2012). Oxidative gene polymorphism and brain tumor risk seems associated, the increased risk
of glioma and meningioma type brain tumors were found to be related with variants in some
antioxidant enzyme genes (Rajaraman et al., 2008) and in a study, MnSOD tissue expression
is said to be a prognostic marker for glioblastoma (Park et al., 2009). SOD and GPx activities
showed a clear decrease proportionally with tumor malignancy, decrease of SOD activity with
the increasing grades of malignancy in brain tumors were implied.
The GSH redox cycle is  one of the most important antioxidative systems (Arrick & Na‐
than,  1984;  Mitchell,  et  al.,  1989;  Tedeschi,  et  al.,  1990).  GSH is  a  primary  endogenous
neuroprotectant  for  the  brain.  GSH  protects  neuron  cells  from  lipid  peroxidation  and
brain  cells  from peroxynitrite  mediated oxidative  damage (Mark  et  al.,  1997;  Koppal  et
al., 1999). GSH, also has roles in the activation of transcription factors, DNA repair, regu‐
lation of enzyme activity and many other metabolic processes (Meister,  1995).  GSH syn‐
thesis,  usage  and export  are  the  processes  on  which  GSH homeostasis  is  dependent  in
glial  and neuronal  cells  (Anderson,  1998).  The main path for  chemotherapy metabolism
is  through the conjugation of  the xenobiotic  with GSH. The removal  of  the GSH conju‐
gates from the cell  causes cellular GSH depletion and cellular redox balance disruption.
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free radical scavenging and metal chelating features, also they can interact with enzymatic and
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in cancer cells and this may initiate lipid peroxidation. Enhanced lipid peroxidation inhibits
cancer cell proliferation and intervenes chemotherapy. Thus, the antioxidant status in cancer
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differentiation and increased clinical malignancy in neuroepithelial origined brain tumors
(Landriscina, et al., 1996; Ria, et al., 2001). MnSOD was found significantly positive in Grade
IV astrocytomas and medulloblastomas and negative in normal brain samples (Cobbs, et al.,
1996). It can be said that MnSOD is overexpressed in most brain tumor types and enhanced
MnSOD expression is related with a poor prognosis. MnSOD seems to be a tumor suppressor
in the proliferative stage. When tumor progresses more aggressive, MnSOD is upregulated.
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(Hempel, et al., 2011; Dhar, et al., 2011). Increase in MnSOD level was seen during the
progression of different types of tumors, including brain, to the metastatic stage. Tumorigen‐
esis and metastasis are dependent on the levels of ROS. A cell having low levels of MnSOD is
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of glioma and meningioma type brain tumors were found to be related with variants in some
antioxidant enzyme genes (Rajaraman et al., 2008) and in a study, MnSOD tissue expression
is said to be a prognostic marker for glioblastoma (Park et al., 2009). SOD and GPx activities
showed a clear decrease proportionally with tumor malignancy, decrease of SOD activity with
the increasing grades of malignancy in brain tumors were implied.
The GSH redox cycle is  one of the most important antioxidative systems (Arrick & Na‐
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al., 1999). GSH, also has roles in the activation of transcription factors, DNA repair, regu‐
lation of enzyme activity and many other metabolic processes (Meister,  1995).  GSH syn‐
thesis,  usage  and export  are  the  processes  on  which  GSH homeostasis  is  dependent  in
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GSH content  depends on the  substrate  availability  in  the  brain  and cysteine  is  the  rate
limiting substrate  for  neuronal  GSH biosynthesis  (Dringen,  et  al.,  1999).  Astrocytes  pro‐
vide neighbour cells the needed precursor amino acids for GSH synthesis (Hirrlinger, et
al., 2010). GSSG levels and the GSH/GSSG ratios can be restored through the GR mediat‐
ed pathway and flow of GSSG leaded by ATP dependent multi drug resistance-associat‐
ed  protein-1  (Mrp1)  transporter  in  astrocytes  and  neurons  (Hirrlinger,  et  al.,  2001;
Casagrande, et al.,  2002; Minich, et al.,  2006). Cultured astrocytes have high levels of re‐
duced  GSH  (Dringen  &  Hamprecht,  1998)  while  oligodendrocyte  precursors  have  high
levels  of  iron but  lower  levels  of  cellular  GSH when compared with astrocytes  or  neu‐
rons (Hussain & Juurlink, 1995; Thornburne & Juurlink, 1996), also oligodendrocyte pre‐
cursors are more sensitive to oxidative stress induced death in relation to GSH depletion
(Back, et al.,  1998). The GSH neutralization system has been shown also in the chemore‐
sistance of medulloblastoma (Colvin, et al.,  1993).  GSH and GST are prevalantly seen in
brain tissue, thus highly expressed in various primary brain tumors (Bredel,  2001).  GSH
content and GST expression was shown to be related to tumor response to nitrogen mus‐
tard therapy in human brain neoplasms (Evans, 1993). Also in another study it was indi‐
cated  that  the  cytotoxic  effect  of  BCNU  in  human  brain  tumor  cells  seems  associated
with the GSH content (Ali-Osman, et al., 1989). When GST isoenzymes in neoplastic and
non-neoplastic  astroglia  were  compared,  GST3  isoenzyme  was  seen  to  be  significantly
higher in tumors (Strange, et al.,  1992).  It  is said that GST expression levels in brain tu‐
mors  seems  in  association  with  the  tumor  histology  as  some  tumor  types  express  en‐
hanced levels but some show only slight rise or decrease when compared to normal cells
(Bredel, 2001). GST was found to be active in high levels in benign tumors such as men‐
ingioma but only two,  three folds higher compared to normal tissue but it  was slightly
increased  in  astrocytoma  (Matsumoto,  et  al.,  1992).  In  glioblastomas,  GSH  levels  were
found significantly lowered compared to normal tissue and merely elevated in meningio‐
ma (Kudo, et al., 1990).
It has been reported that elevation of intracellular GSH in tumour cells is associated with
mitogenic stimulation (Shaw & Chou,  1986),  that  GSH controls  the onset  of  tumour-cell
proliferation by regulating protein kinase C activity and intracellular pH (Terradez et al.,
1993).  GPx and GR decrease and protein oxidation increases in patients with glioblasto‐
ma  multiforme  and  transitional  meningioma  and  clear  different  oxidative  status  was
found in the two kinds of  tumors which represent  specially  one of  the most  malignant
and  most  benign  tumors  respectively  (Tanriverdi  et  al.,  2007)  and  it  was  shown  that
there is  a complex relationship between pro- and anti-apoptotic  molecules in glioblasto‐
ma  multiforme  pathogenesis,  thus  targeting  multiple  pathways  with  advanced  chemo‐
therapeutic  agents  or  radiotheraupetic  regimens  following  total  resections  might  be
helpful in patients with glioblastoma multiforme (Atukeren et al., 2010).
Antioxidant enzymes activity and concentration of nonenzymatic antioxidants in human
brain tumours were evaluated and significant  increases in all  enzyme activities  and de‐
creases in GSH and ascorbate levels were observed in brain tumors (Dudek et al., 2004) and
consistent differences in the levels of antioxidants in different types of brain tumors were
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emphasized in different studies (Hanimoglu et al., 2007; Tanriverdi et al., 2007; Tuzgen et
al., 2007; Zengin et al., 2009).
Serum β-carotene and α-tocopherol levels were found to be decreased in brain tumor pa‐
tients when compared to healthy subjects and also more less in malign tumors than the
benign types (Potishman, et al.,  1991; Zheng, et al, 1993; Palan, et al.,  1996). Few studies
have been done to compare the levels of these antioxidants in various histological types
of brain tumors. It was seen that β-carotene and α-tocopherol levels decreases when ma‐
lignancy  grade  increases  and the  decrease  was  found significant  for  oligodendroglioma
grade I-II,  glioblastoma multiforme and medulloblastoma.  The protective antioxidant ef‐
fects  of  these  two  vitamins  are  suggested  (Brigelius–Flohe,  et  al.,  2002).  The  decreased
antioxidant levels in brain tumor patients reflect the enhanced oxidative damage and in‐
creased cancer  developing possibility,  stating  the  role  of  antioxidants  in  cancer  preven‐
tion and role of oxidative injury as the of cancer (Aggarwal, et al., 2006).
4. The potential therapy in brain tumors regarding antioxidants
Antioxidant consumption is appraised if it can be a pledging therapeutic approach in pre‐
venting or minimizing neuronal oxidative damage (Halliwell, 2001; Uttara et al., 2009). A
relationship between excessive antioxidant consumption or high blood levels and a low cancer
incidence was found in many studies (Comstock, et al., 1992; Van den Brant, et al., 1992). Also
the importance of exogenous utilization of antioxidants with malignant glioma was shown in
various studies (Il'yasova et al., 2009; DeLorenze et al., 2010) yet antioxidant supplementation
by cancer patients during treatment is quite contentious. Indeed, a distinct declination or
recommendation for the simultaneous use of antioxidants with chemotherapy has not been
verified currently. The prospective antioxidant therapeutic approaches should involve either
inhibiting the ROS generation or scavenging. Recently, new strategies for antioxidant con‐
sumption have been studied carefully in order to maximize the influence and safety by
improving drug release and site specific targeting and to limit the adverse effects (Ratnam, et
al., 2006). Cancer cells’ having a a weak antioxidant defense system against oxidative stress
brings about a theoretical basis for the use of ROS generating systems in treatment (Laurent,
et al., 2005). Knowing that ROS have stimulating effects on tumor metastasis, the scavenging
of ROS is also a reasonable strategy to inhibit metastasis (Nishikawa, et al., 2006). Main
strategies as a potential treatment are the inhibition of the antioxidant enzymes and molecules
in cancer cells and the production of ROS leading to apoptosis (Lopez-Lazaro, 2007; McCarty,
et al., 2007). Recent studies involving ROS producing agents implied that their anti cancer and
cytotoxic effects are limited to cancer cells and no toxicity was seen in the surrounding normal
tissue (Yoshikawa, et al., 1995). The main mechanism of most chemotherapy drugs is via ROS
formation, but also free radicals production during chemotherapy is a serious side effects
(Block, et al., 2008). Interactions between chemotherapeutic compounds and antioxidants are
quite complicated and also the dose, the localization and the metabolism of the drug have
different effects. Furthermore, some antioxidants may act as oxidative molecules related with
their relative concentration (Badajatia, et al., 2010).
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The coexpression of catalase was shown to revert malignancy (Hempel, et al., 2011). The
overexpression of catalase protected cancer cell  from excessive peroxide production as a
result of combined menadione/ascorbate anticancer treatment (Glorieux, et  al.,  2011).  Al‐
so,  the  ability  of  ascorbate  to  radiosensitize  primary  human  glioblastoma  cells  and
mouse astrocytes and astrocytoma, was investigated and it  was concluded that pharma‐
cological concentrations of ascorbate radiosensitize glioblastoma primary cells more than
astrocytes  and this  can be  of  clinical  significance  in  therapeutic  approach (Herst,  et  al.,
2012). Besides, the activation of ferroptosis was shown to be resulted in the nonapoptotic
destruction of some cancer cells and inhibiting this process by ferrostatin-1 seems to pro‐
tect from neurodegeneration (Dixon, et al., 2012).
4.1. Targeting GSH pathway
GSH and the GSH related enzyme system might be a distinctive factor for the susceptibility of
several brain tumors to different chemotherapeutic agents (Backos, et al., 2012). Studies have
shown that drug resistance mediated by the GSH/GST system mediated drug resistance in
brain tumors might be the outcome of a change in a GSH related enzyme system and increased
GSH level (Ali-Osman, et al., 1989; Freidman, et al., 1992). Chemotherapeutics, thereby
chemoresistance, were shown to be related with increased cellular GSH content in brain tumor
cell lines (Ali-Osman, et al., 1989; Ali-Osman, et al., 1990). The increased GSH content is related
with tumor drug resistantance so exhaustion of cellular GSH can restore the sensitivity to the
cytotoxic effect of an anticancer agent (Barbosa, et al., 2012). So, it can be suggested that the
depletion of GSH content may increase the sensitivity to different chemotherapeutics. The
multidrug resistance-associated proteins (Mrp) can function as GSH, GSSG and GSH conjugate
carrier (Jedlitschky, et al., 1994; Muller, et al., 1994). Expelling these drug metabolites conju‐
gated with GSH ; changes the intracellular GSH levels distinctly. Mrps are considered to have
a role in resistance development to chemotherapeutics in most human brain tumors (Bredel &
Zentner, 2002). Mrp overexpression is associated with drug resistance in gliomas (Abe, et al.,
1998) and conversely with clinical outcome in neuroblastoma (Norris, et al., 1996). Astrocytes
have a potent GSH biosynthesis and antioxidant coupling is substantial in sustaining neuronal
GSH status and conserving neurons from ROS (Dringen R & Hirrlinger, 2003). Even the
concerned GST polymorphisms have been found to be associated with the survival (Kilburn,
et al., 2010), decreased GSH levels seems to play an important role in the increased sensitivity
of oligodendrogliomas to chemotherapy due to decreased GSH needed for detoxification. The
elevated iron levels in these cells also makes them daintily exquisite to ROS generation based
on chemotherapeutics (Yonezawa, et al., 1996). In a study, alantolactone which inhibits tumor
growth and triggers apoptosis and GSH depletion in glioblastoma, is suggested as a potential
lead compound for antiglioma therapy (Khan, et al., 2012).
4.2. Targeting mitochondria
Cancer cells have distinct metabolic and mitochondrial needs from their normal counterparts
so mitochondrial alterations in the context of metabolic reprogramming are an appealing target
for different therapeutic approaches. Most anti tumor agents act as prooxidants and they
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disturb mitochondrial respiratory chain and enhance mitochondrial oxidative stress (Chou, et
al., 2004). Considering that ROS have a role in activating signaling pathways thereby guiding
to metabolic remodeling; mitochondrial oriented antioxidants involving MitoQ may donate
to normalizing the metabolic phenotype in cancer cells. This antioxidant molecule has already
been indicated to diminish the hypoxic stimulation of ROS and to impair HIF-1alpha protein
by decreasing its transcriptional activity (Sanjuan-Pla, et al., 2005).
Occasionally, overloading the antioxidant system by increasing mitochondrial oxidative stress
over a certain threshold can be encountered leading to cell death. The same process would
take longer to come up in normal cells because the basal mitochondrial oxidative stress would
be lower. In a recent study, sulforaphane, having antioxidant and anti tumor features is
suggested to provide antitumor activity in malignant glioma cells via mitochondria and
caspase dependent pathways (Huang, et al., 2012).
4.3. Therapy via natural antioxidants
A great number of plants are good sources of phytochemical antioxidants and which have
been estimated having cancer fighting ability (Wang, et al., 2011). There is a reasonable
scientific and commercial interest in espialling new anti cancer molecules from natural sources,
involving secondary plant metabolites (Kinghorn, et al., 2003). Phytochemical antioxidants
existing in foods exhibit their anticancer properties via reducing ROS induced oxidative
damage by either scavenging or by increasing endogenous antioxidants (Du, et al., 2007).
Natural antioxidants have the ability to modulate signal transduction pathways by the
activating or inhibiting multiple redox sensitive transcription factors which is asserted as their
potential use as chemopreventive agents for therapy. They can act a part in initiation, promo‐
tion and progression stages of carcinogenesis to prevent cancer progress (Sporn, 1991).
Recently potential chemopreventive activities of dietary polyphenols was shown in most
studies (Thomasset, et al., 2007). The effects of flavonoids being natural polyphenolic antiox‐
idant compounds in brain development, neuroprotection and glial tumor formation are
mentioned and developing new therapeutic approaches was discussed (Nones et al.; 2010).
Epigallocatechin-3-gallate (EGCG) from green tea, curcumin from turmeric, and resveratrol
from grapes are some examples of polyphenols.
Resveratrol has the ability to block the activation of carcinogens and induce their detoxifi‐
cation, thus to prevent ROS damage and alleviate inflammatory responses and to reduce
the proliferation of cancer cells which reflect its chemopreventive property (Aggarwal, et
al., 2004; Shankar, et al., 2007). The chemotherapeutic potential of resveratrol is refered to
its blocking angiogenic and metastatic processes of tumor progression and relieving che‐
motherapy resistance (Aggarwal, et al., 2004; Fulda & Debatin, 2006). The potential thera‐
peutic  effect  of  resveratrol  being a  dietary phytochemical  antioxidant,  is  investigated in
glioma type brain tumors (Gangliano et al., 2010) and glioblastoma multiforme cells exhib‐
ited variable responses to resveratrol depending on the brain associated sulfonation activi‐
ty of the cells and resveratrol seemed to have value in glioblastoma treatment (Sun, et al.,
2012). Also the combination of resveratrol with alkylating agent temozolomide was shown
to improve the efficacy of chemotherapy for brain tumors (Herst, et al., 2012). EGCG also
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1998) and conversely with clinical outcome in neuroblastoma (Norris, et al., 1996). Astrocytes
have a potent GSH biosynthesis and antioxidant coupling is substantial in sustaining neuronal
GSH status and conserving neurons from ROS (Dringen R & Hirrlinger, 2003). Even the
concerned GST polymorphisms have been found to be associated with the survival (Kilburn,
et al., 2010), decreased GSH levels seems to play an important role in the increased sensitivity
of oligodendrogliomas to chemotherapy due to decreased GSH needed for detoxification. The
elevated iron levels in these cells also makes them daintily exquisite to ROS generation based
on chemotherapeutics (Yonezawa, et al., 1996). In a study, alantolactone which inhibits tumor
growth and triggers apoptosis and GSH depletion in glioblastoma, is suggested as a potential
lead compound for antiglioma therapy (Khan, et al., 2012).
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Cancer cells have distinct metabolic and mitochondrial needs from their normal counterparts
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been indicated to diminish the hypoxic stimulation of ROS and to impair HIF-1alpha protein
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Occasionally, overloading the antioxidant system by increasing mitochondrial oxidative stress
over a certain threshold can be encountered leading to cell death. The same process would
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be lower. In a recent study, sulforaphane, having antioxidant and anti tumor features is
suggested to provide antitumor activity in malignant glioma cells via mitochondria and
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been estimated having cancer fighting ability (Wang, et al., 2011). There is a reasonable
scientific and commercial interest in espialling new anti cancer molecules from natural sources,
involving secondary plant metabolites (Kinghorn, et al., 2003). Phytochemical antioxidants
existing in foods exhibit their anticancer properties via reducing ROS induced oxidative
damage by either scavenging or by increasing endogenous antioxidants (Du, et al., 2007).
Natural antioxidants have the ability to modulate signal transduction pathways by the
activating or inhibiting multiple redox sensitive transcription factors which is asserted as their
potential use as chemopreventive agents for therapy. They can act a part in initiation, promo‐
tion and progression stages of carcinogenesis to prevent cancer progress (Sporn, 1991).
Recently potential chemopreventive activities of dietary polyphenols was shown in most
studies (Thomasset, et al., 2007). The effects of flavonoids being natural polyphenolic antiox‐
idant compounds in brain development, neuroprotection and glial tumor formation are
mentioned and developing new therapeutic approaches was discussed (Nones et al.; 2010).
Epigallocatechin-3-gallate (EGCG) from green tea, curcumin from turmeric, and resveratrol
from grapes are some examples of polyphenols.
Resveratrol has the ability to block the activation of carcinogens and induce their detoxifi‐
cation, thus to prevent ROS damage and alleviate inflammatory responses and to reduce
the proliferation of cancer cells which reflect its chemopreventive property (Aggarwal, et
al., 2004; Shankar, et al., 2007). The chemotherapeutic potential of resveratrol is refered to
its blocking angiogenic and metastatic processes of tumor progression and relieving che‐
motherapy resistance (Aggarwal, et al., 2004; Fulda & Debatin, 2006). The potential thera‐
peutic  effect  of  resveratrol  being a  dietary phytochemical  antioxidant,  is  investigated in
glioma type brain tumors (Gangliano et al., 2010) and glioblastoma multiforme cells exhib‐
ited variable responses to resveratrol depending on the brain associated sulfonation activi‐
ty of the cells and resveratrol seemed to have value in glioblastoma treatment (Sun, et al.,
2012). Also the combination of resveratrol with alkylating agent temozolomide was shown
to improve the efficacy of chemotherapy for brain tumors (Herst, et al., 2012). EGCG also
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exhibited the same effect with temozolomide like as resveratrol in another study, in brain
tumor therapy (Chen, et  al.,  2011).  Curcumin as a polyphenol gets attention in blocking
brain tumor formation in a study. The chemopreventive and anticarcinogenic action of cur‐
cumin is shown and suggested as this might be due to its ability to inhibit proteins that ini‐
tiate protective signals (Purkayastha, et al., 2009).
Different  studies  implied  the  importance  of  using  nutritional  antioxidants.  Lycopene,
present in tomato,  was shown for its  potential  therapeutic  benefit  in the adjuvant man‐
agement of high grade gliomas (Puri et al., 2010). Gynostemma pentaphyllum extract se‐
lectively shifted H2O2 concentration in glioma tumor cells to toxic levels due to increased
SOD activity so can be suggested for cancer therapy (Schild et al., 2010) and the apoptot‐
ic  effect  of  γ-Mangostin in  Garcinia  mangostana fruit  was shown and it  was suggested
as a prospective anti brain tumor agent (Chang et al., 2010).
5. Conclusion
The incidence of brain tumors is obviously increasing recently. The occurance of ROS are the
inevitable outcome of the metabolism and they have important roles in many biochemical
processes but they must be precisely kept under control. Antioxidant molecules are that delay,
prevent, or remove the existing oxidative damage to a target molecule. The brain is quite
vulnerable to ROS damage because of its low antioxidant levels. To get over ROS damage, the
brain needs a sufficient supply of antioxidants and it seems convinent that working up with
ROS signaling pathways would provide a great neuroprotective effect. The development of
the suitable antioxidant compounds seems a challenging and pledging strategy for brain tumor
treatment but plenty of work has to be done to emphasize the exact role of antioxidants for
therapy in clinical use.
Adjusting the antioxidant dose and scheduling of the administration or combining different
antioxidants and exploring a more potent and specific antioxidant should be the main theme.
Also the preventive and therapeutic molecule should target multiple biochemical pathways
comprising the processes entailing malignancy and restrain the unwanted side effects and
toxicity in the normal tissue counterparts. In the same time should attend a beneficial task in
stimulating the therapeutic effect of chemotherapy and diminishing certain side effects. It is
clear that there is a deficient evidence concerning the prospective antioxidant therapies in brain
tumors. Regarding to the fact that there is little knowledge concerning complementary therapy
with antioxidant molecules and their effects or side effects, there is a crucial need for further
research of these treatment strategies.
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1. Introduction
Brain tumor surgery during pregnancy has a great concern in Egypt now days. High preva‐
lence of brain tumors during pregnancy y was noticed. There is no accurate statics for the
prevalence. The most common tumors are pituitary tumors, menegioma, gliomas, metastis of
breast carcinomas. Many problems affects anesthesia, as the interaction between many differ‐
ent factors, as the physiological changes during pregnancy, including, cardiovascular, respi‐
ratory changes [1]. Problems occur, during diagnosis, and treatment of tumors. Also problems
during surgery are, drug interactions with the anesthesia drugs, blood loss and transfusion,
prevention preterm labour, and anesthesia for urgent cesarean section during surgery for re‐
moval of brain tumor, in the chapter I tried to summary all these factors from anesthesia point
of views did many cases for brain resection during pregnancy,I hope to give this experience
for any young anesthesit how may facing such cases
1.1. Common tumors during pregnancy
1.1.1. Meningiomas
The incidence of meningiomas is approximately twice as high in women as in men. Specifically,
intracranial meningiomas are twice as common and intraspinal meningiomas nine times as
common in females [2]. Meningiomas also seem to have a relationship to sex hormones with
accelerated growth of these tumors during the luteal phase of the menstrual cycle and during
pregnancy [3]. There may also be an increased incidence of meningiomas in women with breast
cancer, although one study contests this relationship. A large number of studies have examined
the role of androgen, estrogen and progesterone receptors in meningiomas with most finding
progesterone and androgen receptors in a high proportion and low levels of estrogen receptors
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in a small proportion of meningioma specimens obtained at the time of initial surgery and at
recurrence [4].
1.1.2. Pituitary tumors
Pituitary tumors account for approximately 15% of all primary intracranial neoplasms and
occur in higher frequency in women, mainly in the child-bearing years [4].
The female preponderance of these tumors is due to the increased frequency of prolactinomas
in women in the second and third decades. Women are affected four times as commonly as
men and account for 78% of all prolactinomas [5].
1.2. Cranial metastases
1.2.1. Breast cancer
Breast cancer is the most common malignancy among women in North America accounting
for 27% of all cancers. Approximately 181,000 new cases of breast cancer were diagnosed in
1992 and 46,000 women died from the disease the same year. Neurologic complications occur
in approximately 25% of patients with metastatic breast cancer although autopsy studies have
demonstrated central nervous system involvement in 31-57% of examinations [6,7].
2. Problems in management of brain tumors with pregnancy
2.1. Problems in diagnosis
Symptoms of increased intracranial pressure including headache, nausea and vomiting are
similar to the symptoms of early pregnancy, or pregnancy related hypertensive diseas‐
es(eclampsia or preeclampsia ).
The use of Neuro imaging of the pregnant patient with these symptoms become necessary. In
the first trimester it is preferred to be avoided.the MRI is the procedure of choice as there is no
exposure to ionizing radiation. Although there is no evidence that MRI affects the fetus there
is exposure to powerful electromagnetic fields and this imaging modality should be avoided
if possible in the first trimester.Similarly, there is very little evidence regarding the safety of
the ferromagnetic contrast agent gadolinium and this is not sanctioned for use in pregnancy
and should be avoided if possible. In the patient with rapid neurologic deterioration compu‐
terized tomography (CT) may be necessary. This does involve radiation exposure of approx‐
imately 2.5 to 3 rads to the head of the patient and a fetal exposure estimated to be
approximately 1 mrad or less per slice which can be reduced by appropriate shielding of the
uterus with a lead apron. [9] At fetal exposures less than 10 rads no adverse effects in excess
of the background rate of spontaneous abnormalities in 3% of livebirths and the spontaneous
abortion rate of 30% in all pregnancies. Medically indicated exposures of up to 5 rads are
considered acceptable in pregnancy when unavoidable. There has been limited experience
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with the use of iodinated contrast agents during pregnancy and the risks are not precisely
defined. Such agents should be avoided in the first trimester.
2.2. Problems during treatment
Treatment of brain tumors or their complications may be necessary during pregnancy. Cere‐
bral edema and increased intracranial pressure may require the use of glucocorticoids and
mannitol. Glucocorticoids have been used during pregnancy for other reasons including the
prevention of neonatal respiratory distress syndrome and there is no evidence of growth,
physical, motor or developmental deficiencies within the first three years of life. However,
fetal adrenal suppression may occur with long-term, high dose therapy during any part of
pregnancy and necessitates the use of supplemental steroids in the peri-partum period. Al‐
though mannitol does cross the placenta and is excreted by the fetal kidney into the amniotic
fluid no adverse effects have been reported [10].
Cranial irradiation exposes the fetus to higher doses of radiation than diagnostic imaging. In
general, radiation exposure in utero carries a risk of adverse fetal outcomes including spon‐
taneous abortion, anatomic malformation, growth and mental retardation and possibly child‐
hood cancer with the latter risk highest in the first trimester The exposure to the fetus from
scatter is low when conventional radiation therapy is delivered to parts distant from the uterus
and such exposure carries low risk. Strategies to reduce fetal exposure include the use of focal
rather than whole brain irradiation, radiation dose reduction, substitution of heavy charged
particles for photons and deferring radiation until after delivery [11].
Chemotherapy typically involves agents which are teratogenic in the first trimester and asso‐
ciated with adverse fetal outcomes. Properties of chemotherapeutic agents which improve
permeability across the blood brain barrier also facilitate transport across the placenta making
these drugs especially hazardous. Although there is data to suggest that certain chemothera‐
peutic agents are associated with minimal risk in the second and third trimesters, chemother‐
apy for malignant brain tumors should be avoided during pregnancy. Meningiomas are
tumors that are thought to arise from meningothelial cells which make up the arachnoid villi
of the meninges. These lesions account for approximately 20% of all intracranial and 25% of
all intraspinal tumors and the incidence increases with age [11].
2.3. Problems during anesthesia for brain tumor surgery
Altered maternal physiology.
Respiratory system and acid-base balance changes
a. Alveolar ventilation increases 25% by the fourth month of gestation and 45% to 70% by
term. This results in a chronic respiratory alkalosis, with a Paco2 of 28 to 32 mm Hg, a
slightly alkaline pH (e.g., approximately 7.44), and decreased levels of bicarbonate and
buffer base.
b. oxygen consumption increases during gestation, Pao2 usually increases slightly or re‐
mains within the normal range.
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c. Functional residual capacity (FRC) decreases by approximately 20% as the uterus ex‐
pands, which results in decreased oxygen reserve and the potential for airway closure.
d. obesity; perioperative intraabdominal distention; placement of the patient in the supine,
Trendelenburg, or lithotomy positions), airway closure may be sufficient to cause hypo‐
xemia
e. Failed intubation (which is the leading cause of maternal death from anesthesia) is as much
a risk during nonobstetric surgery as it is during cesarean section.
f. rapid development of hypoxemia and acidosis during periods of hypoventilation or apnea
due to decreased FRC, increased oxygen consumption, and diminished buffering capaci‐
ty.
g. induction of general anesthesia occurs more rapidly during pregnancy, because alveolar
hyperventilation and a decreased FRC allow faster equilibration of inhaled agents.
h. Acceleration in the induction of anesthesia is the approximately 30% decrease in the min‐
imum alveolar concentration (MAC) for volatile anesthetic agents that occurs even during
early gestation.
Cardiovascular system changes
a. Cardiac output increases by 30% to 50% during pregnancy because of increases in heart
rate and stroke volume; both systemic and pulmonary vascular resistance decrease.
b. By eight weeks' gestation, 57% of the increase in cardiac output, 78% of the increase in
stroke volume, and 90% of the decrease in systemic vascular resistance that typically are
achieved by 24 weeks' gestation.
c. During the second half of gestation, the weight of the uterus compresses the inferior vena
cava when the mother lies supine; this decreases venous return and cardiac output by
approximately 25% to 30%.
d. Although upper extremity blood pressure may be maintained by compensatory vasocon‐
striction and tachycardia, uteroplacental perfusion is jeopardized whenever the mother
lies supine.
e. Frank hypotension also can occur in the supine parturient, especially when regional or
general anesthesia attenuates or abolishes normal compensatory mechanisms. is essential
to displace the uterus laterally during any operation performed after the twentieth week
of pregnancy.
Factors that can alter uteroplacental blood flow
1. Uterine Contraction
2. Decreased Uterine Blood Flow
3. Pathological Conditions
4. Pharmacological Agents
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Intravenous induction agents
5. Inhalation agents (Desflurane and sevoflurane)
6. Antihypertensive agents
7. b-adrenergic blocking drugs
8. Tocolytic drugs
9. Epidural and subarachnoid opiates
10. Local anesthetics
11. Pharmacological agent added to the local anesthetic
12. Vasopressors
Maintenance of uteroplacental blood flow is the hallmark for fetal well-being; hence an in-
depth knowledge of this subjectis essential for individuals taking care of pregnant women.
Uterine blood flow is determined by the equation.Hence any condition that will significantly
decrease mean [14,15]
Uterine arterial pressure – Uterine venous pressure
Uterine vascular resistance
(1)
So  when  maternal  arterial  pressure  decreases  or  significantly  increase  uterine  vascular
resistance  will  decrease  utero  placental  blood  flow  and,  ultimately,  umbilical  blood
flow.At term, 10% of the cardiac output (700 mL/min) supplies the uterus. The placental
vasculature remains maximally [16,17,18].
Changes in blood volume and blood constituents
• Blood volume expands in the first trimester and increases 30% to 45% by term. A smaller
increase in red blood cell volume than in plasma volume results in a dilutional anemia.
• moderate blood loss is well tolerated during pregnancy, preexisting anemia decreases the
patient's reserve when significant hemorrhage occurs. Fresh blood transfusion is needed to
compensate blood loss during brain tumor surgery [18].
• Pregnancy induces a hypercoagulable state, with increases in fibrinogen; factors VII, VIII,
X, and XII; and fibrin degradation products. Pregnancy is associated with enhanced platelet
turnover, clotting, and fibrinolysis, and there is a wide range in the normal platelet count;
thus pregnancy represents a state of accelerated but compensated intravascular coagulation.
During the postoperative period, pregnant surgical patients are at high risk for throm‐
boembolic complications.
• It is great challenge to Induce hypotensive technique and to maintain the placental perfusion
pressure [19].
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• Incompetence of the lower esophageal sphincter and distortion of gastric and pyloric anat‐
omy result in an increased risk of esophageal reflux and aspiration pneumonitis.
• It seems prudent to consider any pregnant patient at risk for aspiration after 18 to 20 weeks'
gestation.
• Rapid sequence induction to avoid aspiration and deep anesthesia to prevent increase in
the intracranial pressure during brain tumor surgery is another problem.
• preoperative antiacid,sodium citreate, meteclopramid,muscle relaxant as rocuronium.
• complete recovery is needed before extubation.
Altered Responses to Anesthesia
• The decrease in MAC for inhaled anesthetic agents,
• thiopental requirements begin to decrease early in pregnancy.
• Plasma cholinesterase levels decrease by approximately 25% from early in pregnancy until
the seventh postpartum day. Cautions in use of remifentanil and succinylcholine.
• The anesthesiologist should monitor neuromuscular blockade with a nerve stimulator to ensure
adequate reversal before extubation.
• Decreased protein binding associated with low albumin concentrations during pregnancy
may result in a greater fraction of unbound drug, with the potential for greater drug toxicity
during pregnancy.
• Antiepileptic drugs as Carbamazepine and, Phenytoin may potentiate effects of anesthestic
drug used [20,21,22].
Risk of teratogenicity
• Teratogenicity has been defined as any significant postnatal change in function or form in an
offspring after prenatal treatment. Concern about the potential harmful effects of anesthetic
agents stems from their known effects on mammalian cells. These occur at clinical concen‐
trations and include reversible decreases in cell motility, prolongation of DNA synthesis,
and inhibition of cell division.Despite these theoretical concerns, no data specifically link
any of these cellular events with teratogenic changes.
Anticonvulsants
• All anticonvulsants cross the placenta. Pregnant women with epilepsy who ingest anticon‐
vulsant drugs have a fetal congenital anomaly rate of 4% to 8%, which is higher than the 2%
to 3% background incidence quoted for the general population.
• Carbamazepine
• Phenobarbital is used in the treatment of partial and generalized tonic-clonic seizures and
status epilepticus
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• Valproic acid (Depakene, Depakote) is used to treat absence and generalized tonic-clonic
seizures [23,24,25].
Tranquilizers
Some studies have suggested that first-trimester exposure to diazepam increases the risk of
cleft lip.
Lithium
In the International Registry of Lithium Babies, (11.5%) of 217 infants exposed to lithium
during the first trimester of pregnancy were malformed.Eighteen infants had cardiovascu‐
lar anomalies.
Antidepressants
The selective serotonin reuptake inhibitors include sertraline (Zoloft), paroxetine (Paxil),
fluoxetine (Prozac), and citalopram (Celexa). No increased risk of major malformations or
developmental (language and behavior) abnormalities has been identified.
Nitrous oxide
In vivo and embryo culture studies in rats have confirmed that nitrous oxide produces several
adverse reproductive effects, each of which results from exposure at a specific period of sus‐
ceptibility [21].
Use  of  electronic  fetal  monitoring  for  assessing  fetal  well-being  has  become  universal,
used by both physicians and nurses. Monitoring the fetal heart rate is used to determine
adequate cerebral oxygenation of the fetus. As the brain modulates the heart, a decrease
in fetal heart rate is believed to reflect inadequate fetal cerebral oxygenation.External fetal
heart  ratemonitors  use  a  Doppler  detective  device  with  computerized  logic  to  inter‐
pret,and  count  the  Doppler  signals,whereas  internal  fetal  heart  rate  monitors  involve
placement  of  an  electrodeon the  fetal  scalp.  The presenceof  fetal  heart  tones  as  well  as
their  rate  and rhythm are  well-recognized indicators  of  fetal  well-being.  A normal  fetal
heart rate tracing reveals a rate of 110–160 beats/min with minimal to moderate beat-to-
beat variability with or without accelerations. Apretermfetus is expected to have a more
rapid rate with little or no beat-to-beat variabilityand no accelerations (an increasein fetal
heart rate over baseline, usually occurring with fetal movement.
The goal of antepartum fetal surveillance is to document fetal wellbeing,allowing the preg‐
nancy to continue without concern for fetal death.Several antepartum techniques in use in‐
clude fetal movement, nonstress test, contraction stress test, biophysical profile, and umbilical
artery Dopplerflow velocimetry [26,27,,28,29,30]
Prevention of preterm labor
Fetal movement is the easiest means for documenting fetal well-being. The mother can perceive
fetal movements,which serve as a basis for assessment.A diminution in the perception of fetal
movement often precedes fetal death. Perception of 10 distinct movements in a period of up
to 2 hours is considered reassuring. Heart rate reactivity is thought to be a good indicator of
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normal fetal autonomic function. Loss of reactivity is associated most commonly with fetal
sleep but also may result from any central nervous system depression. A nonstress test involves
connecting themother to the fetal heart rate monitor and observing. Non stress test results can
be categorized as reactive or nonreactive.
The non stress test is considered reactive (normal) if two or more fetal heart rate accelerations
are observed within a 20-minute period. The non stress test is considered nonreactive when no
accelerations are observed [32,33]
Guidelines for the management of preterm delivery.
• Confirm diagnosis of preterm labor
• Exclude contraindications to expectant management and/or tocolysis
• Administer corticosteroids, if indicated
• Group B Streptococcus chemoprophylaxis, if indicated
• Pharmacologic tocolysis
• Consider transfer to tertiary care center
There is increased incidence of abortion and preterm delivery. volatile halogenated agents
depress myometrial irritability The prophylactic use of tocolytic agents is controversial; they
are not without risk, and it is unclear whether they affect outcome. Selective administration to
those patients at greatest risk (e.g., those undergoing cervical cerclage) has been suggested
[34,35].
Anesthetic management
1. Unlike other operations wherein thepatient is primarily concerned with him or herself,
the pregnant woman usually is concerned for her baby’swelfare.
2. The anesthesia provider must beaware of the various physiologic changes of pregnancy
and incorporatethem into the anesthetic plan.
3. These physiologic changes have implications for various diseases and must be considered.
4. The central nervous system effect of pregnancy include a reduced local anesthetic re‐
quirement when these agents are given intrathecally or epidurally.
5. Pregnant patients are at increased risk for aspiration during general anesthesia.
6. There is some suggestion that surgery during the first trimester is linked to central nervous
defectsduring surgery.
7. Fetal heart rate monitoring is possible during some surgical procedures but is not uni‐
versally used in theUnited States.
8. Preterm delivery remains the leading cause of perinatal morbidity and mortality in the
United States. Preterm labor is difficult to control with medication; the most promising
medications are the calcium channel-blocking drugs. Magnesium sulfate is frequently
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used and is associated with prolonged depolarizing and nondepolarizing neuromuscu‐
larblockade.
9. The etiology of preeclampsia remains to be elucidated but is believedto be triggered by a
paternal antigen in a susceptible mother.
10. Magnesium sulfate is the most effective medication for the prevention of seizures in
women with preeclampsia.
11. Labetalol is the preferred medicationfor the control of blood pressure in mothers with
preeclampsia.
12. The two causes of antepartum hemorrhage are placenta previa and placental abruption.
Associated with the increase in cesarean sections isa high risk of placenta accreta in pa‐
tients with placenta previa.
13. Perinatal transmission of HIV is low if the viral load is <1,000 copies/mL, and patients
with these levels do not require cesarean section. If theviral load is greater, cesarean sec‐
tion may decrease the risk of perinatal transmission [36,37].
3. Preoperative management
Premedication may be necessary to allay maternal anxiety. Precautions against acid aspiration
should include administration of an H2-receptor antagonist and 30 mL of a clear antacid before
the induction of anesthesia.
4. Choice of anesthesia
The choice of anesthesia should be guided by maternal indications and should take into con‐
sideration the site and the nature of the surgery. No study has correlated improved fetal out‐
come with any anesthetic technique. When possible, local or regional anesthesia (with the
exception of paracervical block) is preferred; this permits the administration of drugs with no
laboratory or clinical evidence of teratogenesis. In addition, maternal respiratory complica‐
tions occur less frequently with local and regional anesthetic techniques. These techniques are
suitable for cases involving cervical cerclage, urologic or lower extremity procedures, and
operations on the arm or hand. Most abdominal operations require general anesthesia, because
the incision typically extends to the upper abdomen, which creates an unacceptable risk of
aspiration in a pregnant patient with an unprotected airway [38,39].
5. Prevention of aortocaval compression
Beginning at 18 to 20 weeks' gestation, the pregnant patient should be transported on her side,
and the uterus should be displaced leftward when she is positioned on the operating table.
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Maternal monitoring should include noninvasive or direct blood pressure measurement, elec‐
trocardiography, pulse oximetry, capnography, temperature monitoring, and the use of a
nerve stimulator. The FHR and uterine activity should be monitored both during and after
surgery when technically feasible.
7. Anesthetic technique
General anesthesia mandates endotracheal intubation beginning at approximately 18 to 20
weeks' gestation or earlier if gastrointestinal function is abnormal. Denitrogenation (i.e., pre‐
oxygenation) should precede the application of cricoid pressure, rapid-sequence induction,
and endotracheal intubation. Drugs with a history of safe use during pregnancy include thi‐
opental, morphine, meperidine, fentanyl, succinylcholine, and most of the nondepolarizing
muscle relaxants. Many obstetric anesthesiologists would now add propofol to the list of “safe”
drugs for use during pregnancy.
A commonly used technique employs a high concentration of oxygen, a muscle relaxant, and
an opioid and/or a moderate concentration of a volatile halogenated agent. Scientific evidence
does not support avoiding nitrous oxide during pregnancy, particularly after the sixth week
of gestation. Omission of nitrous oxide may increase fetal risk if inadequate anesthesia results
or if a high dose of a volatile agent results in maternal hypotension. A cautious approach would
restrict nitrous oxide administration to a concentration of 50% or less and would limit its use
in extremely long operations. Hyperventilation should be avoided; rather, end-tidal CO2
should be maintained in the normal range for pregnancy.
Before the administration of spinal or epidural anesthesia, rapid intravenous infusion of 1 L
of crystalloid seems prudent, although the anesthesiologist should not assume that this will
prevent maternal hypotension. Appropriate vasopressors should be available to treat hypo‐
tension if it occurs. The usual precautions must be taken to guard against a high block and
systemic local anesthetic toxicity.
Regardless of the technique used, avoidance of hypoxemia, hypotension, acidosis, and hyper‐
ventilation are the most critical elements of anesthetic management.
8. Postoperative management
8.1. Postoperative management
The FHR and uterine activity should be monitored during recovery from anesthesia. Adequate
analgesia should be obtained with systemic or spinal opioids. Prophylaxis against venous
thrombosis should be considered [38,39,40,41].
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Case study:
• Pregnant woman 30 weeks of pregnancy, she was complained from multiple menegiomas,
conservative treatment was used throughout pregnancy period. this patient developed sev‐
er continuous vomiting,and rapid deterioration of nutritional status,neuro surgery team
decided urgent operation for decompression of the brain, the patient was referred for ob‐
stetric,and anesthesia consultant.
• Anesthesia examination revealed that :
Patient 35 years old 65 Kg, this the first baby,she complained from infertility for 15 years,she
was hypertensive 150/90 on aldomit.anticovasant drugs was admintsred,liver enzymes was 2
folds,albumen was 2,5, prothrombin was 65% kidney function within normal range. Hb was
6,5gm/dl, Obesteric examination revealed that baby nearly mature,his weigt is under weight.
• Preoperative preparation:
Anesthesia consultant recommended blood transfusion for 4 units of packed RBCs,4 units of
human albumen, 4 units of fresh plasma 2 days before surgery. Preparations of another for
units of fresh blood were for intraoperative losses Preoperative antacid was administered.
Obstetric Preparations was for urgent cesarean section. Pediatric preparing to receive the pre‐
mature neonate if urgent cesarean section was needed
• Anesthesia management:
• Monitoring:
Invasive blood pressure, ECG,endtidal CO2,pulse oximetry, uterine contraction monitor, fetal
Doppler. Postioning: Supine with left lateral tilt,
8.2. Induction of anesthesia
3-5 mg/kg sodium thiopental, rocuronium 04 meg/kg, fentanyl 1mg/kg. Intubation by rapid
sequence, the precautions mentioned above were considered
The operation was long 5 hours, blood loss was replaced, fetal heart was declined at third
hour,urgent cesarean section was done,the pediatric consultant intubated the neonate,and he
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1. Introduction
Surgical management of the orbital and of maxillo-ethmoidal complex disorders is usually
performed in patients with trauma, inflammation and/or neoplasms. Depending on the des‐
tructed craniofacial region rhinotomy, sinusotomy, orbitotomy, maxillectomy and other
types of operations are performed. In case of skull base extension the situation becomes
more complicated leading to the necessity of co-operation of several specialists as well as
modifications of surgical technique. Surgical procedures on eyeball are undertaken mainly
by opthalmologists,but no particular specialty has been yet dedicated for surgical treatment
of other orbital regions. However, an attempt is made by surgeons, such as maxillo-facial
surgeons, ENT surgeons, neurosurgeons, trauma surgeons, oncologic surgeons and rarely
opthalmologists. Patients, in whom operation is performed, are ‘border-line‘ patients and
the anatomical structures that are traumatised belong topographically to above specialties. It
is very uncommon that there is an interdisciplinary team of surgeons available permanently
in hospital to treat the described cases.
In the chapter the authors present as follows: interdisciplinary surgical management of orbi‐
tal region and anterior cranial fossa, then maxillo-ethmoidal complex and anterior cranial
fossa. Additionally, diagnostic problems and treatment of traumas and inflammatory dis‐
eases of the pterygopalatine fossa and infratemporal fossa with their histo-clinical character‐
istics are thoroughly described (Fig.1-2). According to nosologic classification epidemiology,
etiology, diagnosis and surgical techniques including own modifications and clinical results,
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especially in reference to neoplastic tumors is elaborated in both subsections. An integral
part of the chapter consists of histo-clinical characteristic of the tumors of described region.
A separate subdivision is dedicated to orbital complications and of anterior cranial fossa in
the course of pansinusitis. Blow - out fracture is also mentioned in the chapter.
Figure 1. Massive inflammatory infiltration in maxillar sinus, ethmoidal sinus, frontal sinus with extension to anterior
cranial fossa – MRI scan (own archives)
Figure 2. Malignant neoplasm of the orbit with extension to infratemporal fossa CT scan (own archives)
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2. Epidemiology
Nowadays, pansinusitis is one of the most common diseases that occurs almost as often as
arthritis and high blood preassure. Morbidity of chronic pansinusitis is 10,9% (according to
Hastan D et al. ).
Traumas and intoxications are the third causes of deaths in Poland. Higher mortality
present cardiovascular diseases and neoplasms. Traumas of head and neck are responsible
for 60-72% of multi-organ traumas. They usually affect elderly men. They occur mainly due
to collapses and accidents.
According to Szyfter et al. 3% of head and neck neoplasms and 05% of all neoplasms is lo‐
calized in maxillo-ethmoidal complex. They occur mainly in men, in their 60s-80s. They in‐
filtrate maxillar sinus in 50-70% of cases, nasal cavity in 15-30 and ethmoidal sinus in
10-20%. According to anatomical topography and terminology neoplasms of maxillo-eth‐
moidal complex and orbit with skull base extension expand in the region above Ohngren’s
plane that divides the maxillary sinus into an anterior-inferior part and superior-posterior.
Tumors that arise in the first part have better prognosis.
3. Diagnostic methods
Diagnosis of traumas, inflammatory diseases and carcinomas of the described region has to
be very precise in order to use appropriate surgical approach. Apart from basic diagnostic
methods such as thorough anamnesis and examination, the authors emphasise a great role
of nasal and nasopharyngeal endoscopy perfectly suited for the assessment of inflammatory
and tumor penetration of nasal cavity and paranasal sinuses. However, in terms of carcino‐
mas of orbit and the maxillo-ethmoidal complex with skull base penetration it is recom‐
mended to use imaging techniques that improve both the preclinical research and clinical
treatment, such as computed tomography (CT), magnetic resonance imaging (MRI), posi‐
tron emission tomography (PET) and ultrasound imaging. Recently various modalities of
these techniques have been introduced to investigate the progression and treatment results
of brain tumors. Among them we can name CT three-dimensional reconstruction, electron
beam CT, dynamic CT enhancement, CT angiography, CT perfusion enhancement, high-re‐
slution computed tomography (HRCT), diffusion-weighted imaging (DWI-MR), diffusion
tensor imaging (DTI-MR) and many others. However, due to financial reasons conventional
CT and MRI remains the most common diagnostic imaging method in the management of
diseases of the described region.
Also, the authors focus on a great role of fine-needle biopsy as a determinant in diagnosis of
orbital neoplasms and of infratemporal fossa. It has been found that histological types of
maxillo-ethmoidal complex including pterygopalatine fossa and infratemporal fossa are as
follows: pseudotumor, angioma, lymphoma, malignant epithelial neoplasms, neuromas and
neurofibromas. Histological classification of intraorbital tumors has been thoroughly descri‐
bed by Handerson.
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Histopathological results of biopsied tumors are essential for the following treatment, espe‐
cially surgical management.
3.1. Fine-needle aspiration biopsy of orbital tumors
Fine-needle  aspiration biopsy of  orbital  tumors  verifies  whether  the  tumor is  neoplastic
or  non-neoplastic  as  well  as  it  gives  information  about  its  malignancy.  The  most  com‐
mon orbital  tumors  are  pseudotumors.  The possibility  to  perform a  biopsy depends on
the localization of a tumor. In case of meningiomas localized in orbital  conus in patient
with good vision biopsy should be avoided due to the risk of damaging the optic nerve.
Also,  biopsy  of  cavernous  hemangioma  might  develop  complications  such  as  bleeding
and even haemorrhage.
A 25G hollow needle (length- 25 or 40mm)is used in fine-needle biopsy. The place of its in‐
sertion into the examined mass is verified with palpatation. The insertion is carried out
through the skin of eyelids without local anaesthesia. In case of impalpable tumors CT or
MRI is used and the needle is continuously inserted until the resistance.
The consistence od most orbital tumors is solid. In case of cyst there is a liquid found and in
teratomas – sebaceous masses.
The authors emphasise that diagnostic results obtained by fine-needle aspiration biopsy are
not unequivocal and in lymphomas immunohistochemical examination is essential.
Also, it is worth mentioning that the described diagnostic methods are limited by ‘diagnos‐
tic window’ (short time in traumas, more time in inflammatory diseases and neoplasms).
4. Surgical management
Surgical treatment in cases of trauma of craniofacial region, pterygopalatine fossa and infra‐
temporal fossa is undertaken using an approach that gives access to damaged structures
4.1. Common approaches
There are several approaches performed in the operation of described regions that are com‐
monly used. Depending on the main disease (trauma, inflammation, primary tumor, meta‐
stases) and the operated area (nasal cavity, paranasal sinuses, pterygopalatine fossa,
infratemporal fossa) we can name different types of rhinotomy, orbitotomy,sinusotomy,
maxillectomy and craniotomy (Fig.3).
Rhinotomy  enables  an  approach to  nasal  cavity,  ethmoidal  sinuses,  maxillar  sinuses  as
well  as  nasopharynx.  The  first  lateral  rhinotomy  incision  was  introduced  by  Moure  in
1902 (Fig.4).
Since than some other scientist has improved the method, for instance Weber-Ferguson,
whose incision and extensions enable medial maxillectomy(Fig.5-6), sometimes with orbital
exenteration.
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Figure 3. Possible surgical approaches in primary tumors of different regions with skull base penetration
Figure 4. Lateral rhinotomy- Moure’s approach (the line indicates skin incision)
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Figure 5. Weber-Ferguson incision. Lateral rhinotomy with inferior extension (the line indicates skin incision).
Figure 6. Weber-Ferguson incision. Lateral rhinotomy with superior extension (the line indicates skin incision).
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Bechara Y. Ghorayeb has gone further, modifying Weber-Ferguson’s incision. Namely, he
created a V-shaped flap above the medial canthus in order to prevent scar retraction (Fig.7)
Figure 7. Modification of Weber-Ferguson insicion- by Bechara Y. Ghorayeb (the line indicates skin incision).
Common approaches to maxillar sinus include:
• Caldwell – Luc approach in fossa canina
• Denker’s operation of maxillar sinus with resection of the anterior wall of maxillar sinus
and lateral wall of the nasal cavity
In middle 80s of the twentieth century transcaruncular orbitotomy was performed at UCLA
University and it is known as Baylis’s approach. Later, Lynch described his medial orbitoto‐
my (Fig. 8), which gives access to medio-superior part of the orbit and ethmoidal sinus and
sphenoid sinus. Among other orbitotomies there is an anterior orbitotomy (Fig.9), lateral or‐
bitotomy by Kroenlein-Reese-Berke (Fig.10-11) and posterior inferior orbitotomy, in which
the technique is carried out through a standard Caldwell-Luc approach through the maxil‐
lary sinus. The posterior inferior orbital wall is removed and the inferior rectus is retracted
either laterally or medially to gain access to the tumor, which is removed microsurgically.
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Figure 8. Lynch’s medial orbitotomy (the line indicates skin incision)
Figure 9. Anterior orbitotomy – incision in supracilial line (the line indicates skin incision)
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In case of orbitotomy with bone removal, it is worth mentioning the names of particular op‐
eration, depending on the bone removed:
• Naffziger – removal of superior orbital wall
• Sewell – removal of medial orbital wall (ethmoidal sinus)
• Hirsch – removal of inferior orbital wall
• Kroenlein – removal of lateral orbital wall
Figure 10. Kroenlein- Reese-Berke lateral orbitotomy (the line indicates skin incision).
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Figure 11. Lateral Kroenlein – Roose - Berke oribtotomy. Lipoma (own archives).
As far as operations on frontal sinus are concerned, it is essential to mention Kuemmel-Beck
frontal trephine, which provides diagnostic information about the contents of the sinus and
the function of the ostium.However, nowadays there are more and more endoscopic opera‐
tions on the frontal sinus.
More complicated operations that provide wide access to nasal cavities, inferior and medial
part of maxilla, infratemporal fossa and pterygopalatine fossa include midfacial degloving
and cranio-facial resection. While midfacial degloving leaves no scars, cranio-facial resec‐
tion gives wider access to upper parts of nasal cavity, frontal sinus and skull base and it is
usually performed by a team of ENT surgeons and neurosurgeons. If the orbit is involved
orbital exenteration is carried out.
Surgical procedures are the basic method of treatment of tumors of anterior cranial fossa.
This kind of surgical management is usually performed by a team of both ENT surgeons
and neurosurgeons and the common approaches can be divided into extracranial, intracra‐
nial and endoscopic. Among intracranial approaches, transcranial-transbasal one should be
mentioned. It is a frontal craniotomy which gives access to tumors of ethmoidal sinuses in‐
filtrating skull base and sphenoid sinus as well as clival tumors. Subcranial approach is a
modification of this technique. Apart from common orbitotomies we also have orbito-tem‐
poral and orbito-zygomatic approaches. Extracranial approaches are usually transshenoidal.
A separate group of operations on anterior cranial fossa is created by a combination of the
two approaches- extra-and intracranial (known as cranio-facial resection= anterior fossa cra‐
nio-facial resection – AFCFR).
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4.2. Own modifications of common approaches
Surgical treatment in cases of trauma of craniofacial region, pterygopalatine fossa and infra‐
temporal fossa is performed with an approach that gives access to damaged structures. Pre‐
sented surgical procedures are performed with internal approaches due to extensive
character of inflammation/neoplasm. Therefore endoscopic techniques dedicated for limited
diseases are not elaborated in the chapter.
In case of tumors, the resection is conditioned by clinical staging- from endoscopic endonas‐
al tumorectomy, through endoscopic surgery of orbit and pterygopalatine fossa up to ad‐
vanced resections like own modification of “scalp” approach to half of viscerocranium
(lateral rhinotomy+ superior/inferior orbitotomy + Fairbanks- Barbosa’s approach) (Case.1-
Fig.12-16, Case.2 –Fig. 17-20, Case 3 – Fig. 21-23).
Figure 12. Case 1. Massive orbital carcinoma with co-existing active tuberculosis. (The photo was taken on patient’s
agreement)
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Figure 13. Case 1. Massive orbital carcinoma with co-existing active tuberculosis –preoperative CT scan.
Figure 14. Case 1. Massive orbital carcinoma with co-existing active tuberculosis– preoperative CT scan.
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Figure 15. Case 1. Massive orbital carcinoma with co-existing active tuberculosis– intraoperative view. Lateral rhinoto‐
my + superior orbitotomy + subfrontal approach (The photo was taken on patient’s agreement).
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Figure 14. Case 1. Massive orbital carcinoma with co-existing active tuberculosis– preoperative CT scan.
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Figure 16. Case 1. Massive orbital carcinoma with co-existing active tuberculosis– postperative CT scan.
Figure 17. Case 2. Incission line (lateral rhinotomy+ infrerior orbitotomy + Fairbanks- Barbosa’s approach)of modified
approach to massive carcinoma of maxillo-ethmoidal complex – pre-operative image (The photo was taken on pa‐
tient’s agreement).
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Figure 18. Case 2. Incission line of modified approach to massive carcinoma of maxillo-ethmoidal complex – intero‐
perative image
Figure 19. Case 2. Incission line (lateral rhinotomy+ infrerior orbitotomy + Fairbanks- Barbosa’s approach)of modified
approach to massive carcinoma of maxillo-ethmoidal complex – interoperative image
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Figure 18. Case 2. Incission line of modified approach to massive carcinoma of maxillo-ethmoidal complex – intero‐
perative image
Figure 19. Case 2. Incission line (lateral rhinotomy+ infrerior orbitotomy + Fairbanks- Barbosa’s approach)of modified
approach to massive carcinoma of maxillo-ethmoidal complex – interoperative image
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Figure 20. Case 2. Incission line (lateral rhinotomy+ infrerior orbitotomy + Fairbanks- Barbosa’s approach)of modified
approach to massive carcinoma of maxillo-ethmoidal complex – interoperative image. The surgical tool indicated neo‐
plastic tissue.
Figure 21. Case 3.Incission line of modified approach to massive carcinoma of maxillo-ethmoidal complex – post-op‐
erative image (The photo was taken on patient’s agreement).
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Figure 22. Case 3.Incission line of modified approach to massive carcinoma of maxillo-ethmoidal complex – post-op‐
erative image (The photo was taken on patient’s agreement)
Figure 23. Case 3 - Intraoperative image (own archives)
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Figure 20. Case 2. Incission line (lateral rhinotomy+ infrerior orbitotomy + Fairbanks- Barbosa’s approach)of modified
approach to massive carcinoma of maxillo-ethmoidal complex – interoperative image. The surgical tool indicated neo‐
plastic tissue.
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Figure 22. Case 3.Incission line of modified approach to massive carcinoma of maxillo-ethmoidal complex – post-op‐
erative image (The photo was taken on patient’s agreement)
Figure 23. Case 3 - Intraoperative image (own archives)
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In order to receive access to maxillo-ethmoidal complex and frontal sinus as well as anterior cra‐
nial fossa lateral rhinotomy combined with Uffenorde’s approach can be performed (Fig. 24-25)
Figure 24. Case 4. Lateral rhinotomy + Uffenorde scission line- intraoperative image (own archives).
Figure 25. Case 4. Lateral rhinotomy + Uffenorde section line – intraoperative image. Pus in frontal sinus. (own archives).
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Another modification, such as Fairbanks-Barbossa’s approach and lateral pharyngotomy
can be used in order to perform surgical management of pathologies localized in the inferior
part of Ohrngren’s plane (Fig.26-28)
Figure 26. Case 5. A preoperative MRI scan showing tumour mass in left parapharyngeal region with pterygopalatine fos‐
sa and skull base penetration. Tumour reaches the level of lower wall of left maxillary sinus and infratemporal region.
Figure 27. Case 5. A preoperative MRI scan showing a substantial mass effect – tumour mass bulges towards naso‐
pharynx and mesopharynx causing compression and displacement of those structures.
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Figure 28. Case 5. A preoperative MRI scan showing tumour mass directly adjacent to the sphenoid bone and left
parotid gland.
4.3. Other surgical aspects
In advanced neoplasms the operation is combined with simultaneous reconstruction of
damaged areas, while in case of residual tissues an implantation of intraoperative applica‐
tors for brachytherapy might be used (Fig.29.). It is also possible to initiate adjuvant radio‐
therapy without reconstructive surgery.
Figure 29. Case 1. Applicators of brachytherapy implanted intraoperatively. Teletherapy was impossible to be per‐
formed due to active tuberculosis. Follow-up- 2,5 years without recurrence.
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However, reconstructive surgery with vascular microanastomosis seems to be the priceless
method of treatment, resulting in good functional and aesthetic effect.
Occasionally, it is essential to obliterate mechanically the vessel providing blood to trau‐
matised region and/or  use  temporary or  permanent  endovascular  embolization (esp.  in‐
ternal  jugular vein) as the first  step of  therapeutic procedure.  A wide drainage to nasal
cavities  is  crucial  for  proper healing of  inflammations or  inflammatory complications of
orbit and pterygopalatine fossa.
Also, the authors indicate that in the described region there is a risk of expanding the neo‐
plastic and/or inflammatory tissue into ‘critical structures’ such as meninges, optic nerve, in‐
ternal carotid artery, facial nerve and sinus cavernosus limits safe course of surgical
procedures. The situation reveals due to natural extension of neoplastic and/or inflammato‐
ry tissue, intraoperative failure or high-dose radiotherapy. The presence of critical structures
limits safe course of surgical procedure.
It  is  also worth mentioning that  in  the course of  chronic  and,  rarely,  acute  pansinusitis
orbital  complications are observed in 3,7-11 % of  all  patients  hospitalized due to pansi‐
nusitis and they are associated with symptoms such as blurred vision, diplopia, deterio‐
ration  of  visual  acuity,  oedema of  palpebra  and oedema of  the  tissues  of  medial  angle
of the eye. In advanced situations exophthalmia may occur. The process can extend into
extraorbital  structures  resulting  in  their  oedema  and  phlegmons  and/or  abscess  of  the
orbit.  HRCT plays  the  greatest  role  in  diagnosis.  Surgical  treatment  consists  of  external
opening  of  many  sinuses  and  excision  of  the  pathological  tissues  in  the  orbit.  Opthal‐
mological  examination with assessment of  visual  acuity,  morphology of  the eyeball  and
possible  damage  of  optical  nerve  is  essential  in  preoperative  diagnosis  of  above  cases.
Optic nerve and sinus cavernosus are ‘critical  structures in surgical  management of this
limited region.
A separate subdivision should be dedicated to blow-out fracture which is an orbital floor
fracture due to blunt trauma of the head. Very fine bones of this region, in case of their frac‐
ture, cause an entrapment of the orbital content (i.e.extraocular muscles, esp.inferior rectus
and inferior oblique) in maxillar sinus. A damage of infraorbital canal with infraorbital
nerve is often observed and in such case numbness in the region of lower eyelid, cheek, lat‐




• pain during eye movement
• limited movements of eyeball
Computed tomography scanning is preferred in diagnosis of blow-out fractures (Fig.30)
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Figure 30. CT scan- blow-out fracture.
In surgical management of blow-out fractures resection of the injured bone is performed by
orbitotomy or an approach through maxillar sinus. Reconstruction consists of autogenic
grafts (fascia, bone graft) or allogenic ones (silicon, Teflon) (Fig.31.)
Figure 31. A- Blow-our fracture- patomechanism, B- bone graft inserted through nasal cavity, C- allogenic graft insert‐
ed subciliarily
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In most cases oculoplastic surgeons will wait 10-14 days following the trauma in order to
enable an associated oedema and/or heamorrage to be absorbed.
5. Results
The results of surgical management of tumors of described region depend on primary clini‐
cal staging assessed with TNM scale, the stage of malignancy, presence of associated disor‐
ders and patient’s age. Survival rates depend on above factors and application of adjuvant
oncologic treatment utilizing teletherapy, brachytherapy, chemical cytoreduction and com‐
bination of suggested methods.
In summary the authors emphasise the necessity of interdisciplinary treatment of orbit and
maxillo-ethmoidal complex.
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1. Introduction
Cancer  is  the  most  frequently  diagnosed disease-related cause  of  death among children
and adolescents [1]. Of all paediatric cancers, those involving the central nervous system
(CNS), and especially the brain, are collectively among the most common, ranking as the
most common solid tumor and either first  or second overall  (second only to leukaemia)
in the United States (USA) [1]- [5], Canada [6], and Mexico [7]. For example, in the USA
in 2004, 555 cases of CNS cancer-related death were confirmed among children, and 566
for leukemia, representing 25.0% and 25.5%, and therefore accounting, between them, for
more than half of the total number of cancer deaths in individuals under age 20 [1]. Sim‐
ilar numbers through 2011 are published in an on-line report of the National Cancer In‐
stitute [5]. Since in excess of 90% of primary CNS cancers in children originate within the
brain [4], from this point onward, this chapter will generally be limited to primary brain
cancers. The American Brain Tumor Association  has claimed that approximately 4,200 chil‐
dren  younger  than  age  20  will  be  diagnosed  with  a  primary  brain  tumor  in  the  year
2012, of whom 3,020 will be under the age of 15 [8].
Survival rates from brain cancer have improved dramatically over the past forty years,
presumably due to a combination of improved treatments and earlier detection [9]. However,
there are concerns that the incidence of brain cancer has increased and/or is destined to increase
due to the emergence of a host of new risk factors with almost universal exposure, especially
in industrialized countries. Among these novel risk factors is the exponentially increasing use
of hand-held electronic devices like cell phones, iPods, iPads and other electronic reading
devices [10]- [12].
But is the incidence of brain cancer really increasing? Is this increase universal or just in certain
countries and regions? Are these new devices playing a role? This chapter reviews the
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descriptive epidemiology of brain cancer in the paediatric age group, specifically looking at
trends over time, followed by an examination of known and suspected risk factors. The first
question is: Is the incidence of brain cancer really increasing?
2. Descriptive epidemiology
2.1. The incidence of paediatric brain cancer: Trends over time
Before discussing its incidence, it is necessary first to define what is meant by paediatric brain
cancer. For the purposes of this chapter, only primary cancers of the brain will be considered,
excluding metastases to brain from other sources, like lung and breast. Brain tumors are quite
heterogeneous, in terms of both their histology and clinical course and prognosis. There also
are exceedingly rare forms that stem from highly specialized cells, in addition to types that are
more common. Most research on brain cancer has focused on the most common, which also
tend to be the most lethal forms.
Cancers involving neurons themselves are quite rare, the majority of brain cancers involving
cells that originate within the glial cell line [4]. Such glial cell cancers include astrocytomas in
all their different forms and grades, from pilocytic astrocytomas to glioblastoma multiforme;
oligodendrogliomas; other gliomas, and ependymomas. Primitive neuroectodermal tumors
(PNET), which arise from primitive neuroectodermal tissues and include medulloblastomas,
are another relatively common brain neoplasm that tends to arise in very young children;
PNET account for approximately 20% of malignant CNS tumors in children [4]. Together,
astrocytomas, oligodendrogliomas and other gliomas, ependymomas, and PNETs account for
roughly 97% of all malignant paediatric brain tumors [4]. All remaining brain tumors are either
very rare, usually benign, or both; and they all are especially uncommon in children. Primary
CNS lymphomas that arise from the cells and tissues that comprise the CNS lymphatic system
comprise one to two percent of all primary brain tumors, with patients whose immunity is
compromised (e.g., AIDS patients and organ transplant recipients) at especially high risk.
Other brain tumors that can be malignant but are usually benign include meningiomas, that
are quite common, and pituitary and pineal tumors, which are much rarer, especially in
children and adolescents. In this chapter, all brain cancers will be discussed; but the majority
of research that has been conducted on risk factors for brain cancer in children has involved
astrocytomas, oligodendrogliomas and other gliomas, ependymomas, and PNETs [4].
Despite  its  obvious  importance  as  a  medical  issue,  publications  on  general  population
studies (as opposed to case-control studies) assessing brain cancer incidence trends over
time, and especially on its incidence in children, have been surprisingly rare. Almost all
published  general  population  data  are  at  least  a  decade  old,  harkening  back  to  a  time
when there  was  considerable  concern that  the  incidence  of  brain  cancer  was  increasing
[4], [13]- [17]. Exceptions are longitudinal studies in the United Kingdom [18] and in In‐
dia [19]. In the USA, between 1973 and 2001, the overall age-adjusted incidence of brain
cancers  was  6.1  cases  per  100,000  person-years,  of  which  roughly  46%  (2.8  cases  per
100,000 person-years)  were the most  malignant  form,  glioblastoma multiforme [13].  The
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incidence  in  children  was  2.5  per  100,000  person-years.  Overall,  brain  cancer  rates  in‐
creased steadily between 1973 and 1987, but then declined steadily afterwards; however,
across  all  ages,  the  incidence  of  glioblastoma  in  2001  was  greater  than  the  mean  inci‐
dence  over  the  28  years  of  observation  (3.0  versus  2.8  per  100,000).  Though  mortality
across all brain cancers declined over the study period, survival did not improve for glio‐
blastomas [13]. Data specifically on US children under age 15 between 1975 and 1995 re‐
veal a clear increase in brain cancer incidence throughout the study period, rising from a
low of under 2.5 per 100,000 person-years in 1975 and 1976 to highs of roughly 3.2 per
100,000  in  1987  and  1993  [4].  Further  analysis  of  this  trend  identified,  rather  than  a
steady increase, a marked ‘jump’ in rate between the periods before and after 1985 [20],
which corresponds to the marked increase in the availability of magnetic resonance imag‐
ing (MRI) for brain cancer detection in the mid 1980s and consistent with the lack of any
significant  increase  in  brain  cancer  mortality  rate  [4].  Interestingly,  the  noted  increase
was site specific,  with incidence more than doubling in the brainstem and increasing by
more than 50% in the cerebrum, but actually declining in the cerebellum and increasing
by a mere 6% across all other sites [20]. Similarly, in the Northeastern U.S., certain brain
cancers  were  noted  to  increase  in  incidence  between  1954  and  1998  more  than  others,
with annual  increases of  1% in pilocytic  astrocytomas,  1% in primitive neuroectodermal
tumors, and 2.3% in miscellaneous gliomas [21].
The Surveillance Epidemiology and End Results database initially was created by the U.S. National
Cancer Institute (NCI) in 1973 as the coalescence of 9 regional cancer registries to generate
epidemiological data on cancer in the U.S. [22] It has since expanded to collect data on a broad
array of cancers from registries representing 26% of the total U.S. population, and data on
specific cancers are available for 1975 through 2009, including brain and other nervous system
cancers [23]. SEER data demonstrate an overall incidence of brain and other nervous system
cancers (invasive) of 5.85 across both sexes and all ages and races in 1975, with subsequent
peak incidences of 6.51 in 1981, 7.05 in 1990, and 6.91 in 1999, with a gradual decline afterwards
to 6.58 in 2009, for an overall incidence over the 35 years of data collection of 6.60 per 100,000
[24], and an average of 6.50 over the five years 2005 through 2009 [25]. Data by age are currently
only listed for 2005 through 2009, and average 3.1 per 100,000 for those 19 and under, versus
19.6 for those 65 and older [25].
In other countries over roughly the same time period, roughly a 25% increase in cancer
incidence was noted in Austria between 1970 and 2002, with mortality from brain cancer
peaking in 2002 [14]; in Brazil between 1980 and 1998, age-adjusted brain cancer mortality rates
across all age groups increased by approximately 50% (from 2.24 to 3.35 105) [16]; in Norway
between 1970 and 1999, the overall rate of brain and CNS tumors increased from 6.49 to 12.02
cases per 100,000 person-years, an 85% increase, with a trend of continuing increase from
1995-1999, especially in children 0-4 years old and in those 60 years and older [17]; and in India
between 1982 and 2003, statistically-significant 3.1 to 4.7% increases in incidence were noted
at three of five major centres (Mumbai, Bangalore and Chennai) for both males and females
across all ages, while incidence remained stable in Delhi and Bhopal [19]. Over a somewhat
earlier period, incidence and mortality from brain cancer rose significantly in Canada between
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1959 and 1987, though this was most marked in elderly males [26], and incidence doubled
between 1948 and 1988 in New Zealand [27].
Contrary to these increases, in the United Kingdom between 1998 and 2007, no significant time
trends were noted in overall incidence of brain cancers for either gender, or for any specific
age group [18]. Site-specific increases were noted for the temporal lobe in men (0.04 new cases
per year) and women (0.02 per year), accompanied by decreases in the rates of cancers
involving the parietal lobe (-0.03 per year), cerebrum (-0.02 per year) and cerebellum (-0.01 per
year), but in men only. The authors conjectured that the observed increase in the rate of
temporal lobe cancers, if caused by mobile phone use, would constitute less than one additional
case per 100,000 people over the observation period.
Consequently, though clear increases in the incidence of brain cancer were evident interna‐
tionally into the 1990s, since that time there appears to have been relative stabilization, at least
in the U.S and the U.K. Unfortunately, a lack of readily-accessible international data over the
past decade precludes any assumptions beyond these two countries.
2.2. Trends in mortality from brain cancer
Brain cancer is the second leading disease-related (non-traumatic) cause of death among
children and adolescents, behind leukemia, generally accounting for between 500 and 600
deaths per year in the USA since the year 2000 [1], [5]. However, in contrast with trends towards
increasing incidence in many populations, overall there has been a decline in mortality from
brain neoplasms over the past three to four decades, and this decline has been relatively
continuous, even over periods of time when incidence has appeared to rise [4], [13], [20], [28].
In the U.S., this trend has been especially evident in children [4], [13], [20], [28], [29], with five-
year relative survival rates from all brain cancers rising in those under age 15 from 59% between
1975 and 1984 to 67% between 1985 and 1994 [4] to over 70% by 2012 [30]. In terms of absolute
numbers, mortality rates from brain malignancies declined from 1.0 per 10 [5] children in the
1970s, to 0.8 per 100,000 children in the 1990s, and then to roughly 0.6 per 100,000 from 2005
through 2009 in the SEER database [25].
Improvements in survival have been observed with certain neoplastic types much more than
others, with survival rates from ependymomas increasing from 39 to 56% and from gliomas
from 46 to 57% between these two time intervals. Overall improvements in survival generally
have not extended to PNETs/medulloblastomas, with survival increasing only 3%, from 52 to
55% between 1975 and 1994 [4]. Nor have significant improvements been noted with glioblas‐
tomas [13], for which 1-year and 5-year survival rates have consistently fallen below thirty-
five and five percent, respectively [4], [13], [31], [32]. Fortunately, as previously stated, children
are much more likely than adults to have low-grade astrocytomas, in particular pilocytic
astrocytomas and other low-grade gliomas that are almost never fatal and often cured,
depending upon their location and surgical accessibility [33]- [35]. They also are far less likely
to have virtually universally-fatal glioblastomas than adults, in whom they are the most
common brain tumor type [8], [35]. Diffuse pontine gliomas, which account for roughly 15%
of paediatric brain malignancies and arise anytime from infancy through adolescence, peaking
in those between the ages of 7 and 9 years old, have a universally dismal prognosis, with
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median survival times of 12 months or less, irrespective of tumor grade; this is because their
diffuse nature renders them unresectable [3] [6], and they tend to be unresponsive to either
radiation or chemotherapy [37], [38].
At all ages, pediatric brain cancer survival rates have typically been much better than for adults
[4], [13], a fact that largely can be explained by the much higher percentage of low-grade
astrocytomas and gliomas, and much lower percentage of high-grade astrocytomas seen in
children [8], [35]. Even among pediatric patients, however, survival rates vary with age, with
older adolescents (ages 15 to 19) generally having fared better than children under age five, in
whom low survival rates are especially noted for ependymomas and PNETs. This has been
true not only in terms of current rates of survival (between 1986 and 1994, overall survival
from all brain cancers was 77% in those 15 to 19 years old, versus just 45% in those under one
year of age, and 59% in those between 1 and 4 years old), but also in terms of improvement in
survival over time [4].
It  must  be  considered,  however,  that  long-term  survival  in  children  with  brain  cancer
does not necessarily equal ‘cure’, and that low-grade neoplasms are not necessarily cura‐
ble.  How children do long-term is  largely dependent  upon the location and size  of  the
tumor,  its  surgical  accessibility,  and  its  potential  for  re-growth  [33],  [34].  For  example,
even low-grade optic gliomas, localized brainstem gliomas, and medulloblastomas might
never be cured, merely because of their location and associated high risks of surgical in‐
tervention. Moreover, even with lesions for which curative surgery is successful,  consid‐
erable  post-operative  morbidity  can result  secondary to  neurological  damage caused by
the tumor,  especially  if  fast  growing,  and to the surgery itself  [33],  [34],  [39].  Radiation
therapy,  classically used to de-bulk brain tumors prior  to attempted resection,  has been
virtually contra-indicated in infants and preschool children, because of the adverse effects
of radiation on the developing brain.
3. Known risk factors
3.1. Demographic variables (age, gender, and race)
Though relatively few data exist specifically addressing the association between various
demographic factors and childhood brain cancers, the overall relationship between brain
cancer incidence and mortality and patient age, gender and race have been well-established
via a number of published studies [4], [13]- [19], [26]- [28], [40]- [42], as well as the SEER
database [22]- [25]. In those under age twenty, age predicts not only overall incidence of and
mortality from brain cancer, but also the incidence of and rate of survival from specific cancer
types, and the risk of cancer at specific brain locations. From 2005 through 2009, the overall
incidence of brain and other nervous system cancers was 3.7 per 100,000 in infants under one
year of age, peaked to 3.9 in those 1 to 4 years old, and then steadily declined to 2.1 per 100,000
in adolescents between 15 and 19 [13], [25]. These numbers parallel earlier figures for 1986
through 1994, when incidence was 3.6 per 100,000 in infants, peaked to almost 4.0 by age 4,
and then steadily declined to under 1.7 per 100,000 by age 19 [4]. In terms of lesion location,
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Though relatively few data exist specifically addressing the association between various
demographic factors and childhood brain cancers, the overall relationship between brain
cancer incidence and mortality and patient age, gender and race have been well-established
via a number of published studies [4], [13]- [19], [26]- [28], [40]- [42], as well as the SEER
database [22]- [25]. In those under age twenty, age predicts not only overall incidence of and
mortality from brain cancer, but also the incidence of and rate of survival from specific cancer
types, and the risk of cancer at specific brain locations. From 2005 through 2009, the overall
incidence of brain and other nervous system cancers was 3.7 per 100,000 in infants under one
year of age, peaked to 3.9 in those 1 to 4 years old, and then steadily declined to 2.1 per 100,000
in adolescents between 15 and 19 [13], [25]. These numbers parallel earlier figures for 1986
through 1994, when incidence was 3.6 per 100,000 in infants, peaked to almost 4.0 by age 4,
and then steadily declined to under 1.7 per 100,000 by age 19 [4]. In terms of lesion location,
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cerebellar lesions were much more common in children nine years old and under, at 0.93 and
0.97 per 100,000 for those under 5 and 5-9 years old, respectively, than in older children, being
just 0.37 per 100,000 in children over 15 [4]. Similar patterns were evident for brain stem lesions
and brain sites other than the brainstem, cerebellum and cerebrum [4]. Cerebral lesions,
however, predominated among those over age 10 (see Figure 1).
Figure 1.
Age also influences the types of brain cancer seen, especially in terms of ependymomas, most
of which initially present in children under five years of age; and PNET, the incidence of which
decreases steadily with age, from over 1.1 per 100,000 in the first year of life to roughly 0.2 per
100,000 in older teens [4]. The relatively poor prognosis of ependymomas and PNET, relative
to the often low-grade gliomas and astrocytomas of childhood and adolescence, result in
higher mortality rates among those under age five in both the U.S. and the U.K. [4], [41]; but
other studies have also noted lower survival rates in younger versus older children with the
same tumor; for example, low-grade astrocytomas [43] and ependymomas [41], [44].
Being male is considered a moderate risk factor for brain cancer. In the SEER database, over
the entire period from 1975 through 2009, the incidence of CNS cancers was 7.90 per 100,000
in males versus 5.55 per 100,000 in females, and this disparity between the two sexes was
evident every year, the rates being 7.72 and 5.60 per 100,000 in 2009 [24]. Over the entire time
period, the incidence in males averaged 42% higher than in females, and this was relatively
consistent. Similar population-based excess in brain cancers among males have been reported
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in Canada [26], the U.K. [18], Norway [17], Austria [14], India [19], New Zealand [27], and in
69 populations from a subset of cancer registries included in the Cancer Incidence in Five
Continents database, in which male/female incidence rate ratios varied by age, but not by World
Area, suggesting that the observed male versus female difference in brain cancer incidence is
biologically based [45]. At least in the U.S. among children, this gender discrepancy largely is
secondary to male predominance in certain neoplasms more than others, especially in
medulloblastomas and ependymomas [4]. To date, however, no clear association between
gender and cancer mortality rates has been established, especially among children.
Another very clear demographic predictor of brain cancer incidence, mortality, and type is
race. Using the SEER database, between 1975 and 2009, whereas the overall incidence of brain
and other nervous system cancers was 7.18 per 100,000 in whites, it was just 4.08 per 100,000
in blacks [24], 43% lower. This discrepancy between the races persists over the most recent 5-
year data block from 2005-2009, in which the rates were 7.1 and 4.0 per 100,000 (44% lower),
respectively [25]. A similar difference is observed for mortality, with mortality rates among
whites and blacks being 4.6 and 2.5 per 100,000 over the same 2005-2009 time period, making
mortality from brain cancer 46% lower in blacks. The incidence of astrocytic glioma and
medulloblastoma are particularly more prevalent in whites than blacks [46]. A similar low rate
of brain cancer and brain cancer mortality, relative to Caucasians, has been identified for
Hispanics and Asians. In California, for example, in data gleaned from the State Cancer
Registry for 1988-1997, the odds of CNS cancer was 0.70 among blacks (i.e., 70% of the rate
among whites), 0.64 among Asians, and 0.57 among Hispanics relative to Whites. [42] Not all
non-Caucasian populations are protected, however. In New Zealand, at least as of 1988, the
native Maori population exhibited a fourfold increase in their incidence of ependymomas
versus Caucasians, as well as a significant overall increase in all brain cancers [27].
3.2. Family history of cancer or other CNS disease
As will be discussed in the next section, there is a clear association between certain familial
syndromes and brain malignancy. Even beyond this, however, studies support an association
between family history and brain cancer, albeit less conclusive than for age, sex and race, and
generally for brain cancers in general and not just pediatric brain cancers. For example, Farwell
and Flannery compared the occurrence of cancer in parents, siblings, and offspring of 643
patients who had had a CNS tumor in childhood, as recorded in the Connecticut Tumor
Registry, with its occurrence among the parents, siblings, and offspring of 360 controls
matched for sex, birth date, and birthplace [47]. Overall cancer incidence was comparable in
the two groups, but 11 CNS tumors were identified in the relatives of cases, versus none in the
relatives of controls (p = 0.0005). The rate hematopoietic-lymphatic system tumors also was
increased (p = 0.003). In addition, nine siblings of cases but only one sibling of a control had
had cancer as a child. Medulloblastoma and glioblastoma multiforme were overrepresented
in the group of children whose relatives had CNS tumors. Overall, a fivefold increase in CNS
or hematopoietic-lymphatic malignancies was identified in cases versus controls.
In another study in which the nationwide Swedish Family-Cancer Database for the years 1958
through 1996 was used to analyze the risk of brain tumors in offspring ages 15-61 and siblings
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the entire period from 1975 through 2009, the incidence of CNS cancers was 7.90 per 100,000
in males versus 5.55 per 100,000 in females, and this disparity between the two sexes was
evident every year, the rates being 7.72 and 5.60 per 100,000 in 2009 [24]. Over the entire time
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and other nervous system cancers was 7.18 per 100,000 in whites, it was just 4.08 per 100,000
in blacks [24], 43% lower. This discrepancy between the races persists over the most recent 5-
year data block from 2005-2009, in which the rates were 7.1 and 4.0 per 100,000 (44% lower),
respectively [25]. A similar difference is observed for mortality, with mortality rates among
whites and blacks being 4.6 and 2.5 per 100,000 over the same 2005-2009 time period, making
mortality from brain cancer 46% lower in blacks. The incidence of astrocytic glioma and
medulloblastoma are particularly more prevalent in whites than blacks [46]. A similar low rate
of brain cancer and brain cancer mortality, relative to Caucasians, has been identified for
Hispanics and Asians. In California, for example, in data gleaned from the State Cancer
Registry for 1988-1997, the odds of CNS cancer was 0.70 among blacks (i.e., 70% of the rate
among whites), 0.64 among Asians, and 0.57 among Hispanics relative to Whites. [42] Not all
non-Caucasian populations are protected, however. In New Zealand, at least as of 1988, the
native Maori population exhibited a fourfold increase in their incidence of ependymomas
versus Caucasians, as well as a significant overall increase in all brain cancers [27].
3.2. Family history of cancer or other CNS disease
As will be discussed in the next section, there is a clear association between certain familial
syndromes and brain malignancy. Even beyond this, however, studies support an association
between family history and brain cancer, albeit less conclusive than for age, sex and race, and
generally for brain cancers in general and not just pediatric brain cancers. For example, Farwell
and Flannery compared the occurrence of cancer in parents, siblings, and offspring of 643
patients who had had a CNS tumor in childhood, as recorded in the Connecticut Tumor
Registry, with its occurrence among the parents, siblings, and offspring of 360 controls
matched for sex, birth date, and birthplace [47]. Overall cancer incidence was comparable in
the two groups, but 11 CNS tumors were identified in the relatives of cases, versus none in the
relatives of controls (p = 0.0005). The rate hematopoietic-lymphatic system tumors also was
increased (p = 0.003). In addition, nine siblings of cases but only one sibling of a control had
had cancer as a child. Medulloblastoma and glioblastoma multiforme were overrepresented
in the group of children whose relatives had CNS tumors. Overall, a fivefold increase in CNS
or hematopoietic-lymphatic malignancies was identified in cases versus controls.
In another study in which the nationwide Swedish Family-Cancer Database for the years 1958
through 1996 was used to analyze the risk of brain tumors in offspring ages 15-61 and siblings
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via parental cancer probands, among brain tumor patients, standardized incidence ratios (SIR)
were statistically elevated to 1.7, 2.4, and 2.5 for all brain tumors, astrocytomas, and meningi‐
omas, respectively. In addition, parental endometrial cancer and melanoma were associated
with offspring astrocytoma, and parental breast and thyroid cancers with offspring ependy‐
moma and neurinoma, respectively [48]. In a case-control study in Maryland, subjects with a
family history of stomach cancer (odds ratio, OR, 2.2; 95% CI, 1.0-4.6), colon cancer (1.4; 0.9-2.2),
prostate cancer (2.1; 1.1-3.8) or Hodgkin’s disease (2.4; 0.9-6.3) all had an increased odds of
glioma [49], while increased risk of meningioma was noted among those reporting a family
history of benign brain tumor (4.5; 1.0-21.0) or melanoma (4.2; 1.2-15.0), and a family history
of breast cancer was associated with an elevated meningioma risk among subjects 18 to 49
years old, but not older (3.9; 1.4-11.0) [50].
More recently, using the Utah Population Data Base (UPDB), among first degree relatives of
a proband with brain cancer, the relative risk (RR) was found to be almost 4 (3.8) for astrocy‐
tomas, 2.3 for glioblastomas, and 3.3 for both, each of these RR values statistically greater than
1.0; among second degree relatives, only astrocytomas had a relative risk greater than 1.0 (RR
= 1.9) [51]. Finally, in the Ohio Brain Tumor Study (OBTS), Ostrom et al. identified a significant
association between a family brain cancer history and both malignant (e.g., malignant gliomas)
and benign brain tumor subtypes, like meningiomas, acoustic neuromas, and pituitary
adenomas [52]. Overall, the increased risk of brain cancer if a parent or sibling has had brain
cancer has been estimated to be between 3 and 9-fold [4].
Some data also exist that support an association between brain cancer and a family history of
epilepsy [53], [54], and between brain cancer and a family history of mental retardation [53],
though these data are less conclusive. For example, in the 1991-1995 San Francisco Bay Area
Adult Glioma Study, in which both personal and family histories were examined in 462 adults
newly-diagnosed with glioma versus 443 controls, past epilepsy or seizures only were
identified as a personal risk factor, the only family history risk factor identified being brain
cancer, and only when both confirmed and probable family brain cancer cases were considered
(OR 2.3; 95% confidence interval 1.0-5.8) [55]. Cancer in general, and a host of other health
conditions were not significant predictors of glioma cases, either in personal or family history.
3.3. Genetics
Central nervous system cancers occur within a broad range of familial clinical syndromes
including what some consider the prototype CNS tumor syndromes – neurofibromatosis,
types I and II - but also other skin conditions that, along with neurofibromatosis, are collec‐
tively known as the phakomatoses. These additional syndromes include disorders like tuberous
sclerosis, Von Hippel Lindau Disease, and basal cell nevus syndrome. Other familial disorders
have been clearly linked to increased CNS cancer risk as well, like Li-Fraumeni syndrome, a
congenital condition linked to germ-line mutations of the p53 tumor suppressor gene, and
familial polyposis disorders, like Turcot syndrome. Finally, this author has already published
several papers describing the association between CNS tumors and dyschondroplasia
syndromes, in particular Ollier’s disease and Maffucci’s syndrome. A list of this broad array
of genetic familial syndromes associated with increased CNS tumor risk is provided below.
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• Phakomatosis syndromes
• Neurofibromatosis (types 1 and 2, and segmental forms)
• Tuberous sclerosis
• Von Hippel Lindau disease
• Basal cell nevus syndrome
• Other familial syndromes
• Li Fraumeni syndrome





Table 1. Familial Syndromes Associated with CNS Malignancies
4. Neurofibromatosis and other phakomatosis syndromes
The phakomatoses are characterized by the presence of pathological lesions involving the skin,
eyes and central and peripheral nervous system (CNS) [56], all tissues of ectodermal origin.
The phakamotoses otherwise share the features of being autosomal dominant, with variable
expression but high penetrance; and all involving mutations of a tumor suppressor gene.
Initially conceptualized by the ophthalmologist van der Hoeve in the early nineteenth century
[57], they were assumed to primarily consist of three disorders: neurofibromatosis, tuberous
sclerosis, and what we now know as von Hippel-Lindau syndrome. Over time, each of these
three disease labels has been recognized as a collective term for multiple disorders; for
example, neurofibromatosis is not one disease, but a collection of quite distinct diseases. On
occasion, two distinct phakomatosis syndromes (for example, neurofibromatosis and tuberous
sclerosis) have been described in the same patient [58]; but this is rare and may be the result
of chance rather than some increased risk for both conditions. In terms of the current chapter,
these three disorders, as well as more-recently described phakomatoses, share the property of
being associated with an increased risk of malignancies involving the central and, sometimes,
peripheral nervous system.
Neurofibromatosis (NF), which is now recognized not to be one, but at least two distinct
disorders - neurofibromatosis type 1 (NF-1) and neurofibromatosis type 2 (NF-2) [59] - is
the most common of all the phakomatosis syndromes, having been initially described by
Frederick von Recklinghausen in the year 1882 [60]. Each of these two syndromes has its
own diagnostic  criteria  that  are  very  different;  and  whereas  the  characteristic  lesion  in
NF-1 is the neurofibroma, the characteristic lesion in NF-2 is a peripheral nerve Schwan‐
noma or neurolemoma [59], [61]- [63].
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tomas, 2.3 for glioblastomas, and 3.3 for both, each of these RR values statistically greater than
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association between a family brain cancer history and both malignant (e.g., malignant gliomas)
and benign brain tumor subtypes, like meningiomas, acoustic neuromas, and pituitary
adenomas [52]. Overall, the increased risk of brain cancer if a parent or sibling has had brain
cancer has been estimated to be between 3 and 9-fold [4].
Some data also exist that support an association between brain cancer and a family history of
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though these data are less conclusive. For example, in the 1991-1995 San Francisco Bay Area
Adult Glioma Study, in which both personal and family histories were examined in 462 adults
newly-diagnosed with glioma versus 443 controls, past epilepsy or seizures only were
identified as a personal risk factor, the only family history risk factor identified being brain
cancer, and only when both confirmed and probable family brain cancer cases were considered
(OR 2.3; 95% confidence interval 1.0-5.8) [55]. Cancer in general, and a host of other health
conditions were not significant predictors of glioma cases, either in personal or family history.
3.3. Genetics
Central nervous system cancers occur within a broad range of familial clinical syndromes
including what some consider the prototype CNS tumor syndromes – neurofibromatosis,
types I and II - but also other skin conditions that, along with neurofibromatosis, are collec‐
tively known as the phakomatoses. These additional syndromes include disorders like tuberous
sclerosis, Von Hippel Lindau Disease, and basal cell nevus syndrome. Other familial disorders
have been clearly linked to increased CNS cancer risk as well, like Li-Fraumeni syndrome, a
congenital condition linked to germ-line mutations of the p53 tumor suppressor gene, and
familial polyposis disorders, like Turcot syndrome. Finally, this author has already published
several papers describing the association between CNS tumors and dyschondroplasia
syndromes, in particular Ollier’s disease and Maffucci’s syndrome. A list of this broad array
of genetic familial syndromes associated with increased CNS tumor risk is provided below.
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the most common of all the phakomatosis syndromes, having been initially described by
Frederick von Recklinghausen in the year 1882 [60]. Each of these two syndromes has its
own diagnostic  criteria  that  are  very  different;  and  whereas  the  characteristic  lesion  in
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Neurofibromatosis type 1 (NF-1) is the most common form of disease, affecting one in roughly
2500 to 5000 live births [64]- [66]. This renders it more than ten times more common than NF-2
[64], [65]. Though autosomal dominant, up to 50% of cases arise spontaneously from a gene
mutation that occurs on chromosome 17q11.2, which encodes for a large protein called
neurofibromin [64], [66]. This NF-1 gene is a classical tumor suppressor gene, with tumor growth
requiring the loss of BOTH alleles. Neurofibromatosis type 1 has a classical combination of
clinical signs [67], for which the mnemonic CHANSOR has been used. These signs include
Café au lait macules; Hamartomas of the iris (called Lisch nodules); Axillary and Inguinal
Freckling; Neurofibromas; Skeletal lesions – like sphenoid wing dysplasia and thinning of long
bone cortices; Optic gliomas; and in increased Risk of other CNS and systemic tumors. The
disorder is diagnosed using National Institutes of Health (NIH) Consensus Criteria for the
Diagnosis of NF-1 [65]. Besides the classic neurofibroma - which is generally an extra-cranial
lesion that occurs both in paraspinal areas and in peripheral nerves [62], [67], [68] and, though
benign, may transform into a neurofibrosarcoma - numerous other brain tumors are frequently
observed in patients with NF-1. Most common are optic-hypothalamic gliomas, which
manifest in roughly 15% of NF-1 patients. These lesions are categorized into those that involve
just the optic nerve(s), lesions also involving the optic chiasm, and lesions that extend all the
way into the hypothalamus. [69] Hemispheric and cerebellar gliomas are less common than
lesions involving the optic tract [70]. Most are benign or only exhibit low-grade malignant
potential; but all grades of malignancy have been reported [70]. Most are resectable. Brainstem
gliomas also occur, as a heterogeneous group of lesions, with at least three main subtypes: (1)
a diffuse area of brainstem enlargement; (2) focal enhancing nodules with or without cystic
areas; and (3) peri-aqueductal gliomas. All subtypes generally have a very indolent course that
usually does not require treatment, though MRI monitoring is indicated until their indolent
course is confirmed. Some lesions regress on their own [70]. Though controversial, diffuse
brainstem enlargement is presumed to represent gliomatous change, though these lesions have
a more indolent course than brainstem gliomas seen outside of NF-1, such that adjuvant
treatment only is required in that minority of patients whose lesions progress. This being said,
these gliomas occasionally do progress to more malignant forms of astrocytoma, including
glioblastoma [70], [71]. The focal enhancing nodules, with or without cystic areas, generally
are thought to represent pilocytic astrocytomas, given their imaging characteristics. Like
pilocytic astrocytomas elsewhere, they generally are indolent; but their course is unpredictable
and the brainstem so susceptible to major deficits, relative to the cerebral hemispheres, that
ongoing monitoring is required. Small, focal intrinsic lesions may enlarge and then regress
spontaneously. Exophytic tumors often are more aggressive and require treatment.
Finally, peri-aqueductal gliomas occur adjacent to the aqueduct of Sylvius between the 3rd and
4th ventricles in the midbrain. They typically manifest with late-onset aqueductal stenosis,
leading to hydrocephalus. Presumably, they represent low-grade gliomas or glial hamartomas,
and typically are indolent. However, because of their location, shunting often is necessary.
Resection is usually not necessary for any of the brainstem gliomas seen in NF-1 [70], [71].
Neurofibromatosis type 2 (NF-2) is much less common than NF-1, with a prevalence that has
been estimated as roughly one in 25,000 to 50,000 [64], [65], [67]. NF-2 is caused by a mutation
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affecting chromosome 22q12 and the gene product merlin (a moesin-, erzin-, and radixin-like
protein), which sometimes is called schwannomin. Merlin encodes for a polypeptide that may
affect cell growth and motility; more interesting, in terms of its presence in NF-2, is that it is a
tumor inhibitor that often is absent in brain tumors [72]- [74]. In addition, the same chromo‐
somal abnormality is found in spontaneous spinal schwannomas, which suggests that a single
location causes Schwann cell tumor growth [75]. Clinically, NF-2 is a combination of features
that always entails at least one eighth cranial nerve (CN-VIII) neurilemoma, in addition to a
variety of other tumors (e.g., neurofibromas, meningiomas, gliomas, neurilemomas), juvenile
posterior sub-capsular cataracts, and occasional other lesions like café au lait spots. Like NF-1,
it is diagnosed using NIH Consensus Criteria, initially proposed in 1988 [76], but modified in
1997 [77]. Cranial nerve neurolemomas, especially of the eighth cranial nerve (CN-VIII), are
the hallmark lesion of NF-2, with CN-VIII lesions present in roughly 95% of patients with NF-2;
when bilateral, they are diagnostic of NF-2 [63], [67]. As a rule, spinal lesions are more common
in NF-2 than in NF1, while brain lesions are less common in NF-2 than NF-1. In NF-2, this
includes extracranial neurilemomas and meningiomas. But also among the various tumors are
brain neoplasms, particularly ependymomas that are the most common malignancy in NF-2,
versus astrocytomas in NF-1 [62], [63], [70]. These ependymomas usually are well-circumscri‐
bed, and therefore often quite resectable. Their surgical and post-operative management (like
the use of adjuvant therapy) is the same as for intramedullary spinal tumors in patients without
neurofibromatosis.
Tuberous sclerosis, which also is called tuberous sclerosis complex (TSC) and Bourneville’s
disease, is the second most common phakomatosis syndrome, after neurofibromatosis type 1.
It affects anywhere from one in 6000 to one in 30,000 people [78]- [80], with marked variations
in penetrance rendering all estimates somewhat unreliable. The syndrome is autosomal
dominant, but up to 60% of cases arise from spontaneous mutations [78], [80], [81]. Two tumor-
suppressor genes, TSC-1 (tuberous sclerosis complex-1) and TSC-2, are responsible for TS.
Roughly 80-90% of mutations involve TSC-2, while just 10-20% of mutations involve TSC-1
[81]. The genetic locus for TSC-1 is chromosome 9q34, and the TSC-1 gene product is called
hamartin. The genetic locus for TSC-2 is chromosome 16p13.3, and the TSC-2 gene product is
called tuberin. Both hamartin and tuberin appear to have roles in cell differentiation, prolifer‐
ation and migration. The disorder effects cellular differentiation, proliferation and migration
during early development, leading to various diffuse hamartomas and neoplastic lesions that
can affect virtually any body organ [81], [82]. It can present at any age, but most commonly
appears during childhood, especially late childhood. Though skin, heart, lung and renal
involvement are common, neurological involvement is the most common cause of morbidity
and mortality from TS, and the most common cause of death in patients under 30 years old.
Problems stem from a broad variety of intra-cerebral tumors, which include cortical tubers,
subependymal nodules, and subependymal giant cell astrocytomas (SEGA). Subependymal
giant cell astrocytomas develop in between 5 and 15% of TS patients [83], typically developing
in the region of the foramen of Monro, where they frequently cause obstructive hydrocephalus.
Though they are slow-growing and rarely undergo malignant transformation, these tumors
are problematic because of their location and relative inaccessibility for resection. Death
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Neurofibromatosis type 1 (NF-1) is the most common form of disease, affecting one in roughly
2500 to 5000 live births [64]- [66]. This renders it more than ten times more common than NF-2
[64], [65]. Though autosomal dominant, up to 50% of cases arise spontaneously from a gene
mutation that occurs on chromosome 17q11.2, which encodes for a large protein called
neurofibromin [64], [66]. This NF-1 gene is a classical tumor suppressor gene, with tumor growth
requiring the loss of BOTH alleles. Neurofibromatosis type 1 has a classical combination of
clinical signs [67], for which the mnemonic CHANSOR has been used. These signs include
Café au lait macules; Hamartomas of the iris (called Lisch nodules); Axillary and Inguinal
Freckling; Neurofibromas; Skeletal lesions – like sphenoid wing dysplasia and thinning of long
bone cortices; Optic gliomas; and in increased Risk of other CNS and systemic tumors. The
disorder is diagnosed using National Institutes of Health (NIH) Consensus Criteria for the
Diagnosis of NF-1 [65]. Besides the classic neurofibroma - which is generally an extra-cranial
lesion that occurs both in paraspinal areas and in peripheral nerves [62], [67], [68] and, though
benign, may transform into a neurofibrosarcoma - numerous other brain tumors are frequently
observed in patients with NF-1. Most common are optic-hypothalamic gliomas, which
manifest in roughly 15% of NF-1 patients. These lesions are categorized into those that involve
just the optic nerve(s), lesions also involving the optic chiasm, and lesions that extend all the
way into the hypothalamus. [69] Hemispheric and cerebellar gliomas are less common than
lesions involving the optic tract [70]. Most are benign or only exhibit low-grade malignant
potential; but all grades of malignancy have been reported [70]. Most are resectable. Brainstem
gliomas also occur, as a heterogeneous group of lesions, with at least three main subtypes: (1)
a diffuse area of brainstem enlargement; (2) focal enhancing nodules with or without cystic
areas; and (3) peri-aqueductal gliomas. All subtypes generally have a very indolent course that
usually does not require treatment, though MRI monitoring is indicated until their indolent
course is confirmed. Some lesions regress on their own [70]. Though controversial, diffuse
brainstem enlargement is presumed to represent gliomatous change, though these lesions have
a more indolent course than brainstem gliomas seen outside of NF-1, such that adjuvant
treatment only is required in that minority of patients whose lesions progress. This being said,
these gliomas occasionally do progress to more malignant forms of astrocytoma, including
glioblastoma [70], [71]. The focal enhancing nodules, with or without cystic areas, generally
are thought to represent pilocytic astrocytomas, given their imaging characteristics. Like
pilocytic astrocytomas elsewhere, they generally are indolent; but their course is unpredictable
and the brainstem so susceptible to major deficits, relative to the cerebral hemispheres, that
ongoing monitoring is required. Small, focal intrinsic lesions may enlarge and then regress
spontaneously. Exophytic tumors often are more aggressive and require treatment.
Finally, peri-aqueductal gliomas occur adjacent to the aqueduct of Sylvius between the 3rd and
4th ventricles in the midbrain. They typically manifest with late-onset aqueductal stenosis,
leading to hydrocephalus. Presumably, they represent low-grade gliomas or glial hamartomas,
and typically are indolent. However, because of their location, shunting often is necessary.
Resection is usually not necessary for any of the brainstem gliomas seen in NF-1 [70], [71].
Neurofibromatosis type 2 (NF-2) is much less common than NF-1, with a prevalence that has
been estimated as roughly one in 25,000 to 50,000 [64], [65], [67]. NF-2 is caused by a mutation
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affecting chromosome 22q12 and the gene product merlin (a moesin-, erzin-, and radixin-like
protein), which sometimes is called schwannomin. Merlin encodes for a polypeptide that may
affect cell growth and motility; more interesting, in terms of its presence in NF-2, is that it is a
tumor inhibitor that often is absent in brain tumors [72]- [74]. In addition, the same chromo‐
somal abnormality is found in spontaneous spinal schwannomas, which suggests that a single
location causes Schwann cell tumor growth [75]. Clinically, NF-2 is a combination of features
that always entails at least one eighth cranial nerve (CN-VIII) neurilemoma, in addition to a
variety of other tumors (e.g., neurofibromas, meningiomas, gliomas, neurilemomas), juvenile
posterior sub-capsular cataracts, and occasional other lesions like café au lait spots. Like NF-1,
it is diagnosed using NIH Consensus Criteria, initially proposed in 1988 [76], but modified in
1997 [77]. Cranial nerve neurolemomas, especially of the eighth cranial nerve (CN-VIII), are
the hallmark lesion of NF-2, with CN-VIII lesions present in roughly 95% of patients with NF-2;
when bilateral, they are diagnostic of NF-2 [63], [67]. As a rule, spinal lesions are more common
in NF-2 than in NF1, while brain lesions are less common in NF-2 than NF-1. In NF-2, this
includes extracranial neurilemomas and meningiomas. But also among the various tumors are
brain neoplasms, particularly ependymomas that are the most common malignancy in NF-2,
versus astrocytomas in NF-1 [62], [63], [70]. These ependymomas usually are well-circumscri‐
bed, and therefore often quite resectable. Their surgical and post-operative management (like
the use of adjuvant therapy) is the same as for intramedullary spinal tumors in patients without
neurofibromatosis.
Tuberous sclerosis, which also is called tuberous sclerosis complex (TSC) and Bourneville’s
disease, is the second most common phakomatosis syndrome, after neurofibromatosis type 1.
It affects anywhere from one in 6000 to one in 30,000 people [78]- [80], with marked variations
in penetrance rendering all estimates somewhat unreliable. The syndrome is autosomal
dominant, but up to 60% of cases arise from spontaneous mutations [78], [80], [81]. Two tumor-
suppressor genes, TSC-1 (tuberous sclerosis complex-1) and TSC-2, are responsible for TS.
Roughly 80-90% of mutations involve TSC-2, while just 10-20% of mutations involve TSC-1
[81]. The genetic locus for TSC-1 is chromosome 9q34, and the TSC-1 gene product is called
hamartin. The genetic locus for TSC-2 is chromosome 16p13.3, and the TSC-2 gene product is
called tuberin. Both hamartin and tuberin appear to have roles in cell differentiation, prolifer‐
ation and migration. The disorder effects cellular differentiation, proliferation and migration
during early development, leading to various diffuse hamartomas and neoplastic lesions that
can affect virtually any body organ [81], [82]. It can present at any age, but most commonly
appears during childhood, especially late childhood. Though skin, heart, lung and renal
involvement are common, neurological involvement is the most common cause of morbidity
and mortality from TS, and the most common cause of death in patients under 30 years old.
Problems stem from a broad variety of intra-cerebral tumors, which include cortical tubers,
subependymal nodules, and subependymal giant cell astrocytomas (SEGA). Subependymal
giant cell astrocytomas develop in between 5 and 15% of TS patients [83], typically developing
in the region of the foramen of Monro, where they frequently cause obstructive hydrocephalus.
Though they are slow-growing and rarely undergo malignant transformation, these tumors
are problematic because of their location and relative inaccessibility for resection. Death
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primarily results from intractable seizures or SEGA-induced obstructive hydrocephalus; and,
overall, the long-term prognosis is poor.
The average age at first presentation with Von Hippel-Lindau Disease is 26 years, and the
average age at diagnosis 31 [84]. Nonetheless, pediatric cases are not uncommon. Von Hippel-
Lindau disease is autosomal dominant, with 97-99% of cases familial and only 1-3% occurring
as a result of spontaneous mutations. It is associated with inactivation of the tumor-suppressor
gene VHL (Von Hippel Lindau), which is found on chromosome 3p25 [84], [85]. Decreased
levels of the VHL protein, which is important in a critical pathway helping cells to adapt to
hypoxic stress, lead to over-expression of a hypoxia-inducible transcription factor (HIF-1)
which, in turn, results in increased cell proliferation, and the over-expression of several growth
factors, ultimately manifesting as multiple, multi-systemic benign and malignant tumors,
which sometimes are bilateral (e.g., both eyes) [86]. These tumors include haemangioblastomas
of the cerebellum, spine, brainstem and retina (the most common tumor identified); renal clear
cell carcinomas; pheochromocytomas; pancreatic and renal cysts; endolymphatic sac tumors
(ELSTs, of the petrous bone at the cerebellopontine angle) [87]; papillary cystadenomas of the
epididymus or broad ligament; and haemanigiomas of the adrenal glands, liver and lungs. As
with all the other phakomatosis syndromes, the diagnosis is made on clinical grounds using
established, published criteria. Central nervous system manifestations are highly prevalent
[88], [89], with CNS haemangioblastomas occurring in 60 to 80% of patients. Moreover, they
are more likely to be multiple and present at an earlier age than when they occur sporadically,
being a presenting feature in roughly 60% of VHL patients [90]. These lesions may occur
anywhere along the cranioaxial axis, but only 1% of these tumors are supratentorial [90]. The
site of lesion determines the symptoms with which the patient presents. The cerebellum and
brainstem are the most common sites of haemangioblastomas in VHL syndrome [90], where
patients present with headaches, vomiting, lethargy, dysmetria, ataxia, papilloedema,
polycythemia from tumor production of erythropoietin, and/or enlarging cysts that may cause
brainstem compression (solid tumors generally do not cause such compression in VHL
syndrome).
As with almost all the phakomatoses, basal cell nevus syndrome (BCNS) is autosomal
dominant, the offending gene, called PTCH1, localized to chromosome 9q31 in about 85% of
cases. The PTCH1 gene product is a trans-membrane receptor that binds to and regulates a
protein called Sonic the hedgehog homolog (SHH), one of three proteins in the mammalian
signalling pathway family called ‘hedgehog’, and one which plays a key role in the regulation
of organ development in vertebrates, including the growth of fingers and toes and the
organization of the central nervous system. It also controls cell division in adult stem cells and
has been implicated in oncogenesis. Mutations in the PTCH1 gene result in uncontrolled SHH
activation [91]. This rare condition, which affects roughly one in 50 to 60 thousand live births
[84], is characterized by multiple basal cell cancers, often presenting in adolescence. Despite
the relatively innocuous-sounding name, there is a wide range of non-neurological manifes‐
tations, including numerous other benign and malignant tumors, both non-CNS and CNS,
including melanomas, leukaemia, lymphoma, lung and breast cancers, medulloblastomas, and
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meningiomas [92]. Like virtually all the familial cancer syndromes, basal cell nevus syndrome
is diagnosed using diagnostic criteria.
5. Other familial syndromes associated with CNS malignancies
Other familial syndromes associated with paediatric CNS malignancies include Li-Fraumeni
Syndrome (LFS), a very rare autosomal dominant disease that is caused by a germ line
mutation of chromosome p53 in roughly 70% of families in which the syndrome is diagnosed
[93]. Patients exhibit a variety of carcinomas and sarcomas, including premenopausal breast
cancers, osteosarcomas, soft tissue sarcomas, acute leukaemia, cancer involving the adrenal
cortex, and primitive neuroectodermal tumors (PNET) like medulloblastoma. This increased
risk of several malignancies likely stems from deactivation of p53, which normally controls
apoptosis and the repair of damaged DNA. Patients present not only with a variety of cancers,
but with cancers at a very early age, with the mean age at presentation of brain tumors being
25 years. The diagnosis of so-called ‘classic LFS’ is made in any patient under 45 years who
presents with a bone or soft-tissue sarcoma, plus one first-degree relative who presents with
any cancer before age 45, plus one further first or second-degree relative of the same lineage
who has had any cancer before age 45 or a sarcoma at any age [94]. More recently, a related
syndrome, called Li-Fraumeni-like syndrome, has been described, defined as a proband with
any childhood tumor or any sarcoma, brain or adrenocortical tumor before 45 years of age,
who has a first- or second-degree relative with any cancer before the age of 60 [95], [96].
Interestingly, whereas p53 germ-line mutations are found in 70% to 80% of families with classic
Li-Fraumeni syndrome, they only are identified in between 20% and 40% of families with Li-
Fraumeni-like syndrome [8] [4]. The CHK2 checkpoint homolog gene, CHEK2, which is located
on the long (q) arm of chromosome 22, also has been implicated in some families with classic
Li-Fraumeni syndrome. Recently, mutation of another gene, which encodes for the breast
cancer 2 (BRCA2) susceptibility protein, has been found with increased frequency in the non-
classic syndrome [96]. It should be noted that p53 mutations are rare in sporadically occurring
medulloblastomas. Overall, about 10% of LFS patients will develop a glioma before the age of
45, and another 5% a supratentorial primitive neuroectodermal tumor (PNET), like a medul‐
loblastoma, or choroid plexus carcinoma [97].
A Canadian surgeon named Jacques Turcot is accredited with having characterized Tur‐
cot  syndrome,  one of  the  several  familial  polyposis  syndromes associated with familial,
in this case autosomal recessive, inheritance and the presence of multiple colonic adeno‐
mas and adenocarcinomas [98].  An additional feature of Turcot syndrome is its  associa‐
tion  with  several  different  neuroepithelial  tumors  of  the  central  nervous  system,
including astrocytomas, medulloblastomas, pineoblastomas, gangliogliomas, and ependy‐
momas [84]. Turcot syndrome has been categorized into types 1 and 2, with type 1 char‐
acterized by glioblastoma, no familial  adenomatous polyposis,  but often hereditary non-
polyposis-related  colorectal  carcinoma.  Germ-line  mutations  in  a  few  DNA  mismatch
repair  genes  –  PMS2,  MLH1 and MSH2 –  are  associated with  type-1  Turcot  syndrome.
Interestingly, type-1 Turcot syndrome also is associated with café au lait spots [84]. Con‐
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primarily results from intractable seizures or SEGA-induced obstructive hydrocephalus; and,
overall, the long-term prognosis is poor.
The average age at first presentation with Von Hippel-Lindau Disease is 26 years, and the
average age at diagnosis 31 [84]. Nonetheless, pediatric cases are not uncommon. Von Hippel-
Lindau disease is autosomal dominant, with 97-99% of cases familial and only 1-3% occurring
as a result of spontaneous mutations. It is associated with inactivation of the tumor-suppressor
gene VHL (Von Hippel Lindau), which is found on chromosome 3p25 [84], [85]. Decreased
levels of the VHL protein, which is important in a critical pathway helping cells to adapt to
hypoxic stress, lead to over-expression of a hypoxia-inducible transcription factor (HIF-1)
which, in turn, results in increased cell proliferation, and the over-expression of several growth
factors, ultimately manifesting as multiple, multi-systemic benign and malignant tumors,
which sometimes are bilateral (e.g., both eyes) [86]. These tumors include haemangioblastomas
of the cerebellum, spine, brainstem and retina (the most common tumor identified); renal clear
cell carcinomas; pheochromocytomas; pancreatic and renal cysts; endolymphatic sac tumors
(ELSTs, of the petrous bone at the cerebellopontine angle) [87]; papillary cystadenomas of the
epididymus or broad ligament; and haemanigiomas of the adrenal glands, liver and lungs. As
with all the other phakomatosis syndromes, the diagnosis is made on clinical grounds using
established, published criteria. Central nervous system manifestations are highly prevalent
[88], [89], with CNS haemangioblastomas occurring in 60 to 80% of patients. Moreover, they
are more likely to be multiple and present at an earlier age than when they occur sporadically,
being a presenting feature in roughly 60% of VHL patients [90]. These lesions may occur
anywhere along the cranioaxial axis, but only 1% of these tumors are supratentorial [90]. The
site of lesion determines the symptoms with which the patient presents. The cerebellum and
brainstem are the most common sites of haemangioblastomas in VHL syndrome [90], where
patients present with headaches, vomiting, lethargy, dysmetria, ataxia, papilloedema,
polycythemia from tumor production of erythropoietin, and/or enlarging cysts that may cause
brainstem compression (solid tumors generally do not cause such compression in VHL
syndrome).
As with almost all the phakomatoses, basal cell nevus syndrome (BCNS) is autosomal
dominant, the offending gene, called PTCH1, localized to chromosome 9q31 in about 85% of
cases. The PTCH1 gene product is a trans-membrane receptor that binds to and regulates a
protein called Sonic the hedgehog homolog (SHH), one of three proteins in the mammalian
signalling pathway family called ‘hedgehog’, and one which plays a key role in the regulation
of organ development in vertebrates, including the growth of fingers and toes and the
organization of the central nervous system. It also controls cell division in adult stem cells and
has been implicated in oncogenesis. Mutations in the PTCH1 gene result in uncontrolled SHH
activation [91]. This rare condition, which affects roughly one in 50 to 60 thousand live births
[84], is characterized by multiple basal cell cancers, often presenting in adolescence. Despite
the relatively innocuous-sounding name, there is a wide range of non-neurological manifes‐
tations, including numerous other benign and malignant tumors, both non-CNS and CNS,
including melanomas, leukaemia, lymphoma, lung and breast cancers, medulloblastomas, and
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors610
meningiomas [92]. Like virtually all the familial cancer syndromes, basal cell nevus syndrome
is diagnosed using diagnostic criteria.
5. Other familial syndromes associated with CNS malignancies
Other familial syndromes associated with paediatric CNS malignancies include Li-Fraumeni
Syndrome (LFS), a very rare autosomal dominant disease that is caused by a germ line
mutation of chromosome p53 in roughly 70% of families in which the syndrome is diagnosed
[93]. Patients exhibit a variety of carcinomas and sarcomas, including premenopausal breast
cancers, osteosarcomas, soft tissue sarcomas, acute leukaemia, cancer involving the adrenal
cortex, and primitive neuroectodermal tumors (PNET) like medulloblastoma. This increased
risk of several malignancies likely stems from deactivation of p53, which normally controls
apoptosis and the repair of damaged DNA. Patients present not only with a variety of cancers,
but with cancers at a very early age, with the mean age at presentation of brain tumors being
25 years. The diagnosis of so-called ‘classic LFS’ is made in any patient under 45 years who
presents with a bone or soft-tissue sarcoma, plus one first-degree relative who presents with
any cancer before age 45, plus one further first or second-degree relative of the same lineage
who has had any cancer before age 45 or a sarcoma at any age [94]. More recently, a related
syndrome, called Li-Fraumeni-like syndrome, has been described, defined as a proband with
any childhood tumor or any sarcoma, brain or adrenocortical tumor before 45 years of age,
who has a first- or second-degree relative with any cancer before the age of 60 [95], [96].
Interestingly, whereas p53 germ-line mutations are found in 70% to 80% of families with classic
Li-Fraumeni syndrome, they only are identified in between 20% and 40% of families with Li-
Fraumeni-like syndrome [8] [4]. The CHK2 checkpoint homolog gene, CHEK2, which is located
on the long (q) arm of chromosome 22, also has been implicated in some families with classic
Li-Fraumeni syndrome. Recently, mutation of another gene, which encodes for the breast
cancer 2 (BRCA2) susceptibility protein, has been found with increased frequency in the non-
classic syndrome [96]. It should be noted that p53 mutations are rare in sporadically occurring
medulloblastomas. Overall, about 10% of LFS patients will develop a glioma before the age of
45, and another 5% a supratentorial primitive neuroectodermal tumor (PNET), like a medul‐
loblastoma, or choroid plexus carcinoma [97].
A Canadian surgeon named Jacques Turcot is accredited with having characterized Tur‐
cot  syndrome,  one of  the  several  familial  polyposis  syndromes associated with familial,
in this case autosomal recessive, inheritance and the presence of multiple colonic adeno‐
mas and adenocarcinomas [98].  An additional feature of Turcot syndrome is its  associa‐
tion  with  several  different  neuroepithelial  tumors  of  the  central  nervous  system,
including astrocytomas, medulloblastomas, pineoblastomas, gangliogliomas, and ependy‐
momas [84]. Turcot syndrome has been categorized into types 1 and 2, with type 1 char‐
acterized by glioblastoma, no familial  adenomatous polyposis,  but often hereditary non-
polyposis-related  colorectal  carcinoma.  Germ-line  mutations  in  a  few  DNA  mismatch
repair  genes  –  PMS2,  MLH1 and MSH2 –  are  associated with  type-1  Turcot  syndrome.
Interestingly, type-1 Turcot syndrome also is associated with café au lait spots [84]. Con‐
The Epidemiology of Paediatric Brain Cancer — Descriptive Epidemiology and Risk Factors
http://dx.doi.org/10.5772/52427
611
versely,  type-2 Turcot syndrome families have medulloblastomas as their  most common
CNS malignancy, and multiple adenomatous polyps that often undergo malignant trans‐
formation [99].  Unfortunately, medulloblastomas, glioblastomas and anaplastic astrocyto‐
mas  are  the  most  common  CNS  tumors  observed  in  Turcot’s  syndrome,  the  three
combined  accounting  for  95% of  all  CNS tumors  in  these  families  [100];  and  the  latter
two  are  inevitably  fatal.  In  addition,  they  tend  to  occur  early,  with  medulloblastomas
typically diagnosed in children less than 10 years old, and gliomas in those under age 30
[84],  [101]-  [103].  As  such,  and because  some die  of  metastatic  colon cancer  that  some‐
times presents quite early in childhood or the second decade of life, many die as adoles‐
cents or young adults. In one tragic case, for example, doctors in Pittsburgh reported the
case of  a  girl  who developed a medulloblastoma at  the age of  5  years.  Ten years  later,
she  developed  adenocarcinoma  of  the  colon.  Then,  seven  months  after  resection  of  a
Dukes' C2 adenocarcinoma, she presented with a second primary CNS tumor, this time a
glioblastoma multiforme [101].
Rubenstein-Taybi syndrome is an autosomal dominant disorder that is associated with
numerous anatomical/functional abnormalities that include abnormal facies, microcephaly,
broad thumbs, big toes and moderate to severe intellectual impairment. There also is an
increased incidence of neuroepithelial tumors - in particular medulloblastomas, meningiomas,
and oligodendrogliomas [104], though other CNS tumors have been described [105]. A germ-
line mutation in one allele of CRE binding protein (CBP, a transcriptional co-activator for
several c-AMP regulated genes) has been implicated in many cases. CBP binds to the activated
form of GLI, a transcription factor that is important in the regulation of the Sonic the hedgehog
homolog (SHH) that, as stated earlier, controls cell division in adult stem cells and has been
implicated in oncogenesis. The GLI gene is downstream of the PTCH1 gene that is mutated in
basal cell nevus syndrome.
6. Ollier’s disease and Maffucci syndrome
Enchondromatosis, also called dyschondroplasia, is a hamartomatous proliferation of chon‐
drocytes within the metaphysis of bone [106]. Though often asymptomatic and only diagnosed
as an incidental X-ray finding, it can lead to significant deformities, reduced bone length [107],
[108], and occasional pathologic fractures [108]. Moreover, just like the phakomatoses and
familial syndromes like Li-Fraumeni and Turcot syndrome, enchondromatosis appears to
confer a substantial increased risk of a variety of CNS and other malignancies, at least through
the sixth decade of life and as early as the first decade. These tumors include chondrosarcomas
that result from sarcomatous transformation of the enchondromas themselves, as well as other
histologically-distinct malignancies like angiosarcomas, osteosacrcomas, ovarian tumors,
various leukaemias, and a variety of glial-cell based central nervous system tumors (ranging
from stage I to stage IV astrocytomas) [109]. This association with malignancy appears to be
particularly true in instances of multiple enchondromatoses, as in Ollier’s disease and
Maffucci’s syndrome [110], two very rare conditions [111], [112].
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors612
Since Boinet first reported CNS malignancy in a patient with multiple enchondromatosis, [113]
45 additional patients with either Ollier’s disease (OD) or Maffucci’s syndrome (MS) and some
form of intracranial malignancy have been reported in the medical literature, ranging from 6
to 58 years old [114]. Ollier’s disease patients appear to contract their neoplasms at a particu‐
larly early age, including very young childhood [109], [114], [115]. What causes this persistent
increase in malignancy potential is not yet known. We do know that single enchondromas,
outside some greater syndrome, are associated with an elevated risk of malignant change.
Altay et al [116], for example, conducted an 18-year retrospective analysis of 627 cartilage-
forming benign bone tumors, and found that 32 patients had experienced malignant transfor‐
mation, with 14 of these 32 patients initially having had a solitary osteochondroma, ten
multiple osteochondromas, six a solitary enchondroma, one Ollier's disease, and one Maffuc‐
ci's syndrome. The one patient with Ollier's disease had two chondrosarcomas; and the single
patient with multiple osteochondroma had three chondrosarcomas. The overall rate of
malignant transformation for cartilage-originating tumors was 5.1%, being 4.2% for solitary
osteochondromas, 9.2% for multiple osteochondromas, and 4.2% for solitary enchondromas.
A variety of chromosomal abnormalities also have been reported in isolated cases of OD or
MS and chondrosarcoma. These abnormalities include, for example, the interstitial deletion,
del(1)(p11p31.2), as the only chromosomal abnormality identified in a low-grade chondrosar‐
coma in a patient with Ollier’s disease [117]. Also, Bovée et al [118] identified (1) the loss of
heterozygosity (LOH) in a tibial chondrosarcoma and its metastases, exclusively on chromo‐
some bands 13q14 and 9p21, with the LOH not identified in a femoral enchondroma that was
analyzed; and (2) p53 over-expression in a tibial chondrosarcoma and its metastases, not
present in a femoral enchondroma. Meanwhile, Chang et al [119] identified identical male twins
with OD who both developed astrocytomas within their cerebral cortex during their early
twenties; and Robinson et al [120] found evidence of mitogenic neurotransmitters within both
enchondromas and soft tissue hemangiomas in a patient with Maffucci’s syndrome, implying
that the bone and vascular lesions, and possibly malignant tumors, might be related to an
underlying neural abnormality. Having said all this, to date, no consistent chromosomal
abnormalities have been identified in these patients, and all theories regarding the cause of
malignancies in these syndromes remain unproven.
6.1. Ionizing radiation
The first report of a radiation-induced CNS tumor was by Mann et al in 1953 [121]. He described
the case of a 3 year-old girl, born in 1942, who presented with a left optic nerve astrocytoma
that was excised and then irradiated with a total dose over time of 6,500 rads. Six years later,
at age 9, she presented with her first episode of recurring frontal meningiomas, which
subsequently underwent malignant change, leading to her death at age 10. At about the same
time, two independent groups were reporting on the 1.5 to 2-fold increased risk of cancers,
including brain cancers, in children exposed to X-rays in utero [53], [122]- [124]. Subsequently,
more than 280 radiation-induced intracranial tumors have been reported in the literature, the
most common being meningiomas, sarcomas, and gliomas, though ependymomas, Schwan‐
nomas, PNETs, and pituitary adenomas have been described as well [125]. Consequently, the
association between therapeutic radiation to the head and the subsequent risk of brain cancer
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versely,  type-2 Turcot syndrome families have medulloblastomas as their  most common
CNS malignancy, and multiple adenomatous polyps that often undergo malignant trans‐
formation [99].  Unfortunately, medulloblastomas, glioblastomas and anaplastic astrocyto‐
mas  are  the  most  common  CNS  tumors  observed  in  Turcot’s  syndrome,  the  three
combined  accounting  for  95% of  all  CNS tumors  in  these  families  [100];  and  the  latter
two  are  inevitably  fatal.  In  addition,  they  tend  to  occur  early,  with  medulloblastomas
typically diagnosed in children less than 10 years old, and gliomas in those under age 30
[84],  [101]-  [103].  As  such,  and because  some die  of  metastatic  colon cancer  that  some‐
times presents quite early in childhood or the second decade of life, many die as adoles‐
cents or young adults. In one tragic case, for example, doctors in Pittsburgh reported the
case of  a  girl  who developed a medulloblastoma at  the age of  5  years.  Ten years  later,
she  developed  adenocarcinoma  of  the  colon.  Then,  seven  months  after  resection  of  a
Dukes' C2 adenocarcinoma, she presented with a second primary CNS tumor, this time a
glioblastoma multiforme [101].
Rubenstein-Taybi syndrome is an autosomal dominant disorder that is associated with
numerous anatomical/functional abnormalities that include abnormal facies, microcephaly,
broad thumbs, big toes and moderate to severe intellectual impairment. There also is an
increased incidence of neuroepithelial tumors - in particular medulloblastomas, meningiomas,
and oligodendrogliomas [104], though other CNS tumors have been described [105]. A germ-
line mutation in one allele of CRE binding protein (CBP, a transcriptional co-activator for
several c-AMP regulated genes) has been implicated in many cases. CBP binds to the activated
form of GLI, a transcription factor that is important in the regulation of the Sonic the hedgehog
homolog (SHH) that, as stated earlier, controls cell division in adult stem cells and has been
implicated in oncogenesis. The GLI gene is downstream of the PTCH1 gene that is mutated in
basal cell nevus syndrome.
6. Ollier’s disease and Maffucci syndrome
Enchondromatosis, also called dyschondroplasia, is a hamartomatous proliferation of chon‐
drocytes within the metaphysis of bone [106]. Though often asymptomatic and only diagnosed
as an incidental X-ray finding, it can lead to significant deformities, reduced bone length [107],
[108], and occasional pathologic fractures [108]. Moreover, just like the phakomatoses and
familial syndromes like Li-Fraumeni and Turcot syndrome, enchondromatosis appears to
confer a substantial increased risk of a variety of CNS and other malignancies, at least through
the sixth decade of life and as early as the first decade. These tumors include chondrosarcomas
that result from sarcomatous transformation of the enchondromas themselves, as well as other
histologically-distinct malignancies like angiosarcomas, osteosacrcomas, ovarian tumors,
various leukaemias, and a variety of glial-cell based central nervous system tumors (ranging
from stage I to stage IV astrocytomas) [109]. This association with malignancy appears to be
particularly true in instances of multiple enchondromatoses, as in Ollier’s disease and
Maffucci’s syndrome [110], two very rare conditions [111], [112].
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Since Boinet first reported CNS malignancy in a patient with multiple enchondromatosis, [113]
45 additional patients with either Ollier’s disease (OD) or Maffucci’s syndrome (MS) and some
form of intracranial malignancy have been reported in the medical literature, ranging from 6
to 58 years old [114]. Ollier’s disease patients appear to contract their neoplasms at a particu‐
larly early age, including very young childhood [109], [114], [115]. What causes this persistent
increase in malignancy potential is not yet known. We do know that single enchondromas,
outside some greater syndrome, are associated with an elevated risk of malignant change.
Altay et al [116], for example, conducted an 18-year retrospective analysis of 627 cartilage-
forming benign bone tumors, and found that 32 patients had experienced malignant transfor‐
mation, with 14 of these 32 patients initially having had a solitary osteochondroma, ten
multiple osteochondromas, six a solitary enchondroma, one Ollier's disease, and one Maffuc‐
ci's syndrome. The one patient with Ollier's disease had two chondrosarcomas; and the single
patient with multiple osteochondroma had three chondrosarcomas. The overall rate of
malignant transformation for cartilage-originating tumors was 5.1%, being 4.2% for solitary
osteochondromas, 9.2% for multiple osteochondromas, and 4.2% for solitary enchondromas.
A variety of chromosomal abnormalities also have been reported in isolated cases of OD or
MS and chondrosarcoma. These abnormalities include, for example, the interstitial deletion,
del(1)(p11p31.2), as the only chromosomal abnormality identified in a low-grade chondrosar‐
coma in a patient with Ollier’s disease [117]. Also, Bovée et al [118] identified (1) the loss of
heterozygosity (LOH) in a tibial chondrosarcoma and its metastases, exclusively on chromo‐
some bands 13q14 and 9p21, with the LOH not identified in a femoral enchondroma that was
analyzed; and (2) p53 over-expression in a tibial chondrosarcoma and its metastases, not
present in a femoral enchondroma. Meanwhile, Chang et al [119] identified identical male twins
with OD who both developed astrocytomas within their cerebral cortex during their early
twenties; and Robinson et al [120] found evidence of mitogenic neurotransmitters within both
enchondromas and soft tissue hemangiomas in a patient with Maffucci’s syndrome, implying
that the bone and vascular lesions, and possibly malignant tumors, might be related to an
underlying neural abnormality. Having said all this, to date, no consistent chromosomal
abnormalities have been identified in these patients, and all theories regarding the cause of
malignancies in these syndromes remain unproven.
6.1. Ionizing radiation
The first report of a radiation-induced CNS tumor was by Mann et al in 1953 [121]. He described
the case of a 3 year-old girl, born in 1942, who presented with a left optic nerve astrocytoma
that was excised and then irradiated with a total dose over time of 6,500 rads. Six years later,
at age 9, she presented with her first episode of recurring frontal meningiomas, which
subsequently underwent malignant change, leading to her death at age 10. At about the same
time, two independent groups were reporting on the 1.5 to 2-fold increased risk of cancers,
including brain cancers, in children exposed to X-rays in utero [53], [122]- [124]. Subsequently,
more than 280 radiation-induced intracranial tumors have been reported in the literature, the
most common being meningiomas, sarcomas, and gliomas, though ependymomas, Schwan‐
nomas, PNETs, and pituitary adenomas have been described as well [125]. Consequently, the
association between therapeutic radiation to the head and the subsequent risk of brain cancer
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has been well-established, especially since a landmark study performed in Israel and published
in 1988 [126]. In this study, the relationship between radiotherapy in childhood for tinea capitis
and the later development of tumors of the brain and nervous system was evaluated in 10,834
patients treated between 1948 and 1960. Benign and malignant tumors were identified from
the pathology records of all Israeli hospitals and from Israeli national cancer and death
registries. Doses of radiation were estimated retrospectively for each patient (mean, 1.5 Gy).
The incidence of tumors was 1.8 per 10,000 persons per year, and the estimated relative risk
(RR) versus 10,834 matched general-population controls and 5392 non-irradiated siblings 6.9
(95% confidence interval 4.1-11.6) for all tumors and 8.4 (4.8-14.8) for neural tumors of the head
and neck. Increased risks were observed for meningiomas (RR = 9.5), gliomas (2.6), nerve-
sheath tumors (18.8), and other neural tumors (3.4). Moreover, a strong dose-response
relationship was identified, with relative risk approaching 20 beyond estimated doses of 2.5
Gy. Radiotherapy also was associated with an increased risk of death from tumors of the head
and neck, including brain cancers (RR = 3) and leukemia (RR = 2.3) [127].
In an earlier case-control study, 2,215 patients in New York who during childhood had been
given x-ray therapy for tinea capitis between 1940 and 1959 were compared against 1,395
persons matched for age, sex, and race and also treated for tinea capitis over the same period
without x-ray therapy [128]. Excess incidence was noted in irradiated cases of tumors of the
head and neck, including the skin, brain, thyroid, and parotid. However, there was no
increased mortality from malignant neoplasms or any other cause. In another study, diagnostic
X-rays of the head and neck increased the odds of brain tumors by 64% (OR 1.64; 95%CI,
1.04-2.58). [129] Thierry-Chef et al has estimated that the life-time increase in brain cancer risk
among pediatric patients receiving radiation to the brain ranges from 2 to 80%, depending
upon the dose and conditions of exposure [130]. There is, however, a huge range in the latency
time between irradiation and subsequent brain tumor development, from 4 to 47 years among
27 cases described by Chowdhary et al. [125] Clearly, some such tumors may arise in childhood,
and others much later.
7. Suspected/possible risk factors
In addition to risk factors that have been established through consistent results across several
studies, there are several suspected or possible risk factors for which data are either scarce or
conflicting. Difficulties that arise from the study of these risk factors include their somewhat
ubiquitous exposure (e.g., electromagnetic fields), difficulties measuring exposure (e.g., diet,
parental occupation), and their relative novelty (e.g., cell phones and other hand-held electric
devices).
7.1. Electromagnetic fields
Over the past few decades, considerable research has been compiled supporting the association
between electromagnetic field (EMF) exposure and childhood leukemia, such that the Inter‐
national Agency for Research on Cancer has classified extremely-low-frequency magnetic field
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exposure as a possible human carcinogen [131]. However, data linking EMF exposure and
brain cancer are much less conclusive [131]- [135]. Most older studies suffered from various
methodological issues, like the problem of inadequate blinding of those evaluating EMF
exposure, and crude measurements of actual exposure [53]. The first studies to overcome these
short-falls were conducted in Denver, Colorado by Savitz et al. who, in their initial study, had
blinded assessors evaluate the power-line configurations of the homes of all 356 residents in
the five-county 1970 Denver, Colorado Standard Metropolitan Statistical Area between 0 and
14 years of age who had been diagnosed with any form of cancer between 1976 and 1983;
among them were 59 confirmed cases of brain cancer [136]. The odds ratio comparing very
high and high wire codes versus very low, low, and buried wire codes was 1.5 (95% CI = 1.0-2.3)
for total cases, with OR = 2.0 for brain cancer. Subsequently, this same group studied the effect
on childhood cancer of prolonged exposure to 60-H magnetic fields from electric appliances
comparing Denver area children 0-14 years old whose incident cancers had been diagnosed
between 1976 and 1983 versus controls selected by random digit dialing, matched for age, sex,
and telephone exchange area. Parents of 252 cases and 222 controls were interviewed at home
about the use of electric appliances by the mother during pregnancy (prenatal exposure) and
by the child (postnatal exposure). After adjusting for income, prenatal electric blanket exposure
was associated with a significant increase in the incidence of childhood brain cancer (OR = 2.5,
95% CI 1.1-5.5) [137]. Subsequently, Savitz et al assessed for risk in the same Denver population
by comparing risks by high wire code (HWC) versus low wire code (LWC) classifications using
the Wertheimer-Leeper coding method, modified by eliminating the distinction between thick
and thin primaries, distinguishing only between open and spun secondaries, and reducing the
number of categories from five to three [138]. The association between the modified code and
measured magnetic fields was similar to the association with the original wire code. Residences
assigned the high wire code had odds ratios of 1.9 for total cancers (95% CI: 1.1-3.2), 2.9 for
leukemias (1.5-5.5), and 2.5 for brain cancer (1.1-5.5), after adjusting for all other measured
potential risk factors for childhood cancer.
In 2001 [134] and again in 2010 [139], Kheifets et al reviewed all major studies published on
the association between EMF and childhood brain cancers published to date and found that,
where the earlier studies by investigators like Wertheimer and Leeper [140], Savitz et al [136]-
[138] and Tomenius [141] identified an association between EMF exposure and increased brain
cancer risk, later studies and reviews by investigators like Preston-Martin et al [142], Gurney
et al [132], Feychting et al [143], Kheifits et al [133] generally failed to confirm this risk. In their
2010 meta-analysis of brain cancer risk with extremely low-frequency EMF, Kheifits et al
subdivided studies in terms of both the methodology of EMF measurement (long-term,
calculated fields, or spot measurement) and the type of home exposure (home at the time of
cancer diagnosis, longest-lived-in home, and birth home) and found no significantly elevated
odds ratios for any of the six categories, even with exposures ≥ 4µT [139]. This conclusion, that
there are no conclusive data linking EMF exposure with brain cancer risk has been echoed by
others [144], [145].
Relatively few papers have looked at the use of computers, per se. Both Mutnik et al and Wood
specifically assessed the risk of computer use in terms of brain cancer development, and neither
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(95% confidence interval 4.1-11.6) for all tumors and 8.4 (4.8-14.8) for neural tumors of the head
and neck. Increased risks were observed for meningiomas (RR = 9.5), gliomas (2.6), nerve-
sheath tumors (18.8), and other neural tumors (3.4). Moreover, a strong dose-response
relationship was identified, with relative risk approaching 20 beyond estimated doses of 2.5
Gy. Radiotherapy also was associated with an increased risk of death from tumors of the head
and neck, including brain cancers (RR = 3) and leukemia (RR = 2.3) [127].
In an earlier case-control study, 2,215 patients in New York who during childhood had been
given x-ray therapy for tinea capitis between 1940 and 1959 were compared against 1,395
persons matched for age, sex, and race and also treated for tinea capitis over the same period
without x-ray therapy [128]. Excess incidence was noted in irradiated cases of tumors of the
head and neck, including the skin, brain, thyroid, and parotid. However, there was no
increased mortality from malignant neoplasms or any other cause. In another study, diagnostic
X-rays of the head and neck increased the odds of brain tumors by 64% (OR 1.64; 95%CI,
1.04-2.58). [129] Thierry-Chef et al has estimated that the life-time increase in brain cancer risk
among pediatric patients receiving radiation to the brain ranges from 2 to 80%, depending
upon the dose and conditions of exposure [130]. There is, however, a huge range in the latency
time between irradiation and subsequent brain tumor development, from 4 to 47 years among
27 cases described by Chowdhary et al. [125] Clearly, some such tumors may arise in childhood,
and others much later.
7. Suspected/possible risk factors
In addition to risk factors that have been established through consistent results across several
studies, there are several suspected or possible risk factors for which data are either scarce or
conflicting. Difficulties that arise from the study of these risk factors include their somewhat
ubiquitous exposure (e.g., electromagnetic fields), difficulties measuring exposure (e.g., diet,
parental occupation), and their relative novelty (e.g., cell phones and other hand-held electric
devices).
7.1. Electromagnetic fields
Over the past few decades, considerable research has been compiled supporting the association
between electromagnetic field (EMF) exposure and childhood leukemia, such that the Inter‐
national Agency for Research on Cancer has classified extremely-low-frequency magnetic field
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exposure as a possible human carcinogen [131]. However, data linking EMF exposure and
brain cancer are much less conclusive [131]- [135]. Most older studies suffered from various
methodological issues, like the problem of inadequate blinding of those evaluating EMF
exposure, and crude measurements of actual exposure [53]. The first studies to overcome these
short-falls were conducted in Denver, Colorado by Savitz et al. who, in their initial study, had
blinded assessors evaluate the power-line configurations of the homes of all 356 residents in
the five-county 1970 Denver, Colorado Standard Metropolitan Statistical Area between 0 and
14 years of age who had been diagnosed with any form of cancer between 1976 and 1983;
among them were 59 confirmed cases of brain cancer [136]. The odds ratio comparing very
high and high wire codes versus very low, low, and buried wire codes was 1.5 (95% CI = 1.0-2.3)
for total cases, with OR = 2.0 for brain cancer. Subsequently, this same group studied the effect
on childhood cancer of prolonged exposure to 60-H magnetic fields from electric appliances
comparing Denver area children 0-14 years old whose incident cancers had been diagnosed
between 1976 and 1983 versus controls selected by random digit dialing, matched for age, sex,
and telephone exchange area. Parents of 252 cases and 222 controls were interviewed at home
about the use of electric appliances by the mother during pregnancy (prenatal exposure) and
by the child (postnatal exposure). After adjusting for income, prenatal electric blanket exposure
was associated with a significant increase in the incidence of childhood brain cancer (OR = 2.5,
95% CI 1.1-5.5) [137]. Subsequently, Savitz et al assessed for risk in the same Denver population
by comparing risks by high wire code (HWC) versus low wire code (LWC) classifications using
the Wertheimer-Leeper coding method, modified by eliminating the distinction between thick
and thin primaries, distinguishing only between open and spun secondaries, and reducing the
number of categories from five to three [138]. The association between the modified code and
measured magnetic fields was similar to the association with the original wire code. Residences
assigned the high wire code had odds ratios of 1.9 for total cancers (95% CI: 1.1-3.2), 2.9 for
leukemias (1.5-5.5), and 2.5 for brain cancer (1.1-5.5), after adjusting for all other measured
potential risk factors for childhood cancer.
In 2001 [134] and again in 2010 [139], Kheifets et al reviewed all major studies published on
the association between EMF and childhood brain cancers published to date and found that,
where the earlier studies by investigators like Wertheimer and Leeper [140], Savitz et al [136]-
[138] and Tomenius [141] identified an association between EMF exposure and increased brain
cancer risk, later studies and reviews by investigators like Preston-Martin et al [142], Gurney
et al [132], Feychting et al [143], Kheifits et al [133] generally failed to confirm this risk. In their
2010 meta-analysis of brain cancer risk with extremely low-frequency EMF, Kheifits et al
subdivided studies in terms of both the methodology of EMF measurement (long-term,
calculated fields, or spot measurement) and the type of home exposure (home at the time of
cancer diagnosis, longest-lived-in home, and birth home) and found no significantly elevated
odds ratios for any of the six categories, even with exposures ≥ 4µT [139]. This conclusion, that
there are no conclusive data linking EMF exposure with brain cancer risk has been echoed by
others [144], [145].
Relatively few papers have looked at the use of computers, per se. Both Mutnik et al and Wood
specifically assessed the risk of computer use in terms of brain cancer development, and neither
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identified any significant risk [146], [147]. However, both papers were written in the 1990s,
before the recent surge in home computer use, and long before prolonged exposures (e.g., 10
years or greater) to home computers could have occurred.
In one clever paper in which the pros and cons of the association between EMFs and childhood
brain cancer were debated by two teams, each composed of eight international experts, using
12 pre-determined questions, arguments on both sides ultimately concluded that further
research is necessary, an opinion vigorously championed by Carpenter in his paper Electro‐
magnetic fields and cancer: the cost of doing nothing [10]. However, contributing to the confusion
regarding EMF exposure are a number of methodological issues pertaining to the measure‐
ment of EMF, both in and around residences and in the workplace, issues that have sparked
almost as much debate and research as the question of EMF exposure’s role in disease [143],
[148]- [154]. Such issues include questions about the accuracy of EMF measurements, how to
avoid bias in subject selection, where best to measure EMF exposure (e.g., a child’s bedroom
versus elsewhere in or around the home), how to deal international variations in wiring
techniques, how to interpret changes in electrical wiring over time and their effects, and how
to adjust for the myriad of other potential confounders like other household exposures and
exposures, EMF and otherwise, outside of the home. This last issue is, in fact, a problem with
virtually all of the suspected or potential risk factors that are discussed here, including cell
phones and other hand=held electronic devices, which are the topic of the next section.
7.2. Cell phones and other hand-held devices
Over the past 15 years, there has been a virtual explosion in the use of hand-held cellular
devices like cell phones, iPods, iPads, Kindles, and other electronic reading devices. For
example, whereas uncommon in use in 1995, as of 2011, there were more than 4.6 billion active
mobile telephone subscriptions worldwide [155]. This has led to considerable concern
regarding the impact such devices might have upon health and, in particular because of the
issues raised with EMFs, upon brain cancer and leukemia rates.
Over the last decade, most data on cell-phone use and cancer risk have come from the 13-
country INTERPHONE Study, and from Sweden, and the results from these two sources have
been somewhat conflicting. In Sweden, most of the data has been collected by the research
group of Hardell et al. [129], [156] In their most recent study, analysis was performed pooling
data from two case-control studies on patients with malignant brain tumors diagnosed from
1997 through 2003 compared against matched controls alive at the time of study inclusion, and
a third case-control study on deceased patients and controls diagnosed over the same time
period [157]. In total, 1,251 (85%) cases and 2,438 (84%) controls were identified. Brain cancer
risk was noted to increase with latency period and cumulative use in hours, both for mobile
and cordless phones. The greatest level of risk was identified for astrocytoma, the odds ratio
(OR) for the longest (>10 year) latency group for mobile phone use equal to 2.7 (95% CI, 1.9-3.7)
and for cordless phone use 1.8 (1.2-2.9). The risk of astrocytoma was highest in the group with
first use of a wireless phone before the age of 20 (mobile phone use OR = 4.9, 95% CI = 2.2-11;
cordless phone use OR = 3.9, 95% CI = 1.7-8.7). Earlier, Hardell et al had reported on their
comparison of mobile phone use in deceased brain cancer cases relative to controls who had
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died from another type of cancer other than brain tumor, and to controls who had died from
other diseases. Exposure was assessed by a questionnaire sent to the next-of-kin. Replies were
obtained for 346 (75% participation rate) cases, 343 (74%) cancer controls and 276 (60%) controls
with other diseases. Use of mobile phones was associated with an increased risk of brain cancer
that was highest in the >10-year latency group, with an odds ratio of 2.4, (1.4-4.1). The risk
increased with cumulative number of lifetime hours for use, and was highest in those with
more than 2,000 hours of mobile phone use (OR = 3.4; 1.6-7.1). No clear association was found
for the use of cordless phones, though OR was 1.7 (0.8-3.4) among those with >2,000 h of
cumulative use [158]. These findings were interpreted as supporting earlier findings by this
group in other studies.
The INTERPHONE Study has been a multinational case-control study designed to investigate
whether mobile phone use increases the risk of cancer and, more specifically, whether the RF
fields emitted by mobile phones are carcinogenic [159]. As such, the study has focused on
tumors that arise within those tissues most exposed to the RF fields emitted by mobile phones
on the same (ipsilateral) side as phone use. In addition to collecting detailed histories on mobile
phone use, information has been collected on a number of known and potential risk factors
for these tumors. The study has been conducted in 13 countries: Australia, Canada, Denmark,
Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the UK
using a common core protocol. Enrolled in the study have been 2,765 individuals with gliomas,
2,425 with meningiomas, 1,121 with acoustic neuromas, 109 with malignant parotid gland
tumors and 7,658 controls. In addition to assessing brain cancer risk, particular attention has
been paid to estimating the amount and direction of potential recall and participation biases
and their impact upon study results. Results have been presented for countries individually
with consistently no statistically-significant within-country association identified between
phone use and brain cancer identified, as in Germany [160], [161], France [162], Sweden [163],
and Japan [164]. One exception was in Israel, where the odds ratios (OR) for benign and
malignant parotid gland tumors in the highest category of cumulative number of calls and call
time without use of hand-free devices were 1.58 (95% confidence interval: 1.11, 2.24) and 1.49
(1.05, 2.13), respectively [165].
When INTERPHONE data from multiple countries has been compiled, there has been a
significantly increased risk of glioma (OR = 1.40; 95% CI 1.03-1.89), but only among those in
the highest 10% of recalled cumulative call time (more than 1640 h). Any increased risk was
not statistically significant for meningiomas (OR = 1.15; 0.81-1.62) [166]. One issue raised by
the investigators was that there were implausible values of reported use in the highest user
group. Odds ratios for glioma did tend to be greater in the temporal lobe than in other lobes
of the brain, but the CIs around the lobe-specific estimates were wide. The ORs for glioma also
tended to be greater in subjects who reported usual phone use on the same side of the head as
their tumor than on the opposite side. In terms of actual exposure, represented by total
cumulative specific energy (TCSE; J/kg), when 553 glioma and 676 meningioma cases of brain
tumor from the Australian, Canadian, French, Israeli and New Zealand components of the
Interphone Study, whose tumors were localised by neuroradiologists, were compared with
controls matched for age, sex and region, and compared against 1762 and 1911 controls,
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identified any significant risk [146], [147]. However, both papers were written in the 1990s,
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regarding the impact such devices might have upon health and, in particular because of the
issues raised with EMFs, upon brain cancer and leukemia rates.
Over the last decade, most data on cell-phone use and cancer risk have come from the 13-
country INTERPHONE Study, and from Sweden, and the results from these two sources have
been somewhat conflicting. In Sweden, most of the data has been collected by the research
group of Hardell et al. [129], [156] In their most recent study, analysis was performed pooling
data from two case-control studies on patients with malignant brain tumors diagnosed from
1997 through 2003 compared against matched controls alive at the time of study inclusion, and
a third case-control study on deceased patients and controls diagnosed over the same time
period [157]. In total, 1,251 (85%) cases and 2,438 (84%) controls were identified. Brain cancer
risk was noted to increase with latency period and cumulative use in hours, both for mobile
and cordless phones. The greatest level of risk was identified for astrocytoma, the odds ratio
(OR) for the longest (>10 year) latency group for mobile phone use equal to 2.7 (95% CI, 1.9-3.7)
and for cordless phone use 1.8 (1.2-2.9). The risk of astrocytoma was highest in the group with
first use of a wireless phone before the age of 20 (mobile phone use OR = 4.9, 95% CI = 2.2-11;
cordless phone use OR = 3.9, 95% CI = 1.7-8.7). Earlier, Hardell et al had reported on their
comparison of mobile phone use in deceased brain cancer cases relative to controls who had
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on the same (ipsilateral) side as phone use. In addition to collecting detailed histories on mobile
phone use, information has been collected on a number of known and potential risk factors
for these tumors. The study has been conducted in 13 countries: Australia, Canada, Denmark,
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using a common core protocol. Enrolled in the study have been 2,765 individuals with gliomas,
2,425 with meningiomas, 1,121 with acoustic neuromas, 109 with malignant parotid gland
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been paid to estimating the amount and direction of potential recall and participation biases
and their impact upon study results. Results have been presented for countries individually
with consistently no statistically-significant within-country association identified between
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and Japan [164]. One exception was in Israel, where the odds ratios (OR) for benign and
malignant parotid gland tumors in the highest category of cumulative number of calls and call
time without use of hand-free devices were 1.58 (95% confidence interval: 1.11, 2.24) and 1.49
(1.05, 2.13), respectively [165].
When INTERPHONE data from multiple countries has been compiled, there has been a
significantly increased risk of glioma (OR = 1.40; 95% CI 1.03-1.89), but only among those in
the highest 10% of recalled cumulative call time (more than 1640 h). Any increased risk was
not statistically significant for meningiomas (OR = 1.15; 0.81-1.62) [166]. One issue raised by
the investigators was that there were implausible values of reported use in the highest user
group. Odds ratios for glioma did tend to be greater in the temporal lobe than in other lobes
of the brain, but the CIs around the lobe-specific estimates were wide. The ORs for glioma also
tended to be greater in subjects who reported usual phone use on the same side of the head as
their tumor than on the opposite side. In terms of actual exposure, represented by total
cumulative specific energy (TCSE; J/kg), when 553 glioma and 676 meningioma cases of brain
tumor from the Australian, Canadian, French, Israeli and New Zealand components of the
Interphone Study, whose tumors were localised by neuroradiologists, were compared with
controls matched for age, sex and region, and compared against 1762 and 1911 controls,
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respectively, ORs for glioma were below 1.0 within the first four quintiles of TCSE, but above
1.0 in the highest quintile, 1.35, approaching but not quite achieving statistical significance
(95% CI 0.96 to 1.90) [167]. In a complementary analysis in which 44 glioma and 135 meningi‐
oma cases in the most exposed area of the brain were compared against gliomas and menin‐
giomas located elsewhere, increased ORs were noted for tumors in the most exposed part of
the brain in those with 10 or more years of mobile phone use (OR 2.80, 95% CI 1.13 to 6.94 for
glioma). And, in pooled analysis across the four Nordic countries and the UK, increased risk
of a tumor on the same side of the head as reported phone use that has persisted for ≥ 10 years
was noted (OR = 1.8, 95% CI: 1.1-3.1) [168].
No increased risk of acoustic neuroma was identified in any study [169]. Overall, the INTER‐
PHONE investigators concluded that there were no conclusive data linking cell-phone use and
risk of brain malignancies, except after prolonged and exorbitant use. Criticisms have been
made of the INTERPHONE studies, however, relating, among other issues, to recall and
misclassification biases potentially exacerbated by low response rates [170]- [172].
In a meta-analysis drawing from both sets of studies (Hardell et al and INTERPHONE),
Hardell et al found that the odds ratio for glioma (1.0; 95% CI, 0.9-1.1) increased to 1.3 (1.1-1.6)
after a 10-year latency period, with the highest risk identified for ipsilateral exposure (OR=1.9;
1.4-2.4) versus OR=1.2 (0.9-1.7) with contralateral exposure [173]. The odds of acoustic neuroma
(OR=1.0; 0.8-1.1) also increased after a 10-year latency period, but just failed to achieve
statistical significance (OR=1.3; 0.97-1.9), except when ipsilateral exposure was considered
alone (OR=1.6; 1.1-2.4). No consistent pattern of increased risk was uncovered for meningio‐
mas. In terms of age, the highest risk of brain cancer was identified among those who were
under 20 years of age at the time they first started using wireless phones.
Outside these two sources of multiple studies, another source of data stems from the previ‐
ously-mentioned SEER database in the U.S., drawing from which Little et al compared
epidemiological data from 12 registries (Atlanta, Detroit, Los Angeles, San Francisco, San Jose-
Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New Mexico, and Utah) against
incidence trends reported by the INTERPHONE Study Group and Hardell’s group in Sweden
[174]. U.S. population-based data was evaluated for glioma incidence from 1992 to 2008, a
period of time during which mobile phone use increased dramatically from virtually 0% to
almost 100% of the U.S. population. During these years, 24,813 non-Hispanic Caucasians 18
years or older were diagnosed with glioma. Age-specific incidence rates of glioma remained
generally stable from 1992 to 2008 (-0.02% change per year, 95% confidence interval -0.28% to
0.25%), despite the exponential increase in cell-phone use. The authors concluded that the
decline in brain cancer rates they observed was inconsistent with the association between brain
cancer and mobile phone use conjectured by Hardell’s group, since rates should have been at
least 40% higher than observed. On the other hand, they felt that the SEER data could be
consistent with the glioma rates predicted based upon the small proportion of highly-exposed
individuals reported in the INTERPHONE study.
Overall, results on the association between mobile phone use and brain cancer certainly might
be considered suggestive, particularly in terms of long-term risk after years of exposure to cell
phones, especially when used extensively. However, in two just-published reviews, Swerdlow
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et al [155] and Repacholi et al [11] both noted the inconclusiveness of current data, and on the
limitations imposed by the absence of data both on exposures beyond 10 to 15 years, and on
childhood cancers. Echoing Carpenter’s concerns about EMF exposures in general [10], what
is potentially alarming is the potential for further increases in brain cancer risk after latencies
beyond ten years, especially given the now almost-universal use of cell phones and other hand-
held electronic devices by adolescents and children.
7.3. Diet (maternal diet during pregnancy/childhood diet)
Many of the same methodological issues and sources of potential bias (e.g., recall and ascer‐
tainment bias) pertain to maternal and childhood diet as to electromagnetic field exposure,
rendering research to address the association between diet and childhood brain cancer
difficult. For that reason, the research into this issue is, again, inconclusive. The most consis‐
tently positive association between diet and childhood brain cancer risk has been for cured
meats, like hot dogs. In Denver, Colorado, cured and broiled meat consumption by mothers
during pregnancy and by children themselves was assessed in 234 childhood cancer cases
(including 45 brain tumor patients) and 206 controls selected by random digit dialing [175].
Five meat groups (ham, bacon, or sausage; hot dogs; hamburgers; bologna, pastrami, corned
beef, salami, or lunch meat; charcoal-broiled foods) were assessed. Exposures among U.S.
standard metropolitan statistical areas were compared, with adjustments made for confound‐
ers. Maternal hot dog consumption once or more weekly was statistically associated with
childhood brain tumors (OR = 2.3, 95%CI, 1.0-5.4). Meanwhile, among children, eating
hamburgers once or more times per week was associated with a non-statistically increased risk
of ALL (OR = 2.0, CI = 0.9-4.6), as was eating hot dogs once or more times weekly with brain
tumors (2.1; 0.7-6.1). However, among children, the combination of no vitamins and eating
cured meats was associated more strongly with both ALL and brain cancer than either no
vitamins or meat consumption alone, producing ORs between 2 and 7, suggesting possible
adverse effects of dietary nitrites and nitrosamines.
Bunin et al and the Children’s Cancer Group conducted a case-control study specifically
assessing the effects of maternal diet during pregnancy on the risk of childhood astrocytoma
in 155 cases and 155 matched controls, all under age six, the controls selected by random-digit
dialing [176]. A trend again was observed for consumption of cured meats (adjusted odds ratio
[OR] for the highest versus lowest intake quartile = 1.7, p = 0.10). Iron supplements were
associated with a significant decrease in astrocytoma risk (OR = 0.5, 95%CI, 0.3-0.8). No
significant trends were observed for nitrosamine (OR = 0.8, p = 0.60); nitrites (1.3, p = 0.54);
nitrates (0.7, p = 0.43); vitamin C (0.7, p = 0.37); or vitamin E (0.7, p = 0.48). Unfortunately,
income level was a potential confounder.
In yet another high-profile case-control study, Bunin et al examined maternal diet relative to
the risk of primitive neuroectodermal tumors (PNET) of the brain in offspring, with all 166
cases again under the age of six years at diagnosis [177]. As in the previously-mentioned study,
controls were selected by random-digit dialing and matched for age and race. Telephone
interviews with mothers included questions on the frequency of consumption of alcohol,
vitamin and mineral supplements, and 53 specific foods during pregnancy. Significant
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respectively, ORs for glioma were below 1.0 within the first four quintiles of TCSE, but above
1.0 in the highest quintile, 1.35, approaching but not quite achieving statistical significance
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giomas located elsewhere, increased ORs were noted for tumors in the most exposed part of
the brain in those with 10 or more years of mobile phone use (OR 2.80, 95% CI 1.13 to 6.94 for
glioma). And, in pooled analysis across the four Nordic countries and the UK, increased risk
of a tumor on the same side of the head as reported phone use that has persisted for ≥ 10 years
was noted (OR = 1.8, 95% CI: 1.1-3.1) [168].
No increased risk of acoustic neuroma was identified in any study [169]. Overall, the INTER‐
PHONE investigators concluded that there were no conclusive data linking cell-phone use and
risk of brain malignancies, except after prolonged and exorbitant use. Criticisms have been
made of the INTERPHONE studies, however, relating, among other issues, to recall and
misclassification biases potentially exacerbated by low response rates [170]- [172].
In a meta-analysis drawing from both sets of studies (Hardell et al and INTERPHONE),
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after a 10-year latency period, with the highest risk identified for ipsilateral exposure (OR=1.9;
1.4-2.4) versus OR=1.2 (0.9-1.7) with contralateral exposure [173]. The odds of acoustic neuroma
(OR=1.0; 0.8-1.1) also increased after a 10-year latency period, but just failed to achieve
statistical significance (OR=1.3; 0.97-1.9), except when ipsilateral exposure was considered
alone (OR=1.6; 1.1-2.4). No consistent pattern of increased risk was uncovered for meningio‐
mas. In terms of age, the highest risk of brain cancer was identified among those who were
under 20 years of age at the time they first started using wireless phones.
Outside these two sources of multiple studies, another source of data stems from the previ‐
ously-mentioned SEER database in the U.S., drawing from which Little et al compared
epidemiological data from 12 registries (Atlanta, Detroit, Los Angeles, San Francisco, San Jose-
Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New Mexico, and Utah) against
incidence trends reported by the INTERPHONE Study Group and Hardell’s group in Sweden
[174]. U.S. population-based data was evaluated for glioma incidence from 1992 to 2008, a
period of time during which mobile phone use increased dramatically from virtually 0% to
almost 100% of the U.S. population. During these years, 24,813 non-Hispanic Caucasians 18
years or older were diagnosed with glioma. Age-specific incidence rates of glioma remained
generally stable from 1992 to 2008 (-0.02% change per year, 95% confidence interval -0.28% to
0.25%), despite the exponential increase in cell-phone use. The authors concluded that the
decline in brain cancer rates they observed was inconsistent with the association between brain
cancer and mobile phone use conjectured by Hardell’s group, since rates should have been at
least 40% higher than observed. On the other hand, they felt that the SEER data could be
consistent with the glioma rates predicted based upon the small proportion of highly-exposed
individuals reported in the INTERPHONE study.
Overall, results on the association between mobile phone use and brain cancer certainly might
be considered suggestive, particularly in terms of long-term risk after years of exposure to cell
phones, especially when used extensively. However, in two just-published reviews, Swerdlow
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et al [155] and Repacholi et al [11] both noted the inconclusiveness of current data, and on the
limitations imposed by the absence of data both on exposures beyond 10 to 15 years, and on
childhood cancers. Echoing Carpenter’s concerns about EMF exposures in general [10], what
is potentially alarming is the potential for further increases in brain cancer risk after latencies
beyond ten years, especially given the now almost-universal use of cell phones and other hand-
held electronic devices by adolescents and children.
7.3. Diet (maternal diet during pregnancy/childhood diet)
Many of the same methodological issues and sources of potential bias (e.g., recall and ascer‐
tainment bias) pertain to maternal and childhood diet as to electromagnetic field exposure,
rendering research to address the association between diet and childhood brain cancer
difficult. For that reason, the research into this issue is, again, inconclusive. The most consis‐
tently positive association between diet and childhood brain cancer risk has been for cured
meats, like hot dogs. In Denver, Colorado, cured and broiled meat consumption by mothers
during pregnancy and by children themselves was assessed in 234 childhood cancer cases
(including 45 brain tumor patients) and 206 controls selected by random digit dialing [175].
Five meat groups (ham, bacon, or sausage; hot dogs; hamburgers; bologna, pastrami, corned
beef, salami, or lunch meat; charcoal-broiled foods) were assessed. Exposures among U.S.
standard metropolitan statistical areas were compared, with adjustments made for confound‐
ers. Maternal hot dog consumption once or more weekly was statistically associated with
childhood brain tumors (OR = 2.3, 95%CI, 1.0-5.4). Meanwhile, among children, eating
hamburgers once or more times per week was associated with a non-statistically increased risk
of ALL (OR = 2.0, CI = 0.9-4.6), as was eating hot dogs once or more times weekly with brain
tumors (2.1; 0.7-6.1). However, among children, the combination of no vitamins and eating
cured meats was associated more strongly with both ALL and brain cancer than either no
vitamins or meat consumption alone, producing ORs between 2 and 7, suggesting possible
adverse effects of dietary nitrites and nitrosamines.
Bunin et al and the Children’s Cancer Group conducted a case-control study specifically
assessing the effects of maternal diet during pregnancy on the risk of childhood astrocytoma
in 155 cases and 155 matched controls, all under age six, the controls selected by random-digit
dialing [176]. A trend again was observed for consumption of cured meats (adjusted odds ratio
[OR] for the highest versus lowest intake quartile = 1.7, p = 0.10). Iron supplements were
associated with a significant decrease in astrocytoma risk (OR = 0.5, 95%CI, 0.3-0.8). No
significant trends were observed for nitrosamine (OR = 0.8, p = 0.60); nitrites (1.3, p = 0.54);
nitrates (0.7, p = 0.43); vitamin C (0.7, p = 0.37); or vitamin E (0.7, p = 0.48). Unfortunately,
income level was a potential confounder.
In yet another high-profile case-control study, Bunin et al examined maternal diet relative to
the risk of primitive neuroectodermal tumors (PNET) of the brain in offspring, with all 166
cases again under the age of six years at diagnosis [177]. As in the previously-mentioned study,
controls were selected by random-digit dialing and matched for age and race. Telephone
interviews with mothers included questions on the frequency of consumption of alcohol,
vitamin and mineral supplements, and 53 specific foods during pregnancy. Significant
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protective trends were observed for vegetables (OR for the highest versus lowest quartile
group for intake, 0.37; p = 0.005), fruits and fruit juices (OR = 0.28; p = 0.003), vitamin A (0.59;
p = 0.03), vitamin C (0.42; p = 0.009), nitrate (0.44; p = 0.002), and folate (0.38; p = 0.005). Taking
iron (0.43; p = 0.004), calcium (0.42; p = 0.05), and vitamin C (0.35; p = 0.04) supplements at any
time during pregnancy and multivitamins over the first six weeks (0.56; p = 0.02) all were
associated with decreased risk. On multivariate analyses, folate, early multivitamin use, and
iron supplements remained protective [177]. A non-significant trend of increasing risk was
observed for nitrosamine consumption (1.65; p = 0.15).
Concerns over the consumption of nitrates, nitrites and nitroamines have been expressed by
others, given the susceptibility of rats to develop brain tumors in response to N-nitroso urea
exposure, the morphological similarity between these tumors and those observed in humans,
and the presence of nitrate salts in many fertilizers [178]. Consistent with this potential risk,
one meta-analysis of brain cancer risk in U.S. farmers yielded a relative risk of 1.30 (95% CI,
1.09, 1.56) [179], though pesticides, to which farmers also often are exposed, are another
potential explanatory factor. In yet another case-control study, an increased risk of childhood
astrocytomas was detected in association with in utero exposure to nitrites via a residential
water source [180].
7.4. Environmental neurocarcinogens and parental occupation
As confusing and diverse the literature on EMF and diet is, it is even more so with respect to
environmental and occupational exposures, due to the difficulties ascertaining and quantify‐
ing levels of exposure, especially when that exposure is second-hand to a child.
Pesticide exposure, both first-hand and second-hand, has been shown to be associated with
increased brain cancer risk in children in a number of studies; but effects have tended to be
modest and sometimes conflicting. Daniels et al [181] reviewed the results of 31 studies
published between 1970 and 1996 and noted methodological issues in most of them, including
small sample sizes, inadequate measurement of actual exposure, and potential biases related
to the selection of controls. A further inconsistency was the lack of an effect of direct exposure
to the child in studies in which an effect of parental occupational exposure was identified, a
clearly counter-intuitive discovery [181]. Risks also varied with the type of pesticide and type
and level of exposure. For example, Shim et al compared 526 brain cancer cases diagnosed
before age 10 years and identified from statewide cancer registries of four U.S. Atlantic Coast
states versus one-to-one-matched controls selected via random digit dialing [182]. Exposure
risk was assessed through computer-assisted telephone interviews with mothers. Using
information on residential pesticide use and jobs held by fathers over the 2-year period prior
to the child's birth, potential exposures to insecticides, herbicides, and fungicides were
estimated. For each occupation, two raters independently classified the probability and
intensity of exposure. A significantly increased risk of astrocytoma was associated with
exposures to herbicides from residential use (OR = 1.9; 95% CI, 1.2-3.0). Combining parental
exposures to herbicides from both residential and occupational sources, the elevated risk
remained significant (1.8; 1.1-3.1). Little association was observed with primitive neuroecto‐
dermal tumors (PNET) for any of the pesticide classes or exposure sources considered. In
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another study, the risk of childhood brain cancer was again assessed relative to parental
exposure to different classes of pesticide in 154 children diagnosed with astrocytoma and 158
children diagnosed with primitive neuroectodermal tumors (PNET) in the United States and
Canada between 1986 and 1989 [183]. Controls again were selected by random digit dialing
and were individually matched to cases by race, age, and geographic area. Each job in the
fathers' work history and the usual occupation of mothers were assigned a probability,
intensity, and frequency of exposure to insecticides, herbicides, and agricultural and non-
agricultural fungicides. Elevated risks of astrocytoma were identified for paternal exposure
(ever vs. never) to all four classes of pesticides (odds ratios (OR) = 1.4-1.6), while an increased
risk of PNET was observed only for herbicides (OR = 1.5). For mothers, odds ratios for
astrocytoma were elevated for insecticides, herbicides, and non-agricultural fungicides (OR =
1.3-1.6) but not agricultural fungicides (OR = 1.0). Concerns have been raised about the
accuracy of the levels of probability, intensity, and frequency of exposure assigned to mothers
and fathers. Interestingly, both studies that assessed the use of no-pest strips within the home
identified increased childhood brain cancer risk [184], [185]. In the study by Leiss et al, this
effect was dose dependent, with the odds ratio of brain tumors equal to 1.5 (95%CI, 0.9-2.4)
when exposure was limited to just the last three months of pregnancy, versus 1.8 (1.2-2.9) when
exposure was for the full two years prior to and throughout pregnancy [185]. One potential
mechanism for direct pesticide-induced cancer risk is their conversion via nitrites in the
stomach into potentially-carcinogenic N-nitroso compounds [186]; though how this might
affect an unborn child is unclear.
Hair dyes are another environmental and occupational neurocarcinogen that has been shown
to significantly increase brain cancer risk. In a population-based case-control study involving
112 white women in Nebraska newly diagnosed with glioma between July 1988 and June 1993,
versus 215 controls, a 1.7-fold increased risk of glioma was observed among those who had
ever used hair coloring products (95%CI = 1.0-2.9) [187]. This risk increased to 2.4 among those
who had used permanent hair coloring products (95%CI, 1.3-4.5), and the risk of glioblastoma
increased with duration of exposure, to 4.9 (95% CI, 1.6-15.7) after 21 or more years of perma‐
nent hair color use. Higher risks also were observed with earlier age at first use. In another
study, the risk of brain cancer among children born on or after 1980 to women who had
personally used hair dyes over the five years prior to pregnancy was increased 11-fold, though
the confidence limits were broad (95%CI, 1.2-90) [188]. Childhood brain cancers also were
associated with non-work-related maternal exposure to any beauty products (OR = 2.6, 95%CI,
1.2-5.9) and to hair sprays (3.4; 1.0-11).
Choi et al identified a significant risk of childhood brain cancer before age 5 in women living
within one mile of a facility releasing toxic release inventory (TRI) chemicals while pregnant
[189]. In 2008, Clapp, Jacobs and Loechler published a detailed review of environmental and
occupational causes of cancer, a 40-page manuscript with extensive tables that list all chemicals
and other environmental exposures associated with a variety of cancers. For brain cancers,
evidence of an association is considered strong only for ionizing radiation [180].
Occupational exposures have been assessed both for the mother and father, but especial‐
ly  the  latter,  in  terms  of  child  cancer  risk  [4].  Besides  farming/agriculture,  associations
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protective trends were observed for vegetables (OR for the highest versus lowest quartile
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iron (0.43; p = 0.004), calcium (0.42; p = 0.05), and vitamin C (0.35; p = 0.04) supplements at any
time during pregnancy and multivitamins over the first six weeks (0.56; p = 0.02) all were
associated with decreased risk. On multivariate analyses, folate, early multivitamin use, and
iron supplements remained protective [177]. A non-significant trend of increasing risk was
observed for nitrosamine consumption (1.65; p = 0.15).
Concerns over the consumption of nitrates, nitrites and nitroamines have been expressed by
others, given the susceptibility of rats to develop brain tumors in response to N-nitroso urea
exposure, the morphological similarity between these tumors and those observed in humans,
and the presence of nitrate salts in many fertilizers [178]. Consistent with this potential risk,
one meta-analysis of brain cancer risk in U.S. farmers yielded a relative risk of 1.30 (95% CI,
1.09, 1.56) [179], though pesticides, to which farmers also often are exposed, are another
potential explanatory factor. In yet another case-control study, an increased risk of childhood
astrocytomas was detected in association with in utero exposure to nitrites via a residential
water source [180].
7.4. Environmental neurocarcinogens and parental occupation
As confusing and diverse the literature on EMF and diet is, it is even more so with respect to
environmental and occupational exposures, due to the difficulties ascertaining and quantify‐
ing levels of exposure, especially when that exposure is second-hand to a child.
Pesticide exposure, both first-hand and second-hand, has been shown to be associated with
increased brain cancer risk in children in a number of studies; but effects have tended to be
modest and sometimes conflicting. Daniels et al [181] reviewed the results of 31 studies
published between 1970 and 1996 and noted methodological issues in most of them, including
small sample sizes, inadequate measurement of actual exposure, and potential biases related
to the selection of controls. A further inconsistency was the lack of an effect of direct exposure
to the child in studies in which an effect of parental occupational exposure was identified, a
clearly counter-intuitive discovery [181]. Risks also varied with the type of pesticide and type
and level of exposure. For example, Shim et al compared 526 brain cancer cases diagnosed
before age 10 years and identified from statewide cancer registries of four U.S. Atlantic Coast
states versus one-to-one-matched controls selected via random digit dialing [182]. Exposure
risk was assessed through computer-assisted telephone interviews with mothers. Using
information on residential pesticide use and jobs held by fathers over the 2-year period prior
to the child's birth, potential exposures to insecticides, herbicides, and fungicides were
estimated. For each occupation, two raters independently classified the probability and
intensity of exposure. A significantly increased risk of astrocytoma was associated with
exposures to herbicides from residential use (OR = 1.9; 95% CI, 1.2-3.0). Combining parental
exposures to herbicides from both residential and occupational sources, the elevated risk
remained significant (1.8; 1.1-3.1). Little association was observed with primitive neuroecto‐
dermal tumors (PNET) for any of the pesticide classes or exposure sources considered. In
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another study, the risk of childhood brain cancer was again assessed relative to parental
exposure to different classes of pesticide in 154 children diagnosed with astrocytoma and 158
children diagnosed with primitive neuroectodermal tumors (PNET) in the United States and
Canada between 1986 and 1989 [183]. Controls again were selected by random digit dialing
and were individually matched to cases by race, age, and geographic area. Each job in the
fathers' work history and the usual occupation of mothers were assigned a probability,
intensity, and frequency of exposure to insecticides, herbicides, and agricultural and non-
agricultural fungicides. Elevated risks of astrocytoma were identified for paternal exposure
(ever vs. never) to all four classes of pesticides (odds ratios (OR) = 1.4-1.6), while an increased
risk of PNET was observed only for herbicides (OR = 1.5). For mothers, odds ratios for
astrocytoma were elevated for insecticides, herbicides, and non-agricultural fungicides (OR =
1.3-1.6) but not agricultural fungicides (OR = 1.0). Concerns have been raised about the
accuracy of the levels of probability, intensity, and frequency of exposure assigned to mothers
and fathers. Interestingly, both studies that assessed the use of no-pest strips within the home
identified increased childhood brain cancer risk [184], [185]. In the study by Leiss et al, this
effect was dose dependent, with the odds ratio of brain tumors equal to 1.5 (95%CI, 0.9-2.4)
when exposure was limited to just the last three months of pregnancy, versus 1.8 (1.2-2.9) when
exposure was for the full two years prior to and throughout pregnancy [185]. One potential
mechanism for direct pesticide-induced cancer risk is their conversion via nitrites in the
stomach into potentially-carcinogenic N-nitroso compounds [186]; though how this might
affect an unborn child is unclear.
Hair dyes are another environmental and occupational neurocarcinogen that has been shown
to significantly increase brain cancer risk. In a population-based case-control study involving
112 white women in Nebraska newly diagnosed with glioma between July 1988 and June 1993,
versus 215 controls, a 1.7-fold increased risk of glioma was observed among those who had
ever used hair coloring products (95%CI = 1.0-2.9) [187]. This risk increased to 2.4 among those
who had used permanent hair coloring products (95%CI, 1.3-4.5), and the risk of glioblastoma
increased with duration of exposure, to 4.9 (95% CI, 1.6-15.7) after 21 or more years of perma‐
nent hair color use. Higher risks also were observed with earlier age at first use. In another
study, the risk of brain cancer among children born on or after 1980 to women who had
personally used hair dyes over the five years prior to pregnancy was increased 11-fold, though
the confidence limits were broad (95%CI, 1.2-90) [188]. Childhood brain cancers also were
associated with non-work-related maternal exposure to any beauty products (OR = 2.6, 95%CI,
1.2-5.9) and to hair sprays (3.4; 1.0-11).
Choi et al identified a significant risk of childhood brain cancer before age 5 in women living
within one mile of a facility releasing toxic release inventory (TRI) chemicals while pregnant
[189]. In 2008, Clapp, Jacobs and Loechler published a detailed review of environmental and
occupational causes of cancer, a 40-page manuscript with extensive tables that list all chemicals
and other environmental exposures associated with a variety of cancers. For brain cancers,
evidence of an association is considered strong only for ionizing radiation [180].
Occupational exposures have been assessed both for the mother and father, but especial‐
ly  the  latter,  in  terms  of  child  cancer  risk  [4].  Besides  farming/agriculture,  associations
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have  been  reported  for  the  aircraft,  electronics,  petroleum,  and  pulp  and  paper  indus‐
tries, as well as for any industries associated with increased exposures to paints, solvents,
other chemicals, pesticides, ionizing radiation, and electromagnetic fields [4], [190]. Albeit
now more than 20 years old, Savitz and Chen wrote a very thorough paper summarizing
all studies performed to date assessing the risk of childhood brain cancers, hematopoietic
malignancies, and other malignancies relative to both paternal and maternal occupations
[191].  Occupations  were  subdivided  into  motor  vehicle  related  occupations,  machinist
and factory workers,  occupations with paint  exposure,  occupations with chemical  expo‐
sure,  the  petroleum  industry,  occupations  with  exposure  to  aggregated  hydrocarbons,
electronics,  occupations associated with ionizing radiation, occupations with metal expo‐
sure,  agriculture,  construction,  pulp  and  paper,  aerospace  and  aircraft  industries,  and
other occupations (printing workers,  graphic arts  workers,  and glass,  clay and stone in‐
dustry).  For virtually every occupational category, there was at least one study identify‐
ing  a  statistically  increased  odds  ratio  for  childhood  nervous  system  cancer.  Table  2
summarizes that  list,  noting the number of  studies  in each job category,  the number of
studies with an odds ratio for childhood brain cancer > 1.0,  the number of studies with
an odds ratio  statistically  greater  than 1.0,  and the range of  odds ratios  within that  job
category.
Note that, in no category for which there was more than a single study, was every odds ratio
for childhood brain cancer statistically greater than one. Note also that the industries in which
all odds ratios were > 1.0, even if not statistically significant, were the petroleum industry,
electrical work, metal work, and pulp and paper. Note also that some industries, like health
care, were not mentioned. Among mothers, the odds ratios for childhood brain cancer were
3.3 for occupations with chemicals on the skin, 3.0 for occupations involving inhaled chemicals
of fumes, 1.6 for bakers, and 4.0 for occupations requiring protective clothing or equipment
[191]; only the last OR was statistically greater than 1.0.
In a later and also quite thorough review of the literature, published in 1998, Colt and Blair
reviewed 48 papers published between 1974 and 1987, encompassing relative risk estimates
for over 1000 specific cancer/occupation and cancer/exposure combinations [192]. Of these
papers, 23 contained data assessing the relationship between paternal occupations and
childhood nervous system cancers other than neuroblastoma; maternal occupations only were
evaluated in terms of childhood leukemia risk. In table form, these authors listed studies by
exposure, categorizing into electromagnetic fields; paints and pigments; hydrocarbons; metals;
and motor vehicle-related occupations. These results are summarized in Table 3.
As in the review by Savitz and Chen, the results were conflicting, the authors themselves
concluding that the evidence was strongest in support of an association between paternal
exposure to paints and pigments [192]. Results on maternal occupations were scant and yielded
no statistically significant associations.
More recently published studies yield much the same diffuse and inconsistent results [193]-
[196], including one recently published study (2008) in Taiwan in which no associations among
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202 young brain cancer cases, ages 0 to 29 years, were identified across a wide variety of
occupations [197].
Finally, in one novel study, Rosso et al examined whether or not there was an association
between a father’s hobbies and brain cancer risk in their child, specifically looking at medul‐
loblastomas and other PNET in 318 children under age 6 versus 318 randomly selected
population controls [198]. On multivariate analyses, the only significant association was for
lawn care with pesticides [during pregnancy: odds ratio (OR) = 1.6, 95% confidence interval
(CI): 1.0, 2.5; after birth: OR = 1.8, 95% CI: 1.2, 2.8].
7.5. Other potential risk factors
Numerous other risk factors for childhood brain cancer have been reported, albeit mostly in
single studies. Neonatal head circumference was found to be associated with an increased risk
Occupation/Main Exposure Number of studies Number of OR "/>
1.0
# OR statistically "/>
1.0
Range of OR
Motor vehicles 7 3 1 0.6 - 2.8
Machinist & factory workers 5 3 1 0.7 - 4.4
Paint 4 3 1 1.0 - 7.0
Chemicals 6 5 3 0.8 - 10.0
Petroleum 3 3 0 1.3 - 3.1
Aggregated hydrocarbons 6 4 1 0.5 - 3.2
Electrical 4 4 2 1.6 - 11.8
Ionizing radiation 6 5 2 1.0 - 2.2
Metals 3 3 1 1.6 - 2.7
Agriculture 4 2 n/a 0.6 - 2.0
Construction 4 3 2 0.9 - 2.3
Pulp & paper 3 3 1 1.6 - 4.0
Aerospace & aircraft 3 2 1 1.0 - ∞*
Printing workers 1 1 1 4.5
Graphic arts 1 1 1 21.9
Glass, clay, stone 1 1 0 1.5
Total 61 46 18 0.5 - ∞*
Savitz and Chen, 1990 [1] [9] [1]
* ∞ = infinity
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and motor vehicle-related occupations. These results are summarized in Table 3.
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concluding that the evidence was strongest in support of an association between paternal
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of brain cancer by Samuelson et al, who analysed 1,010,366 individuals with 12,378,172 person-
years of follow-up, from which 453 individuals ages 0 to 15 years were diagnosed with brain
cancer [199]. In this population, the relative risk of brain cancer was 1.27 (95%CI 1.16-1.38) for
every 1 cm increase in head circumference, after adjusting for birth-weight, gestational age,
and gender. In another study of 746 invasive CNS cancers in children less than 4 years old,
after adjusting for parental education, elevated birth-weight was associated with an odds ratio
of 1.71 for astrocytoma (95%CI, 1.01-2.90); but birth weight was not associated with an
increased risk of PNET [42].
Prior malignancy has been associated with a variety of malignancies in the literature, including
brain cancer. Some of this increased risk almost certainly is secondary to radiation therapy to
the head and neck [129]. Yet even when head irradiation is not utilized, brain cancer risk may
be increased. Maule et al identified a total of 133 second malignant neoplasms in 16,540 patients
with hematopoietic malignancies (12,731 leukemias, 1246 Hodgkin’s lymphomas, and 2563
non-Hodgkin’s lymphomas) after an average follow-up of 6.5 years [200]. The most frequent
second malignancies after leukemia were brain cancer (standardized incidence ratio [SIR] =
8.52; 95% CI = 5.13 to 13.3), non-Hodgkin’s lymphoma (SIR = 9.41; 4.30 to 17.9), and thyroid
cancer (SIR = 18.8; 8.60 to 35.7). The most frequent after non-Hodgkin’s lymphoma were
thyroid cancer (SIR = 40.4; 14.8 to 88.0) and brain cancer (SIR = 6.97; 1.90 to 17.9). There was no
increased incidence of brain cancer following Hodgkin’s lymphoma.
In Rio de Janeiro, in a hospital-based case-control study involving 231 adults with primary
brain tumors and 261 controls matched for gender and age among in-patients hospitalized for
various conditions unrelated to brain cancer, past head injury was found to be significantly
more frequent among cases (46%) than controls (36%) (OR(adjusted) = 1.49; 95%CI = 1.03-2.15)
[201]. Moreover, a dose-response effect was observed related to the number of head injuries,
and a statistically-borderline association was observed specifically for meningioma (OR(adj)
= 1.63; 0.96-2.75). These results have not yet been replicated and, to date, no such association
has been identified for childhood brain cancer.
Main Exposures # RR estimates Number of RR "/> 1.0 # RR statistically "/> 1.0 Range of RR
Electromagnetic fields 55 45 9 0.3 - 73.3
Paints & pigments 14 13 4 1.0 - ∞
Hydrocarbons 28 12 2 0.4 - 4.0
Metals 17 15 4 0.8 - 5.3
Motor vehicles, etc. 32 12 2 0.1 -5.9
Total 146 97 21 0.1 - ∞
Colt and Blair, 1998 [192]
* ∞ = infinity
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In a nationwide Danish study on the occurrence of cancer among 8,093 Danish individuals
born with an oral cleft deformity between 1936 and 1998 and followed in the Danish Cancer
Registry from 1968 through 1998, a total of 175,863 person-years, the possible association
between cancer and oral clefts was assessed [202]. The expected overall number of all cancers
was 131, but 140 incident cancers were found, corresponding to a standardized incidence ratio
of 1.07 (95%CI, 0.90-1.26). Analyses of the 52 sites for all oral cleft cases and analyses stratified
into three cleft subgroups and two sexes revealed only a few significant associations, one of
which was the increased incidence of primary brain cancer among females, but not males, born
with a cleft palate (SIR = 3.11; 1.14, 6.78).
Finally, medications are often listed as a potential risk factor for brain cancer [203], but there
are almost no data scientifically supporting such a claim. In one case-control study of 163
matched pairs, patients under 15 years of age when diagnosed with astrocytoma between 1980
and 1986 were identified through the tumor registries of eight hospitals in Pennsylvania, New
Jersey, and Delaware [204]. Controls were selected by random digit dialing, and matched to
cases for age, race, and telephone area code and exchange. In this population, maternal anti-
nausea medications significantly increased the risk of childhood astrocytoma [OR = 2.0, p =
0.04], while gestational exposure to marijuana was of borderline significance (OR = 2.8, p =
0.07). Gestational exposures to neurally-active medications, alcohol, and tobacco did not
increase brain cancer risk, consistent with other studies [203]. The association between anti-
emetics and increased brain cancer risk was not identified in another, Swedish study in which
this was assessed [205]. In the Swedish study, no significant changes in risk were noted after
exposure to iron supplementation, anti-emetics, analgesics, antibiotics or any other drug, with
the exception that 10 children with a brain tumor had been exposed to some beta-blocking
agent in utero versus just two children without brain tumor (adjusted OR 5.3, 95%CI 1.2-24.8).
In addition, a tendency towards a protective effect was observed for prenatal exposure to folic
acid (adjusted OR 0.6; 0.3-1.1). Finally, case-control data from M. D. Anderson Cancer Center
and the University of California, San Francisco were pooled to conduct an analysis stratified
by histological subtype of glioma to identify any potentiating effects of inflammation-related
variables and antihistamine use [206]. An association was discovered between long-term
antihistamine use and the increased risk of anaplastic gliomas, especially when the length of
use was considered in conjunction with a history of asthma or allergy: anaplastic cases with
no history of asthma or allergy were 2.94 times more likely than controls to report antihistamine
use lasting 10 years or more; while anaplastic cases with a history of asthma or allergy were
2.34 times more likely. Conversely, anti-inflammatory medication use was protective against
glioblastoma (OR = 0.80; 95%CI: 0.65, 0.99), especially among individuals with no history of
asthma or allergies. No statistically-significant effects of anti-inflammatory drugs or antihist‐
amines were evident for other histological subtypes of glioma.
8. Summary, clinical applications, and directions for future research
Brain cancer is one of the most fear-provoking and lethal of all illnesses, two reasons that
concerns about the potential for increased rates from the use of hand-held electronic devices
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of brain cancer by Samuelson et al, who analysed 1,010,366 individuals with 12,378,172 person-
years of follow-up, from which 453 individuals ages 0 to 15 years were diagnosed with brain
cancer [199]. In this population, the relative risk of brain cancer was 1.27 (95%CI 1.16-1.38) for
every 1 cm increase in head circumference, after adjusting for birth-weight, gestational age,
and gender. In another study of 746 invasive CNS cancers in children less than 4 years old,
after adjusting for parental education, elevated birth-weight was associated with an odds ratio
of 1.71 for astrocytoma (95%CI, 1.01-2.90); but birth weight was not associated with an
increased risk of PNET [42].
Prior malignancy has been associated with a variety of malignancies in the literature, including
brain cancer. Some of this increased risk almost certainly is secondary to radiation therapy to
the head and neck [129]. Yet even when head irradiation is not utilized, brain cancer risk may
be increased. Maule et al identified a total of 133 second malignant neoplasms in 16,540 patients
with hematopoietic malignancies (12,731 leukemias, 1246 Hodgkin’s lymphomas, and 2563
non-Hodgkin’s lymphomas) after an average follow-up of 6.5 years [200]. The most frequent
second malignancies after leukemia were brain cancer (standardized incidence ratio [SIR] =
8.52; 95% CI = 5.13 to 13.3), non-Hodgkin’s lymphoma (SIR = 9.41; 4.30 to 17.9), and thyroid
cancer (SIR = 18.8; 8.60 to 35.7). The most frequent after non-Hodgkin’s lymphoma were
thyroid cancer (SIR = 40.4; 14.8 to 88.0) and brain cancer (SIR = 6.97; 1.90 to 17.9). There was no
increased incidence of brain cancer following Hodgkin’s lymphoma.
In Rio de Janeiro, in a hospital-based case-control study involving 231 adults with primary
brain tumors and 261 controls matched for gender and age among in-patients hospitalized for
various conditions unrelated to brain cancer, past head injury was found to be significantly
more frequent among cases (46%) than controls (36%) (OR(adjusted) = 1.49; 95%CI = 1.03-2.15)
[201]. Moreover, a dose-response effect was observed related to the number of head injuries,
and a statistically-borderline association was observed specifically for meningioma (OR(adj)
= 1.63; 0.96-2.75). These results have not yet been replicated and, to date, no such association
has been identified for childhood brain cancer.
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In a nationwide Danish study on the occurrence of cancer among 8,093 Danish individuals
born with an oral cleft deformity between 1936 and 1998 and followed in the Danish Cancer
Registry from 1968 through 1998, a total of 175,863 person-years, the possible association
between cancer and oral clefts was assessed [202]. The expected overall number of all cancers
was 131, but 140 incident cancers were found, corresponding to a standardized incidence ratio
of 1.07 (95%CI, 0.90-1.26). Analyses of the 52 sites for all oral cleft cases and analyses stratified
into three cleft subgroups and two sexes revealed only a few significant associations, one of
which was the increased incidence of primary brain cancer among females, but not males, born
with a cleft palate (SIR = 3.11; 1.14, 6.78).
Finally, medications are often listed as a potential risk factor for brain cancer [203], but there
are almost no data scientifically supporting such a claim. In one case-control study of 163
matched pairs, patients under 15 years of age when diagnosed with astrocytoma between 1980
and 1986 were identified through the tumor registries of eight hospitals in Pennsylvania, New
Jersey, and Delaware [204]. Controls were selected by random digit dialing, and matched to
cases for age, race, and telephone area code and exchange. In this population, maternal anti-
nausea medications significantly increased the risk of childhood astrocytoma [OR = 2.0, p =
0.04], while gestational exposure to marijuana was of borderline significance (OR = 2.8, p =
0.07). Gestational exposures to neurally-active medications, alcohol, and tobacco did not
increase brain cancer risk, consistent with other studies [203]. The association between anti-
emetics and increased brain cancer risk was not identified in another, Swedish study in which
this was assessed [205]. In the Swedish study, no significant changes in risk were noted after
exposure to iron supplementation, anti-emetics, analgesics, antibiotics or any other drug, with
the exception that 10 children with a brain tumor had been exposed to some beta-blocking
agent in utero versus just two children without brain tumor (adjusted OR 5.3, 95%CI 1.2-24.8).
In addition, a tendency towards a protective effect was observed for prenatal exposure to folic
acid (adjusted OR 0.6; 0.3-1.1). Finally, case-control data from M. D. Anderson Cancer Center
and the University of California, San Francisco were pooled to conduct an analysis stratified
by histological subtype of glioma to identify any potentiating effects of inflammation-related
variables and antihistamine use [206]. An association was discovered between long-term
antihistamine use and the increased risk of anaplastic gliomas, especially when the length of
use was considered in conjunction with a history of asthma or allergy: anaplastic cases with
no history of asthma or allergy were 2.94 times more likely than controls to report antihistamine
use lasting 10 years or more; while anaplastic cases with a history of asthma or allergy were
2.34 times more likely. Conversely, anti-inflammatory medication use was protective against
glioblastoma (OR = 0.80; 95%CI: 0.65, 0.99), especially among individuals with no history of
asthma or allergies. No statistically-significant effects of anti-inflammatory drugs or antihist‐
amines were evident for other histological subtypes of glioma.
8. Summary, clinical applications, and directions for future research
Brain cancer is one of the most fear-provoking and lethal of all illnesses, two reasons that
concerns about the potential for increased rates from the use of hand-held electronic devices
The Epidemiology of Paediatric Brain Cancer — Descriptive Epidemiology and Risk Factors
http://dx.doi.org/10.5772/52427
625
have been raised. To date, however, there is no evidence that brain cancer incidence rates have
increased at all over the same time period that the use of these devices has escalated expo‐
nentially. In the U.S. and U.K., where data are available, brain cancer incidence rates appear
to be stable or declining. Mortality rates also are declining. That being said, there are virtually
no readily-accessible data outside the U.S. and the U.K., and there is some research evidence
that any effects of such devices on brain cancer risk only become significantly and clinically
manifest after years, if not decades of their use. Consequently, it may be too soon to have
detected adverse effects and, if present, to determine the magnitude of such effects on brain
cancer numbers.
Known risk factors for brain cancer are male gender, younger age among pediatric popula‐
tions, and Caucasian race. A family or personal history of cancer, and in particular brain cancer
appears to increase risk as well, as do radiation treatments to the head and neck area. In
addition, a small percentage of brain cancer cases, likely 5 percent or less, occur within the
context of a familial syndrome, the most common of which are neurofibromatosis and tuberous
sclerosis. In such patients, the risk is high for a variety of intracranial and extra-cranial
malignancies, so that continuous vigilance by qualified health care practitioners is paramount.
Unfortunately, research into a variety of suspected brain cancer risk factors has been fraught
with difficulties, given problems accurately evaluating levels of exposure, controlling for
numerous other potentially carcinogenic exposures, and issues like recall and ascertainment
bias. As stated earlier, understanding about the true risk of hand-held devices like cell phones
may not come until they have been in widespread use for several more years, at which point
it may be too late to prevent whatever initial rise in cases results. The same is true for electro‐
magnetic fields from the increasing number of household appliances, especially home
computers that are entering our homes, though the trend has been towards negative-result
studies as methodologies have advanced over the years. As for dietary factors, other than
promoting good diet and moderation in the consumption of cured meats, little more can be
said at this time. And all patients should be advised to exercise caution when partaking in any
occupation, hobby or other activity that places one in regular close contact with chemicals or
ionizing radiation.
Further research clearly is needed to clarify the huge number of yet-unanswered questions,
but this must start with close and international monitoring of brain cancer rates, both overall
and cancer-type specific. In the U.S., the SEER database is a huge advantage; but investigators
need to utilize this database more and publish these results within the medical literature. The
number and completeness of similar databases in other countries this author cannot say; but
again, such databases need to be used for research purposes and resultant findings published
on a regular basis, if changing trends in brain cancer incidence are to be detected early. As for
establishing the magnitude of risk from devices like cell phones, if such risk actually exists,
what are needed are large, prospective, longitudinal studies assessing dose-dependent effects,
since it makes sense that the highest-volume users will be the ones most likely to present
earliest with problems, a contention that already-published results support. Moreover, using
prospective studies will largely counter the problems with recall and ascertainment bias that
has plagued the numerous case-control studies published to date though, admittedly, such
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studies invariably must be larger and, hence costlier. This being said, it is important to recall
those databases already in existence, like the SEER database and State and provincial cancer
registries. Linking prospectively-acquired, multicenter exposure data with some database like
these would provide a powerful research tool in the fight against brain cancer.
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A dramatic increase in knowledge regarding the molecular biology of brain tumors 
has been established over the past few years, and this has lead to the development of 
novel therapeutic strategies for these patients.  In this book a review of the options 
available for the clinical management of patients with these tumors are outlined.   In 
addition advances in radiology both for pre-operative diagnostic purposes along with 
surgical planning are described.  Furthermore a review of newer developments in 
chemotherapy along with the evolving field of photodynamic therapy both for intra-
operative management and subsequent therapy is provided.  A discussion of certain 
surgical management issues along with tumor induced epilepsy is included.  Finally a 
discussion of the management of certain unique problems including brain metastases, 
brainstem glioma, central nervous system lymphoma along with issues involving 
patients with a brain tumor and pregnancy is provided.
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